chrom	chromStart	chromEnd	name	trait	genes	orOrBeta	pValue
chr1	1005805	1005806	rs3934834	Body mass index	NR	.11	6E-7
chr1	2069171	2069172	rs425277	Height	PRKCZ	.02	2E-8
chr1	2069680	2069681	rs3753242	Reasoning	PRKCZ	NR	1E-6
chr1	2392647	2392648	rs2477686	Non-obstructive azoospermia	PEX10, MMEL1	1.39	6E-12
chr1	2513215	2513216	rs734999	Ulcerative colitis	TNFRSF14, MMEL1, PLCH2, C1orf93	1.05	3E-9
chr1	2526745	2526746	rs3748816	Celiac disease	TNFRSF14, MMEL1	1.12	3E-9
chr1	2553623	2553624	rs3890745	Rheumatoid arthritis	TNFRSF14	1.12	4E-6
chr1	2553623	2553624	rs3890745	Rheumatoid arthritis	MMEL1,TNFRSF14	1.12	1E-7
chr1	2709163	2709164	rs4648356	Multiple sclerosis	MMEL1	1.14	1E-14
chr1	3083711	3083712	rs2651899	Migraine	PRDM16	1.11	4E-9
chr1	3280252	3280253	rs6658356	Response to statin therapy	PRDM16,ARHGEF16,MEFGF6	NR	2E-6
chr1	3649561	3649562	rs9662633	Visceral adipose tissue adjusted for BMI	TP73	NR	6E-6
chr1	3651030	3651031	rs12562437	Visceral adipose tissue/subcutaneous adipose tissue ratio	KIAA0495, LRRC47, TP73, CCDC27	NR	2E-6
chr1	3651408	3651409	rs10910018	Visceral fat	KIAA0495,LRRC47,TP73,CCDC27	NR	2E-6
chr1	3651408	3651409	rs10910018	Visceral fat	KIAA0495, LRRC47, TP73, CCDC27	NR	2E-6
chr1	4315203	4315204	rs966321	Factor VII	Intergenic	NR	8E-6
chr1	4668669	4668670	rs3896439	Dental caries	AJAP1	NR	2E-8
chr1	5170711	5170712	rs7513590	Anthropometric traits	Intergenic	.31	5E-6
chr1	5913620	5913621	rs548726	Response to taxane treatment (placlitaxel)	NPHP4	NR	5E-7
chr1	6279369	6279370	rs846111	QT interval	RNF207	1.49	4E-16
chr1	6279369	6279370	rs846111	QT interval	RNF207,NPHP4, CHDS, ACOT7, PLEKHG5, KLH21	1.75	1E-16
chr1	6631430	6631431	rs11587438	White blood cell types	TAS1R1	.08	4E-6
chr1	7521584	7521585	rs1616122	Periodontal microbiota	CAMTA1, VAMP3	1.85	5E-6
chr1	7879062	7879063	rs2797685	Crohn's disease	VAMP3	1.05	7E-9
chr1	8021972	8021973	rs35675666	Ulcerative colitis	TNFRSF9, ERFFI1, UTS2, PARK7	1.08	5E-9
chr1	8046671	8046672	rs12727642	Celiac disease	PARK7, TNFRSF9	1.14	9E-8
chr1	8338354	8338355	rs438895	Economic and political preferences	Intergenic	.38	7E-6
chr1	8422675	8422676	rs2252865	Schizophrenia	NR	1.08	3E-6
chr1	8526141	8526142	rs4908760	Vitiligo	RERE	1.36	7E-15
chr1	8759553	8759554	rs12025126	Vertical cup-disc ratio	RERE	.01	6E-8
chr1	9408958	9408959	rs11121380	Response to tocilizumab in rheumatoid arthritis	SPSB1	11.11	5E-8
chr1	9411468	9411469	rs11121382	Immune response to anthrax vaccine	SPSB1	.10	4E-6
chr1	9432389	9432390	rs9308447	Dental caries	SPSB1	NR	5E-7
chr1	10286175	10286176	rs17396340	Mean platelet volume	KIF1B	.01	3E-8
chr1	10353111	10353112	rs10492972	Multiple sclerosis	KIF1B	1.34	3E-10
chr1	10385470	10385471	rs17401966	Hepatocellular carcinoma	KIF1B,UBE4B,PGD	1.64	2E-18
chr1	10638603	10638604	rs12741973	Optic disc size (rim)	PEX14	.17	7E-6
chr1	10796865	10796866	rs880315	Blood pressure	CASZ1	.74	7E-7
chr1	10796865	10796866	rs880315	Blood pressure	CASZ1	.56	3E-10
chr1	10799576	10799577	rs12046278	Systolic blood pressure	CASZ1	.53	5E-6
chr1	11033081	11033082	rs12565727	Male-pattern baldness	TARDBP	1.33	9E-11
chr1	11046854	11046855	rs9430161	Ewing sarcoma	TARDBP	2.20	1E-20
chr1	11171225	11171226	rs17036350	Corneal curvature	FRAP1	.18	4E-13
chr1	11736599	11736600	rs2336030	Visceral adipose tissue adjusted for BMI	MAD2L2	NR	1E-6
chr1	11788563	11788564	rs4846033	Schizophrenia	Intergenic	2.87	4E-6
chr1	11852515	11852516	rs17375901	Atrial fibrillation	MTHFR, NPPA	1.26	6E-7
chr1	11856377	11856378	rs1801133	Homocysteine levels	MTHFR	.05	8E-35
chr1	11862777	11862778	rs17367504	Blood pressure	MTHFR, NPPB	.53	2E-16
chr1	11862777	11862778	rs17367504	Systolic blood pressure	MTHFR, NPPA, CLCN6, NPPB, AGTRAP	.85	2E-13
chr1	11899032	11899033	rs1023252	Natriuretic peptide levels	CLCN6	.20	4E-16
chr1	12046062	12046063	rs2336384	Platelet counts	MFN2	2.17	1E-8
chr1	15347639	15347640	rs6667220	Chronic obstructive pulmonary disease-related biomarkers	RP1-21O18.1	NR	8E-6
chr1	15792425	15792426	rs2901964	Erectile dysfunction and prostate cancer treatment	ELA2A	5.26	5E-6
chr1	16299311	16299312	rs10927875	Dilated cardiomyopathy	ZBTB17	1.32	1E-9
chr1	16393356	16393357	rs9442235	Cognitive performance	FAM131C	NR	6E-6
chr1	16505319	16505320	rs1497406	Gamma gluatamyl transferase levels	Intergenic	.08	4E-8
chr1	16505319	16505320	rs1497406	Liver enzyme levels (gamma-glutamyl transferase)	RSG1, EPHA2	3.80	3E-19
chr1	17216330	17216331	rs6586513	Allergic rhinitis	CROCC	1.24	4E-6
chr1	17306674	17306675	rs2284746	Pulmonary function	MFAP2	.04	8E-16
chr1	17306674	17306675	rs2284746	Height	MFAP2	.04	4E-29
chr1	17331675	17331676	rs3738814	Height	ATP13A2, SDHB	.06	2E-7
chr1	17674536	17674537	rs2240335	Rheumatoid arthritis	PADI4	NR	2E-8
chr1	17674536	17674537	rs2240335	Rheumatoid arthritis	PADI4	1.50	2E-8
chr1	17722362	17722363	rs7538876	Basal cell carcinoma	PADI4, PADI6,RCC2, ARHGEF10L	1.28	4E-12
chr1	17834741	17834742	rs2254135	Response to hepatitis C treatment	ARHGEF10L	.27	3E-6
chr1	18294486	18294487	rs16861326	Erectile dysfunction and prostate cancer treatment	IGSF21	17.85	2E-6
chr1	18795254	18795255	rs3007729	Diabetic retinopathy	IGSF21, KLHDC7A	1.35	5E-6
chr1	18979873	18979874	rs742071	Orofacial clefts	PAX7	1.32	7E-9
chr1	19032271	19032272	rs2236824	Response to amphetamines	PAX7	NR	2E-6
chr1	19139516	19139517	rs12063142	Parkinson's disease	TAS1R2	NR	5E-7
chr1	19386584	19386585	rs12123383	Response to amphetamines	Intergenic	NR	4E-6
chr1	19568971	19568972	rs710865	Brain structure	KIAA0090, MRT04, AKR7L	NR	1E-7
chr1	19718823	19718824	rs7667	Crohn's disease and psoriasis	CAPZB	1.11	8E-6
chr1	19765517	19765518	rs12045440	Thyroid volume	CAPZB	.07	3E-14
chr1	19765517	19765518	rs12045440	Thyroid volume	CAPZB	1.38	2E-11
chr1	19839114	19839115	rs12138950	Thyroid volume	CAPZB	.10	3E-18
chr1	19843353	19843354	rs10917468	Thyroid volume	CAPZB	1.52	1E-14
chr1	19861105	19861106	rs10917477	Thyroid function	CAPZB	.06	2E-8
chr1	20140035	20140036	rs1317209	Ulcerative colitis	RNF186,OTUD3,PLA2G2E	1.17	2E-10
chr1	20142865	20142866	rs3806308	Ulcerative colitis	RNF186	1.28	7E-9
chr1	20171859	20171860	rs6426833	Ulcerative colitis	Intergenic	1.30	4E-35
chr1	20171859	20171860	rs6426833	Ulcerative colitis	RNF186,OTUD3,PLA2G2E	1.30	2E-21
chr1	20171859	20171860	rs6426833	Ulcerative colitis	OTUD3, PLA2G2E	NR	2E-11
chr1	20171859	20171860	rs6426833	Ulcerative colitis	OTUD3, PLA2G2E	1.37	5E-13
chr1	20227722	20227723	rs4654925	Ulcerative colitis	OTUD3	1.41	9E-22
chr1	21766452	21766453	rs1976403	Liver enzyme levels (alkaline phosphatase)	ALPL, NBPF3	3.60	2E-50
chr1	21786067	21786068	rs4654748	Folate pathway vitamin levels	ALPL	1.45	8E-18
chr1	21820989	21820990	rs10799701	Metabolic traits	ALPL	.13	3E-20
chr1	21821756	21821757	rs1780324	Liver enzyme levels	NBPF3, ALPL, RAP1GAP	.03	7E-15
chr1	21823291	21823292	rs1697421	Phosphorus levels	ALPL,NBPF3	.05	1E-27
chr1	21875915	21875916	rs885814	Response to TNF-alpha inhibitors in rheumatoid arthritis	ALPL	NR	6E-6
chr1	22373623	22373624	rs2501276	Immune response to smallpox vaccine (IL-6)	CDC42	NR	2E-7
chr1	22485870	22485871	rs16826658	Endometriosis	WNT4	1.20	2E-6
chr1	22490723	22490724	rs7521902	Endometriosis	WNT4	1.19	3E-11
chr1	22490723	22490724	rs7521902	Ovarian cancer	NR	1.12	5E-6
chr1	22573941	22573942	rs909814	Testosterone levels	Intergenic	.10	9E-7
chr1	22698446	22698447	rs7524102	Dupuytren's disease	RP11-415K20.1, WNT4	1.28	3E-9
chr1	22698446	22698447	rs7524102	Bone mineral density	ZBTB40	.44	9E-7
chr1	22698446	22698447	rs7524102	Bone mineral density	ZBTB40	.14	1E-6
chr1	22698446	22698447	rs7524102	Ulcerative colitis	Intergenic	1.10	2E-13
chr1	22698446	22698447	rs7524102	Ulcerative colitis	Intergenic	1.10	3E-7
chr1	22698446	22698447	rs7524102	Bone mineral density (spine)	ZBTB40	.09	3E-10
chr1	22698446	22698447	rs7524102	Bone mineral density (hip)	Intergenic	.15	1E-16
chr1	22698446	22698447	rs7524102	Bone mineral density (spine)	ZBTB40	.11	9E-9
chr1	22698446	22698447	rs7524102	Bone mineral density (hip)	ZBTB40	.15	5E-16
chr1	22702857	22702858	rs6696981	Bone mineral density (spine)	Intergenic	.12	2E-8
chr1	22711472	22711473	rs6426749	Bone mineral density (hip)	ZBTB40	.08	9E-8
chr1	23536890	23536891	rs1738475	Height	HTR1D	.03	3E-12
chr1	24431955	24431956	rs3934861	Bipolar disorder (mood-incongruent)	MYOM3	1.25	4E-6
chr1	24519919	24519920	rs4649203	Psoriasis	IL28RA	1.13	7E-8
chr1	24584489	24584490	rs6670533	Fasting insulin-related traits (interaction with BMI)	GRHL3	NR	6E-6
chr1	24626173	24626174	rs10794657	Adiponectin levels	NR	.03	2E-7
chr1	25044110	25044111	rs4601530	Height	CLIC4	.03	2E-12
chr1	25297183	25297184	rs11249215	Ankylosing spondylitis	RUNX3	NR	9E-11
chr1	25303575	25303576	rs10903122	Celiac disease	RUNX3	1.12	2E-10
chr1	25570080	25570081	rs1043879	Erythrocyte sedimentation rate	C1orf63	.09	2E-9
chr1	25674784	25674785	rs3091242	Erythrocyte sedimentation rate	TMEM50A	.10	2E-13
chr1	25768936	25768937	rs10903129	Erythrocyte sedimentation rate	TMEM57	.10	5E-13
chr1	25768936	25768937	rs10903129	Cholesterol, total	TMEM57	.06	5E-10
chr1	25775732	25775733	rs12027135	LDL cholesterol	TMEM57,LDLRAP1	1.10	1E-10
chr1	25775732	25775733	rs12027135	Cholesterol, total	TMEM57,LDLRAP1	1.22	4E-11
chr1	26521139	26521140	rs11809207	Height	CATSPER4	.07	6E-8
chr1	26741543	26741544	rs7532866	Height	LIN28	.02	3E-8
chr1	30185661	30185662	rs1866967	Prostate cancer (gene x gene interaction)	PTPRU	1.22	5E-6
chr1	30431559	30431560	rs1009080	Schizophrenia	NR	1.09	3E-6
chr1	30432218	30432219	rs4949526	Bipolar disorder and schizophrenia	PTPRU	1.28	4E-7
chr1	30525713	30525714	rs2860031	Bipolar disorder (mood-incongruent)	Intergenic	1.22	3E-6
chr1	30567595	30567596	rs910696	Smoking behavior	Intergenic	.08	3E-6
chr1	30627711	30627712	rs2180233	Attention deficit hyperactivity disorder and conduct disorder	Intergenic	NR	9E-6
chr1	34173819	34173820	rs564148	Response to amphetamines	CSMD2	NR	9E-6
chr1	34180841	34180842	rs16835742	Intelligence	CSMD2	NR	8E-8
chr1	34181829	34181830	rs7533254	Intelligence	CSMD2	NR	8E-8
chr1	34186192	34186193	rs528059	Intelligence	CSMD2	NR	8E-8
chr1	34189428	34189429	rs544991	Intelligence	CSMD2	NR	8E-8
chr1	34248063	34248064	rs476463	Brain structure	CSMD2	NR	1E-6
chr1	34359857	34359858	rs2281597	Attention deficit hyperactivity disorder	CSMD2	NR	5E-7
chr1	34750935	34750936	rs771390	Epilepsy (generalized)	C1orf94	1.22	6E-7
chr1	34989236	34989237	rs10914967	Visceral adipose tissue adjusted for BMI	GJB5	NR	6E-6
chr1	35289038	35289039	rs7526035	Formal thought disorder in schizophrenia	GJA4	1.29	9E-6
chr1	35687814	35687815	rs673604	Endometrial cancer	SFPQ	1.21	6E-6
chr1	36904719	36904720	rs6702784	Diabetic retinopathy	C1orf102, LSCM10, MRPS15	1.08	4E-6
chr1	37958812	37958813	rs9253	Hemostatic factors and hematological phenotypes	FLJ11730, BC016328	NR	4E-6
chr1	38196840	38196841	rs731174	Prostate cancer (gene x gene interaction)	EPHA10	1.27	5E-6
chr1	38247152	38247153	rs12117544	Cognitive performance	RP11-109P14.2	NR	8E-6
chr1	38279986	38279987	rs3748682	Hypothyroidism	MTF1	1.19	9E-6
chr1	38602072	38602073	rs7547921	Visceral adipose tissue/subcutaneous adipose tissue ratio	POU3F1	NR	8E-6
chr1	38624128	38624129	rs12131057	Rheumatoid arthritis	POU3F1	1.16	4E-7
chr1	39380384	39380385	rs4246511	Menopause (age at onset)	RHBDL2	.24	9E-17
chr1	40028179	40028180	rs4660293	HDL cholesterol	MACF1,PABPC4	.48	4E-10
chr1	40064960	40064961	rs12037222	C-reactive protein	PABPC4	.05	6E-11
chr1	40132794	40132795	rs873917	Amyotrophic lateral sclerosis	NT5C1A	1.16	8E-6
chr1	41239510	41239511	rs4660456	Platelet counts	NFYC	NR	4E-6
chr1	41530870	41530871	rs6686842	Height	SCMH1	.05	2E-8
chr1	41745769	41745770	rs2154319	Height	SCMH1	.03	2E-12
chr1	41839821	41839822	rs4660531	Bipolar disorder	Intergenic	1.10	3E-6
chr1	43596383	43596384	rs16830359	Cardiac hypertrophy	SLC2A1	NR	1E-7
chr1	43645410	43645411	rs621559	Telomere length	WDR65	.16	2E-6
chr1	44005279	44005280	rs2819332	Amyotrophic lateral sclerosis (age of onset)	PTPRF	NR	5E-6
chr1	44117005	44117006	rs660899	Hypertension risk in short sleep duration	JMJD2A	7.22	4E-6
chr1	44129778	44129779	rs669446	Amyotrophic lateral sclerosis (age of onset)	JMJD2A	NR	5E-6
chr1	44215827	44215828	rs2367725	Aging (time to event)	ST3GAL3	1.08	9E-6
chr1	44319372	44319373	rs3011225	Amyotrophic lateral sclerosis (age of onset)	ST3GAL3	NR	7E-8
chr1	47179309	47179310	rs10789491	Response to hepatitis C treatment	KIAA0494	.31	1E-6
chr1	47284922	47284923	rs12059860	Testosterone levels	CYP4B1	.62	8E-6
chr1	47404185	47404186	rs9332998	Metabolic traits	CYP4A	.16	5E-32
chr1	47918820	47918821	rs527430	Response to antidepressant treatment	FOXD2	NR	4E-7
chr1	48009996	48009997	rs11582540	Response to amphetamines	Intergenic	NR	3E-6
chr1	48321220	48321221	rs946836	White matter integrity	LOC388630	.30	5E-6
chr1	50937847	50937848	rs3827730	Depression and alcohol dependence	FAF1	1.72	4E-6
chr1	51546139	51546140	rs17391905	Ventricular conduction	C1orf185, RNF11, CDKN2C,FAF1	1.35	3E-10
chr1	51859241	51859242	rs6673480	IgE grass sensitization	EPS15	1.35	2E-6
chr1	53581669	53581670	rs3820201	Hippocampal atrophy	SLC1A7	NR	1E-6
chr1	53629584	53629585	rs6695567	Systemic lupus erythematosus	SLC1A7	1.32	4E-6
chr1	53871084	53871085	rs114216682	Chronic obstructive pulmonary disease	FLJ40434	4.49	7E-8
chr1	53978118	53978119	rs6588480	Response to statin therapy	GLIS1,DMRTB1,FLJ40434	NR	8E-6
chr1	54320336	54320337	rs11206226	Nonalcoholic fatty liver disease	YIPF1	1.72	5E-6
chr1	55496038	55496039	rs11206510	Coronary heart disease	PCSK9	1.08	9E-8
chr1	55496038	55496039	rs11206510	LDL cholesterol	PCSK9	.03	1E-10
chr1	55496038	55496039	rs11206510	Myocardial infarction (early onset)	PCSK9	1.15	1E-8
chr1	55496038	55496039	rs11206510	LDL cholesterol	PCSK9	.09	4E-8
chr1	55496038	55496039	rs11206510	LDL cholesterol	PCSK9	3.04	4E-11
chr1	55504649	55504650	rs2479409	LDL cholesterol	PCSK9	2.01	2E-28
chr1	55504649	55504650	rs2479409	Cholesterol, total	PCSK9	1.96	4E-24
chr1	55505646	55505647	rs11591147	Response to statin therapy (LDL-C)	PCSK9	5.00	5E-9
chr1	55505646	55505647	rs11591147	LDL cholesterol	PCSK9	.47	2E-44
chr1	55512994	55512995	rs2495478	Wilms tumor	NR	1.40	1E-7
chr1	55742836	55742837	rs12239436	Coronary heart disease	Intergenic	.09	5E-6
chr1	55958029	55958030	rs1998013	Metabolite levels	PCSK9, USP24	NR	5E-13
chr1	56060950	56060951	rs10888935	Inflammatory biomarkers	Intergenic	NR	7E-7
chr1	56116504	56116505	rs72669744	Lipid metabolism phenotypes	PCSK9	.59	1E-19
chr1	56359812	56359813	rs6684428	Airflow obstruction	PPAP2B	1.23	5E-7
chr1	56850685	56850686	rs11206801	AB1-42	Intergenic	NR	6E-8
chr1	56962820	56962821	rs17114036	Coronary heart disease	PPAP2B	1.17	4E-19
chr1	56966349	56966350	rs17114046	Coronary heart disease	PPAP2B	NR	3E-7
chr1	56966349	56966350	rs17114046	Coronary heart disease	PPAP2B	NR	2E-7
chr1	57126918	57126919	rs2746347	Lymphocyte counts	PRKAA2	NR	4E-7
chr1	57243453	57243454	rs17372114	Resistin levels	C1orf168	.04	5E-7
chr1	57805549	57805550	rs10159302	HIV-1 control	NR	NR	9E-6
chr1	58367235	58367236	rs6679454	Immune reponse to smallpox (secreted IL-10)	DAB1	NR	3E-7
chr1	58757914	58757915	rs527409	Kawasaki disease	DAB1	2.90	1E-6
chr1	59162147	59162148	rs2811893	Diabetic retinopathy	MYSM1	NR	3E-7
chr1	59325625	59325626	rs4601609	Cognitive performance	JUN	NR	5E-6
chr1	59799160	59799161	rs17119280	Response to antipsychotic therapy (extrapyramidal side effects)	FGGY	NR	7E-6
chr1	60084515	60084516	rs12727131	Neutrophil count	FGGY	NR	3E-6
chr1	61041874	61041875	rs12565755	Response to tocilizumab in rheumatoid arthritis	Intergenic	.39	5E-8
chr1	61059258	61059259	rs2989476	Bipolar disorder	NFIA	1.16	3E-6
chr1	61059258	61059259	rs2989476	Bipolar disorder	NR	NR	2E-6
chr1	61095557	61095558	rs472913	Bipolar disorder	NF1A	1.18	2E-7
chr1	61205468	61205469	rs1514178	Phospholipid levels (plasma)	NFIA	.07	2E-7
chr1	61791862	61791863	rs6691768	Celiac disease	NFIA	1.11	1E-7
chr1	61815798	61815799	rs41350144	Bipolar disorder	NF1A	2.27	3E-7
chr1	61820071	61820072	rs17121983	Bipolar disorder	NF1A	2.26	4E-7
chr1	61821818	61821819	rs7556462	Bipolar disorder	NF1A	2.26	4E-7
chr1	61821818	61821819	rs7556462	Bipolar disorder	NF1A	2.26	4E-7
chr1	61822282	61822283	rs4915737	Bipolar disorder	NF1A	2.26	4E-7
chr1	61824388	61824389	rs41453448	Bipolar disorder	NF1A	2.50	2E-7
chr1	61831889	61831890	rs1125777	Bipolar disorder	NF1A	2.50	2E-7
chr1	61831889	61831890	rs1125777	Bipolar disorder	NF1A	2.34	2E-7
chr1	61831937	61831938	rs12568010	Bipolar disorder	NF1A	2.50	2E-7
chr1	61831937	61831938	rs12568010	Bipolar disorder	NF1A	2.34	2E-7
chr1	61873676	61873677	rs9436640	Ventricular conduction	NFIA	.59	5E-18
chr1	62931631	62931632	rs1167998	Triglycerides	DOCK7	.09	2E-12
chr1	62950857	62950858	rs10889332	Metabolite levels	ANGPTL3, DOCK7	NR	8E-15
chr1	62969401	62969402	rs1168029	Lipid metabolism phenotypes	ANGPTL3	.13	3E-13
chr1	62996837	62996838	rs1168013	Triglycerides	DOCK7,ANGPTL3	.04	6E-8
chr1	63025941	63025942	rs2131925	Triglycerides	ANGPTL3,DOCK7	4.94	9E-43
chr1	63025941	63025942	rs2131925	LDL cholesterol	ANGPTL3,DOCK7	1.59	3E-18
chr1	63025941	63025942	rs2131925	Cholesterol, total	ANGPTL3,DOCK7	2.60	5E-41
chr1	63049592	63049593	rs1748195	Triglycerides	ANGPTL3	7.12	2E-10
chr1	63118195	63118196	rs10889353	LDL cholesterol	DOCK7	.06	8E-6
chr1	63118195	63118196	rs10889353	Cholesterol, total	DOCK7	.08	4E-12
chr1	63118195	63118196	rs10889353	Triglycerides	ANGPTL3	.05	3E-7
chr1	63191776	63191777	rs12130333	Triglycerides	ANGPTL3, DOCK7, ATG4C	.11	2E-8
chr1	63480729	63480730	rs17124318	Weight	ATG4C	3.98	4E-6
chr1	63480729	63480730	rs17124318	Body mass index	ATG4C	.07	6E-7
chr1	63586972	63586973	rs7526034	Brain imaging	LOC199897	NR	NS
chr1	63591128	63591129	rs10493340	Blood pressure	Intergenic	NR	2E-6
chr1	64108770	64108771	rs2269241	Type 1 diabetes	PGM1	1.10	4E-7
chr1	64127467	64127468	rs2749097	Alcohol consumption	PGM1	.12	2E-9
chr1	64868351	64868352	rs11208446	Bilirubin levels	RNU7-62P	.12	9E-6
chr1	65815658	65815659	rs1413885	Anticoagulant levels	DNAJC6	.43	3E-7
chr1	65992624	65992625	rs1751492	Soluble leptin receptor levels	LEPR	7.60	6E-13
chr1	66089781	66089782	rs6700896	C-reactive protein	LEPR	14.80	3E-14
chr1	66102256	66102257	rs1805096	C-reactive protein	LEPR	.11	2E-9
chr1	66105943	66105944	rs1892534	C-reactive protein	LEPR	.17	7E-21
chr1	66161460	66161461	rs4420065	C-reactive protein	LEPR	.09	4E-62
chr1	66169678	66169679	rs12753193	Metabolic traits	LEPR	.13	4E-7
chr1	66279124	66279125	rs4384209	Economic and political preferences (feminism/equality)	PDE4B	.13	2E-6
chr1	66310864	66310865	rs10493389	Echocardiographic traits	PDE4B	NR	7E-6
chr1	66762465	66762466	rs546784	Acute lymphoblastic leukemia (childhood)	PDE4B	1.40	9E-6
chr1	66769099	66769100	rs6683977	Acute lymphoblastic leukemia (childhood)	PDE4B	1.41	5E-6
chr1	67590460	67590461	rs11209002	Crohn's disease	IL23R	2.56	2E-7
chr1	67590460	67590461	rs11209002	Crohn's disease	IL23R	1.38	1E-8
chr1	67597118	67597119	rs3762318	Leprosy	IL23R	1.45	3E-11
chr1	67601131	67601132	rs11209003	Crohn's disease	IL23R	2.56	2E-7
chr1	67601131	67601132	rs11209003	Crohn's disease	IL23R	1.38	1E-8
chr1	67653009	67653010	rs2064689	Crohn's disease	IL23R	2.56	2E-7
chr1	67653009	67653010	rs2064689	Crohn's disease	IL23R	1.38	1E-8
chr1	67670212	67670213	rs1004819	Crohn's disease	IL23R	2.56	2E-7
chr1	67670212	67670213	rs1004819	Crohn's disease	IL23R	1.38	1E-8
chr1	67670915	67670916	rs2902440	Crohn's disease	IL23R	2.56	2E-7
chr1	67670915	67670916	rs2902440	Crohn's disease	IL23R	1.38	1E-8
chr1	67675515	67675516	rs11805303	Crohn's disease	IL23R	1.39	6E-12
chr1	67681668	67681669	rs7517847	Crohn's disease	IL23R	NR	3E-12
chr1	67681668	67681669	rs7517847	Inflammatory bowel disease	IL23R	1.61	4E-13
chr1	67685597	67685598	rs11465802	Crohn's disease	IL23R	2.56	2E-7
chr1	67685597	67685598	rs11465802	Crohn's disease	IL23R	1.38	1E-8
chr1	67694201	67694202	rs2201841	Ulcerative colitis	IL23R	1.27	1E-13
chr1	67694201	67694202	rs2201841	Psoriasis	IL23R	1.13	3E-8
chr1	67694201	67694202	rs2201841	Crohn's disease	IL23R	2.56	2E-7
chr1	67694201	67694202	rs2201841	Crohn's disease	IL23R	1.38	1E-8
chr1	67702525	67702526	rs11465804	Crohn's disease	IL23R	1.89	1E-6
chr1	67702525	67702526	rs11465804	Crohn's disease	IL23R	2.50	7E-63
chr1	67702525	67702526	rs11465804	Crohn's disease	IL23R	2.56	2E-7
chr1	67702525	67702526	rs11465804	Crohn's disease	IL23R	1.38	1E-8
chr1	67705957	67705958	rs11209026	Crohn's disease	IL23R	2.84	4E-14
chr1	67705957	67705958	rs11209026	Crohn's disease	IL23R, IL12RB2, C1orf141, SERBP1,SLC35D1	2.20	1E-18
chr1	67705957	67705958	rs11209026	Crohn's disease	IL23R	3.18	4E-21
chr1	67705957	67705958	rs11209026	Ankylosing spondylitis	IL23R	NR	2E-17
chr1	67705957	67705958	rs11209026	Ulcerative colitis	IL23R	1.74	5E-28
chr1	67705957	67705958	rs11209026	Crohn's disease	IL23R	2.66	1E-64
chr1	67705957	67705958	rs11209026	Psoriasis	IL23R	1.49	7E-7
chr1	67705957	67705958	rs11209026	Ankylosing spondylitis	IL23R	1.89	9E-14
chr1	67705957	67705958	rs11209026	Ulcerative colitis	IL23R	NR	3E-10
chr1	67705957	67705958	rs11209026	Ulcerative colitis	IL23R	1.79	1E-8
chr1	67705957	67705958	rs11209026	Inflammatory bowel disease	IL23R	2.56	7E-11
chr1	67705957	67705958	rs11209026	Crohn's disease	IL23R	2.56	2E-7
chr1	67705957	67705958	rs11209026	Crohn's disease	IL23R	1.38	1E-8
chr1	67705957	67705958	rs11209026	Crohn's disease	IL23R	2.92	2E-18
chr1	67705957	67705958	rs11209026	Inflammatory bowel disease	IL23R	3.84	4E-11
chr1	67719128	67719129	rs1343151	Crohn's disease	IL23R	2.56	2E-7
chr1	67719128	67719129	rs1343151	Crohn's disease	IL23R	1.38	1E-8
chr1	67722566	67722567	rs10889676	Crohn's disease	IL23R	2.56	2E-7
chr1	67722566	67722567	rs10889676	Crohn's disease	IL23R	1.38	1E-8
chr1	67725119	67725120	rs10889677	Ulcerative colitis	IL23R	1.29	1E-8
chr1	67725119	67725120	rs10889677	Crohn's disease	IL23R	2.56	2E-7
chr1	67725119	67725120	rs10889677	Crohn's disease	IL23R	1.38	1E-8
chr1	67726103	67726104	rs9988642	Crohn's disease	IL23R	2.56	2E-7
chr1	67726103	67726104	rs9988642	Crohn's disease	IL23R	1.38	1E-8
chr1	67728017	67728018	rs12567232	Crohn's disease	IL23R	2.56	2E-7
chr1	67728017	67728018	rs12567232	Crohn's disease	IL23R	1.38	1E-8
chr1	67730054	67730055	rs6669582	Crohn's disease	IL23R	2.56	2E-7
chr1	67730054	67730055	rs6669582	Crohn's disease	IL23R	1.38	1E-8
chr1	67730627	67730628	rs10789230	Crohn's disease	IL23R	2.56	2E-7
chr1	67730627	67730628	rs10789230	Crohn's disease	IL23R	1.38	1E-8
chr1	67753507	67753508	rs1495965	Behcet's disease	IL23R,IL12RB2	1.35	2E-11
chr1	67760139	67760140	rs924080	Behcet's disease	IL23R,IL12RB2	1.28	7E-9
chr1	67790597	67790598	rs17129789	Primary biliary cirrhosis	IL12RB2	1.52	9E-20
chr1	67822376	67822377	rs3790567	Primary biliary cirrhosis	IL12RB2	1.48	8E-12
chr1	67822376	67822377	rs3790567	Primary biliary cirrhosis	IL12RB2	1.51	3E-11
chr1	67954728	67954729	rs17129789	Primary biliary cirrhosis	IL12RB2	1.52	9E-20
chr1	68635074	68635075	rs1430742	Bone mineral density (spine)	GPR177	.11	3E-13
chr1	68635389	68635390	rs2566755	Bone mineral density (hip)	GPR177	.10	2E-12
chr1	68785212	68785213	rs11209261	Airflow obstruction	GPR177	1.23	3E-6
chr1	69579251	69579252	rs4147141	Inattentive symptoms	Intergenic	NR	8E-6
chr1	69579251	69579252	rs4147141	Attention deficit hyperactivity disorder	Intergenic	NR	6E-6
chr1	69684996	69684997	rs4650135	Inattentive symptoms	Intergenic	NR	5E-6
chr1	70154440	70154441	rs1417437	Orofacial clefts	LRRC7	1.25	9E-6
chr1	70154440	70154441	rs1417437	Orofacial clefts	LRRC7	1.30	4E-6
chr1	70335681	70335682	rs2226284	Hypertension risk in short sleep duration	LRRC7	5.91	3E-8
chr1	70355980	70355981	rs12037173	Attention deficit hyperactivity disorder	LRRC7	NR	4E-6
chr1	70921172	70921173	rs10458561	Antipsychotic-induced QTc interval prolongation	Intergenic	NR	4E-7
chr1	72071128	72071129	rs10493485	Hemostatic factors and hematological phenotypes	NEGR1	NR	2E-6
chr1	72274472	72274473	rs12141391	Systemic lupus erythematosus	NEGR1	NR	7E-6
chr1	72765115	72765116	rs2568958	Weight	NEGR1	3.37	2E-8
chr1	72765115	72765116	rs2568958	Body mass index	NEGR1	3.77	1E-11
chr1	72812439	72812440	rs2815752	Body mass index	NEGR1	.13	2E-22
chr1	72812439	72812440	rs2815752	Body mass index	NEGR1	.10	6E-8
chr1	72823712	72823713	rs990871	Subcutaneous adipose tissue	NEGR1	NR	4E-6
chr1	74339166	74339167	rs11210359	Bipolar disorder and schizophrenia	LRRIQ3	NR	8E-6
chr1	74991643	74991644	rs1514175	Body mass index	TNNI3K	.07	8E-14
chr1	75235316	75235317	rs3931020	Resistin levels	TYW3, CRYZ	.05	6E-12
chr1	75298781	75298782	rs11161851	Visceral fat	TYW3	NR	7E-6
chr1	75770624	75770625	rs1249675	Capecitabine sensitivity	SLC44A5	NR	7E-6
chr1	75913825	75913826	rs1857353	MRI atrophy measures	SLC44A5	.02	2E-6
chr1	76106674	76106675	rs211718	Metabolic traits	ACADM	.16	2E-71
chr1	76106674	76106675	rs211718	Metabolite levels	ACADM	14.60	1E-63
chr1	76484013	76484014	rs12753569	Personality dimensions	Intergenic	.10	8E-6
chr1	76772327	76772328	rs10873876	Acute lymphoblastic leukemia (childhood)	SIAT7C	1.55	4E-6
chr1	78623625	78623626	rs17391694	Height	GIPC2	.04	2E-11
chr1	79238014	79238015	rs4650608	Bipolar disorder	PTGFR	NR	8E-9
chr1	79254761	79254762	rs12730292	Bipolar disorder	Intergenic	1.10	5E-6
chr1	80134122	80134123	rs7533906	Bipolar disorder and schizophrenia	FAM69A	1.30	4E-6
chr1	80243000	80243001	rs12024204	Endometriosis	Intergenic	1.22	6E-6
chr1	80734580	80734581	rs11162963	Aging (time to event)	ELTD1	1.09	4E-6
chr1	82074851	82074852	rs11809789	Bilirubin levels	RP5-837I24.4	.40	6E-6
chr1	82247247	82247248	rs11163372	Temperament	LPHN2	.19	3E-6
chr1	83054798	83054799	rs10874322	Response to taxane treatment (docetaxel)	TTLL7	NR	2E-6
chr1	83311834	83311835	rs11163585	Response to antipsychotic treatment	Intergenic	NR	9E-7
chr1	83489843	83489844	rs12742923	HIV-associated dementia	Intergenic	NR	8E-7
chr1	84254550	84254551	rs7552393	Select biomarker traits	Intergenic	NR	5E-7
chr1	84254734	84254735	rs7539409	Alzheimer's disease	TTLL7	NR	1E-6
chr1	84622512	84622513	rs903263	Breast cancer (male)	PRKACB	1.27	1E-6
chr1	84761347	84761348	rs1085093	Metabolic syndrome	GLTP	NR	3E-6
chr1	84865229	84865230	rs12144715	Response to hepatitis C treatment	DNASE2B	.64	7E-6
chr1	85226298	85226299	rs1750491	Dental caries	LPAR3	NR	2E-6
chr1	85268242	85268243	rs10782529	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	EDG7	1.70	4E-6
chr1	85290408	85290409	rs9728717	Economic and political preferences (time)	EDG7	.14	9E-6
chr1	85311191	85311192	rs1983853	Type 1 diabetes	EDG7	1.20	2E-6
chr1	85772008	85772009	rs233100	Multiple sclerosis	DDAH1	1.08	1E-6
chr1	87613357	87613358	rs7553864	Smoking behavior	AK002179	.08	3E-6
chr1	87705030	87705031	rs6576878	White blood cell types	LMO4	.05	6E-6
chr1	88132379	88132380	rs983332	Response to TNF antagonist treatment	LMO4	NR	5E-6
chr1	88625635	88625636	rs12032672	Periodontal microbiota	PKN2	1.99	1E-6
chr1	88802011	88802012	rs2179965	Cognitive test performance	Intergenic	NR	1E-6
chr1	89123442	89123443	rs6699417	Height	PKN2	.02	5E-9
chr1	89146233	89146234	rs12145922	Liver enzyme levels (gamma-glutamyl transferase)	CCBL2, PKN2	2.80	4E-11
chr1	90875887	90875888	rs2136093	Response to antidepressants	Intergenic	8.30	4E-7
chr1	90943906	90943907	rs2390582	Coronary artery calcification	Intergenic	NR	1E-6
chr1	91288129	91288130	rs3843306	Pulmonary function decline	Intergenic	.18	5E-6
chr1	91569688	91569689	rs164898	Metabolic syndrome	ZNF644	NR	6E-6
chr1	92077096	92077097	rs1192415	Optic disc parameters	CDC7, TGFBR3	.10	8E-17
chr1	92077096	92077097	rs1192415	Optic disc parameters	CDC7,TGFBR3	.06	3E-28
chr1	92077096	92077097	rs1192415	Optic disc size (disc)	HSP90B3P	.25	3E-7
chr1	92211019	92211020	rs17131547	Bone mineral density	TGFBR3	1.20	1E-6
chr1	93009437	93009438	rs7515577	Cholesterol, total	GVI1,EVI5	1.18	3E-8
chr1	93148376	93148377	rs11810217	Multiple sclerosis	EVI5	1.15	6E-15
chr1	93303602	93303603	rs6604026	Multiple sclerosis	EVI5, RPL5	1.17	3E-6
chr1	93303602	93303603	rs6604026	Multiple sclerosis	RPL5	1.15	8E-6
chr1	93323970	93323971	rs10874746	Height	RPL5	.02	7E-11
chr1	93401836	93401837	rs12745968	Bipolar disorder and schizophrenia	NR	1.25	8E-7
chr1	94462768	94462769	rs17110736	Dialysis-related mortality	ABCA4	2.08	5E-6
chr1	94553437	94553438	rs560426	Orofacial clefts	NR	1.42	3E-12
chr1	94553437	94553438	rs560426	Orofacial clefts	IRF6	NR	5E-10
chr1	94611299	94611300	rs2774920	D-dimer levels	ABCA4, ARHGAP29	.05	1E-6
chr1	95053352	95053353	rs12029080	D-dimer levels	F3	10.40	6E-52
chr1	95070040	95070041	rs7542900	Type 2 diabetes	SLC44A3, F3	1.16	6E-6
chr1	95549535	95549536	rs9437689	Phospholipid levels (plasma)	ALG14	.70	5E-8
chr1	95692309	95692310	rs1414896	Non-alcoholic fatty liver disease histology (AST)	Intergenic	.26	2E-6
chr1	96145967	96145968	rs6693882	Pain	NR	NR	2E-6
chr1	96943993	96943994	rs1973993	Weight	NR	2.71	1E-6
chr1	96944796	96944797	rs1555543	Body mass index	PTBP2	.06	4E-10
chr1	97037082	97037083	rs10783050	Body mass index	NR	2.60	4E-6
chr1	97113914	97113915	rs12071951	Schizophrenia	PTBP2	1.14	5E-7
chr1	97164342	97164343	rs7544736	Schizophrenia	PTBP2	1.25	6E-7
chr1	97819666	97819667	rs11165846	Platelet counts	DPYD	NR	9E-6
chr1	98502933	98502934	rs1625579	Schizophrenia	MIR137	1.12	2E-11
chr1	98552831	98552832	rs1198588	Schizophrenia	has-mir-137, DPYD	1.12	5E-7
chr1	99177252	99177253	rs9727115	Proinsulin levels	SNX7	NR	2E-7
chr1	99348835	99348836	rs11166135	Dental caries	LPPR5	NR	1E-6
chr1	99524046	99524047	rs10747502	Myopia (pathological)	LOC100129620	NR	1E-9
chr1	100049784	100049785	rs7543130	Aortic root size	PALMD	.03	1E-7
chr1	100335976	100335977	rs17121403	Pulmonary function decline	Intergenic	.83	7E-6
chr1	101331535	101331536	rs12048904	Multiple sclerosis	EXTL2, VCAM1	1.09	4E-8
chr1	101331535	101331536	rs12048904	Multiple sclerosis	EXTL2	1.09	4E-8
chr1	101407518	101407519	rs11581062	Multiple sclerosis	SLC30A7, VCAM1	1.12	3E-10
chr1	101551925	101551926	rs17410015	Response to antipsychotic treatment	Intergenic	NR	2E-6
chr1	101938476	101938477	rs1948368	Bipolar disorder	NR	1.15	6E-6
chr1	103133908	103133909	rs10874639	Protein quantitative trait loci	COL11A1	NR	3E-6
chr1	103379917	103379918	rs3753841	Glaucoma (primary open-angle)	COL11A1	1.20	9E-10
chr1	104852737	104852738	rs10881542	Glaucoma (primary open-angle)	NR	1.18	2E-6
chr1	107336300	107336301	rs12097821	Non-obstructive azoospermia	PRMT6	1.25	6E-10
chr1	107432575	107432576	rs12726652	Working memory	Intergenic	NR	5E-7
chr1	107463642	107463643	rs12125971	Intelligence	PRMT6	6.93	7E-6
chr1	107546374	107546375	rs17496332	Sex hormone-binding globulin levels	PRMT6	.03	2E-7
chr1	107546374	107546375	rs17496332	Sex hormone-binding globulin levels	PRMT6	.03	1E-11
chr1	107577831	107577832	rs4118325	AIDS	Intergenic	4.17	6E-7
chr1	107830857	107830858	rs10494067	Anorexia nervosa	NTNG1	NR	6E-6
chr1	108366015	108366016	rs4915077	Hypothyroidism	VAV3	1.30	8E-10
chr1	109817191	109817192	rs7528419	Lipoprotein-associated phospholipase A2 activity and mass	CELSR2	.04	1E-17
chr1	109817589	109817590	rs12740374	Lipoprotein-associated phospholipase A2 activity and mass	SORT1	.03	2E-22
chr1	109817589	109817590	rs12740374	Coronary heart disease	CELSR2	.18	9E-29
chr1	109817589	109817590	rs12740374	LDL cholesterol	CELSR2, PSRC1, SORT1	.23	2E-42
chr1	109817837	109817838	rs660240	Cardiovascular disease risk factors	CELSR2	.17	2E-22
chr1	109817837	109817838	rs660240	LDL cholesterol	CELSR2	.04	1E-26
chr1	109818305	109818306	rs629301	LDL cholesterol	CELSR2,PSRC1,SORT1	5.65	1E-170
chr1	109818305	109818306	rs629301	Cholesterol, total	CELSR2,PSRC1,SORT1	5.41	6E-131
chr1	109818529	109818530	rs646776	Coronary heart disease	CELSR2, PSRC1, SORT1	1.14	6E-10
chr1	109818529	109818530	rs646776	Progranulin levels	SORT1,CELSR2,PSRC1	.18	2E-30
chr1	109818529	109818530	rs646776	Response to statin therapy	CELSR2,PSRC1, SORT1	NR	4E-6
chr1	109818529	109818530	rs646776	Myocardial infarction (early onset)	CELSR2, PSRC1, SORT1	1.19	8E-12
chr1	109818529	109818530	rs646776	LDL cholesterol	CELSR2	.16	8E-23
chr1	109818529	109818530	rs646776	Cholesterol, total	CELSR2	.13	9E-22
chr1	109818529	109818530	rs646776	LDL cholesterol	CELSR2, PSRC1, SORT1	.16	2E-12
chr1	109818529	109818530	rs646776	LDL cholesterol	CELSR2,PSRC1,SORT1	.16	3E-29
chr1	109822165	109822166	rs599839	Metabolite levels	CELSR2, PSRC1, SORT1	5.23	2E-19
chr1	109822165	109822166	rs599839	Coronary heart disease	SORT1	1.11	3E-10
chr1	109822165	109822166	rs599839	Lipoprotein-associated phospholipase A2 activity and mass	PSRC1	5.50	3E-15
chr1	109822165	109822166	rs599839	LDL cholesterol	CELSR2,PSRC1	.16	1E-33
chr1	109822165	109822166	rs599839	LDL cholesterol	CELSR2,PSRC1,SORT1	5.48	6E-33
chr1	109822165	109822166	rs599839	LDL cholesterol	CELSR2,PSRC1	.95	1E-7
chr1	109822165	109822166	rs599839	Coronary heart disease	PSRC1	1.29	4E-9
chr1	109999837	109999838	rs1933182	Chronic kidney disease	SYPL2,ATXN7L2,CYB561D1,PSMA5,AMIGO1,SORT1	.01	1E-7
chr1	110031187	110031188	rs12049330	Major depressive disorder	ATXN7L2, SYPL2, CYB561D1	1.44	6E-6
chr1	110119731	110119732	rs6537837	Major depressive disorder	GNAT2, GNAI3, AMPD2	1.43	1E-6
chr1	110352476	110352477	rs10494112	Paget's disease	CSF1, EPS8LS	1.72	7E-35
chr1	110366082	110366083	rs484959	Paget's disease	CSF1	1.82	5E-24
chr1	110645326	110645327	rs17025426	Visceral adipose tissue/subcutaneous adipose tissue ratio	UBL4B, FAM40A, SLC6A17, ALX3	NR	2E-6
chr1	110770222	110770223	rs958798	Self-rated health	KCNC4	.03	4E-7
chr1	111033808	111033809	rs4839431	Immune reponse to smallpox (secreted IFN-alpha)	CYMP	NR	2E-7
chr1	111237684	111237685	rs12061304	Panic disorder	Intergenic	NR	1E-6
chr1	111417914	111417915	rs2885805	Cytomegalovirus antibody response	CD53	.21	5E-6
chr1	111684275	111684276	rs1335645	Liver enzyme levels (gamma-glutamyl transferase)	CEPT1, DENND2D	4.30	7E-9
chr1	112192121	112192122	rs494453	Osteoporosis	RAP1A	NR	4E-8
chr1	112392359	112392360	rs12044963	Immune reponse to smallpox (secreted IFN-alpha)	KCND3	NR	9E-10
chr1	112437343	112437344	rs2798334	Visceral adipose tissue adjusted for BMI	KCND3	NR	1E-6
chr1	112464375	112464376	rs17029069	Cardiac repolarization	KCND3	1.29	8E-6
chr1	112856569	112856570	rs7555668	Cognitive performance	RP5-965F6.2	NR	3E-6
chr1	113190806	113190807	rs17030613	Blood pressure	ST7L, CAPZA1	.49	8E-6
chr1	113190806	113190807	rs17030613	Blood pressure	ST7L, CAPZA1	.38	1E-8
chr1	113216542	113216543	rs2932538	Systolic blood pressure	MOV10	.39	1E-9
chr1	113216542	113216543	rs2932538	Hypertension	MOV10	.05	3E-7
chr1	113216542	113216543	rs2932538	Diastolic blood pressure	MOV10	.24	1E-9
chr1	113216542	113216543	rs2932538	Blood pressure	MOV10	.25	8E-6
chr1	113313562	113313563	rs11590090	Hyperactive-impulsive symptoms	Intergenic	NR	3E-6
chr1	114303807	114303808	rs6679677	Hypothyroidism	PHTF1, RSBN1, PTPN22	1.36	3E-13
chr1	114303807	114303808	rs6679677	Type 1 diabetes	PTPN22	NR	1E-40
chr1	114303807	114303808	rs6679677	Rheumatoid arthritis	PTPN22	1.79	6E-42
chr1	114303807	114303808	rs6679677	Type 1 diabetes	PTPN22	1.82	5E-26
chr1	114303807	114303808	rs6679677	Rheumatoid arthritis	PTPN22	1.98	6E-25
chr1	114303807	114303808	rs6679677	Type 1 diabetes	PHTF1, PTPN22	1.89	8E-24
chr1	114377567	114377568	rs2476601	Myasthenia gravis	PTPN22	1.71	8E-10
chr1	114377567	114377568	rs2476601	Type 1 diabetes autoantibodies	PTPN22	2.00	2E-111
chr1	114377567	114377568	rs2476601	Crohn's disease	PTPN22	1.26	4E-9
chr1	114377567	114377568	rs2476601	Rheumatoid arthritis	PTPN22	1.94	9E-74
chr1	114377567	114377568	rs2476601	Vitiligo	PTPN22	1.39	1E-7
chr1	114377567	114377568	rs2476601	Rheumatoid arthritis	PTPN22	NR	2E-21
chr1	114377567	114377568	rs2476601	Type 1 diabetes	PTPN22	NR	9E-85
chr1	114377567	114377568	rs2476601	Crohn's disease	PTPN22	1.31	1E-8
chr1	114377567	114377568	rs2476601	Rheumatoid arthritis	PTPN22	1.72	2E-11
chr1	114377567	114377568	rs2476601	Type 1 diabetes	PTPN22	1.80	1E-7
chr1	114377567	114377568	rs2476601	Type 1 diabetes	PTPN22	1.98	2E-80
chr1	114715583	114715584	rs2774292	Bipolar disorder and schizophrenia	NR	2.09	3E-6
chr1	115734090	115734091	rs195204	Alcoholism (heaviness of drinking)	Intergenic	.10	9E-6
chr1	115875644	115875645	rs4332358	Bipolar disorder and schizophrenia	NR	1.26	5E-6
chr1	116310966	116310967	rs4074536	Ventricular conduction	CASQ2	.42	2E-8
chr1	117038286	117038287	rs12025416	Multiple sclerosis	CD58	1.45	1E-7
chr1	117100956	117100957	rs1335532	Multiple sclerosis	CD58	1.22	3E-16
chr1	117100956	117100957	rs1335532	Multiple sclerosis	CD58	1.28	1E-7
chr1	117104214	117104215	rs2300747	Multiple sclerosis	CD58	1.37	6E-9
chr1	117104214	117104215	rs2300747	Multiple sclerosis	CD58	1.30	3E-10
chr1	117469780	117469781	rs2806864	Erectile dysfunction and prostate cancer treatment	PTGFRN	6.42	6E-7
chr1	117751364	117751365	rs12046117	Arthritis (juvenile idiopathic)	VTCN1	1.58	1E-6
chr1	118855586	118855587	rs9428104	Height	SPAG17	.04	6E-23
chr1	118868404	118868405	rs17038182	Height	Intergenic	.30	5E-7
chr1	118883972	118883973	rs12735613	Height	SPAG17	.08	4E-11
chr1	119503842	119503843	rs984222	Waist-hip ratio	TBX15, WARS2	.03	9E-25
chr1	120257575	120257576	rs477992	Metabolic traits	PHGDH	.05	3E-14
chr1	120517958	120517959	rs10923931	Type 2 diabetes	NOTCH2, ADAM30	1.13	4E-8
chr1	121200489	121200490	rs6600671	Hip geometry	Intergenic	NR	6E-7
chr1	121280612	121280613	rs11249433	Breast cancer	Intergenic	1.16	7E-10
chr1	144992180	144992181	rs2863344	Capecitabine sensitivity	PDE4DIP	NR	2E-6
chr1	145395603	145395604	rs12091564	Coronary heart disease	HFE2	NR	2E-7
chr1	145416055	145416056	rs10218795	Coronary heart disease	HFE2	NR	2E-7
chr1	145723644	145723645	rs1967017	Urate levels	PDZK1	3.33	4E-8
chr1	145725688	145725689	rs12129861	Uric acid levels	PDZK1	.06	3E-9
chr1	146508933	146508934	rs12122100	HIV-1 control	NR	NR	1E-6
chr1	146560563	146560564	rs11239930	AIDS progression	NBPF14	1.47	2E-6
chr1	146854835	146854836	rs4950322	Protein quantitative trait loci	CHD1L	NR	7E-7
chr1	146854835	146854836	rs4950322	Protein quantitative trait loci	CHD1L	NR	2E-7
chr1	147226790	147226791	rs1891498	Cognitive performance	GJA5	NR	9E-6
chr1	149892871	149892872	rs11205277	Height	SF3B4	.05	5E-32
chr1	149892871	149892872	rs11205277	Height	Histone class 2A,MTMR11, SV2A, SF3B4	5.10	1E-10
chr1	150860470	150860471	rs7412746	Melanoma	ARNT, SETDB1, LASS2, ANXA9, MCL1, CTSK	1.15	9E-11
chr1	150951476	150951477	rs267734	Chronic kidney disease	ANXA9,FAM63A,PRUNE,BNIPL,LASS2,SETDB1	.01	1E-12
chr1	150961868	150961869	rs1722784	Melanoma	ANXA9	1.12	2E-6
chr1	151895092	151895093	rs10788819	Hair morphology	AL450992.4	NR	2E-8
chr1	152037514	152037515	rs3124314	Hair morphology	AL591893.2	NR	4E-6
chr1	152062766	152062767	rs17646946	Common traits (Other)	TCHH	.29	2E-42
chr1	152083324	152083325	rs11803731	Hair morphology	TCHH	6.11	3E-31
chr1	152300816	152300817	rs3126085	Atopic dermatitis	FLG	1.22	6E-12
chr1	152316589	152316590	rs3120665	Personality dimensions	Intergenic	.14	4E-6
chr1	152454590	152454591	rs908922	Hair morphology	LCE5A	NR	4E-6
chr1	152492558	152492559	rs4845783	Asthma	CRCT1	NR	6E-6
chr1	152493153	152493154	rs499697	Common traits (Other)	LCE3E	.13	1E-10
chr1	152537953	152537954	rs10888501	Response to antipsychotic treatment	Intergenic	9.00	1E-6
chr1	152550017	152550018	rs4085613	Psoriasis	LCE3D, LCE3A	1.32	7E-30
chr1	152551275	152551276	rs4112788	Psoriasis	LCE3D	1.29	3E-10
chr1	153479997	153479998	rs4845552	Hippocampal atrophy	S100A5	NR	6E-6
chr1	153769399	153769400	rs9426935	Lentiform nucleus volume	LOC343052	96.63	5E-6
chr1	153774275	153774276	rs4434872	Conduct disorder (symptom count)	LOC343052	.08	8E-6
chr1	153848995	153848996	rs7414227	Lentiform nucleus volume	GATAD2B	99.50	3E-6
chr1	153913769	153913770	rs2252508	Lentiform nucleus volume	DENND4B	97.78	5E-6
chr1	153939129	153939130	rs11264736	Lentiform nucleus volume	SLC39A1	98.69	4E-6
chr1	154418878	154418879	rs4537545	C-reactive protein	IL6R	11.50	2E-14
chr1	154426263	154426264	rs4129267	Asthma	IL6R	1.09	2E-8
chr1	154426263	154426264	rs4129267	C-reactive protein	IL6R	.08	2E-48
chr1	154426263	154426264	rs4129267	Protein quantitative trait loci	IL6R	NR	2E-57
chr1	154426263	154426264	rs4129267	Pulmonary function	IL6R	NR	7E-6
chr1	154437895	154437896	rs2229238	Coronary heart disease	ILR6	1.45	7E-7
chr1	154814267	154814268	rs6666258	Atrial fibrillation	KCNN3, PMVK	1.18	2E-14
chr1	154814352	154814353	rs13376333	Atrial fibrillation	KCNN3	1.52	2E-21
chr1	155108166	155108167	rs12726330	Parkinson's disease	GBA	1.71	5E-8
chr1	155126947	155126948	rs10908458	Liver enzyme levels (gamma-glutamyl transferase)	DPM3, EFNA1, PKLR	3.70	2E-15
chr1	155162066	155162067	rs4072037	Esophageal cancer and gastric cancer	NR	1.33	4E-7
chr1	155162066	155162067	rs4072037	Magnesium levels	MUC1	.01	2E-36
chr1	155194979	155194980	rs2049805	Renal function-related traits (BUN)	MTX1, GBA	.01	2E-12
chr1	155868624	155868625	rs2282301	Conduct disorder (interaction)	RIT1	2.88	7E-6
chr1	155927751	155927752	rs2364403	Amyotrophic lateral sclerosis (age of onset)	ARHGEF2	NR	1E-6
chr1	156030036	156030037	rs34372695	Parkinson's disease	SYT11	1.47	4E-12
chr1	156341493	156341494	rs7525133	Visceral adipose tissue adjusted for BMI	RHBG	NR	5E-6
chr1	156356479	156356480	rs6686886	Subcutaneous adipose tissue	CCT3, C1orf182, C1orf61, RHBG	NR	9E-6
chr1	156456300	156456301	rs3790455	Migraine	MEF2D	1.20	7E-11
chr1	156869046	156869047	rs12566888	Platelet aggregation	PEAR1	NR	5E-19
chr1	156869046	156869047	rs12566888	Platelet aggregation	PEAR1	NR	4E-16
chr1	157130565	157130566	rs6427356	Attention deficit hyperactivity disorder and conduct disorder	ETV3L, ETV3	NR	8E-6
chr1	157437509	157437510	rs6686423	Renal sinus fat	FCRL5	.19	8E-6
chr1	157669277	157669278	rs3761959	Graves' disease	FCRL3	1.23	2E-13
chr1	157669277	157669278	rs3761959	Multiple sclerosis	FCRL3	1.08	3E-6
chr1	157670815	157670816	rs7528684	Type 1 diabetes autoantibodies	FCRL3	1.52	1E-11
chr1	158585414	158585415	rs2779116	Glycated hemoglobin levels	SPTA1	.02	3E-9
chr1	158612547	158612548	rs857721	Other erythrocyte phenotypes	SPTA1	.00	1E-10
chr1	158932554	158932555	rs1101999	Asthma	PYHIN1	NR	4E-9
chr1	159005648	159005649	rs1772408	Celiac disease and Rheumatoid arthritis	IFI16	NR	8E-7
chr1	159147451	159147452	rs3026968	Inflammatory biomarkers	CADM3	NR	9E-14
chr1	159148512	159148513	rs1474747	Select biomarker traits	IGSF4B	NR	3E-6
chr1	159173886	159173887	rs3027009	Lean body mass and age at menarche (combined)	DARC	NR	7E-7
chr1	159174682	159174683	rs2814778	White blood cell count	DARC	1.35	7E-55
chr1	159174682	159174683	rs2814778	Neutrophil count	DARC	NR	1E-8
chr1	159175353	159175354	rs12075	Monocyte chemoattractant protein-1	DARC	NR	1E-21
chr1	159175353	159175354	rs12075	Inflammatory biomarkers	DARC	NR	4E-51
chr1	159175353	159175354	rs12075	White blood cell count	DARC	1.27	5E-24
chr1	159175526	159175527	rs13962	IgE levels	DARC	.09	2E-11
chr1	159196764	159196765	rs10489849	Select biomarker traits	IGSF4B	NR	1E-6
chr1	159218265	159218266	rs3845624	Inflammatory biomarkers	DARC	NR	2E-11
chr1	159272059	159272060	rs2251746	IgE levels	FCER1A	.09	5E-26
chr1	159272059	159272060	rs2251746	IgE levels	FCER1A	19.20	2E-20
chr1	159278250	159278251	rs2494250	Select biomarker traits	FCER1A,OR10J3	NR	1E-14
chr1	159326879	159326880	rs4656784	IgE levels	OR10J3	.08	2E-16
chr1	159342438	159342439	rs6687840	Chemerin levels	OR10J3	NR	7E-6
chr1	159357683	159357684	rs4446959	Chemerin levels	OR10J1	NR	8E-6
chr1	159405958	159405959	rs4128725	Select biomarker traits	OR10J1	NR	4E-12
chr1	159453936	159453937	rs4133289	Hemostatic factors and hematological phenotypes	OR10J1,OR10J5	NR	2E-7
chr1	159647987	159647988	rs12093699	Protein quantitative trait loci	CRP	NR	6E-6
chr1	159655517	159655518	rs726640	C-reactive protein	CRPP1, CRP	.44	2E-13
chr1	159674932	159674933	rs876537	C-reactive protein	CRP	.29	1E-9
chr1	159678815	159678816	rs2794520	C-reactive protein	CRP	.16	2E-186
chr1	159678815	159678816	rs2794520	Metabolic traits	CRP	.47	3E-22
chr1	159678815	159678816	rs2794520	Select biomarker traits	CRP	NR	3E-8
chr1	159680867	159680868	rs2808630	Lung cancer	CRP	1.22	7E-6
chr1	159684664	159684665	rs3091244	C-reactive protein	CRP	.20	6E-28
chr1	159685135	159685136	rs3093059	C-reactive protein	CRP	.16	4E-21
chr1	159691558	159691559	rs1341665	Inflammatory biomarkers	CRP	NR	2E-20
chr1	159692572	159692573	rs2808634	C-reactive protein	CRP, APCS, DARC, FCER1A, DUSP23, OR10J1, OR10J5, OR10J3, OLFML2B, IFI16, FCRL6	.15	3E-10
chr1	159698548	159698549	rs7553007	C-reactive protein	CRP, APCS, DARC, FCER1A, DUSP23, OR10J1, OR10J5, OR10J3, OLFML2B, IFI16, FCRL6	.27	1E-37
chr1	159698548	159698549	rs7553007	C-reactive protein	CRP	.13	1E-9
chr1	159698548	159698549	rs7553007	C-reactive protein	CRP	20.70	8E-44
chr1	159700038	159700039	rs11265260	C-reactive protein	CRP	NR	7E-6
chr1	159710516	159710517	rs11265263	Vaccine-related adverse events	Intergenic	NR	3E-6
chr1	159753182	159753183	rs4233356	Interstitial lung disease	DUSP23	2.51	9E-6
chr1	160421915	160421916	rs16832015	Cognitive performance	VANGL2	NR	2E-6
chr1	160630142	160630143	rs11265461	Schizophrenia (treatment refractory)	SLAMF1	1.45	2E-7
chr1	160746075	160746076	rs576523	Capecitabine sensitivity	Intergenic	NR	2E-7
chr1	160830267	160830268	rs4656940	Crohn's disease	CD244,ITLN1	1.15	6E-7
chr1	160852045	160852046	rs2274910	Crohn's disease	ITLN1	1.14	1E-9
chr1	160864220	160864221	rs2199936	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	ABCG2	2.80	2E-10
chr1	160864220	160864221	rs2199936	Cardiovascular disease risk factors	ABCG2	.19	2E-17
chr1	160864220	160864221	rs2199936	Urate levels	ABCG2	1.86	3E-23
chr1	160864220	160864221	rs2199936	Urate levels	ABCG2	18.08	1E-75
chr1	161272440	161272441	rs4657015	Visceral adipose tissue adjusted for BMI	LOC642502, PCP4L1, MPZ, SDHC	NR	8E-6
chr1	161472157	161472158	rs10800309	Ulcerative colitis	FCGR2A,FCGR2C	1.20	3E-9
chr1	161479744	161479745	rs1801274	Kawasaki disease	FCGR2A	1.32	7E-11
chr1	161479744	161479745	rs1801274	Ulcerative colitis	FCGR2A, FCGR2B, HSPA6	1.21	2E-20
chr1	161479744	161479745	rs1801274	Ulcerative colitis	FCGR2A	1.59	2E-12
chr1	161540856	161540857	rs67418890	Lipid metabolism phenotypes	FCGR2B, FCGR2A	.19	1E-10
chr1	161915500	161915501	rs10918270	Parkinson's disease (age of onset)	ATF6	2.26	8E-6
chr1	162014631	162014632	rs2880058	QT interval	NOS1AP	.19	2E-10
chr1	162033889	162033890	rs12143842	QT interval	NOS1AP	3.14	2E-15
chr1	162033889	162033890	rs12143842	QT interval	OLFML2B, NOS1AP	.18	1E-83
chr1	162033889	162033890	rs12143842	QT interval	NOS1AP	2.88	2E-78
chr1	162033889	162033890	rs12143842	QT interval	NOS1AP	3.15	2E-78
chr1	162085308	162085309	rs1415259	Electrocardiographic traits	NOS1AP	2.53	7E-10
chr1	162085684	162085685	rs10494366	Electrocardiographic traits	NOS1AP	12.20	5E-22
chr1	162085684	162085685	rs10494366	QT interval	NOS1AP	4.90	1E-10
chr1	162112909	162112910	rs16857031	QT interval	NOS1AP	2.63	1E-34
chr1	162133116	162133117	rs12029454	QT interval	NOS1AP	2.98	3E-45
chr1	162195737	162195738	rs4657175	QT interval	NOS1AP	1.71	1E-9
chr1	162210609	162210610	rs4657178	QT interval	NOS1AP	2.19	7E-33
chr1	163956502	163956503	rs424950	Sex hormone-binding globulin levels	Intergenic	.08	5E-6
chr1	164739170	164739171	rs6670655	Height	PBX1	1.26	3E-6
chr1	165180088	165180089	rs1532815	Response to acetaminophen (hepatotoxicity)	LMX1A	NR	6E-7
chr1	165394881	165394882	rs466639	Menarche (age at onset)	RXRG	4.20	1E-13
chr1	165403902	165403903	rs285480	Personality dimensions	RXRG	NR	4E-7
chr1	165409094	165409095	rs10800098	AIDS	RXRG	3.29	4E-6
chr1	165448156	165448157	rs10918196	Lentiform nucleus volume	LOC400794	93.94	9E-6
chr1	165616587	165616588	rs6686643	Total ventricular volume	MGST3	.00	7E-6
chr1	165687204	165687205	rs4656461	Glaucoma	TMCO1	1.51	6E-14
chr1	165718978	165718979	rs7555523	Intraocular pressure	TMCO1	.28	2E-8
chr1	165831648	165831649	rs4657482	Testicular germ cell tumor	Intergenic	1.14	2E-6
chr1	167156499	167156500	rs9803659	Liver enzyme levels	POU2F1	.03	4E-6
chr1	167408669	167408670	rs840016	Rheumatoid arthritis	CD247	1.11	2E-6
chr1	167411383	167411384	rs864537	Celiac disease and Rheumatoid arthritis	CD247	NR	2E-11
chr1	167411383	167411384	rs864537	Celiac disease	CD247	1.10	4E-7
chr1	167420424	167420425	rs2056626	Systemic sclerosis	CD247	1.23	3E-6
chr1	167420424	167420425	rs2056626	Systemic sclerosis	CD247	1.20	1E-6
chr1	167420424	167420425	rs2056626	Systemic sclerosis	CD247	1.16	3E-9
chr1	167718498	167718499	rs4145462	Alzheimer's disease (late onset)	MPZL1	NR	1E-6
chr1	167903078	167903079	rs10489202	Schizophrenia	BRP44, DCAF6	1.23	1E-8
chr1	168618640	168618641	rs1412337	Morbidity-free survival	DPT	NR	2E-9
chr1	169073345	169073346	rs1320976	QT interval	ATP1B1	2.06	2E-10
chr1	169099482	169099483	rs10919071	QT interval	ATP1B1	2.05	1E-15
chr1	169135126	169135127	rs16861990	Venous thromboembolism	NME7	2.02	2E-12
chr1	169135126	169135127	rs16861990	D-dimer levels	NME7	.06	2E-6
chr1	169477573	169477574	rs6687813	D-dimer levels	F5	10.10	2E-14
chr1	169491554	169491555	rs2420371	Hemostatic factors and hematological phenotypes	F5	1.16	4E-80
chr1	169514005	169514006	rs1018827	Venous thromboembolism	F5, SLC19A2, NME7	2.52	2E-26
chr1	169519048	169519049	rs6025	Venous thromboembolism	F5	3.57	2E-22
chr1	169550962	169550963	rs6703865	Hippocampal atrophy	F5, SELP	NR	1E-9
chr1	169551681	169551682	rs6028	Activated partial thromboplastin time	F5, SELP	.23	3E-9
chr1	169563950	169563951	rs6136	Soluble levels of adhesion molecules	SELP	22.60	4E-61
chr1	169580289	169580290	rs2235302	Soluble levels of adhesion molecules	SELP	7.30	4E-16
chr1	169608916	169608917	rs1569476	Total ventricular volume	SELP	.00	3E-7
chr1	169995801	169995802	rs1541160	Amyotrophic lateral sclerosis	KIFAP3	.58	2E-8
chr1	170569316	170569317	rs3903239	Atrial fibrillation	PRRX1	1.14	8E-14
chr1	170633895	170633896	rs659580	Response to angiotensin II receptor blocker therapy	PRRX1	1.28	1E-6
chr1	171091874	171091875	rs1795240	Lentiform nucleus volume	FMO3, FMO6P	112.27	5E-8
chr1	171261192	171261193	rs6660565	Sudden cardiac arrest	FMO1	1.12	2E-6
chr1	171949749	171949750	rs10914144	Platelet counts	DNM3	3.42	2E-12
chr1	171949749	171949750	rs10914144	Mean platelet volume	DNM3	.01	1E-24
chr1	171949749	171949750	rs10914144	Mean platelet volume	DNM3	.01	2E-14
chr1	172053286	172053287	rs17346452	Height	DNM3	.04	1E-23
chr1	172189888	172189889	rs678962	Height	DNM3	5.40	3E-8
chr1	172241250	172241251	rs2421992	Height	DNM3	NR	5E-8
chr1	172346547	172346548	rs1011731	Waist-hip ratio	DNM3, PIGC	.03	1E-17
chr1	172710999	172711000	rs859637	Celiac disease	FASLG, TNFSF18, TNFSF4	1.10	2E-6
chr1	172853459	172853460	rs7517810	Crohn's disease	TNFSF18,TNFSF4,FASLG	1.22	2E-15
chr1	172862233	172862234	rs9286879	Crohn's disease	Intergenic	1.19	2E-9
chr1	172898376	172898377	rs12035082	Crohn's disease	Intergenic	1.14	2E-7
chr1	173191474	173191475	rs2205960	Systemic lupus erythematosus	TNFSF4	1.46	3E-32
chr1	173301515	173301516	rs1342038	Diabetic retinopathy	TNFSF4, LOC730070	1.49	4E-6
chr1	173309712	173309713	rs10798269	Systemic lupus erythematosus	Intergenic	1.22	1E-7
chr1	175120078	175120079	rs6701037	Alcohol dependence	KIAA0040	NR	2E-7
chr1	175296447	175296448	rs3766680	Tonometry	TNR	NR	4E-6
chr1	176792248	176792249	rs1325598	Height	PAPPA2	.02	1E-9
chr1	177852579	177852580	rs633715	Menarche (age at onset)	SEC16B	2.60	2E-8
chr1	177855516	177855517	rs516636	Body mass index	SEC16B	.05	3E-9
chr1	177889479	177889480	rs543874	Body mass index	SEC16B	.22	4E-23
chr1	177913518	177913519	rs10913469	Weight	SEC16B, RASAL2	3.82	1E-8
chr1	177913518	177913519	rs10913469	Body mass index	SEC16B, RASAL2	3.36	6E-8
chr1	178142207	178142208	rs316274	Immune response to smallpox vaccine (IL-6)	RASAL2	NR	8E-7
chr1	179071755	179071756	rs1325195	IgE grass sensitization	ABL2	1.17	5E-6
chr1	179469313	179469314	rs12047808	Multiple sclerosis (age of onset)	C1orf125	NR	6E-6
chr1	180962281	180962282	rs1411478	Progressive supranuclear palsy	STX6	1.27	4E-11
chr1	182168884	182168885	rs1689800	HDL cholesterol	ZNF648	.47	3E-10
chr1	183170947	183170948	rs1028771	Coronary heart disease	LAMC2	.22	4E-6
chr1	183176429	183176430	rs525410	Systemic lupus erythematosus	LAMC2	1.33	6E-7
chr1	183837031	183837032	rs4651156	Response to antidepressants	RGL1	12.60	3E-6
chr1	183852913	183852914	rs10797919	Attention deficit hyperactivity disorder and conduct disorder	RGL1, GLT25D2	NR	9E-6
chr1	184002873	184002874	rs756199	Height	GLT25D2	.05	7E-6
chr1	184020944	184020945	rs2274432	Height	C1orf19,GLT25D2	5.30	8E-9
chr1	184023528	184023529	rs1046934	Height	TSEN15	.04	2E-31
chr1	186632316	186632317	rs10911902	Schizophrenia	Intergenic	1.79	2E-6
chr1	186725002	186725003	rs4140564	Knee osteoarthritis	PTGS2, PLA2G4A	1.59	3E-6
chr1	186870071	186870072	rs12720541	Epilepsy (generalized)	PLA2G4A	1.21	9E-6
chr1	187902980	187902981	rs655167	Hypothyroidism	LOC100129274	1.26	7E-6
chr1	188379427	188379428	rs12125250	Economic and political preferences	Intergenic	.12	4E-6
chr1	189589338	189589339	rs10489759	Immune response to smallpox vaccine (IL-6)	LOC647132	NR	8E-8
chr1	189723622	189723623	rs10737562	Systemic lupus erythematosus	Intergenic	1.30	7E-6
chr1	189861403	189861404	rs1400544	Subclinical atherosclerosis traits (other)	Intergenic	NR	6E-6
chr1	190066385	190066386	rs1935881	Echocardiographic traits	FAM5C	NR	6E-6
chr1	190841672	190841673	rs2053302	Response to statin therapy	FAM5C,LOC647132	NR	4E-6
chr1	191559355	191559356	rs10801047	Crohn's disease	Intergenic	1.47	3E-8
chr1	192431997	192431998	rs12067906	Blood pressure	RGS21, PPP3CA	NR	9E-7
chr1	192536812	192536813	rs2816316	Celiac disease	RGS1	1.25	2E-17
chr1	192536812	192536813	rs2816316	Celiac disease	RGS1	1.39	3E-11
chr1	192541020	192541021	rs1323292	Multiple sclerosis	RGS1	1.12	2E-8
chr1	192995212	192995213	rs9427573	Cannabis dependence	UCHL5	2.56	5E-6
chr1	193734899	193734900	rs2025934	Subcutaneous adipose tissue	CDC73	NR	3E-6
chr1	193921547	193921548	rs606149	Major depressive disorder	LOC647167	1.25	3E-6
chr1	195531422	195531423	rs1890645	Neonatal lupus	Intergenic	2.98	4E-6
chr1	195914272	195914273	rs7517337	Total ventricular volume	KCNT2	.00	2E-6
chr1	196042661	196042662	rs7512769	Bipolar disorder and schizophrenia	NR	1.29	2E-6
chr1	196620916	196620917	rs3753394	Complement C3 and C4 levels	CFH, CFHR1, CFHR3	.05	7E-11
chr1	196646175	196646176	rs1329424	Age-related macular degeneration	CFH	1.88	6E-16
chr1	196659236	196659237	rs1061170	Age-related macular degeneration (GA)	CFH	2.78	5E-67
chr1	196659236	196659237	rs1061170	Age-related macular degeneration (CNV)	CFH	2.78	1E-108
chr1	196659236	196659237	rs1061170	Age-related macular degeneration	CFH	2.41	1E-261
chr1	196659236	196659237	rs1061170	Age-related macular degeneration	CFH	NR	4E-117
chr1	196660260	196660261	rs10801555	Age-related macular degeneration	CFH	2.33	2E-47
chr1	196679454	196679455	rs10737680	Age-related macular degeneration	CFH	3.11	2E-76
chr1	196686917	196686918	rs6677604	Nephropathy	CFH, CFHR3, CFHR1, CFHR4, CHFR2, CFHR5	1.47	3E-10
chr1	196696932	196696933	rs1410996	Age-related macular degeneration	CFH	NR	2E-111
chr1	196701050	196701051	rs380390	Age-related macular degeneration	CFH	4.60	4E-8
chr1	196702809	196702810	rs1329428	Age-related macular degeneration	CFH	2.78	3E-64
chr1	196760416	196760417	rs426736	Meningococcal disease	CFH,CFHR3	1.59	5E-13
chr1	196844592	196844593	rs6428370	Acute lymphoblastic leukemia (childhood)	Intergenic	1.43	7E-6
chr1	197020657	197020658	rs2990510	Erectile dysfunction	F13B	NR	6E-6
chr1	197325907	197325908	rs2786098	Asthma	DENND1B, CRB1	1.43	2E-13
chr1	197727641	197727642	rs1998598	Crohn's disease	DENND1B	1.04	9E-9
chr1	197781197	197781198	rs12134279	Primary biliary cirrhosis	DENND1B	1.34	2E-14
chr1	199356515	199356516	rs16844716	Dialysis-related mortality	Intergenic	1.65	9E-6
chr1	200007431	200007432	rs3790844	Pancreatic cancer	NR5A2	1.30	2E-10
chr1	200672905	200672906	rs7512898	Electrocardiographic conduction measures	NR	NR	5E-6
chr1	200826768	200826769	rs2292096	Epilepsy	CAMSAP1L1	1.59	1E-8
chr1	200877561	200877562	rs7554511	Ulcerative colitis	C1orf106	1.19	2E-13
chr1	200877561	200877562	rs7554511	Crohn's disease	C1orf106,KIF21B	1.14	2E-7
chr1	200877561	200877562	rs7554511	Ulcerative colitis	KIF21B	NR	1E-6
chr1	200881594	200881595	rs7522462	Multiple sclerosis	C1orf106, KIF21B	1.11	2E-9
chr1	200892136	200892137	rs296547	Celiac disease	Intergenic	1.12	4E-9
chr1	200935865	200935866	rs11584383	Ulcerative colitis	K1F21B	1.27	2E-7
chr1	200935865	200935866	rs11584383	Crohn's disease	Intergenic	1.18	1E-11
chr1	200960306	200960307	rs2297909	Ankylosing spondylitis	KIF21B	NR	5E-12
chr1	201081942	201081943	rs2281845	Permanent tooth development	CACNA1S	.10	8E-17
chr1	201262431	201262432	rs860554	Panic disorder	PKP1	NR	5E-8
chr1	201884951	201884952	rs2819348	Breast size	ATP2B4	.08	3E-6
chr1	201952573	201952574	rs4950806	Butyrylcholinesterase levels	RNPEP	.14	9E-16
chr1	203155881	203155882	rs4950928	YKL-40 levels	CHI3L1	.30	1E-13
chr1	203654023	203654024	rs10900585	Malaria	ATP2B4	1.64	2E-10
chr1	204112983	204112984	rs3795578	Response to acetaminophen (hepatotoxicity)	ETNK2	NR	7E-6
chr1	204572070	204572071	rs12143943	Cognitive performance	MDM4	NR	5E-6
chr1	204784017	204784018	rs7552806	Dental caries	NFASC	NR	3E-6
chr1	204784017	204784018	rs7552806	Dental caries	NFASC	NR	3E-6
chr1	205235989	205235990	rs1668873	Mean platelet volume	TMCC2	.01	1E-20
chr1	205237136	205237137	rs1668871	Platelet counts	TMCC2	2.80	3E-14
chr1	205244952	205244953	rs1172130	Mean platelet volume	TMCC2	.01	4E-27
chr1	205676262	205676263	rs12748961	White blood cell types	SLC45A3, NUKS1	.06	4E-8
chr1	205678125	205678126	rs16856186	Pulmonary function decline	Intergenic	.27	9E-6
chr1	205713377	205713378	rs823128	Parkinson's disease	PARK16, NUCKS1	1.52	7E-8
chr1	205752664	205752665	rs947211	Parkinson's disease	PARK16, SLC45A3, NUCKS1, RAB7L1, SLC41A1, PM20D1	1.30	2E-12
chr1	205764639	205764640	rs823156	Parkinson's disease	SLC41A1	1.21	1E-7
chr1	205896234	205896235	rs11240594	Response to antipsychotic treatment	SLC26A9	NR	1E-7
chr1	206626827	206626828	rs2483058	Cholesterol and Triglycerides	SRGAP2	.20	9E-7
chr1	206939903	206939904	rs3024505	Type 1 diabetes autoantibodies	IL10	1.20	5E-10
chr1	206939903	206939904	rs3024505	Ulcerative colitis	IL10, IL19	1.25	6E-17
chr1	206939903	206939904	rs3024505	Crohn's disease	IL10,IL19	1.12	2E-14
chr1	206939903	206939904	rs3024505	Ulcerative colitis	IL10,IL19	1.23	1E-8
chr1	206939903	206939904	rs3024505	Type 1 diabetes	IL10	1.19	2E-9
chr1	206939903	206939904	rs3024505	Ulcerative colitis	IL10	1.46	1E-12
chr1	206943967	206943968	rs3024493	Ulcerative colitis	IL10	1.35	1E-12
chr1	206943967	206943968	rs3024493	Ulcerative colitis	IL10	NR	8E-8
chr1	206944644	206944645	rs1518111	Behcet's disease	IL10	1.45	4E-18
chr1	206946633	206946634	rs1800871	Behcet's disease	IL10	1.45	1E-14
chr1	207032750	207032751	rs574773	Economic and political preferences	Intergenic	.20	2E-6
chr1	207269857	207269858	rs3813948	C4b binding protein levels	C4BPB, C4BPA	NR	4E-10
chr1	207652175	207652176	rs17045328	Type 2 diabetes	CR2	1.38	7E-6
chr1	207692048	207692049	rs6656401	Alzheimer's disease	CR1	1.22	3E-10
chr1	207757514	207757515	rs12034598	Inflammatory biomarkers	CR1	NR	9E-14
chr1	207784967	207784968	rs3818361	Alzheimer's disease	CR1	1.18	4E-14
chr1	207784967	207784968	rs3818361	Alzheimer's disease	CR1	1.22	3E-10
chr1	207786288	207786289	rs6701713	Alzheimer's disease (late onset)	CR1	1.16	5E-10
chr1	207803594	207803595	rs12034383	Erythrocyte sedimentation rate	CR1	.13	2E-28
chr1	207872289	207872290	rs7527798	Erythrocyte sedimentation rate	CR1L	.10	2E-9
chr1	207875174	207875175	rs4844614	LDL cholesterol	CR1L	.10	2E-7
chr1	208024819	208024820	rs12731740	Biomedical quantitative traits	CD46, LOC148696	1.09	3E-9
chr1	208128721	208128722	rs2745967	Resting heart rate	CD34	5.40	7E-8
chr1	208757585	208757586	rs17259784	Cardiac hypertrophy	PLXNA2	NR	6E-6
chr1	209334216	209334217	rs4382726	Response to amphetamines	Intergenic	NR	4E-6
chr1	209727256	209727257	rs12130212	Obesity (extreme)	CAMK1G	NR	2E-6
chr1	209977110	209977111	rs861020	Orofacial clefts	IRF6	1.44	3E-12
chr1	209988046	209988047	rs10863790	Cleft lip	IRF6	1.72	1E-14
chr1	209989269	209989270	rs642961	Orofacial clefts	IRF6	NR	2E-6
chr1	210536024	210536025	rs7527939	Schizophrenia	HHAT	2.63	6E-9
chr1	212155007	212155008	rs17018311	Temperament (bipolar disorder)	INTS7	4.21	2E-8
chr1	212237797	212237798	rs10863936	Height	DTL	.02	2E-9
chr1	213855587	213855588	rs17706439	RR interval (heart rate)	Intergenic	.18	3E-6
chr1	214118089	214118090	rs340849	Alzheimer's disease	Intergenic	1.69	8E-6
chr1	214159255	214159256	rs340874	Fasting glucose-related traits (interaction with BMI)	PROX1	NR	4E-9
chr1	214159255	214159256	rs340874	Fasting glucose-related traits	PROX1	NR	7E-12
chr1	214159255	214159256	rs340874	Fasting glucose-related traits	PROX1	NR	5E-6
chr1	214830616	214830617	rs438034	Response to antineoplastic agents	CENPF	1.88	5E-6
chr1	216632947	216632948	rs10495024	Testosterone levels	Intergenic	.10	6E-6
chr1	216716536	216716537	rs12757165	Cardiac hypertrophy	ESRRG	NR	1E-7
chr1	217058478	217058479	rs1436900	Optic disc size (cup)	ESRRG	.14	7E-6
chr1	217527023	217527024	rs1497828	Dialysis-related mortality	GPATCH2, ESRRG	1.41	4E-6
chr1	217718131	217718132	rs2059397	Visceral adipose tissue adjusted for BMI	GPATCH2	NR	6E-6
chr1	218609701	218609702	rs6684205	Height	TGFB2	.03	2E-12
chr1	218705813	218705814	rs1018040	Hyperactive-impulsive symptoms	Intergenic	NR	8E-6
chr1	218705813	218705814	rs1018040	Attention deficit hyperactivity disorder	Intergenic	NR	5E-6
chr1	218860067	218860068	rs993925	Pulmonary function	TGFB2	.03	1E-8
chr1	219644223	219644224	rs2605100	Adiposity	LYPLAL1	.04	3E-8
chr1	219651132	219651133	rs12022722	Visceral adipose tissue/subcutaneous adipose tissue ratio	LYPLAL1	NR	2E-6
chr1	219657162	219657163	rs11118316	Visceral adipose tissue/subcutaneous adipose tissue ratio	LYPLAL1	NR	3E-9
chr1	219673827	219673828	rs1417066	Osteoarthritis	NR	1.07	1E-6
chr1	219676041	219676042	rs2791553	Adiponectin levels	LYPLAL1	.02	5E-7
chr1	219700518	219700519	rs2785980	Fasting insulin-related traits (interaction with BMI)	LYPLAL1	NR	2E-8
chr1	219727778	219727779	rs3001032	Adiponectin levels	LYPLAL1	.02	4E-8
chr1	219743718	219743719	rs11118346	Height	LYPLAL1	.03	2E-12
chr1	219750716	219750717	rs4846567	Waist-hip ratio	LYPLAL1	.06	5E-33
chr1	220658233	220658234	rs12563333	Bipolar disorder	MARK1	NR	6E-8
chr1	220914919	220914920	rs337161	Response to antipsychotic therapy (extrapyramidal side effects)	Intergenic	NR	3E-6
chr1	220929355	220929356	rs1494373	Response to antipsychotic therapy (extrapyramidal side effects)	MOSC2	NR	6E-6
chr1	220973562	220973563	rs2642442	LDL cholesterol	MOSC1	1.09	6E-11
chr1	220973562	220973563	rs2642442	Cholesterol, total	MOSC1	1.38	5E-13
chr1	220977332	220977333	rs6693017	Monocyte early outgrowth colony forming units	MOSC1	.24	3E-7
chr1	221010204	221010205	rs12073837	F-cell distribution	MOSC1	1.39	2E-6
chr1	221028507	221028508	rs11118620	Heart failure	LOC100129376	1.15	7E-6
chr1	221551538	221551539	rs12733856	Mortality among heart failure patients	LOC400804	1.56	3E-6
chr1	221617075	221617076	rs12032381	Dupuytren's disease	LOC100132626	6.22	6E-6
chr1	222045445	222045446	rs6691170	Colorectal cancer	DUSP10	1.06	1E-9
chr1	222164947	222164948	rs6687758	Progressive supranuclear palsy	Intergenic	1.27	6E-8
chr1	222164947	222164948	rs6687758	Colorectal cancer	DUSP10	1.09	2E-9
chr1	222271766	222271767	rs873549	Keloid	Intergenic	1.77	6E-23
chr1	222823528	222823529	rs17465637	Coronary heart disease	MIA3	1.14	1E-8
chr1	222823528	222823529	rs17465637	Myocardial infarction (early onset)	MIA3	1.14	1E-9
chr1	222823528	222823529	rs17465637	Coronary heart disease	MIA3	1.20	1E-6
chr1	222923350	222923351	rs6683071	Cognitive performance	FAM177B	NR	4E-6
chr1	224538939	224538940	rs11579964	Major depressive disorder	CNIH4,NVL,WDR26	1.19	4E-6
chr1	226564690	226564691	rs3219090	Melanoma	PARP1	1.15	9E-8
chr1	226855888	226855889	rs10916025	Subcutaneous adipose tissue	ITPKB	NR	6E-6
chr1	227797949	227797950	rs1390401	Height	ZNF678	.04	5E-9
chr1	227911882	227911883	rs10799445	Height	JMJD4	.03	2E-13
chr1	228996621	228996622	rs801112	Endometriosis	RHOU	1.65	5E-6
chr1	228997834	228997835	rs801114	Basal cell carcinoma	RHOU	1.28	6E-12
chr1	229019147	229019148	rs11585386	Aging	RHOU, RAB4A	NR	5E-6
chr1	230294915	230294916	rs2144300	Triglycerides	GALNT2	4.25	8E-7
chr1	230294915	230294916	rs2144300	HDL cholesterol	GALNT2	1.11	3E-14
chr1	230295690	230295691	rs4846914	Triglycerides	GALNT2	2.76	2E-14
chr1	230295690	230295691	rs4846914	HDL cholesterol	GALNT2	.61	4E-21
chr1	230295690	230295691	rs4846914	HDL cholesterol	GALNT2	.05	4E-8
chr1	230295690	230295691	rs4846914	Triglycerides	GALNT2	.08	7E-15
chr1	230295690	230295691	rs4846914	HDL cholesterol	GALNT2	.07	2E-13
chr1	230295788	230295789	rs10127775	Metabolite levels	GALNT2	NR	1E-9
chr1	230304987	230304988	rs10489615	HDL cholesterol	GALNT2	.02	4E-9
chr1	230307181	230307182	rs4846922	Metabolic syndrome	GALNT2	.08	4E-8
chr1	230674825	230674826	rs701157	Attention deficit hyperactivity disorder and conduct disorder	LOC729257	NR	4E-6
chr1	230922950	230922951	rs12038826	Myopia (pathological)	CAPN9	NR	7E-6
chr1	231816841	231816842	rs12042938	Neuranatomic and neurocognitive phenotypes	DISC1	NR	4E-36
chr1	231844346	231844347	rs12044355	Alzheimer's disease	DISC1	NR	9E-6
chr1	231899703	231899704	rs2793086	Response to antineoplastic agents	DISC1	3.01	9E-6
chr1	232155150	232155151	rs16856202	Amyotrophic lateral sclerosis	DISC1	2.00	8E-6
chr1	232246026	232246027	rs10746514	Response to statin therapy	DISC1, SIA1L2, DISC2	NR	1E-6
chr1	232519149	232519150	rs669408	Immunoglobulin A	SIPA1L2	1.33	1E-6
chr1	233340153	233340154	rs12027542	Type 2 diabetes	PCNXL2	1.41	4E-7
chr1	233643855	233643856	rs10910200	Diabetic retinopathy	KIAA1804, KCNK1	1.35	6E-6
chr1	233719983	233719984	rs11800854	Periodontal microbiota	KCNK1, KIAA1804	8.12	4E-6
chr1	233719983	233719984	rs11800854	Periodontal microbiota	KCNK1, KIAA1804	12.30	3E-7
chr1	234583617	234583618	rs10489896	Cognitive test performance	TARBP1	NR	6E-6
chr1	234662889	234662890	rs271738	Bipolar disorder	IRF2BP2	1.32	5E-6
chr1	234726011	234726012	rs744487	Coronary heart disease	Intergenic	.07	5E-6
chr1	234816553	234816554	rs482329	Life threatening arrhythmia	IRF2BP2	1.60	6E-6
chr1	234858596	234858597	rs514230	LDL cholesterol	IRF2BP2,TOMM20	1.13	9E-12
chr1	234858596	234858597	rs514230	Cholesterol, total	IRF2BP2,TOMM20	1.36	5E-14
chr1	234984987	234984988	rs2069084	HIV-1 control	Intergenic	NR	6E-6
chr1	235092599	235092600	rs908327	Immune reponse to smallpox (secreted IL-2)	TOMM20	NR	5E-10
chr1	235600128	235600129	rs6429082	Adiposity	TBCE	NR	3E-7
chr1	235720897	235720898	rs291353	Aging traits	GNG4	NR	6E-6
chr1	236179868	236179869	rs3768080	Cutaneous nevi	NID1	.07	7E-8
chr1	236313126	236313127	rs7520258	Working memory	GPR137B	NR	5E-7
chr1	237266602	237266603	rs7554607	Acute lymphoblastic leukemia (childhood)	RYR2	1.49	2E-6
chr1	237621238	237621239	rs1478912	Response to taxane treatment (docetaxel)	RYR2	NR	6E-6
chr1	237911003	237911004	rs2819770	Exercise treadmill test traits	RYR2	NR	4E-6
chr1	237990121	237990122	rs2819742	Response to cerivastatin	RYR2	2.08	2E-7
chr1	238103500	238103501	rs2499604	Non-alcoholic fatty liver disease histology (AST)	ZP4	.39	2E-6
chr1	238724740	238724741	rs10754644	Economic and political preferences (feminism/equality)	Intergenic	.09	7E-6
chr1	238908352	238908353	rs2689154	Pancreatic cancer	MIPEPP2	1.20	6E-6
chr1	239075713	239075714	rs1915279	Treatment response for severe sepsis	KRT18P32	NR	2E-6
chr1	239436541	239436542	rs2820037	Hypertension	RYR2,CHRM3,ZP4	1.54	8E-7
chr1	239601968	239601969	rs6677208	Platelet counts	CHRM3	NR	3E-6
chr1	239970096	239970097	rs12059546	Epilepsy (generalized)	CHRM3	1.42	4E-8
chr1	240445595	240445596	rs17672135	Coronary heart disease	Intergenic	1.43	2E-6
chr1	240706106	240706107	rs10495471	Immune response to smallpox vaccine (IL-6)	GREM2	NR	2E-7
chr1	240846123	240846124	rs4659996	Ankle-brachial index	GREM2	.00	7E-6
chr1	241878546	241878547	rs12569163	Radiation response	WDR64	NR	2E-6
chr1	242040774	242040775	rs1635501	Menopause (age at onset)	EXO1	.16	8E-10
chr1	243608966	243608967	rs6703335	Schizophrenia	NR	1.09	5E-8
chr1	243943083	243943084	rs4132509	RR interval (heart rate)	AKT3	.18	2E-6
chr1	244173871	244173872	rs10927101	Diabetic retinopathy	AKT3, ZNF238	1.33	2E-6
chr1	244176423	244176424	rs476141	Diabetic retinopathy	AKT3, ZNF238	1.37	1E-7
chr1	244390563	244390564	rs10429924	Schizophrenia	Intergenic	1.61	1E-6
chr1	244511175	244511176	rs4658627	Asthma (childhood onset)	C1orf100	.13	6E-6
chr1	244533213	244533214	rs3101457	Smoking behavior	C1orf100	.04	3E-7
chr1	247214877	247214878	rs4925540	Response to taxane treatment (docetaxel)	ZNF670	NR	2E-6
chr1	247348188	247348189	rs3738443	Alcohol dependence	ZNF124	NR	4E-6
chr1	247600300	247600301	rs1539019	Fibrinogen	NLRP3	.04	1E-8
chr1	247601594	247601595	rs12239046	C-reactive protein	NLRP3	.05	1E-15
chr1	247675558	247675559	rs7550918	Platelet counts	LOC148824	3.13	3E-11
chr1	247689531	247689532	rs1881797	Acute lymphoblastic leukemia (childhood)	OR2C3	1.52	7E-6
chr1	248039450	248039451	rs3811444	Platelet counts	TRIM58	3.35	6E-9
chr1	248496862	248496863	rs4481887	Common traits (Other)	OR2M7	1.67	7E-24
chr1	249168435	249168436	rs12032643	Myopia (pathological)	Intergenic	NR	1E-9
chr10	566378	566379	rs11252926	Alzheimer's disease	DIP2C	1.39	8E-6
chr10	618684	618685	rs17221323	Immune reponse to smallpox (secreted IFN-alpha)	DIP2C	NR	1E-7
chr10	1078781	1078782	rs12762955	Response to angiotensin II receptor blocker therapy	C10orf110	1.17	8E-6
chr10	1156164	1156165	rs10794720	Chronic kidney disease	WDR37	.01	1E-8
chr10	1406363	1406364	rs11250464	Radiation response	ADARB2	NR	6E-6
chr10	1630820	1630821	rs2999399	Emphysema-related traits	ADARB2	1.47	6E-6
chr10	1676530	1676531	rs6560749	Quantitative traits	ADARB2	.34	8E-6
chr10	1676530	1676531	rs6560749	Quantitative traits	ADARB2	.32	2E-6
chr10	2532018	2532019	rs729397	Response to statin therapy	LOC727878,LOC728209,LOC441546	NR	8E-6
chr10	3155172	3155173	rs7896691	Disc degeneration (lumbar)	PFKP	.17	2E-6
chr10	3284006	3284007	rs2764980	Attention deficit hyperactivity disorder and conduct disorder	PITRM1	NR	9E-6
chr10	3418123	3418124	rs1570854	Economic and political preferences (environmentalism)	Intergenic	.08	7E-6
chr10	3516104	3516105	rs2165468	Bone mineral density	Intergenic	NR	1E-6
chr10	3658918	3658919	rs705469	Capecitabine sensitivity	Intergenic	NR	7E-6
chr10	3667725	3667726	rs705471	Capecitabine sensitivity	Intergenic	NR	7E-6
chr10	3862541	3862542	rs6601764	Crohn's disease	NR	1.16	9E-6
chr10	4050002	4050003	rs2031577	Longevity	RP11-433J20.2	NR	1E-6
chr10	4151120	4151121	rs10795130	Sex hormone-binding globulin levels	Intergenic	.10	7E-6
chr10	4655564	4655565	rs10458787	Body mass index	Intergenic	.09	1E-6
chr10	4719795	4719796	rs1391511	Neonatal lupus	AKR1E2, LOC338588	1.84	7E-6
chr10	5009758	5009759	rs2904804	Economic and political preferences (immigration/crime)	AKR1C1	.12	6E-6
chr10	5138035	5138036	rs2518049	Metabolic traits	AKR1C	.07	7E-13
chr10	5348336	5348337	rs1987511	Intelligence	UCN3	NR	9E-8
chr10	5349870	5349871	rs7475343	Intelligence	UCN3	NR	9E-8
chr10	5353689	5353690	rs9423406	Intelligence	UCN3	NR	9E-8
chr10	5354676	5354677	rs7896729	Intelligence	UCN3	NR	9E-8
chr10	5886733	5886734	rs2380205	Breast cancer	ANKRD16,FBXO18	1.06	5E-7
chr10	6037725	6037726	rs7911500	Inflammatory biomarkers	IL2RA	NR	5E-9
chr10	6053162	6053163	rs12722605	Inflammatory biomarkers	IL2RA	NR	3E-7
chr10	6094696	6094697	rs61839660	Type 1 diabetes	IL2RA	1.60	5E-9
chr10	6097282	6097283	rs12722495	Type 1 diabetes autoantibodies	IL2RA	1.61	1E-38
chr10	6098823	6098824	rs706779	Vitiligo	IL2RA,RBM17,PFKB3	1.27	3E-9
chr10	6098948	6098949	rs706778	Rheumatoid arthritis	IL2RA	1.14	1E-11
chr10	6099044	6099045	rs2104286	Multiple sclerosis	IL2RA	1.16	7E-6
chr10	6099044	6099045	rs2104286	Multiple sclerosis	IL2RA	1.15	9E-8
chr10	6101712	6101713	rs3118470	Multiple sclerosis	IL2RA	1.12	3E-11
chr10	6101712	6101713	rs3118470	Alopecia areata	IL2RA	1.41	2E-12
chr10	6102011	6102012	rs12722489	Multiple sclerosis	IL2RA	1.23	4E-8
chr10	6102011	6102012	rs12722489	Crohn's disease	IL2RA	1.11	3E-9
chr10	6102011	6102012	rs12722489	Multiple sclerosis	IL2RA	1.25	3E-8
chr10	6110828	6110829	rs7090512	Multiple sclerosis	IL2RA	1.19	5E-20
chr10	6123494	6123495	rs12251307	Type 1 diabetes	IL2RA	NR	1E-13
chr10	6123494	6123495	rs12251307	Type 1 diabetes	IL2RA	NR	2E-6
chr10	6315793	6315794	rs7077335	Myopia (pathological)	Intergenic	NR	2E-12
chr10	6390449	6390450	rs947474	Type 1 diabetes	PRKCQ	1.10	4E-9
chr10	6393259	6393260	rs4750316	Rheumatoid arthritis	PRKCQ	1.15	2E-6
chr10	6393259	6393260	rs4750316	Rheumatoid arthritis	PRKCQ	1.14	4E-6
chr10	6407736	6407737	rs11258317	Bipolar disorder and schizophrenia	NR	1.23	6E-6
chr10	6472890	6472891	rs11258747	Type 1 diabetes	PRKCQ	NR	1E-7
chr10	6606540	6606541	rs4748153	Immune response to smallpox vaccine (IL-6)	PRKCQ	NR	3E-8
chr10	6946751	6946752	rs2501677	Fasting insulin-related traits (interaction with BMI)	SFMBT2	NR	3E-6
chr10	7089015	7089016	rs10905099	Orofacial clefts	NR	3.45	8E-6
chr10	7736903	7736904	rs11255291	Ovarian reserve	ITIH2	NR	2E-6
chr10	8093033	8093034	rs501764	Hodgkin's lymphoma	GATA3	1.25	7E-8
chr10	8150712	8150713	rs10508343	Response to treatment for acute lymphoblastic leukemia	Intergenic	3.81	8E-6
chr10	8701218	8701219	rs10795668	Colorectal cancer	Intergenic	1.12	3E-13
chr10	8972017	8972018	rs10508372	Asthma	LOC338591	1.16	2E-15
chr10	9363876	9363877	rs12247397	Immune reponse to smallpox (secreted IL-1beta)	LOC389936	NR	3E-9
chr10	10601859	10601860	rs11256676	Dental caries	SFTA1P	NR	5E-6
chr10	11000338	11000339	rs62209	Alzheimer's disease (late onset)	CUGBP2	2.04	2E-7
chr10	12051815	12051816	rs10795917	Prostate cancer (gene x gene interaction)	UPF2	1.24	7E-7
chr10	12277991	12277992	rs7068966	Pulmonary function	CDC123	.03	6E-13
chr10	12277991	12277992	rs7068966	Pulmonary function	CDC123	.03	3E-12
chr10	12307893	12307894	rs11257655	Type 2 diabetes	CDC123	1.15	7E-9
chr10	12314996	12314997	rs10906115	Type 2 diabetes	CDC123,CAMK1D	1.13	1E-8
chr10	12328009	12328010	rs12779790	Type 2 diabetes	CDC123,CAMK1D	1.11	1E-10
chr10	12918763	12918764	rs7909670	Height	CCDC3	.02	3E-9
chr10	13103284	13103285	rs525455	Platelet aggregation	MST151	NR	7E-7
chr10	13155725	13155726	rs1561570	Paget's disease	OPTN	1.67	4E-38
chr10	13155725	13155726	rs1561570	Paget's disease	OPTN	1.54	6E-13
chr10	13755543	13755544	rs1541010	RR interval (heart rate)	FRMD4A	.15	1E-6
chr10	13991864	13991865	rs7081208	Alzheimer's disease	FRMD4A	1.68	1E-10
chr10	14008444	14008445	rs2446581	Alzheimer's disease	FRMD4A	1.68	1E-10
chr10	14016158	14016159	rs17314229	Alzheimer's disease	FRMD4A	1.68	1E-10
chr10	15561542	15561543	rs7077361	Parkinson's disease	ITGA8	1.19	5E-6
chr10	15719620	15719621	rs7895372	Quantitative traits	ITGA8	.35	6E-6
chr10	16299950	16299951	rs10508503	Obesity	PTER	1.56	2E-7
chr10	16919051	16919052	rs1801239	Urinary albumin excretion	CUBN, RSU1	.08	1E-11
chr10	16997890	16997891	rs10508517	Quantitative traits	CUBN	.18	6E-6
chr10	17130692	17130693	rs11254363	Folate pathway vitamin levels	CUBN	21.49	1E-6
chr10	17142525	17142526	rs6602175	MRI atrophy measures	CUBN	.01	3E-6
chr10	17388142	17388143	rs359312	Response to treatment for acute lymphoblastic leukemia	ST8SIA6	3.91	9E-8
chr10	17891821	17891822	rs2437258	Cardiovascular disease risk factors	MRC1	.10	3E-10
chr10	18138746	18138747	rs2437258	Cardiovascular disease risk factors	MRC1	.10	3E-10
chr10	18388433	18388434	rs10508558	Bipolar disorder and schizophrenia	NR	1.54	9E-6
chr10	18397246	18397247	rs17661538	Response to antipsychotic treatment	Intergenic	NR	1E-6
chr10	18419971	18419972	rs4373814	Systolic blood pressure	CACNB2	.37	5E-11
chr10	18419971	18419972	rs4373814	Hypertension	CACNB2	.05	9E-8
chr10	18419971	18419972	rs4373814	Diastolic blood pressure	CACNB2	.22	4E-10
chr10	18708797	18708798	rs11014166	Systolic blood pressure	CACNB2	.50	7E-7
chr10	18708797	18708798	rs11014166	Hypertension	CACNB2	.09	6E-8
chr10	18708797	18708798	rs11014166	Diastolic blood pressure	CACNB2	.37	1E-8
chr10	18727958	18727959	rs12258967	Blood pressure	CACNB2	.43	2E-16
chr10	18730367	18730368	rs7069923	Quantitative traits	CACNB2	.19	1E-6
chr10	18759628	18759629	rs7076247	Protein quantitative trait loci	CACNB2	NR	6E-6
chr10	18950554	18950555	rs10829156	Sudden cardiac arrest	Intergenic	1.28	4E-7
chr10	19929512	19929513	rs1326986	Ankylosing spondylitis	NR	1.90	4E-6
chr10	20542633	20542634	rs1571942	Diabetic retinopathy	PLXDC2	NR	3E-7
chr10	20593086	20593087	rs12219125	Diabetic retinopathy	Intergenic	NR	9E-9
chr10	20674652	20674653	rs12772794	Neutrophil count	AL353790.1, RP11-337N19.1	NR	7E-6
chr10	20792333	20792334	rs7897194	Bipolar disorder	Intergenic	2.91	8E-6
chr10	20810524	20810525	rs16920624	Response to antidepressants	Intergenic	16.00	7E-7
chr10	20899607	20899608	rs2359536	Peripheral artery disease	Intergenic	1.84	2E-6
chr10	21567564	21567565	rs3847375	Schizophrenia	Intergenic	1.46	1E-6
chr10	21830103	21830104	rs11012732	Meningioma	MLLT10	1.46	2E-14
chr10	23665437	23665438	rs1398024	Crohn's disease and sarcoidosis (combined)	C10orf67	1.23	4E-6
chr10	24495585	24495586	rs11013962	Common traits (Other)	NR	NR	3E-7
chr10	24634955	24634956	rs2484873	Cognitive performance	KIAA1217	NR	4E-7
chr10	25918878	25918879	rs12775535	Immune response to smallpox vaccine (IL-6)	GPR158	NR	4E-9
chr10	26734586	26734587	rs2992257	Response to angiotensin II receptor blocker therapy	APBB1IP	8.63	3E-7
chr10	26774693	26774694	rs786870	Inflammatory biomarkers	APBB1IP	NR	5E-7
chr10	27693304	27693305	rs1334893	Fasting insulin-related traits (interaction with BMI)	PTCHD3	NR	5E-6
chr10	28025770	28025771	rs10508727	Immune response to smallpox vaccine (IL-6)	MKX	NR	1E-10
chr10	28382932	28382933	rs927675	MRI atrophy measures	MPP7	.00	2E-6
chr10	28504943	28504944	rs11006923	Alzheimer's disease	MPP7	1.59	9E-6
chr10	28617634	28617635	rs1148186	Pulmonary function decline	Intergenic	.22	7E-6
chr10	29289030	29289031	rs11007350	Cannabis dependence	Intergenic	1.37	3E-6
chr10	29291897	29291898	rs1612122	Major depressive disorder (broad)	NR	1.17	7E-6
chr10	30008662	30008663	rs1927457	Normalized brain volume	SVIL	NR	8E-6
chr10	30096627	30096628	rs2986971	Non-alcoholic fatty liver disease histology (lobular)	Intergenic	.49	3E-6
chr10	30177887	30177888	rs3006564	Orofacial clefts	Intergenic	1.32	5E-6
chr10	30316071	30316072	rs3739998	Coronary heart disease	KIAA1462	1.15	1E-11
chr10	30335121	30335122	rs2505083	Coronary heart disease	KIAA1462	1.07	4E-8
chr10	30519831	30519832	rs2995271	Pancreatitis	NR	1.27	8E-7
chr10	30834631	30834632	rs11008099	QT interval	NR	2.74	9E-6
chr10	30912029	30912030	rs399593	Dental caries	LYZL2	NR	9E-9
chr10	31366270	31366271	rs2994684	Response to antipsychotic treatment	Intergenic	NR	3E-7
chr10	31415105	31415106	rs793108	Multiple sclerosis	ZNF438	1.08	3E-6
chr10	31495973	31495974	rs1250307	Disc degeneration (lumbar)	Intergenic	.68	4E-6
chr10	31512097	31512098	rs2484992	Disc degeneration (lumbar)	Intergenic	.68	5E-6
chr10	31515131	31515132	rs2484990	Disc degeneration (lumbar)	Intergenic	.68	4E-6
chr10	31990622	31990623	rs7081678	Waist-hip ratio	ZEB1	.03	6E-6
chr10	32309004	32309005	rs1775715	Bipolar disorder (mood-incongruent)	KIF5B	1.18	5E-6
chr10	32634971	32634972	rs2370759	Sexual dysfunction (female)	EPC1	.24	2E-6
chr10	33294774	33294775	rs11009175	Depression (quantitative trait)	ITGB1	.16	5E-6
chr10	34088052	34088053	rs1412115	Schizophrenia	NRP1, PARD3	NR	6E-6
chr10	34231274	34231275	rs7905537	Emphysema-related traits	PARD3	1.85	8E-7
chr10	34257611	34257612	rs1780436	Major depressive disorder	PARD3	NR	3E-6
chr10	34817987	34817988	rs563507	Acute lymphoblastic leukemia (childhood)	PARD3	2.00	9E-6
chr10	35287649	35287650	rs17582416	Crohn's disease	Intergenic	1.16	2E-9
chr10	35535694	35535695	rs12242110	Crohn's disease	CREM	1.15	1E-9
chr10	35554053	35554054	rs12261843	Ulcerative colitis	CCNY	1.07	7E-10
chr10	36060308	36060309	rs11010290	Antineutrophil cytoplasmic antibody-associated vasculitis	FZD8	NR	9E-6
chr10	36648039	36648040	rs1779876	Protein quantitative trait loci	FZD8,ANKRD30A	NR	3E-6
chr10	36885920	36885921	rs1360573	Periodontal microbiota	ANKRD30A, FZD8	2.75	2E-6
chr10	37508449	37508450	rs1148259	Metabolite levels	ANKRD30A	NR	3E-9
chr10	37559579	37559580	rs1200821	Hemostatic factors and hematological phenotypes	ANKRD30A	NR	6E-6
chr10	37982096	37982097	rs7474896	Obesity (extreme)	ZNF248	1.46	9E-7
chr10	43341104	43341105	rs2142991	Progressive supranuclear palsy	BMS1	1.30	3E-7
chr10	43612608	43612609	rs2742234	Hirschsprung's disease	RET, GALNACT-2, RASGEF1A	NR	4E-18
chr10	43814048	43814049	rs2503875	Multiple sclerosis	Intergenic	1.66	2E-7
chr10	44524674	44524675	rs17154929	HIV-associated dementia	Intergenic	NR	1E-7
chr10	44753866	44753867	rs501120	Coronary heart disease	CXCL12	1.33	9E-8
chr10	44775823	44775824	rs1746048	Coronary heart disease	CXCL12	1.09	3E-10
chr10	44775823	44775824	rs1746048	Myocardial infarction (early onset)	CXCL12	1.17	7E-9
chr10	45123378	45123379	rs11239177	Bipolar disorder and schizophrenia	NR	1.23	3E-6
chr10	45161108	45161109	rs1480597	Parkinson's disease	Intergenic	2.50	2E-6
chr10	45319653	45319654	rs7911712	Emphysema-related traits	AL139 119.2	2.05	6E-6
chr10	46024728	46024729	rs11239550	Mean corpuscular volume	MARCH8	.00	1E-10
chr10	49699956	49699957	rs4838605	Diabetic retinopathy	ARHGAP22	NR	2E-9
chr10	49735562	49735563	rs10776612	Conduct disorder (case status)	ARHGAP22	1.33	2E-6
chr10	49936335	49936336	rs11101442	Systemic lupus erythematosus	c10orf64	NR	3E-6
chr10	49985109	49985110	rs10857636	Response to antidepressant treatment	WDFY4	NR	2E-7
chr10	50025395	50025396	rs7097397	Systemic lupus erythematosus	WDFY4	1.30	8E-12
chr10	50109222	50109223	rs3849150	Subclinical atherosclerosis traits (other)	LRRC18	NR	2E-6
chr10	50119053	50119054	rs1913517	Systemic lupus erythematosus	LRRC18, WDFY4	1.24	7E-12
chr10	50224765	50224766	rs2244967	Uric acid levels	RP11-523018.1	.13	5E-6
chr10	50561506	50561507	rs4838508	HIV-1 control	Intergenic	NR	2E-6
chr10	50576632	50576633	rs12220898	Inflammatory biomarkers	DRGX	NR	1E-6
chr10	51524970	51524971	rs3123078	Prostate cancer	NR	NR	1E-19
chr10	51549495	51549496	rs10993994	Prostate cancer	MSMB	1.18	5E-6
chr10	51549495	51549496	rs10993994	Prostate-specific antigen levels	MSMB	9.20	7E-13
chr10	51549495	51549496	rs10993994	Prostate cancer	MSMB	NR	3E-8
chr10	51549495	51549496	rs10993994	Prostate cancer	MSMB	1.25	9E-29
chr10	51549495	51549496	rs10993994	Prostate cancer	MSMB	1.16	7E-13
chr10	52119296	52119297	rs2574975	Response to amphetamines	SGMS1	NR	5E-6
chr10	53493472	53493473	rs7922491	Asthma	PRKG1	1.13	5E-7
chr10	54223976	54223977	rs1733724	Ventricular conduction	DKK1	.49	3E-8
chr10	54223976	54223977	rs1733724	Electrocardiographic traits	DKK1	5.62	7E-8
chr10	55294873	55294874	rs583012	Select biomarker traits	Intergenic	NR	2E-6
chr10	55384742	55384743	rs12256830	Immune response to smallpox vaccine (IL-6)	PCDH15	NR	2E-10
chr10	56391302	56391303	rs1937395	Pulmonary function decline	Intergenic	.16	1E-6
chr10	56790968	56790969	rs10740609	Weight	PCDH15	3.41	5E-6
chr10	56848984	56848985	rs16906916	Response to tocilizumab in rheumatoid arthritis	Intergenic	14.00	8E-7
chr10	57416960	57416961	rs1916521	Cardiac hypertrophy	ZWINT	NR	5E-7
chr10	59189177	59189178	rs4462262	Diabetic retinopathy	Intergenic	NR	9E-8
chr10	59913150	59913151	rs1819658	Crohn's disease	UBE2D1	1.19	9E-17
chr10	60082667	60082668	rs16912145	Brain imaging	UBE2D1	NR	NS
chr10	61413352	61413353	rs12356193	Uric acid levels	SLC16A9	.08	1E-8
chr10	61449563	61449564	rs7094971	Metabolic traits	SLC16A9	.05	3E-14
chr10	62085336	62085337	rs10761482	Schizophrenia	ANK3	1.16	8E-6
chr10	62179811	62179812	rs10994336	Bipolar disorder	ANK3	1.45	9E-9
chr10	62181127	62181128	rs10994338	Bipolar disorder and major depressive disorder (combined)	ANK3	NR	5E-7
chr10	62185493	62185494	rs4948418	Bipolar disorder	ANK3	NR	4E-10
chr10	62279123	62279124	rs10994397	Bipolar disorder	ANK3	1.22	3E-7
chr10	62346637	62346638	rs16915157	Schizophrenia	Intergenic	1.13	7E-7
chr10	62346637	62346638	rs16915157	Schizophrenia	NR	1.10	5E-6
chr10	63307474	63307475	rs2787702	Response to taxane treatment (placlitaxel)	TMEM26	NR	9E-6
chr10	63348766	63348767	rs1350172	Response to taxane treatment (placlitaxel)	C10orf107	NR	4E-7
chr10	63467552	63467553	rs4590817	Blood pressure	C10orf107	.58	2E-18
chr10	63524590	63524591	rs1530440	Diastolic blood pressure	c10orf107, TMEM26, RTKN2, RHOBTB1, ARID5B	.39	1E-9
chr10	63636530	63636531	rs2675609	Serum total protein level	ARID5B	.04	2E-6
chr10	63723576	63723577	rs10821936	Acute lymphoblastic leukemia (childhood)	ARID5B	1.91	1E-15
chr10	63752158	63752159	rs7089424	Acute lymphoblastic leukemia (childhood)	ARID5B	1.65	7E-19
chr10	63785088	63785089	rs10821944	Rheumatoid arthritis	ARID5B	1.16	6E-18
chr10	63958111	63958112	rs3125734	Rheumatoid arthritis	RTKN2	1.20	5E-9
chr10	64187563	64187564	rs7089814	Breast size	ZNF365, ALDH7A1P4, ADO	.10	3E-9
chr10	64223382	64223383	rs10995170	Intelligence	ZNF365	4.42	3E-7
chr10	64251976	64251977	rs10822013	Breast cancer	ZNF365	1.12	6E-9
chr10	64278681	64278682	rs10995190	Mammographic density	ZNF365	.18	1E-9
chr10	64278681	64278682	rs10995190	Breast cancer	ZNF365	1.16	5E-15
chr10	64398465	64398466	rs10995251	Atopic dermatitis	ZNF365	1.28	6E-20
chr10	64415183	64415184	rs7076156	Crohn's disease	ZNF365, ERG2, ADO	1.19	7E-9
chr10	64438485	64438486	rs10995271	Crohn's disease	ZNF365	1.25	4E-20
chr10	64445563	64445564	rs10761659	Crohn's disease	ZNF365	1.28	5E-6
chr10	64445563	64445564	rs10761659	Crohn's disease	ZNF365	1.23	4E-22
chr10	64445563	64445564	rs10761659	Crohn's disease	Intergenic	1.23	2E-6
chr10	64470674	64470675	rs224136	Crohn's disease	Intergenic	1.67	1E-10
chr10	64560469	64560470	rs1444418	Atopic dermatitis	ADO, EGR2	1.17	2E-7
chr10	64580574	64580575	rs224278	Ewing sarcoma	EGR2, ADO, ZNF365	1.66	4E-17
chr10	64655912	64655913	rs10995356	Temperament	EGR2	.11	3E-6
chr10	65006455	65006456	rs6479891	Arthritis (juvenile idiopathic)	JMJD1C	1.19	2E-7
chr10	65026857	65026858	rs10995485	Response to fenofibrate	JMJ1C	1.18	2E-6
chr10	65027609	65027610	rs10761731	Platelet counts	JMJD1C	3.85	2E-24
chr10	65027609	65027610	rs10761731	Triglycerides	JMJD1C	2.38	3E-12
chr10	65050658	65050659	rs7075195	Mean platelet volume	JMJD1C	.01	2E-44
chr10	65104499	65104500	rs7896518	Mean platelet volume	JMJD1C	5.18	2E-12
chr10	65121564	65121565	rs12355784	Liver enzyme levels	JMJD1C	.03	5E-10
chr10	65133155	65133156	rs2393967	Mean platelet volume	JMJD1C	.01	3E-21
chr10	65133821	65133822	rs7923609	Liver enzyme levels (alkaline phosphatase)	JMJD1C, NRBF2	2.20	6E-23
chr10	65138909	65138910	rs7910927	Sex hormone-binding globulin levels	JMJD1C	.05	6E-35
chr10	65138909	65138910	rs7910927	Sex hormone-binding globulin levels	JMJD1C	.05	2E-13
chr10	65138909	65138910	rs7910927	Sex hormone-binding globulin levels	JMJD1C	.05	0E0
chr10	65261183	65261184	rs2893923	Platelet aggregation	JMJD1C	NR	5E-8
chr10	65274926	65274927	rs10761779	Liver enzyme levels	REEP3	.03	7E-10
chr10	65315396	65315397	rs12411988	Arthritis (juvenile idiopathic)	REEP3	1.18	3E-7
chr10	65337152	65337153	rs10822184	Androgen levels	JMJD1C	.06	1E-8
chr10	66448471	66448472	rs7900909	Response to statin therapy	ANXA2P3, LOC645084, RPL7AP1	NR	8E-6
chr10	68088507	68088508	rs10762058	Asthma (toluene diisocyanate-induced)	CTNNA3	5.00	6E-6
chr10	68165266	68165267	rs2441755	Dental caries	CTNNA3	NR	4E-6
chr10	68640950	68640951	rs4142041	Nicotine dependence	CTNNA3	1.14	6E-6
chr10	69967446	69967447	rs6480314	Optic disc size (disc)	MYPN	.24	2E-7
chr10	69991852	69991853	rs7916697	Optic disc parameters	ATOH7	.09	2E-15
chr10	70000880	70000881	rs1900004	Vertical cup-disc ratio	ATOH7, PBLD	.01	2E-8
chr10	70000880	70000881	rs1900004	Optic disc parameters	ATOH7,PBLD	.07	3E-35
chr10	70011837	70011838	rs3858145	Optic disc size (disc)	ATOH7	.30	3E-10
chr10	70011837	70011838	rs3858145	Optic disc size (cup)	ATOH7	.21	2E-7
chr10	70019370	70019371	rs12571093	Optic disc size (disc)	PBLD	.31	2E-10
chr10	70626428	70626429	rs10998466	Disc degeneration (lumbar)	Intergenic	.53	4E-6
chr10	70712061	70712062	rs2017305	Depression (quantitative trait)	DDX21	.22	9E-6
chr10	70931473	70931474	rs1802295	Type 2 diabetes	VPS26A	1.08	4E-8
chr10	70939800	70939801	rs10998624	Immune reponse to smallpox (secreted IL-1beta)	SUPV3L1, VPS26A	NR	1E-9
chr10	71093391	71093392	rs16926246	Glycated hemoglobin levels	HK1	.09	3E-54
chr10	71093391	71093392	rs16926246	Hemoglobin	HK1	.11	2E-11
chr10	71093391	71093392	rs16926246	Hematocrit	HK1	.33	1E-13
chr10	71099912	71099913	rs7072268	Glycated hemoglobin levels	HK1	.05	2E-25
chr10	71263263	71263264	rs1227969	Response to taxane treatment (placlitaxel)	TSPAN15	NR	6E-7
chr10	71538291	71538292	rs4746003	Alzheimer's disease	RP11-242G20.2	1.30	6E-6
chr10	71583197	71583198	rs7077164	Non-alcoholic fatty liver disease histology (lobular)	COL13A1	.67	7E-6
chr10	71588503	71588504	rs1227756	Non-alcoholic fatty liver disease histology (lobular)	COL13A1	.57	2E-7
chr10	72040804	72040805	rs41322152	Acute lymphoblastic leukemia (childhood)	NPFFR1	2.52	8E-6
chr10	72332439	72332440	rs10999409	Obesity (extreme)	PRF1	1.30	5E-6
chr10	72462993	72462994	rs17600642	Bipolar disorder	NR	NR	5E-6
chr10	72483009	72483010	rs1816002	Weight	NR	2.08	8E-6
chr10	72527516	72527517	rs12761224	Prion diseases	NR	1.39	6E-6
chr10	72982984	72982985	rs16928529	Attention deficit hyperactivity disorder	UNC5B	NR	4E-6
chr10	73135918	73135919	rs1417210	Vitiligo	SLC29A3, CDH23, UNC5B	1.14	2E-8
chr10	73527046	73527047	rs1867982	Pulmonary function decline	Intergenic	.20	6E-6
chr10	73806287	73806288	rs1678618	Smoking behavior	SPOCK2	.06	8E-7
chr10	73849638	73849639	rs1245541	Insulin-like growth factors	SPOCK2	NR	5E-7
chr10	75421207	75421208	rs10824026	Atrial fibrillation	SYNPO2L	1.15	4E-9
chr10	76295788	76295789	rs7924176	Permanent tooth development	ADK	.11	6E-18
chr10	76703005	76703006	rs10466033	Breast size	COMTD1,SPA17P1	.44	6E-6
chr10	76808759	76808760	rs7919006	Weight	NR	4.00	4E-6
chr10	78157571	78157572	rs10509373	Response to tamoxifen in breast cancer	C10orf11	4.51	6E-8
chr10	78315223	78315224	rs11001819	Pulmonary function	C10orf11	.03	3E-12
chr10	78646535	78646536	rs2116830	Obesity	KCNMA1	1.26	3E-10
chr10	79444752	79444753	rs4979906	Mortality among heart failure patients	KCNMA1	1.23	7E-6
chr10	79680433	79680434	rs754466	Liver enzyme levels (gamma-glutamyl transferase)	DLG5	3.50	6E-10
chr10	80100860	80100861	rs2395528	Conduct disorder (interaction)	Intergenic	1.46	6E-6
chr10	80841147	80841148	rs704010	Breast cancer	ZMIZ1	1.07	4E-9
chr10	80925576	80925577	rs7916441	Height	PPIF	NR	6E-10
chr10	80955066	80955067	rs703965	Bipolar disorder	NR	1.15	8E-6
chr10	81015895	81015896	rs11593576	Vitiligo	ZMIZ1	1.14	8E-7
chr10	81032884	81032885	rs1250544	Crohn's disease and psoriasis	ZMIZ1	1.16	7E-14
chr10	81034669	81034670	rs1250542	Multiple sclerosis	ZMIZ1	1.15	4E-7
chr10	81036006	81036007	rs1250540	Multiple sclerosis	ZMIZ1	1.12	2E-6
chr10	81058026	81058027	rs1250552	Celiac disease	ZMIZ1	1.12	9E-10
chr10	81060316	81060317	rs1250550	Multiple sclerosis	ZMIZ1	1.10	6E-9
chr10	81060316	81060317	rs1250550	Crohn's disease	ZMIZ1	1.19	1E-30
chr10	81060316	81060317	rs1250550	Inflammatory bowel disease (early onset)	ZMIZ1	1.16	6E-9
chr10	81121695	81121696	rs2145998	Height	PPIF	.03	4E-13
chr10	81139461	81139462	rs941873	Height	Intergenic	.04	4E-7
chr10	81694949	81694950	rs1923539	Chronic obstructive pulmonary disease-related biomarkers	RP11-479O17.4	NR	5E-9
chr10	81705432	81705433	rs7078012	Chronic obstructive pulmonary disease-related biomarkers	SFTPD	NR	5E-9
chr10	81735980	81735981	rs3923564	Chronic obstructive pulmonary disease-related biomarkers	SFTPD	NR	2E-27
chr10	81788103	81788104	rs12220777	Chronic obstructive pulmonary disease-related biomarkers	RP11-369J21.5, RP11-369J21.6	NR	7E-11
chr10	81847913	81847914	rs728616	Chronic obstructive pulmonary disease-related biomarkers	RP11-369J21.2	NR	2E-12
chr10	81882369	81882370	rs3851050	Chronic obstructive pulmonary disease-related biomarkers	RP11-369J21.4	NR	1E-11
chr10	81911724	81911725	rs1953600	Sarcoidosis	ANXA11	NR	1E-6
chr10	81933747	81933748	rs6585424	Chronic obstructive pulmonary disease-related biomarkers	ANXA11	NR	1E-10
chr10	82377589	82377590	rs6586111	Capecitabine sensitivity	SH2D4B	NR	7E-6
chr10	82699490	82699491	rs1484170	Cardiac hypertrophy	NRG3	NR	1E-6
chr10	83153245	83153246	rs588517	Carotid atherosclerosis in HIV infection	Intergenic	NR	8E-6
chr10	83819124	83819125	rs4933824	Response to iloperidone treatment (QT prolongation)	NRG3	NR	2E-6
chr10	85422853	85422854	rs2224865	Eosinophilic esophagitis (pediatric)	NR	1.44	9E-6
chr10	87634923	87634924	rs1970525	Periodontal microbiota	GRID1, MI346, WAPAL	2.89	4E-6
chr10	87846958	87846959	rs7910620	Cardiac structure and function	GRID1	.17	7E-7
chr10	89338632	89338633	rs9664222	Longevity	MINPP1	1.22	7E-7
chr10	89443309	89443310	rs10887741	Exercise (leisure time)	PAPSS2	1.32	4E-6
chr10	90023032	90023033	rs10509540	Type 1 diabetes	C10orf59	1.33	1E-28
chr10	90727333	90727334	rs1926203	Lung cancer	NR	1.12	1E-6
chr10	90771828	90771829	rs2234978	Immunoglobulin A	ACTA2, FAS	1.32	6E-6
chr10	90826778	90826779	rs1937332	Atrioventricular conduction	FAS,CH25H	2.60	7E-7
chr10	90964613	90964614	rs11203032	Heart failure	CH25H	1.22	8E-6
chr10	91002926	91002927	rs1412444	Coronary heart disease	LIPA	1.10	4E-8
chr10	91002926	91002927	rs1412444	Coronary heart disease	LIPA	1.09	3E-13
chr10	91372532	91372533	rs11185790	Metabolic traits	PANK1	.31	3E-7
chr10	91962669	91962670	rs2250245	Economic and political preferences (feminism/equality)	Intergenic	.11	2E-6
chr10	91963462	91963463	rs2250149	Economic and political preferences (feminism/equality)	Intergenic	.11	1E-6
chr10	92632898	92632899	rs4586057	Economic and political preferences (time)	RPP30	.14	5E-6
chr10	93348119	93348120	rs1329650	Smoking behavior	LOC100188947	.37	6E-10
chr10	94168796	94168797	rs2263638	Airflow obstruction	IDE	1.28	3E-6
chr10	94347829	94347830	rs6583826	Type 2 diabetes	KIF11	1.18	7E-6
chr10	94462881	94462882	rs1111875	Type 2 diabetes	HHEX	1.21	7E-12
chr10	94462881	94462882	rs1111875	Type 2 diabetes	HHEX	1.13	6E-10
chr10	94462881	94462882	rs1111875	Type 2 diabetes	HHEX	1.13	6E-10
chr10	94462881	94462882	rs1111875	Type 2 diabetes	HHEX	1.19	3E-6
chr10	94465558	94465559	rs5015480	Type 2 diabetes	HHEX	1.18	2E-9
chr10	94465558	94465559	rs5015480	Type 2 diabetes	HHEX	1.17	9E-6
chr10	94465558	94465559	rs5015480	Type 2 diabetes	HHEX,IDE	1.18	1E-15
chr10	94465558	94465559	rs5015480	Type 2 diabetes	HHEX	1.17	7E-8
chr10	94465558	94465559	rs5015480	Type 2 diabetes	HHEX	1.13	5E-6
chr10	94481916	94481917	rs7923837	Multiple sclerosis	HHEX	1.10	5E-9
chr10	94485210	94485211	rs2497306	Dehydroepiandrosterone sulphate levels	HHEX	.04	5E-9
chr10	94839641	94839642	rs2068888	Triglycerides	CYP26A1	2.28	2E-8
chr10	95348181	95348182	rs10882272	Retinol levels	RBP4	.03	7E-15
chr10	95895176	95895177	rs9663362	Blood pressure	PLCE-1	.27	5E-9
chr10	95895939	95895940	rs932764	Systolic blood pressure	PLCE1	.48	7E-16
chr10	95895939	95895940	rs932764	Hypertension	PLCE1	.06	9E-9
chr10	95895939	95895940	rs932764	Diastolic blood pressure	PLCE1	.19	8E-7
chr10	96013704	96013705	rs9419788	Personality dimensions	PLCE1	NR	4E-8
chr10	96035979	96035980	rs11187837	Sudden cardiac arrest	PLCE1	1.79	4E-7
chr10	96058297	96058298	rs3765524	Dengue shock syndrome	PLCE1	1.25	3E-10
chr10	96058297	96058298	rs3765524	Esophageal cancer and gastric cancer	PLCE1,NOC3L	1.35	2E-9
chr10	96058635	96058636	rs117607728	Chronic obstructive pulmonary disease	PLCE1	3.00	4E-7
chr10	96066340	96066341	rs2274223	Esophageal cancer	PLCE1	1.34	4E-20
chr10	96070374	96070375	rs3781264	Esophageal cancer and gastric cancer	PLCE1,NOC3L	1.36	4E-9
chr10	96405328	96405329	rs12772169	Acenocoumarol maintenance dosage	CYP2C18	NR	8E-12
chr10	96405501	96405502	rs12777823	Response to clopidogrel therapy	CYP2C18, CYP2C19, CYP2C9, CYP2C8	NR	2E-13
chr10	96547462	96547463	rs12767583	Acenocoumarol maintenance dosage	CYP2C19	NR	3E-7
chr10	96702046	96702047	rs1799853	Warfarin maintenance dose	CYP2C9	.54	1E-31
chr10	96707201	96707202	rs4086116	Warfarin maintenance dose	CYP2C9	NR	6E-12
chr10	96734338	96734339	rs10509680	Warfarin maintenance dose	CYP2C9	NR	4E-7
chr10	96741052	96741053	rs1057910	Warfarin maintenance dose	CYP2C9	1.11	3E-79
chr10	96751269	96751270	rs2185570	Dehydroepiandrosterone sulphate levels	CYP2C9	.06	2E-8
chr10	96766933	96766934	rs2860975	Immune response to smallpox vaccine (IL-6)	CYP2C9	NR	2E-7
chr10	96797469	96797470	rs1934953	Immune response to smallpox vaccine (IL-6)	CYP2C8	NR	5E-7
chr10	96798547	96798548	rs1934951	Osteonecrosis of the jaw	CYP2C8	12.75	1E-6
chr10	96852689	96852690	rs72820627	Response to amphetamines	Intergenic	NR	7E-6
chr10	98135504	98135505	rs10786284	Attention deficit hyperactivity disorder	TLL2	NR	2E-6
chr10	99359738	99359739	rs2297644	Metabolite levels	DHDPSL	.15	1E-12
chr10	99637577	99637578	rs531676	Metabolic syndrome	CRTAC1	NR	9E-6
chr10	100127550	100127551	rs17109512	Aspartate aminotransferase	GOT1	NR	3E-14
chr10	100156852	100156853	rs7072216	Metabolite levels	PYROXD2, C10orf33	1.19	8E-15
chr10	100300181	100300182	rs10786436	Type 1 diabetes	NR	1.10	8E-7
chr10	101274364	101274365	rs7078219	Dental caries	NKX2-3	NR	6E-6
chr10	101284236	101284237	rs4409764	Crohn's disease	NKX2-3	1.22	2E-20
chr10	101287763	101287764	rs10883365	Crohn's disease	NKX2-3	1.20	6E-8
chr10	101287763	101287764	rs10883365	Crohn's disease	NKX2-3	1.18	4E-10
chr10	101290300	101290301	rs6584283	Ulcerative colitis	Intergenic	1.21	8E-21
chr10	101290300	101290301	rs6584283	Ulcerative colitis	NKX2-3	1.22	2E-6
chr10	101290300	101290301	rs6584283	Ulcerative colitis	NKX2, NKX3	NR	2E-7
chr10	101291592	101291593	rs11190140	Ulcerative colitis	NKX2-3	1.20	1E-8
chr10	101291592	101291593	rs11190140	Crohn's disease	NKX2-3	1.20	3E-16
chr10	101292389	101292390	rs11190141	Crohn's disease	NKX2-3, SLC25A28, GOT1, ENTPD7, CNNM1, COX15, CUTC	1.34	5E-7
chr10	101795360	101795361	rs10883437	Liver enzyme levels (alanine transaminase)	CPN1	2.30	4E-9
chr10	101805441	101805442	rs11599750	Height	CPN1	.03	2E-13
chr10	101861434	101861435	rs11597390	Liver enzyme levels	CPN1, CHUK, ERLIN1	.04	2E-8
chr10	102075478	102075479	rs603424	Phospholipid levels (plasma)	PKD2L1	1.40	6E-14
chr10	102075478	102075479	rs603424	Metabolic traits	SCD	.12	3E-57
chr10	102501570	102501571	rs4509693	Alzheimer's disease	PAX2	NR	6E-6
chr10	102979206	102979207	rs11190870	Scoliosis	LBX1	1.56	1E-19
chr10	104591392	104591393	rs17115100	Parkinson's disease	CYP17A1, C10orf32, CNNM2, SFXN2	1.25	7E-8
chr10	104594506	104594507	rs1004467	Systolic blood pressure	CYP17A1	1.05	1E-10
chr10	104719095	104719096	rs12413409	Coronary heart disease	CYP17A1, CNNM2, NT5C2	1.12	1E-9
chr10	104719095	104719096	rs12413409	Coronary heart disease	Intergenic	NR	4E-6
chr10	104719095	104719096	rs12413409	Intracranial aneurysm	CNNM2	1.29	1E-9
chr10	104775907	104775908	rs7914558	Schizophrenia	CNNM2	1.22	2E-8
chr10	104846177	104846178	rs11191548	Systolic blood pressure	CYP17A1, NT5C2	1.10	7E-26
chr10	104846177	104846178	rs11191548	Blood pressure	CYP17A1, NT5C2	.53	8E-11
chr10	104846177	104846178	rs11191548	Blood pressure	CNNM2, NT5C2, CYP17A1	.58	7E-12
chr10	104846177	104846178	rs11191548	Blood pressure	CNNM2, NT5C2, CYP17A1	1.18	4E-17
chr10	104846177	104846178	rs11191548	Systolic blood pressure	CYP17A1, AS3MT, CNNM2, NT5C2	1.16	7E-24
chr10	104906210	104906211	rs11191580	Schizophrenia	NT5C2, CNNM2, other genes	1.23	2E-9
chr10	104906210	104906211	rs11191580	Schizophrenia	NT5C2	1.20	3E-8
chr10	104939214	104939215	rs11191593	Blood pressure	CYP17A1, NT5C2	.66	1E-15
chr10	105033014	105033015	rs1712517	Migraine	INA	1.13	9E-6
chr10	105257785	105257786	rs7071247	Platelet aggregation	NEURL	NR	2E-7
chr10	105647094	105647095	rs3814219	Endothelial function traits	OBFC1	NR	9E-7
chr10	105675945	105675946	rs9419958	Telomere length	OBFC1	.08	9E-11
chr10	105677896	105677897	rs4387287	Telomere length	OBFC1	.10	2E-11
chr10	105714398	105714399	rs7913069	Uterine fibroids	SLK, OBFC1	1.47	9E-14
chr10	105846073	105846074	rs1320448	Cardiac hypertrophy	COL17A1	NR	2E-8
chr10	105966403	105966404	rs515910	Attention deficit hyperactivity disorder	C10orf79	NR	4E-6
chr10	107516351	107516352	rs17119461	Melanoma	NR	8.40	7E-12
chr10	109569849	109569850	rs12570947	Prion diseases	NR	1.45	4E-6
chr10	111735749	111735750	rs17095355	Biliary atresia	XPNPEP1,ADD3	1.77	7E-9
chr10	112006485	112006486	rs716595	Normalized brain volume	MXI1	NR	8E-6
chr10	112877800	112877801	rs2065779	Insomnia (caffeine-induced)	RP11-479A21.1	1.82	3E-6
chr10	112909104	112909105	rs869244	Platelet aggregation	ADRA2A	NR	3E-12
chr10	113042092	113042093	rs10885122	Fasting glucose-related traits (interaction with BMI)	ADRA2A	NR	9E-8
chr10	113042092	113042093	rs10885122	Fasting glucose-related traits	ADRA2A	NR	3E-16
chr10	113042092	113042093	rs10885122	Fasting glucose-related traits	ADRA2A	NR	2E-6
chr10	113933885	113933886	rs2255141	LDL cholesterol	GPAM	1.08	2E-9
chr10	113933885	113933886	rs2255141	Cholesterol, total	GPAM	1.14	2E-10
chr10	114479261	114479262	rs7342028	Ventricular conduction	VTI1A	.48	5E-10
chr10	114498475	114498476	rs7086803	Lung cancer	VTI1A	1.28	4E-18
chr10	114754087	114754088	rs7901695	Coronary heart disease	TCF7L2	1.19	1E-6
chr10	114754087	114754088	rs7901695	Type 2 diabetes	TCF7L2	1.37	1E-48
chr10	114756040	114756041	rs4506565	Fasting glucose-related traits	TCF7L2	NR	1E-8
chr10	114756040	114756041	rs4506565	Type 2 diabetes	TCF7L2	1.36	5E-12
chr10	114758348	114758349	rs7903146	Type 2 diabetes	TCF7L2	1.26	4E-21
chr10	114758348	114758349	rs7903146	Type 2 diabetes	TCF7L2	1.58	2E-40
chr10	114758348	114758349	rs7903146	Fasting insulin-related traits (interaction with BMI)	TCF7L2	NR	3E-6
chr10	114758348	114758349	rs7903146	Fasting glucose-related traits (interaction with BMI)	TCF7L2	NR	2E-14
chr10	114758348	114758349	rs7903146	Type 2 diabetes	TCF7L2	1.46	2E-15
chr10	114758348	114758349	rs7903146	Proinsulin levels	TCF7L2	NR	2E-20
chr10	114758348	114758349	rs7903146	Glycated hemoglobin levels	TCF7L2	.05	1E-7
chr10	114758348	114758349	rs7903146	Metabolic syndrome	TCF7L2	1.33	7E-7
chr10	114758348	114758349	rs7903146	Type 2 diabetes	TCF7L2	1.40	2E-51
chr10	114758348	114758349	rs7903146	Type 2 diabetes and other traits	TCF7L2	1.48	1E-30
chr10	114758348	114758349	rs7903146	Type 2 diabetes	TCF7L2	1.54	8E-12
chr10	114758348	114758349	rs7903146	Type 2 diabetes	TCF7L2	1.49	9E-30
chr10	114758348	114758349	rs7903146	Type 2 diabetes	TCF7L2	1.31	6E-16
chr10	114758348	114758349	rs7903146	Type 2 diabetes	TCF7L2	1.37	3E-23
chr10	114758348	114758349	rs7903146	Type 2 diabetes	TCF7L2	1.71	5E-8
chr10	114758348	114758349	rs7903146	Type 2 diabetes	TCF7L2	1.34	1E-8
chr10	114758348	114758349	rs7903146	Type 2 diabetes	TCF7L2	1.38	2E-31
chr10	114758348	114758349	rs7903146	Type 2 diabetes	TCF7L2	1.38	2E-10
chr10	114758348	114758349	rs7903146	Type 2 diabetes	TCF7L2	1.65	2E-34
chr10	114788814	114788815	rs12243326	Two-hour glucose challenge	TCF7L2	.08	1E-7
chr10	115235113	115235114	rs1472750	Myopia (pathological)	Intergenic	NR	5E-9
chr10	115481017	115481018	rs3814231	Vitiligo	CASP7	1.23	4E-8
chr10	115756129	115756130	rs82625	Gaucher disease severity	ADRB1	NR	2E-6
chr10	115781526	115781527	rs2782980	Blood pressure	ADRB1	.34	2E-9
chr10	115814391	115814392	rs10885531	Adiponectin levels	NR	.02	4E-6
chr10	116139028	116139029	rs4751674	Cognitive performance	AFAP1L2	NR	4E-6
chr10	116327549	116327550	rs10885582	Prostate cancer (gene x gene interaction)	ABLIM1	1.37	4E-6
chr10	117512587	117512588	rs10490919	Information processing speed	ATRNL1	.12	2E-6
chr10	118397970	118397971	rs10885997	Phospholipid levels (plasma)	PNLIPRP2	.80	8E-9
chr10	118575605	118575606	rs740363	Heart failure	KIAA1598	NR	9E-6
chr10	118827559	118827560	rs7078160	Orofacial clefts	NR	NR	6E-10
chr10	118827559	118827560	rs7078160	Orofacial clefts	NR	1.38	4E-11
chr10	118827559	118827560	rs7078160	Orofacial clefts	KIAA1598, VAX1	1.36	2E-8
chr10	119181870	119181871	rs181500	Bipolar disorder and schizophrenia	Intergenic	1.24	5E-6
chr10	119210374	119210375	rs6585436	Cardiac repolarization	PDZD8, EMX2	2.08	6E-6
chr10	119379655	119379656	rs181654	Airflow obstruction	EMX2	.81	1E-7
chr10	119418103	119418104	rs2184898	Conduct disorder (case status)	Intergenic	1.33	3E-6
chr10	120278943	120278944	rs12413624	Pancreatic cancer	PRLHR	1.23	5E-11
chr10	121149402	121149403	rs10886471	Type 2 diabetes	GRK5	1.12	7E-9
chr10	121429632	121429633	rs2234962	Dilated cardiomyopathy	BAG3	1.52	4E-12
chr10	122720973	122720974	rs4752485	Pulmonary function decline	Intergenic	.15	7E-6
chr10	122900622	122900623	rs2901286	Response to treatment for acute lymphoblastic leukemia	intergenic	4.66	4E-6
chr10	122939373	122939374	rs7085142	Visceral fat	BRWD2	NR	6E-6
chr10	123032518	123032519	rs11199874	Prostate cancer	Intergenic	NR	3E-10
chr10	123033548	123033549	rs10788160	Prostate-specific antigen levels	FGFR2	10.20	5E-15
chr10	123332576	123332577	rs3750817	Breast cancer	FGFR2	1.22	8E-8
chr10	123337334	123337335	rs2981579	Breast cancer	FGFR2	1.43	4E-31
chr10	123337334	123337335	rs2981579	Breast cancer	FGFR2	1.17	2E-10
chr10	123346115	123346116	rs2981575	Breast cancer	FGFR2	1.28	1E-8
chr10	123346189	123346190	rs1219648	Breast cancer	FGFR2	1.31	1E-30
chr10	123346189	123346190	rs1219648	Breast cancer	FGFR2	1.32	2E-13
chr10	123346189	123346190	rs1219648	Breast cancer	FGFR2	1.20	1E-10
chr10	123352316	123352317	rs2981582	Breast cancer	FGFR2	1.26	2E-76
chr10	123625189	123625190	rs10510102	Breast cancer	FGFR2	1.12	2E-6
chr10	123913329	123913330	rs17103138	Myopia (pathological)	TACC2	NR	2E-7
chr10	124165614	124165615	rs6585827	Height	PLEKHA1	.05	2E-6
chr10	124214447	124214448	rs10490924	Age-related macular degeneration (GA)	ARMS2, HTRA1	2.52	7E-47
chr10	124214447	124214448	rs10490924	Age-related macular degeneration (CNV)	ARMS2,HTRA1	3.67	2E-138
chr10	124214447	124214448	rs10490924	Age-related macular degeneration (CNV vs. GA)	ARMS2,HTRA1	1.38	7E-14
chr10	124214447	124214448	rs10490924	Age-related macular degeneration	ARMS2, HTRA1	3.00	3E-72
chr10	124214447	124214448	rs10490924	Age-related macular degeneration	HTRA1	2.94	4E-322
chr10	124214447	124214448	rs10490924	Age-related macular degeneration	ARMS2,HTRA1	2.75	1E-60
chr10	124214447	124214448	rs10490924	Age-related macular degeneration	ARMS2,HTRA1	NR	5E-119
chr10	124219274	124219275	rs3793917	Age-related macular degeneration	ARMS2,HTRA1	3.40	4E-60
chr10	124220543	124220544	rs11200638	Age-related macular degeneration (wet)	HTRA1	1.60	8E-12
chr10	126144178	126144179	rs2459210	Hemostatic factors and hematological phenotypes	LHPP	4.35	9E-6
chr10	126275913	126275914	rs12773846	Subcutaneous adipose tissue	LHPP	NR	7E-6
chr10	126696871	126696872	rs4962416	Prostate cancer	CTBP2	1.17	2E-7
chr10	127699935	127699936	rs10901513	Visceral fat	ADAM12, FANK1	NR	6E-6
chr10	128777389	128777390	rs9733352	Apolipoprotein Levels	DOCK1	.06	4E-8
chr10	129274502	129274503	rs4363506	Amyotrophic lateral sclerosis	Intergenic	1.90	7E-7
chr10	129678673	129678674	rs6482992	Parkinson's disease (motor and cognition)	CLRN3	2.03	4E-6
chr10	129737630	129737631	rs12049671	Response to amphetamines	PTPRE	NR	7E-6
chr10	129933455	129933456	rs2387326	Select biomarker traits	PTPRE, MKI67	NR	1E-6
chr10	129998371	129998372	rs1329189	Orofacial clefts	Intergenic	1.30	5E-6
chr10	130137104	130137105	rs11818629	HIV-1 control	Intergenic	NR	3E-6
chr10	130248925	130248926	rs9804317	Cognitive performance	RP11-264E18.1	NR	7E-6
chr10	131426021	131426022	rs477692	Response to temozolomide	MGMT	NR	1E-8
chr10	131992244	131992245	rs4751178	Speech perception in dyslexia	NR	NR	7E-6
chr10	132056414	132056415	rs4751185	HIV-1 susceptibility	GLRX3, TXNL3	NR	7E-6
chr10	132747886	132747887	rs10829848	Insulin-related traits	TCERGIL	.25	1E-7
chr10	132747886	132747887	rs10829848	Insulin-related traits	TCERG1L	.30	3E-8
chr10	132947961	132947962	rs10741243	Type 2 diabetes	TCERG1L	1.75	5E-6
chr10	133172118	133172119	rs10734105	Crohn's disease	TCERG1L	1.27	3E-8
chr10	133330025	133330026	rs11018023	Temperament	TCERG1L	.21	7E-6
chr10	133957760	133957761	rs954820	Chronic obstructive pulmonary disease-related biomarkers	JAKMIP3	NR	4E-6
chr10	135306157	135306158	rs1536827	Visceral adipose tissue/subcutaneous adipose tissue ratio	CYP2E1	NR	4E-6
chr11	202855	202856	rs11602954	Mean platelet volume	BET1L	.01	1E-14
chr11	203787	203788	rs2280543	Intracranial aneurysm	BET1L	1.25	3E-6
chr11	203787	203788	rs2280543	Uterine fibroids	ODF3, BET1L, RIC8A, SIRT3	1.39	4E-12
chr11	243267	243268	rs505404	Platelet counts	PSMD13,NLRP6	4.66	7E-25
chr11	270714	270715	rs17655730	Mean platelet volume	PSMD13,NLRP6	.01	2E-15
chr11	589563	589564	rs4963128	Systemic lupus erythematosus	KIAA1542	1.33	4E-6
chr11	589563	589564	rs4963128	Systemic lupus erythematosus	KIAA1542	1.28	3E-10
chr11	1874071	1874072	rs907611	Ulcerative colitis	LSP1	1.08	1E-10
chr11	1909005	1909006	rs3817198	Breast cancer	LSP1	1.07	3E-9
chr11	1941945	1941946	rs909116	Breast cancer	LSP1	1.17	7E-7
chr11	2169773	2169774	rs3741208	Type 1 diabetes	INS	1.25	2E-7
chr11	2170142	2170143	rs1004446	Type 1 diabetes autoantibodies	IGF2AS	1.40	3E-23
chr11	2170142	2170143	rs1004446	Type 1 diabetes	INS	1.61	4E-9
chr11	2182223	2182224	rs689	Type 1 diabetes autoantibodies	INS	NR	5E-196
chr11	2213165	2213166	rs7111341	Type 1 diabetes	INS	NR	4E-48
chr11	2233573	2233574	rs7127900	Prostate cancer	IGF2, IGF2AS, INS, TH	1.22	3E-33
chr11	2484802	2484803	rs2074238	QT interval	KCNQ1	7.88	3E-17
chr11	2486119	2486120	rs16928297	QT interval	NR	1.25	2E-6
chr11	2489341	2489342	rs12296050	Electrocardiographic traits	KCNQ1	13.16	8E-11
chr11	2489341	2489342	rs12296050	QT interval	KCNQ1	1.44	3E-17
chr11	2502318	2502319	rs12576239	QT interval	KCNQ1	1.75	1E-15
chr11	2550729	2550730	rs179429	Platelet aggregation	KCNQ1	NR	7E-6
chr11	2691470	2691471	rs231362	Type 2 diabetes	KCNQ1	1.08	3E-13
chr11	2752608	2752609	rs231906	QT interval	KCNQ1	1.51	2E-6
chr11	2766281	2766282	rs2237878	Protein quantitative trait loci	KCNQ1	NR	1E-6
chr11	2810730	2810731	rs2237886	Height	KCNQ1	.05	2E-13
chr11	2839750	2839751	rs2237892	Type 2 diabetes	KCNQ1	1.32	1E-7
chr11	2839750	2839751	rs2237892	Type 2 diabetes	KCNQ1	1.20	4E-6
chr11	2839750	2839751	rs2237892	Type 2 diabetes	KCNQ1	1.33	1E-26
chr11	2839750	2839751	rs2237892	Type 2 diabetes	KCNQ1	1.40	2E-42
chr11	2844215	2844216	rs163182	Type 2 diabetes	KCNQ1	1.28	2E-17
chr11	2857193	2857194	rs2237895	Type 2 diabetes	KCNQ1	1.29	1E-9
chr11	2858545	2858546	rs2237897	Type 2 diabetes	KCNQ1	1.33	1E-16
chr11	2936951	2936952	rs16928809	Bilirubin levels	SLC22A18	.06	1E-7
chr11	2953722	2953723	rs3847646	Calcium levels	SLC22A18,PHLDA2,CDKN1C,NAP1L4	.03	5E-6
chr11	3036323	3036324	rs739401	Longevity	CARS	NR	1E-6
chr11	4496845	4496846	rs2278170	Amyotrophic lateral sclerosis	OR52K1	1.43	7E-6
chr11	5225446	5225447	rs7950726	HbA2 levels	HBB	NR	1E-11
chr11	5225634	5225635	rs11036238	Malaria	HBB	1.59	4E-11
chr11	5264145	5264146	rs2071348	Beta thalassemia/hemoglobin E disease	HBE1, HBG2, HBG1, HBD, HBBP1	4.05	3E-15
chr11	5306508	5306509	rs4910742	Inflammatory biomarkers	HBB	NR	2E-9
chr11	5306508	5306509	rs4910742	Fetal hemoglobin levels	HBB	.58	1E-21
chr11	5518155	5518156	rs372091	Malaria	HBB	2.17	6E-14
chr11	7367094	7367095	rs10769780	Phospholipid levels (plasma)	SYT9	.80	3E-8
chr11	7708280	7708281	rs7932813	Waist circumference	OVCH2	NR	5E-6
chr11	7968358	7968359	rs878860	Atopic dermatitis	OR10A3, NLRP10	1.31	2E-22
chr11	8014776	8014777	rs12420464	Depression (quantitative trait)	EIF3F	.38	3E-6
chr11	8243797	8243798	rs11041816	Fasting glucose-related traits (interaction with BMI)	LMO1	NR	2E-7
chr11	8252852	8252853	rs110419	Neuroblastoma	LMO1	1.32	1E-13
chr11	8252852	8252853	rs110419	Neuroblastoma	LMO1	1.34	5E-16
chr11	8484088	8484089	rs10769908	Body mass index	STK33	NR	1E-6
chr11	8604592	8604593	rs4929949	Body mass index	RPL27A, TUB	.06	3E-9
chr11	8639199	8639200	rs4929923	Menarche (age at onset)	TRIM66	2.30	1E-8
chr11	10350537	10350538	rs7129220	Systolic blood pressure	ADM	.62	3E-12
chr11	10350537	10350538	rs7129220	Diastolic blood pressure	ADM	.30	6E-8
chr11	10350537	10350538	rs7129220	Blood pressure	ADM	.38	4E-7
chr11	10388781	10388782	rs2923084	HDL cholesterol	ADM,AMPD3	.41	5E-8
chr11	10390580	10390581	rs6484218	Schizophrenia, bipolar disorder and depression (combined)	ADM	NR	4E-8
chr11	10669227	10669228	rs7940646	Platelet aggregation	MRVI1	NR	1E-6
chr11	10740365	10740366	rs2018368	Bipolar disorder and schizophrenia	NR	1.24	1E-6
chr11	11228373	11228374	rs2722769	Type 2 diabetes	GALNTL4, LOC729013	1.35	2E-6
chr11	11504227	11504228	rs7940423	Response to tocilizumab in rheumatoid arthritis	Intergenic	10.90	1E-7
chr11	12070664	12070665	rs16910421	Visceral fat	DKK3	NR	4E-6
chr11	12072502	12072503	rs923175	Response to taxane treatment (docetaxel)	DKK3	NR	7E-6
chr11	12469396	12469397	rs7120489	Mortality among heart failure patients	PARVA	1.35	7E-6
chr11	12698039	12698040	rs7926971	Height	TEAD1	.02	4E-10
chr11	13293904	13293905	rs900145	Menarche (age at onset)	ARNTL	2.30	2E-8
chr11	13361523	13361524	rs6486122	Plasminogen activator inhibitor type 1 levels (PAI-1)	ARNTL	.05	2E-10
chr11	13620171	13620172	rs9630182	Bone mineral density	PTH	.11	4E-7
chr11	14098481	14098482	rs17556665	Inflammatory biomarkers	SPON1	NR	1E-6
chr11	14784109	14784110	rs11023332	Adiponectin levels	NR	.02	7E-6
chr11	14910233	14910234	rs1993116	Vitamin D levels	CYP2R1	.25	3E-17
chr11	14914877	14914878	rs10741657	Vitamin D insufficiency	CYP2R1	NR	3E-20
chr11	14915309	14915310	rs2060793	Vitamin D levels	CYP2R1	.25	3E-17
chr11	15355245	15355246	rs11605083	Prostate cancer (gene x gene interaction)	INSC	1.28	4E-6
chr11	15694461	15694462	rs7117858	Bone mineral density (hip)	SOX6	.09	6E-10
chr11	15952293	15952294	rs11023787	Wrist bone mass	SOX6	NR	5E-16
chr11	16040174	16040175	rs16932455	Capecitabine sensitivity	SOX6	NR	2E-6
chr11	16389593	16389594	rs297325	Obesity and osteoporosis	SOX6	NR	4E-7
chr11	16403510	16403511	rs4756846	Obesity and osteoporosis	SOX6	NR	5E-7
chr11	16902267	16902268	rs381815	Blood pressure	PLEKHA7	.24	7E-6
chr11	16902267	16902268	rs381815	Blood pressure	PLEKHA7	.30	3E-8
chr11	16902267	16902268	rs381815	Systolic blood pressure	PLEKHA7	.65	2E-9
chr11	16917218	16917219	rs11024074	Diastolic blood pressure	PLEKHA7	.33	1E-6
chr11	17008604	17008605	rs11024102	Glaucoma (primary open-angle)	PLEKHA7	1.22	5E-12
chr11	17160147	17160148	rs4356203	Schizophrenia	NR	1.09	1E-7
chr11	17316028	17316029	rs1330	Height	NUCB2	.02	5E-9
chr11	17408629	17408630	rs5215	Type 2 diabetes	KCNJ11	1.16	4E-7
chr11	17408629	17408630	rs5215	Type 2 diabetes	KCNJ11	1.14	5E-11
chr11	17409571	17409572	rs5219	Type 2 diabetes	KCNJ11	1.19	5E-7
chr11	17409571	17409572	rs5219	Type 2 diabetes	KCNJ11	1.25	1E-9
chr11	17409571	17409572	rs5219	Type 2 diabetes	KCNJ11	1.14	7E-11
chr11	17409571	17409572	rs5219	Type 2 diabetes	KCNJ11	1.15	1E-7
chr11	18265798	18265799	rs12282742	Bipolar disorder and schizophrenia	NR	1.67	1E-6
chr11	18285773	18285774	rs4638289	Amyloid A Levels	SAA1	.31	3E-53
chr11	18323516	18323517	rs4353250	Amyloid A Levels	HPS5, GTF2H1	.27	2E-51
chr11	18325145	18325146	rs2403254	Metabolic traits	HPS5	.11	1E-20
chr11	18419805	18419806	rs2896526	Amyloid A Levels	LDHA, LDHC	.22	4E-22
chr11	18632983	18632984	rs10128711	Cholesterol, total	SPTY2D1	1.06	3E-8
chr11	18689652	18689653	rs12295403	Ovarian reserve	TMEM86A	NR	5E-6
chr11	19569562	19569563	rs874426	Attention deficit hyperactivity disorder (time to onset)	Intergenic	NR	4E-6
chr11	19599970	19599971	rs10741780	HIV-1 susceptibility	AC023950.6	.00	6E-6
chr11	20562518	20562519	rs7128311	Response to treatment for acute lymphoblastic leukemia	intergenic	13.90	5E-6
chr11	20698928	20698929	rs1793004	Crohn's disease	NELL1	1.30	3E-6
chr11	20984204	20984205	rs61883261	Response to amphetamines	NELL1	NR	9E-6
chr11	21058730	21058731	rs4569005	Adverse response to lamotrigine and phenytoin	NELL1	NR	5E-6
chr11	21620947	21620948	rs1573535	Cannbis use (initiation)	NELL1	.03	4E-6
chr11	22114092	22114093	rs11026412	Parkinson's disease	Intergenic	1.16	3E-6
chr11	22829756	22829757	rs7111546	Dialysis-related mortality	GAS2	1.72	2E-6
chr11	22843154	22843155	rs712022	Dialysis-related mortality	SVIP	1.61	6E-6
chr11	23044591	23044592	rs10833905	Sudden cardiac arrest	Intergenic	1.32	7E-7
chr11	24252527	24252528	rs16912285	Visceral adipose tissue/subcutaneous adipose tissue ratio	LUZP2	NR	7E-6
chr11	24611129	24611130	rs12361953	Alzheimer's disease (late onset)	LUZP2	NR	8E-7
chr11	24678818	24678819	rs4561213	Magnesium levels	LUZP2	.00	3E-7
chr11	24739803	24739804	rs10834449	Intelligence	LUZP2	NR	8E-8
chr11	24740433	24740434	rs2716458	Intelligence	LUZP2	NR	8E-8
chr11	24741658	24741659	rs12798374	Intelligence	LUZP2	NR	8E-8
chr11	24741756	24741757	rs1021261	Intelligence	LUZP2	NR	8E-8
chr11	24849565	24849566	rs10500991	Iron status biomarkers	LUZP2	NR	2E-6
chr11	25207703	25207704	rs12794435	Ovarian cancer	NR	1.16	5E-6
chr11	26605330	26605331	rs12295638	Obesity (extreme)	MUC15	1.49	4E-6
chr11	27563381	27563382	rs988712	Obesity	BDNF	1.36	5E-17
chr11	27583128	27583129	rs7481311	Weight	BDNF	3.50	3E-6
chr11	27583128	27583129	rs7481311	Body mass index	BDNF	3.15	8E-6
chr11	27667201	27667202	rs925946	Weight	BDNF	3.80	4E-9
chr11	27667201	27667202	rs925946	Body mass index	BDNF	3.85	9E-10
chr11	27679915	27679916	rs6265	Smoking behavior	BDNF	1.06	2E-8
chr11	27679915	27679916	rs6265	Weight	BDNF	4.00	2E-7
chr11	27679915	27679916	rs6265	Body mass index	BDNF	4.58	5E-10
chr11	27725985	27725986	rs10767664	Body mass index	BDNF	.19	5E-26
chr11	27728538	27728539	rs2030323	Body mass index	BDNF	.05	4E-16
chr11	28009462	28009463	rs1568889	Bipolar disorder	NR	NR	2E-6
chr11	29162135	29162136	rs1602565	Schizophrenia	Intergenic	1.16	3E-6
chr11	29195136	29195137	rs1491818	Amyotrophic lateral sclerosis (age of onset)	Intergenic	NR	8E-6
chr11	30382898	30382899	rs12294104	Menopause (age at onset)	Intergenic	.23	1E-11
chr11	30467499	30467500	rs11031093	Dental caries	MPPED2	1.36	8E-6
chr11	30508107	30508108	rs545610	Dental caries	Intergenic	1.34	9E-6
chr11	30749089	30749090	rs963837	Renal function-related traits (sCR)	MPPED2, DCDC5	.00	3E-9
chr11	30749089	30749090	rs963837	Renal function-related traits (eGRFcrea)	MPPED2, DCDC5	.00	1E-9
chr11	30760334	30760335	rs3925584	Chronic kidney disease	MPPED2	.01	8E-18
chr11	30760334	30760335	rs3925584	Magnesium levels	DCDC5	.01	5E-16
chr11	30768677	30768678	rs10767873	Renal function-related traits (BUN)	MPPED2l, DCDC5	.01	5E-16
chr11	31210770	31210771	rs16921914	Bone mineral density (spine)	DCDC5	.08	2E-9
chr11	31905533	31905534	rs652722	Body mass index	PAX6	2.75	8E-8
chr11	32364186	32364187	rs2057178	Tuberculosis	WT1	1.10	3E-11
chr11	32522006	32522007	rs10767942	Attention deficit hyperactivity disorder	Intergenic	NR	8E-6
chr11	32895663	32895664	rs10767971	Parkinson's disease (age of onset)	QSER1, PRRG4	3.24	5E-7
chr11	33588209	33588210	rs10437629	Suicide attempts in bipolar disorder	C11orf41	1.34	4E-6
chr11	33868606	33868607	rs11032423	Cognitive performance	LMO2	NR	8E-6
chr11	34605434	34605435	rs5028798	Volumetric brain MRI	EHF	NR	3E-6
chr11	34655362	34655363	rs286913	Response to antipsychotic treatment	EHF	NR	7E-8
chr11	34805848	34805849	rs7929679	Chronic obstructive pulmonary disease-related biomarkers	APIP, EHF	NR	7E-9
chr11	34834203	34834204	rs12793173	Cystic fibrosis severity	APIP, EHF	NR	1E-9
chr11	35155731	35155732	rs2785173	Response to Vitamin E supplementation	CD44	1.94	3E-6
chr11	35280851	35280852	rs10768122	Vitiligo	CD44	1.22	2E-9
chr11	35329614	35329615	rs3794087	Essential tremor	SLC1A2	1.43	1E-7
chr11	35701235	35701236	rs7928794	Response to antipsychotic therapy (extrapyramidal side effects)	TRIM44	NR	8E-6
chr11	37012536	37012537	rs391317	Inflammatory biomarkers	Intergeic	NR	5E-7
chr11	37870980	37870981	rs16930685	Cutaneous nevi	C11orf74	.10	2E-6
chr11	38288592	38288593	rs11034653	Immune reponse to smallpox (secreted IL-12p40)	LOC100132631	NR	2E-7
chr11	39327958	39327959	rs12808199	Osteoporosis	LRRC4C	.21	9E-7
chr11	39908661	39908662	rs11035577	Temperament (bipolar disorder)	LRRC4C	1.03	6E-6
chr11	40837712	40837713	rs4611189	Reasoning	Intergenic	NR	6E-7
chr11	41852663	41852664	rs1484948	RR interval (heart rate)	Intergenic	.16	2E-6
chr11	41915365	41915366	rs9300039	Type 2 diabetes	Intergenic	1.48	6E-8
chr11	42315885	42315886	rs7394570	Immune response to smallpox vaccine (IL-6)	LOC387761	NR	1E-6
chr11	43086093	43086094	rs10501293	Cognitive performance	API5	NR	5E-6
chr11	43728329	43728330	rs11037575	Neuroblastoma	HSD17B12	1.23	5E-8
chr11	44603327	44603328	rs730129	Hemostatic factors and hematological phenotypes	CD82	2.55	7E-6
chr11	44843133	44843134	rs11038167	Schizophrenia	TSPAN18	1.29	1E-11
chr11	45813580	45813581	rs12285276	Visceral fat	CRY2, SLC35C1	NR	9E-6
chr11	45873090	45873091	rs11605924	Fasting glucose-related traits (interaction with BMI)	CRY2	NR	4E-15
chr11	45873090	45873091	rs11605924	Fasting glucose-related traits	CRY2	NR	1E-14
chr11	46052574	46052575	rs16938437	Menarche (age at onset)	PHF21A	3.70	6E-8
chr11	46379441	46379442	rs11038871	Immunoglobulin A	DGKZ, MDK, AMBRA1, HARBI1, ATG13, F2, CKAP5	1.36	2E-6
chr11	46722220	46722221	rs7932354	Bone mineral density (hip)	ARHGAP1	.07	4E-9
chr11	46743246	46743247	rs3136441	HDL cholesterol	LRP4,NR1H3	.78	3E-18
chr11	46849359	46849360	rs1007738	Bone mineral density (hip)	LRP4	.08	7E-7
chr11	46893107	46893108	rs2306029	D-dimer levels	LRP4	.03	8E-6
chr11	47127152	47127153	rs7117404	D-dimer levels	C11orf49	.04	9E-6
chr11	47275063	47275064	rs10838681	Metabolic syndrome	NR1H3	.08	1E-9
chr11	47286289	47286290	rs7120118	HDL cholesterol	NR1H3	.04	4E-8
chr11	47293798	47293799	rs10501320	Proinsulin levels	MADD	NR	1E-88
chr11	47312891	47312892	rs10838687	Proinsulin levels	MADD	NR	7E-12
chr11	47336319	47336320	rs7944584	Fasting glucose-related traits (interaction with BMI)	MADD	NR	4E-12
chr11	47336319	47336320	rs7944584	Fasting glucose-related traits	MADD	NR	2E-18
chr11	47440757	47440758	rs2293579	Serum albumin level	PSMC3	.01	8E-8
chr11	47440757	47440758	rs2293579	Serum albumin level	PSMC3	.01	1E-7
chr11	47650992	47650993	rs3817334	Body mass index	MTCH2, NDUFS3, CUGBP1	.06	2E-12
chr11	47663048	47663049	rs10838738	Body mass index	MTCH2	.07	5E-9
chr11	48098279	48098280	rs10838801	Height	PTPRJ/SLC39A13	.03	4E-12
chr11	48115088	48115089	rs3942852	Acute lymphoblastic leukemia (childhood)	PTPRJ	NR	1E-6
chr11	48207258	48207259	rs11039571	D-dimer levels	PTPRJ	.04	9E-6
chr11	48333359	48333360	rs1483121	Fasting glucose-related traits (interaction with BMI)	OR4S1	NR	2E-8
chr11	48382470	48382471	rs1351696	D-dimer levels	OR4C45	.04	8E-6
chr11	48518892	48518893	rs7395662	HDL cholesterol	MADD, FOLH1	.07	6E-11
chr11	49559171	49559172	rs1814175	Height	FOLH1	.02	2E-8
chr11	51414217	51414218	rs5017948	Height	OR4A5	.03	3E-8
chr11	55136218	55136219	rs7927370	Systemic lupus erythematosus	OR4A15	1.92	7E-6
chr11	55862090	55862091	rs2945816	Phospholipid levels (plasma)	OR812	.80	2E-8
chr11	56175670	56175671	rs1945213	Acute lymphoblastic leukemia (childhood)	OR8U8	NR	4E-8
chr11	56175670	56175671	rs1945213	Acute lymphoblastic leukemia (childhood)	OR8U8	1.30	3E-8
chr11	56242260	56242261	rs7939886	Myopia (pathological)	Intergenic	NR	2E-7
chr11	56440235	56440236	rs11228719	Orofacial clefts	NR	1.64	4E-6
chr11	56466098	56466099	rs1397048	Hemostatic factors and hematological phenotypes	OR5AP2, OR5AR1, OR9G1, OR9G4	NR	7E-8
chr11	57203008	57203009	rs11229030	Crohn's disease	SLC43A3, PRG2, PRG3	1.15	8E-9
chr11	58472798	58472799	rs2507838	Body mass (lean)	GLYAT	NR	2E-8
chr11	59633492	59633493	rs526934	Folate pathway vitamin levels	TCN1	27.62	2E-6
chr11	59837191	59837192	rs2298585	Vitamin B12 levels	MS4A3	71.80	3E-15
chr11	59939306	59939307	rs610932	Alzheimer's disease	MS4A6A, MS4A4E	1.11	2E-14
chr11	59997665	59997666	rs600550	Lipoprotein-associated phospholipase A2 activity and mass	MS4A4E	.01	2E-11
chr11	60023086	60023087	rs1562990	Alzheimer's disease	MS4A	1.14	4E-11
chr11	60034428	60034429	rs4938933	Alzheimer's disease (late onset)	MS4A4A	1.12	8E-12
chr11	60760611	60760612	rs17824933	Multiple sclerosis	CD6	1.18	4E-9
chr11	60793650	60793651	rs4939490	Multiple sclerosis	CD6	1.30	1E-9
chr11	60832281	60832282	rs650258	Multiple sclerosis	CD5, CD6	1.12	2E-11
chr11	61417471	61417472	rs1692120	Phospholipid levels (plasma)	DAGLA	.01	1E-8
chr11	61490485	61490486	rs198426	Phospholipid levels (plasma)	DAGLA	.02	3E-9
chr11	61494326	61494327	rs4963243	Immune reponse to smallpox (secreted IL-2)	DAGLA	NR	2E-7
chr11	61551355	61551356	rs174535	Phospholipid levels (plasma)	C11orf9	.08	6E-58
chr11	61551355	61551356	rs174535	Phospholipid levels (plasma)	C11orf9	.07	1E-151
chr11	61551926	61551927	rs174536	Phospholipid levels (plasma)	C11orf9	.02	1E-63
chr11	61557802	61557803	rs102275	Metabolite levels	FADS1,FADS2,FADS3	NR	4E-264
chr11	61557802	61557803	rs102275	Phospholipid levels (plasma)	FADS1, FADS2, FADS3	.00	1E-203
chr11	61557802	61557803	rs102275	Phospholipid levels (plasma)	C11orf10	.07	8E-153
chr11	61557802	61557803	rs102275	Phospholipid levels (plasma)	C11orf10	.02	7E-64
chr11	61557802	61557803	rs102275	Crohn's disease	FADS1	1.08	2E-11
chr11	61557802	61557803	rs102275	Metabolic syndrome	C11orf10	NR	6E-7
chr11	61560080	61560081	rs174538	Phospholipid levels (plasma)	C11orf10	.08	5E-58
chr11	61564298	61564299	rs4246215	Platelet counts	FEN1	2.45	3E-10
chr11	61564298	61564299	rs4246215	Phospholipid levels (plasma)	FEN1	.02	9E-60
chr11	61564298	61564299	rs4246215	Phospholipid levels (plasma)	FEN1	.08	6E-55
chr11	61564298	61564299	rs4246215	Phospholipid levels (plasma)	FEN1	.07	1E-139
chr11	61569829	61569830	rs174546	Metabolic syndrome	FADS1	.03	6E-7
chr11	61569829	61569830	rs174546	Triglycerides	FADS1,FADS2,FADS3	3.82	5E-24
chr11	61569829	61569830	rs174546	LDL cholesterol	FADS1,FADS2,FADS3	1.71	1E-21
chr11	61569829	61569830	rs174546	HDL cholesterol	FADS1,FADS2,FADS3	.73	2E-22
chr11	61569829	61569830	rs174546	Cholesterol, total	FADS1,FADS2,FADS3	1.78	2E-22
chr11	61569829	61569830	rs174546	LDL cholesterol	FADS1, FADS2	.10	1E-7
chr11	61570782	61570783	rs174547	Comprehensive strength and appendicular lean mass	FADS1, FADS2	NR	2E-7
chr11	61570782	61570783	rs174547	Lipid metabolism phenotypes	FADS1, FADS2, FADS3	.57	8E-262
chr11	61570782	61570783	rs174547	Metabolic traits	FADS1	.18	9E-116
chr11	61570782	61570783	rs174547	Phospholipid levels (plasma)	FADS1	.07	4E-154
chr11	61570782	61570783	rs174547	Phospholipid levels (plasma)	FADS1	.02	3E-64
chr11	61570782	61570783	rs174547	Resting heart rate	FADS1	6.20	2E-9
chr11	61570782	61570783	rs174547	Metabolite levels	FADS1	36.30	7E-179
chr11	61570782	61570783	rs174547	Triglycerides	FADS1, FADS2, FADS3	.06	2E-14
chr11	61570782	61570783	rs174547	HDL cholesterol	FADS1, FADS2, FADS3	.09	2E-12
chr11	61571347	61571348	rs174548	Triglycerides	FADS1	.03	5E-14
chr11	61571347	61571348	rs174548	HDL cholesterol	FADS1	.01	1E-12
chr11	61571347	61571348	rs174548	Metabolite levels	FADS1	NR	5E-8
chr11	61571381	61571382	rs174549	Comprehensive strength and appendicular lean mass	FADS1, FADS2	NR	8E-7
chr11	61571477	61571478	rs174550	Fasting glucose-related traits (interaction with BMI)	FADS1	NR	2E-9
chr11	61571477	61571478	rs174550	Phospholipid levels (plasma)	FADS1	.08	1E-57
chr11	61571477	61571478	rs174550	Fasting glucose-related traits	FADS1	NR	5E-13
chr11	61571477	61571478	rs174550	Fasting glucose-related traits	FADS1	NR	2E-15
chr11	61597211	61597212	rs174570	LDL cholesterol	FADS2, FADS3	.11	4E-13
chr11	61597211	61597212	rs174570	HDL cholesterol	FADS2, FADS3	.06	4E-6
chr11	61597211	61597212	rs174570	Cholesterol, total	FADS2, FADS3	.09	2E-10
chr11	61597971	61597972	rs1535	Phospholipid levels (plasma)	FADS2	.02	3E-63
chr11	61597971	61597972	rs1535	Phospholipid levels (plasma)	FADS2	.07	3E-152
chr11	61597971	61597972	rs1535	Metabolic syndrome	FADS2	.03	4E-7
chr11	61597971	61597972	rs1535	Response to statin therapy	FADS2, FADS1, FEN	NR	7E-6
chr11	61600341	61600342	rs174574	Phospholipid levels (plasma)	FADS2	.08	4E-55
chr11	61609749	61609750	rs174583	Response to statin therapy	FADS2, FADS1, FADS3	NR	3E-6
chr11	61623139	61623140	rs174601	Liver enzyme levels (alkaline phosphatase)	C11orf10, FADS1, FADS2	1.70	3E-9
chr11	61639572	61639573	rs174448	Phospholipid levels (plasma)	FADS3	.05	7E-28
chr11	61639572	61639573	rs174448	Phospholipid levels (plasma)	FADS3	.01	4E-25
chr11	61639572	61639573	rs174448	Phospholipid levels (plasma)	FADS3	.05	3E-60
chr11	61655304	61655305	rs1000778	Sphingolipid levels	FADS3	.62	7E-13
chr11	61663690	61663691	rs174468	Phospholipid levels (plasma)	RAB3IL1	.04	3E-35
chr11	61663690	61663691	rs174468	Phospholipid levels (plasma)	RAB3IL1	.05	2E-17
chr11	61663690	61663691	rs174468	Phospholipid levels (plasma)	RAB3IL1	.01	1E-12
chr11	61678753	61678754	rs174479	Sphingolipid levels	FADS1, FADS2, FADS3	.00	2E-14
chr11	61711474	61711475	rs2521572	Phospholipid levels (plasma)	BEST1	.05	2E-9
chr11	61712130	61712131	rs2727261	Estradiol levels	BEST1, FTH1	.16	3E-6
chr11	61722644	61722645	rs1109748	Phospholipid levels (plasma)	BEST1	.05	5E-9
chr11	61746290	61746291	rs10792320	Phospholipid levels (plasma)	FTH1	.02	8E-8
chr11	61795585	61795586	rs11230874	Phospholipid levels (plasma)	FTH1	.07	2E-8
chr11	61815802	61815803	rs4963452	Phospholipid levels (plasma)	INCENP	.02	6E-7
chr11	62103419	62103420	rs2463822	Chronic obstructive pulmonary disease-related biomarkers	ASRGL1	NR	1E-10
chr11	62186541	62186542	rs3741240	Chronic obstructive pulmonary disease-related biomarkers	SCGB1A1	NR	1E-26
chr11	62197426	62197427	rs2077224	Chronic obstructive pulmonary disease-related biomarkers	AHNAK	NR	2E-14
chr11	62199816	62199817	rs17157266	Chronic obstructive pulmonary disease-related biomarkers	AHNAK	NR	1E-9
chr11	62771387	62771388	rs11231299	Visceral fat	SLC22A8	NR	5E-6
chr11	63173683	63173684	rs7101446	Economic and political preferences	SLC22A9	.15	3E-6
chr11	63592620	63592621	rs10897449	Electroencephalographic traits in alcoholism	C11orf84	.10	7E-6
chr11	63963946	63963947	rs11607165	Attention deficit hyperactivity disorder	STIP1	NR	4E-6
chr11	63979642	63979643	rs12575642	Attention deficit hyperactivity disorder	FERMT3	NR	1E-6
chr11	63991800	63991801	rs1059440	Attention deficit hyperactivity disorder	TRPT1	NR	4E-6
chr11	64048911	64048912	rs477895	Mean platelet volume	BAD	4.19	5E-8
chr11	64097232	64097233	rs694739	Crohn's disease	PRDX5,ESRRA	1.10	6E-10
chr11	64097232	64097233	rs694739	Alopecia areata	PRDX5	1.33	4E-7
chr11	64107476	64107477	rs479777	Sarcoidosis	CCDC88B, KCNK4, PRDX5, BAD, GPR137	1.18	3E-18
chr11	64129721	64129722	rs538147	Leprosy	RPS6KA4	1.17	7E-6
chr11	64129721	64129722	rs538147	Primary biliary cirrhosis	RPS6KA4	1.23	2E-10
chr11	64331461	64331462	rs17300741	Uric acid levels	SLC22A11	.06	7E-14
chr11	64334113	64334114	rs2078267	Urate levels	SLC22A11	6.80	2E-26
chr11	64334113	64334114	rs2078267	Urate levels	SLC22A11	1.26	1E-6
chr11	64357071	64357072	rs505802	Uric acid levels	SLC22A12	.06	2E-9
chr11	64359220	64359221	rs12800450	Urate levels	SLC22A12	1.19	3E-16
chr11	64464084	64464085	rs504915	Renal function-related traits (urea)	SLC22A12	.23	3E-63
chr11	64525215	64525216	rs589691	Urate levels	Intergenic	.15	9E-8
chr11	64546390	64546391	rs606458	Urate levels	MEN1,SF1,MAP4K2,PYGM,RASGRP2,CDC42BPG,NRXN2	.18	6E-11
chr11	64557053	64557054	rs493573	Urate levels	MAP4K2	.80	2E-17
chr11	64584230	64584231	rs470763	Economic and political preferences (fairness)	Intergenic	.11	5E-6
chr11	65249144	65249145	rs17146964	Vertical cup-disc ratio	SCYL1	.01	4E-9
chr11	65336818	65336819	rs3782089	Height	SSSCA1	.06	4E-13
chr11	65349755	65349756	rs6591182	Non-alcoholic fatty liver disease histology (lobular)	LTBP3, EHBP1L1	.54	9E-7
chr11	65506821	65506822	rs4014195	Chronic kidney disease	RNASEH2C,KAT5,OVOL1	.01	1E-7
chr11	65513106	65513107	rs593982	Atopic dermatitis	OVOL1	1.23	6E-7
chr11	65551956	65551957	rs479844	Atopic dermatitis	OVOL1	1.14	1E-13
chr11	66335307	66335308	rs2242663	Bipolar disorder	NR	1.20	1E-6
chr11	66551001	66551002	rs10896135	Bipolar disorder	ZDHHC24, YIF1A, TMEM151A, SYT12, SPTBN2,SLC29A2, SF3B2, RIN1, RCE1, RBM4B, RBM4, RBM14, RAB1B, PELI3, PC, PACS1, NPAS4, MRPL11, LRFN4, KLC2, GAL3ST3, DPP3, CTSF, CNIH2, CD248, CCS, CCDC87, C11orf86, C11orf80, BRMS1, BBS1, B3GNT1, ACTN3	1.12	2E-7
chr11	66662730	66662731	rs7122539	HIV-1 susceptibility	PC	.00	8E-6
chr11	66826159	66826160	rs7112925	Height	RHOD	.02	9E-10
chr11	68192345	68192346	rs599083	Bone mineral density (spine)	LRP5	.07	5E-8
chr11	68201294	68201295	rs3736228	Bone mineral density	LRP5	.13	6E-12
chr11	68840159	68840160	rs3750965	Hair color	NR	NR	3E-7
chr11	68846398	68846399	rs35264875	Blond vs. brown hair color	TPCN2	2.49	4E-30
chr11	68978579	68978580	rs11228565	Prostate cancer	Intergenic	1.23	7E-12
chr11	68994496	68994497	rs7931342	Prostate cancer	Intergenic	1.19	2E-12
chr11	68994666	68994667	rs10896449	Prostate cancer	Intergenic	1.10	2E-9
chr11	68995957	68995958	rs7130881	Prostate cancer	Intergenic	1.31	9E-9
chr11	68995957	68995958	rs7130881	Prostate cancer	NR	NR	8E-13
chr11	69143283	69143284	rs7102705	Breast size	IFITM9P, CCND1	.09	5E-6
chr11	69234493	69234494	rs4980785	Renal cell carcinoma	NR	NR	2E-6
chr11	69239740	69239741	rs7105934	Renal cell carcinoma	Intergenic	1.45	8E-14
chr11	69328763	69328764	rs614367	Breast cancer	MYEOV,CCND1,ORAOV1,FGF19,FGF4,FGF3	1.15	3E-15
chr11	69596522	69596523	rs4084127	Type 1 diabetes	NR	1.11	3E-6
chr11	70506205	70506206	rs525304	Response to fenofibrate (adiponectin levels)	SHANK2	.04	3E-6
chr11	71167448	71167449	rs12785878	Vitamin D insufficiency	DHCR7,NADSYN1	NR	2E-27
chr11	71194558	71194559	rs3829251	Vitamin D levels	NADSYN1,DHCR7	.18	3E-9
chr11	71234106	71234107	rs11234027	Vitamin D levels	NADSYN1,DHCR7	.18	3E-9
chr11	72250122	72250123	rs12418204	Optic disc size (cup)	PDE2A	.31	5E-6
chr11	72373495	72373496	rs3781913	Rheumatoid arthritis	PDE2A, ARAP1	1.12	6E-10
chr11	72432984	72432985	rs11603334	Fasting glucose-related traits (interaction with BMI)	ARAP1	NR	2E-14
chr11	72432984	72432985	rs11603334	Proinsulin levels	ARAP1	NR	3E-102
chr11	72433097	72433098	rs1552224	Type 2 diabetes	CENTD2	1.14	1E-22
chr11	72894847	72894848	rs1791933	Insomnia (caffeine-induced)	P2RY2	3.70	8E-6
chr11	74168410	74168411	rs2270676	Corneal astigmatism	KCNE3	1.29	5E-6
chr11	74345549	74345550	rs3824999	Colorectal cancer	POLD3	1.08	4E-10
chr11	75276177	75276178	rs606452	Height	SERPINH1	.04	2E-9
chr11	75282051	75282052	rs634552	Height	SERPINH1	.04	4E-13
chr11	75909618	75909619	rs4944092	PR interval	WNT11	1.19	3E-8
chr11	76270682	76270683	rs7130588	Asthma	LRRC32	1.09	2E-8
chr11	76299193	76299194	rs2155219	IgE grass sensitization	C11orf30, LRRC32	1.22	1E-8
chr11	76299193	76299194	rs2155219	Allergic rhinitis	C11orf30, LRRC32	1.17	4E-8
chr11	76299193	76299194	rs2155219	Ulcerative colitis	Intergenic	1.13	5E-16
chr11	76301315	76301316	rs7927894	Atopic dermatitis	C11orf30	1.22	8E-10
chr11	76301315	76301316	rs7927894	Crohn's disease	C11orf30	1.16	1E-9
chr11	76301374	76301375	rs7927997	Crohn's disease	C11orf30	1.17	6E-13
chr11	76332209	76332210	rs11236809	Atopic dermatitis	C11orf30	1.24	3E-6
chr11	76823483	76823484	rs3781684	Cognitive performance	CAPN5	NR	7E-6
chr11	77154638	77154639	rs527589	Orofacial clefts	NR	1.75	3E-6
chr11	78091149	78091150	rs2373115	Alzheimer's disease (late onset)	GAB2	4.06	1E-10
chr11	78095372	78095373	rs10899489	Menarche (age at onset)	GAB2	3.10	8E-9
chr11	79065100	79065101	rs530965	Cognitive test performance	Intergenic	NR	4E-6
chr11	79077192	79077193	rs12576775	Bipolar disorder	ODZ4	1.14	4E-8
chr11	79083619	79083620	rs12290811	Bipolar disorder	NR	1.20	4E-6
chr11	80377051	80377052	rs17140547	Lentiform nucleus volume	Intergenic	532.56	8E-6
chr11	80562737	80562738	rs11232369	Cognitive performance	AC018897.4	NR	8E-6
chr11	80854374	80854375	rs1357339	HIV-1 control	Intergenic	NR	5E-6
chr11	80985547	80985548	rs1458095	Body mass index	NR	.19	7E-6
chr11	82723071	82723072	rs11233413	Economic and political preferences (feminism/equality)	RAB30	.11	4E-7
chr11	83455706	83455707	rs3885683	Protein quantitative trait loci	DLG2	NR	8E-6
chr11	83620786	83620787	rs790356	Wilms tumor	DLG2	1.28	4E-15
chr11	84417845	84417846	rs10501570	Parkinson's disease	DLG2	5.00	7E-6
chr11	84822320	84822321	rs1452928	Hip geometry	Intergenic	NR	7E-7
chr11	85017475	85017476	rs17148090	Phospholipid levels (plasma)	DLG2	.70	4E-8
chr11	85164750	85164751	rs10898392	Height	TMEM126B, TMEM126A	NR	3E-6
chr11	85677470	85677471	rs17817600	Alzheimer's disease	PICALM	1.33	2E-8
chr11	85783737	85783738	rs621942	Tourette syndrome	PICALM	1.22	9E-6
chr11	85787823	85787824	rs536841	Alzheimer's disease	PICALM	1.16	3E-9
chr11	85800278	85800279	rs561655	Alzheimer's disease (late onset)	PICALM	1.15	7E-11
chr11	85838807	85838808	rs10792830	Alzheimer's disease	AP003097.1	1.25	6E-6
chr11	85868639	85868640	rs3851179	Alzheimer's disease	PICALM	1.16	1E-9
chr11	86055900	86055901	rs6592284	Cognitive performance	C11orf73	NR	2E-6
chr11	87819426	87819427	rs1386330	Multiple sclerosis (age of onset)	RAB38	NR	2E-6
chr11	88321723	88321724	rs16914280	HIV-1 control	Intergenic	NR	3E-7
chr11	88557990	88557991	rs10831496	Tanning	GRM5	.14	5E-9
chr11	88741659	88741660	rs5016282	Attention deficit hyperactivity disorder	GRM5	NR	1E-6
chr11	88911695	88911696	rs1042602	Skin pigmentation	TYR	4.36	4E-10
chr11	88911695	88911696	rs1042602	Freckles	TYR	1.32	2E-11
chr11	89005252	89005253	rs1847134	Eye color	TYR	1.58	1E-15
chr11	89011045	89011046	rs1393350	Melanoma	TYR	1.30	2E-13
chr11	89011045	89011046	rs1393350	Eye color	TYR	.28	3E-9
chr11	89011045	89011046	rs1393350	Vitiligo	TYR	1.53	2E-18
chr11	89011045	89011046	rs1393350	Melanoma	TYR	1.29	2E-14
chr11	89011045	89011046	rs1393350	Tanning	TYR	.19	2E-13
chr11	89011045	89011046	rs1393350	Skin sensitivity to sun	TYR	1.26	2E-6
chr11	89011045	89011046	rs1393350	Blue vs. green eyes	TYR	1.52	3E-12
chr11	89345024	89345025	rs1488902	Amyotrophic lateral sclerosis	NR	1.15	3E-6
chr11	89502375	89502376	rs2130017	Response to taxane treatment (docetaxel)	TRIM49	NR	8E-6
chr11	89875436	89875437	rs11018874	White blood cell types	NAALAD2	.08	2E-9
chr11	90586899	90586900	rs12274302	HIV-1 control	Intergenic	NR	4E-7
chr11	90884338	90884339	rs1528753	Aging traits	Intergenic	NR	8E-8
chr11	90956213	90956214	rs4491175	Response to angiotensin II receptor blocker therapy	MIR1261	1.10	8E-6
chr11	91952153	91952154	rs1350445	Subclinical atherosclerosis traits (other)	Intergenic	NR	9E-6
chr11	92651001	92651002	rs7950811	Conduct disorder (symptom count)	Intergenic	.16	1E-8
chr11	92651001	92651002	rs7950811	Conduct disorder (case status)	Intergenic	1.65	9E-7
chr11	92673827	92673828	rs1387153	Metabolic syndrome (bivariate traits)	LOC100128354	.19	8E-9
chr11	92673827	92673828	rs1387153	Metabolic syndrome (bivariate traits)	LOC100128354	.21	2E-9
chr11	92673827	92673828	rs1387153	Glycated hemoglobin levels	MTNR1B	.03	4E-11
chr11	92673827	92673828	rs1387153	Type 2 diabetes	MTNR1B	1.09	8E-15
chr11	92673827	92673828	rs1387153	Fasting plasma glucose	MTNR1B	.07	2E-36
chr11	92681012	92681013	rs10830956	Metabolic syndrome (bivariate traits)	LOC100128354	.20	5E-11
chr11	92691531	92691532	rs2166706	Fasting plasma glucose	MTNR1B	.07	2E-9
chr11	92698426	92698427	rs10830962	Metabolic syndrome	MTNR1B	.12	5E-16
chr11	92698426	92698427	rs10830962	Diabetes (gestational)	MTNR1B	1.45	2E-13
chr11	92698426	92698427	rs10830962	Metabolite levels	MTNR1B	.04	1E-16
chr11	92708709	92708710	rs10830963	Fasting glucose-related traits (interaction with BMI)	MTNR1B	NR	4E-105
chr11	92708709	92708710	rs10830963	Fasting plasma glucose	MTNR1B	1.38	1E-12
chr11	92708709	92708710	rs10830963	Metabolite levels	MTNR1B	.14	3E-11
chr11	92708709	92708710	rs10830963	Fasting glucose-related traits	MTNR1B	NR	6E-175
chr11	92708709	92708710	rs10830963	Fasting glucose-related traits	MTNR1B	NR	3E-43
chr11	92708709	92708710	rs10830963	Fasting plasma glucose	MTNR1B	.07	3E-50
chr11	92719680	92719681	rs10830964	Insomnia (caffeine-induced)	MTNR1B	1.61	5E-6
chr11	92722760	92722761	rs1447352	Metabolic traits	MTNR1B	.05	6E-8
chr11	93166730	93166731	rs2658782	Pulmonary function decline	FLJ25393	.19	4E-6
chr11	94132138	94132139	rs3758785	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)	GPR83	NR	2E-6
chr11	94271662	94271663	rs11020821	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)	FUT4	NR	4E-6
chr11	94271662	94271663	rs11020821	Response to angiotensin II receptor blocker therapy	FUT4	1.40	9E-7
chr11	94312322	94312323	rs2212361	Attention deficit hyperactivity disorder symptoms (interaction)	PIWIL4	.97	9E-7
chr11	94667963	94667964	rs10831284	Attention deficit hyperactivity disorder and conduct disorder	AMOTL1, CWC15, JMJD2D	NR	2E-6
chr11	95311421	95311422	rs4409785	Vitiligo	TYR	1.34	2E-13
chr11	95311421	95311422	rs4409785	Multiple sclerosis	Intergenic	1.10	6E-7
chr11	95422866	95422867	rs1939875	Eosinophilic esophagitis (pediatric)	NR	1.54	3E-6
chr11	95866699	95866700	rs10765792	Sudden cardiac arrest	Intergenic	1.54	8E-13
chr11	96000099	96000100	rs7115578	Response to treatment for acute lymphoblastic leukemia	MAML2	1.86	8E-6
chr11	96959524	96959525	rs11224899	Formal thought disorder in schizophrenia	JRKL	1.90	2E-6
chr11	97574983	97574984	rs11212364	Information processing speed	AP005434.1	.26	3E-6
chr11	97682563	97682564	rs2405657	Amyotrophic lateral sclerosis	NR	1.19	3E-6
chr11	98125403	98125404	rs2509843	Bipolar disorder and schizophrenia	CNTN5	1.27	2E-7
chr11	98466267	98466268	rs4237591	Non-alcoholic fatty liver disease histology (lobular)	Intergenic	.33	2E-6
chr11	99493172	99493173	rs10501920	Atrial fibrillation	CNTN5	NR	9E-6
chr11	99585735	99585736	rs952700	Volumetric brain MRI	CNTN5	NR	6E-6
chr11	100043419	100043420	rs12803066	Myopia (pathological)	CNTN5	NR	4E-6
chr11	100173536	100173537	rs11223581	Immune reponse to smallpox (secreted IL-2)	CNTN5	NR	9E-9
chr11	100593537	100593538	rs633185	Systolic blood pressure	FLJ32810, TMEM133	.57	1E-17
chr11	100593537	100593538	rs633185	Hypertension	FLJ32810, TMEM133	.07	5E-11
chr11	100593537	100593538	rs633185	Diastolic blood pressure	FLJ32810, TMEM133	.33	2E-15
chr11	100593537	100593538	rs633185	Blood pressure	FLJ32810, TMEM133	.33	7E-10
chr11	102070638	102070639	rs1894116	Polycystic ovary syndrome	YAP1	1.27	1E-22
chr11	102155473	102155474	rs2852894	MRI atrophy measures	YAP1, BIRC3	.02	1E-6
chr11	102691481	102691482	rs11225434	Matrix metalloproteinase levels	MMP-1	.39	9E-29
chr11	102695107	102695108	rs495366	Matrix metalloproteinase levels	MMP	.44	6E-34
chr11	102733162	102733163	rs12808148	Alzheimer's disease	MMP3, MMP12	1.23	1E-6
chr11	103418157	103418158	rs716274	Small-cell lung cancer	DYNC2H1	1.83	9E-8
chr11	103525753	103525754	rs7118412	Disc degeneration (lumbar)	Intergenic	.09	9E-6
chr11	103526023	103526024	rs7103004	Disc degeneration (lumbar)	Intergenic	.09	9E-6
chr11	103529631	103529632	rs12805875	Disc degeneration (lumbar)	Intergenic	.09	9E-6
chr11	103530365	103530366	rs4554859	Disc degeneration (lumbar)	Intergenic	.09	9E-6
chr11	103589093	103589094	rs1917445	Neutrophil count	PDGFD	NR	6E-7
chr11	103660566	103660567	rs974819	Coronary heart disease	PDGFD	1.07	2E-9
chr11	103808151	103808152	rs10895547	Coronary heart disease	PDGFD	.07	3E-6
chr11	104334238	104334239	rs11226373	Matrix metalloproteinase levels	MMP-1, MMP-3	.44	2E-18
chr11	106330161	106330162	rs10895959	Inattentive symptoms	Intergenic	NR	3E-6
chr11	106496037	106496038	rs1791581	Visceral adipose tissue/subcutaneous adipose tissue ratio	GUCY1A2	NR	8E-6
chr11	107481517	107481518	rs10431058	Common traits (Other)	NR	NR	8E-7
chr11	108175461	108175462	rs1801516	Melanoma	ATM	1.19	3E-9
chr11	108283160	108283161	rs11212617	Response to metformin	ATM	NR	3E-9
chr11	108283160	108283161	rs11212617	Response to metformin	ATM, C111orf65	1.35	3E-9
chr11	109995943	109995944	rs746463	Exercise treadmill test traits	Intergenic	NR	5E-6
chr11	110395857	110395858	rs12785341	Renal sinus fat	ARHGAP20	.29	8E-6
chr11	111171708	111171709	rs3802842	Colorectal cancer	LOC120376	1.14	4E-7
chr11	111171708	111171709	rs3802842	Colorectal cancer	Intergenic	1.11	6E-10
chr11	111275132	111275133	rs4938534	Primary biliary cirrhosis	POU2AF1	1.39	2E-8
chr11	112023826	112023827	rs1834481	Interleukin-18 levels	BCO2	NR	1E-8
chr11	112051168	112051169	rs2115763	Interleukin-18 levels	BCO2	NR	4E-9
chr11	112064430	112064431	rs7105056	Immune reponse to smallpox (secreted IL-12p40)	BCO2	NR	1E-8
chr11	112085315	112085316	rs2250417	Protein quantitative trait loci	IL18	NR	7E-13
chr11	112456220	112456221	rs7105881	Response to antipsychotic treatment	Intergenic	NR	3E-7
chr11	112991617	112991618	rs1436109	Left ventricular mass	NCAM1	NR	9E-7
chr11	112991617	112991618	rs1436109	Left ventricular mass	NCAM1	NR	4E-9
chr11	112991617	112991618	rs1436109	Left ventricular mass	NCAM1	NR	3E-7
chr11	113106454	113106455	rs12279261	Entorhinal cortical thickness	NCAM1	.11	9E-6
chr11	113296618	113296619	rs1079596	Select biomarker traits	DRD2	NR	3E-6
chr11	113309868	113309869	rs11214606	Working memory	DRD2	NR	5E-7
chr11	113961761	113961762	rs17116334	Conduct disorder (interaction)	ZBTB16	1.30	9E-6
chr11	114191015	114191016	rs2847476	Volumetric brain MRI	NNMT	NR	3E-6
chr11	114231254	114231255	rs11214966	Asthma	C11orf71	NR	6E-7
chr11	114431955	114431956	rs678170	Ulcerative colitis	Intergenic	1.09	5E-14
chr11	114621468	114621469	rs1712790	Urinary albumin excretion	FAM55B	NR	2E-6
chr11	115140552	115140553	rs7950069	Orofacial clefts	NR	NR	5E-6
chr11	115764044	115764045	rs638882	Hip geometry	Intergenic	NR	4E-6
chr11	116298366	116298367	rs490592	Brain structure	Intergenic	NR	1E-6
chr11	116400381	116400382	rs7941534	Bipolar disorder and schizophrenia	NR	1.27	8E-6
chr11	116520526	116520527	rs1240773	HIV-1 susceptibility	BUD13	NR	8E-6
chr11	116584986	116584987	rs4938303	Triglycerides	BUD13,ZNF259,APOA5,APOA4,APOC3,APOA1	.07	4E-21
chr11	116599391	116599392	rs180358	Multiple sclerosis (severity)	MGC13125	NR	6E-6
chr11	116603723	116603724	rs12272004	Carotenoid and tocopherol levels	APOA5	.07	8E-10
chr11	116603723	116603724	rs12272004	Triglycerides	APOA1, APOA4, APOA5, APOC3	.18	5E-13
chr11	116603723	116603724	rs12272004	LDL cholesterol	APOA1, APOA4, APOA5, APOC3	.18	5E-13
chr11	116603723	116603724	rs12272004	Cholesterol, total	APOA1, APOA4, APOA5, APOC3	.11	7E-7
chr11	116607436	116607437	rs1558861	LDL cholesterol	BUD13, ZNF259, APOA5,APOA4,APOC3,APOA1	.03	2E-6
chr11	116607436	116607437	rs1558861	Triglycerides	LOC440069, MGC13125	17.00	2E-26
chr11	116613659	116613660	rs12280753	Cardiovascular disease risk factors	CADM1,BUD13,APOA5	.69	8E-6
chr11	116617239	116617240	rs11216126	HDL cholesterol	Intergenic	.03	3E-34
chr11	116619072	116619073	rs28927680	Triglycerides	APOA1, APOC3, APOA4, APOA5, ZNF259, BUD13	.26	2E-17
chr11	116626257	116626258	rs11825181	Triglycerides-Blood Pressure (TG-BP)	BUD13	.32	3E-9
chr11	116633861	116633862	rs11820589	Metabolic syndrome (bivariate traits)	BUD13	.32	6E-9
chr11	116639103	116639104	rs10790162	Waist Circumference - Triglycerides (WC-TG)	BUD13	.39	7E-16
chr11	116639103	116639104	rs10790162	Metabolic syndrome	BUD13	.25	5E-9
chr11	116639103	116639104	rs10790162	HDL Cholesterol - Triglycerides (HDLC-TG)	BUD13	.38	3E-15
chr11	116648916	116648917	rs964184	Metabolite levels	APOA1, APOC3, APOA4, APOA5	NR	8E-20
chr11	116648916	116648917	rs964184	Response to Vitamin E supplementation	BUD13,ZNF259	.88	4E-7
chr11	116648916	116648917	rs964184	Response to Vitamin E supplementation	BUD13, ZNF259, APOA5, LOC100128347, SIK3	.07	3E-12
chr11	116648916	116648917	rs964184	Metabolic syndrome	ZNF259	.23	3E-31
chr11	116648916	116648917	rs964184	Phospholipid levels (plasma)	APOA5	1.00	2E-10
chr11	116648916	116648917	rs964184	Lipoprotein-associated phospholipase A2 activity and mass	ZNF259	.03	8E-11
chr11	116648916	116648917	rs964184	Vitamin E levels	BUD13, ZNF259, APOA5	.04	8E-12
chr11	116648916	116648917	rs964184	Coronary heart disease	ZNF259, APOA5, APOA4, APOC3, APOA1	1.13	1E-17
chr11	116648916	116648917	rs964184	HDL cholesterol	ZNF259, APOA5,APOA4,APOC3,APOA1	.03	2E-11
chr11	116648916	116648917	rs964184	Triglycerides	APOA1,APOC3,APOA4,APOA5	16.95	7E-240
chr11	116648916	116648917	rs964184	LDL cholesterol	APOA1,APOC3,APOA4,APOA5	2.85	1E-26
chr11	116648916	116648917	rs964184	HDL cholesterol	APOA1,APOC3,APOA4,APOA5	1.50	5E-47
chr11	116648916	116648917	rs964184	Cholesterol, total	APOA1,APOC3,APOA4,APOA5	4.68	6E-57
chr11	116648916	116648917	rs964184	Hypertriglyceridemia	APOA5	3.28	5E-24
chr11	116648916	116648917	rs964184	Triglycerides	APOA1, APOC3, APOA4, APOA5	.30	4E-62
chr11	116648916	116648917	rs964184	HDL cholesterol	APOA1, APOC3, APOA4, APOA5	.17	1E-12
chr11	116649134	116649135	rs11823543	Triglycerides-Blood Pressure (TG-BP)	ZNF259	.35	3E-9
chr11	116652206	116652207	rs12286037	Metabolic syndrome (bivariate traits)	ZNF259	.32	1E-8
chr11	116652206	116652207	rs12286037	Lipoprotein-associated phospholipase A2 activity and mass	ZNF259	6.40	4E-8
chr11	116652206	116652207	rs12286037	Triglycerides	APOA5, APOA4, APOC3, APOA1	25.82	1E-26
chr11	116652422	116652423	rs6589566	LDL cholesterol	APOA1,APOC3,APOA5	NR	3E-11
chr11	116653295	116653296	rs2075290	Waist Circumference - Triglycerides (WC-TG)	ZNF259	.41	1E-16
chr11	116653295	116653296	rs2075290	Metabolic syndrome	ZNF259	.26	2E-9
chr11	116653295	116653296	rs2075290	HDL Cholesterol - Triglycerides (HDLC-TG)	ZNF259	.39	2E-14
chr11	116654434	116654435	rs603446	Triglycerides	ZNF259, APOA1, APOC3, APOA4, APOA5, BUD13	.09	2E-86
chr11	116660685	116660686	rs2266788	Waist Circumference - Triglycerides (WC-TG)	APOA5	.41	2E-16
chr11	116660685	116660686	rs2266788	Triglycerides-Blood Pressure (TG-BP)	APOA5	.37	4E-8
chr11	116660685	116660686	rs2266788	Metabolic syndrome	APOA5	.26	2E-9
chr11	116660685	116660686	rs2266788	HDL Cholesterol - Triglycerides (HDLC-TG)	APOA5	.39	5E-13
chr11	116662578	116662579	rs651821	Lipid metabolism phenotypes	APOA1, APOC3, APOA4, APOA5	.27	8E-20
chr11	116662578	116662579	rs651821	Triglycerides	APOA5	NR	9E-26
chr11	116681007	116681008	rs1263173	Coronary heart disease	APOA5	.09	2E-7
chr11	116684027	116684028	rs7396835	Quantitative traits	Intergenic	.23	1E-9
chr11	116722040	116722041	rs10047462	Iron status biomarkers	APOA	.04	4E-25
chr11	116732511	116732512	rs2075292	Triglycerides	APOA1,KIAA0999,LOC645044	8.70	5E-8
chr11	116782973	116782974	rs11216185	Infantile hypertrophic pyloric stenosis	NR	1.57	1E-7
chr11	116829652	116829653	rs7120173	Visceral adipose tissue adjusted for BMI	KIAA0999	NR	5E-6
chr11	116973928	116973929	rs12269901	Coronary heart disease	Intergenic	.07	2E-6
chr11	117037360	117037361	rs7112513	Protein quantitative trait loci	PAFAH1B2	NR	6E-9
chr11	117075565	117075566	rs508487	Cardiovascular disease risk factors	PCSK7	.24	2E-10
chr11	117091608	117091609	rs236918	Iron status biomarkers	PCSK7	.04	1E-27
chr11	117156892	117156893	rs1047964	Cardiovascular disease risk factors	BACE1	4.67	8E-7
chr11	117531730	117531731	rs10892151	Triglycerides	APOA1, APOC3, APOA4, APOA5, DSCAML1	NR	3E-29
chr11	118145685	118145686	rs17122021	Pain	NR	NR	7E-7
chr11	118477366	118477367	rs498872	Glioma	PHLDB1	1.22	5E-11
chr11	118477366	118477367	rs498872	Glioma	PHLDB1	1.18	1E-8
chr11	118573518	118573519	rs4639966	Systemic lupus erythematosus	NR	1.29	1E-16
chr11	118574674	118574675	rs494459	Height	TREH	.02	2E-8
chr11	118611780	118611781	rs10892279	Celiac disease and Rheumatoid arthritis	DDX6	NR	1E-12
chr11	118698536	118698537	rs638893	Vitiligo	CXCR5, DDX6, PHLDB1, TREH, AK021715,	1.22	2E-9
chr11	118743771	118743772	rs6421571	Primary biliary cirrhosis	CXCR5	1.37	3E-12
chr11	118754352	118754353	rs630923	Multiple sclerosis	CXCR5	1.12	3E-7
chr11	119099905	119099906	rs4938642	Platelet counts	CBL	4.73	8E-11
chr11	120026747	120026748	rs2084898	Stroke (pediatric)	TRIM29	3.04	4E-7
chr11	120026747	120026748	rs2084898	Stroke (pediatric)	TRIM29	2.37	4E-6
chr11	120040441	120040442	rs2444240	Corneal curvature	TRIM29	.04	4E-7
chr11	120809459	120809460	rs12797755	Cognitive performance	GRIK4	NR	8E-6
chr11	121204600	121204601	rs4936613	Response to taxane treatment (placlitaxel)	SC5DL	NR	6E-6
chr11	121243715	121243716	rs72991	Response to tocilizumab in rheumatoid arthritis	Intergenic	2.45	5E-7
chr11	121954656	121954657	rs7121446	Cardiovascular disease risk factors	SORL1, BLID	.15	3E-6
chr11	122030189	122030190	rs577948	Myopia (pathological)	BLID, LOC399959	1.37	2E-7
chr11	122189464	122189465	rs565229	Hemostatic factors and hematological phenotypes	Intergenic	NR	4E-6
chr11	122522374	122522375	rs7941030	HDL cholesterol	UBASH3B	.31	3E-8
chr11	122522374	122522375	rs7941030	Cholesterol, total	UBASH3B	.97	2E-10
chr11	122870682	122870683	rs6589964	Menarche (age at onset)	BSX	2.70	2E-12
chr11	123361396	123361397	rs735665	Chronic lymphocytic leukemia	NR	1.52	3E-12
chr11	123361396	123361397	rs735665	Follicular lymphoma	Intergenic	1.81	4E-9
chr11	123361396	123361397	rs735665	Chronic lymphocytic leukemia	GRAMD1B	1.45	4E-12
chr11	123595926	123595927	rs2126709	Response to antipsychotic therapy (extrapyramidal side effects)	ZNF202	NR	4E-7
chr11	124017492	124017493	rs4936894	Aging (time to death)	VWA5A	.09	2E-6
chr11	124537994	124537995	rs544368	Bipolar disorder	NR	1.22	6E-6
chr11	124606284	124606285	rs12807809	Schizophrenia	NRGN	1.15	2E-9
chr11	125170638	125170639	rs1426153	Alcohol and nictotine co-dependence	PKNOX2	NR	2E-6
chr11	125172592	125172593	rs750338	Alcohol dependence	PKNOX2	NR	1E-6
chr11	125178402	125178403	rs10893366	Alcohol dependence	PKNOX2	NR	8E-6
chr11	125179852	125179853	rs12284594	Substance dependence	PKNOX2	1.77	7E-8
chr11	125241045	125241046	rs12273350	Creutzfeldt-Jakob disease (variant)	NR	NR	2E-6
chr11	125304008	125304009	rs1783925	Formal thought disorder in schizophrenia	PKNOX2	1.39	4E-7
chr11	125323964	125323965	rs11220082	Schizophrenia	PKNOX2, FEZ1, El24	1.10	7E-7
chr11	125461708	125461709	rs548181	Schizophrenia	STT3A	1.10	1E-6
chr11	125873101	125873102	rs7104745	Breast size	KIRREL3	.07	6E-6
chr11	125905257	125905258	rs472926	Alzheimer's disease (late onset)	CDON	NR	3E-6
chr11	126028716	126028717	rs563519	Heart failure	RPUSD4	1.45	3E-6
chr11	126243951	126243952	rs11220462	LDL cholesterol	ST3GAL4	1.95	1E-15
chr11	126243951	126243952	rs11220462	Cholesterol, total	ST3GAL4	2.01	2E-11
chr11	126281896	126281897	rs4937126	Coronary heart disease	Intergenic	1.06	5E-6
chr11	126283784	126283785	rs2236653	Liver enzyme levels (alkaline phosphatase)	ST3GAL4	1.50	2E-9
chr11	126296588	126296589	rs4935969	Hair color	NR	NR	4E-7
chr11	126619189	126619190	rs1557488	Attention deficit hyperactivity disorder and conduct disorder	KIRREL3	NR	5E-6
chr11	126809704	126809705	rs1939992	Protein quantitative trait loci	KIRREL3	NR	1E-6
chr11	126859156	126859157	rs620875	Response to antipsychotic treatment	KIRREL3	NR	3E-6
chr11	127081590	127081591	rs4529888	Amyotrophic lateral sclerosis	Intergenic	1.14	5E-6
chr11	127761665	127761666	rs7927044	Asthma (childhood onset)	NR	.16	7E-9
chr11	128189100	128189101	rs4937314	Alzheimer's disease (late onset)	Intergenic	NR	7E-6
chr11	128206409	128206410	rs6590322	Hippocampal atrophy	Intergenic	NR	9E-6
chr11	128311058	128311059	rs6590330	Systemic lupus erythematosus	ETS1	1.37	2E-25
chr11	128328958	128328959	rs1128334	Systemic lupus erythematosus	ETS1	1.29	2E-11
chr11	128380973	128380974	rs11221332	Celiac disease	ETS1	1.21	5E-16
chr11	128492738	128492739	rs4937362	Rheumatoid arthritis	ETS1, FLI1	1.09	8E-7
chr11	128582556	128582557	rs665440	Myopia (pathological)	FLI1	NR	2E-8
chr11	128586154	128586155	rs654723	Height	FLI1	.03	4E-11
chr11	129473689	129473690	rs7107217	Breast cancer	BARX2, TMEM45B	1.08	5E-7
chr11	129473689	129473690	rs7107217	Type 2 diabetes	TMEM45B, BARX2	1.18	3E-7
chr11	130273229	130273230	rs11222084	Blood pressure	ADAMTS-8	.34	2E-11
chr11	130830747	130830748	rs10894294	Schizophrenia	Intergenic	1.10	3E-7
chr11	130830747	130830748	rs10894294	Schizophrenia	NR	1.08	3E-6
chr11	131320069	131320070	rs1550976	Asperger disorder	NTM	NR	3E-6
chr11	131336073	131336074	rs992564	Bipolar disorder and schizophrenia	NR	1.62	4E-6
chr11	132010116	132010117	rs4468361	Chronic obstructive pulmonary disease-related biomarkers	NTM, OPCML	NR	8E-6
chr11	132829861	132829862	rs1567127	Visceral adipose tissue/subcutaneous adipose tissue ratio	OPCML	NR	1E-6
chr11	133566984	133566985	rs4397868	Menopause (age at onset)	NR	.40	3E-7
chr11	134088681	134088682	rs1031381	Cognitive test performance	NCAPD3	NR	6E-6
chr11	134482465	134482466	rs1944866	Myopia (pathological)	Intergenic	NR	2E-6
chr11	134626886	134626887	rs11223996	Myopia (pathological)	Intergenic	NR	7E-7
chr12	219987	219988	rs2011738	Response to angiotensin II receptor blocker therapy	IQSEC3	1.34	6E-6
chr12	349297	349298	rs10774021	Chronic kidney disease	SLC6A13, JARID1A, SLC6A12	1.05	1E-9
chr12	783483	783484	rs12425791	Stroke	NINJ2	1.29	1E-9
chr12	1064437	1064438	rs10849605	Lung cancer	RAD52	1.08	6E-7
chr12	1856952	1856953	rs12230440	Adverse response to lamotrigine and phenytoin	ADIPOR2	NR	3E-6
chr12	2091256	2091257	rs11062040	Response to gemcitabine in pancreatic cancer	DCP1B	1.40	8E-6
chr12	2345294	2345295	rs1006737	Bipolar disorder and major depressive disorder (combined)	CACNA1C	1.18	3E-8
chr12	2345294	2345295	rs1006737	Bipolar disorder	CACNA1C	1.18	7E-8
chr12	2349583	2349584	rs4765905	Schizophrenia	TCF4	1.36	1E-7
chr12	2349583	2349584	rs4765905	Schizophrenia	CACNA1C	1.11	2E-7
chr12	2349583	2349584	rs4765905	Schizophrenia	CACNA1C	1.08	2E-6
chr12	2419895	2419896	rs4765913	Bipolar disorder	CANCNA1C	1.14	2E-8
chr12	2729631	2729632	rs216013	Warfarin maintenance dose	CACNA1C	NR	9E-7
chr12	2882543	2882544	rs10848704	Quantitative traits	ENSG00000118975, FKBP4	.29	2E-6
chr12	3750127	3750128	rs4766152	Cytomegalovirus antibody response	EFCAB4B	.22	5E-6
chr12	3757547	3757548	rs887304	Non-alcoholic fatty liver disease histology (lobular)	EFCAB4B	.36	8E-7
chr12	3814237	3814238	rs10848911	Male infertility	EFCAB4B	NR	4E-6
chr12	3913426	3913427	rs2058350	Cognitive performance	PARP11	NR	8E-6
chr12	4118316	4118317	rs4238010	Major depressive disorder	CCND2	1.72	6E-6
chr12	4425121	4425122	rs10849033	Acute lymphoblastic leukemia (childhood)	C12orf5	2.55	9E-6
chr12	4606167	4606168	rs2970818	Phosphorus levels	FGF6,RAD51AP1,FGF23	.05	4E-9
chr12	5140483	5140484	rs12302829	Conduct disorder (symptom count)	Intergenic	.35	8E-6
chr12	5797100	5797101	rs12579350	Panic disorder	TMEM16B	NR	4E-9
chr12	6289218	6289219	rs1558324	Mean platelet volume	CD9,VWF	.01	2E-21
chr12	6291092	6291093	rs7342306	Platelet counts	CD9,VWF	2.53	4E-11
chr12	6440008	6440009	rs1800693	Multiple sclerosis	TNFRSF1A	1.12	4E-14
chr12	6440008	6440009	rs1800693	Primary biliary cirrhosis	TNFRSF1A	1.22	2E-9
chr12	6440008	6440009	rs1800693	Multiple sclerosis	TNFRSF1A	1.20	2E-11
chr12	6442642	6442643	rs4149584	Multiple sclerosis	TNFRSF1A	1.58	5E-6
chr12	6502741	6502742	rs11616188	Ankylosing spondylitis	LTBR-TNFRSF1A	NR	4E-12
chr12	6580581	6580582	rs10492096	Hip geometry	VAMP1	NR	3E-6
chr12	6683286	6683287	rs1057510	Myopia (pathological)	CHD4	NR	6E-6
chr12	6938871	6938872	rs3741920	Response to Vitamin E supplementation	CD4,LEPREL2, GNB3	.04	4E-6
chr12	9371331	9371332	rs6487679	Non-alcoholic fatty liver disease histology (AST)	PZP	.40	1E-6
chr12	9380858	9380859	rs10771431	Breast size	LOC642846, LOC728715	.07	2E-6
chr12	9833627	9833628	rs3764021	Type 1 diabetes	NR	1.57	5E-8
chr12	9855957	9855958	rs11052552	Type 1 diabetes	NR	1.49	7E-7
chr12	9876090	9876091	rs10466829	Multiple sclerosis	CLECL1	1.09	1E-8
chr12	9910163	9910164	rs4763879	Type 1 diabetes	CD69	1.09	2E-11
chr12	11547531	11547532	rs2900174	Response to gemcitabine in pancreatic cancer	PRB2	3.30	1E-6
chr12	11648417	11648418	rs2908835	Information processing speed	AC007450.3	.14	7E-6
chr12	11855623	11855624	rs2187642	Height	ETV6	4.60	2E-6
chr12	11855772	11855773	rs2856321	Height	ETV6	.03	5E-15
chr12	13629380	13629381	rs1531228	Barrett's esophagus	NR	.20	9E-6
chr12	13787845	13787846	rs2160519	Cognitive performance	GRIN2B	NR	2E-6
chr12	13872043	13872044	rs2268118	Immune reponse to smallpox (secreted IL-2)	GRIN2B	NR	1E-8
chr12	13927895	13927896	rs6488619	Ovarian reserve	GRIN2B	NR	9E-7
chr12	14064460	14064461	rs4764039	Total ventricular volume	GRIN2B	.00	3E-6
chr12	14115481	14115482	rs4764043	Aging (time to event)	GRIN2B	1.17	6E-6
chr12	14653866	14653867	rs2900333	Testicular germ cell cancer	ATF7IP	1.27	6E-10
chr12	14660183	14660184	rs3827886	Response to amphetamines	PLBD1	NR	7E-6
chr12	15735441	15735442	rs2300290	Cognitive function	PTPRO	1.10	1E-8
chr12	15930804	15930805	rs17415853	Protein quantitative trait loci	EPS8	NR	7E-7
chr12	16406689	16406690	rs10772915	Visceral fat	MGST1	NR	5E-6
chr12	16609037	16609038	rs10772939	Economic and political preferences	Intergenic	.11	5E-6
chr12	17373738	17373739	rs9971637	Amyotrophic lateral sclerosis	NR	1.48	2E-6
chr12	19801594	19801595	rs6486986	Cognitive performance	AC090059.9	NR	8E-6
chr12	19866128	19866129	rs4762767	Pulmonary function	AEBP2	.03	8E-6
chr12	20063967	20063968	rs10841397	Response to amphetamines	Intergenic	NR	9E-6
chr12	20230638	20230639	rs10770612	Aortic root size	PDE3A	.03	2E-8
chr12	20473757	20473758	rs7134375	HDL cholesterol	PDE3A	.40	4E-8
chr12	20498035	20498036	rs7955516	Adiponectin levels	PDE3A	.02	4E-8
chr12	20521653	20521654	rs10841496	Male infertility	PDE3A	NR	5E-7
chr12	20531755	20531756	rs1348582	QT interval	PDE3A	.20	1E-6
chr12	20758612	20758613	rs11611208	Height	PDE3A, SLCO1C1, SLCO1B3	11.40	2E-6
chr12	20840838	20840839	rs11045392	Response to TNF-alpha inhibitors in rheumatoid arthritis	PDE3A	3.30	2E-6
chr12	20857466	20857467	rs10770705	Height	SLCO1C1	.03	8E-18
chr12	20860092	20860093	rs3794271	Response to TNF-alpha inhibitors in rheumatoid arthritis	SLCO1C1	3.20	4E-6
chr12	21074121	21074122	rs2117032	Bilirubin levels	SLCO1B3	.13	3E-14
chr12	21331548	21331549	rs4149056	Sex hormone-binding globulin levels	SLCO1B1	.03	2E-8
chr12	21331548	21331549	rs4149056	Bilirubin levels	SLCO1B1,LST-3TM12,SLCO1A2	.05	7E-13
chr12	21331548	21331549	rs4149056	Response to statin therapy	SLCO1B1	4.50	2E-9
chr12	21368721	21368722	rs4363657	Bilirubin levels	SLCO1B1	.06	5E-8
chr12	21378020	21378021	rs4149081	Metabolic traits	SLCO1B1	.21	3E-22
chr12	21457433	21457434	rs11568563	Progressive supranuclear palsy	SLCO1A2	1.47	7E-8
chr12	22151572	22151573	rs10743430	Entorhinal cortical thickness	CMAS	.22	6E-7
chr12	22365834	22365835	rs2216228	Non-alcoholic fatty liver disease histology (lobular)	ST8SIA1	.45	4E-6
chr12	23639916	23639917	rs2120771	Economic and political preferences (feminism/equality)	Intergenic	.11	3E-6
chr12	23946145	23946146	rs11047102	Systemic sclerosis	SOX5	1.24	5E-6
chr12	23946145	23946146	rs11047102	Systemic sclerosis	SOX5	1.36	1E-7
chr12	24184543	24184544	rs10842262	Non-obstructive azoospermia	SOX5	1.23	2E-9
chr12	24278820	24278821	rs7979575	Response to statin therapy	SOX5, FLJ32894, BCAT1	NR	2E-6
chr12	24389659	24389660	rs1464500	Response to antipsychotic treatment	SOX5	NR	1E-7
chr12	24394371	24394372	rs1522232	AIDS	SOX5	2.22	2E-6
chr12	24770877	24770878	rs17287293	Resting heart rate	Intergenic	8.60	2E-10
chr12	24788338	24788339	rs11047543	PR interval	SOX5, C12orf67	2.09	3E-13
chr12	26453282	26453283	rs718314	Renal cell carcinoma	ITPR2	1.19	9E-10
chr12	26453282	26453283	rs718314	Waist-hip ratio	ITPR2, SSPN	.04	2E-17
chr12	26636385	26636386	rs2306677	Amyotrophic lateral sclerosis	ITPR2	1.58	3E-6
chr12	28156080	28156081	rs12371778	Breast size	PTHLH, LOC100129646	.16	1E-8
chr12	28228566	28228567	rs522958	Hyperactive-impulsive symptoms	Intergenic	NR	8E-7
chr12	28228566	28228567	rs522958	Attention deficit hyperactivity disorder	Intergenic	NR	1E-6
chr12	28534414	28534415	rs2638953	Height	CCDC91	.03	7E-17
chr12	29435479	29435480	rs2015599	Mean platelet volume	MLSTD1	.01	6E-16
chr12	29872317	29872318	rs16934812	Schizophrenia	TMTC1	1.34	7E-6
chr12	30104141	30104142	rs2046383	Heart failure	TMTC1	1.39	3E-6
chr12	30113882	30113883	rs1463605	Aging traits	Intergenic	NR	7E-8
chr12	32380500	32380501	rs10844154	Emphysema-related traits	BICD1	1.46	6E-7
chr12	32380500	32380501	rs10844154	Weight	NR	1.87	4E-6
chr12	32436408	32436409	rs708224	Pancreatic cancer	BICD1	1.32	3E-7
chr12	32476726	32476727	rs261902	Normalized brain volume	BICD1	NR	4E-6
chr12	32537487	32537488	rs11051970	Response to tocilizumab in rheumatoid arthritis	Intergenic	2.08	1E-6
chr12	33701165	33701166	rs9300212	Cognitive test performance	Intergenic	NR	8E-6
chr12	38743507	38743508	rs6582630	Drug-induced liver injury (flucloxacillin)	ALG10B	2.82	1E-6
chr12	40352995	40352996	rs10877840	Parkinson's disease	SLC2A13	1.15	1E-6
chr12	40428560	40428561	rs1994090	Parkinson's disease	LRRK2	1.39	3E-8
chr12	40601939	40601940	rs11175593	Crohn's disease	LRRK2, MUC19	1.54	3E-10
chr12	40620807	40620808	rs1491942	Parkinson's disease	LRRK2	1.17	6E-15
chr12	40620807	40620808	rs1491942	Parkinson's disease	LRRK2	1.27	6E-14
chr12	40734201	40734202	rs34637584	Parkinson's disease	LRRK2	9.62	2E-28
chr12	40757327	40757328	rs34778348	Parkinson's disease	LRRK2	2.23	3E-21
chr12	40792299	40792300	rs11564258	Crohn's disease	MUC19,LRRK2	1.74	6E-21
chr12	41247741	41247742	rs312273	Bipolar disorder	Intergenic	1.57	9E-6
chr12	41721429	41721430	rs1880887	Protein quantitative trait loci	PDZRN4,CNTN1	NR	1E-10
chr12	41965860	41965861	rs1458175	Multiple sclerosis	PDZRN4	1.34	2E-6
chr12	42171981	42171982	rs871392	Biochemical measures	Intergenic	.26	3E-6
chr12	43160743	43160744	rs12316797	Visceral adipose tissue/subcutaneous adipose tissue ratio	PRICKLE1	NR	1E-6
chr12	43160824	43160825	rs2731006	Panic disorder	Intergenic	NR	4E-6
chr12	43253414	43253415	rs1520832	Heart failure	PRICKLE1	1.39	1E-6
chr12	43929995	43929996	rs275380	Adverse response to lamotrigine and phenytoin	ADAMTS20	NR	1E-6
chr12	44153825	44153826	rs4251424	Immune reponse to smallpox (secreted TNF-alpha)	IRAK4, PUS7L	NR	2E-8
chr12	45774907	45774908	rs17095830	Ankylosing spondylitis	ANO6	1.29	2E-8
chr12	45925754	45925755	rs7960483	Hypertension	AN06	NR	1E-7
chr12	45930972	45930973	rs10785581	Hypertension	AN06	NR	1E-7
chr12	46485837	46485838	rs1373549	Hippocampal atrophy	ARID2, SFRS2IP	NR	8E-6
chr12	47372269	47372270	rs2711721	Prostate cancer (gene x gene interaction)	AMIGO2	1.28	2E-6
chr12	47639525	47639526	rs11610206	Alzheimer's disease	FAM113B	NR	3E-7
chr12	48403764	48403765	rs11168351	Bipolar disorder and schizophrenia	NR	1.22	9E-6
chr12	48811099	48811100	rs4489787	Prostate cancer (gene x gene interaction)	ANP32D	1.47	1E-6
chr12	49218170	49218171	rs2070615	Bipolar disorder	RND1, DDX23, CANCNB3	1.10	1E-6
chr12	49676009	49676010	rs10875943	Prostate cancer	PRPH	1.07	7E-12
chr12	50247467	50247468	rs7138803	Body mass index	FAIM2	.12	2E-17
chr12	50247467	50247468	rs7138803	Waist circumference	FAIM2, BCDIN3D	NR	8E-7
chr12	50247467	50247468	rs7138803	Weight	BCDIN3D, FAIM2	3.27	2E-7
chr12	50247467	50247468	rs7138803	Body mass index	BCDIN3D, FAIM2	3.28	1E-7
chr12	50319085	50319086	rs297941	Obsessive-compulsive disorder	FAIM2, AQP2	1.23	5E-7
chr12	51155662	51155663	rs11169552	Colorectal cancer	DIP2B, ATF1	1.09	2E-10
chr12	51213432	51213433	rs17291650	Sudden cardiac arrest	ATF1	1.43	3E-7
chr12	51357541	51357542	rs12304921	Type 2 diabetes	NR	2.50	7E-6
chr12	51703833	51703834	rs766903	Aging (time to death)	BIN2	.09	2E-6
chr12	52263955	52263956	rs17126180	Reasoning	ANKRD33	NR	9E-7
chr12	53273903	53273904	rs902774	Prostate cancer	KRT8, EIF4B, TENC1	1.17	5E-9
chr12	53727954	53727955	rs2016266	Bone mineral density (spine)	SP7	.07	1E-8
chr12	53731890	53731891	rs10876432	Bone mineral density (spine)	SP7	.08	1E-7
chr12	53916714	53916715	rs12321906	Height	ATF7	.05	5E-6
chr12	54041191	54041192	rs11170631	Height	ATF7, ATP5G2	.05	9E-7
chr12	54114157	54114158	rs941184	Panic disorder	CALCOCO1	NR	3E-7
chr12	54159276	54159277	rs7969151	Tanning	LOC440100	.13	2E-6
chr12	54270227	54270228	rs2120991	Biliary atresia	HOXC13	2.14	9E-6
chr12	54342683	54342684	rs1443512	Waist-hip ratio	HOXC13	.04	6E-16
chr12	54687231	54687232	rs10506328	Mean platelet volume	NR	.01	5E-7
chr12	54712307	54712308	rs10876550	Mean platelet volume	COPZ1,NFE2,CBX5	.01	2E-14
chr12	55098995	55098996	rs1153188	Type 2 diabetes	DCD	1.08	2E-7
chr12	56070667	56070668	rs55874825	Response to amphetamines	Intergenic	NR	3E-7
chr12	56364320	56364321	rs2069408	Asthma	CDK2	1.15	1E-10
chr12	56390635	56390636	rs705702	Polycystic ovary syndrome	RAB5B, SUOX	1.27	9E-26
chr12	56401084	56401085	rs10876864	Vitiligo	PMEL, DGKA, CDK2, RAB5B, SUOX, ZNFN1A4, RPS26, ERBB3, PA2G4	1.18	8E-12
chr12	56412486	56412487	rs1701704	Type 1 diabetes autoantibodies	IKZF4	1.25	5E-18
chr12	56412486	56412487	rs1701704	Asthma	IKZF4	1.19	2E-13
chr12	56412486	56412487	rs1701704	Alopecia areata	IKZF4	1.34	3E-8
chr12	56412486	56412487	rs1701704	Type 1 diabetes	RAB5B, SUOX, IKZF4, ERBB3, CDK2	1.25	9E-10
chr12	56416927	56416928	rs2456973	Vitiligo	IKZF4	1.29	3E-14
chr12	56439208	56439209	rs12580100	Psoriasis	RPS26	1.17	1E-6
chr12	56470624	56470625	rs11171739	Type 1 diabetes	ERBB3	1.34	1E-11
chr12	56482179	56482180	rs2292239	Type 1 diabetes autoantibodies	ERBB3	1.30	3E-27
chr12	56482179	56482180	rs2292239	Type 1 diabetes	ERBB3	NR	2E-25
chr12	56482179	56482180	rs2292239	Type 1 diabetes	ERBB3	NR	3E-16
chr12	56482179	56482180	rs2292239	Type 1 diabetes	ERBB3	1.28	2E-20
chr12	56518407	56518408	rs11171747	Systemic sclerosis	RPL41, ESYT1	1.23	6E-8
chr12	56737972	56737973	rs2066808	Psoriasis	IL23A	1.49	2E-7
chr12	56737972	56737973	rs2066808	Psoriasis	IL23A, STAT2	1.34	1E-9
chr12	56740681	56740682	rs2066807	Height	STAT2	.05	1E-13
chr12	56828055	56828056	rs11171846	Immune reponse to smallpox (secreted IFN-alpha)	TIMELESS	NR	6E-10
chr12	56863769	56863770	rs2657880	Metabolite levels	SPRYD4, GLS2	NR	7E-30
chr12	56865055	56865056	rs2638315	Metabolite levels	GLS2	.29	2E-35
chr12	56865337	56865338	rs2657879	Metabolic traits	GLS2	.04	3E-17
chr12	56938382	56938383	rs2657888	Adiponectin levels	NR	.02	8E-6
chr12	57023283	57023284	rs941207	Platelet counts	PTGES3,BAZ2A	2.75	2E-10
chr12	57055290	57055291	rs2950390	Mean platelet volume	PTGES3,BAZ2A	.01	7E-14
chr12	57065712	57065713	rs2958154	Age-related macular degeneration	NR	NR	2E-6
chr12	57146068	57146069	rs2277339	Menopause (age at onset)	PRIM1	.38	2E-19
chr12	57204159	57204160	rs12367822	Platelet aggregation	HSD17B6	NR	1E-6
chr12	57489708	57489709	rs1059513	IgE levels	STAT6, NAB2	.12	2E-12
chr12	57503774	57503775	rs167769	Eosinophilic esophagitis (pediatric)	STAT6	1.36	2E-6
chr12	57527282	57527283	rs11172113	Migraine	LRP1	1.16	3E-8
chr12	57527282	57527283	rs11172113	Pulmonary function	LRP1	.03	1E-8
chr12	57527282	57527283	rs11172113	Migraine	LRP1	1.11	4E-9
chr12	57534469	57534470	rs1466535	Abdominal aortic aneurysm	LRP1	1.15	5E-10
chr12	57792579	57792580	rs11613352	Triglycerides	LRP1	2.70	4E-10
chr12	57792579	57792580	rs11613352	HDL cholesterol	LRP1	.46	2E-8
chr12	57809455	57809456	rs1106766	Urate levels	R3HDM2,INHBC	5.16	2E-11
chr12	57968714	57968715	rs1678542	Rheumatoid arthritis	KIF5A,PIP4K2C	1.12	9E-8
chr12	58062666	58062667	rs10876993	Celiac disease and Rheumatoid arthritis	CDK4	NR	4E-6
chr12	58133255	58133256	rs12368653	Multiple sclerosis	AGAP2, CYP27B1	1.10	2E-9
chr12	58162738	58162739	rs703842	Multiple sclerosis	METTL1, CYP27B1	1.23	5E-11
chr12	59259627	59259628	rs11172782	Heart failure	LRIG3	1.46	7E-8
chr12	59440231	59440232	rs17121944	Temperament (bipolar disorder)	Intergenic	2.66	4E-6
chr12	60797702	60797703	rs10506410	Cardiac hypertrophy	FAM19A2	NR	2E-6
chr12	62610859	62610860	rs11615916	Pulmonary function decline	USP15	.24	7E-6
chr12	63004582	63004583	rs7302017	Waist circumference	PPM1H	1.71	5E-6
chr12	63445091	63445092	rs10506458	Hemostatic factors and hematological phenotypes	Intergenic	NR	5E-6
chr12	65252117	65252118	rs939876	Cognitive performance	TBC1D30	NR	2E-6
chr12	65534623	65534624	rs6581612	Hippocampal volume	WIF1	63.30	7E-11
chr12	65718298	65718299	rs17178006	Hippocampal volume	MSRB3	123.80	5E-11
chr12	65783377	65783378	rs10506525	Primary tooth development (time to first tooth eruption)	MSRB3	.46	6E-9
chr12	65783377	65783378	rs10506525	Primary tooth development (number of teeth)	MSRB3	.18	9E-7
chr12	65842257	65842258	rs1494508	Temperament	MSRB3	.20	2E-6
chr12	66117557	66117558	rs2358944	Type 2 diabetes nephropathy	MSRB3, HMGA2	1.33	4E-6
chr12	66160970	66160971	rs10784496	AB1-42	Intergenic	NR	3E-7
chr12	66174893	66174894	rs1531343	Type 2 diabetes	HMGA2	1.10	4E-9
chr12	66224460	66224461	rs2272046	Polycystic ovary syndrome	HMGA2	1.43	2E-21
chr12	66227256	66227257	rs7979673	Height	HMGA2	.06	7E-10
chr12	66343809	66343810	rs10784502	Brain structure	HMGA2	#######	1E-12
chr12	66351825	66351826	rs1351394	Height	HMGA2	.06	2E-65
chr12	66358346	66358347	rs1042725	Head circumference (infant)	HMGA2	.07	3E-10
chr12	66358346	66358347	rs1042725	Height	HMGA2	.05	3E-18
chr12	66358346	66358347	rs1042725	Height	HMGA2	.48	3E-20
chr12	66358346	66358347	rs1042725	Height	HMGA2	.40	6E-16
chr12	66359751	66359752	rs8756	Height	HMGA2	.07	4E-7
chr12	66359751	66359752	rs8756	Height	HMGA2	.08	5E-14
chr12	66359751	66359752	rs8756	Height	HMGA2	6.60	2E-16
chr12	66364508	66364509	rs12424086	Permanent tooth development	HMGA2	.11	2E-12
chr12	66364508	66364509	rs12424086	Primary tooth development (time to first tooth eruption)	HMGA2	.29	8E-6
chr12	66364508	66364509	rs12424086	Primary tooth development (number of teeth)	HMGA2	.22	4E-6
chr12	66371879	66371880	rs7968682	Height	HMGA2	.04	4E-10
chr12	66394663	66394664	rs4026608	Aortic root size	HMGA2	.03	2E-9
chr12	67628830	67628831	rs1082714	Hippocampal atrophy	CAND1	NR	5E-6
chr12	68500074	68500075	rs7134599	Ulcerative colitis	IFNG, IL26	1.19	1E-16
chr12	68504591	68504592	rs1558744	Ulcerative colitis	IFNG,IL26	1.16	4E-12
chr12	68504591	68504592	rs1558744	Ulcerative colitis	IFNG, IL26, IL22	1.35	3E-12
chr12	68532076	68532077	rs12321565	Bipolar disorder and schizophrenia	NR	1.35	5E-6
chr12	68596660	68596661	rs2870946	Ulcerative colitis	IL26	1.54	5E-7
chr12	68779412	68779413	rs416350	Temperament (bipolar disorder)	MDM1	2.10	4E-8
chr12	69370755	69370756	rs9943849	Major depressive disorder	CPM	1.37	3E-6
chr12	69727189	69727190	rs317689	Response to diuretic therapy	LYZ, YEATS4, FRS2	NR	3E-7
chr12	69762986	69762987	rs315135	Response to diuretic therapy	LYZ, YEATS4, FRS2	NR	3E-7
chr12	69824023	69824024	rs7297610	Response to diuretic therapy	LYZ, YEATS4, FRS2	NR	3E-7
chr12	69827657	69827658	rs10748128	Height	FRS2	.04	2E-20
chr12	69828680	69828681	rs11177669	Height	LYZ,YEATS4,FRS2,CPSF6,CCT2,LRRC10	4.50	3E-6
chr12	70054909	70054910	rs1373453	Orofacial clefts	NR	NR	2E-6
chr12	70331826	70331827	rs789560	Attention deficit hyperactivity disorder and conduct disorder	C12orf28	NR	7E-6
chr12	70690084	70690085	rs2904524	Amyotrophic lateral sclerosis (age of onset)	CNOT2	NR	5E-6
chr12	71577100	71577101	rs1495377	Creutzfeldt-Jakob disease (variant)	NR	NR	2E-6
chr12	71577100	71577101	rs1495377	Type 2 diabetes	NR	1.28	7E-6
chr12	71634793	71634794	rs4760790	Type 2 diabetes	TSPAN8,LGR5	1.11	4E-6
chr12	71663101	71663102	rs7961581	Type 2 diabetes	TSPAN8,LGR5	1.09	1E-9
chr12	72071044	72071045	rs10748180	Economic and political preferences (time)	THAP2	.12	5E-6
chr12	72125284	72125285	rs11178918	Economic and political preferences (time)	Intergenic	.18	8E-6
chr12	72724033	72724034	rs12831974	Rheumatoid arthritis	TRHDE	1.27	6E-6
chr12	72724033	72724034	rs12831974	Rheumatoid arthritis	TRHDE	1.27	6E-6
chr12	73307581	73307582	rs10879517	Cognitive performance	AC131213.4	NR	4E-6
chr12	73601131	73601132	rs11615274	Body mass index and cholesterol (psychopharmacological treatment)	Intergenic	NR	9E-8
chr12	73828955	73828956	rs7963521	Chemerin levels	TRHDE	NR	9E-6
chr12	73989836	73989837	rs1154865	Breast cancer	Intergenic	NR	7E-7
chr12	74586209	74586210	rs10506701	Bone mineral density	Intergenic	NR	1E-6
chr12	76220617	76220618	rs7307780	Sudden cardiac arrest	Intergenic	1.45	5E-15
chr12	77009059	77009060	rs2669010	Systemic lupus erythematosus	RPL7AP59	1.28	5E-6
chr12	77729384	77729385	rs1402279	Smoking behavior	Intergenic	1.51	5E-6
chr12	77899509	77899510	rs17788937	Myopia (pathological)	Intergenic	NR	4E-15
chr12	78485993	78485994	rs300489	Self-rated health	NAV3	.03	5E-6
chr12	80062229	80062230	rs7297018	Attention deficit hyperactivity disorder and conduct disorder	PAWR	NR	4E-6
chr12	80496922	80496923	rs10506821	Hip geometry	Intergenic	NR	2E-7
chr12	81843127	81843128	rs12426725	Schizophrenia	PPFIA2	1.37	4E-6
chr12	82984878	82984879	rs12425131	Immune response to smallpox vaccine (IL-6)	TMTC2	NR	2E-6
chr12	83019187	83019188	rs11115322	Immune response to smallpox vaccine (IL-6)	TMTC2	NR	3E-6
chr12	83164555	83164556	rs12317459	Prostate cancer (gene x gene interaction)	TMTC2	2.06	4E-6
chr12	84008274	84008275	rs2403106	Neonatal lupus	TMTC2	2.48	3E-6
chr12	84564067	84564068	rs1545843	Major depressive disorder	SLC6A15	1.40	1E-9
chr12	88890670	88890671	rs995030	Testicular germ cell tumor	KITLG	2.55	1E-31
chr12	88890670	88890671	rs995030	Testicular germ cell tumor	KITLG	2.69	3E-30
chr12	88953560	88953561	rs3782181	Testicular germ cell cancer	KITLG	2.22	2E-26
chr12	88953958	88953959	rs4474514	Testicular cancer	KITLG	3.07	6E-15
chr12	89328334	89328335	rs12821256	Blond vs. brown hair color	KITLG	2.32	4E-30
chr12	90008958	90008959	rs2681472	Hypertension	ATP2B1	.15	2E-11
chr12	90008958	90008959	rs2681472	Diastolic blood pressure	ATP2B1	.50	1E-9
chr12	90013088	90013089	rs2681492	Systolic blood pressure	ATP2B1	.85	4E-11
chr12	90060585	90060586	rs17249754	Blood pressure	ATP2B1	.39	6E-10
chr12	90060585	90060586	rs17249754	Blood pressure	ATP2B1	.56	1E-17
chr12	90060585	90060586	rs17249754	Blood pressure	ATP2B1	1.17	8E-20
chr12	90060585	90060586	rs17249754	Blood pressure	ATP2B1	.58	2E-13
chr12	90060585	90060586	rs17249754	Biomedical quantitative traits	ATP2B1	.63	3E-6
chr12	90060585	90060586	rs17249754	Biomedical quantitative traits	ATP2B1	1.06	1E-7
chr12	90081187	90081188	rs7136259	Coronary heart disease	ATP2B1	1.11	6E-10
chr12	90305778	90305779	rs7965584	Magnesium levels	ATP2B1	.07	1E-16
chr12	90443481	90443482	rs10858945	Optic disc size (cup)	LOC643153	.17	6E-6
chr12	90609016	90609017	rs10745527	vWF and FVIII levels	dessert	.16	5E-6
chr12	91077507	91077508	rs1847461	Smoking behavior	Intergenic	1.80	8E-6
chr12	91980373	91980374	rs10777317	Sudden cardiac arrest	DCN	1.12	5E-6
chr12	92164301	92164302	rs10777332	Biochemical measures	Intergenic	.24	5E-6
chr12	92305269	92305270	rs17019682	Heart failure	BTG1	1.47	2E-6
chr12	92890519	92890520	rs10219495	Sudden cardiac arrest	PLEKHG7	1.14	5E-6
chr12	93550300	93550301	rs1836127	Non-alcoholic fatty liver disease histology (other)	Intergenic	.76	3E-6
chr12	93976953	93976954	rs3825199	Height	SOCS2, MRPL42, CRADD, UBE2N	6.20	2E-7
chr12	93978503	93978504	rs11107116	Height	SOCS2	.05	1E-34
chr12	93978503	93978504	rs11107116	Height	SOCS2	.04	6E-10
chr12	94120338	94120339	rs10859563	Height	SOCS2	NR	3E-12
chr12	95711875	95711876	rs10859871	Endometriosis	VEZT	1.20	5E-13
chr12	95959787	95959788	rs7136572	Response to antidepressant treatment	USP44	NR	3E-7
chr12	96027758	96027759	rs17356907	Breast size	NEDD1, MIR135A2	.08	1E-6
chr12	96271427	96271428	rs1036429	Pulmonary function	CCDC38	.04	2E-11
chr12	96479266	96479267	rs2660869	Height	LTA4H	4.39	3E-6
chr12	96807916	96807917	rs11108495	Weight	C12orf55	1.55	4E-6
chr12	96858361	96858362	rs12423247	Phospholipid levels (plasma)	CDK17	.80	3E-8
chr12	97689767	97689768	rs10777845	Sudden cardiac arrest	Intergenic	1.12	5E-6
chr12	99190371	99190372	rs2036225	Amyotrophic lateral sclerosis (age of onset)	ANKS1B	NR	8E-6
chr12	99816841	99816842	rs7968606	Response to antipsychotic treatment	ANKS1B	10.00	3E-7
chr12	99961348	99961349	rs2373011	Waist circumference	ANKS1B	1.71	2E-6
chr12	99961348	99961349	rs2373011	Body mass index	ANKS1B	.03	9E-6
chr12	100266112	100266113	rs11110077	Working memory	ANKS1B	NR	4E-7
chr12	101753953	101753954	rs10507130	Coronary artery calcification	DRIM	NR	7E-6
chr12	102373787	102373788	rs7971536	Height	CCDC53/GNPTAB	.03	8E-14
chr12	102513530	102513531	rs2292303	Height	NUP37, C12orf48, PMCH	.51	8E-6
chr12	102726337	102726338	rs1520223	Height	IGF1	.56	9E-7
chr12	102799597	102799598	rs5742692	Height	IGF1	.07	4E-8
chr12	102875568	102875569	rs35767	Fasting insulin-related traits	IGF1	NR	3E-8
chr12	102875568	102875569	rs35767	Fasting insulin-related traits	IGF1	NR	2E-9
chr12	102875568	102875569	rs35767	Fasting glucose-related traits	IGF1	NR	3E-8
chr12	102875568	102875569	rs35767	Fasting glucose-related traits	IGF1	NR	2E-9
chr12	102912557	102912558	rs35747	Fasting insulin-related traits (interaction with BMI)	IGF1	NR	1E-9
chr12	103125689	103125690	rs2172873	Uterine fibroids	NR	1.18	2E-6
chr12	103483093	103483094	rs10745954	C-reactive protein	ASCL1	.04	2E-11
chr12	103495150	103495151	rs10778213	C-reactive protein	Unknown	.12	1E-10
chr12	103912505	103912506	rs10861032	Coronary restenosis	C12orf42, STAB2, NT5DC3	NR	1E-7
chr12	104139033	104139034	rs7306642	vWF and FVIII levels	STAB2	.30	3E-6
chr12	104192823	104192824	rs4964805	Attention deficit hyperactivity disorder	NT5DC3	NR	5E-6
chr12	104317995	104317996	rs1165668	Coronary heart disease	HSP90B1	NR	3E-9
chr12	104318171	104318172	rs1165669	Coronary heart disease	HSP90B1	NR	3E-9
chr12	104421807	104421808	rs2629751	Hepatitis C induced liver fibrosis	GLT8D2	NR	1E-7
chr12	105017163	105017164	rs12811699	Cannabis dependence	CHST11	1.74	8E-6
chr12	106785553	106785554	rs6539267	Tourette syndrome	POLR3B, TCP11L2, FLJ45508	1.27	6E-6
chr12	106949986	106949987	rs4964469	Parkinson's disease	Intergenic	1.16	2E-7
chr12	106950694	106950695	rs3891355	Cognitive test performance	POLR3B, RFX4	NR	3E-6
chr12	107704704	107704705	rs1820460	Cognitive performance	BTBD11	NR	8E-6
chr12	108602969	108602970	rs7313402	Temperament (bipolar disorder)	WSCD2	1.13	8E-6
chr12	108699031	108699032	rs1878022	Response to platinum-based chemotherapy in non-small-cell lung cancer	CMKLR1	1.33	5E-7
chr12	108742819	108742820	rs17040430	Bipolar disorder	CMKLR1	1.89	9E-7
chr12	108767332	108767333	rs10861905	Erectile dysfunction and prostate cancer treatment	CMKLR1	33.95	8E-7
chr12	109025426	109025427	rs8179116	Conduct disorder (symptom count)	SELPLG	.23	3E-6
chr12	109840939	109840940	rs9943753	HDL cholesterol	MYO1H,KCTD10,UBE3B,MMAB,MVK	.02	3E-6
chr12	109895167	109895168	rs2338104	HDL cholesterol	MMAB,MVK	.07	1E-10
chr12	109895167	109895168	rs2338104	HDL cholesterol	MVK,MMAB	.48	3E-8
chr12	110000192	110000193	rs7134594	HDL cholesterol	MMAB,MVK	.44	7E-15
chr12	110368200	110368201	rs2292354	Metabolic syndrome	GIT2	NR	7E-6
chr12	110704486	110704487	rs11065611	Protein quantitative trait loci	ATP2A2	NR	1E-7
chr12	111333621	111333622	rs10849915	Alcohol consumption	CCDC63	.55	1E-23
chr12	111340242	111340243	rs10774610	Drinking behavior	CCDC63	3.33	9E-120
chr12	111414460	111414461	rs12229654	HDL cholesterol	MYL2	.03	3E-23
chr12	111414460	111414461	rs12229654	Gamma glutamyl transpeptidase	MYL2	.01	9E-58
chr12	111414460	111414461	rs12229654	Alcohol consumption	MYL2	.79	4E-35
chr12	111708457	111708458	rs1265564	Type 1 diabetes	CUX2	1.45	1E-16
chr12	111884607	111884608	rs3184504	Hypothyroidism	SH2B3, ATXN2, LOC100101246, BRAP, NAA25, C12orf51, PTPN11	1.20	3E-12
chr12	111884607	111884608	rs3184504	Platelet counts	SH2B3	3.99	1E-26
chr12	111884607	111884608	rs3184504	Diastolic blood pressure	SH2B3	.45	4E-25
chr12	111884607	111884608	rs3184504	Type 1 diabetes autoantibodies	SH2B3	1.30	2E-38
chr12	111884607	111884608	rs3184504	Coronary heart disease	SH2B3	1.07	6E-6
chr12	111884607	111884608	rs3184504	Rheumatoid arthritis	SH2B3	1.08	6E-6
chr12	111884607	111884608	rs3184504	Type 1 diabetes	SH2B3	NR	3E-27
chr12	111884607	111884608	rs3184504	Systolic blood pressure	SH2B3	.58	5E-9
chr12	111884607	111884608	rs3184504	Diastolic blood pressure	SH2B3	.48	3E-14
chr12	111884607	111884608	rs3184504	Eosinophil counts	SH2B3	7.60	7E-19
chr12	111904370	111904371	rs4766578	Vitiligo	SH2B3	1.32	4E-18
chr12	111910218	111910219	rs10774625	Retinal vascular caliber	ATXN2,PTPN11,SH2B3	1.50	2E-13
chr12	112007755	112007756	rs653178	Blood pressure	ATXN2	.43	7E-20
chr12	112007755	112007756	rs653178	Celiac disease and Rheumatoid arthritis	SH2B3	NR	3E-19
chr12	112007755	112007756	rs653178	Chronic kidney disease	ATXN2	.01	4E-11
chr12	112007755	112007756	rs653178	Celiac disease	SH2B3	1.20	7E-21
chr12	112007755	112007756	rs653178	Diastolic blood pressure	ATXN2, SH2B3	.46	3E-18
chr12	112007755	112007756	rs653178	Celiac disease	SH2B3, ATXN2	1.21	8E-8
chr12	112072423	112072424	rs11065987	LDL cholesterol	BRAP	.97	2E-9
chr12	112072423	112072424	rs11065987	Cholesterol, total	BRAP	.96	7E-12
chr12	112072423	112072424	rs11065987	Hemoglobin	TRAFD1	.06	1E-11
chr12	112072423	112072424	rs11065987	Hematocrit	SH2B3, ATXN2	.17	1E-12
chr12	112168008	112168009	rs11066015	Esophageal cancer	ACAD10	1.38	7E-21
chr12	112190437	112190438	rs6490294	Mean platelet volume	ACAD10	4.38	5E-9
chr12	112211832	112211833	rs2238151	Stroke (ischemic)	ALDH2	1.13	1E-6
chr12	112241765	112241766	rs671	Renal function-related traits (sCR)	ALDH2	.00	3E-10
chr12	112241765	112241766	rs671	Intracranial aneurysm	ALDH2	1.24	3E-6
chr12	112241765	112241766	rs671	Triglycerides	ALDH2	NR	2E-6
chr12	112241765	112241766	rs671	Coronary heart disease	ALDH2	1.43	2E-34
chr12	112241765	112241766	rs671	Drinking behavior	ALDH2, BRAP	6.25	4E-211
chr12	112241765	112241766	rs671	Esophageal cancer	BRAP, ALDH2	1.67	3E-24
chr12	112486817	112486818	rs17696736	Type 1 diabetes	C12orf30	NR	6E-18
chr12	112486817	112486818	rs17696736	Type 1 diabetes	SH2B3,LNK,TRAFD1,PTPN11	1.34	2E-14
chr12	112486817	112486818	rs17696736	Type 1 diabetes	C12orf30	1.22	2E-16
chr12	112521447	112521448	rs4767364	Upper aerodigestive tract cancers	ALDH2	1.13	2E-8
chr12	112645400	112645401	rs2074356	Renal function-related traits (BUN)	C12orf51	.01	2E-9
chr12	112645400	112645401	rs2074356	HDL cholesterol	C12orf51	.04	7E-37
chr12	112645400	112645401	rs2074356	Gamma glutamyl transpeptidase	C12orf51	.02	3E-126
chr12	112645400	112645401	rs2074356	Esophageal cancer	C12orf51	1.56	2E-31
chr12	112645400	112645401	rs2074356	Alcohol consumption	C12orf51,ALDH2	1.06	9E-59
chr12	112645400	112645401	rs2074356	Biomedical quantitative traits	C12orf51	.01	8E-12
chr12	112817782	112817783	rs11066280	Coronary heart disease	C12orf51	1.19	2E-11
chr12	112817782	112817783	rs11066280	Metabolite levels	C12orf51	.00	8E-22
chr12	112817782	112817783	rs11066280	Metabolite levels	C12orf51	.00	3E-63
chr12	112817782	112817783	rs11066280	Esophageal cancer	RPL6	1.30	2E-15
chr12	112817782	112817783	rs11066280	Blood pressure	RPL6, PTPN11, ALDH2	1.56	8E-31
chr12	112817782	112817783	rs11066280	Blood pressure	RPL6, PTPN11, ALDH2	1.01	1E-35
chr12	112871371	112871372	rs11066301	Hematological parameters	PTPN11	4.65	8E-12
chr12	113100993	113100994	rs17824620	Platelet counts	RPH3A,PTPN11	2.46	1E-8
chr12	113173493	113173494	rs3803064	Platelet counts	AC007425.1	NR	7E-6
chr12	113365620	113365621	rs11066453	Gamma glutamyl transpeptidase	Intergenic	.01	6E-44
chr12	113409175	113409176	rs2072134	HDL cholesterol	OAS3	.02	6E-6
chr12	113409175	113409176	rs2072134	Alcohol consumption	OAS3	.61	6E-17
chr12	113491783	113491784	rs7956193	Visceral adipose tissue adjusted for BMI	DTX1, OAS2, RASAL1	NR	1E-6
chr12	113607501	113607502	rs2384207	Response to fenofibrate (adiponectin levels)	DDX54, TPCN1, SLC24A6, OAS1, OAS2, OAS3	.06	5E-8
chr12	113979655	113979656	rs11066587	Quantitative traits	Intergenic	.26	5E-6
chr12	114637422	114637423	rs7294372	Visceral fat	TBX5	NR	3E-6
chr12	114637847	114637848	rs4767234	Airflow obstruction	TBX5	1.17	6E-7
chr12	114793239	114793240	rs883079	Ventricular conduction	TBX5	.49	1E-10
chr12	114795442	114795443	rs3825214	Electrocardiographic traits	TBX5	7.35	3E-13
chr12	114795442	114795443	rs3825214	Electrocardiographic traits	TBX5	7.36	3E-12
chr12	114795442	114795443	rs3825214	Electrocardiographic traits	TBX5	5.88	1E-7
chr12	114802137	114802138	rs1895585	PR interval	TBX5	3.19	1E-19
chr12	114868137	114868138	rs1265507	Mammographic density	TBX5, TBX3	NR	1E-8
chr12	115094259	115094260	rs11067228	Prostate-specific antigen levels	TBX3	8.30	2E-11
chr12	115346423	115346424	rs1896312	PR interval	TBX5, TBX3	1.95	3E-17
chr12	115352730	115352731	rs2384550	Blood pressure	TBX5, TBX3	.23	4E-6
chr12	115352730	115352731	rs2384550	Diastolic blood pressure	TBX3, TBX5	.35	4E-8
chr12	115380392	115380393	rs10850408	Alzheimer's disease	Intergenic	1.59	9E-7
chr12	115381739	115381740	rs10850409	Ventricular conduction	TBX3	.49	3E-10
chr12	115502717	115502718	rs2194980	Metabolite levels	Intergenic	NR	3E-7
chr12	115552436	115552437	rs35444	Blood pressure	TBX3	.63	8E-7
chr12	115552436	115552437	rs35444	Blood pressure	TBX3	.50	1E-10
chr12	115891402	115891403	rs7315438	Colorectal cancer	MED13L	1.11	6E-6
chr12	117002657	117002658	rs2089222	Acute lymphoblastic leukemia (childhood)	KRTHB5	2.26	8E-8
chr12	117295332	117295333	rs17429217	Alzheimer's disease (age of onset)	HRK, RNFT2	NR	3E-6
chr12	117327591	117327592	rs7294919	Hippocampal volume	HRK	107.80	3E-11
chr12	117327591	117327592	rs7294919	Brain structure	HRK, FBXW8	47.58	7E-16
chr12	117751424	117751425	rs478597	Inattentive symptoms	Intergenic	NR	8E-6
chr12	118169908	118169909	rs4304868	Visceral adipose tissue adjusted for BMI	KSR2	NR	8E-6
chr12	118311742	118311743	rs4767631	Biochemical measures	KSR2	.12	6E-7
chr12	118353870	118353871	rs10444502	Biochemical measures	KSR2	.17	6E-6
chr12	118893247	118893248	rs11613092	Hemostatic factors and hematological phenotypes	SUDS3	8.16	6E-6
chr12	119387917	119387918	rs1997111	T-tau	Intergenic	NR	1E-8
chr12	119818508	119818509	rs11064768	Schizophrenia	CCDC60	NR	1E-6
chr12	119989645	119989646	rs7137869	Aging traits	CCDC60	NR	6E-7
chr12	120455763	120455764	rs11064994	Cognitive performance	CCDC64	NR	6E-6
chr12	120880433	120880434	rs17431357	Insulin resistance/response	TRIAP1	34.00	1E-6
chr12	120974509	120974510	rs614226	Type 1 diabetes nephropathy	RNF10, COQ5	1.35	2E-6
chr12	121160614	121160615	rs2066938	Metabolic traits	ACADS	.61	4E-305
chr12	121175523	121175524	rs2014355	Metabolite levels	ACADS	21.50	5E-96
chr12	121236257	121236258	rs1039302	Quantitative traits	SPPL3	.21	5E-6
chr12	121363723	121363724	rs6489785	Longevity	HNF1A, TCF1	NR	1E-6
chr12	121388961	121388962	rs2650000	Metabolic traits	LEF1	.40	3E-11
chr12	121388961	121388962	rs2650000	LDL cholesterol	HNF1A	.07	2E-8
chr12	121402931	121402932	rs7305618	C-reactive protein	HNF1A	.27	1E-8
chr12	121402931	121402932	rs7305618	Type 2 diabetes	HNF1A	1.14	2E-8
chr12	121403723	121403724	rs7953249	Chronic obstructive pulmonary disease-related biomarkers	HNF1A, TCF1	NR	1E-6
chr12	121403723	121403724	rs7953249	N-glycan levels	HNF1A,C12orf43,OASL	.17	2E-8
chr12	121416649	121416650	rs1169288	Gamma gluatamyl transferase levels	HNF1A	.13	2E-18
chr12	121416649	121416650	rs1169288	LDL cholesterol	HNF1A	1.42	1E-15
chr12	121416649	121416650	rs1169288	Cholesterol, total	HNF1A	1.45	1E-14
chr12	121420259	121420260	rs7979473	C-reactive protein	HNF1A	.12	1E-10
chr12	121420806	121420807	rs1183910	C-reactive protein	HNF1A	.15	2E-124
chr12	121420806	121420807	rs1183910	C-reactive protein	HNF1A	13.80	1E-30
chr12	121423955	121423956	rs2393791	C-reactive protein and white blood cell count	HNF1A	.05	3E-9
chr12	121423955	121423956	rs2393791	Gamma glutamyl transpeptidase	HNF1A	.01	7E-30
chr12	121424860	121424861	rs7310409	Liver enzyme levels (gamma-glutamyl transferase)	HNF1A, C12orf27	6.80	7E-45
chr12	121424860	121424861	rs7310409	C-reactive protein	HNF1A	.07	3E-8
chr12	121424860	121424861	rs7310409	C-reactive protein	HNF1A	.15	7E-17
chr12	121435586	121435587	rs2259816	C-reactive protein	HNF1A, OASL, C12orf43	.14	3E-10
chr12	121435586	121435587	rs2259816	Coronary heart disease	HNF1A,C12orf43	1.08	5E-7
chr12	121438843	121438844	rs735396	N-glycan levels	HNF1A,C12orf43,OASL	.17	4E-8
chr12	121439432	121439433	rs1169310	C-reactive protein	HNF1A	.13	2E-8
chr12	121442669	121442670	rs1169313	Liver enzyme levels	HNF1A, C12orf27, C12orf43	.01	2E-10
chr12	121460685	121460686	rs7957197	Type 2 diabetes	HNF1A	1.07	2E-8
chr12	121471336	121471337	rs3213545	Cardiovascular disease risk factors	OASL	.12	4E-15
chr12	121622303	121622304	rs3751143	Chronic obstructive pulmonary disease-related biomarkers	P2RX7	NR	4E-6
chr12	121938184	121938185	rs10849893	Fasting glucose-related traits (interaction with BMI)	FBXL10	NR	2E-6
chr12	122365582	122365583	rs7961894	Platelet counts	WDR66	3.92	1E-10
chr12	122365582	122365583	rs7961894	Mean platelet volume	WDR66	.03	1E-103
chr12	122365582	122365583	rs7961894	Mean platelet volume	WDR66	.03	3E-44
chr12	122365582	122365583	rs7961894	Mean platelet volume	WDR66	.03	7E-48
chr12	122395776	122395777	rs830124	Urinary metabolites	WDR66, HPD	NR	1E-46
chr12	123174742	123174743	rs601339	Adiponectin levels	GPR109A	.03	4E-6
chr12	123296293	123296294	rs12817488	Parkinson's disease	CCDC62, HIP1R	1.14	3E-13
chr12	123457618	123457619	rs7296418	Platelet counts	ABCB9	NR	2E-6
chr12	123575741	123575742	rs1727307	Platelet counts	PITPNM2	NR	3E-6
chr12	123656724	123656725	rs1790100	Multiple sclerosis	MPHOSPH9	1.11	7E-7
chr12	123796237	123796238	rs4759375	HDL cholesterol	SBNO1	.86	8E-9
chr12	123822710	123822711	rs7980687	Head circumference (infant)	SBNO1	.07	8E-9
chr12	123823545	123823546	rs11830103	Height	SBNO1	.04	4E-15
chr12	124203831	124203832	rs6488898	Adiponectin levels	ATP6V0A2, GPR109A, DNAH10	.05	3E-10
chr12	124399549	124399550	rs1316952	Visceral adipose tissue/subcutaneous adipose tissue ratio	DNAH10	NR	9E-7
chr12	124399549	124399550	rs1316952	Visceral adipose tissue/subcutaneous adipose tissue ratio	DNAH10	NR	1E-7
chr12	124399549	124399550	rs1316952	Visceral adipose tissue adjusted for BMI	DNAH10	NR	5E-6
chr12	124460166	124460167	rs4765127	Triglycerides	CCDC92,ZNF664	2.42	1E-8
chr12	124460166	124460167	rs4765127	HDL cholesterol	CCDC92,ZNF664	.44	3E-10
chr12	124499541	124499542	rs1048497	Visceral adipose tissue/subcutaneous adipose tissue ratio	ZNF664	NR	7E-6
chr12	124499541	124499542	rs1048497	Visceral adipose tissue adjusted for BMI	ZNF664	NR	9E-6
chr12	124519845	124519846	rs1716403	Response to fenofibrate (adiponectin levels)	Intergenic	.14	2E-6
chr12	125033932	125033933	rs12423712	Cognitive performance	NCOR2	NR	7E-6
chr12	125261592	125261593	rs838880	HDL cholesterol	SCARB1	.61	3E-14
chr12	125307052	125307053	rs11057830	Vitamin E levels	SCARB1	.03	8E-9
chr12	125312424	125312425	rs10846744	Lipoprotein-associated phospholipase A2 activity and mass	SCARB1	4.60	1E-8
chr12	125316742	125316743	rs11057841	Lipoprotein-associated phospholipase A2 activity and mass	SCARB1	.03	6E-14
chr12	125320849	125320850	rs4765623	Renal cell carcinoma	SCARB1	1.15	3E-8
chr12	127792613	127792614	rs1823172	Sudden cardiac arrest	Intergenic	1.17	5E-7
chr12	127813740	127813741	rs10744304	Depression (quantitative trait)	Intergenic	.15	9E-6
chr12	128304417	128304418	rs11059374	Response to amphetamines	Intergenic	NR	2E-6
chr12	129095071	129095072	rs7296262	Suicide attempts in bipolar disorder	TMEM132C	1.22	1E-6
chr12	129300693	129300694	rs1385374	Systemic lupus erythematosus	SLC15A4	1.26	2E-11
chr12	129324937	129324938	rs10744391	Renal sinus fat	GLT1D1	.22	1E-6
chr12	129475938	129475939	rs643473	Aging	LOC100129252, NLRP9P	NR	9E-6
chr12	130630934	130630935	rs11060736	Gambling	Intergenic, FZD10, FLJ31485	.29	4E-6
chr12	131022009	131022010	rs1464108	Alzheimer's disease	RIMBP2	1.28	8E-6
chr12	131352561	131352562	rs7304057	Response to amphetamines	Intergenic	NR	4E-6
chr12	131390753	131390754	rs7299940	Panic disorder	Intergenic	NR	7E-6
chr12	131525052	131525053	rs3847687	Longevity	GPR133	NR	1E-6
chr12	131576190	131576191	rs1569019	Height	GPR133	.95	5E-8
chr12	131621761	131621762	rs885389	RR interval (heart rate)	GPR133	.17	4E-8
chr12	131862902	131862903	rs7965445	Mortality among heart failure patients	LOC338797	1.30	2E-6
chr12	131939919	131939920	rs10466868	Protein quantitative trait loci	GPR133	NR	1E-6
chr12	132085195	132085196	rs7315621	Longevity	AC117500.2	NR	1E-6
chr12	132325238	132325239	rs6598163	Migraine	MMP17	1.15	5E-7
chr12	133345808	133345809	rs12282	Immune response to smallpox vaccine (IL-6)	ANKLE2, GOLGA3	NR	3E-7
chr13	19311240	19311241	rs9552416	Fasting insulin-related traits (interaction with BMI)	TUBA3C	NR	3E-24
chr13	20736215	20736216	rs6490525	Capecitabine sensitivity	Intergenic	NR	4E-6
chr13	21209511	21209512	rs7326068	Schizophrenia, bipolar disorder and depression (combined)	IFT88	NR	3E-6
chr13	21280033	21280034	rs735539	Dental caries	IFT88	NR	4E-6
chr13	22305098	22305099	rs518590	Response to antipsychotic treatment	Intergenic	NR	2E-7
chr13	22487624	22487625	rs17369571	Protein quantitative trait loci	FGF3	NR	1E-7
chr13	22709669	22709670	rs7318731	RR interval (heart rate)	Intergenic	.14	1E-6
chr13	23228690	23228691	rs1034200	Central corneal thickness	AVGR8,AL354828.1	.14	4E-9
chr13	23294032	23294033	rs373767	Myopia (pathological)	ZC3H11B	.16	3E-10
chr13	23692977	23692978	rs4770394	Bipolar disorder	SGCG	1.59	9E-6
chr13	23744378	23744379	rs9507041	Cannabis dependence	Intergenic	1.55	8E-6
chr13	23755126	23755127	rs4770403	Alcohol dependence	NR	1.33	6E-6
chr13	23903790	23903791	rs4770433	Protein quantitative trait loci	SACS	NR	4E-6
chr13	24042509	24042510	rs10162002	Hypothyroidism	SACS, TNFRSF19	1.23	5E-6
chr13	24127209	24127210	rs1572072	Nasopharyngeal carcinoma	TNFRSF19	1.19	1E-8
chr13	24205194	24205195	rs9510787	Nasopharyngeal carcinoma	TNFRSF19	1.20	2E-9
chr13	24293858	24293859	rs753955	Lung cancer	MIPEP	1.18	2E-12
chr13	24296861	24296862	rs7324557	Visceral adipose tissue adjusted for BMI	TNFRSF19, MIPEP	NR	8E-6
chr13	24432466	24432467	rs9318086	Myopia (pathological)	MIPEP, C1QTNF9B-AS1, C1QTNF9B	1.32	2E-16
chr13	24504954	24504955	rs2765086	Weight	NR	3.86	6E-6
chr13	24598383	24598384	rs17079773	Inattentive symptoms	Intergenic	NR	5E-6
chr13	24654227	24654228	rs17079928	Orofacial clefts	SPATA13	1.33	6E-6
chr13	24658355	24658356	rs9805786	Depression and alcohol dependence	SPATA13	1.65	7E-6
chr13	24795488	24795489	rs715921	Airflow obstruction	SPATA13	1.20	8E-7
chr13	25082629	25082630	rs9581094	Sudden cardiac arrest	PARP4	1.70	7E-7
chr13	26037959	26037960	rs4770837	Bipolar disorder and schizophrenia	NR	1.25	5E-6
chr13	26724327	26724328	rs17511627	Alzheimer's disease	Intergenic	1.75	5E-6
chr13	27415672	27415673	rs9319321	Asthma (toluene diisocyanate-induced)	Intergenic	5.20	3E-6
chr13	27531266	27531267	rs17085007	Ulcerative colitis	Intergenic	1.16	1E-16
chr13	27531266	27531267	rs17085007	Ulcerative colitis	USP12	1.35	7E-8
chr13	27879525	27879526	rs10507380	Electrocardiographic traits	RPL21	NR	8E-6
chr13	27920610	27920611	rs9512637	Alcoholism (heaviness of drinking)	Intergenic	.11	1E-7
chr13	28020179	28020180	rs4771122	Body mass index	MTIF3, GTF3A	.09	9E-10
chr13	28058403	28058404	rs7336332	Weight	NR	4.01	1E-6
chr13	28077143	28077144	rs9512730	Schizophrenia	Intergenic	1.52	5E-6
chr13	28197435	28197436	rs7097	Large B-cell lymphoma	LNX2	1.44	7E-6
chr13	28429737	28429738	rs9512900	Attention deficit hyperactivity disorder and conduct disorder	GSX1, PDX1	NR	9E-6
chr13	28491197	28491198	rs2293941	Fasting glucose-related traits (interaction with BMI)	PDX1	NR	5E-10
chr13	28929710	28929711	rs17086609	Cognitive performance	FLT1	NR	5E-6
chr13	29278449	29278450	rs1305088	Non-alcoholic fatty liver disease histology (other)	SLC46A3	.58	9E-6
chr13	29431337	29431338	rs1161463	Attention deficit hyperactivity disorder symptoms (interaction)	Intergenic	1.72	2E-6
chr13	29961331	29961332	rs2388082	Insomnia (caffeine-induced)	MTUS2	1.69	4E-6
chr13	30458736	30458737	rs9314986	Biliary atresia	UBL3	2.95	2E-6
chr13	30885222	30885223	rs185694	Antineutrophil cytoplasmic antibody-associated vasculitis	KATNAL1	NR	4E-6
chr13	31113378	31113379	rs11618202	MRI atrophy measures	HMGB1	.00	7E-6
chr13	33147547	33147548	rs7332115	Height	PDS5B/BRCA2	.02	6E-10
chr13	33387245	33387246	rs990324	Total ventricular volume	PDS5B	.01	5E-6
chr13	33693836	33693837	rs9315204	Intracranial aneurysm	STARD13	1.20	3E-9
chr13	34654917	34654918	rs690705	Alzheimer's disease	RFC3	NR	6E-7
chr13	36177818	36177819	rs1777672	HIV-1 control	Intergenic	NR	4E-7
chr13	36351765	36351766	rs7328278	Asthma (childhood onset)	NR	.13	3E-6
chr13	36476446	36476447	rs6563210	Height	DCLK1	.04	7E-7
chr13	36531547	36531548	rs34065801	Breast size	FAM48A	.10	6E-6
chr13	36652616	36652617	rs1926320	Vertical cup-disc ratio	DCLK1	.01	1E-8
chr13	36663301	36663302	rs9315385	Heart rate variability traits	DCAMKL1	NR	8E-6
chr13	36771016	36771017	rs7327064	Economic and political preferences	SOHLH2	.14	6E-6
chr13	38035188	38035189	rs1590305	Hip geometry	Intergenic	NR	3E-6
chr13	38531580	38531581	rs9548119	Self-rated health	Intergenic	.03	9E-6
chr13	39370594	39370595	rs9594293	Cytomegalovirus antibody response	FREM2	.23	7E-6
chr13	39516626	39516627	rs9315632	Metabolic syndrome	STOML3	NR	3E-6
chr13	40118067	40118068	rs9315702	Hippocampal atrophy	LHFP	NR	2E-8
chr13	40350911	40350912	rs7993214	Psoriasis	COG6	1.41	2E-6
chr13	40505509	40505510	rs9548988	Ulcerative colitis	Intergenic	1.10	3E-7
chr13	40807482	40807483	rs10492681	Select biomarker traits	Intergenic	NR	2E-6
chr13	40948150	40948151	rs913246	Bipolar disorder and schizophrenia	NR	1.94	7E-6
chr13	41013976	41013977	rs941823	Ulcerative colitis	Intergenic	1.12	4E-12
chr13	41109428	41109429	rs2755237	Central corneal thickness	FOXO1	.17	1E-8
chr13	41110883	41110884	rs2721051	Central corneal thickness	FOXO1	.24	5E-10
chr13	41558109	41558110	rs7329174	Systemic lupus erythematosus	ELF1	1.26	1E-8
chr13	42139244	42139245	rs17594362	Multiple sclerosis	KIAA0564	1.11	4E-6
chr13	42631718	42631719	rs6561030	Height	DGKH	.05	7E-6
chr13	42653436	42653437	rs1012053	Bipolar disorder	DGKH	1.59	2E-8
chr13	42754521	42754522	rs4142110	Nephrolithiasis	DGKH	1.14	5E-9
chr13	42951448	42951449	rs9533090	Bone mineral density (spine)	AKAP11	.12	5E-25
chr13	42952144	42952145	rs9594738	Bone mineral density	RANKL	.15	4E-6
chr13	42952144	42952145	rs9594738	Bone mineral density (hip)	RANKL	.10	2E-8
chr13	43032592	43032593	rs9594759	Bone mineral density (spine)	RANKL	.12	2E-17
chr13	43032592	43032593	rs9594759	Bone mineral density (spine)	RANKL	.17	2E-21
chr13	43052879	43052880	rs2062305	Crohn's disease	TNFSF11	1.10	5E-10
chr13	43116132	43116133	rs1021188	Bone mineral density	RANKL	3.89	2E-14
chr13	43128576	43128577	rs9525638	Cortical thickness	TNFSF11, RANKL	.09	4E-9
chr13	43727848	43727849	rs1324015	Cognitive performance	DNAJC15	NR	9E-6
chr13	44217063	44217064	rs4942242	Response to tocilizumab in rheumatoid arthritis	ENOX1	.13	2E-7
chr13	44457924	44457925	rs3764147	Crohn's disease	C13orf31	1.17	1E-10
chr13	44457924	44457925	rs3764147	Leprosy	C13orf31	1.68	4E-54
chr13	44457924	44457925	rs3764147	Crohn's disease	Unknown	1.25	2E-13
chr13	44627787	44627788	rs17065323	Uric acid levels	NR	4.29	4E-6
chr13	44637404	44637405	rs9567349	Prostate cancer (gene x gene interaction)	NCRNA00284	1.64	4E-6
chr13	44808173	44808174	rs9533799	Amyotrophic lateral sclerosis	Intergenic	1.17	4E-6
chr13	45055090	45055091	rs17065868	Antineutrophil cytoplasmic antibody-associated vasculitis	TSC22D1	NR	3E-6
chr13	45900266	45900267	rs7323755	Myopia (pathological)	Intergenic	NR	2E-13
chr13	46833716	46833717	rs958546	Atrial fibrillation	Intergenic	NR	5E-6
chr13	47573615	47573616	rs12583882	Subcutaneous adipose tissue	HTR2A	NR	6E-6
chr13	47898878	47898879	rs1417205	Cannbis use (initiation)	GNG5P5	.06	8E-7
chr13	48162557	48162558	rs2478333	QT interval	Intergenic	.17	4E-8
chr13	48198715	48198716	rs1575891	Cardiac hypertrophy	HTR2A	NR	6E-6
chr13	48387721	48387722	rs8001976	Aging (time to event)	SUCLA2	1.09	3E-6
chr13	48436924	48436925	rs11620399	Visceral adipose tissue/subcutaneous adipose tissue ratio	SUCLA2	NR	5E-6
chr13	48436924	48436925	rs11620399	Visceral adipose tissue adjusted for BMI	SUCLA2	NR	5E-6
chr13	50080846	50080847	rs2031532	Cardiac hypertrophy	PHF11	NR	5E-6
chr13	50306220	50306221	rs3736830	Menopause (age at onset)	KPNA3	.18	9E-8
chr13	50835714	50835715	rs2762051	Celiac disease	Intergenic	1.13	7E-7
chr13	50841322	50841323	rs806321	Multiple sclerosis	DLEU1	1.08	5E-7
chr13	50842439	50842440	rs9596270	Multiple sclerosis	Intergenic	1.35	7E-7
chr13	50986117	50986118	rs201789	Anthropometric traits	XTP6	.17	6E-6
chr13	51066622	51066623	rs1262778	Bipolar disorder and major depressive disorder (combined)	Intergenic	NR	8E-6
chr13	51094113	51094114	rs9316500	Pulmonary function decline	DLEU7	.14	5E-6
chr13	51105333	51105334	rs3118905	Height	DLEU7	.06	1E-45
chr13	51106554	51106555	rs1239947	Height	DLEU7	3.80	8E-6
chr13	51111354	51111355	rs3116602	Height	DLEU7	.04	7E-9
chr13	51116900	51116901	rs3118914	Height	DLEU7	.08	4E-10
chr13	53494693	53494694	rs9536318	Airflow obstruction	PCDH8	1.25	8E-7
chr13	53517883	53517884	rs732949	Immune response to anthrax vaccine	PCDH8,OLFM4	.17	8E-6
chr13	53968090	53968091	rs10507577	Select biomarker traits	Intergenic	NR	3E-6
chr13	54064980	54064981	rs9568856	Obesity	OLFM4	1.22	2E-9
chr13	54435236	54435237	rs6561750	Bipolar disorder and schizophrenia	NR	1.23	9E-6
chr13	54581086	54581087	rs9536591	Stroke	Intergenic	1.92	6E-6
chr13	56772695	56772696	rs1512651	Warfarin maintenance dose	NR	NR	6E-6
chr13	58904312	58904313	rs10492604	Sleep duration	Intergenic	NR	4E-6
chr13	59128525	59128526	rs4886088	Subcutaneous adipose tissue	PCDH17	NR	8E-6
chr13	59953465	59953466	rs12585963	Breast size	TDRD3	.08	2E-6
chr13	61113738	61113739	rs4886238	Menopause (age at onset)	TDRD3	.17	1E-10
chr13	61513668	61513669	rs7337573	Phospholipid levels (plasma)	PCDH20	.80	2E-8
chr13	61678911	61678912	rs3106598	Longevity	PCDH20	NR	1E-6
chr13	63436799	63436800	rs2204037	QT interval	NR	1.38	5E-7
chr13	63634349	63634350	rs9317284	Bone mineral density	Intergenic	NR	2E-7
chr13	63638328	63638329	rs3119939	Asthma	PCDH20	1.08	8E-6
chr13	66120783	66120784	rs1333026	Body mass index	Intergenic	NR	8E-6
chr13	66356340	66356341	rs17077331	Pulmonary function decline	PCDH9	.50	4E-6
chr13	66481814	66481815	rs1585440	Pancreatic cancer	LOC387933	1.30	9E-6
chr13	66967621	66967622	rs17081231	Obesity	PCDH9	NR	7E-7
chr13	67696144	67696145	rs2875517	Dental caries	PCDH9	NR	3E-6
chr13	69530663	69530664	rs2066219	Diabetes related insulin traits	Intergenic	NR	9E-6
chr13	70430092	70430093	rs2325244	Response to amphetamines	KLHL1	NR	8E-7
chr13	70454959	70454960	rs11843309	Bilirubin levels	KLHL1	.21	7E-6
chr13	70455660	70455661	rs7984606	Cognitive performance	KLHL1	NR	8E-6
chr13	70846202	70846203	rs9572423	Major depressive disorder	Intergenic	1.54	9E-6
chr13	71883213	71883214	rs9592783	Longevity	DACH1	NR	1E-6
chr13	72174352	72174353	rs9919839	Adverse response to lamotrigine and phenytoin	DACH1	NR	2E-6
chr13	72347695	72347696	rs626277	Chronic kidney disease	DACH1	.01	3E-11
chr13	72688773	72688774	rs9652236	Obsessive-compulsive disorder	DACH1, MZT1	1.40	5E-6
chr13	72768708	72768709	rs4083578	Cognitive performance	AL445923.10	NR	8E-6
chr13	73728138	73728139	rs9600079	Prostate cancer	Intergenic	1.18	3E-9
chr13	73741148	73741149	rs11838472	Myopia (pathological)	Intergenic	NR	3E-17
chr13	73908845	73908846	rs9573163	Pancreatic cancer	NR	1.26	5E-13
chr13	73916627	73916628	rs9543325	Pancreatic cancer	KLF5, KLF12	1.26	3E-11
chr13	73932113	73932114	rs1886449	Pancreatic cancer	LOC730242	1.51	9E-6
chr13	74520185	74520186	rs1886512	Ventricular conduction	KLF12	.40	1E-8
chr13	74730391	74730392	rs8000245	Optic disc size (rim)	LOC730245	.21	8E-6
chr13	74742321	74742322	rs12429889	Sudden cardiac arrest	Intergenic	1.64	5E-20
chr13	74995659	74995660	rs17714988	Immune reponse to smallpox (secreted IFN-alpha)	hCG_1820717	NR	3E-7
chr13	75128113	75128114	rs17718828	Phospholipid levels (plasma)	KLF12	.80	1E-8
chr13	75776267	75776268	rs548097	Heart failure	TBC1D4	1.62	6E-7
chr13	76326281	76326282	rs539514	Type 1 diabetes	LMO7	1.43	6E-11
chr13	78808913	78808914	rs9574199	Total ventricular volume	EDNRB, POU4F1	.00	7E-6
chr13	79359423	79359424	rs17070284	Cognitive performance	RP11-600P1.2	NR	3E-6
chr13	79410573	79410574	rs11838918	Conduct disorder (symptom count)	Intergenic	.28	1E-8
chr13	79410573	79410574	rs11838918	Conduct disorder (case status)	Intergenic	2.26	3E-6
chr13	79455831	79455832	rs1218282	Response to statin therapy	LOC390415, LOC647298, C13orf7	NR	5E-6
chr13	80299721	80299722	rs2039553	Pancreatic cancer	NDFIP2	1.73	7E-6
chr13	80623345	80623346	rs7981942	Fasting insulin-related traits (interaction with BMI)	SPRY2	NR	2E-6
chr13	80668873	80668874	rs9574565	Orofacial clefts	SPRY2	1.31	3E-7
chr13	80692810	80692811	rs8001641	Orofacial clefts	SPRY2	1.35	9E-11
chr13	80692810	80692811	rs8001641	Orofacial clefts	SPRY2	1.31	3E-10
chr13	80717155	80717156	rs1359790	Type 2 diabetes	SPRY2	1.15	6E-9
chr13	80959206	80959207	rs534870	Adiposity	SPRY2	.03	7E-8
chr13	84130231	84130232	rs6563353	Response to citalopram treatment	Intergenic	NR	2E-6
chr13	85032326	85032327	rs17371334	Temperament (bipolar disorder)	SLITRK1	1.05	2E-6
chr13	85054265	85054266	rs9546711	Coronary heart disease	Intergenic	1.66	2E-6
chr13	86690526	86690527	rs7984869	Economic and political preferences (fairness)	Intergenic	.12	3E-6
chr13	87242856	87242857	rs4773460	Hippocampal atrophy	Intergenic	NR	2E-6
chr13	88704705	88704706	rs7323893	Coronary heart disease	Intergenic	.14	1E-7
chr13	88762345	88762346	rs969962	Cognitive performance	AL354896.16	NR	9E-6
chr13	90622454	90622455	rs2882281	Longevity	RP11-388D4.1	NR	1E-6
chr13	90865545	90865546	rs16944141	Prostate cancer (gene x gene interaction)	MIR622	1.54	3E-6
chr13	92015976	92015977	rs8002779	Height	GPC5	.05	3E-6
chr13	92024573	92024574	rs7319045	Height	GPC5	.03	1E-11
chr13	92203812	92203813	rs16946160	Nephrotic syndrome (acquired)	GPC5	1.39	3E-7
chr13	92445228	92445229	rs2352028	Lung cancer	GPC5	1.46	6E-6
chr13	93213475	93213476	rs1413191	HIV-1 control	GPC5	NR	5E-6
chr13	93323145	93323146	rs17267292	Metabolite levels	GPC5	NR	1E-7
chr13	93331885	93331886	rs9523762	Multiple sclerosis	GPC5	1.36	1E-6
chr13	93581790	93581791	rs9523848	Breast size	GPC6	.08	3E-6
chr13	93938705	93938706	rs11839514	Visceral fat	GPC6	NR	4E-6
chr13	94011168	94011169	rs9561329	Neuroticism	GPC6	.17	1E-7
chr13	94341095	94341096	rs9561428	Bipolar disorder and schizophrenia	NR	1.83	9E-6
chr13	94408505	94408506	rs7995215	Attention deficit hyperactivity disorder	GPC6	NR	1E-8
chr13	94870764	94870765	rs1572050	Renal sinus fat	GPC6	.31	6E-6
chr13	94952831	94952832	rs9301951	Disc degeneration (lumbar)	GPC6	.26	9E-7
chr13	95463391	95463392	rs9302001	Panic disorder	Intergenic	NR	3E-7
chr13	95680284	95680285	rs4148546	Longevity	ABCC4	NR	1E-6
chr13	95874955	95874956	rs1926657	Breast cancer	ABCC4	NR	2E-6
chr13	95898206	95898207	rs4148441	Platelet counts	ABCC4	4.12	7E-12
chr13	96951432	96951433	rs2038823	Diabetic retinopathy	HS6ST3	NR	5E-11
chr13	98016415	98016416	rs9556711	Alcoholism (alcohol use disorder factor score)	MBNL2	.16	2E-6
chr13	98016415	98016416	rs9556711	Alcoholism (alcohol dependence factor score)	MBNL2	.17	8E-7
chr13	98831594	98831595	rs9556893	Response to amphetamines	FARP1	NR	6E-6
chr13	98960761	98960762	rs4318070	Total ventricular volume	FARP1	.00	7E-6
chr13	98966316	98966317	rs688872	Brain structure	FARP1	NR	1E-6
chr13	98994029	98994030	rs9584805	Non-alcoholic fatty liver disease histology (lobular)	FARP1	.44	2E-6
chr13	99126302	99126303	rs9517320	Longevity	STK24	NR	1E-6
chr13	99131293	99131294	rs912330	Alzheimer's disease	STK24	1.85	4E-6
chr13	99385989	99385990	rs9582259	Immune reponse to smallpox (secreted IL-1beta)	SLC15A1	NR	3E-8
chr13	100041737	100041738	rs7335046	Basal cell carcinoma	UBAC2	1.26	3E-8
chr13	100518633	100518634	rs41281112	Vitamin B12 levels	CLYBL	83.60	9E-10
chr13	100555037	100555038	rs7992643	Attention deficit hyperactivity disorder	CLYBL	NR	5E-6
chr13	100638391	100638392	rs13542	Orofacial clefts	NR	NR	1E-6
chr13	101708309	101708310	rs2044117	Bipolar disorder and schizophrenia	NALCN	1.30	5E-7
chr13	102000944	102000945	rs7996217	HIV-associated dementia	NALCN	NR	7E-7
chr13	102051089	102051090	rs9557635	Non-small cell lung cancer	NALCN	NR	9E-6
chr13	102553247	102553248	rs9557754	QT interval	NR	1.23	8E-6
chr13	103867103	103867104	rs912969	Smoking behavior	Intergenic	.14	8E-6
chr13	103928006	103928007	rs1529276	Prostate cancer	Intergenic	NR	2E-6
chr13	103969490	103969491	rs4771450	Uric acid levels	NR	.23	2E-6
chr13	104060086	104060087	rs9586179	Phospholipid levels (plasma)	SLC10A2	.05	4E-7
chr13	104091544	104091545	rs583464	Response to amphetamines	Intergenic	NR	3E-6
chr13	104186918	104186919	rs16962638	Insulin resistance/response	Intergenic	15.00	6E-6
chr13	105039145	105039146	rs17450420	Esophageal cancer  (alcohol interaction)	SLC10A2	1.70	5E-8
chr13	105807022	105807023	rs16965962	Response to citalopram treatment	Intergenic	NR	3E-7
chr13	105807022	105807023	rs16965962	Response to citalopram treatment	Intergenic	NR	3E-7
chr13	106096811	106096812	rs11618212	Myopia (pathological)	Intergenic	NR	5E-12
chr13	106589140	106589141	rs7336109	Visceral fat	DAOA	NR	9E-6
chr13	106651660	106651661	rs4996815	Bipolar disorder and schizophrenia	DAOA	1.28	1E-7
chr13	106785264	106785265	rs1372791	Immune reponse to smallpox (secreted IL-2)	LOC341604	NR	4E-7
chr13	107780315	107780316	rs1927745	Depression (quantitative trait)	FAM155A	.16	5E-6
chr13	108257219	108257220	rs957788	Anorexia nervosa	FAM155A	NR	8E-6
chr13	108816224	108816225	rs10492664	Attention deficit hyperactivity disorder and conduct disorder	LIG4, ABHD13	NR	1E-6
chr13	109347658	109347659	rs7984522	Blood pressure	MYO16	NR	7E-7
chr13	109502848	109502849	rs17485138	Dental caries	MYO16	NR	7E-6
chr13	110818597	110818598	rs3742207	Arterial stiffness	COL4A1	21.00	5E-8
chr13	110960711	110960712	rs4773144	Coronary heart disease	COL4A1, COL4A2	1.07	4E-9
chr13	110960942	110960943	rs3809346	Coronary artery calcification	COL4A2	.10	9E-7
chr13	111030577	111030578	rs7319311	Bipolar disorder and schizophrenia	NR	1.25	4E-6
chr13	111470037	111470038	rs767210	Cognitive performance	RP11-120J20.1	NR	3E-7
chr13	111818831	111818832	rs4773330	Bilirubin levels	ARHGEF7	.04	8E-6
chr13	112181436	112181437	rs9555810	Menarche (age at onset)	C13orf16, ARHGEF7	2.30	6E-8
chr13	112221296	112221297	rs7333181	Menopause (age at onset)	LOC121793, ARHGEF7	.52	3E-8
chr13	113331867	113331868	rs7998202	Glycated hemoglobin levels	ATP11A,TUBGCP3	.03	5E-9
chr13	113694508	113694509	rs11842874	Osteoarthritis	MCF2L	1.17	2E-8
chr13	113760033	113760034	rs561241	Prothrombin time	F7	.04	4E-56
chr13	113760033	113760034	rs561241	Factor VII	MCF2L, AB116074, AK092739, AK123267, AB002360, F7, CR603372, F10, PROZ	NR	5E-16
chr13	114012897	114012898	rs7317038	Mean platelet volume	GRTP1	.01	8E-12
chr13	114622596	114622597	rs9604529	Response to tocilizumab in rheumatoid arthritis	Intergenic	.35	7E-7
chr14	20957432	20957433	rs12147450	Response to antipsychotic therapy (extrapyramidal side effects)	Intergenic	NR	6E-7
chr14	21024618	21024619	rs1243647	Prostate cancer (gene x gene interaction)	RNASE9	1.33	1E-6
chr14	21725653	21725654	rs17197037	Bipolar disorder	HNRNPC	1.17	2E-6
chr14	23002683	23002684	rs1154155	Narcolepsy	TRA@	1.54	5E-7
chr14	23002683	23002684	rs1154155	Narcolepsy	TRA-alpha, TRAJ10	1.69	3E-22
chr14	23589056	23589057	rs2239633	Acute lymphoblastic leukemia (childhood)	CEBPE	1.34	3E-7
chr14	23840032	23840033	rs10137082	Type 1 diabetes	NR	1.10	6E-6
chr14	23861810	23861811	rs365990	Electrocardiographic traits	MYH6	5.25	9E-11
chr14	23865884	23865885	rs452036	Resting heart rate	MYH6	7.80	4E-14
chr14	23977009	23977010	rs223116	Resting heart rate	MYH7,NDNG	7.40	3E-8
chr14	24033069	24033070	rs2281680	Sudden cardiac arrest	AP1G2	1.38	6E-8
chr14	24381514	24381515	rs12436436	Bipolar disorder	NR	1.30	5E-6
chr14	24830849	24830850	rs1950500	Height	NFATC4	.03	2E-18
chr14	24883886	24883887	rs8017377	LDL cholesterol	CBLN3,KIAA0323	1.17	4E-11
chr14	25102159	25102160	rs8192917	Vitiligo	GZMB	1.28	3E-8
chr14	25271519	25271520	rs854384	MRI atrophy measures	STXBP6	.00	1E-6
chr14	25479541	25479542	rs11850957	Subcutaneous adipose tissue	STXBP6	NR	6E-6
chr14	25503798	25503799	rs10147992	White blood cell types	STXBP6	.06	1E-8
chr14	27260042	27260043	rs1951082	Attention deficit hyperactivity disorder and conduct disorder	Intergenic	NR	5E-6
chr14	27406891	27406892	rs17111920	Bipolar disorder and schizophrenia	NR	2.41	3E-6
chr14	27800176	27800177	rs2877832	Diabetes related insulin traits	Intergenic	NR	3E-6
chr14	27800176	27800177	rs2877832	Diabetes related insulin traits	Intergenic	NR	2E-6
chr14	29021927	29021928	rs7493138	Longevity	FOXG1	NR	1E-6
chr14	29116694	29116695	rs12587311	Phospholipid levels (plasma)	FOXG1	.01	5E-7
chr14	29249348	29249349	rs2038256	Multiple sclerosis--Brain Glutamate Levels	FOXG1B	NR	2E-6
chr14	30515111	30515112	rs11847697	Body mass index	PRKD1	.17	6E-11
chr14	30594656	30594657	rs225848	Sexual dysfunction (SSRI/SNRI-related)	RP11-269 C4.1	4.42	1E-6
chr14	32093547	32093548	rs7142881	Response to iloperidone treatment (QT prolongation)	NUBPL	NR	2E-6
chr14	32353249	32353250	rs2039485	Brain lesion load	NUBPL	NR	6E-6
chr14	32433857	32433858	rs915071	Bipolar disorder and schizophrenia	NR	1.23	2E-6
chr14	32851024	32851025	rs1951681	Economic and political preferences (environmentalism)	AKAP6	.19	6E-6
chr14	33207521	33207522	rs2300835	Fasting insulin-related traits (interaction with BMI)	AKAP6	NR	5E-7
chr14	33282469	33282470	rs2383378	Anorexia nervosa	AKAP6	NR	6E-6
chr14	33381097	33381098	rs12146962	Ankylosing spondylitis	NR	1.14	9E-6
chr14	33476265	33476266	rs4982029	Schizophrenia, bipolar disorder and depression (combined)	NPAS3	NR	4E-6
chr14	33480921	33480922	rs8015959	Bipolar disorder	NR	1.59	5E-6
chr14	33586562	33586563	rs17460823	Inflammatory biomarkers	NPAS3	NR	2E-6
chr14	35682171	35682172	rs12586317	Psoriasis	NFKBIA, PSMA6	1.15	2E-8
chr14	35832665	35832666	rs8016947	Psoriasis	NFKBIA	1.19	2E-11
chr14	36397679	36397680	rs1168987	Response to antineoplastic agents	Intergenic	2.27	5E-6
chr14	36649245	36649246	rs944289	Thyroid cancer	NKX2-1	1.37	2E-9
chr14	36738360	36738361	rs116909374	Thyroid cancer	MBIP	2.09	5E-11
chr14	37000048	37000049	rs17104630	Height	NKX2-1	.42	8E-6
chr14	39020504	39020505	rs10498345	Coronary spasm	Intergenic	2.33	9E-7
chr14	41523461	41523462	rs1959947	Hemostatic factors and hematological phenotypes	LRFN5	4.76	7E-6
chr14	42655274	42655275	rs2154294	Alcoholism (12-month weekly alcohol consumption)	Intergenic	.08	3E-6
chr14	47403683	47403684	rs12883384	Neuroticism	MAMDC1	NR	7E-7
chr14	47863834	47863835	rs7159841	Hemostatic factors and hematological phenotypes	MAMDC1	NR	2E-7
chr14	47874556	47874557	rs17118552	Response to tocilizumab in rheumatoid arthritis	MDGA2	17.19	2E-7
chr14	48015981	48015982	rs1160351	Sexual dysfunction (SSRI/SNRI-related)	MDGA2	2.92	3E-7
chr14	48564955	48564956	rs7151223	Cognitive performance	AL358335.4	NR	1E-6
chr14	49372800	49372801	rs2352904	Cognitive test performance	Intergenic	NR	2E-6
chr14	49463483	49463484	rs11845208	Immune reponse to smallpox (secreted IL-2)	ATP5GP2	NR	1E-7
chr14	49534424	49534425	rs8013477	Visceral adipose tissue/subcutaneous adipose tissue ratio	RPS29	NR	4E-6
chr14	49951349	49951350	rs1530947	Visceral fat	RPS29	NR	5E-6
chr14	50877982	50877983	rs1265879	Cognitive performance	CDKL1	NR	4E-6
chr14	50973631	50973632	rs17718580	Cognitive performance	MAP4K5	NR	8E-7
chr14	51084234	51084235	rs17122693	Cognitive performance	ATL1,SPG3A	NR	3E-7
chr14	51170878	51170879	rs8020441	Cognitive performance	NIN	NR	5E-7
chr14	51403530	51403531	rs7142143	Acute lymphoblastic leukemia (childhood)	PYGL	3.61	7E-9
chr14	51919821	51919822	rs7153703	Total ventricular volume	FRMD6	.01	3E-6
chr14	52010798	52010799	rs7140150	Brain structure	FRMD6	NR	5E-7
chr14	52077088	52077089	rs1006973	Anticoagulant levels	FRMD6	NR	8E-6
chr14	52233275	52233276	rs11626056	Hippocampal atrophy	FRMD6	NR	1E-6
chr14	52518810	52518811	rs730532	Pulmonary function	NID2	NR	6E-6
chr14	52989227	52989228	rs745080	Orofacial clefts	TXNDC16	1.59	8E-7
chr14	53837484	53837485	rs12434047	Economic and political preferences (fairness)	Intergenic	.13	3E-6
chr14	54072857	54072858	rs1380131	Alcoholism (heaviness of drinking)	Intergenic	.15	9E-6
chr14	54167471	54167472	rs210359	Immune reponse to smallpox (secreted IFN-alpha)	BMP4	NR	8E-8
chr14	54290829	54290830	rs12431733	Parkinson's disease	BMP4	1.13	3E-6
chr14	54410918	54410919	rs4444235	Colorectal cancer	BMP4	1.11	8E-10
chr14	54857285	54857286	rs4293296	Working memory	CDKN3	NR	3E-6
chr14	55348117	55348118	rs3783637	Rheumatoid arthritis	GCH1	1.10	2E-6
chr14	55614635	55614636	rs2274273	Protein biomarker	LGALS3, DLGAP5	.19	2E-188
chr14	56525568	56525569	rs398652	Telomere length	PELI2	.12	2E-6
chr14	56886685	56886686	rs17832777	Chronic obstructive pulmonary disease-related biomarkers	PELI2	NR	6E-6
chr14	57221138	57221139	rs878889	Type 1 diabetes nephropathy	Intergenic	1.43	8E-7
chr14	58119195	58119196	rs10134944	Bipolar disorder	NR	NR	1E-6
chr14	58119195	58119196	rs10134944	Bipolar disorder	NR	1.45	7E-6
chr14	58200724	58200725	rs1092015	Bipolar disorder and schizophrenia	NR	2.04	8E-6
chr14	58355047	58355048	rs8013190	HIV-1 control	Intergenic	NR	7E-8
chr14	58385364	58385365	rs1335515	Attention deficit hyperactivity disorder (time to onset)	Intergenic	NR	8E-6
chr14	58397915	58397916	rs808225	Pulmonary function	Intergenic	NR	7E-6
chr14	59334127	59334128	rs4901869	Panic disorder	Intergenic	NR	6E-6
chr14	60683429	60683430	rs216518	Allergic rhinitis	PPM1A, DHRS7	1.21	2E-6
chr14	60957278	60957279	rs2093210	Height	SIX6	.03	6E-17
chr14	61072874	61072875	rs10483727	Glaucoma (primary open-angle)	SIX1, SIX6	1.32	4E-11
chr14	61072874	61072875	rs10483727	Glaucoma (primary open-angle)	SIX1, SIX6	1.27	9E-8
chr14	61072874	61072875	rs10483727	Vertical cup-disc ratio	SIX1	.01	1E-11
chr14	61072874	61072875	rs10483727	Optic disc size (rim)	SIX1	.15	9E-6
chr14	61308336	61308337	rs6573333	Immune reponse to smallpox (secreted IFN-alpha)	MNAT1	NR	3E-10
chr14	61908331	61908332	rs1957895	Rheumatoid arthritis	PRKCH	1.09	4E-7
chr14	62185294	62185295	rs8005745	Select biomarker traits	Intergenic	NR	4E-6
chr14	62518347	62518348	rs6573416	Self-rated health	SYT16	.03	3E-6
chr14	62654697	62654698	rs973968	Iron status biomarkers	Q6ZUR9	NR	3E-6
chr14	62678302	62678303	rs1514928	Attention deficit hyperactivity disorder	Intergenic	NR	3E-6
chr14	62732663	62732664	rs10146615	Economic and political preferences (immigration/crime)	Intergenic	.14	7E-6
chr14	63177143	63177144	rs869834	Subcutaneous adipose tissue	KCNH5	NR	2E-6
chr14	63953521	63953522	rs11158493	Response to antineoplastic agents	PPP2R5E	2.00	9E-7
chr14	64232385	64232386	rs17101394	Sphingolipid levels	SGPP1	.00	3E-57
chr14	64235555	64235556	rs7157785	Sphingolipid levels	SGPP1	.00	9E-66
chr14	64275811	64275812	rs7144584	Pulmonary function decline	SYNE2	.32	6E-7
chr14	64680847	64680848	rs1152591	Atrial fibrillation	SYNE2	1.13	6E-13
chr14	64899054	64899055	rs10498514	Cognitive performance	MTHFD1	NR	8E-7
chr14	65475539	65475540	rs4466998	Mean corpuscular volume	FNTB	.00	5E-8
chr14	65645249	65645250	rs7158173	Anthropometric traits	MAX	.11	4E-6
chr14	65747758	65747759	rs1256531	Conduct disorder (symptom count)	Intergenic	.09	4E-6
chr14	65758641	65758642	rs7159888	N-glycan levels	FUT8	.26	3E-18
chr14	65865624	65865625	rs7147624	Chronic obstructive pulmonary disease-related biomarkers	FUT8	NR	5E-6
chr14	65914866	65914867	rs10483776	N-glycan levels	FUT8	.22	1E-8
chr14	66262962	66262963	rs8007846	Multiple sclerosis--Brain Glutamate Levels	FUT8	NR	9E-6
chr14	67975821	67975822	rs1077989	Phospholipid levels (plasma)	PLEKHH1	.00	9E-18
chr14	68520905	68520906	rs8022206	Platelet counts	RAD51L1	3.20	2E-10
chr14	68699593	68699594	rs1314913	Breast cancer (male)	RAD51B	1.57	3E-13
chr14	68749926	68749927	rs3784099	Breast cancer (survival)	RAD51L1	1.43	3E-7
chr14	68749926	68749927	rs3784099	Breast cancer (survival)	RAD51L1	1.49	1E-7
chr14	68753592	68753593	rs911263	Primary biliary cirrhosis	RAD51L1	1.29	2E-11
chr14	68788923	68788924	rs1956529	Primary tooth development (number of teeth)	RAD51L1	.51	3E-8
chr14	68813114	68813115	rs1570106	Height	RAD51L1	.03	8E-9
chr14	69034681	69034682	rs999737	Breast cancer	RAD51L1	1.06	2E-7
chr14	69210198	69210199	rs4902642	Crohn's disease	ZFP36L1	1.07	2E-10
chr14	69254190	69254191	rs4902647	Multiple sclerosis	ZFP36L1	1.11	9E-12
chr14	69263598	69263599	rs1465788	Type 1 diabetes	Intergenic	1.16	2E-12
chr14	69278203	69278204	rs4899260	Celiac disease	ZFP36L1	1.12	4E-7
chr14	69408696	69408697	rs2268983	Smoking behavior	ACTN1	1.52	7E-6
chr14	70517182	70517183	rs12883884	Cystic fibrosis severity	SLC8A3	NR	8E-6
chr14	70644168	70644169	rs7146198	Corneal curvature	SLC8A3	.05	4E-6
chr14	71249801	71249802	rs17108533	Reasoning	MAP3K9	NR	1E-6
chr14	71352647	71352648	rs36563	Alcohol dependence	Intergenic	1.33	5E-6
chr14	71395603	71395604	rs2810114	Alcohol dependence	NR	1.29	4E-6
chr14	71507600	71507601	rs11848070	Alzheimer's disease (late onset)	PCNX	NR	6E-6
chr14	71666296	71666297	rs17767225	Alzheimer's disease (late onset)	Intergenic	NR	8E-6
chr14	72057354	72057355	rs11848785	Ventricular conduction	SIPA1L1	.50	1E-10
chr14	72432148	72432149	rs4902960	Economic and political preferences (environmentalism)	RGS6	.19	1E-6
chr14	72692492	72692493	rs699363	Obesity (extreme)	RGS6	NR	5E-6
chr14	72883873	72883874	rs7159300	Smoking cessation	RGS6	NR	4E-6
chr14	73019235	73019236	rs4903031	C-reactive protein	RGS6	.03	5E-6
chr14	73081067	73081068	rs2526932	C-reactive protein and white blood cell count	Intergenic	.28	6E-13
chr14	73756298	73756299	rs10483853	Coronary artery calcification	NUMB	NR	6E-6
chr14	73767213	73767214	rs2333194	Bipolar disorder (mood-incongruent)	NUMB	1.20	7E-7
chr14	74551969	74551970	rs2239557	Common traits (Other)	NR	NR	3E-7
chr14	74990745	74990746	rs862034	Height	LTBP2	.03	7E-14
chr14	75322793	75322794	rs8014204	Caffeine consumption	NR	.07	5E-6
chr14	75365728	75365729	rs732765	Non-small cell lung cancer	DLST	NR	7E-6
chr14	75626041	75626042	rs910316	Height	TMED10	.05	1E-7
chr14	75814027	75814028	rs11621969	Periodontal microbiota	FOS, JDP2	2.46	9E-7
chr14	75960535	75960536	rs7155603	Rheumatoid arthritis	BATF	1.16	1E-7
chr14	76005556	76005557	rs2300603	Multiple sclerosis	BATF	1.11	2E-8
chr14	76129590	76129591	rs724743	Height	TTLL5	.10	1E-7
chr14	76613677	76613678	rs935334	Blood pressure	Intergenic	NR	3E-6
chr14	76650763	76650764	rs2121070	Blood pressure	C14orf118	NR	5E-6
chr14	76703350	76703351	rs7156960	Acute lymphoblastic leukemia (childhood)	C14orf118	1.22	3E-6
chr14	76703350	76703351	rs7156960	Acute lymphoblastic leukemia (childhood)	C14orf118	NR	1E-6
chr14	76812490	76812491	rs2360997	Attention deficit hyperactivity disorder symptoms (interaction)	Intergenic	1.30	8E-6
chr14	77497974	77497975	rs183266	Adverse response to lamotrigine and phenytoin	IRF2BPL	NR	5E-6
chr14	77684669	77684670	rs4467006	Bipolar disorder	Intergenic	1.59	7E-6
chr14	77684841	77684842	rs2287375	Bipolar disorder	Intergenic	1.61	5E-6
chr14	78534905	78534906	rs3850370	Response to platinum-based chemotherapy in non-small-cell lung cancer	SKIIP, SNW1, ALKBH1, NRXN3	1.31	4E-6
chr14	78786076	78786077	rs11624704	Obesity	NRXN3	NR	3E-9
chr14	78786158	78786159	rs6574433	Cognitive performance	AC007056.4-3	NR	6E-6
chr14	79936963	79936964	rs10150332	Body mass index	NRXN3	.13	3E-11
chr14	79945161	79945162	rs10146997	Waist circumference	NRXN3	.65	5E-8
chr14	80002095	80002096	rs7147705	Amyotrophic lateral sclerosis (age of onset)	NRXN3	NR	6E-6
chr14	81451228	81451229	rs12101261	Graves' disease	TSHR	1.35	7E-24
chr14	81523127	81523128	rs17111394	Optic disc size (rim)	TSHR	.22	4E-6
chr14	81575453	81575454	rs8017455	Hair morphology	TSHR	NR	6E-6
chr14	81594379	81594380	rs3783938	Visceral fat	TSHR	NR	8E-7
chr14	84775208	84775209	rs11159647	Alzheimer's disease	Intergenic	NR	2E-6
chr14	85654018	85654019	rs12436689	Pulmonary function decline	FLRT2	.21	7E-6
chr14	87506247	87506248	rs11624056	Sudden cardiac arrest	Intergenic	1.43	3E-8
chr14	88295599	88295600	rs4322600	Breast cancer	GALC	1.18	4E-6
chr14	88472594	88472595	rs8005161	Crohn's disease	GALC,GPR65	1.23	4E-18
chr14	88487688	88487689	rs2119704	Multiple sclerosis	GPR65	1.22	2E-10
chr14	88559991	88559992	rs6574988	Bipolar disorder	NR	NR	4E-6
chr14	88826681	88826682	rs17124581	Information processing speed	SPATA7	.27	3E-6
chr14	90034971	90034972	rs8004664	Fasting glucose-related traits (interaction with BMI)	FOXN3	NR	3E-6
chr14	90301034	90301035	rs12100561	Hepatocellular carcinoma	C14orf143	1.52	4E-6
chr14	90679909	90679910	rs8017423	Mortality among heart failure patients	KCNK13	1.64	7E-6
chr14	90758890	90758891	rs2282032	Longevity	C14orf102	NR	1E-6
chr14	91022184	91022185	rs17793829	Cytomegalovirus antibody response	TTC7B	.20	9E-6
chr14	92427221	92427222	rs7153027	Height	TRIP11, FBLN5, ATXN3, CPSF2	5.70	1E-10
chr14	92459957	92459958	rs8007661	Height	TRIP11,ATXN3	.42	6E-10
chr14	92485880	92485881	rs7155279	Height	TRIP11	.02	1E-10
chr14	92556054	92556055	rs17807815	Orofacial clefts	ATXN3	2.38	6E-6
chr14	92636712	92636713	rs1009170	Dialysis-related mortality	SLC24A4, CPSF2	2.00	2E-6
chr14	92763390	92763391	rs4900109	Iris characteristics	SLC324A4	.17	8E-21
chr14	92773662	92773663	rs12896399	Hair color	SLC24A4	.31	5E-13
chr14	92773662	92773663	rs12896399	Eye color	SLC24A4	.34	1E-16
chr14	92773662	92773663	rs12896399	Eye color	SLC24A4	1.73	2E-23
chr14	92773662	92773663	rs12896399	Black vs. blond hair color	SLC24A4	.18	8E-21
chr14	92773662	92773663	rs12896399	Blue vs. green eyes	SLC24A4	2.06	4E-38
chr14	92773662	92773663	rs12896399	Blond vs. brown hair color	SLC24A4	2.56	1E-48
chr14	92972161	92972162	rs4904947	Dialysis-related mortality	RIN3, SLC24A4	1.90	8E-6
chr14	93103308	93103309	rs10498635	Paget's disease	RIN3	1.44	3E-11
chr14	93501025	93501026	rs8006385	Platelet counts	ITPK1	3.59	1E-10
chr14	94205344	94205345	rs6575353	Insomnia (caffeine-induced)	PRIMA1	1.47	1E-6
chr14	94563192	94563193	rs7157940	Anthropometric traits	LOC122509, FAM14B	.12	3E-6
chr14	94796183	94796184	rs61280460	Breast size	SERPINA6, CLMN	.10	8E-7
chr14	94844842	94844843	rs1303	Metabolite levels	SERPINA1	NR	5E-48
chr14	94863635	94863636	rs7151526	Antineutrophil cytoplasmic antibody-associated vasculitis	SERPINA11, SERPINA1	1.69	2E-9
chr14	95012383	95012384	rs11160190	Vaspin levels	vaspin, serpinA4	.04	4E-41
chr14	95671870	95671871	rs1187614	Response to antipsychotic treatment	CLMN	NR	2E-7
chr14	95720677	95720678	rs8014194	Response to statin therapy	CLMN, FLJ45244, DICER1	NR	2E-8
chr14	96027152	96027153	rs8005962	Tuberculosis	NR	1.20	8E-6
chr14	96122407	96122408	rs8015016	QT interval	TCL6	.18	5E-7
chr14	96169130	96169131	rs7158782	Adverse response to aromatase inhibitors	TCL1A	2.13	8E-7
chr14	96175977	96175978	rs11849538	Adverse response to aromatase inhibitors	TCL1A	NR	7E-7
chr14	96206069	96206070	rs2369304	Neutrophil count	AL139020.1	NR	9E-6
chr14	97103806	97103807	rs17094273	Tanning	Intergenic	.20	9E-8
chr14	97345805	97345806	rs4905558	Neutrophil count	VRK1	NR	8E-6
chr14	98303330	98303331	rs1471356	Radiation response	LOC100132612	NR	9E-6
chr14	98463156	98463157	rs7140601	Immune response to smallpox vaccine (IL-6)	LOC100132612	NR	7E-7
chr14	98498950	98498951	rs4900384	Type 1 diabetes	Intergenic	1.09	4E-9
chr14	98499457	98499458	rs10144042	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	C14orf177	1.40	2E-6
chr14	98588320	98588321	rs7152623	Aortic stiffness	BCL11B	.08	3E-15
chr14	98642571	98642572	rs10484128	Hemostatic factors and hematological phenotypes	Intergenic	NR	6E-6
chr14	98670157	98670158	rs857228	Sexual dysfunction (SSRI/SNRI-related)	AL163760.3	2.56	3E-6
chr14	98840442	98840443	rs1459148	Response to antipsychotic therapy (extrapyramidal side effects)	Intergenic	NR	2E-6
chr14	99607479	99607480	rs2693676	Corneal curvature	BCL11B	.04	7E-6
chr14	100133941	100133942	rs2895811	Coronary heart disease	HHIPL1	1.07	1E-10
chr14	100625901	100625902	rs7157599	Sudden cardiac arrest	DEGS2	1.13	1E-7
chr14	100684191	100684192	rs2766692	Electroencephalographic traits in alcoholism	Intergenic	.11	2E-6
chr14	101032216	101032217	rs6575793	Menarche (age at onset)	BEGAIN	2.30	1E-8
chr14	101142889	101142890	rs730570	Type 2 diabetes	C14orf70	1.14	8E-6
chr14	101159415	101159416	rs7149242	Platelet counts	C14orf70,DLK1	2.14	3E-8
chr14	101251988	101251989	rs1884537	Optic disc size (disc)	MEG3	.13	2E-6
chr14	101306044	101306045	rs941576	Type 1 diabetes	DLK1, MEG3, RTL1, DIO3	1.11	1E-10
chr14	101727106	101727107	rs2400997	Prostate cancer (gene x gene interaction)	MIR656	1.25	3E-6
chr14	102360744	102360745	rs7142002	Autism	PPP2R5C	1.56	3E-6
chr14	102454932	102454933	rs4906172	Menopause (age at onset)	NR	.36	3E-6
chr14	103040086	103040087	rs11628318	Platelet counts	RCOR1	2.57	2E-10
chr14	103377320	103377321	rs10133111	Brain imaging in schizophrenia (interaction)	TRAF3	NR	5E-6
chr14	103484824	103484825	rs751837	Large B-cell lymphoma	CDC42BPB	3.51	3E-7
chr14	103563194	103563195	rs8017161	Primary biliary cirrhosis	TNFAIP2	1.22	3E-13
chr14	103566784	103566785	rs2297067	Platelet counts	C14orf73	3.54	2E-10
chr14	103572814	103572815	rs944002	Mean platelet volume	C14orf73	.01	5E-11
chr14	103572814	103572815	rs944002	Gamma gluatamyl transferase levels	C14orf73	.13	5E-13
chr14	103572814	103572815	rs944002	Liver enzyme levels (gamma-glutamyl transferase)	C14orf73	6.30	6E-29
chr14	104509075	104509076	rs11622475	Bipolar disorder	NR	NR	2E-6
chr14	104509075	104509076	rs11622475	Bipolar disorder	NR	1.13	8E-6
chr14	105391004	105391005	rs2841277	Rheumatoid arthritis	PLD4	1.15	2E-14
chr14	105729791	105729792	rs3000073	Mean platelet volume	BRF1	.01	3E-11
chr14	106232584	106232585	rs10136766	IgG levels	IGHG3, IGHG1, IGHG2	.23	8E-16
chr14	107176212	107176213	rs10129255	Kawasaki disease	IGHV	1.32	7E-6
chr15	25078786	25078787	rs3867498	Pulmonary function	SNRPN	NR	1E-6
chr15	25894657	25894658	rs6576443	Immune reponse to smallpox (secreted IFN-alpha)	ATP10A	NR	6E-9
chr15	25912338	25912339	rs17636733	Cardiac hypertrophy	UBE3A	NR	2E-7
chr15	26277544	26277545	rs4906844	Cortical thickness	LOC100128714	.07	1E-8
chr15	26288393	26288394	rs6576507	Insulin resistance/response	ATP10A	13.00	7E-6
chr15	26288393	26288394	rs6576507	Insulin resistance/response	ATP10A	14.00	4E-7
chr15	26424046	26424047	rs547843	Smoking behavior	LOC503519	.04	6E-7
chr15	26973085	26973086	rs8043440	Cognitive performance	GABRB3	NR	2E-6
chr15	27012140	27012141	rs3212335	Longevity	GABRB3	NR	1E-6
chr15	27507772	27507773	rs17137734	Corneal curvature	GABRG3	.09	9E-6
chr15	27997246	27997247	rs17565841	Parkinson's disease (age of onset)	OCA2	2.84	3E-6
chr15	28356858	28356859	rs1129038	Vitiligo	OCA2, HERC2	1.22	4E-8
chr15	28365617	28365618	rs12913832	Hair color	OCA2	.97	9E-88
chr15	28365617	28365618	rs12913832	Eye color	OCA2	8.43	3E-52
chr15	28365617	28365618	rs12913832	Eye color	OCA2	2.49	1E-300
chr15	28365617	28365618	rs12913832	Eye color traits	HERC2,OCA	NR	1E-300
chr15	28365617	28365618	rs12913832	Black vs. red hair color	HERC2	.44	1E-77
chr15	28365617	28365618	rs12913832	Black vs. blond hair color	HERC2	.44	4E-103
chr15	28513363	28513364	rs916977	Iris color	HERC2	NR	1E-43
chr15	28530181	28530182	rs1667394	Eye color	HERC2, OCA2	.35	2E-20
chr15	28530181	28530182	rs1667394	Blue vs. green eyes	OCA2	6.74	2E-53
chr15	28530181	28530182	rs1667394	Blue vs. brown eyes	OCA2	29.43	1E-241
chr15	28530181	28530182	rs1667394	Blond vs. brown hair color	OCA2	4.94	6E-35
chr15	29006092	29006093	rs8033165	Black vs. red hair color	Intergenic	.15	2E-12
chr15	29006092	29006093	rs8033165	Black vs. blond hair color	Intergenic	.12	5E-11
chr15	29239816	29239817	rs17680945	Temperament	APBA2	.92	2E-6
chr15	29731443	29731444	rs11856574	Life threatening arrhythmia	KIAA0574	2.02	5E-6
chr15	29888395	29888396	rs1471225	Inattentive symptoms	Intergenic	NR	8E-6
chr15	31334361	31334362	rs17815774	Response to antipsychotic treatment	TRPM1	9.00	3E-6
chr15	31463377	31463378	rs7169523	Myasthenia gravis	NR	1.40	2E-6
chr15	31829706	31829707	rs2125623	Mortality among heart failure patients	OTUD7A	1.23	1E-6
chr15	32994755	32994756	rs4779584	Colorectal cancer	SCG5, GREM1	1.18	2E-8
chr15	32994755	32994756	rs4779584	Colorectal cancer	Intergenic	1.23	5E-7
chr15	33050422	33050423	rs1258763	Orofacial clefts	NR	NR	2E-6
chr15	33050422	33050423	rs1258763	Orofacial clefts	FMN1, GREM1	1.52	1E-6
chr15	33905409	33905410	rs2229116	Carotid atherosclerosis in HIV infection	RYR3	NR	3E-8
chr15	35006072	35006073	rs634990	Refractive error	GJD2,ACTC1,GOLGA8B	.23	2E-14
chr15	35068308	35068309	rs543686	Prostate cancer (gene x gene interaction)	ACTC1	1.24	4E-6
chr15	36293604	36293605	rs4923705	Attention deficit hyperactivity disorder	ATPBD4	1.51	2E-6
chr15	36313964	36313965	rs10520045	Major depressive disorder	Intergenic	1.32	7E-6
chr15	36349845	36349846	rs1898036	Response to tocilizumab in rheumatoid arthritis	Intergenic	7.73	2E-7
chr15	37342601	37342602	rs8041675	Hyperactive-impulsive symptoms	MEIS2	NR	4E-6
chr15	37349801	37349802	rs1568679	Response to antipsychotic treatment	MEIS2	NR	1E-8
chr15	37449618	37449619	rs17439560	Response to amphetamines	Intergenic	NR	4E-6
chr15	38511982	38511983	rs16966460	Bipolar disorder	NR	1.26	4E-6
chr15	38822904	38822905	rs7403531	Type 2 diabetes	RASGRP1	1.10	4E-9
chr15	38838263	38838264	rs8035957	Type 1 diabetes	RASGRP1	1.14	4E-6
chr15	38907040	38907041	rs7171171	Type 1 diabetes autoantibodies	RASGRP1	NR	2E-7
chr15	38986367	38986368	rs12912251	Bipolar disorder	C15orf53	1.10	3E-6
chr15	38986367	38986368	rs12912251	Bipolar disorder and major depressive disorder (combined)	C15orf53	NR	1E-6
chr15	38995490	38995491	rs12899449	Bipolar disorder	C15orf53, RASGRP1	1.20	4E-7
chr15	39003762	39003763	rs2643217	Bipolar disorder and schizophrenia	NR	1.27	6E-6
chr15	39148648	39148649	rs2624265	Metabolic traits	Intergenic	.07	4E-7
chr15	39315357	39315358	rs12907914	Cardiac hypertrophy	C15orf54	NR	1E-6
chr15	40322551	40322552	rs2250402	Corneal curvature	EIF2AK4	.06	6E-6
chr15	40339493	40339494	rs4924410	Ewing sarcoma	EIF2AK4, SRP14, BMF	1.46	7E-9
chr15	40360740	40360741	rs7181230	Dehydroepiandrosterone sulphate levels	BMF	.05	5E-11
chr15	40595626	40595627	rs1869901	Schizophrenia	NR	1.07	3E-6
chr15	40700021	40700022	rs10518693	Metabolic traits	IVD	.09	1E-13
chr15	41196383	41196384	rs8036080	Visceral adipose tissue/subcutaneous adipose tissue ratio	CHAC1, RHOV, DLL4, SPINT1, VPS18	NR	3E-6
chr15	42683786	42683787	rs2412710	Triglycerides	CAPN3	7.00	2E-8
chr15	42984287	42984288	rs16957063	Protein quantitative trait loci	CDAN1	NR	5E-7
chr15	43559230	43559231	rs748404	Lung cancer	TGM5	1.15	1E-6
chr15	44219606	44219607	rs16948098	Serum albumin level	FRMD5, WDR76	.02	2E-8
chr15	44245930	44245931	rs2929282	Triglycerides	FRMD5	5.13	2E-11
chr15	45500046	45500047	rs765787	Uric acid levels	SLC28A2	20.90	3E-6
chr15	45641224	45641225	rs2453533	Chronic kidney disease	GATM, SPATA5L1	NR	5E-22
chr15	45698792	45698793	rs2467853	Renal function and chronic kidney disease	SPATA5L1, GATM	.01	6E-14
chr15	45801034	45801035	rs950027	Response to fenofibrate (adiponectin levels)	SLC30A4	.04	5E-6
chr15	45985070	45985071	rs12594515	Weight	SQRDL	1.71	5E-6
chr15	45985070	45985071	rs12594515	Waist circumference	SQRDL	1.73	7E-6
chr15	46639807	46639808	rs4775302	Prostate cancer	Intergenic	NR	4E-8
chr15	47892297	47892298	rs1898111	Eating disorders	SEMA6D	1.15	8E-6
chr15	48392164	48392165	rs1834640	Skin pigmentation	SLC24A5	12.50	1E-50
chr15	48633152	48633153	rs11637235	Protein quantitative trait loci	DUT	NR	3E-6
chr15	48900585	48900586	rs1876206	Breast cancer	FBN1	NR	6E-6
chr15	48914774	48914775	rs1036476	Thoracic aortic aneurysms and dissections	FBN1	1.90	6E-13
chr15	49039796	49039797	rs784411	Prostate cancer (gene x gene interaction)	CEP152	1.42	1E-7
chr15	49192790	49192791	rs8023445	Major depressive disorder	SHC4	NR	2E-6
chr15	49221590	49221591	rs10519201	Eating disorders	SHC4	1.16	6E-6
chr15	49735296	49735297	rs4338740	Thyroid volume	C15orf33, FGF7	.07	1E-12
chr15	49735296	49735297	rs4338740	Thyroid volume	C15orf33, FGF7	1.45	3E-13
chr15	49939845	49939846	rs8039808	Response to antidepressant treatment	DTWD1	NR	5E-7
chr15	50873343	50873344	rs2414059	QT interval	NR	1.24	2E-6
chr15	51352248	51352249	rs1124769	Cognitive performance	TNFAIP8L3	NR	9E-6
chr15	51516054	51516055	rs2899472	AB1-42	CYP19A1	NR	2E-9
chr15	51530494	51530495	rs16964211	Height	CYP19A1	.05	2E-9
chr15	51534546	51534547	rs727479	Estradiol levels	CYP19A1, MIR4713	.11	5E-7
chr15	51569409	51569410	rs2305707	Height	CYP19A1	.06	7E-7
chr15	51969667	51969668	rs17525472	Asthma	SCG3	NR	2E-6
chr15	53279377	53279378	rs719714	Cognitive function	WDR72	9.45	4E-8
chr15	53805824	53805825	rs7168365	Longevity	WDR72	NR	1E-6
chr15	53907947	53907948	rs17730281	Renal function-related traits (BUN)	WDR72	.01	3E-11
chr15	53942927	53942928	rs17730436	Renal function-related traits (sCR)	WDR72	.01	1E-13
chr15	53942927	53942928	rs17730436	Renal function-related traits (eGRFcrea)	WDR72	.01	6E-13
chr15	53946592	53946593	rs491567	Chronic kidney disease	WDR72	.01	3E-13
chr15	54341464	54341465	rs1897031	Cognitive performance	UNC13C	NR	1E-6
chr15	54680631	54680632	rs10518765	Select biomarker traits	Intergenic	NR	1E-6
chr15	54868667	54868668	rs2553218	Immune response to smallpox vaccine (IL-6)	UNC13C	NR	8E-7
chr15	55456509	55456510	rs16976033	Neutrophil count	RSL24D1	NR	7E-6
chr15	56194876	56194877	rs8032158	Keloid	NEDD4	1.51	6E-13
chr15	56340895	56340896	rs7169431	Chronic lymphocytic leukemia	NEDD4, RFX7	1.36	5E-7
chr15	57762792	57762793	rs2934442	Bipolar disorder (age of onset and psychomotor symptoms)	CGNL1	1.02	1E-6
chr15	57910163	57910164	rs937254	Coronary heart disease	GCOM1	.08	1E-6
chr15	58080616	58080617	rs1559777	Myopia (pathological)	Intergenic	NR	1E-6
chr15	58213413	58213414	rs1550576	Hypertension	ALDH1A2	1.92	3E-6
chr15	58471978	58471979	rs16939881	Metabolite levels	AQP9	NR	3E-27
chr15	58635582	58635583	rs4775031	Cognitive performance	LIPC	NR	2E-6
chr15	58674668	58674669	rs539901	Non-small cell lung cancer	LIPC	NR	8E-6
chr15	58674694	58674695	rs4775041	Metabolite levels	LIPC	NR	1E-7
chr15	58674694	58674695	rs4775041	Triglycerides	LIPC	3.62	2E-8
chr15	58674694	58674695	rs4775041	HDL cholesterol	LIPC	1.38	3E-20
chr15	58678511	58678512	rs10468017	Phospholipid levels (plasma)	LIPC	.00	7E-43
chr15	58678511	58678512	rs10468017	Cardiovascular disease risk factors	LIPC	.10	3E-12
chr15	58678511	58678512	rs10468017	Age-related macular degeneration	LIPC	1.19	3E-12
chr15	58678511	58678512	rs10468017	Metabolic syndrome (bivariate traits)	LIPC	.16	6E-8
chr15	58678511	58678512	rs10468017	Age-related macular degeneration	LIPC	1.22	1E-8
chr15	58678511	58678512	rs10468017	HDL cholesterol	LIPC	.10	8E-23
chr15	58680642	58680643	rs35853021	Lipid metabolism phenotypes	LIPC	.31	7E-76
chr15	58680953	58680954	rs2043085	Metabolic syndrome (bivariate traits)	LIPC	.17	1E-8
chr15	58683365	58683366	rs1532085	Metabolite levels	LIPC	NR	9E-104
chr15	58683365	58683366	rs1532085	Metabolic syndrome	LIPC	.13	5E-24
chr15	58683365	58683366	rs1532085	Triglycerides	LIPC	2.99	2E-13
chr15	58683365	58683366	rs1532085	HDL cholesterol	LIPC	1.45	3E-96
chr15	58683365	58683366	rs1532085	Cholesterol, total	LIPC	1.54	9E-20
chr15	58683365	58683366	rs1532085	HDL cholesterol	LIPC	.13	1E-35
chr15	58683365	58683366	rs1532085	Cholesterol, total	LIPC	.05	4E-7
chr15	58683365	58683366	rs1532085	HDL cholesterol	LIPC	.05	2E-10
chr15	58687879	58687880	rs493258	Age-related macular degeneration	Intergenic	1.16	2E-8
chr15	58687879	58687880	rs493258	Age-related macular degeneration	LIPC	1.14	1E-7
chr15	58694019	58694020	rs16940212	HDL cholesterol	Intergenic	.02	1E-24
chr15	58723674	58723675	rs1800588	HDL cholesterol	LIPC	.14	2E-32
chr15	58726743	58726744	rs261334	HDL cholesterol	LIPC	.03	5E-22
chr15	58746829	58746830	rs3825776	Amyotrophic lateral sclerosis	LIPC	1.34	9E-6
chr15	59174538	59174539	rs7179456	Asperger disorder	SLTM,RNF111	NR	7E-6
chr15	59487929	59487930	rs2306786	Metabolite levels	MYO1E, CCNB2, RNF111	NR	1E-10
chr15	59719168	59719169	rs28890483	Bipolar disorder and schizophrenia	NR	1.39	9E-6
chr15	59824986	59824987	rs17302400	Visceral adipose tissue adjusted for BMI	FAM81A	NR	7E-6
chr15	60781512	60781513	rs3743266	Menarche (age at onset)	RORA	2.00	8E-7
chr15	60878029	60878030	rs340005	Gamma gluatamyl transferase levels	RORA	.08	2E-8
chr15	60883280	60883281	rs339969	Liver enzyme levels (gamma-glutamyl transferase)	RORA	4.50	7E-20
chr15	60894964	60894965	rs340029	C-reactive protein	RORA	.03	4E-9
chr15	60910549	60910550	rs3784609	Total ventricular volume	RORA	.00	3E-6
chr15	61060706	61060707	rs12591650	Subcutaneous adipose tissue	RORA	NR	7E-7
chr15	61069987	61069988	rs11071559	Asthma	RORA	1.18	1E-7
chr15	61164198	61164199	rs1902618	Pulmonary function decline	RORA	.22	2E-6
chr15	61267095	61267096	rs12912233	Depression (quantitative trait)	RORA	.15	6E-7
chr15	61329787	61329788	rs809736	Response to citalopram treatment	RORA	1.52	8E-6
chr15	61702778	61702779	rs3884558	Response to amphetamines	Intergenic	NR	5E-6
chr15	61840102	61840103	rs4775413	Schizophrenia	NR	1.08	2E-6
chr15	61870942	61870943	rs12592967	Schizophrenia	Intergenic	1.10	3E-7
chr15	62001131	62001132	rs10519131	Parkinson's disease	Intergenic	1.22	1E-6
chr15	62312839	62312840	rs4143844	Bipolar disorder and schizophrenia	NR	1.43	4E-6
chr15	62332979	62332980	rs17271305	Two-hour glucose challenge	VPS13C	.06	1E-7
chr15	62380258	62380259	rs7178424	Height	C2CD4A	.02	6E-9
chr15	62383154	62383155	rs4502156	Proinsulin levels	VPS13C, C2CD4A, C2CD4B	NR	4E-20
chr15	62396388	62396389	rs7172432	Type 2 diabetes	C2CD4A,C2CD4B	1.11	9E-14
chr15	62396941	62396942	rs7173964	Fasting glucose-related traits (interaction with BMI)	VPS13C	NR	6E-12
chr15	62404381	62404382	rs1436955	Type 2 diabetes	C2CD4B	1.13	7E-7
chr15	62414013	62414014	rs1436953	Type 2 diabetes	C2CD4A, C2CD4B	1.14	8E-6
chr15	62433961	62433962	rs11071657	Fasting glucose-related traits	C2CD4B	NR	4E-8
chr15	63312631	63312632	rs1873147	Orofacial clefts	TPM1	1.43	8E-7
chr15	63333723	63333724	rs3809566	Platelet counts	TPM1	2.44	4E-10
chr15	63341995	63341996	rs11071720	Mean platelet volume	TPM1	.01	2E-8
chr15	63396866	63396867	rs2652834	HDL cholesterol	LACTB	.39	9E-9
chr15	63422771	63422772	rs2652822	Metabolic traits	LACTB	.09	7E-27
chr15	63737924	63737925	rs10519210	Heart failure	USP3	1.53	1E-8
chr15	63915785	63915786	rs11630290	Iris characteristics	HERC1	.09	1E-6
chr15	65153689	65153690	rs12595292	Coronary heart disease	PLEKHO2	.11	9E-6
chr15	65183800	65183801	rs1719271	Platelet counts	ANKDD1A	3.41	1E-11
chr15	67066562	67066563	rs11858577	Subcutaneous adipose tissue	SMAD6	NR	9E-6
chr15	67442595	67442596	rs17293632	Crohn's disease	SMAD3	1.12	3E-19
chr15	67446784	67446785	rs744910	Asthma	SMAD3	1.12	4E-9
chr15	67458638	67458639	rs17228212	Coronary heart disease	SMAD3	1.21	2E-7
chr15	67702906	67702907	rs7359257	Menarche (age at onset)	IQCH	1.70	2E-6
chr15	68036851	68036852	rs12593813	Restless legs syndrome	MAP2K5, SKOR1	1.41	1E-22
chr15	68036851	68036852	rs12593813	Restless legs syndrome	MAP2K5, LBXCOR1	1.50	1E-15
chr15	68080885	68080886	rs4776970	Body mass index	MAP2K5	2.55	2E-9
chr15	68086837	68086838	rs2241423	Body mass index	MAP2K5, LBXCOR1	.13	1E-18
chr15	68198910	68198911	rs448720	Cognitive performance	RNU6-2,RNU6-1	NR	5E-6
chr15	68715031	68715032	rs7164335	Attention deficit hyperactivity disorder	ITGA11	NR	1E-7
chr15	68735585	68735586	rs1445021	Coronary heart disease	Intergenic	.14	9E-6
chr15	68892988	68892989	rs11856323	Cognitive performance	CORO2B	NR	1E-7
chr15	69059083	69059084	rs8030672	Esophageal cancer	ANP32A	1.56	1E-11
chr15	69398025	69398026	rs1392635	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	NOX5	1.70	2E-6
chr15	69650052	69650053	rs11072089	Bipolar disorder and schizophrenia	NR	1.89	3E-6
chr15	69995343	69995344	rs17374222	Rheumatoid arthritis	KIF3	1.13	2E-6
chr15	70006872	70006873	rs4776472	Atrial fibrillation	Intergenic	NR	8E-6
chr15	70018989	70018990	rs7176508	Chronic lymphocytic leukemia	NR	1.42	3E-11
chr15	70018989	70018990	rs7176508	Chronic lymphocytic leukemia	Intergenic	1.37	5E-12
chr15	70048156	70048157	rs10152591	Height	TLE3	.04	3E-10
chr15	70480613	70480614	rs6494849	Bipolar disorder	NR	1.23	7E-6
chr15	70576137	70576138	rs1971791	Amyotrophic lateral sclerosis	Intergenic	1.26	1E-6
chr15	71109146	71109147	rs1549318	Proinsulin levels	LARP6	NR	2E-10
chr15	71645119	71645120	rs12899618	Pulmonary function	THSD4	.09	7E-15
chr15	71679958	71679959	rs2044029	Airflow obstruction	THSD4	1.17	1E-7
chr15	72161402	72161403	rs12902421	Height	MYO9A	.06	3E-8
chr15	73652173	73652174	rs7164883	Atrial fibrillation	HCN4	1.19	3E-17
chr15	73978336	73978337	rs8038465	Liver enzyme levels (gamma-glutamyl transferase)	CD276	2.40	1E-9
chr15	74012436	74012437	rs1038094	Bipolar disorder	CD276	1.27	9E-6
chr15	74219581	74219582	rs3825942	Glaucoma (exfoliation)	LOXL1	20.10	3E-21
chr15	74229064	74229065	rs893817	Aortic root size	LOXL1	.02	3E-6
chr15	74241505	74241506	rs750460	Height	PML	NR	4E-12
chr15	74305965	74305966	rs8039584	Myopia (pathological)	PML	NR	5E-8
chr15	74336632	74336633	rs5742915	Paget's disease	PML	1.34	2E-14
chr15	74336632	74336633	rs5742915	Height	PML	.03	1E-15
chr15	74716608	74716609	rs8036030	Airflow obstruction	SEMA7A	1.18	8E-6
chr15	75019448	75019449	rs2470893	Coffee consumption	CYP1A1, CYP1A2	.07	2E-11
chr15	75019448	75019449	rs2470893	Caffeine consumption	LMAN1L, EDC3, CYP1A2, CYP1A1, CSK	.12	5E-14
chr15	75027879	75027880	rs2472297	Coffee consumption	CYP1A1, CYP1A2	.31	5E-14
chr15	75033399	75033400	rs2472299	Coronary heart disease	Intergenic	NR	3E-6
chr15	75044237	75044238	rs2472304	Caffeine consumption	CYP1A2	.08	3E-7
chr15	75077366	75077367	rs1378942	Systolic blood pressure	CYP1A1, ULK3	.61	6E-23
chr15	75077366	75077367	rs1378942	Diastolic blood pressure	CYP1A1, ULK3	.42	3E-26
chr15	75077366	75077367	rs1378942	Blood pressure	CSK	.39	2E-15
chr15	75077366	75077367	rs1378942	Diastolic blood pressure	CYP1A1, CYP1A2, CSK, LMAN1L, CPLX3, ARID3B	.43	1E-23
chr15	75125644	75125645	rs6495122	Coffee consumption	CPLX3, ULK3	.05	7E-9
chr15	75125644	75125645	rs6495122	Caffeine consumption	ULK3, SCAMP2, MP1, LMAN1L, CYP1A2, CSK, COX5A, CPLX3, C14orf17	.07	6E-7
chr15	75125644	75125645	rs6495122	Diastolic blood pressure	CSK, ULK3	.40	2E-10
chr15	75382541	75382542	rs12148488	Caffeine consumption	SCAMP5, PPCDC	.07	6E-7
chr15	75718668	75718669	rs8028182	Sudden cardiac arrest	SIN3A	1.36	3E-6
chr15	75755466	75755467	rs4886707	Height	SIN3A, PTPN9	.06	8E-8
chr15	76158982	76158983	rs1394125	Chronic kidney disease	UBE2Q2,FBX022	.01	3E-17
chr15	76546932	76546933	rs1914816	Response to tocilizumab in rheumatoid arthritis	ETFA	.87	7E-7
chr15	77747189	77747190	rs7178572	Type 2 diabetes	HMG20A	1.11	1E-8
chr15	77747189	77747190	rs7178572	Type 2 diabetes	HMG20A	1.09	7E-11
chr15	77777631	77777632	rs7119	Type 2 diabetes	HMG20A	1.24	5E-7
chr15	77851534	77851535	rs2137111	Anticoagulant levels	LRRN6A	NR	7E-6
chr15	77963886	77963887	rs9652490	Essential tremor	LINGO1	1.55	1E-9
chr15	78530939	78530940	rs1533665	Personality dimensions	ACSBG1	.10	7E-6
chr15	78783276	78783277	rs11858836	Chronic obstructive pulmonary disease	CHRNA3, CHRNA5, IREB2	1.29	1E-6
chr15	78789487	78789488	rs13180	Chronic obstructive pulmonary disease	CHRNA3, CHRNA5, IREB2	1.30	2E-8
chr15	78806022	78806023	rs8034191	Lung cancer	CHRNA3	1.29	3E-26
chr15	78806022	78806023	rs8034191	Chronic obstructive pulmonary disease	CHRNA3,CHRNA4,CHRNA5, LOC123688	1.40	1E-10
chr15	78806022	78806023	rs8034191	Lung cancer	LOC123688, PSMA4, CHRNA3, CHRNA5, CHRNB4	1.38	1E-8
chr15	78806022	78806023	rs8034191	Lung cancer	CHRNA3,CHRNA5, CHRNB4, PSMA4, LOC123688	1.30	5E-20
chr15	78806022	78806023	rs8034191	Lung cancer	CHRNA3, CHRNA5, PSMA4, LOC123688	1.30	3E-18
chr15	78816056	78816057	rs8031948	Airflow obstruction	AGPHD1	1.22	3E-9
chr15	78827630	78827631	rs28675338	Chronic obstructive pulmonary disease	AGPHD1	5.21	1E-7
chr15	78833222	78833223	rs12901682	Response to tocilizumab in rheumatoid arthritis	PSMA4	135.02	4E-8
chr15	78851614	78851615	rs2036527	Smoking behavior	CHRNA5	.04	2E-8
chr15	78851614	78851615	rs2036527	Pulmonary function	CHRNA5	.03	7E-7
chr15	78863471	78863472	rs667282	Smoking behavior	CHRNA5	.03	2E-7
chr15	78867481	78867482	rs17486278	Airflow obstruction	CHRNA5	1.18	2E-7
chr15	78894338	78894339	rs1051730	Smoking behavior	CHRNA3	1.02	3E-73
chr15	78894338	78894339	rs1051730	Smoking behavior	CHRNA5,CHRNA3	.08	2E-66
chr15	78894338	78894339	rs1051730	Smoking behavior	NR	.80	2E-69
chr15	78894338	78894339	rs1051730	Lung adenocarcinoma	CHRNA3, CHRNA5	1.31	2E-51
chr15	78894338	78894339	rs1051730	Lung cancer	Intergenic	1.35	1E-15
chr15	78894338	78894339	rs1051730	Nicotine dependence	CHRNA3,CHRNA5,CHRNB4	.10	6E-20
chr15	78898722	78898723	rs12914385	Serum albumin level	CHRNA3, CHRNA5	.01	6E-7
chr15	78898722	78898723	rs12914385	Pulmonary function	CHRNA3	.03	5E-7
chr15	78908031	78908032	rs8042374	Lung cancer	NR	NR	8E-12
chr15	78926017	78926018	rs950776	Sudden cardiac arrest	CHRNB4	1.09	4E-7
chr15	79080233	79080234	rs1994016	Coronary heart disease	ADAMTS7	1.19	5E-13
chr15	79089110	79089111	rs3825807	Coronary heart disease	ADAMTS7	1.08	1E-12
chr15	79111092	79111093	rs4380028	Coronary heart disease	ADAMTS7, MORF4L1	1.07	4E-9
chr15	79224682	79224683	rs2289700	Bipolar disorder	CTSH	2.13	9E-6
chr15	79235445	79235446	rs3825932	Type 1 diabetes	CTSH	NR	8E-8
chr15	79235445	79235446	rs3825932	Type 1 diabetes	CTSH	1.16	3E-15
chr15	79274045	79274046	rs3743200	RR interval (heart rate)	RASGRF1	.16	2E-6
chr15	79451868	79451869	rs939658	Refractive error	RASGRF1	.15	2E-9
chr15	80432221	80432222	rs11634397	Type 2 diabetes	ZFAND6	1.06	2E-9
chr15	80694921	80694922	rs2278702	Bipolar disorder	NR	1.21	6E-6
chr15	81001277	81001278	rs12148329	Immune response to smallpox vaccine (IL-6)	FAM108C1	NR	9E-7
chr15	81533694	81533695	rs7172689	Inattentive symptoms	IL16	NR	4E-6
chr15	82352199	82352200	rs12324805	Body mass index	RKHD3	NR	7E-6
chr15	83254707	83254708	rs783540	Chronic lymphocytic leukemia	CPEB1	1.18	4E-6
chr15	83352281	83352282	rs11638815	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	AP3B2	4.10	1E-6
chr15	83726178	83726179	rs1568657	Kawasaki disease	BTBD1	1.41	7E-6
chr15	84286491	84286492	rs2562784	Height	SH3GL3,ADAMTSL3	.34	6E-8
chr15	84315883	84315884	rs2554380	Height	ADAMTSL3, SH3GL3	4.50	9E-7
chr15	84522754	84522755	rs1383484	Height	ADAMTSL3	.04	9E-7
chr15	84568157	84568158	rs10906982	Height	SH3GL3,ADAMTSL3	.07	5E-7
chr15	84568157	84568158	rs10906982	Height	ADAMTSL3	.05	2E-8
chr15	84573040	84573041	rs7183263	Height	ADAMTSL3	.07	4E-7
chr15	84580581	84580582	rs11259936	Height	ADAMTSL3	.04	2E-35
chr15	84582123	84582124	rs4842838	Height	ADAMTSL3	.06	1E-7
chr15	84582123	84582124	rs4842838	Height	ADAMTSL3	.06	3E-8
chr15	85430968	85430969	rs3743162	Alzheimer's disease (age of onset)	SLC28A1, ZNF592, ALPK3	NR	9E-6
chr15	85825566	85825567	rs6496932	Central corneal thickness	PDE8A,AKAP13	.13	1E-8
chr15	86369429	86369430	rs7176093	Aging traits	KLHL25	NR	7E-6
chr15	86859475	86859476	rs12901001	Barrett's esophagus	NR	.15	6E-6
chr15	86984239	86984240	rs16977195	Schizophrenia	AGBL1	6.01	2E-6
chr15	87053845	87053846	rs2011905	Cytomegalovirus antibody response	AGBL1	.22	2E-6
chr15	87191976	87191977	rs2469184	Activated partial thromboplastin time	AGBL1	.16	4E-8
chr15	87436744	87436745	rs17647114	Response to antidepressant treatment	AGBL1	NR	4E-7
chr15	87695510	87695511	rs11636768	Migraine	AGBL1	1.25	5E-7
chr15	88661738	88661739	rs9806762	Gaucher disease severity	NTRK3	NR	7E-6
chr15	89245238	89245239	rs4932194	Dupuytren's disease	ISG20	1.22	8E-7
chr15	89359688	89359689	rs8041863	Height	ACAN	.04	8E-8
chr15	89388904	89388905	rs16942341	Height	ACAN	.13	4E-27
chr15	89395625	89395626	rs2280470	Height	ACAN	NR	1E-14
chr15	89398104	89398105	rs2351491	Height	ACAN	.06	2E-9
chr15	89617080	89617081	rs420017	Height	Intergenic	.04	7E-6
chr15	89863927	89863928	rs2307449	Menopause (age at onset)	POLG	.18	4E-13
chr15	89902031	89902032	rs4932217	Height	POLG	.66	8E-7
chr15	90374256	90374257	rs2028299	Type 2 diabetes	AP3S2	1.10	2E-11
chr15	90447945	90447946	rs7178909	Common traits (Other)	NR	NR	5E-7
chr15	90893667	90893668	rs6496667	Rheumatoid arthritis	ZNF774	1.09	1E-6
chr15	91114375	91114376	rs12915189	Information processing speed	CRTC3	.14	3E-6
chr15	91437387	91437388	rs2521501	Systolic blood pressure	FURIN, FES	.65	5E-19
chr15	91437387	91437388	rs2521501	Hypertension	FURIN, FES	.06	7E-7
chr15	91437387	91437388	rs2521501	Diastolic blood pressure	FURIN, FES	.36	2E-15
chr15	91437387	91437388	rs2521501	Blood pressure	FES	.34	3E-8
chr15	91450440	91450441	rs2677744	Attention deficit hyperactivity disorder	MAN2A2	NR	1E-6
chr15	91521336	91521337	rs8042680	Type 2 diabetes	PRC1	1.07	2E-10
chr15	91717351	91717352	rs886144	Metabolite levels	SV2B	NR	2E-7
chr15	92211773	92211774	rs7164176	Response to tocilizumab in rheumatoid arthritis	Intergenic	.28	5E-7
chr15	92445872	92445873	rs3924426	Response to iloperidone treatment (QT prolongation)	SLCO3A1	NR	2E-6
chr15	92552028	92552029	rs7495052	Inattentive symptoms	SLCO3A1	NR	3E-6
chr15	92657372	92657373	rs207954	Acute lymphoblastic leukemia (childhood)	SLCO3A1	NR	1E-6
chr15	92883839	92883840	rs12905014	Airflow obstruction	ST8SIA2	1.75	4E-7
chr15	93044338	93044339	rs8040009	Alcoholism (heaviness of drinking)	C15orf32	.12	3E-7
chr15	93044338	93044339	rs8040009	Bipolar disorder	ST8SIA2,C15orf32	1.40	6E-6
chr15	93050965	93050966	rs1455782	Pulmonary function	FLJ32831	NR	4E-6
chr15	93131631	93131632	rs2173063	Subcutaneous adipose tissue	LOC400451	NR	3E-6
chr15	93179174	93179175	rs285757	HIV-1 susceptibility	FAM174B	NR	7E-6
chr15	93638400	93638401	rs7168353	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)	RGMA	NR	1E-6
chr15	93877424	93877425	rs4777845	Adiponectin levels	NR	.06	9E-6
chr15	94036687	94036688	rs7175404	Attention deficit hyperactivity disorder	AK094352	NR	6E-7
chr15	94141832	94141833	rs12437854	Type 1 diabetes nephropathy	RGMA, MCTP2	1.80	2E-9
chr15	94689652	94689653	rs2388436	Hoarding	Intergenic	.51	6E-6
chr15	94939507	94939508	rs4984390	Drug-induced liver injury (flucloxacillin)	MCTP2	3.27	4E-6
chr15	95165579	95165580	rs1014922	Sudden cardiac arrest	MCTP2	1.36	3E-6
chr15	95511836	95511837	rs6496074	Cognitive performance	MCTP2	NR	3E-6
chr15	96052741	96052742	rs933769	Alcoholism (alcohol dependence factor score)	Intergenic	.10	7E-6
chr15	96141866	96141867	rs10520789	Response to TNF-alpha inhibitors in rheumatoid arthritis	NR2F2	NR	6E-7
chr15	96156367	96156368	rs4321143	Conduct disorder (interaction)	Intergenic	1.13	7E-6
chr15	96332860	96332861	rs2567426	Information processing speed	AC015574.1	.13	3E-6
chr15	96708290	96708291	rs8023580	Sex hormone-binding globulin levels	NR2F2	.04	8E-8
chr15	96708290	96708291	rs8023580	Sex hormone-binding globulin levels	NR2F2	.03	8E-12
chr15	96708290	96708291	rs8023580	Sex hormone-binding globulin levels	NR2F2	.03	0E0
chr15	96830549	96830550	rs2398162	Hypertension	Intergenic	1.31	6E-6
chr15	96844726	96844727	rs7181753	Electroencephalographic traits in alcoholism	Intergenic	.13	3E-6
chr15	97002652	97002653	rs11637980	Prostate cancer (gene x gene interaction)	NR2F2	1.47	2E-6
chr15	97018732	97018733	rs113154706	Response to amphetamines	Intergenic	NR	7E-6
chr15	97262426	97262427	rs4533251	Attention deficit hyperactivity disorder and conduct disorder	SPATA8	NR	4E-6
chr15	98518791	98518792	rs4965121	Neuroticism	ARRDC4	.84	1E-6
chr15	98876028	98876029	rs970843	Obesity (extreme)	FLJ39743	NR	5E-6
chr15	99072904	99072905	rs12719740	Arthritis (juvenile idiopathic)	IGF1R, FAM169B	1.15	7E-7
chr15	99194895	99194896	rs2871865	Height	IGF1R	.06	3E-21
chr15	100759613	100759614	rs4965598	Height	ADAMTS17	.03	4E-13
chr15	100786270	100786271	rs4533267	Height	ADAMTS17	5.60	3E-8
chr15	101251718	101251719	rs184234	Response to taxane treatment (placlitaxel)	ASB7	NR	1E-6
chr15	101875122	101875123	rs11855415	Handedness in dyslexia	PCSK6	.35	2E-8
chr16	304802	304803	rs7189020	Mean corpuscular volume	ITFG3	.00	2E-12
chr16	309154	309155	rs1122794	Mean corpuscular hemoglobin	ITFG3	.00	3E-10
chr16	630664	630665	rs1981483	Disc degeneration (lumbar)	PIGQ	.11	4E-6
chr16	637211	637212	rs2017567	Disc degeneration (lumbar)	Intergenic	.10	9E-6
chr16	661334	661335	rs7204439	Disc degeneration (lumbar)	RAB40C	.11	4E-6
chr16	675679	675680	rs763014	Height	RAB40C	.24	5E-6
chr16	792189	792190	rs11648796	Height	NARFL	.03	1E-13
chr16	1073551	1073552	rs2744148	Multiple sclerosis	SOX8	1.12	8E-8
chr16	1838835	1838836	rs1065656	Insulin-like growth factors	NUBP2, IGFALS	NR	1E-11
chr16	2097157	2097158	rs2516739	Longevity	NTHL1	NR	1E-6
chr16	2249375	2249376	rs26868	Height	CASKIN1	.03	9E-17
chr16	3023604	3023605	rs886427	Metabolic syndrome	PKMYT1	NR	6E-6
chr16	3124919	3124920	rs4349147	HIV-1 susceptibility	IL32	.00	8E-6
chr16	4038386	4038387	rs2444217	Body mass index	ADCY9	NR	9E-8
chr16	4103870	4103871	rs2601828	Partial epilepsies	ADCY9	1.12	1E-6
chr16	5001379	5001380	rs9635542	Lung cancer-asbestos exposure interaction	PPL	NR	4E-6
chr16	5585851	5585852	rs870288	Subcutaneous adipose tissue	FAM86A	NR	9E-6
chr16	5585851	5585852	rs870288	Phospholipid levels (plasma)	ALG1	.80	1E-8
chr16	6113660	6113661	rs6500744	Conduct disorder (interaction)	A2BP1	.91	3E-6
chr16	6699260	6699261	rs11643447	Visceral adipose tissue adjusted for BMI	A2BP1	NR	2E-7
chr16	6817374	6817375	rs6500818	Dengue shock syndrome	NR	1.31	2E-7
chr16	6910384	6910385	rs12921846	Attention deficit hyperactivity disorder and conduct disorder	A2BP1	NR	9E-6
chr16	7227121	7227122	rs9302841	Response to antipsychotic therapy (extrapyramidal side effects)	A2BP1	NR	2E-6
chr16	7415551	7415552	rs4787008	Diabetic retinopathy	A2BP1, LOC100131413, LOC100131080	1.47	6E-7
chr16	7504853	7504854	rs9924951	Metabolite levels	A2BP1	NR	5E-7
chr16	7753703	7753704	rs12444931	Bipolar disorder and schizophrenia	NR	1.22	5E-6
chr16	7836296	7836297	rs3112740	Smoking behavior	Intergenic	2.16	6E-6
chr16	8329326	8329327	rs2034588	Response to antidepressant treatment	Intergenic	NR	2E-6
chr16	9382328	9382329	rs8061903	HIV-1 viral setpoint	AC087190.5-2	NR	5E-6
chr16	9399723	9399724	rs631208	IgE grass sensitization	Intergenic	1.18	2E-6
chr16	9744094	9744095	rs17550532	Sudden cardiac arrest	Intergenic	1.33	2E-6
chr16	9862555	9862556	rs11866328	Hepatitis B	GRIN2A	1.68	2E-8
chr16	10183086	10183087	rs1463132	HIV-1 control	NR	NR	8E-6
chr16	10559262	10559263	rs13335336	Response to antipsychotic treatment	ATF7IP2	NR	7E-7
chr16	10633164	10633165	rs11074889	Attention deficit hyperactivity disorder	EMP2	1.68	7E-7
chr16	10975310	10975311	rs4781011	Ulcerative colitis	CIITA	1.12	3E-6
chr16	11081248	11081249	rs6498142	Immunoglobulin A	CLEC16A	1.56	2E-7
chr16	11158884	11158885	rs887864	Allergic rhinitis	CLEC16A	1.16	1E-6
chr16	11166687	11166688	rs11865121	Multiple sclerosis	CLEC16A	1.15	2E-7
chr16	11177800	11177801	rs7200786	Multiple sclerosis	CLEC16A	1.15	9E-17
chr16	11179872	11179873	rs12708716	Type 1 diabetes autoantibodies	CLEC16A	1.20	5E-14
chr16	11179872	11179873	rs12708716	Type 1 diabetes	CLEC16A	NR	2E-16
chr16	11179872	11179873	rs12708716	Type 1 diabetes	CLEC16A	NR	7E-13
chr16	11179872	11179873	rs12708716	Type 1 diabetes	KIAA0350	1.19	5E-7
chr16	11179872	11179873	rs12708716	Type 1 diabetes	KIAA0350	1.23	3E-18
chr16	11187782	11187783	rs12924729	Primary biliary cirrhosis	CLEC16A	1.29	3E-12
chr16	11210414	11210415	rs9923856	Atopic dermatitis	CLEC16A	1.17	6E-6
chr16	11238782	11238783	rs2903692	Type 1 diabetes	KIAA0350	1.54	7E-11
chr16	11249328	11249329	rs6498169	Multiple sclerosis	KIAA0350	1.14	4E-6
chr16	11347857	11347858	rs4780355	Crohn's disease and psoriasis	SOCS1	1.16	1E-13
chr16	11364078	11364079	rs416603	Type 1 diabetes	C16orf75, PRM3, TNP2	1.06	3E-6
chr16	11403892	11403893	rs12928822	Celiac disease	CIITA, SOCS1, CLEC16A	1.16	3E-8
chr16	11406802	11406803	rs7191700	Multiple sclerosis	TNP2, PRM3, PRM2, PRM1, C16orf75	1.15	6E-7
chr16	11641179	11641180	rs7203193	Coronary heart disease	Intergenic	.08	3E-6
chr16	11691752	11691753	rs8049607	QT interval	LITAF	1.63	7E-7
chr16	11691752	11691753	rs8049607	QT interval	LITAF	1.25	6E-15
chr16	11691752	11691753	rs8049607	QT interval	LITAF,CLEC16A, SNN, ZC3H7A, TNFRSF17	1.23	5E-15
chr16	12016918	12016919	rs10852344	Menopause (age at onset)	Intergenic	.17	1E-11
chr16	12641114	12641115	rs1641895	Visceral adipose tissue adjusted for BMI	LOC92017	NR	5E-7
chr16	13061610	13061611	rs7192086	Schizophrenia	Intergenic	1.12	6E-6
chr16	13253955	13253956	rs153091	Response to antipsychotic treatment	LOC729993	NR	2E-6
chr16	13656884	13656885	rs2903308	Response to citalopram treatment	Intergenic	NR	2E-6
chr16	13976355	13976356	rs2113334	Metabolic syndrome	ERCC4	NR	3E-6
chr16	14038173	14038174	rs3136202	Conduct disorder (symptom count)	ERCC4	.07	6E-6
chr16	14045398	14045399	rs4781563	Bilirubin levels	ERCC4	.16	2E-6
chr16	14388304	14388305	rs1659127	Menarche (age at onset)	MKL2	2.40	4E-9
chr16	14388304	14388305	rs1659127	Height	MKL2	.03	1E-11
chr16	15082864	15082865	rs4985167	Phospholipid levels (plasma)	PDXDC1	.01	3E-7
chr16	15129969	15129970	rs7200543	Metabolic traits	PDXDC1	.07	5E-16
chr16	15131973	15131974	rs1136001	Height	PDXDC1, NTAN1	.05	7E-6
chr16	15140210	15140211	rs4500751	Phospholipid levels (plasma)	PDXDC1	.00	6E-23
chr16	15148645	15148646	rs11075253	Lipid metabolism phenotypes	PDXC1, C20:2, C20:3	.14	5E-15
chr16	19028548	19028549	rs4265793	Response to angiotensin II receptor blocker therapy	TMC7	1.22	6E-6
chr16	19156015	19156016	rs8062326	Alcohol dependence	SYT17	NR	4E-6
chr16	19933599	19933600	rs12444979	Body mass index	GPRC5B, IQCK	.17	3E-21
chr16	20257866	20257867	rs12597579	Body mass index	GP2	4.09	1E-8
chr16	20342571	20342572	rs12444268	Type 1 diabetes	Intergenic	1.10	2E-7
chr16	20351230	20351231	rs11859916	Femoral neck bone geometry	UMOD	NR	2E-6
chr16	20364587	20364588	rs4293393	Chronic kidney disease and serum creatinine levels	UMOD	1.25	4E-10
chr16	20365653	20365654	rs13333226	Hypertension	UMOD	1.15	4E-11
chr16	20367689	20367690	rs12917707	Chronic kidney disease	UMOD,ACSM5,GP2,PDILT	NR	1E-20
chr16	20367689	20367690	rs12917707	Renal function and chronic kidney disease	UMOD	.02	5E-16
chr16	20367689	20367690	rs12917707	Renal function and chronic kidney disease	UMOD	1.25	2E-12
chr16	20400838	20400839	rs11864909	Renal function-related traits (sCR)	UMOD	.01	1E-10
chr16	20400838	20400839	rs11864909	Renal function-related traits (eGRFcrea)	UMOD	.01	4E-10
chr16	20674491	20674492	rs151222	Schizophrenia	ACSM1, BUCS1	2.10	6E-6
chr16	20680205	20680206	rs433598	Schizophrenia	ACSM1	1.13	3E-6
chr16	21113271	21113272	rs16970881	Immune reponse to smallpox (secreted IL-10)	DNAH3	NR	1E-7
chr16	23067259	23067260	rs8049603	Multiple sclerosis	NR	1.19	1E-6
chr16	23634025	23634026	rs420259	Bipolar disorder	NR	NR	9E-9
chr16	23634025	23634026	rs420259	Bipolar disorder	PALB2,NDUFAB1,DCTN5	2.08	6E-8
chr16	23765773	23765774	rs4968031	Platelet counts	AC130454.2, AC130454.1	NR	1E-6
chr16	23888839	23888840	rs7404928	Rheumatoid arthritis	PRKCB1	1.08	4E-6
chr16	24531717	24531718	rs11643520	Brain structure	RBBP6	NR	6E-7
chr16	27056454	27056455	rs2203512	Cognitive performance	AC092725.3	NR	3E-7
chr16	27374399	27374400	rs1801275	IgE levels	IL4R	.05	1E-7
chr16	27434926	27434927	rs8057551	Bone mineral density	IL21R	.11	2E-6
chr16	28490516	28490517	rs151181	Crohn's disease	IL27,SH2B1,EIF3C,LAT,CD19	1.07	2E-11
chr16	28539847	28539848	rs4788084	Type 1 diabetes autoantibodies	IL27	1.15	1E-8
chr16	28539847	28539848	rs4788084	Type 1 diabetes	IL27	1.09	3E-13
chr16	28837514	28837515	rs8049439	Inflammatory bowel disease (early onset)	IL27, CCDC101, CLN3, EIF3C, NUPR1, SULT1A1, SULT1A2	1.14	2E-9
chr16	28883240	28883241	rs7498665	Body mass index	SH2B1	.15	5E-11
chr16	28883240	28883241	rs7498665	Weight	SH2B1, ATP2A1	3.69	1E-9
chr16	28883240	28883241	rs7498665	Body mass index	SH2B1, ATP2A1	3.63	3E-10
chr16	28885658	28885659	rs7359397	Body mass index	SH2B1, APOB48R, SULT1A2, AC138894.2, ATXN2L, TUFM	.15	2E-20
chr16	29885446	29885447	rs4787483	Anthropometric traits	SEZ6L2	.16	2E-6
chr16	29906545	29906546	rs4787484	Response to taxane treatment (placlitaxel)	SEZ6L2	NR	1E-6
chr16	30635658	30635659	rs7186852	Systemic lupus erythematosus	NR	1.29	3E-7
chr16	30642866	30642867	rs7197475	Systemic lupus erythematosus	NR	1.31	3E-8
chr16	30918486	30918487	rs11649653	Triglycerides	CTF1	2.13	3E-8
chr16	30942624	30942625	rs10782001	Psoriasis	FBXL19,POL3S	1.16	9E-10
chr16	31048078	31048079	rs10871454	Warfarin maintenance dose	VKORC1	NR	5E-34
chr16	31095170	31095171	rs11865038	Parkinson's disease	POL3S	1.14	4E-7
chr16	31107688	31107689	rs9923231	Warfarin maintenance dose	VKORC1	NR	9E-31
chr16	31107688	31107689	rs9923231	Warfarin maintenance dose	VKORC1	.97	3E-181
chr16	31313252	31313253	rs9888739	Systemic lupus erythematosus	ITGAM	1.80	1E-15
chr16	31313252	31313253	rs9888739	Systemic lupus erythematosus	ITGAM	1.62	2E-23
chr16	31334235	31334236	rs11150610	Systemic lupus erythematosus	ITGAM	NR	2E-6
chr16	31347747	31347748	rs3925075	IgA nephropathy	Intergenic	1.15	5E-6
chr16	31368873	31368874	rs11574637	Systemic lupus erythematosus	ITGAM, ITGAX	1.33	3E-11
chr16	32480923	32480924	rs13380637	Response to amphetamines	Intergenic	NR	5E-6
chr16	48621401	48621402	rs6500395	Response to tocilizumab in rheumatoid arthritis	ENSG00000102921	2.20	6E-7
chr16	49394275	49394276	rs8057939	Prostate cancer (gene x gene interaction)	C16orf78	1.37	5E-6
chr16	49750789	49750790	rs17281813	Inattentive symptoms	ZNF423	NR	3E-6
chr16	50103733	50103734	rs4785204	Esophageal cancer (squamous cell)	HEATR3	1.24	2E-20
chr16	50719102	50719103	rs9302752	Leprosy	NOD2	1.59	4E-40
chr16	50739581	50739582	rs17221417	Crohn's disease	NOD2	1.29	4E-11
chr16	50756773	50756774	rs5743289	Inflammatory bowel disease	NOD2	1.46	4E-10
chr16	50756773	50756774	rs5743289	Crohn's disease	NOD2	NR	6E-17
chr16	50756773	50756774	rs5743289	Crohn's disease	CARD15	NR	1E-6
chr16	50756880	50756881	rs2076756	Crohn's disease	NOD2	1.46	3E-10
chr16	50756880	50756881	rs2076756	Crohn's disease	NOD2, CYLD, SNX20, NKD1	1.66	1E-37
chr16	50756880	50756881	rs2076756	Crohn's disease	NOD2	1.53	4E-69
chr16	50756880	50756881	rs2076756	Crohn's disease	CARD15	1.71	1E-21
chr16	50756880	50756881	rs2076756	Crohn's disease	CARD15	NR	7E-14
chr16	50756880	50756881	rs2076756	Inflammatory bowel disease	CARD15	NR	5E-10
chr16	50763778	50763778	rs2066847	Crohn's disease	NOD2	1.62	2E-15
chr16	50763778	50763778	rs2066847	Crohn's disease	NOD2	3.99	3E-24
chr16	50854417	50854418	rs16948876	Leprosy	CYLD	1.56	2E-10
chr16	51158709	51158710	rs10521222	C-reactive protein	SALL1	.10	9E-13
chr16	51330530	51330531	rs4131099	Personality dimensions	Intergenic	.11	4E-6
chr16	51458289	51458290	rs1362756	Optic disc parameters	SALL1	.03	5E-9
chr16	52347818	52347819	rs4784165	Polycystic ovary syndrome	TOX3	1.15	4E-11
chr16	52586340	52586341	rs3803662	Breast cancer (male)	TOX3, LOC643174	1.50	4E-15
chr16	52586340	52586341	rs3803662	Breast cancer	TOX3	1.22	4E-7
chr16	52586340	52586341	rs3803662	Breast cancer	TOX3	1.30	3E-15
chr16	52586340	52586341	rs3803662	Breast cancer	TOX3	1.16	1E-9
chr16	52586340	52586341	rs3803662	Breast cancer	TNRC9	1.28	6E-19
chr16	52586340	52586341	rs3803662	Breast cancer	TNRC9, LOC643714	1.20	1E-36
chr16	52599187	52599188	rs4784227	Breast cancer	TOX3	1.24	1E-28
chr16	52624737	52624738	rs3104767	Restless legs syndrome	TOX3, BC034767	1.35	9E-19
chr16	52635163	52635164	rs3112612	Breast cancer	TOX3	1.15	4E-10
chr16	52912298	52912299	rs1344484	Bipolar disorder	RPGRIP1L	NR	2E-6
chr16	53757739	53757740	rs1421084	Subcutaneous adipose tissue	FTO	NR	3E-6
chr16	53769676	53769677	rs6499640	Weight	FTO	5.50	6E-14
chr16	53769676	53769677	rs6499640	Body mass index	FTO	5.25	4E-13
chr16	53800753	53800754	rs9940128	Metabolic syndrome	FTO	.09	2E-9
chr16	53800953	53800954	rs1421085	Obesity	FTO	1.39	1E-28
chr16	53803573	53803574	rs1558902	Obesity	FTO	.09	1E-7
chr16	53803573	53803574	rs1558902	Body mass index	FTO	.39	5E-120
chr16	53803573	53803574	rs1558902	Obesity (extreme)	FTO	1.37	7E-13
chr16	53803573	53803574	rs1558902	Waist circumference	FTO	NR	5E-19
chr16	53809246	53809247	rs1121980	Body mass index	FTO	.06	4E-8
chr16	53809246	53809247	rs1121980	Obesity (early onset extreme)	FTO	1.66	1E-7
chr16	53813366	53813367	rs17817449	Obesity	FTO	NR	2E-12
chr16	53816274	53816275	rs8050136	Adiposity	FTO	.06	3E-26
chr16	53816274	53816275	rs8050136	Body mass in chronic obstructive pulmonary disease	FTO	NR	4E-8
chr16	53816274	53816275	rs8050136	Weight	FTO	7.05	5E-36
chr16	53816274	53816275	rs8050136	Body mass index	FTO	8.04	1E-47
chr16	53816274	53816275	rs8050136	Type 2 diabetes	FTO	1.30	2E-17
chr16	53816274	53816275	rs8050136	Type 2 diabetes	FTO	1.15	7E-6
chr16	53816274	53816275	rs8050136	Type 2 diabetes	FTO	1.23	7E-14
chr16	53816274	53816275	rs8050136	Type 2 diabetes	FTO	1.17	1E-12
chr16	53820526	53820527	rs9939609	Type 2 diabetes	FTO	1.25	1E-20
chr16	53820526	53820527	rs9939609	Menarche (age at onset)	FTO	2.10	3E-8
chr16	53820526	53820527	rs9939609	Biomedical quantitative traits	FTO	.24	2E-7
chr16	53820526	53820527	rs9939609	Body mass index	FTO	.33	4E-51
chr16	53820526	53820527	rs9939609	Type 2 diabetes	FTO	1.34	2E-7
chr16	53820526	53820527	rs9939609	Body mass index	FTO	.36	2E-20
chr16	53821614	53821615	rs7202116	Body mass index	FTO	.04	2E-10
chr16	53825487	53825488	rs9941349	Obesity (extreme)	FTO	1.48	6E-12
chr16	53830464	53830465	rs9930506	Obesity-related traits	FTO	.12	9E-7
chr16	53830464	53830465	rs9930506	Obesity-related traits	FTO	.13	9E-7
chr16	53830464	53830465	rs9930506	Obesity-related traits	FTO	.16	3E-8
chr16	53831770	53831771	rs9922619	Subcutaneous adipose tissue	FTO	NR	6E-8
chr16	53839134	53839135	rs8044769	Osteoarthritis	FTO	1.07	4E-6
chr16	53842907	53842908	rs12149832	Body mass index	FTO	.07	5E-22
chr16	53845486	53845487	rs11642841	Type 2 diabetes	FTO	1.13	3E-8
chr16	54027970	54027971	rs12596210	Sex hormone-binding globulin levels	FTO	.12	9E-6
chr16	54494423	54494424	rs9921518	Dialysis-related mortality	IRX5, IRX3	2.11	9E-6
chr16	55245036	55245037	rs17291845	Information processing speed	AC109462.1	.19	5E-6
chr16	55255190	55255191	rs2001970	Visceral fat	IRX6	NR	9E-6
chr16	56725172	56725173	rs8064100	Gambling	MT1X, MT11P, MT1H, MT1G, MT1F, MT1B, NUP93	.15	3E-6
chr16	56969147	56969148	rs2217332	Metabolic syndrome	HERPUD1	NR	3E-6
chr16	56985138	56985139	rs9989419	HDL cholesterol	CETP	.04	1E-32
chr16	56985138	56985139	rs9989419	HDL cholesterol	CETP	2.66	9E-27
chr16	56985138	56985139	rs9989419	HDL cholesterol	CETP	1.72	3E-31
chr16	56988043	56988044	rs173539	Metabolite levels	CETP	NR	3E-70
chr16	56988043	56988044	rs173539	Cardiovascular disease risk factors	CETP	.26	3E-65
chr16	56988043	56988044	rs173539	Metabolic syndrome (bivariate traits)	CETP	.29	1E-16
chr16	56988043	56988044	rs173539	Metabolic syndrome	CETP	.16	9E-9
chr16	56988043	56988044	rs173539	HDL Cholesterol - Triglycerides (HDLC-TG)	CETP	.26	5E-16
chr16	56988043	56988044	rs173539	HDL cholesterol	CETP	.25	4E-75
chr16	56989589	56989590	rs247616	Lipoprotein-associated phospholipase A2 activity and mass	CETP	.02	3E-8
chr16	56989589	56989590	rs247616	Cardiovascular disease risk factors	CETP,HERPUD1	2.99	1E-23
chr16	56990715	56990716	rs247617	Metabolic syndrome	CETP	.25	9E-60
chr16	56993323	56993324	rs3764261	Lipoprotein-associated phospholipase A2 activity and mass	CETP	.02	7E-21
chr16	56993323	56993324	rs3764261	Lipid metabolism phenotypes	CETP	.22	1E-36
chr16	56993323	56993324	rs3764261	Age-related macular degeneration	CETP	1.15	7E-9
chr16	56993323	56993324	rs3764261	Metabolic syndrome (bivariate traits)	CETP	.29	3E-13
chr16	56993323	56993324	rs3764261	Metabolic syndrome	CETP	.07	1E-48
chr16	56993323	56993324	rs3764261	Triglycerides	CETP	2.88	1E-12
chr16	56993323	56993324	rs3764261	LDL cholesterol	CETP	1.45	9E-13
chr16	56993323	56993324	rs3764261	HDL cholesterol	CETP	3.39	7E-380
chr16	56993323	56993324	rs3764261	Cholesterol, total	CETP	1.67	7E-14
chr16	56993323	56993324	rs3764261	Age-related macular degeneration	CETP	1.19	7E-7
chr16	56993323	56993324	rs3764261	HDL cholesterol	CETP	6.20	3E-12
chr16	56993323	56993324	rs3764261	HDL cholesterol	CETP	.09	7E-29
chr16	56993323	56993324	rs3764261	Waist circumference and related phenotypes	CETP	NR	1E-27
chr16	56993323	56993324	rs3764261	HDL cholesterol	CETP	3.47	2E-57
chr16	56995235	56995236	rs1800775	HDL cholesterol	CETP, NUP93, SLC12A3, HERPUD1	3.09	4E-93
chr16	56995235	56995236	rs1800775	HDL cholesterol	CETP	.18	1E-73
chr16	56995235	56995236	rs1800775	Triglycerides	CETP	2.10	3E-13
chr16	56995235	56995236	rs1800775	Triglycerides	CETP	1.60	3E-6
chr16	56997232	56997233	rs1864163	HDL cholesterol	CETP	4.12	7E-39
chr16	57002731	57002732	rs9939224	Metabolic syndrome (bivariate traits)	CETP	.31	7E-12
chr16	57005478	57005479	rs1532624	Cholesterol	CETP	9.99	3E-20
chr16	57005478	57005479	rs1532624	HDL cholesterol	CETP	.21	9E-94
chr16	57006589	57006590	rs7499892	Biochemical measures	CETP	.24	9E-6
chr16	57012378	57012379	rs12708980	HDL cholesterol	CETP	.04	2E-28
chr16	57047298	57047299	rs16965039	Coronary heart disease	CETP	.14	6E-7
chr16	57058581	57058582	rs821470	Bipolar disorder and schizophrenia	NLRC5	1.25	3E-6
chr16	57563670	57563671	rs8052123	Cataracts in type 2 diabetes	CCDC102A	NR	5E-6
chr16	58075281	58075282	rs12447804	Pulmonary function	MMP15	.04	4E-8
chr16	58566303	58566304	rs37060	QT interval	NDRG4, CNOT1	1.52	1E-7
chr16	58567237	58567238	rs37062	Electrocardiographic traits	NDRG4	6.09	1E-6
chr16	58567237	58567238	rs37062	QT interval	CNOT1,GINS3, NDRG4, SLC38A7, GOT2	1.75	3E-25
chr16	58622177	58622178	rs7188697	QT interval	NDRG4	1.66	7E-25
chr16	58759331	58759332	rs12600277	Aortic root size	GOT2	.14	3E-6
chr16	60314655	60314656	rs9932186	Phospholipid levels (plasma)	CDH8	.80	3E-8
chr16	60733602	60733603	rs17822114	Myopia (pathological)	Intergenic	NR	3E-18
chr16	61123146	61123147	rs2639889	Morbidity-free survival	Intergenic	NR	9E-7
chr16	61778094	61778095	rs8048207	Non-small cell lung cancer	CDH8	NR	8E-6
chr16	62100210	62100211	rs8050940	Myopia (pathological)	Intergenic	NR	1E-26
chr16	62377152	62377153	rs11645366	Cystic fibrosis severity	CDH8	NR	7E-6
chr16	63955446	63955447	rs1381102	Attention deficit hyperactivity disorder and conduct disorder	Intergenic	NR	6E-6
chr16	67225500	67225501	rs3729639	Coronary heart disease	LCAT	.09	2E-11
chr16	67708896	67708897	rs12449157	HDL cholesterol	GFOD2,LCAT	.02	2E-7
chr16	67902069	67902070	rs2271293	HDL cholesterol	CTCF, PRMT8	.13	8E-16
chr16	67902069	67902070	rs2271293	HDL cholesterol	LCAT	.07	9E-13
chr16	67911516	67911517	rs8060686	Metabolic syndrome	EDC4	.11	2E-10
chr16	67911516	67911517	rs8060686	Coronary heart disease	EDC4	.07	8E-6
chr16	67928041	67928042	rs16942887	HDL cholesterol	LCAT	1.27	8E-33
chr16	67971379	67971380	rs11574514	Crohn's disease	PSMB10	1.44	2E-7
chr16	68013470	68013471	rs255049	HDL cholesterol	LCAT	.05	3E-8
chr16	68024994	68024995	rs255052	HDL cholesterol	LCAT	.74	1E-7
chr16	68326199	68326200	rs6499165	Metabolic traits	SLC7A6	.11	1E-18
chr16	68383046	68383047	rs7197653	Magnesium levels	PRMT7	.01	2E-6
chr16	68591229	68591230	rs1728785	Ulcerative colitis	CDH1	1.17	3E-8
chr16	68600350	68600351	rs17689437	HIV-1 viral setpoint	ZFP90	NR	6E-6
chr16	68600350	68600351	rs17689437	Reasoning	ZFP90	NR	1E-6
chr16	68674787	68674788	rs6499188	Ulcerative colitis	ZFP90	1.14	4E-8
chr16	68820945	68820946	rs9929218	Colorectal cancer	CDH1	1.10	1E-8
chr16	69135048	69135049	rs8047014	Attention deficit hyperactivity disorder	HAS3	NR	4E-6
chr16	69588571	69588572	rs1364063	Menarche (age at onset)	NFAT5	2.10	2E-8
chr16	70913983	70913984	rs12149070	Chronic obstructive pulmonary disease-related biomarkers	HYDIN	NR	8E-6
chr16	71634810	71634811	rs4788815	Metabolite levels	TAT	NR	4E-13
chr16	71634810	71634811	rs4788815	Metabolite levels	TAT	.15	2E-17
chr16	71653636	71653637	rs2334880	Malaria	MARVELD3	1.19	2E-6
chr16	71965195	71965196	rs16973500	Attention deficit hyperactivity disorder and conduct disorder	PKD1L3, KIAA0174, DHODH	NR	7E-6
chr16	72108092	72108093	rs2000999	Haptoglobin levels	HP	.14	8E-59
chr16	72108092	72108093	rs2000999	LDL cholesterol	HP,HPR,DHX38	2.00	2E-22
chr16	72108092	72108093	rs2000999	Cholesterol, total	HP,HPR,DHX38	2.34	3E-24
chr16	72114001	72114002	rs217181	Metabolite levels	HP, HPR, DHX38	NR	1E-36
chr16	72220372	72220373	rs7186908	Liver enzyme levels (alkaline phosphatase)	HPR, PMFBP1	2.00	5E-9
chr16	72756100	72756101	rs10500569	Metabolite levels	ZFHX3	NR	7E-12
chr16	72931084	72931085	rs16971384	Coronary heart disease	ZFHX3	.07	5E-6
chr16	73009023	73009024	rs7199343	Kawasaki disease	ZFHX3	1.56	2E-6
chr16	73029159	73029160	rs7193343	Atrial fibrillation	ZFHX3	1.21	1E-10
chr16	73051619	73051620	rs2106261	Atrial fibrillation	ZFHX3	1.24	3E-16
chr16	73051619	73051620	rs2106261	Atrial fibrillation	ZFHX3	1.25	2E-15
chr16	73068677	73068678	rs879324	Stroke (ischemic)	ZFHX3	1.25	2E-8
chr16	73439354	73439355	rs9934948	Breast cancer (survival)	Intergenic	1.29	6E-6
chr16	73501535	73501536	rs12446956	Major depressive disorder	Intergenic	1.22	1E-6
chr16	73581057	73581058	rs7191888	Multiple sclerosis (severity)	C16orf47	NR	6E-6
chr16	74076251	74076252	rs2716601	Treatment response for severe sepsis	LOC441506	NR	1E-6
chr16	74472695	74472696	rs10871290	Breast cancer	GLG1	NR	4E-7
chr16	74881819	74881820	rs16948255	HIV-1 control	Intergenic	NR	1E-6
chr16	75247244	75247245	rs7202877	Type 1 diabetes	Intergenic	1.28	3E-15
chr16	75390315	75390316	rs2865531	Pulmonary function	CFDP1	.03	2E-11
chr16	75991445	75991446	rs1948632	Tuberculosis	NR	1.55	8E-6
chr16	76318541	76318542	rs7193230	Response to amphetamines	CNTNAP4	NR	5E-6
chr16	76566156	76566157	rs4485401	Sphingolipid levels	CNTNAP4	.80	2E-8
chr16	76878861	76878862	rs13330107	Inattentive symptoms	Intergenic	NR	9E-6
chr16	76890125	76890126	rs17679567	Response to TNF-alpha inhibitors in rheumatoid arthritis	CNTNAP4	NR	9E-6
chr16	77329640	77329641	rs7192208	White matter integrity	ADAMTS18	.48	2E-6
chr16	77427768	77427769	rs11864477	Bone mineral density	ADAMTS18	1.00	2E-8
chr16	77916190	77916191	rs435746	Bipolar disorder and schizophrenia	NR	1.28	3E-6
chr16	78188737	78188738	rs12716852	Pulmonary function	WWOX	.03	2E-7
chr16	78258809	78258810	rs2059238	Cardiac structure and function	WWOX	.02	3E-6
chr16	78569956	78569957	rs17706989	Reasoning	WWOX	NR	1E-6
chr16	78631793	78631794	rs2859631	Radiation response	WWOX	NR	1E-6
chr16	78952438	78952439	rs9923451	Obesity	WWOX	NR	8E-7
chr16	79073420	79073421	rs17713676	Response to amphetamines	WWOX	NR	8E-6
chr16	79406917	79406918	rs17797882	Type 2 diabetes	WWOX	1.08	9E-7
chr16	79585020	79585021	rs7498403	Height	MAF	NR	5E-6
chr16	79645988	79645989	rs889472	Renal function-related traits (urea)	MAF	.07	1E-9
chr16	79652540	79652541	rs386965	Multiple sclerosis	MAF	1.09	4E-6
chr16	79682750	79682751	rs1424233	Obesity	MAF	1.12	4E-13
chr16	79744547	79744548	rs17767419	Thyroid volume	MAF	.07	9E-15
chr16	79749275	79749276	rs3813579	Thyroid volume	MAF	1.32	4E-10
chr16	79749352	79749353	rs3813582	Thyroid function	LOC440389, MAF	.07	6E-10
chr16	80497600	80497601	rs4581712	Liver enzyme levels (gamma-glutamyl transferase)	DYNLRB2	3.20	3E-9
chr16	81156521	81156522	rs4889240	Attention deficit hyperactivity disorder and conduct disorder	PKD1L2, C16orf46	NR	7E-6
chr16	81264596	81264597	rs6564851	Carotenoid and tocopherol levels	BCMO1	.15	2E-24
chr16	81303758	81303759	rs4889294	Protein quantitative trait loci	BCM01	NR	5E-7
chr16	81489372	81489373	rs16955379	Type 2 diabetes	CMIP	1.08	3E-7
chr16	81534789	81534790	rs2925979	Adiponectin levels	CMIP	.04	3E-21
chr16	81534789	81534790	rs2925979	HDL cholesterol	CMIP	.45	2E-11
chr16	82377780	82377781	rs4087296	Bone mineral density	Intergenic	NR	3E-7
chr16	82379952	82379953	rs4082514	Cognitive performance	AC009117.8	NR	3E-6
chr16	82485250	82485251	rs8053728	Response to fenofibrate (adiponectin levels)	CDH13	.18	6E-6
chr16	82519227	82519228	rs1991867	D-dimer levels	CDH13	.04	4E-6
chr16	82594382	82594383	rs4783227	Response to antipsychotic treatment	Intergenic	NR	4E-7
chr16	82642650	82642651	rs11646213	Hypertension	CDH13	1.28	8E-6
chr16	82650716	82650717	rs3865188	Adiponectin levels	CDH13	.09	3E-83
chr16	82650716	82650717	rs3865188	Adiponectin levels	CDH13	.11	4E-30
chr16	82662267	82662268	rs4783244	Adiponectin levels	CDH13	.35	6E-17
chr16	82663287	82663288	rs12051272	Adiponectin levels	CDH13	.26	1E-14
chr16	82663287	82663288	rs12051272	Adiponectin levels	CDH13,CMIP	.26	6E-48
chr16	82663287	82663288	rs12051272	Adiponectin levels	CDH13	NR	5E-40
chr16	82746936	82746937	rs11646411	Attention deficit hyperactivity disorder	CDH13	NR	7E-6
chr16	82817590	82817591	rs12386026	Tuberculosis	NR	1.66	2E-6
chr16	83212397	83212398	rs8055236	Coronary heart disease	Intergenic	1.91	6E-6
chr16	83284337	83284338	rs10514585	Depression (quantitative trait)	CDH13	.15	5E-6
chr16	83487470	83487471	rs17216786	Response to antipsychotic treatment	CDH13	NR	1E-6
chr16	83639334	83639335	rs6563943	Height	CDH13	.05	6E-6
chr16	83709665	83709666	rs8058532	Response to amphetamines	CDH13	NR	2E-6
chr16	83757327	83757328	rs3784962	Cognitive performance	AC009063.8	NR	6E-6
chr16	83757327	83757328	rs3784962	Cognitive performance	AC009063.8	NR	3E-6
chr16	83764203	83764204	rs3096277	Blood pressure	CDH13	NR	1E-9
chr16	84213683	84213684	rs4150167	Autism	TAF1C	1.96	3E-7
chr16	84274404	84274405	rs746080	Visceral adipose tissue adjusted for BMI	ADAD2, TAF1C, KCNG4, WFDC1	NR	6E-6
chr16	84423033	84423034	rs8048576	Chronic obstructive pulmonary disease-related biomarkers	ATP2C2	NR	9E-13
chr16	84446383	84446384	rs10514604	Attention deficit hyperactivity disorder	ATP2C2	NR	8E-7
chr16	84578240	84578241	rs371915	Eosinophilic esophagitis (pediatric)	NR	1.90	2E-8
chr16	84685508	84685509	rs11647936	Waist circumference	KLHL36	2.29	4E-6
chr16	84987678	84987679	rs2326458	Height	ZDHHC7, CRISPLD2, USP10	5.10	8E-7
chr16	85092747	85092748	rs8056742	Amyotrophic lateral sclerosis	KIAA0513	1.27	5E-7
chr16	85944438	85944439	rs391525	Chronic lymphocytic leukemia	IRF8	1.56	3E-9
chr16	85975658	85975659	rs305061	Chronic lymphocytic leukemia	NR	1.33	9E-8
chr16	85975658	85975659	rs305061	Chronic lymphocytic leukemia	IRF8	1.22	4E-7
chr16	85991704	85991705	rs11642873	Systemic sclerosis	IRF8	1.33	2E-12
chr16	86011032	86011033	rs13333054	Multiple sclerosis	IRF8	1.11	1E-8
chr16	86014240	86014241	rs16940202	Ulcerative colitis	Intergenic	1.15	6E-19
chr16	86017662	86017663	rs17445836	Multiple sclerosis	IRF8	1.25	4E-9
chr16	86018632	86018633	rs2280381	Rheumatoid arthritis	IRF8	1.12	2E-6
chr16	86019270	86019271	rs11117432	Primary biliary cirrhosis	Intergenic	1.31	5E-11
chr16	86365570	86365571	rs2696835	Diabetic retinopathy	IRF8, LOC732275	2.27	3E-6
chr16	86381183	86381184	rs11641231	Response to statin therapy	LOC401864, LOC283904, LOC729464	NR	8E-6
chr16	86403117	86403118	rs9936833	Barrett's esophagus	FOXF1, LOC732275	1.14	3E-10
chr16	86710659	86710660	rs10048146	Bone mineral density (spine)	FOXL1	.09	2E-8
chr16	86710659	86710660	rs10048146	Bone mineral density (hip)	FOXL1	.09	2E-7
chr16	87111629	87111630	rs12933233	Alzheimer's disease (age of onset)	NR	NR	8E-6
chr16	87461968	87461969	rs9646303	Major depressive disorder	FBXO31,MAP1LC3B,ZCCHC14	NR	5E-6
chr16	87991050	87991051	rs4843747	Menopause (age at onset)	NR	.39	2E-7
chr16	88298123	88298124	rs12447690	Central corneal thickness	ZNF469,BANP	.16	6E-22
chr16	88298123	88298124	rs12447690	Central corneal thickness	ZNF469	.16	9E-11
chr16	88331639	88331640	rs9938149	Central corneal thickness	ZNF469	.16	1E-12
chr16	88777241	88777242	rs8052560	Height	CTU2/GALNS	.03	3E-8
chr16	89667336	89667337	rs154659	Tanning	MC1R	.14	7E-8
chr16	89755902	89755903	rs258322	Melanoma	MC1R	1.70	3E-27
chr16	89755902	89755903	rs258322	Melanoma	MC1R	1.67	3E-27
chr16	89755902	89755903	rs258322	Black vs. red hair color	MC1R	.36	2E-23
chr16	89818088	89818089	rs9926296	Vitiligo	MC1R	1.27	2E-13
chr16	89818731	89818732	rs12931267	Hair color	MC1R	.56	5E-87
chr16	89818731	89818732	rs12931267	Hair color	MC1R	.56	3E-10
chr16	89818731	89818732	rs12931267	Freckling	MC1R	1.88	8E-62
chr16	89851032	89851033	rs16966142	Caffeine consumption	NR	.12	6E-6
chr16	89986116	89986117	rs1805007	Basal cell carcinoma	MC1R	1.55	4E-17
chr16	89986116	89986117	rs1805007	Skin sensitivity to sun	MC1R	2.94	2E-55
chr16	89986116	89986117	rs1805007	Red vs non-red hair color	MC1R	12.47	2E-142
chr16	89986116	89986117	rs1805007	Freckles	MC1R	4.37	1E-96
chr16	89986116	89986117	rs1805007	Blond vs. brown hair color	MC1R	2.34	2E-13
chr16	90066935	90066936	rs4785763	Melanoma	MC1R	1.36	6E-22
chr16	90084560	90084561	rs11648785	Tanning	MC1R	.14	3E-9
chr17	38923	38924	rs7217319	AIDS progression	RPH3AL	1.48	4E-6
chr17	831666	831667	rs2360111	Economic and political preferences	NXN	.11	3E-6
chr17	1618362	1618363	rs11078597	Serum albumin level	SERPINF2, WDR81	.02	7E-13
chr17	1618362	1618363	rs11078597	Serum albumin level	SERPINF2, WDR81	.02	1E-14
chr17	1634103	1634104	rs12150338	Calcium levels	PRPF8,MGC14376,WDR81,SMYD4,SERPINF1,SERPINF2	.05	7E-7
chr17	2125604	2125605	rs1231206	Coronary heart disease	Intergenic	1.07	9E-10
chr17	2126503	2126504	rs216172	Coronary heart disease	SMG6, SRR	1.07	1E-9
chr17	2143459	2143460	rs10852932	Aortic root size	SMG6, SRR, TSR1, SGSM2	.03	2E-11
chr17	2171636	2171637	rs17761864	Esophageal cancer (squamous cell)	SMG6	1.21	2E-11
chr17	2216257	2216258	rs391300	Type 2 diabetes	SRR	1.28	3E-9
chr17	2262702	2262703	rs4790333	Proinsulin levels	SGSM2	NR	3E-9
chr17	2428507	2428508	rs9891572	HDL cholesterol	Intergenic	.05	2E-7
chr17	2771511	2771512	rs12603284	Sudden cardiac arrest	GARNL4	1.89	3E-6
chr17	3393067	3393068	rs923375	Myopia (pathological)	ASPA	NR	4E-16
chr17	3664974	3664975	rs220470	Attention deficit hyperactivity disorder	ITGAE	NR	1E-7
chr17	3786906	3786907	rs758642	Smoking behavior	CAMKK1	.08	7E-6
chr17	4683034	4683035	rs12051548	Metabolite levels	GLTPD2, TM4SF5, VM01	NR	1E-11
chr17	4683034	4683035	rs12051548	Sphingolipid levels	PLD2	.00	1E-9
chr17	4836380	4836381	rs6065	Platelet counts	GP1BA	4.19	3E-11
chr17	5907442	5907443	rs9303196	Non-small cell lung cancer	NR	1.43	8E-6
chr17	6093950	6093951	rs3744728	Bipolar disorder (mood-incongruent)	WSC domain containing 1	1.51	3E-6
chr17	6607017	6607018	rs218676	Economic and political preferences (time)	SLC13A5	.15	5E-6
chr17	7091649	7091650	rs314253	Liver enzyme levels (alkaline phosphatase)	ASGR1, DLG4	2.10	8E-12
chr17	7118321	7118322	rs507506	Adiponectin levels	NR	.02	2E-6
chr17	7142850	7142851	rs117616209	Metabolite levels	SLC2A4	.51	3E-14
chr17	7417662	7417663	rs6761	Protein quantitative trait loci	SHBG	NR	3E-7
chr17	7462554	7462555	rs11552708	IgM levels	TNFSF13	NR	4E-9
chr17	7462968	7462969	rs3803800	IgA levels	TNFSF13	NR	3E-7
chr17	7462968	7462969	rs3803800	Non-albumin protein levels	TNFSF13	.10	7E-15
chr17	7462968	7462969	rs3803800	IgA nephropathy	TNFSF13	1.21	9E-11
chr17	7469228	7469229	rs11078697	IgM levels	SENP3	NR	4E-7
chr17	7484811	7484812	rs9901675	Sex hormone-binding globulin levels	SHBG	.06	1E-7
chr17	7491176	7491177	rs4227	IgA nephropathy	MPDU1	1.23	4E-10
chr17	7512073	7512074	rs11653545	IgM levels	FXR2	NR	2E-7
chr17	7521914	7521915	rs12150660	Sex hormone-binding globulin levels	SHBG	.09	6E-30
chr17	7521914	7521915	rs12150660	Sex hormone-binding globulin levels	SHBG	.11	4E-80
chr17	7521914	7521915	rs12150660	Sex hormone-binding globulin levels	SHBG	.08	2E-55
chr17	7521914	7521915	rs12150660	Sex hormone-binding globulin levels	SHBG	.10	2E-106
chr17	7521914	7521915	rs12150660	Testosterone levels	SHBG	31.80	1E-41
chr17	7534677	7534678	rs6258	Sex hormone-binding globulin levels	SHBG	.27	3E-46
chr17	7534677	7534678	rs6258	Testosterone levels	SHBG	82.30	2E-22
chr17	7537791	7537792	rs727428	Androgen levels	SHBG	.07	1E-12
chr17	7537791	7537792	rs727428	Androgen levels	SHBG	.10	1E-11
chr17	7537791	7537792	rs727428	Sex hormone-binding globulin levels	FXR2, SHBG, SAT2, ATP1B2	.13	2E-16
chr17	7545720	7545721	rs1641537	Sex hormone-binding globulin levels	SHBG	.06	1E-24
chr17	7552122	7552123	rs72829446	Androgen levels	SHBG	.16	9E-10
chr17	7552122	7552123	rs72829446	Androgen levels	SHBG	.10	6E-8
chr17	7578114	7578115	rs1625895	Sex hormone-binding globulin levels	SHBG	.12	2E-21
chr17	7633691	7633692	rs16956936	Type 1 diabetes	Intergenic	1.09	5E-7
chr17	8130866	8130867	rs3027247	Parkinson's disease (motor and cognition)	C17orf68	1.89	9E-6
chr17	8136091	8136092	rs3027234	Telomere length	CTC1	.06	2E-8
chr17	8943928	8943929	rs8076457	Orofacial clefts	NR	NR	2E-7
chr17	10033678	10033679	rs11656696	Intraocular pressure	GAS7	.19	1E-8
chr17	10574158	10574159	rs6503319	Malaria	SCO1	1.21	7E-7
chr17	11803460	11803461	rs4792192	Myopia (pathological)	DNAH9	NR	3E-6
chr17	12047543	12047544	rs1870584	Response to amphetamines	MAP2K4	NR	5E-6
chr17	12637370	12637371	rs9905820	Testosterone levels	MYOCD	.09	4E-6
chr17	12804549	12804550	rs7209847	Economic and political preferences	RICH2	.27	9E-6
chr17	13062794	13062795	rs9900808	Cannbis use (initiation)	Intergenic	.08	2E-6
chr17	13539803	13539804	rs10521232	Tonometry	HS3ST3A1	NR	4E-6
chr17	13559079	13559080	rs10521233	Asthma (childhood onset)	NR	.14	3E-6
chr17	13684916	13684917	rs4792394	Conduct disorder (symptom count)	Intergenic	.06	9E-6
chr17	13733805	13733806	rs12949531	Systemic lupus erythematosus	Intergenic	NR	8E-6
chr17	13910548	13910549	rs17608059	Temperament	COX10	.09	3E-7
chr17	14294020	14294021	rs3848445	Protein quantitative trait loci	HS3ST3B1	NR	8E-9
chr17	14629745	14629746	rs9899891	Visceral adipose tissue/subcutaneous adipose tissue ratio	FLJ45831	NR	4E-6
chr17	15193055	15193056	rs1380181	QT interval	NR	1.97	3E-7
chr17	15331516	15331517	rs2906966	Pulmonary function	CDRT4	NR	8E-6
chr17	15826020	15826021	rs859267	Immune reponse to smallpox (secreted IL-12p40)	ADORA2B	NR	3E-7
chr17	16246015	16246016	rs7477	Amyotrophic lateral sclerosis	CENPV, PIGL	1.30	3E-7
chr17	16845166	16845167	rs4792800	IgG levels	TNFRSF13B	NR	1E-12
chr17	16848749	16848750	rs4561508	Serum total protein level	TNFRSF13B	.05	2E-11
chr17	16848749	16848750	rs4561508	Serum total protein level	TNFRSF13B	.04	2E-18
chr17	16848749	16848750	rs4561508	Serum total protein level	TNFRSF13B	.04	1E-9
chr17	16863637	16863638	rs4985726	Non-albumin protein levels	TNFRSF13B	.14	7E-24
chr17	16863637	16863638	rs4985726	Non-albumin protein levels	TNFRSF13B	.11	1E-14
chr17	16933403	16933404	rs11867934	Diabetic retinopathy	LOC100128283, TNFRSF13B, MPRIP	1.43	7E-6
chr17	17543721	17543722	rs12936587	Coronary heart disease	RASD1, SMCR3, PEMT	1.07	4E-10
chr17	17715100	17715101	rs11868035	Parkinson's disease	SREBF1, RAI1	1.18	6E-8
chr17	18753869	18753870	rs4924935	Pancreatic cancer	PRPSAP2	1.37	8E-6
chr17	19804246	19804247	rs397969	Platelet counts	AKAP10	2.13	2E-9
chr17	21284222	21284223	rs4640244	Height	KCNJ12	.02	2E-8
chr17	21707059	21707060	rs1975974	Psoriasis	NR	1.17	1E-7
chr17	25320888	25320889	rs73317122	Response to amphetamines	Intergenic	NR	4E-6
chr17	25541277	25541278	rs4795519	Chronic myeloid leukemia	WSB1, FAM27L	1.85	1E-12
chr17	25567079	25567080	rs12602978	Dental caries	WSB1	NR	7E-7
chr17	26106674	26106675	rs4795067	Psoriasis	NOS2	1.19	4E-11
chr17	26601132	26601133	rs2006933	Amyotrophic lateral sclerosis	Intergenic	1.27	9E-7
chr17	27675225	27675226	rs11653144	Mean platelet volume	TAOK1	.13	4E-8
chr17	27703348	27703349	rs2138852	Mean platelet volume	TAOK1	.02	1E-22
chr17	27703348	27703349	rs2138852	Mean platelet volume	TAOK1	.02	7E-28
chr17	27714586	27714587	rs8076739	Mean platelet volume	TAOK1	.01	5E-38
chr17	27814495	27814496	rs559972	Platelet counts	TAOK1	3.26	3E-18
chr17	27917770	27917771	rs3110496	Height	ANKRD13B	.02	7E-9
chr17	29164022	29164023	rs3764419	Height	ATAD5/RNF135	.04	2E-21
chr17	29247714	29247715	rs3760318	Height	CRLF3, ATAD5, CENTA2, RNF135	6.00	2E-9
chr17	29333515	29333516	rs17826255	Myopia (pathological)	LOC646021	NR	8E-9
chr17	30343281	30343282	rs17780086	Height	LRRC37B	.03	3E-8
chr17	30877657	30877658	rs225190	Pancreatic cancer	MYO1D	1.26	6E-6
chr17	30896454	30896455	rs225212	Hypertension risk in short sleep duration	MYO1D	5.08	5E-6
chr17	31737420	31737421	rs1354492	vWF and FVIII levels	ACCN1	.16	2E-6
chr17	32287448	32287449	rs11650066	Coronary heart disease	Intergenic	NR	6E-6
chr17	32464153	32464154	rs9901756	Hypothyroidism	LOC100131744, CCL2	1.21	7E-6
chr17	32593664	32593665	rs3091315	Crohn's disease	CCL2,CCL7	1.20	2E-13
chr17	32593973	32593974	rs3091316	Crohn's disease	CCL7, CCL2, CCL11, CCL8, CCL13, CCL1	1.14	4E-8
chr17	33324381	33324382	rs2074518	QT interval	LIG3,RFFL	1.05	6E-12
chr17	33843511	33843512	rs8070473	Depression (quantitative trait)	SLFN12L	.16	2E-6
chr17	33884803	33884804	rs10512472	Platelet counts	SNORD7,AP2B1	3.64	2E-14
chr17	33944054	33944055	rs16971217	Mean platelet volume	SNORD7,AP2B1	.01	4E-12
chr17	34819190	34819191	rs4796217	Protein quantitative trait loci	CCL4L2	NR	4E-21
chr17	35189090	35189091	rs17138064	Orofacial clefts	Intergenic	1.92	5E-7
chr17	35850552	35850553	rs712039	Tuberculosis	NR	1.21	3E-6
chr17	35898341	35898342	rs2074409	Response to angiotensin II receptor blocker therapy	SYNRG	1.20	2E-6
chr17	36026334	36026335	rs6607284	Bipolar disorder and schizophrenia	NR	1.23	7E-6
chr17	36098039	36098040	rs4430796	Type 2 diabetes	HNF1B	1.19	2E-11
chr17	36098039	36098040	rs4430796	Endometrial cancer	HNF1B	1.19	7E-10
chr17	36098039	36098040	rs4430796	Prostate-specific antigen levels	HNF1B	9.40	6E-11
chr17	36098039	36098040	rs4430796	Type 2 diabetes	HNF1B,TCF2	1.14	2E-6
chr17	36098039	36098040	rs4430796	Prostate cancer	Intergenic	1.19	8E-6
chr17	36098039	36098040	rs4430796	Prostate cancer	HNF1B	1.18	1E-9
chr17	36098039	36098040	rs4430796	Prostate cancer	TCF2	1.22	1E-11
chr17	36101155	36101156	rs7501939	Prostate cancer	TCF2	1.19	2E-6
chr17	36101155	36101156	rs7501939	Prostate cancer	HNF1B	NR	1E-12
chr17	36101155	36101156	rs7501939	Prostate cancer	NR	NR	3E-18
chr17	36101155	36101156	rs7501939	Prostate cancer	HNF1B	1.41	9E-12
chr17	36922195	36922196	rs1043515	Height	PIP4K2B	.02	3E-10
chr17	37543448	37543449	rs7208487	Primary biliary cirrhosis	ORMDL3	1.32	8E-7
chr17	37813855	37813856	rs11869286	HDL cholesterol	STARD3	.51	3E-14
chr17	37922258	37922259	rs907092	Primary biliary cirrhosis	IKZF3	1.29	8E-6
chr17	37976468	37976469	rs9303277	Primary biliary cirrhosis	IKZF3, ZPBP2, GSDMB, ORMDL3	1.44	4E-9
chr17	37976468	37976469	rs9303277	Primary biliary cirrhosis	IKZF3,ZPBP2,GSDMB,ORMDL3	1.38	2E-9
chr17	38040762	38040763	rs2872507	Type 1 diabetes autoantibodies	ORMDL3	1.10	2E-6
chr17	38040762	38040763	rs2872507	Ulcerative colitis	IKZF3, ORMDL3, IKZF3, PNMT, ZPBP2, GSDML	1.15	5E-11
chr17	38040762	38040763	rs2872507	Crohn's disease	GSMDL,ZPBP2,ORMDL3,IKZF3	1.14	2E-9
chr17	38040762	38040763	rs2872507	Rheumatoid arthritis	IKZF3	1.10	9E-7
chr17	38040762	38040763	rs2872507	Crohn's disease	ORMDL3	1.12	5E-9
chr17	38051347	38051348	rs8067378	Ulcerative colitis	GSDMB	1.12	1E-7
chr17	38062195	38062196	rs2305480	Asthma	GSDMB	1.18	1E-7
chr17	38062195	38062196	rs2305480	Ulcerative colitis	ORMDL3,ZPBP2M,GSDML	1.15	3E-8
chr17	38064404	38064405	rs11078927	Asthma	GSDMB	NR	2E-16
chr17	38066239	38066240	rs2290400	Type 1 diabetes	ORMDL3	1.15	6E-13
chr17	38069948	38069949	rs7216389	Asthma	ORMDL3	1.45	9E-11
chr17	38089343	38089344	rs4794820	Asthma	ORMDL3	1.33	1E-8
chr17	38095173	38095174	rs6503525	Asthma	ORMDL3	1.33	5E-7
chr17	38110688	38110689	rs17609240	Hematological parameters	GSDMA, ORMDL3	.02	9E-9
chr17	38121992	38121993	rs3894194	Asthma	GSDMA	1.17	5E-9
chr17	38128647	38128648	rs3859192	White blood cell count	GSDMA	.14	2E-12
chr17	38156711	38156712	rs4794822	White blood cell types	PSMD3, CSF3	.09	4E-16
chr17	38156711	38156712	rs4794822	Neutrophil count	PSMD3, CSF3	.10	6E-10
chr17	38166878	38166879	rs8078723	C-reactive protein and white blood cell count	Intergenic	.16	3E-9
chr17	38770285	38770286	rs7221109	Type 1 diabetes	Intergenic	1.05	1E-9
chr17	39046880	39046881	rs2315504	Height	KRT23, KRT20	1.90	8E-6
chr17	39250638	39250639	rs4006360	Bipolar disorder and schizophrenia	NR	1.23	4E-6
chr17	39897263	39897264	rs6503659	Esophageal cancer (squamous cell)	HAP1	1.27	3E-16
chr17	40481528	40481529	rs2293152	Multiple sclerosis	STAT3	1.22	4E-8
chr17	40507979	40507980	rs9891119	Multiple sclerosis	STAT3	1.11	2E-10
chr17	40514200	40514201	rs744166	Multiple sclerosis	STAT3	1.15	3E-10
chr17	40514200	40514201	rs744166	Crohn's disease	STAT3	1.18	7E-12
chr17	40570771	40570772	rs11871801	Crohn's disease	MLX,STAT3	1.15	3E-8
chr17	41807330	41807331	rs1513670	Bone mineral density (hip)	SOST	.08	2E-8
chr17	42064986	42064987	rs9895585	Response to taxane treatment (placlitaxel)	PYY	NR	9E-6
chr17	42193184	42193185	rs228769	Bone mineral density (spine)	HDAC5	.07	4E-6
chr17	42193184	42193185	rs228769	Bone mineral density (hip)	HDAC5	.08	2E-8
chr17	42225546	42225547	rs227584	Bone mineral density (hip)	C17orf53	.07	9E-7
chr17	42442343	42442344	rs708382	Platelet counts	FAM171A2,ITGA2B	2.44	2E-8
chr17	43208120	43208121	rs12946454	Systolic blood pressure	PLCD3, ACBD4, HEXIM1, HEXIM2	.57	1E-8
chr17	43212962	43212963	rs2291447	Economic and political preferences	ACBD4	.11	2E-6
chr17	43216280	43216281	rs4986172	Height	ACBD4	.03	2E-16
chr17	43403004	43403005	rs4792814	Multiple sclerosis	MAP3K14	1.08	3E-6
chr17	43513440	43513441	rs11012	Parkinson's disease	PLEKHM1, MAPT, IMP5	1.43	6E-8
chr17	43666491	43666492	rs2458179	Response to amphetamines	Intergenic	NR	7E-6
chr17	43714849	43714850	rs2942168	Parkinson's disease	MAPT	1.27	1E-28
chr17	43719142	43719143	rs393152	Parkinson's disease	MAPT,  C17orf69, KIAA1267, LOC644246	1.30	2E-16
chr17	43795432	43795433	rs11655470	Head circumference (infant)	CRHR1, MAPT	.05	4E-6
chr17	43805193	43805194	rs9303521	Bone mineral density (spine)	CRHR1	.07	1E-8
chr17	43805193	43805194	rs9303521	Bone mineral density (hip)	CRHR1	.06	4E-6
chr17	43923682	43923683	rs12185268	Parkinson's disease	MAPT	1.30	3E-14
chr17	43924218	43924219	rs12373124	Male-pattern baldness	Intergenic	1.33	5E-10
chr17	44019711	44019712	rs242557	Progressive supranuclear palsy	MAPT	1.43	9E-18
chr17	44081063	44081064	rs8070723	Progressive supranuclear palsy	MAPT	5.11	2E-118
chr17	44081063	44081064	rs8070723	Parkinson's disease	MAPT	1.30	7E-12
chr17	44187256	44187257	rs9303525	Intracranial volume	MAPT, GRN, CRHR1, STH	14.90	8E-15
chr17	44334706	44334707	rs2458179	Response to amphetamines	Intergenic	NR	7E-6
chr17	44788309	44788310	rs183211	Parkinson's disease	NSF	NR	3E-7
chr17	44828930	44828931	rs199533	Parkinson's disease	MAPT	1.35	1E-6
chr17	44828930	44828931	rs199533	Parkinson's disease	NSF	1.28	1E-14
chr17	44856640	44856641	rs199515	Parkinson's disease	WNT3	1.32	3E-17
chr17	44859143	44859144	rs415430	Parkinson's disease	WNT3	NR	7E-7
chr17	44865438	44865439	rs2074404	Celiac disease	Intergenic	1.11	1E-6
chr17	44949099	44949100	rs11079740	Antineutrophil cytoplasmic antibody-associated vasculitis	WNT9B	1.10	9E-6
chr17	45013270	45013271	rs17608766	Systolic blood pressure	GOSR2	.56	1E-10
chr17	45013270	45013271	rs17608766	Blood pressure	GOSR2	.53	6E-15
chr17	45013270	45013271	rs17608766	Blood pressure	GOSR2	.36	2E-7
chr17	45013270	45013271	rs17608766	Ventricular conduction	GOSR2	.53	5E-10
chr17	45425114	45425115	rs7206971	LDL cholesterol	OSBPL7	.87	4E-9
chr17	45425114	45425115	rs7206971	Cholesterol, total	OSBPL7	1.01	1E-8
chr17	45768835	45768836	rs8070463	Multiple sclerosis	KPNB1, TBKBP1, TBX21	1.15	1E-7
chr17	45768835	45768836	rs8070463	Ankylosing spondylitis	TBKBP1	NR	5E-8
chr17	46123003	46123004	rs72823592	Epilepsy (generalized)	PNPO, ATAD4, CDK5RAP3, COPZ2, hsa-mir-152, NFE2L1, CBX1, SNX11, SKAP1	1.30	9E-9
chr17	46123931	46123932	rs3764400	Body mass index	CBX1	NR	4E-7
chr17	46357119	46357120	rs2084881	Ovarian cancer	NR	1.12	2E-6
chr17	46411499	46411500	rs9303542	Ovarian cancer	SKAP1	1.11	1E-6
chr17	46617018	46617019	rs6504340	Primary tooth development (number of teeth)	HOXB1, HOXB2	.44	6E-7
chr17	46669429	46669430	rs9299	Obesity	HOXB5	1.14	4E-9
chr17	46720564	46720565	rs2326017	Cognitive performance	AC103702.3	NR	3E-7
chr17	46988596	46988597	rs46522	Coronary heart disease	UBE2Z, GIP, ATP5G1, SNF8	1.06	2E-8
chr17	47084710	47084711	rs9674544	Primary tooth development (time to first tooth eruption)	IGF2BP1	.25	8E-7
chr17	47084710	47084711	rs9674544	Primary tooth development (number of teeth)	IGF2BP1	.27	2E-8
chr17	47390013	47390014	rs2072153	Height	ZNF652	.02	4E-8
chr17	47402806	47402807	rs12940887	Blood pressure	ZNF652	.25	2E-7
chr17	47436748	47436749	rs7210100	Prostate cancer	ZNF652	1.51	3E-13
chr17	47440465	47440466	rs16948048	Diastolic blood pressure	ZNF652, PHB	.31	5E-9
chr17	47445750	47445751	rs2411984	Sex hormone-binding globulin levels	ZNF652	.03	4E-14
chr17	47445750	47445751	rs2411984	Sex hormone-binding globulin levels	ZNF652	.03	2E-10
chr17	47564011	47564012	rs1035050	Bipolar disorder	NR	1.17	9E-6
chr17	47566311	47566312	rs16948200	Immune reponse to smallpox (secreted IL-2)	NGFR	NR	2E-8
chr17	48274290	48274291	rs2075555	Breast cancer	COL1A1	NR	8E-8
chr17	48289069	48289070	rs2586502	Response to taxane treatment (docetaxel)	COL1A1	NR	1E-6
chr17	48591208	48591209	rs6504663	Visceral fat	MYCBPAP	NR	9E-6
chr17	49244746	49244747	rs4605213	Height	NME2	.02	3E-8
chr17	49613784	49613785	rs9635759	Menarche (age at onset)	CA10	3.00	7E-13
chr17	51237940	51237941	rs8073783	Conduct disorder (interaction)	Intergenic	1.76	8E-6
chr17	53757786	53757787	rs1549519	Height	TMEM100, PCTP	.05	6E-9
chr17	54192522	54192523	rs1431318	Cannabis dependence	Intergenic	1.41	9E-7
chr17	54203359	54203360	rs8065311	Cannabis dependence	Intergenic	1.43	2E-6
chr17	54278714	54278715	rs1019238	Cannabis dependence	ANKFN1	1.45	6E-7
chr17	54430154	54430155	rs12449568	Height	ANKFN1	.25	2E-6
chr17	54615616	54615617	rs17760296	Orofacial clefts	NOG	1.50	7E-6
chr17	54773237	54773238	rs227731	Orofacial clefts	NR	1.23	2E-8
chr17	54773237	54773238	rs227731	Orofacial clefts	NOG	1.38	1E-8
chr17	54778816	54778817	rs227724	Height	NOG	.03	7E-15
chr17	54839758	54839759	rs1401796	Height	NOG	NR	2E-8
chr17	54850328	54850329	rs4794665	Height	NOG, DGKE, TRIM25, COIL, RISK	3.60	1E-7
chr17	55119993	55119994	rs8073390	Response to amphetamines	Intergenic	NR	7E-6
chr17	55823551	55823552	rs8077059	Sex hormone-binding globulin levels	Intergenic	.08	5E-6
chr17	55866286	55866287	rs12938916	Bipolar disorder	NR	NR	5E-7
chr17	56010959	56010960	rs8074980	Multiple sclerosis--Brain Glutamate Levels	CUEDC1	NR	2E-6
chr17	56448296	56448297	rs2257205	Pancreatic cancer	RNF43	1.38	8E-6
chr17	56584204	56584205	rs2302189	Dental caries	Intergenic	1.33	8E-6
chr17	56847944	56847945	rs9303401	Cognitive test performance	PPM1E	NR	5E-6
chr17	57850250	57850251	rs11650106	Lipoprotein-associated phospholipase A2 activity and mass	TMEM49	.01	3E-9
chr17	58024274	58024275	rs180515	Multiple sclerosis	RPS6KB1	1.09	9E-8
chr17	58966537	58966538	rs7224438	Immune reponse to smallpox (secreted IL-2)	BCAS3	NR	4E-7
chr17	59239220	59239221	rs11868441	Renal function-related traits (BUN)	BCAS3	.01	2E-9
chr17	59286643	59286644	rs8068952	Vertical cup-disc ratio	BCAS3	.01	3E-8
chr17	59456588	59456589	rs9895661	Renal function-related traits (sCR)	BCAS3	.00	7E-11
chr17	59456588	59456589	rs9895661	Renal function-related traits (eGRFcrea)	BCAS3	.01	5E-11
chr17	59456588	59456589	rs9895661	Chronic kidney disease	BCAS3,TBX2,C17orf82	.01	1E-15
chr17	59483765	59483766	rs8068318	Creatinine levels	TBX2	.80	3E-10
chr17	59496648	59496649	rs2079795	Height	TBX2	.04	2E-24
chr17	59496648	59496649	rs2079795	Height	C17orf82, TBX2, TBX4	.40	3E-6
chr17	59497276	59497277	rs757608	Height	BCAS3, NACA2, TBX2, TBX4	4.40	6E-8
chr17	60778931	60778932	rs2251393	Sudden cardiac arrest	Intergenic	1.13	4E-7
chr17	61563457	61563458	rs4329	Metabolic traits	ACE	.13	8E-20
chr17	61566030	61566031	rs4343	Angiotensin-converting enzyme activity	ACE	16.20	3E-25
chr17	61712963	61712964	rs7209435	Height	MAP3K3, WDR68, LYK5, MT1F	4.80	7E-7
chr17	61763030	61763031	rs11658329	Height	MAP3K3	.05	5E-10
chr17	61763030	61763031	rs11658329	Height	MAP3K3	.05	6E-10
chr17	61966464	61966465	rs2665838	Height	CSH1/GH1	.04	5E-25
chr17	61977247	61977248	rs2854160	Height	Intergenic	.05	5E-8
chr17	62007497	62007498	rs2070776	Height	GH region	NR	9E-9
chr17	62408298	62408299	rs6504218	Coronary heart disease	Intergenic	NR	1E-6
chr17	63642541	63642542	rs8074751	Attention deficit hyperactivity disorder	CCDC46	1.45	1E-6
chr17	64133725	64133726	rs7209395	Weight	NR	1.75	3E-6
chr17	64318356	64318357	rs9912468	Ventricular conduction	PRKCA	.39	1E-8
chr17	64779429	64779430	rs3889237	Height	PRKCA	.06	3E-8
chr17	64917032	64917033	rs17645023	Bipolar disorder and schizophrenia	CACNG5	NR	6E-7
chr17	65898808	65898809	rs7216064	Lung cancer	BPTF	1.16	7E-6
chr17	65898808	65898809	rs7216064	Lung adenocarcinoma	BPTF	1.20	7E-11
chr17	66875293	66875294	rs4148008	HDL cholesterol	ABCA8	.42	2E-10
chr17	67802351	67802352	rs11870477	Response to TNF-alpha inhibitors in rheumatoid arthritis	MAP2K6	NR	3E-6
chr17	68090206	68090207	rs11867479	Height	KCNJ16/KCNJ2	.03	2E-10
chr17	68190825	68190826	rs8079702	Primary tooth development (time to first tooth eruption)	KCNJ2	1.62	4E-22
chr17	68190825	68190826	rs8079702	Primary tooth development (number of teeth)	KCNJ2	1.15	1E-14
chr17	68259445	68259446	rs623011	Thyrotoxic hypokalemic periodic paralysis	KCNJ2	5.47	4E-12
chr17	68291132	68291133	rs6501384	Eosinophilic esophagitis (pediatric)	NR	1.41	6E-6
chr17	68326337	68326338	rs312691	Thyrotoxic hypokalemic periodic paralysis	KCNJ16, KCNJ2	3.20	8E-14
chr17	68494991	68494992	rs17779747	QT interval	KCNJ2	1.02	6E-12
chr17	68521860	68521861	rs7219669	Cardiac repolarization	KCNJ2	1.70	6E-14
chr17	68644188	68644189	rs17718586	Sudden cardiac arrest	Intergenic	1.53	2E-8
chr17	68878486	68878487	rs1015657	Formal thought disorder in schizophrenia	KCNJ2	1.32	2E-6
chr17	69108752	69108753	rs1859962	Prostate cancer	Intergenic	1.27	3E-11
chr17	69108752	69108753	rs1859962	Prostate cancer	NR	NR	2E-16
chr17	69108752	69108753	rs1859962	Prostate cancer	Intergenic	1.26	1E-6
chr17	69108752	69108753	rs1859962	Prostate cancer	Intergenic	1.20	3E-10
chr17	70098160	70098161	rs9913711	Liver enzyme levels (gamma-glutamyl transferase)	FLJ37644, SOX9	2.40	1E-9
chr17	70363394	70363395	rs12941150	Pulmonary function decline	SOX9	.22	7E-6
chr17	70696102	70696103	rs8066857	Amyotrophic lateral sclerosis	SLC39A11	1.48	8E-6
chr17	70826403	70826404	rs12943829	Visceral adipose tissue adjusted for BMI	SLC39A11	NR	2E-6
chr17	71335259	71335260	rs3816995	Panic disorder	SDK2	NR	2E-7
chr17	72268207	72268208	rs7219585	Information processing speed	DNAI2	.20	1E-6
chr17	72699832	72699833	rs10512597	Fibrinogen	CD300LF, SLC9A3R1, NAT9	6.45	8E-11
chr17	73060072	73060073	rs11077773	Information processing speed	KCTD2	.24	8E-6
chr17	73872947	73872948	rs1055129	White matter hyperintensity burden	TRIM47	NR	3E-11
chr17	73888671	73888672	rs3744028	White matter hyperintensity burden	TRIM65	NR	4E-15
chr17	74997896	74997897	rs4789400	Cannbis use (initiation)	MGAT5B	.07	5E-6
chr17	75004212	75004213	rs11653989	Cardiac repolarization	MGAT5B, SEC14L	1.61	3E-6
chr17	75211207	75211208	rs3744064	Cognitive performance	SEC14L1	NR	7E-7
chr17	75400099	75400100	rs892961	Airflow obstruction	SEPT9	1.18	9E-6
chr17	75701696	75701697	rs9906155	Body mass index	SEPT9	.05	9E-6
chr17	75944649	75944650	rs16970672	Alzheimer's disease	AC015804.1	1.29	2E-6
chr17	76403983	76403984	rs4129767	HDL cholesterol	PGS1	.40	5E-9
chr17	76881702	76881703	rs4789939	Dupuytren's disease	AC100788.1, TIMP2	1.22	6E-7
chr17	78324258	78324259	rs12051723	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	RNF213	2.20	3E-6
chr17	78348493	78348494	rs6565681	Moyamoya disease	RNF213	4.82	2E-8
chr17	78737286	78737287	rs7215564	Myopia (pathological)	KIAA1303	NR	2E-6
chr17	79261808	79261809	rs10445407	Longevity	SLC38A10	NR	1E-6
chr17	79596810	79596811	rs9894429	Eye color traits	NPLOC4,HGS	.12	9E-14
chr17	80408814	80408815	rs9303029	Protein quantitative trait loci	C17orf62	NR	4E-7
chr17	80685532	80685533	rs1046896	Glycated hemoglobin levels	FN3K	.04	2E-26
chr17_ctg5_hap1	18140	18141	rs4792814	Multiple sclerosis	MAP3K14	1.08	3E-6
chr17_ctg5_hap1	128502	128503	rs11012	Parkinson's disease	PLEKHM1, MAPT, IMP5	1.43	6E-8
chr17_ctg5_hap1	531223	531224	rs2458179	Response to amphetamines	Intergenic	NR	7E-6
chr17_ctg5_hap1	678812	678813	rs9303525	Intracranial volume	MAPT, GRN, CRHR1, STH	14.90	8E-15
chr17_ctg5_hap1	786678	786679	rs8070723	Progressive supranuclear palsy	MAPT	5.11	2E-118
chr17_ctg5_hap1	786678	786679	rs8070723	Parkinson's disease	MAPT	1.30	7E-12
chr17_ctg5_hap1	847977	847978	rs242557	Progressive supranuclear palsy	MAPT	1.43	9E-18
chr17_ctg5_hap1	943320	943321	rs12373124	Male-pattern baldness	Intergenic	1.33	5E-10
chr17_ctg5_hap1	943856	943857	rs12185268	Parkinson's disease	MAPT	1.30	3E-14
chr17_ctg5_hap1	1062227	1062228	rs9303521	Bone mineral density (spine)	CRHR1	.07	1E-8
chr17_ctg5_hap1	1062227	1062228	rs9303521	Bone mineral density (hip)	CRHR1	.06	4E-6
chr17_ctg5_hap1	1072009	1072010	rs11655470	Head circumference (infant)	CRHR1, MAPT	.05	4E-6
chr17_ctg5_hap1	1148169	1148170	rs393152	Parkinson's disease	MAPT,  C17orf69, KIAA1267, LOC644246	1.30	2E-16
chr17_ctg5_hap1	1152430	1152431	rs2942168	Parkinson's disease	MAPT	1.27	1E-28
chr17_ctg5_hap1	1201687	1201688	rs2458179	Response to amphetamines	Intergenic	NR	7E-6
chr17_ctg5_hap1	1421238	1421239	rs2458179	Response to amphetamines	Intergenic	NR	7E-6
chr18	278795	278796	rs7226677	Bipolar disorder and major depressive disorder (combined)	COLEC12,THOC1	NR	4E-6
chr18	278795	278796	rs7226677	Bipolar disorder	NR	1.24	7E-6
chr18	1595020	1595021	rs8097348	Exercise (leisure time)	C18orf2	1.36	7E-6
chr18	2498053	2498054	rs1879352	Acute lymphoblastic leukemia (childhood)	Intergenic	1.53	9E-6
chr18	2948028	2948029	rs10460009	Type 2 diabetes	LPIN2	1.35	9E-6
chr18	3328745	3328746	rs1623523	Antineutrophil cytoplasmic antibody-associated vasculitis	MRLC2	NR	3E-6
chr18	3522005	3522006	rs8083633	Economic and political preferences (time)	DLGAP1	.15	1E-6
chr18	4721358	4721359	rs1557305	Eating disorders	DLGAP1	1.11	5E-6
chr18	4773109	4773110	rs7237848	White blood cell types	Intergenic	.07	2E-7
chr18	5857090	5857091	rs11662763	Immunoglobulin A	L3MBTL4	1.56	5E-6
chr18	6567181	6567182	rs948426	Hypothyroidism	LOC100130480	1.14	1E-6
chr18	6939946	6939947	rs597503	Sudden cardiac arrest	Intergenic	1.45	2E-8
chr18	6941107	6941108	rs4398173	Response to citalopram treatment	LAMA1	NR	4E-6
chr18	6941661	6941662	rs3810046	Response to citalopram treatment	LAMA1	NR	5E-7
chr18	7042910	7042911	rs16951095	Non-small cell lung cancer	NR	1.30	7E-6
chr18	7068461	7068462	rs8090011	Type 2 diabetes	LAMA1	1.13	8E-9
chr18	7755770	7755771	rs7243299	Dialysis-related mortality	PTPRM	1.63	8E-6
chr18	8209268	8209269	rs8098064	Dialysis-related mortality	PTPRM	1.42	4E-6
chr18	9288455	9288456	rs2864527	Dental caries	TWSG1	NR	4E-6
chr18	10899027	10899028	rs11080466	Non-small cell lung cancer	APCDD1, NAPG, FAM38B	1.47	1E-6
chr18	11987271	11987272	rs7506045	Stroke	IMPA2	5.39	7E-7
chr18	12550746	12550747	rs1940973	Immune response to smallpox vaccine (IL-6)	SPIRE1	NR	8E-7
chr18	12606462	12606463	rs9959145	Immune response to smallpox vaccine (IL-6)	SPIRE1	NR	3E-8
chr18	12779946	12779947	rs2542151	Type 1 diabetes autoantibodies	PTPN2	1.30	4E-13
chr18	12779946	12779947	rs2542151	Type 1 diabetes	PTPN2	NR	9E-8
chr18	12779946	12779947	rs2542151	Crohn's disease	PTPN2	1.35	5E-17
chr18	12779946	12779947	rs2542151	Crohn's disease	PTPN2	1.30	2E-7
chr18	12779946	12779947	rs2542151	Crohn's disease	PTPN2	1.15	3E-8
chr18	12779946	12779947	rs2542151	Type 1 diabetes	PTPN2	1.30	1E-14
chr18	12797693	12797694	rs2847297	Rheumatoid arthritis	PTPN2	1.10	2E-8
chr18	12809339	12809340	rs1893217	Celiac disease and Rheumatoid arthritis	PTPN2	NR	5E-12
chr18	12809339	12809340	rs1893217	Crohn's disease	PTPN2	1.25	1E-14
chr18	12809339	12809340	rs1893217	Celiac disease	PTPN2	1.17	3E-10
chr18	12809339	12809340	rs1893217	Type 1 diabetes	PTPN2	NR	4E-15
chr18	12821592	12821593	rs2847281	Esophageal cancer (squamous cell)	PTPN2	1.20	2E-11
chr18	12821592	12821593	rs2847281	C-reactive protein	PTPN2	.03	2E-8
chr18	19261412	19261413	rs11662721	Phospholipid levels (plasma)	ABHD3	.00	1E-8
chr18	20190794	20190795	rs4331426	Tuberculosis	GATA6,CTAGE1,RBBP8,CABLES1	1.19	7E-9
chr18	20223694	20223695	rs11661542	Intracranial aneurysm	RBBP8	1.22	1E-12
chr18	20720972	20720973	rs11082304	Platelet counts	CABLES1	2.48	5E-11
chr18	20720972	20720973	rs11082304	Smoking behavior	CABLES1	.03	6E-6
chr18	20724327	20724328	rs4800148	Height	CABLES1, RBBP8, C18orf45	6.40	4E-9
chr18	20727610	20727611	rs4800452	Height	CABLES1	.05	4E-30
chr18	20735407	20735408	rs4369779	Height	CABLES1	.06	3E-6
chr18	21140431	21140432	rs1805081	Obesity	NPC1	1.33	3E-7
chr18	21365852	21365853	rs11082762	Amyotrophic lateral sclerosis	LAMA3	1.16	7E-7
chr18	21749614	21749615	rs9635963	Protein quantitative trait loci	OSBPL1A	NR	2E-7
chr18	21938657	21938658	rs7227401	Osteoporosis	OSBPL1A	.17	4E-7
chr18	22136568	22136569	rs12954803	Response to taxane treatment (docetaxel)	HRH4	NR	8E-6
chr18	22731359	22731360	rs8083432	Adverse response to lamotrigine and phenytoin	ZNF521	NR	6E-6
chr18	23257185	23257186	rs1840440	Weight	NR	2.16	3E-7
chr18	23892671	23892672	rs1791780	Visceral adipose tissue adjusted for BMI	TAF4B	NR	4E-7
chr18	24156424	24156425	rs16942421	Sudden cardiac arrest	KCTD1	1.68	8E-10
chr18	25569057	25569058	rs2298574	vWF and FVIII levels	CDH2	.27	6E-6
chr18	25773015	25773016	rs4800843	Response to amphetamines	Intergenic	NR	3E-6
chr18	25926058	25926059	rs11083271	Non-alcoholic fatty liver disease histology (lobular)	Intergenic	.61	8E-6
chr18	26059111	26059112	rs4131805	Hip geometry	Intergenic	NR	2E-6
chr18	26606646	26606647	rs2155929	Temperament (bipolar disorder)	CDH2	1.01	5E-6
chr18	26676671	26676672	rs4145170	Cognitive performance	AC105245.4	NR	3E-6
chr18	28141687	28141688	rs2729409	Protein quantitative trait loci	DSC3	NR	3E-6
chr18	28902321	28902322	rs7236477	Eosinophilic esophagitis (pediatric)	DSG1	2.22	7E-6
chr18	29038122	29038123	rs1941184	Parkinson's disease (age of onset)	DSG3	2.28	4E-6
chr18	29187278	29187279	rs1667255	Retinol levels	TTR	.03	6E-14
chr18	29273128	29273129	rs10438933	Amyotrophic lateral sclerosis	B4GALT6	1.30	1E-6
chr18	30927774	30927775	rs6507016	Prostate cancer (gene x gene interaction)	C18orf34	1.28	4E-6
chr18	31420009	31420010	rs1013696	Response to antidepressants	Intergenic	17.80	4E-6
chr18	31645378	31645379	rs7239368	Response to citalopram treatment	NOL4	1.45	9E-6
chr18	33097959	33097960	rs9953852	Capecitabine sensitivity	Intergenic	NR	3E-6
chr18	34107451	34107452	rs17651157	Response to antipsychotic treatment	FHOD3	NR	1E-7
chr18	34928638	34928639	rs4799915	Response to iloperidone treatment (QT prolongation)	BRUNOL4	NR	3E-6
chr18	35198295	35198296	rs10502675	Response to amphetamines	Intergenic	NR	3E-6
chr18	35214005	35214006	rs2162440	Telomere length	BRUNOL4, PIKC3C	106.00	3E-6
chr18	38765658	38765659	rs17697518	Obesity	KC6	1.17	7E-7
chr18	40023781	40023782	rs12606301	Economic and political preferences (immigration/crime)	Intergenic	.17	5E-6
chr18	40058881	40058882	rs7235528	Economic and political preferences (immigration/crime)	Intergenic	.17	4E-6
chr18	40075955	40075956	rs8090196	Economic and political preferences (immigration/crime)	Intergenic	.18	3E-6
chr18	40102640	40102641	rs1346987	Economic and political preferences (immigration/crime)	Intergenic	.18	2E-6
chr18	40105656	40105657	rs7231412	Economic and political preferences (immigration/crime)	Intergenic	.17	6E-6
chr18	40288292	40288293	rs8085804	Cognitive performance	RIT2	NR	8E-6
chr18	40437650	40437651	rs16977065	Response to tocilizumab in rheumatoid arthritis	Intergenic	33.72	1E-7
chr18	40591083	40591084	rs9958208	Acute lymphoblastic leukemia (childhood)	RIT2	1.62	5E-6
chr18	40673379	40673380	rs12456492	Parkinson's disease	RIT2	1.19	2E-10
chr18	40678234	40678235	rs4130047	Parkinson's disease	RIT2, SYT4	1.16	2E-7
chr18	40808797	40808798	rs17664267	Conduct disorder (interaction)	Intergenic	1.39	7E-6
chr18	40872272	40872273	rs12457996	Major depressive disorder	Intergenic	1.15	6E-6
chr18	42090666	42090667	rs2048485	Schizophrenia	Intergenic	1.40	8E-6
chr18	42439885	42439886	rs991014	Ventricular conduction	SETBP1	.42	6E-10
chr18	42725661	42725662	rs998124	Prostate cancer (gene x gene interaction)	MIR4319	1.33	5E-6
chr18	42800147	42800148	rs10502861	Male-pattern baldness	SETBP1	1.28	3E-9
chr18	42956671	42956672	rs2243803	Menarche (age at onset)	SLC14A2	2.00	3E-7
chr18	43153948	43153949	rs10502868	Biochemical measures	SLC14A2	.04	7E-6
chr18	43187129	43187130	rs7227483	Renal function-related traits (BUN)	SLC14A2	.01	7E-18
chr18	43202403	43202404	rs7232775	Metabolite levels	SLC14A2	.01	8E-14
chr18	43309910	43309911	rs17674580	Bladder cancer	SLC14A1	1.17	8E-11
chr18	43316965	43316966	rs7238033	Bladder cancer	SLC14A1	1.20	9E-9
chr18	44585419	44585420	rs2576037	Personality dimensions	KATNAL2	.41	1E-7
chr18	44752237	44752238	rs1398217	Menarche (age at onset)	FUSSEL18	2.70	2E-13
chr18	45815416	45815417	rs1944582	Response to taxane treatment (docetaxel)	KIAA0427	NR	4E-6
chr18	46453462	46453463	rs4939827	Colorectal cancer	SMAD7	1.14	1E-7
chr18	46453462	46453463	rs4939827	Colorectal cancer	SMAD7	1.18	2E-6
chr18	46453462	46453463	rs4939827	Colorectal cancer	SMAD7	1.20	8E-28
chr18	46453462	46453463	rs4939827	Colorectal cancer	SMAD7	1.16	1E-12
chr18	46579969	46579970	rs357894	Dental caries	SMAD7	NR	4E-6
chr18	46587653	46587654	rs1787200	Height	DYM	.04	7E-10
chr18	46587653	46587654	rs1787200	Height	DYM	.05	1E-10
chr18	46959499	46959500	rs9967417	Height	DYM	.04	9E-25
chr18	46991159	46991160	rs8099594	Height	DYM	.05	3E-7
chr18	47159089	47159090	rs7240405	HDL cholesterol	LIPG	2.27	5E-10
chr18	47160813	47160814	rs7228085	Lipid metabolism phenotypes	LIPG	.11	7E-11
chr18	47160952	47160953	rs7241918	HDL cholesterol	LIPG	1.31	3E-49
chr18	47160952	47160953	rs7241918	Cholesterol, total	LIPG	1.94	2E-19
chr18	47167213	47167214	rs4939883	HDL cholesterol	LIPG	.10	2E-11
chr18	47167213	47167214	rs4939883	Cholesterol, total	LIPG	.07	2E-11
chr18	47167213	47167214	rs4939883	HDL cholesterol	LIPG	.14	7E-15
chr18	47181667	47181668	rs2156552	HDL cholesterol	LIPG	.03	2E-12
chr18	47181667	47181668	rs2156552	HDL cholesterol	LIPG, ACAA2	.07	2E-7
chr18	47181667	47181668	rs2156552	HDL cholesterol	LIPG	1.20	6E-12
chr18	47843533	47843534	rs1036935	Chronic lymphocytic leukemia	CXXC1, MBD1	1.22	2E-6
chr18	48378233	48378234	rs732528	Entorhinal cortical thickness	ME2	.11	7E-6
chr18	48524160	48524161	rs9807334	Immune reponse to smallpox (secreted IFN-alpha)	ELAC1	NR	2E-7
chr18	48690618	48690619	rs7230711	Immune response to anthrax vaccine	SMAD4, MEX3C	.16	1E-6
chr18	48713039	48713040	rs8096445	Immune response to smallpox vaccine (IL-6)	MEX3C	NR	9E-9
chr18	50285397	50285398	rs768048	Alcoholism (alcohol use disorder factor score)	DCC	.11	8E-6
chr18	50517775	50517776	rs7504990	Gallbladder cancer	DCC	6.95	7E-8
chr18	52752016	52752017	rs12966547	Schizophrenia	CCDC68	1.40	3E-8
chr18	52863107	52863108	rs1970671	Diabetic retinopathy	CCDC68, TCF4	1.37	3E-6
chr18	53058237	53058238	rs17594526	Schizophrenia	TCF4	1.44	1E-7
chr18	53155001	53155002	rs9960767	Schizophrenia	TCF4	1.23	4E-9
chr18	53194960	53194961	rs17512836	Schizophrenia	TCF4	1.23	1E-6
chr18	53207206	53207207	rs1452787	Sclerosing cholangitis and ulcerative colitis (combined)	TCF4	1.33	3E-8
chr18	53210301	53210302	rs613872	Fuchs's corneal dystrophy	TCF4	5.47	1E-18
chr18	53664281	53664282	rs1978503	Breast cancer	Intergenic	NR	1E-6
chr18	53855524	53855525	rs12604483	HIV-1 susceptibility	AC009271.7	NR	7E-6
chr18	54397621	54397622	rs17750015	Depression and alcohol dependence	WDR7	1.68	8E-6
chr18	54752313	54752314	rs1557351	Multiple sclerosis (age of onset)	WDR7	NR	4E-6
chr18	54983553	54983554	rs1120787	HIV-1 control	Intergenic	NR	7E-6
chr18	55322501	55322502	rs12968116	Liver enzyme levels (gamma-glutamyl transferase)	ATP8B1	4.80	9E-10
chr18	55434201	55434202	rs7236632	Attention deficit hyperactivity disorder and conduct disorder	ATP8B1	NR	6E-6
chr18	55454376	55454377	rs10503019	Vitiligo	ATP8B1	NR	3E-6
chr18	55627839	55627840	rs11875185	Antineutrophil cytoplasmic antibody-associated vasculitis	Intergenic	NR	7E-6
chr18	55810732	55810733	rs549476	Response to amphetamines	NEDD4L	NR	3E-6
chr18	55910522	55910523	rs158856	Insomnia (caffeine-induced)	NEDD4L	1.41	7E-6
chr18	56084053	56084054	rs4503880	Liver enzyme levels (gamma-glutamyl transferase)	NEDD4L	3.60	3E-12
chr18	56109858	56109859	rs8099014	Platelet counts	AC105105.1	NR	6E-6
chr18	56213389	56213390	rs12456021	Multiple sclerosis	ALPK2	1.10	4E-6
chr18	56384191	56384192	rs7238078	Multiple sclerosis	MALT1	1.12	3E-9
chr18	56752053	56752054	rs1037757	Alzheimer's disease (age of onset)	LOC390958, Sec11C	NR	8E-6
chr18	57503377	57503378	rs8093763	Bleomycin sensitivity	PMAIP, Noxa	.18	3E-8
chr18	57751013	57751014	rs12957347	Metabolic syndrome	PMAIP1	NR	7E-6
chr18	57828636	57828637	rs2331841	Body mass index	MC4R	.05	2E-11
chr18	57839768	57839769	rs571312	Body mass index	MC4R	.23	6E-42
chr18	57849022	57849023	rs12967135	HDL cholesterol	RPS3A,MC4R	.42	7E-9
chr18	57851096	57851097	rs17782313	Height	MC4R	.03	4E-11
chr18	57851096	57851097	rs17782313	Obesity	MC4R	1.22	5E-15
chr18	57851096	57851097	rs17782313	Body mass index	MC4R	.20	5E-18
chr18	57851096	57851097	rs17782313	Body mass index	MC4R	.05	3E-15
chr18	57851762	57851763	rs10871777	Obesity (extreme)	MC4R	1.22	6E-11
chr18	57882786	57882787	rs489693	Antipsychotic drug-induced weight gain	MC4R	NR	6E-12
chr18	57882786	57882787	rs489693	Waist circumference	MC4R	NR	4E-7
chr18	57884749	57884750	rs12970134	Weight	MC4R	4.66	5E-13
chr18	57884749	57884750	rs12970134	Body mass index	MC4R	4.38	1E-12
chr18	57884749	57884750	rs12970134	Waist circumference and related phenotypes	MC4R	.88	2E-9
chr18	57963116	57963117	rs17773430	Obesity and blood pressure	MC4R	NR	6E-6
chr18	58067036	58067037	rs11878133	Age-related macular degeneration	NR	NR	4E-6
chr18	58109189	58109190	rs4257308	Tuberculosis	NR	1.55	6E-6
chr18	60054856	60054857	rs884205	Bone mineral density (spine)	TNFRSF11A	.08	9E-9
chr18	60060734	60060735	rs2957128	Paget's disease	TNFRSF11A	1.46	2E-11
chr18	60082092	60082093	rs3018362	Paget's disease	TNFRSF11A	1.45	8E-21
chr18	60082092	60082093	rs3018362	Paget's disease	TNFRSF11A	1.52	5E-13
chr18	60082092	60082093	rs3018362	Bone mineral density (hip)	RANK	.07	1E-6
chr18	60126111	60126112	rs694419	Serum albumin level	TNFRSF11A, ZCCHC2	.01	4E-9
chr18	60126111	60126112	rs694419	Serum albumin level	TNFRSF11A, ZCCHC2	.01	1E-8
chr18	61877155	61877156	rs4534959	Airflow obstruction	SERPINB8	1.72	7E-7
chr18	62998774	62998775	rs8083346	D-dimer levels	Intergenic	.03	6E-6
chr18	63031235	63031236	rs470490	Atrioventricular conduction	C18orf20, LOC643448	2.45	5E-6
chr18	65017099	65017100	rs2124349	Cognitive performance	C18orf4,DSEL	NR	4E-6
chr18	65285278	65285279	rs17077540	Major depressive disorder	DSEL	1.61	2E-7
chr18	65400424	65400425	rs13353224	Hyperactive-impulsive symptoms	Intergenic	NR	9E-6
chr18	66314071	66314072	rs1704734	Bipolar disorder and schizophrenia	NR	1.32	6E-6
chr18	67142856	67142857	rs17184557	Osteoporosis	DOK6	.13	9E-7
chr18	67516845	67516845	rs893001	Mean platelet volume	CD226	.01	1E-10
chr18	67531641	67531642	rs763361	Type 1 diabetes autoantibodies	CD226	1.12	1E-9
chr18	67531641	67531642	rs763361	Type 1 diabetes	CD226	1.16	1E-8
chr18	67536495	67536496	rs12969657	Mean platelet volume	CD226	.01	3E-11
chr18	68142413	68142414	rs8092443	Response to antipsychotic treatment	Intergenic	NR	1E-6
chr18	68153619	68153620	rs11663206	Response to antipsychotic treatment	Intergenic	NR	2E-6
chr18	68628077	68628078	rs2660917	Iron status biomarkers	Intergenic	NR	8E-6
chr18	68842242	68842243	rs17083844	Systemic lupus erythematosus	SOCS6	NR	6E-6
chr18	69248594	69248595	rs1539909	Response to TNF-alpha inhibitors in rheumatoid arthritis	CBLN2	NR	4E-6
chr18	69439072	69439073	rs17085106	Orofacial clefts	Intergenic	4.07	4E-8
chr18	69774277	69774278	rs337718	Multiple sclerosis (severity)	CBLN2	NR	9E-6
chr18	70227020	70227021	rs17086172	Airflow obstruction	CBLN	1.35	7E-6
chr18	70442067	70442068	rs41418949	Economic and political preferences (time)	NETO1	.36	6E-7
chr18	71058621	71058622	rs1943816	P-tau181p	Intergenic	NR	1E-7
chr18	71878516	71878517	rs9951925	Chronic obstructive pulmonary disease-related biomarkers	AC090398.2	NR	2E-6
chr18	72787045	72787046	rs17056274	Estradiol levels	ZNF407	.66	4E-6
chr18	73192445	73192446	rs1865721	Intelligence	C18orf62	3.90	5E-6
chr18	73527635	73527636	rs1017745	Response to amphetamines	Intergenic	NR	6E-6
chr18	74101940	74101941	rs4891159	Longevity	ZNF516	NR	1E-6
chr18	74318609	74318610	rs13381277	Dental caries	ZNF516	NR	4E-6
chr18	74735134	74735135	rs11663697	QT interval	NR	13.71	9E-6
chr18	74859043	74859044	rs1789110	Age-related macular degeneration (GA)	MBP	1.33	4E-7
chr18	74987631	74987632	rs2717128	RR interval (heart rate)	Intergenic	.19	1E-6
chr18	75653522	75653523	rs11661856	Inflammatory biomarkers	Intergenic	NR	1E-6
chr18	76409596	76409597	rs2002842	Rheumatoid arthritis	SALL3	1.61	6E-6
chr18	76415449	76415450	rs66591657	Response to amphetamines	Intergenic	NR	4E-6
chr18	76591634	76591635	rs12967884	Subcutaneous adipose tissue	SALL3	NR	7E-6
chr18	77573547	77573548	rs4799088	Amyotrophic lateral sclerosis	NR	1.15	9E-6
chr19	348742	348743	rs6510725	Non-small cell lung cancer	MIER2	NR	3E-6
chr19	950379	950380	rs2159128	Vertical cup-disc ratio	ARID3A	.02	3E-7
chr19	1046519	1046520	rs3764650	Alzheimer's disease	ABCA7	1.23	5E-17
chr19	1056491	1056492	rs3752246	Alzheimer's disease (late onset)	ABCA7	1.15	6E-7
chr19	1124834	1124835	rs740495	Crohn's disease	GPX4,SBNO2	1.16	8E-12
chr19	1207237	1207238	rs3764640	Alzheimer's disease	STK11	1.47	8E-6
chr19	1811602	1811603	rs7250872	Bipolar disorder	NR	1.21	2E-6
chr19	2160528	2160529	rs3803915	Body mass index	NR	.13	5E-6
chr19	2170953	2170954	rs12986413	Height	DOT1L	.31	3E-8
chr19	2177192	2177193	rs12982744	Osteoarthritis	DOT1L	.09	1E-11
chr19	2177192	2177193	rs12982744	Height	DOT1L	.03	3E-16
chr19	2275078	2275079	rs2523178	Height	C19orf35	.06	8E-6
chr19	3159768	3159769	rs11880198	Heart failure	GNA15	1.23	6E-6
chr19	3251218	3251219	rs17764205	Bipolar disorder and schizophrenia	NR	1.36	5E-6
chr19	3318509	3318510	rs11669592	Non-alcoholic fatty liver disease histology (other)	Intergenic	1.31	4E-6
chr19	3428833	3428834	rs7507204	Height	NFIC	.04	4E-16
chr19	3927770	3927771	rs10412199	Aging (time to event)	ATCAY	1.10	3E-6
chr19	4830627	4830628	rs6510827	Vitiligo	TICAM1	1.19	9E-8
chr19	5582534	5582535	rs732505	vWF and FVIII levels	SAFB2	.25	9E-6
chr19	5839745	5839746	rs3760776	Vitamin B12 levels	FUT6	49.78	4E-13
chr19	5839745	5839746	rs3760776	N-glycan levels	NRTN,FUT6,FUT3	.30	9E-10
chr19	5839745	5839746	rs3760776	N-glycan levels	NRTN,FUT6,FUT3	.41	4E-17
chr19	5839745	5839746	rs3760776	N-glycan levels	NRTN,FUT6,FUT3	.34	3E-12
chr19	5839745	5839746	rs3760776	N-glycan levels	NRTN,FUT6,FUT3	.34	1E-12
chr19	6080481	6080482	rs11880706	Bipolar disorder and schizophrenia	NR	1.44	2E-6
chr19	6668971	6668972	rs1077667	Multiple sclerosis	TNFSF14	1.16	9E-14
chr19	6690770	6690771	rs3745567	Complement C3 and C4 levels	C3	.09	2E-9
chr19	6718386	6718387	rs2230199	Age-related macular degeneration (GA)	C3	1.83	5E-13
chr19	6718386	6718387	rs2230199	Age-related macular degeneration (CNV)	C3	1.61	1E-12
chr19	6718386	6718387	rs2230199	Age-related macular degeneration	C3	1.53	5E-29
chr19	6718386	6718387	rs2230199	Age-related macular degeneration	C3, R102G	1.44	1E-8
chr19	6718386	6718387	rs2230199	Age-related macular degeneration	C3	NR	2E-8
chr19	6718386	6718387	rs2230199	Age-related macular degeneration	C3	1.74	1E-10
chr19	7166108	7166109	rs2059807	Polycystic ovary syndrome	INSR	1.14	1E-8
chr19	7184761	7184762	rs891088	Height	INSR	.03	2E-12
chr19	7196564	7196565	rs2115386	Diabetic retinopathy	INSR, LOC100131165, LOC100128567	1.12	3E-6
chr19	7223847	7223848	rs4804416	Hypothyroidism	INSR	1.13	5E-6
chr19	7424527	7424528	rs6603109	Sexual dysfunction (SSRI/SNRI-related)	AC119396.1	5.13	2E-6
chr19	7734510	7734511	rs3745367	Resistin levels	RETN	.04	3E-6
chr19	7909882	7909883	rs558718	HIV-1 control	EVI5L	NR	4E-6
chr19	8271720	8271721	rs7258249	Sphingolipid levels	LASS4	.00	1E-34
chr19	8271720	8271721	rs7258249	Sphingolipid levels	LASS4	.00	2E-27
chr19	8433195	8433196	rs7255436	HDL cholesterol	ANGPTL4	.45	3E-8
chr19	8469737	8469738	rs2967605	HDL cholesterol	ANGPTL4	.12	1E-8
chr19	8644030	8644031	rs4072910	Height	ADAMTS10	.03	4E-13
chr19	8671999	8672000	rs7249094	Height	ADAMTS10, MYO1F, PRAM1, OR2Z1	4.30	1E-6
chr19	8789380	8789381	rs2164983	Atopic dermatitis	ACTL9	1.16	7E-9
chr19	10000321	10000322	rs1862471	Menarche (age at onset)	OLFM2	2.00	2E-7
chr19	10213153	10213154	rs8109578	Protein quantitative trait loci	ANGPTL6	NR	4E-7
chr19	10394791	10394792	rs1799969	Soluble ICAM-1	ICAM1	24.90	1E-120
chr19	10394791	10394792	rs1799969	Soluble ICAM-1	ICAM1	28.19	4E-47
chr19	10395682	10395683	rs5498	Soluble ICAM-1	ICAM1	13.80	6E-89
chr19	10395682	10395683	rs5498	Soluble ICAM-1	ICAM1	13.22	5E-25
chr19	10397237	10397238	rs281437	Soluble ICAM-1	ICAM1	10.10	3E-10
chr19	10397402	10397403	rs3093030	Soluble levels of adhesion molecules	ICAM-1	4.15	4E-23
chr19	10469974	10469975	rs12720356	Crohn's disease	TYK2,ICAM1,ICAM3	1.12	1E-12
chr19	10469974	10469975	rs12720356	Psoriasis	TYK2	1.40	4E-11
chr19	10472932	10472933	rs280519	Psoriasis	TYK2	1.13	4E-9
chr19	10475651	10475652	rs2304256	Type 1 diabetes autoantibodies	TYK2	NR	1E-10
chr19	10475651	10475652	rs2304256	Type 1 diabetes	TYK2	1.16	4E-9
chr19	10520063	10520064	rs8112449	Multiple sclerosis	CDC37, TYK2	1.08	1E-6
chr19	10838485	10838486	rs11671653	Coronary heart disease	DNM2	.11	9E-7
chr19	11092138	11092139	rs11669133	Coronary heart disease	SMARCA4	.17	1E-8
chr19	11163600	11163601	rs1122608	Coronary heart disease	LDLR	1.14	1E-9
chr19	11163600	11163601	rs1122608	Myocardial infarction (early onset)	LDLR	1.15	2E-9
chr19	11188152	11188153	rs55791371	Lipid metabolism phenotypes	LDLR	.26	8E-17
chr19	11195029	11195030	rs11668477	LDL cholesterol	LDLR	.13	2E-7
chr19	11202305	11202306	rs6511720	Metabolite levels	LDLR	NR	4E-9
chr19	11202305	11202306	rs6511720	Lipoprotein-associated phospholipase A2 activity and mass	LDLR	.05	3E-11
chr19	11202305	11202306	rs6511720	Cardiovascular disease risk factors	LDLR	.15	5E-11
chr19	11202305	11202306	rs6511720	Carotid intima media thickness	LDLR	.18	1E-7
chr19	11202305	11202306	rs6511720	LDL cholesterol	LDLR	6.99	4E-117
chr19	11202305	11202306	rs6511720	Cholesterol, total	LDLR	7.09	7E-97
chr19	11202305	11202306	rs6511720	LDL cholesterol	LDLR	.26	2E-26
chr19	11202305	11202306	rs6511720	LDL cholesterol	LDLR	.26	2E-51
chr19	11202305	11202306	rs6511720	LDL cholesterol	LDLR	9.17	4E-26
chr19	11210911	11210912	rs2228671	LDL cholesterol	LDLR	.14	4E-14
chr19	11210911	11210912	rs2228671	Cholesterol, total	LDLR	.16	9E-24
chr19	11227325	11227326	rs2738446	Metabolite levels	LDLR	2.95	2E-12
chr19	11238472	11238473	rs2738459	LDL cholesterol	LDLR	.02	7E-6
chr19	11330941	11330942	rs17699030	Bipolar disorder and schizophrenia	NR	1.71	8E-6
chr19	11334294	11334295	rs4804155	Coronary heart disease	DOCK6	.08	5E-6
chr19	11347492	11347493	rs737337	HDL cholesterol	DOCK6,LOC55908	.64	3E-9
chr19	11682494	11682495	rs7253363	Multiple sclerosis (severity)	ACP5	NR	9E-6
chr19	12146369	12146370	rs3745672	Multiple sclerosis	ZNF433	7.39	1E-6
chr19	12225371	12225372	rs17638629	Cognitive performance	CTC-359D24.2	NR	7E-6
chr19	12691184	12691185	rs7247513	Bipolar disorder	NR	NR	2E-6
chr19	12932268	12932269	rs7255045	Mean corpuscular volume	RTBDN	.00	2E-12
chr19	13001546	13001547	rs11085824	Mean corpuscular hemoglobin	GCDH	.00	1E-11
chr19	14351573	14351574	rs4528684	Mortality among heart failure patients	LPHN1	1.42	1E-6
chr19	15677709	15677710	rs1273516	Response to tocilizumab in rheumatoid arthritis	Intergenic	4.26	9E-7
chr19	15724202	15724203	rs3764563	Inflammatory biomarkers	CYP4F8	NR	3E-7
chr19	15990430	15990431	rs2108622	Response to Vitamin E supplementation	CYP4F2, LOC729645	.04	2E-7
chr19	15990430	15990431	rs2108622	Vitamin E levels	CYP4F2	.03	1E-10
chr19	15990430	15990431	rs2108622	Warfarin maintenance dose	CYP4F2	NR	3E-8
chr19	15990430	15990431	rs2108622	Acenocoumarol maintenance dosage	CYP4F2	NR	3E-10
chr19	15990430	15990431	rs2108622	Warfarin maintenance dose	CYP4F2	.21	3E-10
chr19	16185558	16185559	rs8109288	Mean platelet volume	TPM4	8.72	5E-10
chr19	16185558	16185559	rs8109288	Mean platelet volume	TPM4	.26	3E-9
chr19	16185558	16185559	rs8109288	Platelet counts	TPM4	11.95	3E-10
chr19	16185558	16185559	rs8109288	Mean platelet volume	TPM4	.03	1E-11
chr19	16548374	16548375	rs10411936	Multiple sclerosis	EPS15L1	1.16	2E-7
chr19	17118432	17118433	rs11666377	Brain lesion load	CPAMD8	NR	7E-6
chr19	17283302	17283303	rs2279008	Height	MYO9B	.03	3E-8
chr19	17389703	17389704	rs8170	Ovarian cancer	C19orf62,MERIT40	1.12	4E-6
chr19	17389703	17389704	rs8170	Breast cancer	ABHD8,ANKLE1,C19orf62	1.26	2E-9
chr19	17392893	17392894	rs8100241	Breast cancer	NR	1.14	4E-8
chr19	17394123	17394124	rs2363956	Ovarian cancer	ANKLE1	1.10	1E-7
chr19	17590280	17590281	rs11666579	Response to antidepressants	SLC27A1	14.40	3E-6
chr19	17752688	17752689	rs12608932	Amyotrophic lateral sclerosis	UNC13A	1.37	5E-8
chr19	17752688	17752689	rs12608932	Amyotrophic lateral sclerosis	UNC13A	1.25	3E-14
chr19	18304699	18304700	rs874628	Multiple sclerosis	MPV17L2	1.11	1E-8
chr19	18467885	18467886	rs7248363	Bipolar disorder and schizophrenia	NR	1.30	1E-6
chr19	18747604	18747605	rs3764628	Orofacial clefts	Intergenic	1.89	4E-6
chr19	18817902	18817903	rs10423674	Menarche (age at onset)	CRTC1	2.30	6E-9
chr19	19361734	19361735	rs1064395	Bipolar disorder	NCAN	1.17	2E-9
chr19	19407717	19407718	rs10401969	LDL cholesterol	SF4,CILP2	.05	1E-11
chr19	19407717	19407718	rs10401969	Triglycerides	CSPG3,CILP2,PBX4	7.83	2E-29
chr19	19407717	19407718	rs10401969	LDL cholesterol	CSPG3,CILP2,PBX4	3.11	7E-22
chr19	19407717	19407718	rs10401969	Cholesterol, total	CSPG3,CILP2,PBX4	4.74	3E-38
chr19	19407717	19407718	rs10401969	LDL cholesterol	NCAN, CILP2, PBX4	.05	2E-8
chr19	19658471	19658472	rs16996148	Triglycerides	CILP2, PBX4	.10	4E-9
chr19	19658471	19658472	rs16996148	LDL cholesterol	CILP2, PBX4	.10	3E-8
chr19	19658471	19658472	rs16996148	Triglycerides	NCAN,CILP2	6.10	3E-9
chr19	19658471	19658472	rs16996148	LDL cholesterol	NCAN,CILP2	3.32	3E-9
chr19	19662219	19662220	rs17216525	Triglycerides	NCAN,CILP2,PBX4	.11	4E-11
chr19	19789527	19789528	rs2304130	Sphingolipid levels	LPAR2	.80	6E-9
chr19	19789527	19789528	rs2304130	Triglycerides	CILP2,ZNF101	.07	4E-8
chr19	19789527	19789528	rs2304130	Triglycerides	NCAN	.10	3E-6
chr19	19789527	19789528	rs2304130	LDL cholesterol	NCAN	.12	3E-6
chr19	19789527	19789528	rs2304130	Cholesterol, total	NCAN	.15	2E-15
chr19	20036175	20036176	rs10411195	Smoking behavior	ZNF505	.21	6E-6
chr19	21666209	21666210	rs2562456	Pain	LOC400680, ZNF429	NR	2E-10
chr19	21956135	21956136	rs8101143	Capecitabine sensitivity	Intergenic	NR	2E-7
chr19	22359439	22359440	rs412658	Telomere length	ZNF676	.05	1E-8
chr19	22515250	22515251	rs1975174	Telomere length	ZNF676	.05	2E-6
chr19	22614121	22614122	rs931608	Dental caries	ZNF98	NR	1E-6
chr19	22614121	22614122	rs931608	Response to statin therapy (LDL-C)	LOC342994, ZNF98	4.20	3E-7
chr19	22741674	22741675	rs8111998	Corneal structure	Intergenic	1.71	8E-7
chr19	24222785	24222786	rs7260598	Response to taxane treatment (placlitaxel)	ZNF254	NR	6E-6
chr19	24355492	24355493	rs11668609	Response to taxane treatment (docetaxel)	ZNF254	NR	3E-6
chr19	29736341	29736342	rs11083866	Lentiform nucleus volume	Intergenic	114.77	5E-6
chr19	30079603	30079604	rs10403021	Diabetic retinopathy	VSTM2B	1.01	2E-6
chr19	30296852	30296853	rs8102137	Bladder cancer	CCNE1	1.13	2E-11
chr19	30990699	30990700	rs3786800	Myopia (pathological)	ZNF536	NR	3E-12
chr19	31099889	31099890	rs746961	Select biomarker traits	ZNF536	NR	8E-7
chr19	31596777	31596778	rs12459897	Phospholipid levels (plasma)	TSHZ3	.09	8E-7
chr19	31801129	31801130	rs1078373	Cognitive performance	TSHZ3	NR	6E-6
chr19	31911128	31911129	rs11880316	Estradiol levels	Intergenic	.41	4E-6
chr19	32917454	32917455	rs2111504	Bipolar disorder	DPY19L3	1.74	2E-6
chr19	33356890	33356891	rs12460876	Chronic kidney disease	SLC7A9,CCDC123,ECAT8	.01	3E-15
chr19	33364627	33364628	rs8101881	Urinary metabolites	SLC7A9	NR	6E-27
chr19	33453658	33453659	rs4805834	Creatinine levels	SLC7A9	1.00	5E-11
chr19	33532299	33532300	rs10411210	Colorectal cancer	RHPN2	1.15	5E-9
chr19	33713927	33713928	rs8106493	Visceral adipose tissue/subcutaneous adipose tissue ratio	SLC7A10	NR	5E-6
chr19	33713927	33713928	rs8106493	Visceral adipose tissue adjusted for BMI	SLC7A10	NR	1E-6
chr19	33750313	33750314	rs10500264	Inflammatory bowel disease (early onset)	Intergenic	1.21	4E-10
chr19	33757061	33757062	rs736289	Crohn's disease	intergenic	1.06	9E-9
chr19	33893007	33893008	rs3786897	Type 2 diabetes	PEPD	1.10	1E-8
chr19	33899064	33899065	rs731839	Adiponectin levels	PEPD	.03	8E-12
chr19	33906122	33906123	rs4805885	Adiponectin levels	PEPD	.03	2E-8
chr19	33909709	33909710	rs8182584	Fasting insulin-related traits (interaction with BMI)	PEPD	NR	9E-8
chr19	34168272	34168273	rs4805924	Working memory	CHST8	NR	6E-7
chr19	34309531	34309532	rs29941	Body mass index	KCTD15	.06	3E-9
chr19	34309531	34309532	rs29941	Weight	KCTD15, CHST8	3.73	5E-9
chr19	34309531	34309532	rs29941	Body mass index	KCTD15, CHST8	4.18	7E-12
chr19	34322136	34322137	rs11084753	Body mass index	KCTD15	.06	2E-8
chr19	34766587	34766588	rs10407640	Functional MRI	KIAA0355	.31	7E-6
chr19	35555189	35555190	rs4806073	Serum albumin level	HPN, SCN1B	.03	4E-18
chr19	35555189	35555190	rs4806073	Serum albumin level	HPN, SCN1B	.03	3E-15
chr19	35559473	35559474	rs11671010	Serum albumin level	HPN, SCN1B	NR	2E-13
chr19	35973288	35973289	rs6510489	Bipolar disorder	Intergenic	1.92	8E-6
chr19	38325535	38325536	rs16975963	Longevity	AC016582.2	NR	1E-6
chr19	38735612	38735613	rs8102476	Prostate cancer	Intergenic	1.12	2E-11
chr19	38912763	38912764	rs892055	Asperger disorder	ODF3L2	NR	5E-6
chr19	39580736	39580737	rs472265	Type 2 diabetes	FLJ16165	1.39	9E-6
chr19	39731782	39731783	rs12980275	Lipid levels in hepatitis C treatment	IL28B	NR	5E-17
chr19	39738786	39738787	rs12979860	Response to hepatitis C treatment	IL28B	2.00	1E-28
chr19	39743164	39743165	rs8099917	Response to hepatitis C treatment	IL28B	3.00	1E-20
chr19	39743164	39743165	rs8099917	Chronic Hepatitis C infection	IL28B, IL28A, IL29	2.31	6E-9
chr19	39743164	39743165	rs8099917	Response to hepatitis C treatment	IL28A, IL28B	1.98	9E-9
chr19	39743164	39743165	rs8099917	Response to hepatitis C treatment	IL28B	27.10	3E-32
chr19	41224203	41224204	rs28493229	Kawasaki disease	ITPKC	1.52	2E-12
chr19	41281015	41281016	rs2233152	Kawasaki disease	NUMBL,MIA	1.52	4E-10
chr19	41302705	41302706	rs7937	Chronic obstructive pulmonary disease	RAB4B, EGLN2, CYP2A6	1.37	3E-9
chr19	41310570	41310571	rs3733829	Smoking behavior	CYP2A6,EGLN2	.33	1E-8
chr19	41354532	41354533	rs1801272	Smoking behavior	NR	9.40	5E-6
chr19	41358623	41358624	rs4105144	Smoking behavior	CYP2A6,RAB4D	.39	2E-12
chr19	41363764	41363765	rs8102683	Smoking behavior	CYP2A6	2.76	4E-42
chr19	41521637	41521638	rs7260329	Smoking behavior	CYP2B6	.20	6E-6
chr19	41673847	41673848	rs8105815	Prion diseases	NR	1.39	8E-6
chr19	41937094	41937095	rs17318596	Height	ATP5SL	.03	5E-16
chr19	41985586	41985587	rs11672691	Prostate cancer	ATP5SL, CEACAM21	1.11	1E-8
chr19	41985586	41985587	rs11672691	Prostate cancer	ATP5SL, CEACAM21	1.08	2E-12
chr19	42066278	42066279	rs4803480	Schizophrenia	ATP5SL, CEACAM21	NR	1E-7
chr19	42521107	42521108	rs8099939	Bipolar disorder	GRIK5	1.95	2E-6
chr19	44511388	44511389	rs2191566	Acute lymphoblastic leukemia (childhood)	ZNF230	1.52	4E-7
chr19	44614207	44614208	rs2061333	Alzheimer's disease	ZNF224	NR	2E-6
chr19	44888275	44888276	rs4142248	Myopia (pathological)	ZNF285A	NR	3E-15
chr19	44932971	44932972	rs1434579	Tuberculosis	NR	1.46	4E-6
chr19	44970934	44970935	rs644148	Personality dimensions	ZNF180	.15	9E-7
chr19	44970934	44970935	rs644148	Personality dimensions	ZNF180	.14	8E-6
chr19	45146102	45146103	rs7255066	Multiple sclerosis	PVR	1.09	1E-6
chr19	45376283	45376284	rs519113	HDL cholesterol	PVRL2, TOMM40, APOE	.02	8E-11
chr19	45382033	45382034	rs6859	Alzheimer's disease	PVRL2	1.58	5E-7
chr19	45382033	45382034	rs6859	Alzheimer's disease (late onset)	PVRL2	1.41	1E-7
chr19	45382033	45382034	rs6859	Alzheimer's disease	PVRL2, TOMM40, APOE	NR	6E-14
chr19	45392253	45392254	rs6857	Alzheimer's disease (age of onset)	PVRL2	NR	2E-10
chr19	45395265	45395266	rs157580	Alzheimer's disease	APOE	1.69	8E-89
chr19	45395265	45395266	rs157580	Alzheimer's disease biomarkers	TOMM40	NR	1E-6
chr19	45395265	45395266	rs157580	Alzheimer's disease	TOMM40, APOE	NR	1E-40
chr19	45395265	45395266	rs157580	LDL cholesterol	TOMM40, APOE	.11	2E-19
chr19	45395265	45395266	rs157580	HDL cholesterol	TOMM40, APOE	.06	4E-7
chr19	45395265	45395266	rs157580	LDL cholesterol	APO cluster	.11	5E-8
chr19	45395618	45395619	rs2075650	Age-related macular degeneration	TOMM40	1.37	8E-8
chr19	45395618	45395619	rs2075650	Cardiovascular disease risk factors	TOMM40	.12	4E-8
chr19	45395618	45395619	rs2075650	Cardiovascular disease risk factors	TOMM40	.15	2E-14
chr19	45395618	45395619	rs2075650	Alzheimer's disease biomarkers	TOMM40	NR	1E-6
chr19	45395618	45395619	rs2075650	AB1-42	TOMM40	NR	3E-7
chr19	45395618	45395619	rs2075650	Alzheimer's disease (late onset)	APOE,TOMM40	2.94	5E-36
chr19	45395618	45395619	rs2075650	Alzheimer's disease	APOE	2.53	1E-295
chr19	45395618	45395619	rs2075650	Brain imaging	TOMM40	NR	NS
chr19	45395618	45395619	rs2075650	Alzheimer's disease	TOMM40, APOE	NR	3E-11
chr19	45395618	45395619	rs2075650	Alzheimer's disease	APOE	NR	2E-16
chr19	45395618	45395619	rs2075650	Alzheimer's disease	APOE, TOMM40	2.53	2E-157
chr19	45395618	45395619	rs2075650	Cholesterol, total	TOMM40, APOE	.14	3E-19
chr19	45395618	45395619	rs2075650	C-reactive protein	APOE	NR	1E-7
chr19	45396218	45396219	rs157582	Metabolic syndrome	TOMM40, APOE	.10	1E-8
chr19	45403411	45403412	rs1160985	C-reactive protein	TOMM40	.13	4E-13
chr19	45410001	45410002	rs769449	C-reactive protein	APOE	.26	9E-21
chr19	45411940	45411941	rs429358	Alzheimer's disease biomarkers	APOE	NR	1E-6
chr19	45411940	45411941	rs429358	Brain imaging	APOE	NR	NS
chr19	45412078	45412079	rs7412	LDL cholesterol	APOE	12.30	2E-9
chr19	45412078	45412079	rs7412	Response to statin therapy (LDL-C)	APOE	6.20	2E-47
chr19	45412078	45412079	rs7412	Lipid metabolism phenotypes	APOE, APOC1, APOC2	.75	3E-58
chr19	45414450	45414451	rs439401	HDL Cholesterol - Triglycerides (HDLC-TG)	LOC100129500	.24	1E-8
chr19	45414450	45414451	rs439401	Alzheimer's disease biomarkers	LOC100129500	NR	1E-6
chr19	45414450	45414451	rs439401	Triglycerides	APOE,APOC1,APOC2	5.50	1E-30
chr19	45414450	45414451	rs439401	Triglycerides	TOMM40, APOE	.09	2E-9
chr19	45415639	45415640	rs445925	Lipoprotein-associated phospholipase A2 activity and mass	APOC1, APOE	.07	1E-56
chr19	45415639	45415640	rs445925	Apolipoprotein Levels	APOE/APOC1	.23	4E-11
chr19	45415639	45415640	rs445925	Apolipoprotein Levels	APOE, APOC1	.15	2E-14
chr19	45415639	45415640	rs445925	Metabolite levels	APOE, APOEC1, APOEC2	NR	6E-42
chr19	45415639	45415640	rs445925	Carotid intima media thickness	APOC1	1.22	4E-6
chr19	45415639	45415640	rs445925	Carotid intima media thickness	APOC1	.02	2E-8
chr19	45415639	45415640	rs445925	Cardiovascular disease risk factors	APOE	11.96	9E-19
chr19	45422945	45422946	rs4420638	Alzheimer's disease	APOE, TOMM40, APOC1	3.45	8E-149
chr19	45422945	45422946	rs4420638	Cognitive decline	TOMM40, APOE	NR	4E-27
chr19	45422945	45422946	rs4420638	Alzheimer's disease (age of onset)	APOE, TOMM40, APOC1	NR	1E-12
chr19	45422945	45422946	rs4420638	Lipoprotein-associated phospholipase A2 activity and mass	APOC1	.05	5E-30
chr19	45422945	45422946	rs4420638	Longevity	APOC1	NR	2E-16
chr19	45422945	45422946	rs4420638	C-reactive protein	APOC1	.24	9E-139
chr19	45422945	45422946	rs4420638	C-reactive protein	APOE-CI-CII cluster	.14	3E-7
chr19	45422945	45422946	rs4420638	LDL cholesterol	APOE,APOC1,APOC4,APOC2	.06	2E-40
chr19	45422945	45422946	rs4420638	LDL cholesterol	APOE,APOC1,APOC2	7.14	9E-147
chr19	45422945	45422946	rs4420638	HDL cholesterol	APOE,APOC1,APOC2	1.06	4E-21
chr19	45422945	45422946	rs4420638	Cholesterol, total	APOE,APOC1,APOC2	6.83	5E-111
chr19	45422945	45422946	rs4420638	Lipoprotein-associated phospholipase A2 activity and mass	APOC1	8.00	6E-24
chr19	45422945	45422946	rs4420638	C-reactive protein	APOE, APOC1, APOCII	21.80	5E-27
chr19	45422945	45422946	rs4420638	Quantitative traits	TOMM40, APOC2, APOE, APOC4, APOC1	.22	5E-6
chr19	45422945	45422946	rs4420638	Quantitative traits	TOMM40, APOC2, APOE, APOC4, APOC1	.28	3E-7
chr19	45422945	45422946	rs4420638	Quantitative traits	TOMM40, APOC2, APOE, APOC4, APOC1	.28	2E-6
chr19	45422945	45422946	rs4420638	LDL cholesterol	APOE, APOC1, APOC4, APOC2	.29	4E-27
chr19	45422945	45422946	rs4420638	LDL cholesterol	APOE, APOC1, APOC4, APOC2	NR	2E-7
chr19	45422945	45422946	rs4420638	LDL cholesterol	APOC1	.06	1E-20
chr19	45422945	45422946	rs4420638	LDL cholesterol	APOE, APOC1, APOC4, APOC2	.19	1E-60
chr19	45422945	45422946	rs4420638	LDL cholesterol	APOE,APOC1,APOC4	6.61	3E-43
chr19	45422945	45422946	rs4420638	Alzheimer's disease	APOE, APOC1	NR	2E-44
chr19	45422945	45422946	rs4420638	Alzheimer's disease	APOE	NR	1E-39
chr19	45422945	45422946	rs4420638	Alzheimer's disease (late onset)	APOE	4.01	1E-39
chr19	45422945	45422946	rs4420638	Triglycerides	APOE cluster	2.40	3E-13
chr19	45432556	45432557	rs7259004	Sphingolipid levels	APOE-C1, APOE-C2, APOE-C4	.00	5E-10
chr19	45695737	45695738	rs2159324	Quantitative traits	MGC2650, BLOC1S3, XTP7	.21	4E-7
chr19	45695737	45695738	rs2159324	Quantitative traits	MGC2650, BLOC1S3, XTP7	.19	2E-6
chr19	45740770	45740771	rs17356664	Platelet counts	EXOC3L2	2.60	4E-10
chr19	45854918	45854919	rs13181	Lung Cancer (DNA repair capacity)	ERCC2, XPD	NR	9E-7
chr19	46034557	46034558	rs8111589	Depression and alcohol dependence	OPA3	1.64	4E-6
chr19	46172277	46172278	rs11671664	Body mass index	GIPR	.05	7E-14
chr19	46172277	46172278	rs11671664	Body mass index	GIPR, QPCTL	4.22	6E-14
chr19	46182303	46182304	rs10423928	Two-hour glucose challenge	GIPR	.09	3E-12
chr19	46195755	46195756	rs7245708	Subcutaneous adipose tissue	QPTCL, FBXO46, EML2, SNRPD2, GIPR	NR	2E-6
chr19	46195755	46195756	rs7245708	Subcutaneous adipose tissue	QPCTL, FBXO46, EML2, SNRPD2, GIPR	NR	1E-6
chr19	46202171	46202172	rs2287019	Body mass index	QPCTL, GIPR	.15	2E-16
chr19	46307405	46307406	rs8111071	Sudden cardiac arrest	RSHL1	2.01	4E-6
chr19	47207653	47207654	rs11083846	Chronic lymphocytic leukemia	PRKD2,STRN4	1.35	4E-9
chr19	47208480	47208481	rs425105	Type 1 diabetes	Intergenic	1.16	3E-11
chr19	47268372	47268373	rs11668878	Chronic lymphocytic leukemia	NR	1.37	4E-7
chr19	47569002	47569003	rs3810291	Body mass index	TMEM160, ZC3H4	.09	2E-12
chr19	47661492	47661493	rs307896	Multiple sclerosis	SAE1	1.09	5E-7
chr19	48205724	48205725	rs3745760	HIV-1 susceptibility	GLTSCR1	.00	8E-7
chr19	48401892	48401893	rs2637125	Dehydroepiandrosterone sulphate levels	SULT2A1	.09	3E-19
chr19	48522868	48522869	rs3815908	Intelligence	ELSPBP1	NR	3E-8
chr19	48525506	48525507	rs2303690	Intelligence	ELSPBP1	NR	3E-8
chr19	48527581	48527582	rs3936340	Intelligence	ELSPBP1	NR	3E-8
chr19	48527581	48527582	rs3936340	Intelligence	ELSPBP1	6.80	2E-6
chr19	48531215	48531216	rs2560966	Intelligence	ELSPBP1	NR	3E-8
chr19	49206171	49206172	rs516246	Liver enzyme levels (gamma-glutamyl transferase)	FUT2	2.30	8E-10
chr19	49206416	49206417	rs492602	Cholesterol, total	FUT2,FLJ36070	1.27	2E-10
chr19	49206416	49206417	rs492602	Vitamin B12 levels	FUT2	.09	5E-17
chr19	49206602	49206603	rs281377	Liver enzyme levels (alkaline phosphatase)	FUT2	1.80	1E-15
chr19	49206630	49206631	rs1047781	Vitamin B12 levels	FUT2	70.21	4E-36
chr19	49206984	49206985	rs602662	Folate pathway vitamin levels	FUT2	49.77	3E-20
chr19	49208864	49208865	rs504963	Crohn's disease	FUT2	NR	2E-8
chr19	49209009	49209010	rs503279	Metabolic traits	FUT2	.13	4E-20
chr19	49214273	49214274	rs281379	Crohn's disease	FUT2,RASIP1	1.07	7E-12
chr19	49214469	49214470	rs281380	Multiple sclerosis	MAMSTR	1.08	2E-6
chr19	49228271	49228272	rs2287921	Bipolar disorder	SPHK2, SEC1, RPL18, RASIP1, NTN5, MAMSTR, IZUMO1, FUT2, FUT1, FGF21, FAM83E, DBP, CA11	1.10	3E-6
chr19	49228271	49228272	rs2287921	Retinal vascular caliber	RASIP1,IZUMO1,FUT1,FUT2,CA11,FGF21,FLJ36070	2.10	2E-25
chr19	49869050	49869051	rs2303759	Multiple sclerosis	DKKL1	1.11	5E-9
chr19	50000008	50000009	rs2280401	Serum total protein level	RPS11, FCGRT	.05	7E-8
chr19	50000008	50000009	rs2280401	Serum total protein level	RPS11, FCGRT	.02	3E-6
chr19	50000008	50000009	rs2280401	Serum albumin level	RPS11, FCGRT	.01	8E-7
chr19	50000008	50000009	rs2280401	Serum albumin level	RPS11, FCGRT	.01	6E-9
chr19	50000008	50000009	rs2280401	Metabolite levels	RPS11	.03	9E-13
chr19	50223265	50223266	rs3810265	Panic disorder	Intergenic	NR	4E-6
chr19	50721073	50721074	rs4802666	Disc degeneration (lumbar)	MYH14	.13	5E-6
chr19	50926741	50926742	rs3745516	Primary biliary cirrhosis	SPIB	1.38	2E-13
chr19	50926741	50926742	rs3745516	Primary biliary cirrhosis	SPIB	1.46	8E-11
chr19	51349089	51349090	rs266849	Prostate-specific antigen levels	NR	NR	6E-10
chr19	51361756	51361757	rs17632542	Prostate-specific antigen levels	KLK3	39.10	3E-46
chr19	51364622	51364623	rs2735839	Prostate cancer	KLK3	1.20	2E-18
chr19	51726612	51726613	rs3826656	Alzheimer's disease	CD33	NR	6E-6
chr19	51727961	51727962	rs3865444	Alzheimer's disease (late onset)	CD33	1.10	2E-9
chr19	51773801	51773802	rs1878047	Body mass index	NR	.06	5E-6
chr19	52084835	52084836	rs1543922	Response to tocilizumab in rheumatoid arthritis	Intergenic	34.48	3E-7
chr19	52372975	52372976	rs10411161	Breast cancer	ZNF577	1.42	7E-6
chr19	53284134	53284135	rs10404486	Phospholipid levels (plasma)	ZNF600	.80	9E-9
chr19	53384184	53384185	rs6509701	Alzheimer's disease	ZNF320	1.41	5E-6
chr19	53682041	53682042	rs16984547	Asthma	ZNF665	1.43	4E-6
chr19	54604821	54604822	rs10423754	Response to taxane treatment (docetaxel)	OSCAR	NR	9E-6
chr19	54792760	54792761	rs386000	HDL cholesterol	LILRA3,LILRB2	.83	4E-16
chr19	54797847	54797848	rs103294	Prostate cancer	LILRA3	1.28	5E-16
chr19	55526344	55526345	rs1671152	Platelet aggregation	GP6	NR	8E-14
chr19	55819844	55819845	rs1172822	Menarche and menopause (age at onset)	BRSK1	.49	2E-19
chr19	55819844	55819845	rs1172822	Menopause (age at onset)	BRSK1, TMEM224, SUV420H2	.39	6E-11
chr19	55833663	55833664	rs11668344	Menopause (age at onset)	TMEM150B	.42	1E-59
chr19	55879871	55879872	rs1126757	Response to antidepressants	IL11	10.40	3E-6
chr19	56313527	56313528	rs299175	Multiple sclerosis (severity)	NLRP11	NR	4E-6
chr19	56320662	56320663	rs12461110	Menopause (age at onset)	NLRP11	.16	9E-10
chr19	56451048	56451049	rs2043599	Immune reponse to smallpox (secreted IFN-alpha)	NLRP13, NLRP8	NR	5E-7
chr19	57678193	57678194	rs11672517	Dupuytren's disease	DUXA, ZNF264	1.34	7E-14
chr19	57760017	57760018	rs2014572	Hyperactive-impulsive symptoms	LOC390980	NR	7E-6
chr19	58770882	58770883	rs260461	Attention deficit hyperactivity disorder	ZNF544	NR	8E-6
chr1_gl000192_random	119140	119141	rs12149070	Chronic obstructive pulmonary disease-related biomarkers	HYDIN	NR	8E-6
chr2	38937	38938	rs11542478	Information processing speed	FAM110C	.19	9E-6
chr2	112495	112496	rs300774	Suicide attempts in bipolar disorder	Intergenic	1.22	5E-8
chr2	315214	315215	rs4643574	Cognitive performance	AC079779.6	NR	5E-6
chr2	614167	614168	rs2947411	Menarche (age at onset)	TMEM18	2.80	2E-8
chr2	622826	622827	rs2867125	Body mass index	TMEM18	.31	3E-49
chr2	634904	634905	rs6548238	Body mass index	TMEM18	.26	1E-18
chr2	644952	644953	rs7561317	Weight	TMEM18	6.47	2E-18
chr2	644952	644953	rs7561317	Body mass index	TMEM18	6.12	4E-17
chr2	663482	663483	rs12999373	Response to fenofibrate (adiponectin levels)	TMEM18	.14	3E-6
chr2	663482	663483	rs12999373	Uric acid levels	TMEM18	17.65	2E-6
chr2	1777149	1777150	rs6735179	Response to antipsychotic treatment	Intergenic	NR	1E-7
chr2	1925992	1925993	rs2241685	Attention deficit hyperactivity disorder	MYT1L	NR	8E-6
chr2	2519512	2519513	rs10199521	Diabetic retinopathy	MYT1L, LOC7029897	1.46	3E-6
chr2	3841419	3841420	rs11677370	Type 2 diabetes	Intergenic	1.35	3E-6
chr2	4318975	4318976	rs11686135	Pulmonary function decline	Intergenic	.37	4E-6
chr2	5907879	5907880	rs16864170	Chronic kidney disease	SOX11	1.30	2E-7
chr2	6134939	6134940	rs1405262	HIV-1 control	NR	NR	6E-6
chr2	6694518	6694519	rs10495537	Visceral adipose tissue adjusted for BMI	LOC129607	NR	5E-7
chr2	6697087	6697088	rs962528	Visceral fat	LOC129607	NR	8E-6
chr2	7147972	7147973	rs6741819	Response to antipsychotic treatment	RNF144A	NR	2E-7
chr2	8434184	8434185	rs3102947	IgE levels	ID2	.06	2E-7
chr2	8530255	8530256	rs13008689	Longevity	AC011747.3	NR	1E-6
chr2	8949069	8949070	rs7587928	Neutrophil count	KIDINS220	NR	2E-7
chr2	9250037	9250038	rs1109670	Multiple sclerosis	DDEF2	1.38	9E-6
chr2	9721895	9721896	rs6432018	Heart rate variability traits	YWHAQ	NR	8E-7
chr2	9924386	9924387	rs2357266	Self-rated health	Intergenic	.02	4E-6
chr2	11220561	11220562	rs6739054	Cognitive performance	AC062028.1	NR	2E-6
chr2	11510947	11510948	rs6716724	Sudden cardiac arrest	E2F6	1.39	6E-7
chr2	11727506	11727507	rs13394619	Endometriosis	GREB1	1.15	6E-9
chr2	12037178	12037179	rs17605562	Hair morphology	AC096559.2	NR	9E-6
chr2	12037491	12037492	rs4027132	Bipolar disorder	NR	NR	3E-6
chr2	12568995	12568996	rs10929808	Bipolar disorder and schizophrenia	NR	1.37	4E-6
chr2	12640740	12640741	rs1534422	Type 1 diabetes	Intergenic	1.08	2E-6
chr2	12964496	12964497	rs10198628	Pericardial fat	TRIB2	NR	5E-14
chr2	12968899	12968900	rs10180496	Dental caries	TRIB2	NR	1E-7
chr2	14398051	14398052	rs16861531	Response to antidepressant treatment	Intergenic	NR	7E-7
chr2	14801500	14801501	rs7602441	Visceral adipose tissue adjusted for BMI	FAM84A	NR	7E-6
chr2	15664755	15664756	rs7581919	Conduct disorder (case status)	NAG	1.85	8E-6
chr2	15729819	15729820	rs3755132	Wilms tumor	DDX1, MYCN	1.45	1E-14
chr2	15782470	15782471	rs807624	Wilms tumor	DDX1, MYCN	1.33	1E-14
chr2	15863001	15863002	rs6431731	Chronic kidney disease	DDX1	.01	4E-8
chr2	15926167	15926168	rs2544527	Pulmonary function	DDX1	.03	9E-6
chr2	15961598	15961599	rs7586898	Hair morphology	AC113608.1	NR	2E-6
chr2	16715407	16715408	rs4441471	Orofacial clefts	NR	NR	8E-7
chr2	17427584	17427585	rs11889338	Alzheimer's disease	Intergenic	1.55	9E-6
chr2	17609238	17609239	rs12185578	Subcutaneous adipose tissue	RAD51AP2	NR	9E-6
chr2	17775031	17775032	rs4038131	Alzheimer's disease	VSNL1	1.54	6E-7
chr2	17988657	17988658	rs214034	Response to amphetamines	Intergenic	NR	7E-6
chr2	18234445	18234446	rs16984239	Amyotrophic lateral sclerosis	Intergenic	2.10	2E-6
chr2	18243533	18243534	rs4075511	Temperament (bipolar disorder)	Intergenic	.93	3E-6
chr2	18540643	18540644	rs7580332	Amyotrophic lateral sclerosis	Intergenic	1.22	9E-6
chr2	19134747	19134748	rs1876040	Cognitive performance	AC092594.1	NR	6E-8
chr2	19945576	19945577	rs2123536	Coronary heart disease	TTC32, WDR35	1.12	7E-11
chr2	19958495	19958496	rs17564315	Inflammatory biomarkers	Intergenic	NR	7E-7
chr2	19999345	19999346	rs6728440	Inflammatory biomarkers	Intergenic	NR	2E-7
chr2	20261684	20261685	rs7565124	Major depressive disorder	LAPTM4A	NR	2E-6
chr2	20688518	20688519	rs13021401	Systemic sclerosis	RHOB	1.21	3E-6
chr2	20888264	20888265	rs13385191	Prostate cancer	C2orf43	1.15	8E-8
chr2	20903014	20903015	rs4971516	LDL cholesterol	APOB	NR	2E-52
chr2	20903014	20903015	rs4971516	LDL cholesterol	APOB	NR	2E-40
chr2	21100777	21100778	rs7569328	Coronary heart disease	Intergenic	.10	1E-7
chr2	21123351	21123352	rs6711016	Metabolic syndrome	APOB	.08	4E-8
chr2	21198899	21198900	rs11902417	HDL cholesterol	APOB	.02	4E-7
chr2	21204024	21204025	rs6544366	Triglycerides	APOB	.04	2E-7
chr2	21206182	21206183	rs6754295	Triglycerides	APOB	.08	3E-8
chr2	21206182	21206183	rs6754295	HDL cholesterol	APOB	.07	4E-8
chr2	21208210	21208211	rs7557067	Triglycerides	APOB	.08	9E-12
chr2	21225280	21225281	rs1042034	Triglycerides	APOB	5.99	1E-45
chr2	21225280	21225281	rs1042034	HDL cholesterol	APOB	.90	1E-30
chr2	21231591	21231592	rs6413458	Lipoprotein-associated phospholipase A2 activity and mass	APOB	.04	2E-7
chr2	21232194	21232195	rs693	LDL cholesterol	APOB	.10	4E-17
chr2	21232194	21232195	rs693	Cholesterol, total	APOB	.10	9E-23
chr2	21232194	21232195	rs693	LDL cholesterol	APOB	.12	3E-11
chr2	21232194	21232195	rs693	Triglycerides	APOB	.08	2E-7
chr2	21232194	21232195	rs693	LDL cholesterol	APOB	.12	1E-21
chr2	21232194	21232195	rs693	Triglycerides	APOB	NR	7E-7
chr2	21237543	21237544	rs673548	Metabolite levels	APOB	NR	1E-13
chr2	21237543	21237544	rs673548	Metabolic syndrome	APOB	.11	1E-10
chr2	21237543	21237544	rs673548	Metabolic traits	APOB	.08	2E-8
chr2	21243999	21244000	rs10199768	Cardiovascular disease risk factors	APOB	.11	8E-15
chr2	21263899	21263900	rs1367117	LDL cholesterol	APOB	4.05	4E-114
chr2	21263899	21263900	rs1367117	Cholesterol, total	APOB	4.16	4E-96
chr2	21286056	21286057	rs515135	LDL cholesterol	APOB	.04	2E-20
chr2	21286056	21286057	rs515135	LDL cholesterol	APOB	.16	5E-29
chr2	21288320	21288321	rs562338	LDL cholesterol	APOB	.04	1E-9
chr2	21288320	21288321	rs562338	LDL cholesterol	APOB	4.89	6E-22
chr2	21294974	21294975	rs541041	Response to statin therapy	APOB, FLJ21820, GDF7	NR	8E-6
chr2	21389658	21389659	rs4635554	Hypertriglyceridemia	APOB	1.67	2E-7
chr2	21577742	21577743	rs219553	Erectile dysfunction and prostate cancer treatment	APOB	5.56	7E-6
chr2	21840092	21840093	rs1117324	Response to antipsychotic treatment	Intergenic	NR	3E-7
chr2	22297002	22297003	rs7600502	C-reactive protein and white blood cell count	Intergenic	.39	3E-9
chr2	22576099	22576100	rs1605834	Bipolar disorder and schizophrenia	NR	1.32	8E-6
chr2	22736986	22736987	rs17043947	Self-rated health	Intergenic	.07	2E-7
chr2	22822158	22822159	rs13015955	Coronary heart disease	Intergenic	.18	4E-7
chr2	23187503	23187504	rs2681019	Dialysis-related mortality	KLHL29	2.58	8E-8
chr2	23238942	23238943	rs41458646	Alzheimer's disease (late onset)	Intergenic	NR	8E-6
chr2	23414650	23414651	rs1449984	Depression (quantitative trait)	Intergenic	.15	7E-6
chr2	23548613	23548614	rs2577720	F-cell distribution	UBXD4	.82	8E-6
chr2	23898316	23898317	rs4665630	Coronary heart disease	KLHL29	1.21	1E-7
chr2	24247513	24247514	rs7561273	Quantitative traits	ENSG00000173957, UBXD4, FKBP1B, FLJ21945	.22	6E-6
chr2	24521765	24521766	rs6707600	Working memory	ITSN2	NR	3E-6
chr2	24692808	24692809	rs2165738	Type 1 diabetes	Intergenic	1.07	4E-6
chr2	25131315	25131316	rs6545814	Body mass index	ADCY3, DNAJC27	3.26	1E-13
chr2	25158007	25158008	rs713586	Body mass index	RBJ, ADCY3, POMC	.14	6E-22
chr2	25187598	25187599	rs4665736	Height	DNAJC27	.03	7E-16
chr2	25276283	25276284	rs6733301	Height	ADCY3, RBJ, POMC, DNMT3A, DTNB	7.50	8E-7
chr2	25301754	25301755	rs478222	Type 1 diabetes	EFR3B, 3NCOA1, C2orf79, CENPO, ADCY3, DNAJC27, POMC, DNMT3A	1.22	4E-9
chr2	25492466	25492467	rs13428812	Crohn's disease	DNMT3A	1.06	9E-10
chr2	25659243	25659244	rs6746082	Multiple myeloma	DTNB	1.29	4E-7
chr2	25887557	25887558	rs11684202	Coronary heart disease	DTNB	.09	6E-6
chr2	26272601	26272602	rs13388915	Immune response to smallpox vaccine (IL-6)	RAB10	NR	8E-6
chr2	26526418	26526419	rs6753473	Non-small cell lung cancer	GPR113	NR	4E-6
chr2	26782620	26782621	rs1011108	Periodontal microbiota	OTOF, C2Orf70, CIB4	1.79	2E-6
chr2	27152873	27152874	rs1371614	Fasting glucose-related traits (interaction with BMI)	DPYSL5	NR	2E-12
chr2	27598096	27598097	rs4665972	Breast size	GCKR, SLC4A1AP	.08	1E-6
chr2	27715415	27715416	rs2303369	Menopause (age at onset)	FNDC4	.18	2E-12
chr2	27730939	27730940	rs1260326	Lipoprotein-associated phospholipase A2 activity and mass	GCKR	.01	5E-6
chr2	27730939	27730940	rs1260326	Serum total protein level	GCKR, FNDC4	.03	4E-6
chr2	27730939	27730940	rs1260326	Serum total protein level	GCKR, FNDC4	.02	6E-8
chr2	27730939	27730940	rs1260326	Serum albumin level	GCKR-FNDC4	.01	4E-19
chr2	27730939	27730940	rs1260326	Serum albumin level	GCKR, FNDC4	.03	2E-8
chr2	27730939	27730940	rs1260326	Serum albumin level	GCKR, FNDC4	.01	3E-14
chr2	27730939	27730940	rs1260326	Metabolite levels	GCKR	NR	1E-12
chr2	27730939	27730940	rs1260326	Non-albumin protein levels	GCKR	.08	3E-9
chr2	27730939	27730940	rs1260326	Metabolite levels	GCKR	.15	3E-18
chr2	27730939	27730940	rs1260326	Platelet counts	GCKR	2.33	9E-10
chr2	27730939	27730940	rs1260326	Liver enzyme levels (gamma-glutamyl transferase)	C2orf16, GCKR	3.20	4E-13
chr2	27730939	27730940	rs1260326	Cardiovascular disease risk factors	GCKR	.08	2E-8
chr2	27730939	27730940	rs1260326	C-reactive protein	GCKR	.07	5E-40
chr2	27730939	27730940	rs1260326	Triglycerides	GCKR	8.76	6E-133
chr2	27730939	27730940	rs1260326	Cholesterol, total	GCKR	1.91	7E-27
chr2	27730939	27730940	rs1260326	Hypertriglyceridemia	GCKR	1.75	7E-9
chr2	27730939	27730940	rs1260326	Chronic kidney disease	GCKR, IFT172, FNDC4	.01	3E-14
chr2	27730939	27730940	rs1260326	Two-hour glucose challenge	GCKR	.07	3E-10
chr2	27730939	27730940	rs1260326	Metabolic traits	GCKR	.09	4E-10
chr2	27730939	27730940	rs1260326	Triglycerides	GCKR	.12	2E-31
chr2	27730939	27730940	rs1260326	Waist circumference and related phenotypes	GCKR	NR	4E-8
chr2	27741236	27741237	rs780094	Fasting insulin-related traits (interaction with BMI)	GCKR	NR	3E-10
chr2	27741236	27741237	rs780094	Fasting glucose-related traits (interaction with BMI)	GCKR	NR	4E-24
chr2	27741236	27741237	rs780094	Metabolic syndrome	GCKR	.13	6E-20
chr2	27741236	27741237	rs780094	Metabolic traits	GCKR	.10	6E-53
chr2	27741236	27741237	rs780094	Phospholipid levels (plasma)	GCKR	.02	9E-9
chr2	27741236	27741237	rs780094	Fasting insulin-related traits	GCKR	NR	4E-20
chr2	27741236	27741237	rs780094	Fasting insulin-related traits	GCKR	NR	3E-24
chr2	27741236	27741237	rs780094	Fasting glucose-related traits	GCKR	NR	6E-38
chr2	27741236	27741237	rs780094	Fasting glucose-related traits	GCKR	NR	4E-20
chr2	27741236	27741237	rs780094	Fasting glucose-related traits	GCKR	NR	3E-24
chr2	27741236	27741237	rs780094	Uric acid levels	GCKR	.05	1E-9
chr2	27741236	27741237	rs780094	Triglycerides	GCKR	.10	3E-20
chr2	27741236	27741237	rs780094	C-reactive protein	GCKR	.14	7E-15
chr2	27741236	27741237	rs780094	Triglycerides	GCKR	.13	3E-14
chr2	27741236	27741237	rs780094	Triglycerides	GCKR	8.59	6E-32
chr2	27741236	27741237	rs780094	LDL cholesterol	GCKR	NR	5E-7
chr2	27742602	27742603	rs780093	Sex hormone-binding globulin levels	GCKR	.04	9E-11
chr2	27742602	27742603	rs780093	Sex hormone-binding globulin levels	GCKR	.03	7E-8
chr2	27742602	27742603	rs780093	Sex hormone-binding globulin levels	GCKR	.03	2E-16
chr2	27742602	27742603	rs780093	Breast size	SLC4A1AP	.07	5E-6
chr2	27742602	27742603	rs780093	Waist Circumference - Triglycerides (WC-TG)	GCKR	.19	2E-12
chr2	27742602	27742603	rs780093	Triglycerides-Blood Pressure (TG-BP)	GCKR	.18	3E-10
chr2	27742602	27742603	rs780093	Crohn's disease	GCKR	1.15	5E-11
chr2	27742602	27742603	rs780093	Urate levels	GCKR	5.15	4E-17
chr2	27742602	27742603	rs780093	Calcium levels	GCKR,IFT172,FNDC4,C2orf16	.02	7E-6
chr2	27743153	27743154	rs780092	Triglycerides	GCKR	.05	5E-27
chr2	27743153	27743154	rs780092	Metabolite levels	GCKR	.02	5E-18
chr2	27748623	27748624	rs1260333	Triglycerides	GCKR	.05	2E-19
chr2	27801758	27801759	rs1919128	Waist Circumference - Triglycerides (WC-TG)	C2orf16	.18	2E-9
chr2	27815509	27815510	rs13022873	Waist Circumference - Triglycerides (WC-TG)	ZNF512	.17	5E-9
chr2	27840639	27840640	rs4666002	Phospholipid levels (plasma)	GCKR	.00	7E-11
chr2	27851917	27851918	rs3749147	Waist Circumference - Triglycerides (WC-TG)	CCDC121	.18	1E-9
chr2	27907472	27907473	rs17006206	Alzheimer's disease	SLC4A1AP	2.05	2E-6
chr2	27995780	27995781	rs3736594	Fasting glucose-related traits (interaction with BMI)	MRPL33	NR	1E-15
chr2	28646800	28646801	rs6547853	Type 1 diabetes	FOSL2	1.19	8E-7
chr2	29280760	29280761	rs882632	Major depressive disorder	FAM179A, C2orf71	1.34	2E-6
chr2	30445025	30445026	rs7579944	Celiac disease and Rheumatoid arthritis	LBH	NR	1E-8
chr2	30526779	30526780	rs6708166	vWF and FVIII levels	LBH	.17	1E-6
chr2	31314554	31314555	rs1000916	HIV-1 viral setpoint	GALNT14	NR	9E-6
chr2	31464384	31464385	rs649729	Mean platelet volume	EHD3	.01	1E-12
chr2	31464828	31464829	rs647316	Mean platelet volume	EHD3	.01	3E-11
chr2	31474241	31474242	rs597800	Estradiol levels	EHD3	.15	5E-7
chr2	31482299	31482300	rs625132	Platelet counts	EHD3	4.24	9E-14
chr2	32865520	32865521	rs1031261	Hippocampal atrophy	TTC27	NR	2E-6
chr2	33121503	33121504	rs6728021	Immune response to smallpox vaccine (IL-6)	LTBP1	NR	4E-8
chr2	33301946	33301947	rs542631	Immune reponse to smallpox (secreted IFN-alpha)	LTBP1	NR	1E-7
chr2	33361424	33361425	rs6714546	Height	LTBP1	.03	2E-9
chr2	33471191	33471192	rs3769528	Height	LTBP1	.08	8E-8
chr2	33527298	33527299	rs41464348	Height	LTBP1	.37	7E-6
chr2	33701889	33701890	rs13385731	Systemic lupus erythematosus	RASGRP3	1.43	1E-15
chr2	34284851	34284852	rs9308945	Hypertension (young onset)	LOC344371, MYADML, FAM98A, RASGRP3	NR	3E-10
chr2	34284983	34284984	rs6711736	Hypertension (young onset)	LOC344371, MYADML, FAM98A, RASGRP3	NR	3E-10
chr2	34285193	34285194	rs6729869	Hypertension (young onset)	LOC344371, MYADML, FAM98A, RASGRP3	NR	3E-10
chr2	34305256	34305257	rs10495809	Hypertension (young onset)	LOC344371, MYADML, FAM98A, RASGRP3	NR	3E-10
chr2	34480074	34480075	rs6733379	Attention deficit hyperactivity disorder and conduct disorder	Intergenic	NR	4E-6
chr2	34631031	34631032	rs6543833	Ovarian reserve	MYADML	NR	8E-8
chr2	35093292	35093293	rs7600259	Response to amphetamines	Intergenic	NR	1E-6
chr2	35526917	35526918	rs6750486	Conduct disorder (symptom count)	Intergenic	.10	6E-6
chr2	36526435	36526436	rs1863080	Anthropometric traits	CRIM1	.31	8E-6
chr2	36673554	36673555	rs7562790	Ventricular conduction	CRIM1	.39	8E-9
chr2	37248014	37248015	rs17020136	Ventricular conduction	HEATR5B, STRN	.51	2E-9
chr2	37731664	37731665	rs960902	Response to TNF-alpha inhibitors in rheumatoid arthritis	QPCT	NR	8E-6
chr2	37750979	37750980	rs4352210	RR interval (heart rate)	Intergenic	.14	2E-6
chr2	37940541	37940542	rs4670766	Total ventricular volume	CDC42EP3	.01	2E-6
chr2	37960612	37960613	rs17511102	Height	CDC42EP3	.06	2E-18
chr2	37977016	37977017	rs604381	Conduct disorder (interaction)	Intergenic	1.26	8E-6
chr2	38044343	38044344	rs4670779	Bone mineral density (spine)	LOC344382	.07	4E-6
chr2	38277831	38277832	rs6741148	Erectile dysfunction and prostate cancer treatment	FAM82A1	5.20	4E-6
chr2	38916969	38916970	rs6741892	5-HTT brain serotonin transporter levels	GALM	NR	5E-6
chr2	39109557	39109558	rs3099950	Amyotrophic lateral sclerosis	NR	NR	8E-6
chr2	39843196	39843197	rs7587205	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)	AC007246.3	NR	4E-6
chr2	39947720	39947721	rs2716734	Erectile dysfunction and prostate cancer treatment	TMEM178	5.97	2E-6
chr2	39959059	39959060	rs2540226	Personality dimensions	THUMPD2	.13	3E-6
chr2	40396077	40396078	rs404005	HIV-associated dementia	SLC8A1	NR	3E-7
chr2	40757790	40757791	rs13017846	QT interval	SLC8A1	.07	8E-14
chr2	42004996	42004997	rs719593	Conduct disorder (interaction)	Intergenic	2.05	5E-6
chr2	42276920	42276921	rs4952590	Atopy	SGK493	1.92	2E-6
chr2	42981238	42981239	rs930421	Attention deficit hyperactivity disorder	OXER1	NR	6E-6
chr2	42985802	42985803	rs6719977	Hyperactive-impulsive symptoms	OXER1	NR	2E-6
chr2	43325569	43325570	rs6718520	Multiple sclerosis	THADA	1.17	3E-8
chr2	43359060	43359061	rs12466022	Multiple sclerosis	Intergenic	1.11	6E-10
chr2	43540124	43540125	rs7590268	Orofacial clefts	THADA	1.42	1E-8
chr2	43540124	43540125	rs7590268	Orofacial clefts	THADA	1.42	9E-8
chr2	43553948	43553949	rs1465618	Prostate cancer	THADA	1.08	2E-8
chr2	43587503	43587504	rs6732426	Hair morphology	THADA	NR	1E-7
chr2	43638837	43638838	rs13429458	Response to amphetamines	THADA	NR	6E-6
chr2	43638837	43638838	rs13429458	Polycystic ovary syndrome	NR	1.49	4E-13
chr2	43638837	43638838	rs13429458	Polycystic ovary syndrome	ZFP36L2,LOC100129726,THADA	1.49	2E-23
chr2	43687878	43687879	rs17030845	Platelet counts	THADA	3.58	1E-10
chr2	43721507	43721508	rs12478601	Polycystic ovary syndrome	ZFP36L2,LOC100129726,THADA	1.39	3E-23
chr2	43732822	43732823	rs7578597	Type 2 diabetes	THADA	1.15	1E-9
chr2	43806917	43806918	rs10495903	Crohn's disease	THADA	1.14	2E-14
chr2	44065089	44065090	rs6756629	LDL cholesterol	ABCG5	.16	3E-10
chr2	44065089	44065090	rs6756629	Cholesterol, total	ABCG5	.15	2E-11
chr2	44066246	44066247	rs11887534	Gallstones	ABCG8	2.20	1E-14
chr2	44072575	44072576	rs4299376	LDL cholesterol	ABCG5,ABCG8	2.75	2E-47
chr2	44072575	44072576	rs4299376	Cholesterol, total	ABCG5,ABCG8	3.01	4E-45
chr2	44073655	44073656	rs41360247	Phytosterol levels	ABCG8	14.00	6E-25
chr2	44073880	44073881	rs6544713	LDL cholesterol	ABCG8	.15	2E-20
chr2	44074430	44074431	rs4245791	Phytosterol levels	ABCG8	12.00	2E-50
chr2	44662474	44662475	rs13414205	Immune reponse to smallpox (secreted TNF-alpha)	CAMKMT	NR	7E-8
chr2	44768201	44768202	rs2341459	Height	C2orf34	.03	8E-10
chr2	45154907	45154908	rs528301	Alcohol and nictotine co-dependence	SIX3	NR	5E-6
chr2	45188352	45188353	rs895636	Metabolite levels	SIX2, SIX3	.04	1E-12
chr2	45646823	45646824	rs3213787	Glaucoma	SRBD1	2.80	3E-9
chr2	46176961	46176962	rs6751349	QT interval	NR	1.22	8E-6
chr2	46332168	46332169	rs12712969	Pulmonary function decline	Intergenic	.15	7E-6
chr2	46353165	46353166	rs10495928	Hemoglobin	PRKCE	.06	7E-13
chr2	46360906	46360907	rs10168349	Hematocrit	PRKCE	.19	4E-15
chr2	46537603	46537604	rs7579899	Renal cell carcinoma	EPAS1	1.15	2E-9
chr2	46634644	46634645	rs12623288	Hair morphology	AC016912.4	NR	3E-6
chr2	46642248	46642249	rs2346177	Coronary heart disease	Intergenic	.07	2E-6
chr2	46826025	46826026	rs17818399	Height	PIGF, CRIPT	1.13	3E-7
chr2	46921284	46921285	rs12474201	Height	SOCS5	.03	3E-13
chr2	47022542	47022543	rs76351433	Chronic obstructive pulmonary disease	SOCS5	1.45	2E-7
chr2	47229838	47229839	rs17540621	Response to statin therapy	TTC7A,MCFD2,FLJ40172	NR	2E-6
chr2	47240011	47240012	rs10194115	Erectile dysfunction and prostate cancer treatment	TTC7A	9.00	5E-7
chr2	47399063	47399064	rs815815	Dialysis-related mortality	CALM2	1.51	7E-7
chr2	47844504	47844505	rs6544997	Vitiligo	KCNK12	NR	7E-6
chr2	47885475	47885476	rs2969775	Alzheimer's disease	AC079250.1	1.47	2E-6
chr2	48646398	48646399	rs10454142	Sex hormone-binding globulin levels	LHCGR	.02	1E-7
chr2	48978158	48978159	rs13405728	Polycystic ovary syndrome	LHCGR	1.35	4E-9
chr2	48978158	48978159	rs13405728	Polycystic ovary syndrome	GTF2A1L,LHCGR,FSHR	1.41	8E-21
chr2	49177600	49177601	rs7591064	Radiation response	FSHR	NR	5E-6
chr2	49201327	49201328	rs2268363	Erectile dysfunction and prostate cancer treatment	FSHR	7.03	5E-8
chr2	49201611	49201612	rs2268361	Polycystic ovary syndrome	FSHR	1.15	1E-12
chr2	49955496	49955497	rs17039212	Systemic lupus erythematosus	Intergenic	NR	9E-6
chr2	50516017	50516018	rs1356888	Longevity	NRXN1	NR	1E-6
chr2	50731317	50731318	rs6754640	Temperament	NRXN1	.15	1E-6
chr2	50744773	50744774	rs10176705	Personality dimensions	NRXN1	.10	9E-6
chr2	51667738	51667739	rs1206397	Cognitive performance	AC007402.3	NR	3E-7
chr2	51736993	51736994	rs1406428	Response to tocilizumab in rheumatoid arthritis	Intergenic	2.74	2E-7
chr2	52703589	52703590	rs12619788	Economic and political preferences (immigration/crime)	Intergenic	.11	8E-6
chr2	53237319	53237320	rs1160297	Hemostatic factors and hematological phenotypes	Intergenic	NR	1E-6
chr2	53266128	53266129	rs2357013	Hemostatic factors and hematological phenotypes	Intergenic	NR	6E-6
chr2	53782558	53782559	rs13407662	Stroke (ischemic)	Intergenic	1.95	5E-8
chr2	54347749	54347750	rs1559040	Sudden cardiac arrest	ACYP2	1.54	4E-8
chr2	54684556	54684557	rs11898505	Bone mineral density (spine)	SPTBN1	.07	2E-8
chr2	54684556	54684557	rs11898505	Bone mineral density (spine)	SPTBN1	.07	4E-6
chr2	54684556	54684557	rs11898505	Bone mineral density (spine)	SPTBN1	.08	8E-7
chr2	54718180	54718181	rs4557020	Myopia (pathological)	SPTBN1	.12	3E-7
chr2	55081375	55081376	rs12713280	Economic and political preferences	Intergenic	.12	6E-6
chr2	55156629	55156630	rs6726292	Obesity (extreme)	RTN4	1.39	1E-6
chr2	55516322	55516323	rs2589113	Height	CCDC88A	.04	2E-8
chr2	55843412	55843413	rs782590	Metabolic syndrome	SMEK2	.09	4E-8
chr2	56008903	56008904	rs7577894	Amyotrophic lateral sclerosis	EFEMP1	1.41	1E-6
chr2	56089539	56089540	rs1367226	Height	EFEMP1	NR	4E-8
chr2	56096891	56096892	rs3791679	Height	EFEMP1	.07	6E-9
chr2	56096891	56096892	rs3791679	Height	EFEMP1, PNPT1	5.80	6E-11
chr2	56111308	56111309	rs3791675	Height	EFEMP1	.05	3E-35
chr2	56111308	56111309	rs3791675	Height	EFEMP1	.09	3E-7
chr2	56111308	56111309	rs3791675	Height	EFEMP1	.45	4E-6
chr2	56111308	56111309	rs3791675	Height	EFEMP1	.42	2E-9
chr2	56111308	56111309	rs3791675	Height	EFEMP1	.09	2E-12
chr2	56363376	56363377	rs6751715	HIV-1 control	Intergenic	NR	1E-6
chr2	56592082	56592083	rs17268785	Menarche (age at onset)	CCDC85A	3.20	1E-10
chr2	57934054	57934055	rs13026414	Epilepsy (generalized)	Intergenic	1.23	2E-9
chr2	58094872	58094873	rs2717068	Epilepsy (generalized)	Intergenic	1.27	4E-7
chr2	58222927	58222928	rs2312147	Schizophrenia	VRK2	1.09	3E-7
chr2	59036915	59036916	rs6719884	Myasthenia gravis	NR	1.35	3E-6
chr2	59036915	59036916	rs6719884	Myasthenia gravis	NR	1.35	3E-6
chr2	59072968	59072969	rs17552189	Cannabis dependence	Intergenic	1.40	4E-6
chr2	59282590	59282591	rs991964	Uterine fibroids	NR	1.15	9E-6
chr2	59302876	59302877	rs887912	Body mass index	FANCL	.10	2E-12
chr2	59499346	59499347	rs10490113	Breast cancer	Intergenic	NR	5E-6
chr2	60281607	60281608	rs6712720	Monocyte early outgrowth colony forming units	BCL11A	.16	4E-6
chr2	60500143	60500144	rs10202231	Response to antipsychotic treatment	Intergenic	NR	7E-7
chr2	60534198	60534199	rs6545803	Nevirapine-induced rash	Intergenic	NR	6E-6
chr2	60584818	60584819	rs243021	Type 2 diabetes	BCL11A	1.08	3E-15
chr2	60608758	60608759	rs2540917	Mean corpuscular volume	BCL11A	.00	1E-14
chr2	60713234	60713235	rs10189857	F-cell distribution	BCL11A	1.98	2E-16
chr2	60713234	60713235	rs10189857	F-cell distribution	BCL11A	1.07	2E-7
chr2	60714860	60714861	rs6545816	F-cell distribution	BCL11A	1.98	2E-16
chr2	60714860	60714861	rs6545816	F-cell distribution	BCL11A	1.07	2E-7
chr2	60715178	60715179	rs6545817	F-cell distribution	BCL11A	1.98	2E-16
chr2	60715178	60715179	rs6545817	F-cell distribution	BCL11A	1.07	2E-7
chr2	60718042	60718043	rs1427407	F-cell distribution	BCL11A	1.98	2E-16
chr2	60718042	60718043	rs1427407	F-cell distribution	BCL11A	1.07	2E-7
chr2	60718042	60718043	rs1427407	F-cell distribution	BCL11A	13.10	6E-31
chr2	60718346	60718347	rs7599488	F-cell distribution	BCL11A	1.98	2E-16
chr2	60718346	60718347	rs7599488	F-cell distribution	BCL11A	1.07	2E-7
chr2	60719073	60719074	rs1896294	F-cell distribution	BCL11A	1.98	2E-16
chr2	60719073	60719074	rs1896294	F-cell distribution	BCL11A	1.07	2E-7
chr2	60719969	60719970	rs766432	F-cell distribution	BCL11A	1.98	2E-16
chr2	60719969	60719970	rs766432	F-cell distribution	BCL11A	1.07	2E-7
chr2	60719969	60719970	rs766432	Beta thalassemia/hemoglobin E disease	BCL11A	2.80	1E-10
chr2	60720245	60720246	rs11886868	F-cell distribution	BCL11A	1.98	2E-16
chr2	60720245	60720246	rs11886868	F-cell distribution	BCL11A	1.07	2E-7
chr2	60720245	60720246	rs11886868	Fetal hemoglobin levels	BCL11A	.48	7E-35
chr2	60720588	60720589	rs10195871	F-cell distribution	BCL11A	1.98	2E-16
chr2	60720588	60720589	rs10195871	F-cell distribution	BCL11A	1.07	2E-7
chr2	60720756	60720757	rs10172646	F-cell distribution	BCL11A	1.98	2E-16
chr2	60720756	60720757	rs10172646	F-cell distribution	BCL11A	1.07	2E-7
chr2	60720950	60720951	rs4671393	F-cell distribution	BCL11A	1.98	2E-16
chr2	60720950	60720951	rs4671393	F-cell distribution	BCL11A	1.07	2E-7
chr2	60721310	60721311	rs7584113	F-cell distribution	BCL11A	1.98	2E-16
chr2	60721310	60721311	rs7584113	F-cell distribution	BCL11A	1.07	2E-7
chr2	60721346	60721347	rs7557939	F-cell distribution	BCL11A	1.98	2E-16
chr2	60721346	60721347	rs7557939	F-cell distribution	BCL11A	1.07	2E-7
chr2	60722039	60722040	rs6706648	F-cell distribution	BCL11A	1.98	2E-16
chr2	60722039	60722040	rs6706648	F-cell distribution	BCL11A	1.07	2E-7
chr2	60722240	60722241	rs6738440	F-cell distribution	BCL11A	1.98	2E-16
chr2	60722240	60722241	rs6738440	F-cell distribution	BCL11A	1.07	2E-7
chr2	60723265	60723266	rs7565301	F-cell distribution	BCL11A	1.98	2E-16
chr2	60723265	60723266	rs7565301	F-cell distribution	BCL11A	1.07	2E-7
chr2	60723671	60723672	rs6729815	F-cell distribution	BCL11A	1.98	2E-16
chr2	60723671	60723672	rs6729815	F-cell distribution	BCL11A	1.07	2E-7
chr2	60724085	60724086	rs1896295	F-cell distribution	BCL11A	1.98	2E-16
chr2	60724085	60724086	rs1896295	F-cell distribution	BCL11A	1.07	2E-7
chr2	60724086	60724087	rs1896296	F-cell distribution	BCL11A	1.98	2E-16
chr2	60724086	60724087	rs1896296	F-cell distribution	BCL11A	1.07	2E-7
chr2	60725450	60725451	rs7606173	F-cell distribution	BCL11A	1.98	2E-16
chr2	60725450	60725451	rs7606173	F-cell distribution	BCL11A	1.07	2E-7
chr2	60762501	60762502	rs2556378	Attention deficit hyperactivity disorder	BCL11A	NR	7E-6
chr2	61066665	61066666	rs1432295	Hodgkin's lymphoma	REL	1.22	2E-8
chr2	61081541	61081542	rs702873	Psoriatic arthritis	REL	1.20	2E-7
chr2	61081541	61081542	rs702873	Psoriasis	REL	1.12	4E-9
chr2	61091949	61091950	rs842636	Psoriasis	NR	1.15	6E-6
chr2	61136128	61136129	rs13031237	Rheumatoid arthritis	REL	1.13	8E-7
chr2	61164330	61164331	rs13017599	Psoriatic arthritis	REL	1.27	1E-8
chr2	61164330	61164331	rs13017599	Rheumatoid arthritis	REL	1.21	2E-12
chr2	61186828	61186829	rs13003464	Crohn's disease	PUS10, PEX13, REL, KIAA1841, C2orf74, PAPOLG, USP34	1.05	5E-9
chr2	61186828	61186829	rs13003464	Ulcerative colitis	REL,CCDC139,PUS10	1.13	7E-9
chr2	61186828	61186829	rs13003464	Celiac disease	REL, AHSA2	1.15	4E-13
chr2	61204855	61204856	rs7608910	Ulcerative colitis	PUS10	1.19	2E-14
chr2	61217541	61217542	rs10188217	Crohn's disease and celiac disease	PUS10	NR	1E-11
chr2	61224258	61224259	rs10181042	Crohn's disease	C2orf74,REL	1.14	7E-9
chr2	61772256	61772257	rs6545883	Tuberculosis	NR	1.20	5E-6
chr2	62452660	62452661	rs11900673	Rheumatoid arthritis	B3GNT2	1.11	1E-8
chr2	62551471	62551472	rs10865331	Ankylosing spondylitis	Intergenic	NR	7E-34
chr2	62551471	62551472	rs10865331	Ankylosing spondylitis	B3GNT2	1.27	2E-19
chr2	62713532	62713533	rs6545946	Crohn's disease	TMEM17, EHBP1, CPAMD8, AK3	1.16	7E-9
chr2	63131730	63131731	rs721048	Prostate cancer	EHBP1	1.15	8E-9
chr2	63301163	63301164	rs6545977	Prostate cancer	EHBP1	NR	5E-7
chr2	63596835	63596836	rs11683229	Protein quantitative trait loci	LOC51057	NR	6E-6
chr2	64349201	64349202	rs7604693	Kawasaki disease	PELI1	2.70	2E-6
chr2	64495626	64495627	rs1529102	Breast size	RPL23AP37, LOC100128607	.07	6E-6
chr2	65027623	65027624	rs11683197	Visceral fat	SERTAD2	NR	5E-6
chr2	65208073	65208074	rs10211524	Metabolite levels	SLC1A4	NR	3E-10
chr2	65220909	65220910	rs2160387	Metabolite levels	SLC1A4	.17	3E-22
chr2	65595585	65595586	rs934734	Rheumatoid arthritis	SPRED2	1.13	5E-10
chr2	65608908	65608909	rs1876518	Celiac disease and Rheumatoid arthritis	SPRED2	NR	2E-8
chr2	65758524	65758525	rs3845817	Bipolar disorder	Intergenic	1.10	2E-6
chr2	65862377	65862378	rs1457451	Iron status biomarkers	Q6ZNG6	NR	3E-6
chr2	66756975	66756976	rs3891585	PR interval	MEIS1	2.13	1E-11
chr2	66771999	66772000	rs11897119	PR interval	MEIS1	1.36	5E-11
chr2	66781452	66781453	rs2300478	Restless legs syndrome	MEIS1	1.68	3E-49
chr2	66781452	66781453	rs2300478	Restless legs syndrome	MEIS1	1.74	3E-28
chr2	67864674	67864675	rs4141819	Endometriosis	NR	1.15	9E-8
chr2	67942479	67942480	rs724568	Major depressive disorder (broad)	BC043421	1.17	5E-6
chr2	67973886	67973887	rs13432159	Response to antidepressant treatment	Intergenic	NR	9E-8
chr2	67976787	67976788	rs6724422	Response to antidepressant treatment	Intergenic	NR	4E-7
chr2	68070224	68070225	rs6747972	Restless legs syndrome	Intergenic	1.23	9E-11
chr2	68359896	68359897	rs4078978	Immune reponse to smallpox (secreted IFN-alpha)	WDR92	NR	2E-18
chr2	68570771	68570772	rs9309413	Metabolite levels	PLEK	NR	2E-9
chr2	68598954	68598955	rs17035378	Celiac disease	PLEK	1.14	8E-9
chr2	68646782	68646783	rs7592330	Multiple sclerosis	PLEK, FBXO48, C2orf13	1.15	2E-7
chr2	68647094	68647095	rs7595037	Multiple sclerosis	PLEK	1.11	5E-11
chr2	69063908	69063909	rs10496166	RR interval (heart rate)	Intergenic	.18	4E-6
chr2	69198387	69198388	rs4254535	Lung cancer	NR	1.12	5E-6
chr2	69287942	69287943	rs4315565	Height	ANTXR1	.06	1E-8
chr2	69723709	69723710	rs7577851	Parkinson's disease (age of onset)	AAK1	6.85	9E-6
chr2	70736218	70736219	rs454305	Neutrophil count	TGFA	NR	5E-6
chr2	70764687	70764688	rs432203	Longevity	TGFA	NR	1E-6
chr2	71958479	71958480	rs2900976	Protein quantitative trait loci	DYSF	NR	1E-6
chr2	73743981	73743982	rs9309473	Metabolite levels	ALMS1, NAT8, TPRKB, DUSP11	1.10	1E-11
chr2	73818935	73818936	rs13391552	Metabolic traits	NAT8	.37	5E-252
chr2	73868327	73868328	rs13538	Chronic kidney disease	NAT8,NAT8B,ALMS1	.01	5E-14
chr2	73900899	73900900	rs10206899	Creatinine levels	NAT8,NAT8B,ALMS1,DUSP11,TPRKB	1.00	1E-15
chr2	74245776	74245777	rs6546886	Dialysis-related mortality	TET3, DGUOK	2.13	3E-6
chr2	74463565	74463566	rs13006863	Immune reponse to smallpox (secreted TNF-alpha)	SLC4A5	NR	5E-7
chr2	74939175	74939176	rs1137	Myopia (pathological)	SEMA4F	.12	4E-6
chr2	74972080	74972081	rs205611	Iris characteristics	AC007387.1	.12	1E-6
chr2	75074966	75074967	rs681900	Femoral neck bone geometry	HK2	NR	3E-6
chr2	75926564	75926565	rs2298948	Hippocampal atrophy	GCFC2	NR	5E-8
chr2	76240360	76240361	rs436000	Economic and political preferences (fairness)	Intergenic	.13	8E-7
chr2	76375710	76375711	rs10204325	Economic and political preferences (fairness)	Intergenic	.13	1E-7
chr2	76759574	76759575	rs74529274	Response to amphetamines	Intergenic	NR	9E-6
chr2	78075243	78075244	rs7595103	Attention deficit hyperactivity disorder and conduct disorder	Intergenic	NR	7E-6
chr2	79539987	79539988	rs13409348	Bipolar disorder	CTNNA2	1.20	3E-6
chr2	79687251	79687252	rs399885	Response to antipsychotic treatment	Intergenic	NR	5E-7
chr2	79709353	79709354	rs7570469	Response to antipsychotic treatment	Intergenic	NR	6E-7
chr2	79922801	79922802	rs11695685	Protein quantitative trait loci	CTNNA2	NR	5E-7
chr2	81668807	81668808	rs10496265	Aging traits	Intergenic	NR	1E-8
chr2	81751123	81751124	rs10496262	Aging traits	Intergenic	NR	3E-7
chr2	81856525	81856526	rs12615721	Pulmonary function decline	Intergenic	.30	8E-6
chr2	81872921	81872922	rs12052359	Bilirubin levels	AC013262.1	.22	7E-6
chr2	83029468	83029469	rs17022444	Response to antipsychotic therapy (extrapyramidal side effects)	Intergenic	NR	1E-10
chr2	83292564	83292565	rs10496288	Hypertension	Intergenic	NR	2E-9
chr2	83293379	83293380	rs10496289	Hypertension	Intergenic	NR	2E-9
chr2	84245167	84245168	rs13398848	Conduct disorder (case status)	Intergenic	1.59	5E-6
chr2	84246585	84246586	rs1447537	RR interval (heart rate)	Intergenic	.15	4E-6
chr2	84350916	84350917	rs1534238	Response to antipsychotic treatment	Intergenic	NR	3E-6
chr2	85699749	85699750	rs7577642	Protein quantitative trait loci	SH2D6	NR	7E-6
chr2	85794296	85794297	rs10187424	Prostate cancer	GGCX, VAMP8, VAMP5, RNF181	1.09	3E-15
chr2	87044315	87044316	rs6547705	Progressive supranuclear palsy	CD8B	1.28	1E-8
chr2	88166460	88166461	rs9636470	Alcohol and nictotine co-dependence	RGPD2	NR	3E-8
chr2	88315792	88315793	rs12714207	Bilirubin levels	KRCC1	.03	5E-7
chr2	88659587	88659588	rs1659258	Visceral fat	THNSL2	NR	2E-8
chr2	88895350	88895351	rs7571971	Progressive supranuclear palsy	EIF2AK3	1.33	4E-13
chr2	88924621	88924622	rs11684404	Height	EIF2AK3	.03	1E-13
chr2	97228038	97228039	rs4907240	Event-related brain oscillations	ARID5A	.25	4E-6
chr2	97405439	97405440	rs2271893	Bipolar disorder	LMAN2L	NR	2E-10
chr2	97410948	97410949	rs6746896	Bipolar disorder	LMAN2L, FER1L5, CNNM4	1.10	2E-6
chr2	97413487	97413488	rs2314398	Bipolar disorder	Intergenic	1.17	3E-6
chr2	97500799	97500800	rs9948	Erectile dysfunction and prostate cancer treatment	CNNM3	4.90	6E-6
chr2	99083891	99083892	rs12617721	Bipolar disorder (mood-incongruent)	INPP4A	1.20	7E-6
chr2	99239930	99239931	rs12618769	Bipolar disorder	MGAT4A	1.25	1E-6
chr2	99382891	99382892	rs7578035	Bipolar disorder	TXNDC9, TSGA10, REV1, MRPL30, MITD1, MGAT4A, LYG1, LYG2, LIPT1, EIF5B, C2orf55, C2orf15	1.09	3E-6
chr2	99465501	99465502	rs6733011	Bipolar disorder	Intergenic	1.17	3E-6
chr2	100460653	100460654	rs7583877	Type 1 diabetes nephropathy	AFF3	1.29	3E-7
chr2	100460653	100460654	rs7583877	Type 1 diabetes nephropathy	AFF3	1.29	1E-8
chr2	100806939	100806940	rs11676922	Rheumatoid arthritis	AFF3	1.12	1E-14
chr2	100825366	100825367	rs9653442	Type 1 diabetes	AFF3, LOC150577	1.11	5E-6
chr2	100835733	100835734	rs10865035	Rheumatoid arthritis	AFF3	1.12	2E-6
chr2	101424330	101424331	rs7565981	Creutzfeldt-Jakob disease (variant)	NPAS2	2.98	4E-8
chr2	101668856	101668857	rs2278729	Osteoporosis	TBC1D8	.19	1E-7
chr2	101922169	101922170	rs6711606	Pancreatic cancer	RNF149	2.81	4E-6
chr2	102663627	102663628	rs2310173	Ulcerative colitis	IL1R2	1.09	3E-12
chr2	102663627	102663628	rs2310173	Ankylosing spondylitis	IL1R2	1.18	5E-7
chr2	102953616	102953617	rs3771180	Asthma	IL1RL1	NR	2E-15
chr2	102955081	102955082	rs13408661	Asthma	IL1RL1, IL18R1	1.23	1E-9
chr2	102957715	102957716	rs1420101	Eosinophil counts	IL1RL1	6.40	5E-14
chr2	102971199	102971200	rs9807989	Asthma	IL18R1,IL1R1	1.33	6E-8
chr2	102971864	102971865	rs13015714	Atopic dermatitis	IL1RL1, IL18R1, IL18RAP	1.27	8E-18
chr2	102971864	102971865	rs13015714	Celiac disease	IL1RL1,IL18R1,IL18RAP, SLC9A4	1.28	4E-9
chr2	102986221	102986222	rs3771166	Asthma	IL18R1	1.15	3E-9
chr2	103054448	103054449	rs2058660	Crohn's disease	IL18RAP,IL12RL2,IL18R1,IL1RL1	1.19	2E-12
chr2	103070567	103070568	rs917997	Celiac disease	IL18RAP, IL18R1, IL1RL1, IL1RL2	1.19	1E-15
chr2	103091539	103091540	rs17027258	White blood cell types	SLC9A4	.06	7E-6
chr2	103335440	103335441	rs33993717	Response to amphetamines	MFSD9	NR	5E-6
chr2	103770237	103770238	rs6735786	Bone mineral density (hip)	NR	.07	2E-6
chr2	104298540	104298541	rs264943	HIV-1 viral setpoint	Intergenic	NR	7E-6
chr2	104983266	104983267	rs7570682	Bipolar disorder	NR	NR	3E-6
chr2	105158637	105158638	rs17624523	Response to taxane treatment (docetaxel)	POU3F3	NR	8E-6
chr2	105378956	105378957	rs12615966	Pancreatic cancer	LOC284998	3.15	7E-6
chr2	105837597	105837598	rs6712932	Type 2 diabetes	Intergenic	1.52	6E-6
chr2	105897739	105897740	rs1020064	AIDS	TGFBRAP1	2.94	7E-6
chr2	107678487	107678488	rs1357692	Alzheimer's disease	Intergenic	1.16	9E-6
chr2	109635256	109635257	rs4676049	Alzheimer's disease (late onset)	Intergenic	1.76	4E-8
chr2	111599705	111599706	rs4849121	IgA nephropathy	ACOXL	1.15	4E-7
chr2	111707404	111707405	rs3789119	Economic and political preferences (immigration/crime)	ACOXL	.14	4E-6
chr2	111797457	111797458	rs17483466	Chronic lymphocytic leukemia	NR	1.43	5E-9
chr2	111797457	111797458	rs17483466	Chronic lymphocytic leukemia	ACOXL,BCL2L11	1.39	2E-10
chr2	111797530	111797531	rs3789080	Prostate cancer (gene x gene interaction)	ACOXL	1.41	4E-6
chr2	111836537	111836538	rs7578982	White blood cell types	ACOXL	.05	4E-7
chr2	111949326	111949327	rs6738028	Dehydroepiandrosterone sulphate levels	BCL2L11	.04	2E-8
chr2	111989371	111989372	rs6720394	Primary sclerosing cholangitis	BCL2L11	1.29	4E-8
chr2	112003866	112003867	rs2271404	Atopic dermatitis	LOC100505634	1.17	3E-7
chr2	112665200	112665201	rs17174870	Multiple sclerosis	MERTK	1.11	1E-8
chr2	112770769	112770770	rs4374383	Hepatitis C induced liver fibrosis	MERTK	NR	1E-9
chr2	113529182	113529183	rs6542095	Endometriosis	IL1A	1.50	3E-6
chr2	113529239	113529240	rs11677416	Working memory	IL1A	NR	7E-7
chr2	113691403	113691404	rs12467847	Response to amphetamines	Intergenic	NR	5E-6
chr2	113832311	113832312	rs6761276	Protein quantitative trait loci	IL1RN	NR	7E-6
chr2	113841029	113841030	rs6734238	C-reactive protein	IL1F10, IL1RN	.11	9E-10
chr2	113841029	113841030	rs6734238	C-reactive protein	IL1F10	.05	2E-17
chr2	113978939	113978940	rs11123170	Renal function-related traits (BUN)	PAX8	.01	3E-10
chr2	115049817	115049818	rs4513299	Inflammatory biomarkers	Intergenic	NR	4E-6
chr2	116241185	116241186	rs1375144	Bipolar disorder	NR	NR	2E-6
chr2	116655794	116655795	rs272000	Attention deficit hyperactivity disorder	Intergenic	NR	9E-6
chr2	119395690	119395691	rs651477	Multiple sclerosis	EN1	1.38	7E-6
chr2	119845316	119845317	rs17189298	T-tau	Intergenic	NR	3E-7
chr2	120321816	120321817	rs2587695	Attention deficit hyperactivity disorder	MGC33657	NR	3E-7
chr2	120513132	120513133	rs13401620	Breast size	EPB41L5	.10	2E-6
chr2	121089730	121089731	rs17625845	Breast size	INHBB	.13	5E-10
chr2	121195180	121195181	rs7581710	Obesity	INHBB	NR	2E-7
chr2	121245121	121245122	rs4849887	Breast size	INHBB, LOC84931, GLI2	.17	3E-11
chr2	121701288	121701289	rs11122834	Erectile dysfunction and prostate cancer treatment	GLI2	4.93	5E-6
chr2	121812223	121812224	rs4848143	Capecitabine sensitivity	Intergenic	NR	9E-6
chr2	122018762	122018763	rs17006292	Behcet's disease	TFCP2L1	4.17	5E-9
chr2	123126478	123126479	rs10496584	Lentiform nucleus volume	Intergenic	158.69	4E-6
chr2	123127788	123127789	rs2037892	Lentiform nucleus volume	Intergenic	156.70	5E-6
chr2	123136889	123136890	rs1919922	Lentiform nucleus volume	Intergenic	155.52	5E-6
chr2	123141544	123141545	rs4848768	Lentiform nucleus volume	Intergenic	154.60	6E-6
chr2	123225622	123225623	rs17007761	Immune reponse to smallpox (secreted IFN-alpha)	LOC728241	NR	1E-8
chr2	123291021	123291022	rs1527243	Erectile dysfunction and prostate cancer treatment	TSN	6.67	1E-6
chr2	123641610	123641611	rs17367118	Attention deficit hyperactivity disorder	Intergenic	NR	9E-6
chr2	124983055	124983056	rs1170612	Schizophrenia	CNTNAP5	1.37	9E-6
chr2	124983055	124983056	rs1170612	Schizophrenia	CNTNAP5	1.40	6E-6
chr2	124998363	124998364	rs1367248	Tonometry	CNTNAP5	NR	3E-6
chr2	125281909	125281910	rs17727261	Response to antipsychotic treatment	CNTNAP5	10.00	5E-7
chr2	125327949	125327950	rs2901331	Response to statin therapy	CNTNAP5	NR	6E-6
chr2	127330953	127330954	rs1550404	Intelligence	GYPC	7.05	1E-6
chr2	127662896	127662897	rs13418717	Heart failure	LOC339760	1.46	3E-6
chr2	127852020	127852021	rs10207628	Alzheimer's disease	BIN1	1.41	1E-6
chr2	127887984	127887985	rs12989701	Alzheimer's disease (late onset)	BIN1	1.23	3E-10
chr2	127889636	127889637	rs7561528	Alzheimer's disease	BIN1	1.25	6E-11
chr2	127889636	127889637	rs7561528	Alzheimer's disease (late onset)	BIN1	1.17	4E-14
chr2	127894614	127894615	rs744373	Alzheimer's disease	BIN1	1.18	2E-9
chr2	127894614	127894615	rs744373	Alzheimer's disease	BIN1	1.17	3E-14
chr2	127894614	127894615	rs744373	Alzheimer's disease (late onset)	BIN1	1.19	1E-10
chr2	127982644	127982645	rs7567389	Self-rated health	CYP27C1	.03	2E-6
chr2	128176039	128176040	rs1799810	Self-rated health	Intergenic	.02	9E-6
chr2	128177376	128177377	rs1158867	Protein C levels	PROC	.12	4E-36
chr2	129478841	129478842	rs4662834	Bleomycin sensitivity	NR	.08	5E-6
chr2	130468365	130468366	rs10928927	Chronic obstructive pulmonary disease	Intergenic	17.54	3E-7
chr2	133144391	133144392	rs16831128	Conduct disorder (symptom count)	Intergenic	.08	5E-6
chr2	133144391	133144392	rs16831128	Conduct disorder (case status)	Intergenic	1.45	4E-7
chr2	133188105	133188106	rs13420028	Hypertension	GPR39	NR	1E-10
chr2	133189238	133189239	rs10188442	Hypertension	GPR39	NR	1E-10
chr2	133746629	133746630	rs1437898	Multiple sclerosis (age of onset)	FLJ34870	NR	8E-6
chr2	134005568	134005569	rs10496702	Bipolar disorder and schizophrenia	NAP5	1.40	7E-7
chr2	134040518	134040519	rs7577925	Attention deficit hyperactivity disorder	FLJ34870	NR	3E-6
chr2	134363031	134363032	rs7588567	Glaucoma (primary open-angle)	NCKAP5	1.18	4E-7
chr2	134434823	134434824	rs7567288	Height	NCKAP5	.03	2E-12
chr2	134437958	134437959	rs1901440	Response to gemcitabine in pancreatic cancer	Intergenic	34.00	3E-6
chr2	135143286	135143287	rs12467609	Subcutaneous adipose tissue	MGAT5	NR	7E-6
chr2	135539966	135539967	rs6430538	Parkinson's disease	Intergenic	1.15	2E-7
chr2	135592380	135592381	rs6710823	Parkinson's disease	ACMSD	1.10	7E-9
chr2	135803424	135803425	rs4954218	Corneal structure	RAB3GAP1	1.61	1E-9
chr2	135837905	135837906	rs7570971	Cholesterol, total	RAB3GAP1	1.18	1E-8
chr2	136506926	136506927	rs6430585	Corneal structure	UBXD2	1.39	1E-6
chr2	136545298	136545299	rs16832011	Phospholipid levels (plasma)	LCT	.02	3E-7
chr2	136976254	136976255	rs882300	Multiple sclerosis	CXCR4	1.19	1E-7
chr2	136976254	136976255	rs882300	Electrocardiographic traits	Intergenic	NR	3E-7
chr2	137015990	137015991	rs4452212	Telomere length	CXCR4	.05	2E-6
chr2	137338939	137338940	rs934299	Cognitive test performance	Intergenic	NR	9E-6
chr2	137491120	137491121	rs1582861	Subcutaneous adipose tissue	THSD7B	NR	3E-6
chr2	137555223	137555224	rs1427593	Pancreatic cancer	THSD7B	1.49	7E-6
chr2	138142163	138142164	rs13405020	Non-small cell lung cancer	THSD7B	NR	7E-6
chr2	139671954	139671955	rs9636231	Alcohol dependence	NXPH2	NR	8E-6
chr2	140147831	140147832	rs1399645	Male infertility	NXPH2	NR	9E-7
chr2	141362057	141362058	rs491391	Optic disc size (disc)	LRP1B	.41	3E-7
chr2	141721141	141721142	rs12474609	Aging	LRP1B	NR	6E-9
chr2	141795619	141795620	rs10210358	Erectile dysfunction and prostate cancer treatment	LRP1B	5.34	2E-6
chr2	142228508	142228509	rs12472911	Menarche (age at onset)	LRP1B	2.50	2E-7
chr2	142959930	142959931	rs2890652	Body mass index	LRP1B	.09	1E-10
chr2	144428607	144428608	rs10928195	Quantitative traits	ARHGAP15	.36	4E-6
chr2	145359908	145359909	rs10496964	Epilepsy (generalized)	ZEB2	1.47	9E-9
chr2	146125522	146125523	rs10427255	Common traits (Other)	Intergenic	1.32	1E-11
chr2	147372023	147372024	rs10928302	HIV-1 control	Intergenic	NR	8E-6
chr2	148478335	148478336	rs7584099	Response to statin therapy	ACVR2A, ORC4L, LOC647065	NR	5E-7
chr2	149387967	149387968	rs10191411	Protein quantitative trait loci	EPC2	NR	4E-6
chr2	149557859	149557860	rs2121433	Alzheimer's disease biomarkers	EPC2	NR	1E-6
chr2	149568395	149568396	rs4499362	Alzheimer's disease biomarkers	EPC2	NR	1E-6
chr2	150147277	150147278	rs10432496	Immune reponse to smallpox (secreted IL-2)	LOC100129594	NR	6E-8
chr2	150397217	150397218	rs7578361	Acute lymphoblastic leukemia (childhood)	Intergenic	1.40	8E-6
chr2	150457623	150457624	rs10170236	Acute lymphoblastic leukemia (childhood)	LOC642340	1.45	4E-6
chr2	150697147	150697148	rs11889862	Menopause (age at onset)	NR	.36	2E-6
chr2	151126402	151126403	rs6716455	Alcoholism (alcohol use disorder factor score)	Intergenic	.12	7E-7
chr2	151126402	151126403	rs6716455	Alcoholism (alcohol dependence factor score)	Intergenic	.11	9E-6
chr2	151637935	151637936	rs7560163	Type 2 diabetes	RBM43, RND3	1.33	7E-9
chr2	151725791	151725792	rs10195263	Immune reponse to smallpox (secreted IFN-alpha)	LOC344332	NR	3E-8
chr2	152253917	152253918	rs10197940	Lung cancer	TNFAIP6, RIF1	1.12	5E-6
chr2	155070566	155070567	rs958672	Aging traits	GALNT13	NR	2E-6
chr2	155226676	155226677	rs707040	Sudden cardiac arrest	Intergenic	1.17	6E-6
chr2	155226676	155226677	rs707040	Sudden cardiac arrest	Intergenic	1.17	6E-6
chr2	156888499	156888500	rs1918172	Attention deficit hyperactivity disorder	Intergenic	NR	5E-6
chr2	156925285	156925286	rs16839962	Response to statin therapy	NR4A2, GPD2, LOC728038	NR	9E-6
chr2	157096775	157096776	rs17188434	Menarche (age at onset)	NR4A2	4.50	1E-9
chr2	157552859	157552860	rs7601713	QT interval	Intergenic	.16	2E-6
chr2	158780203	158780204	rs10183640	Sudden cardiac arrest	Intergenic	1.12	5E-7
chr2	158977793	158977794	rs2074955	P-tau181p	UPP2	NR	1E-7
chr2	160069755	160069756	rs13022357	Sudden cardiac arrest	Intergenic	1.72	1E-6
chr2	160190208	160190209	rs4665058	Sudden cardiac arrest	BAZ2B	1.92	2E-10
chr2	160917496	160917497	rs4664308	Nephropathy (idiopathic membranous)	PLA2R1,LY75,ITGB6,RBMS1	2.28	9E-29
chr2	161171453	161171454	rs7593730	Type 2 diabetes	RBMS1,  ITGB6	1.11	4E-8
chr2	161380887	161380888	rs10192369	Amyotrophic lateral sclerosis	RBMS1	1.17	9E-6
chr2	161781772	161781773	rs1722636	Subcutaneous adipose tissue	TANK	NR	6E-7
chr2	161785168	161785169	rs1829975	Treatment response for severe sepsis	TANK	NR	6E-6
chr2	162910222	162910223	rs6741949	Hippocampal volume	DPP4	52.80	3E-7
chr2	162959747	162959748	rs2270447	Common traits (Other)	NR	NR	8E-7
chr2	163110535	163110536	rs2111485	Vitiligo	IFIH1	1.30	5E-15
chr2	163124050	163124051	rs1990760	Type 1 diabetes autoantibodies	IFIH1	1.20	2E-14
chr2	163124050	163124051	rs1990760	Immunoglobulin A	IFIH1	1.49	7E-10
chr2	163124050	163124051	rs1990760	Type 1 diabetes	IFIH1	NR	7E-9
chr2	163124050	163124051	rs1990760	Type 1 diabetes	IFIH1	1.18	2E-11
chr2	163260690	163260691	rs17716942	Psoriasis	IFIH1	1.29	1E-13
chr2	163781786	163781787	rs1424760	Phospholipid levels (plasma)	KCNH7	.70	4E-8
chr2	164317875	164317876	rs12476047	Response to antipsychotic treatment	FIGN	3.21	3E-6
chr2	164906819	164906820	rs16849225	Blood pressure	FIGN, GRB14	.75	4E-11
chr2	164915207	164915208	rs13002573	Blood pressure	FIGN	.31	2E-8
chr2	164963485	164963486	rs1446468	Blood pressure	FIGN	.34	6E-12
chr2	165501848	165501849	rs3923113	Type 2 diabetes	GRB14	1.09	1E-8
chr2	165513090	165513091	rs10195252	Waist-hip ratio	GRB14	.05	4E-34
chr2	165513090	165513091	rs10195252	Triglycerides	COBLL1	2.01	2E-10
chr2	165540799	165540800	rs12328675	HDL cholesterol	COBLL1	.68	3E-10
chr2	165551200	165551201	rs7607980	Fasting insulin-related traits (interaction with BMI)	COBLL1, GRB14	NR	4E-20
chr2	165577163	165577164	rs10221833	Response to statin therapy	COBLL1, LOC728184, GRB14	NR	6E-6
chr2	165750389	165750390	rs13424957	Coronary heart disease	Intergenic	1.24	3E-6
chr2	165890732	165890733	rs776488	Common traits (Other)	NR	NR	2E-7
chr2	166583243	166583244	rs6710518	Bone mineral density	GALNT3	.06	5E-10
chr2	166704293	166704294	rs5001812	Response to fenofibrate	NR	4.67	2E-7
chr2	166942139	166942140	rs11904006	Response to amphetamines	Intergenic	NR	6E-6
chr2	166943276	166943277	rs11890028	Epilepsy (generalized)	SCN1A	1.18	4E-6
chr2	167377977	167377978	rs13015447	Amyotrophic lateral sclerosis	SCN7A	1.41	7E-6
chr2	169041385	169041386	rs6749447	Blood pressure	STK39	1.90	2E-7
chr2	169117024	169117025	rs2102808	Parkinson's disease	STK39	1.18	4E-10
chr2	169143034	169143035	rs9917256	Parkinson's disease	Intergenic	1.19	3E-6
chr2	169389090	169389091	rs13393173	Response to TNF antagonist treatment	LASS6	NR	4E-6
chr2	169757353	169757354	rs1402837	Glycated hemoglobin levels	G6PC2	.02	5E-10
chr2	169763147	169763148	rs560887	Metabolite levels	G6PC2	NR	4E-15
chr2	169763147	169763148	rs560887	Fasting glucose-related traits (interaction with BMI)	G6PC2	NR	2E-113
chr2	169763147	169763148	rs560887	Fasting plasma glucose	G6PC2	1.29	2E-6
chr2	169763147	169763148	rs560887	Metabolic syndrome	G6PC2	.15	5E-26
chr2	169763147	169763148	rs560887	Metabolite levels	G6PC2	.15	2E-17
chr2	169763147	169763148	rs560887	Fasting glucose-related traits	G6PC2	NR	9E-218
chr2	169763147	169763148	rs560887	Fasting glucose-related traits	G6PC2	NR	2E-66
chr2	169763147	169763148	rs560887	Metabolic traits	G6PC2, ABCB11	.06	6E-10
chr2	169763147	169763148	rs560887	Fasting plasma glucose	G6PC2	.06	1E-57
chr2	169763147	169763148	rs560887	Fasting plasma glucose	G6PC2	.06	4E-23
chr2	169774070	169774071	rs563694	Fasting plasma glucose	G6PC2,ABCB11	NR	4E-7
chr2	169782879	169782880	rs569805	Metabolic syndrome (bivariate traits)	ABCB11	.16	9E-8
chr2	169784412	169784413	rs16856247	Metabolite levels	ABCB11	.06	2E-15
chr2	169791437	169791438	rs552976	Glycated hemoglobin levels	G6PC2,ABCB11	.05	8E-18
chr2	169840573	169840574	rs16856332	Liver enzyme levels (alkaline phosphatase)	ABCB11	3.90	2E-9
chr2	170133085	170133086	rs830998	Anorexia nervosa	LRP2	NR	9E-6
chr2	171365888	171365889	rs10176755	Visceral fat	MYO3B	NR	7E-6
chr2	171540822	171540823	rs2080401	Coronary heart disease	Intergenic	.72	7E-6
chr2	171733224	171733225	rs4668338	Uric acid levels	NR	4.29	3E-6
chr2	171822465	171822466	rs4668356	Cognitive performance	GORASP2	NR	1E-6
chr2	171990970	171990971	rs10183486	Menopause (age at onset)	TLK1	.20	2E-14
chr2	172127919	172127920	rs4667682	Hippocampal atrophy	METTL8	NR	5E-6
chr2	173311552	173311553	rs12621278	Prostate cancer	ITGA6	1.33	9E-23
chr2	173493077	173493078	rs836589	Erectile dysfunction	PDK1	NR	2E-6
chr2	174362348	174362349	rs7590983	Anthropometric traits	Intergenic	.46	6E-6
chr2	176239848	176239849	rs4972755	Bipolar disorder and major depressive disorder (combined)	Intergenic	NR	3E-6
chr2	176289318	176289319	rs2461751	Electrocardiographic conduction measures	Intergenic	4.54	8E-6
chr2	176654737	176654738	rs7566934	Information processing speed	EXTL2P1	.13	7E-6
chr2	176717740	176717741	rs9287989	Periodontal microbiota	KIAA1715, EVX2, EXTLP2	1.80	4E-6
chr2	176991778	176991779	rs2592394	Magnesium levels	HOXD9	.00	5E-7
chr2	177042632	177042633	rs2072590	Ovarian cancer	HOXD1,HOXD3	1.16	5E-14
chr2	177909594	177909595	rs1529093	Non-alcoholic fatty liver disease histology (other)	Intergenic	4.13	2E-6
chr2	178684719	178684720	rs7567851	Height	PDE11A	.04	3E-8
chr2	179104297	179104298	rs34479159	Breast size	TTN	.09	6E-6
chr2	179248419	179248420	rs7580640	QT interval	NR	3.64	3E-6
chr2	179641974	179641975	rs12476289	QT interval	TTN	.29	2E-6
chr2	180566677	180566678	rs16866933	Sudden cardiac arrest	ZNF385B	1.69	6E-14
chr2	181041285	181041286	rs16867225	Prostate cancer (gene x gene interaction)	CWC22	1.56	3E-6
chr2	181362378	181362379	rs16867321	Obesity	UBE2E3	NR	2E-6
chr2	181513728	181513729	rs918959	Systemic lupus erythematosus	Intergenic	1.72	2E-6
chr2	181996044	181996045	rs13010713	Celiac disease	ITGA4, UBE2E3	1.13	5E-11
chr2	182007799	182007800	rs1018326	Ankylosing spondylitis	NR	1.24	2E-6
chr2	182261868	182261869	rs7602460	Atrioventricular conduction	Intergenic	2.42	6E-6
chr2	182323664	182323665	rs12988934	White blood cell types	ITGA4	.11	2E-14
chr2	182455993	182455994	rs993648	Response to iloperidone treatment (QT prolongation)	CERKL	NR	3E-6
chr2	185778427	185778428	rs1344706	Schizophrenia	ZNF804A	1.12	2E-7
chr2	188196468	188196469	rs840616	Coronary heart disease	Intergenic	NR	7E-7
chr2	188343496	188343497	rs7586970	Coronary heart disease	Intergenic	NR	9E-6
chr2	190678544	190678545	rs5743030	Subcutaneous adipose tissue	PMS1	NR	5E-6
chr2	190985679	190985680	rs13034723	Body mass index	KLF9	.07	2E-8
chr2	191538561	191538562	rs10931468	Primary biliary cirrhosis	STAT4	1.50	2E-19
chr2	191902757	191902758	rs3821236	Systemic sclerosis	STAT4	1.31	9E-8
chr2	191902757	191902758	rs3821236	Systemic sclerosis	STAT4	1.30	3E-9
chr2	191902757	191902758	rs3821236	Systemic lupus erythematosus	STAT4	1.49	8E-11
chr2	191964632	191964633	rs7574865	Systemic lupus erythematosus	STAT4	1.48	4E-14
chr2	191964632	191964633	rs7574865	Primary biliary cirrhosis	STAT4	1.35	1E-6
chr2	191964632	191964633	rs7574865	Systemic sclerosis	STAT4	1.38	2E-13
chr2	191964632	191964633	rs7574865	Systemic lupus erythematosus	STAT4	1.41	8E-6
chr2	191964632	191964633	rs7574865	Systemic lupus erythematosus	STAT4	1.77	2E-20
chr2	191964632	191964633	rs7574865	Celiac disease and Rheumatoid arthritis	STAT4	NR	4E-10
chr2	191964632	191964633	rs7574865	Rheumatoid arthritis	STAT4	1.16	3E-7
chr2	191964632	191964633	rs7574865	Rheumatoid arthritis	STAT4	1.17	2E-6
chr2	191964632	191964633	rs7574865	Systemic lupus erythematosus	STAT4	1.51	5E-42
chr2	191964632	191964633	rs7574865	Systemic lupus erythematosus	STAT4	NR	9E-14
chr2	192010487	192010488	rs7574070	Behcet's disease	STAT4	1.44	4E-8
chr2	192015071	192015072	rs7572482	Behcet's disease	STAT4	1.44	4E-8
chr2	192017770	192017771	rs897200	Behcet's disease	STAT4	1.44	4E-8
chr2	192017770	192017771	rs897200	Behcet's disease	STAT4	1.45	6E-9
chr2	192117237	192117238	rs13030978	Liver enzyme levels (gamma-glutamyl transferase)	MYO1B, STAT4	3.70	1E-11
chr2	192914361	192914362	rs10497721	Diabetes (incident)	TMEFF2	NR	7E-7
chr2	192955504	192955505	rs13007495	Sudden cardiac arrest	TMEFF2	1.47	4E-6
chr2	193333902	193333903	rs1385351	HIV-1 control	Intergenic	NR	4E-6
chr2	193984620	193984621	rs17662626	Schizophrenia	PCGEM1	1.20	5E-8
chr2	194872182	194872183	rs2176528	Bipolar disorder	Intergenic	1.12	4E-6
chr2	195871818	195871819	rs10172965	Temperament	SLC39A10	.30	6E-6
chr2	198631713	198631714	rs700651	Intracranial aneurysm	BOLL, PLCL1	1.24	4E-8
chr2	198896894	198896895	rs6738825	Crohn's disease	PLCL1	1.06	4E-9
chr2	198962242	198962243	rs7595412	Hip bone size	PLCL1	5.00	2E-6
chr2	198987934	198987935	rs988583	Neutrophil count	PLCL1	NR	6E-6
chr2	199169095	199169096	rs13398206	Prostate cancer (gene x gene interaction)	PLCL1	1.24	4E-6
chr2	199632564	199632565	rs12617311	Menarche (age at onset)	PLCL1	3.00	6E-13
chr2	199679109	199679110	rs10189905	Corneal astigmatism	Intergenic	1.32	6E-7
chr2	200290358	200290359	rs1992950	Ulcerative colitis	SATB2	1.10	5E-6
chr2	200676925	200676926	rs7605378	Osteoporosis	LOC348751, FONG	1.25	2E-8
chr2	201021953	201021954	rs1569175	Response to treatment for acute lymphoblastic leukemia	C2orf47	2.73	9E-7
chr2	201150039	201150040	rs295137	Asthma (bronchodilator response)	SPATS2L	NR	1E-6
chr2	201158121	201158122	rs12612420	Exercise (leisure time)	DNAPTP6	1.43	8E-6
chr2	201571142	201571143	rs2540051	Intelligence	AOX1	NR	6E-8
chr2	201576283	201576284	rs7563911	Intelligence	AOX1	NR	6E-8
chr2	201580953	201580954	rs7589014	Intelligence	AOX1	NR	6E-8
chr2	201582192	201582193	rs2348114	Intelligence	AOX1	NR	6E-8
chr2	201648638	201648639	rs13430864	Response to citalopram treatment	AOX2P	NR	5E-7
chr2	202162810	202162811	rs13016963	Melanoma	CASP8	1.14	9E-10
chr2	202807195	202807196	rs17385675	Response to antipsychotic treatment	Intergenic	NR	3E-6
chr2	202859616	202859617	rs6754521	Response to amphetamines	Intergenic	NR	5E-6
chr2	202949850	202949851	rs1521882	Attention deficit hyperactivity disorder and conduct disorder	FLJ39061, FZD7	NR	8E-6
chr2	203745884	203745885	rs6725887	Coronary heart disease	WDR12	1.14	1E-9
chr2	203745884	203745885	rs6725887	Myocardial infarction (early onset)	WDR12	1.17	1E-8
chr2	204165170	204165171	rs11888559	Height	CYP20A1	1.05	2E-6
chr2	204249398	204249399	rs11675251	Butyrylcholinesterase levels	ABI2	.15	4E-18
chr2	204272089	204272090	rs1376877	Subclinical atherosclerosis traits (other)	ABI2	NR	4E-7
chr2	204693875	204693876	rs231735	Rheumatoid arthritis	CTLA4	1.17	6E-9
chr2	204721751	204721752	rs1024161	Graves' disease	CD28, CTLA4	1.30	2E-17
chr2	204721751	204721752	rs1024161	Alopecia areata	CTLA4,ICOS	1.44	4E-13
chr2	204734486	204734487	rs231779	Hypothyroidism	CTLA4	1.13	7E-6
chr2	204738918	204738919	rs3087243	Type 1 diabetes autoantibodies	CTLA4	1.20	2E-17
chr2	204738918	204738919	rs3087243	Rheumatoid arthritis	CTLA4	1.15	1E-8
chr2	204738918	204738919	rs3087243	Type 1 diabetes	CTLA4	NR	1E-15
chr2	204738918	204738919	rs3087243	Type 1 diabetes	CTLA4	NR	8E-11
chr2	204802577	204802578	rs4675374	Celiac disease	CTLA4, ICOS, CD28	1.14	6E-9
chr2	205128020	205128021	rs6738181	Alzheimer's disease (late onset)	Intergenic	NR	5E-6
chr2	205864831	205864832	rs2335704	Tuberculosis	Intergenic	1.19	2E-6
chr2	206086170	206086171	rs4675502	Autism	PARD3B	1.28	4E-7
chr2	206150593	206150594	rs1207421	Knee osteoarthritis	PARD3B	1.46	6E-6
chr2	206318592	206318593	rs11884476	AIDS progression	PARD3B	3.32	3E-9
chr2	206836611	206836612	rs7603514	Obesity (extreme)	FLJ20309	1.36	8E-6
chr2	207121781	207121782	rs2058710	Bipolar disorder and schizophrenia	ZDBF2, GPR1, ADAM23	1.24	9E-6
chr2	207634235	207634236	rs2277912	Height	FASTKD2	1.07	5E-6
chr2	207840331	207840332	rs4675644	Pulmonary function decline	Intergenic	.18	9E-6
chr2	207877464	207877465	rs1453160	Subcutaneous adipose tissue	CPO	NR	4E-6
chr2	208994044	208994045	rs2242073	Attention deficit hyperactivity disorder	CRYGC	NR	8E-6
chr2	209578599	209578600	rs13383928	Lung cancer-asbestos exposure interaction	PTHR2	NR	2E-6
chr2	211060049	211060050	rs2286963	Metabolite levels	ACADL	13.80	3E-60
chr2	211569721	211569722	rs2371030	Non-small cell lung cancer	CPS1	NR	3E-6
chr2	211616893	211616894	rs2216405	Metabolic traits	CPS1	.12	2E-27
chr2	213168767	213168768	rs7588550	Type 1 diabetes nephropathy	ERBB4	1.52	2E-7
chr2	213296862	213296863	rs13393577	Breast cancer	ERBB4	1.53	9E-14
chr2	213824044	213824045	rs12619285	Eosinophil counts	IKZF2	6.30	5E-10
chr2	215635793	215635794	rs3768716	Neuroblastoma	BARD1	1.39	5E-13
chr2	215653886	215653887	rs7587476	Neuroblastoma	BARD1	1.37	4E-14
chr2	215672545	215672546	rs6435862	Neuroblastoma (high-risk)	BARD1	1.68	9E-18
chr2	216285374	216285375	rs17458018	Coronary heart disease	FN	1.22	7E-6
chr2	216893636	216893637	rs1344694	Alcohol dependence	NR	1.27	5E-6
chr2	216898657	216898658	rs7590720	Alcohol dependence	PECR	1.35	1E-8
chr2	217208570	217208571	rs6756590	Migraine	MARCH4	1.14	1E-6
chr2	217481270	217481271	rs9288520	Esophageal cancer  (alcohol interaction)	IGFB2	1.33	4E-11
chr2	217554212	217554213	rs2241193	Visceral fat	IGFBP5	NR	1E-7
chr2	217878208	217878209	rs6435957	Primary tooth development (number of teeth)	Intergenic	.37	4E-7
chr2	217894755	217894756	rs4491709	Permanent tooth development	TNP1	.10	2E-14
chr2	217905831	217905832	rs13387042	Breast cancer	Intergenic	1.16	2E-10
chr2	217905831	217905832	rs13387042	Breast cancer	Intergenic	1.18	9E-6
chr2	217905831	217905832	rs13387042	Breast cancer	Intergenic	1.21	2E-10
chr2	217905831	217905832	rs13387042	Breast cancer	Intergenic	1.25	2E-8
chr2	217905831	217905832	rs13387042	Breast cancer	Intergenic	1.20	1E-13
chr2	218123647	218123648	rs2553026	Height	Intergenic	.06	6E-8
chr2	218271897	218271898	rs1351164	Height	TNS1	.03	2E-14
chr2	218310339	218310340	rs966423	Thyroid cancer	DIRC3	1.34	1E-9
chr2	218523161	218523162	rs6435999	Height	Intergenic	.04	7E-7
chr2	218683153	218683154	rs2571445	Pulmonary function	TNS1	.07	1E-12
chr2	218729864	218729865	rs3791950	Height	TNS1	.06	2E-6
chr2	219010145	219010146	rs11676348	Ulcerative colitis	IL8RA, SLC11A1, IL8RB, AAMP, ARPC	1.07	1E-10
chr2	219279096	219279097	rs7607369	Amyotrophic lateral sclerosis	Intergenic	1.15	7E-6
chr2	219514758	219514759	rs10187066	Height	IHH	NR	2E-7
chr2	219545308	219545309	rs2303565	Amyotrophic lateral sclerosis	STK36, TTLL4, ZNF142	1.17	6E-7
chr2	219756382	219756383	rs7349332	Common traits (Other)	WNT10A	.19	3E-14
chr2	219756382	219756383	rs7349332	Hair morphology	WNT10A	NR	1E-6
chr2	219840890	219840891	rs359965	Immune response to smallpox vaccine (IL-6)	FEV, LOC151300	NR	2E-6
chr2	219908368	219908369	rs12470505	Height	CCDC108/IHH	.04	9E-12
chr2	219934347	219934348	rs1052483	Height	IHH, CRYBA2, FEV, SLC23A3, TUBA1	6.90	1E-6
chr2	219943845	219943846	rs6724465	Height	IHH	.06	2E-8
chr2	219949183	219949184	rs16859517	Height	IHH	.05	5E-6
chr2	220668737	220668738	rs3815854	Orofacial clefts	NR	NR	7E-6
chr2	221720087	221720088	rs10932886	Brain imaging	EPHA4	NR	E
chr2	221899443	221899444	rs10498091	Echocardiographic traits	Intergenic	NR	6E-6
chr2	222801698	222801699	rs824931	Body mass index	NR	.07	3E-6
chr2	223068285	223068286	rs7559271	Facial morphology	PAX3	.39	4E-16
chr2	223917982	223917983	rs12621643	Acute lymphoblastic leukemia (childhood)	KCNE4	1.48	3E-6
chr2	223936737	223936738	rs1440072	Waist circumference	KCNE4	3.66	8E-7
chr2	223936737	223936738	rs1440072	Body mass index	KCNE4	.06	4E-6
chr2	223937558	223937559	rs960246	C-reactive protein and white blood cell count	Intergenic	.22	1E-9
chr2	224274621	224274622	rs16864755	Osteoporosis-related phenotypes	SCG2	.24	4E-6
chr2	224459682	224459683	rs16864968	Response to hepatitis C treatment	SCG2	.83	3E-6
chr2	225047743	225047744	rs2629046	Height	SERPINE2	.02	8E-12
chr2	226237909	226237910	rs1517484	Attention deficit hyperactivity disorder (time to onset)	Intergenic	NR	5E-7
chr2	227000985	227000986	rs6758183	Corneal astigmatism	Intergenic	1.39	3E-6
chr2	227020652	227020653	rs7578326	Type 2 diabetes	IRS1	1.11	5E-20
chr2	227068079	227068080	rs2943634	Fasting insulin-related traits (interaction with BMI)	IRS1	NR	2E-14
chr2	227068079	227068080	rs2943634	Coronary heart disease	pseudogene	1.21	2E-7
chr2	227093584	227093585	rs2943640	Visceral adipose tissue/subcutaneous adipose tissue ratio	IRS1	NR	4E-6
chr2	227093744	227093745	rs2943641	Type 2 diabetes and other traits	LOC64673, IRS1	1.19	9E-12
chr2	227100697	227100698	rs2972146	Triglycerides	IRS1	1.89	2E-8
chr2	227100697	227100698	rs2972146	HDL cholesterol	IRS1	.46	2E-9
chr2	227105920	227105921	rs2943650	Adiposity	IRS1	.03	4E-11
chr2	227122215	227122216	rs1515110	Adiponectin levels	NR	.02	2E-7
chr2	227179629	227179630	rs925735	Adiponectin levels	IRS1	.02	2E-8
chr2	227562138	227562139	rs7558386	P-tau181p	Intergenic	NR	1E-7
chr2	227773465	227773466	rs3820928	Pulmonary function	RHBDD1	NR	5E-6
chr2	227915923	227915924	rs2272205	Immune reponse to smallpox (secreted IFN-alpha)	COL4A4	NR	3E-9
chr2	228481418	228481419	rs11889798	Immune reponse to smallpox (secreted TNF-alpha)	C2orf83, LOC729968	NR	4E-7
chr2	228715374	228715375	rs7591163	Blood pressure	CCL20, WDR69	NR	3E-7
chr2	229969797	229969798	rs6436839	Reasoning	PID1	NR	3E-6
chr2	231091222	231091223	rs13397985	Chronic lymphocytic leukemia	NR	1.39	2E-7
chr2	231091222	231091223	rs13397985	Chronic lymphocytic leukemia	SP140, SP110	1.41	6E-10
chr2	231106723	231106724	rs10201872	Multiple sclerosis	SP140	1.14	2E-10
chr2	231116873	231116874	rs7423615	Crohn's disease	SP140	1.12	3E-13
chr2	231420400	231420401	rs17275498	Cognitive performance	AC010149.4	NR	8E-6
chr2	232796609	232796610	rs749052	Height	NPPC, DIS3L2, COPS7B, PDE6D, PTMA	8.70	1E-6
chr2	232797965	232797966	rs2580816	Height	NPPC	.05	6E-22
chr2	233077063	233077064	rs7571816	Height	DIS3L2	.06	9E-9
chr2	233155109	233155110	rs6717918	Height	DIS3L2, ALPP, NPPC	.44	3E-9
chr2	233426525	233426526	rs1656402	Non-small cell lung cancer	EIF4E2	2.38	8E-8
chr2	233513174	233513175	rs2140773	Liver enzyme levels (gamma-glutamyl transferase)	EFHD1, LOC100129166	2.90	1E-9
chr2	233998480	233998481	rs10933436	Coronary heart disease	Intergenic	1.06	7E-6
chr2	234158838	234158839	rs10210302	Crohn's disease	ATG16L1	1.19	5E-14
chr2	234180409	234180410	rs3828309	Crohn's disease	ATG16L1	1.25	2E-32
chr2	234183367	234183368	rs2241880	Crohn's disease	ATG16L1, SAG, DGKD, INPP5D, USP40	1.32	1E-12
chr2	234183367	234183368	rs2241880	Crohn's disease	ATG16L1	1.32	3E-6
chr2	234183367	234183368	rs2241880	Crohn's disease	ATG16L1	1.45	1E-13
chr2	234184416	234184417	rs3792109	Crohn's disease	ATG16L1	1.38	5E-9
chr2	234184416	234184417	rs3792109	Crohn's disease	ATG16L1	1.34	7E-41
chr2	234273241	234273242	rs838705	Calcium levels	SAG,DGKD	.02	9E-6
chr2	234406654	234406655	rs6704644	Bilirubin levels	USP40	.08	8E-8
chr2	234502120	234502121	rs13394720	HIV-1 control	Intergenic	NR	5E-7
chr2	234565282	234565283	rs11892031	Bladder cancer	UGT1A	1.19	1E-7
chr2	234584323	234584324	rs2602381	Attention deficit hyperactivity disorder	UGT1A9	1.42	4E-6
chr2	234668569	234668570	rs887829	Cholelithiasis-related traits in sickle cell anemia	UGT1A1, UGT1A10	.19	5E-25
chr2	234668569	234668570	rs887829	Bilirubin levels	UGT1A1	.23	2E-22
chr2	234668569	234668570	rs887829	Metabolic traits	UGT1A	.29	3E-74
chr2	234668569	234668570	rs887829	Bilirubin levels	UGT1A1	.57	1E-69
chr2	234672638	234672639	rs6742078	Circulating cell-free DNA	UGT1A1	.34	2E-23
chr2	234672638	234672639	rs6742078	Bilirubin levels	UGT1A1	.23	5E-324
chr2	234673308	234673309	rs4148325	Bilirubin levels	UGT1A	.17	5E-62
chr2	234698789	234698790	rs2361502	Bilirubin levels	LOC339766	.10	7E-23
chr2	234814058	234814059	rs10187654	Pulmonary function decline	Intergenic	.15	9E-6
chr2	234825092	234825093	rs10166942	Migraine	TRPM8	1.28	1E-12
chr2	234825092	234825093	rs10166942	Migraine	TRPM8	1.18	6E-12
chr2	235210726	235210727	rs12151790	Osteoporosis	SPP2	.40	5E-7
chr2	235601063	235601064	rs4663476	Response to angiotensin II receptor blocker therapy	AC010148.1	1.23	8E-6
chr2	235615196	235615197	rs6736997	Pancreatic cancer	ARL4C	1.57	6E-6
chr2	235900170	235900171	rs11676855	Dialysis-related mortality	SH3BP4	1.43	9E-6
chr2	235960892	235960893	rs10174126	Orofacial clefts	SH3BP4	1.59	7E-7
chr2	236795342	236795343	rs13025591	Schizophrenia	CENTG2	1.11	8E-8
chr2	236795342	236795343	rs13025591	Schizophrenia	NR	1.07	6E-6
chr2	237156548	237156549	rs13390159	Response to statin therapy	ASB18,LOC728087,IQCA	NR	2E-7
chr2	237521841	237521842	rs7607316	Airflow obstruction	CXCR7	1.29	3E-6
chr2	238270893	238270894	rs10202497	Aging (time to event)	COL6A3	1.12	8E-6
chr2	238387227	238387228	rs7584330	Prostate cancer	Intergenic	1.06	3E-9
chr2	238443225	238443226	rs2292884	Prostate cancer	MLPH	1.14	4E-8
chr2	238672424	238672425	rs11680012	Adiposity	LRRFIP1	.58	4E-6
chr2	239095421	239095422	rs12472274	Phospholipid levels (plasma)	ILKAP	.80	2E-8
chr2	239306267	239306268	rs3739070	Iris characteristics	TRAF3IP1	.16	6E-6
chr2	239306267	239306268	rs3739070	Iris characteristics	TRAF3IP1	.25	2E-12
chr2	239349361	239349362	rs3769124	Pulmonary function	ASB1	.05	7E-8
chr2	239694630	239694631	rs9287638	Male-pattern baldness	HDAC4	1.31	1E-12
chr2	239877147	239877148	rs12477314	Pulmonary function	HDAC4	.04	2E-12
chr2	239877147	239877148	rs12477314	Pulmonary function	HDAC4	.03	1E-7
chr2	240418659	240418660	rs6743931	Response to antipsychotic therapy (extrapyramidal side effects)	Intergenic	NR	2E-6
chr2	240843637	240843638	rs12618573	Response to amphetamines	Intergenic	NR	8E-6
chr2	241308504	241308505	rs1574192	Brain imaging in schizophrenia (interaction)	GPC1	NR	4E-6
chr2	241495012	241495013	rs4305276	Mean platelet volume	ANKMY1	.01	2E-11
chr2	241515595	241515596	rs2953145	Bipolar disorder	NR	1.84	7E-6
chr2	241563738	241563739	rs4676410	Sclerosing cholangitis and ulcerative colitis (combined)	GPR35	1.38	2E-9
chr2	241579107	241579108	rs4676406	Ulcerative colitis	GPR35	1.14	8E-11
chr2	242012728	242012729	rs6721345	Sex hormone-binding globulin levels	SNED1, MTERFD2	1.13	3E-6
chr2	242262985	242262986	rs12694997	Height	SEPT2	.02	1E-8
chr2	242371100	242371101	rs757978	Chronic lymphocytic leukemia	NR	1.46	3E-6
chr2	242371100	242371101	rs757978	Chronic lymphocytic leukemia	FARP2	1.38	2E-9
chr2	242502955	242502956	rs12479254	Brain structure	BOK, THAP4	NR	6E-7
chr20	351943	351944	rs6051520	Information processing speed	TRIB3	.18	2E-7
chr20	1205885	1205886	rs397020	Multiple sclerosis	C20orf46	1.41	8E-7
chr20	1610550	1610551	rs2281808	Type 1 diabetes	Intergenic	1.11	1E-11
chr20	1759589	1759590	rs6080550	Non-obstructive azoospermia	LOC100289473	1.27	2E-9
chr20	1923733	1923734	rs6136489	Mean platelet volume	SIRPA	.01	8E-11
chr20	1924706	1924707	rs13042885	Mean platelet volume	SIRPA	.01	6E-14
chr20	1941170	1941171	rs6045676	Aortic root size	SIRPA, PDYN	.11	3E-8
chr20	1995533	1995534	rs6081597	Immune response to smallpox vaccine (IL-6)	PDYN	NR	7E-7
chr20	2518564	2518565	rs6049839	Systemic lupus erythematosus	TMC2	1.37	8E-6
chr20	2755487	2755488	rs6138892	Response to tocilizumab in rheumatoid arthritis	Intergenic	10.93	3E-7
chr20	3185122	3185123	rs11697186	Response to hepatitis C treatment	DDRGK1	4.50	5E-17
chr20	3185122	3185123	rs11697186	Response to hepatitis C treatment	DDRGK1	33.33	9E-25
chr20	3187732	3187733	rs6139030	Response to hepatitis C treatment	ITPA	25.00	2E-25
chr20	3187732	3187733	rs6139030	Response to hepatitis C treatment	ITPA	3.90	1E-15
chr20	3193841	3193842	rs1127354	Ribavirin-induced anemia	DDRGK1,ITPA	NR	4E-44
chr20	3193841	3193842	rs1127354	Chronic Hepatitis C infection	ITPA	NR	2E-58
chr20	3193892	3193893	rs7270101	Chronic Hepatitis C infection	ITPA	NR	9E-76
chr20	3381548	3381549	rs965469	IFN-related cytopenia	ITPA	NR	1E-9
chr20	3756596	3756597	rs13043330	Visceral adipose tissue adjusted for BMI	HSPA12B	NR	7E-6
chr20	3776174	3776175	rs3761218	Bipolar disorder	NR	NR	1E-6
chr20	3776174	3776175	rs3761218	Bipolar disorder	NR	1.03	7E-6
chr20	3827308	3827309	rs4815617	Asthma	KIAA1271	NR	8E-6
chr20	4101799	4101800	rs1741344	Height	SMOX	.02	3E-9
chr20	4169078	4169079	rs16989303	Panic disorder	SMOX	NR	6E-6
chr20	4611876	4611877	rs6052699	Platelet aggregation	PRNP	NR	2E-6
chr20	4677091	4677092	rs6107516	Creutzfeldt-Jakob disease (variant)	PRNP	NR	3E-18
chr20	4680250	4680251	rs1799990	Prion diseases	PRNP	1.30	7E-7
chr20	4680250	4680251	rs1799990	Creutzfeldt-Jakob disease	PRNP	NR	2E-21
chr20	4698625	4698626	rs6116492	Creutzfeldt-Jakob disease (variant)	PRNP	NR	5E-7
chr20	5037773	5037774	rs261360	Hair morphology	AL121890.2	NR	3E-6
chr20	5588448	5588449	rs238295	Cortical structure	GPCPD1	NR	6E-9
chr20	5840538	5840539	rs4815868	Information processing speed	C20orf196	.16	8E-6
chr20	5935384	5935385	rs236114	Menopause (age at onset)	MCM8	.50	1E-10
chr20	5943692	5943693	rs454422	HIV-1 control	MCM8	NR	1E-6
chr20	5948226	5948227	rs16991615	Menopause (age at onset)	MCM8	.95	1E-73
chr20	5948226	5948227	rs16991615	Menarche and menopause (age at onset)	TRMT6, MCM8	1.07	1E-21
chr20	6035227	6035228	rs2326679	Menopause (age at onset)	NR	.32	2E-6
chr20	6404280	6404281	rs961253	Colorectal cancer	Intergenic	1.12	2E-10
chr20	6620892	6620893	rs967417	Height	BMP2	4.30	2E-8
chr20	6621684	6621685	rs2145270	Body mass index	BMP2	NR	6E-6
chr20	6626217	6626218	rs2145272	Height	BMP2	.04	2E-24
chr20	6980634	6980635	rs6085820	Alzheimer's disease (late onset)	Intergenic	NR	9E-6
chr20	7106288	7106289	rs1884302	Sagittal craniosynostosis	BMP2	4.38	1E-39
chr20	7180055	7180056	rs6085920	Uric acid levels	NR	.40	6E-6
chr20	7294902	7294903	rs6054906	Response to amphetamines	Intergenic	NR	3E-6
chr20	7552503	7552504	rs6108011	Hemostatic factors and hematological phenotypes	Intergenic	NR	6E-6
chr20	8114703	8114704	rs6118083	Cognitive performance	PLCB1	NR	7E-6
chr20	8277942	8277943	rs2745761	Response to irinotecan in non-small-cell lung cancer	PLCB1	4.80	6E-6
chr20	8836770	8836771	rs6056209	Cognitive performance	PLCB1	NR	2E-6
chr20	9365302	9365303	rs2072910	Neutrophil count	PLCB4	.11	3E-10
chr20	10639542	10639543	rs2273061	Bone mineral density	JAG1	.07	5E-8
chr20	10850463	10850464	rs1884136	Information processing speed	RP4-697P8.2	.20	9E-6
chr20	10969029	10969030	rs1327235	Systolic blood pressure	JAG1	.34	2E-8
chr20	10969029	10969030	rs1327235	Diastolic blood pressure	JAG1	.30	1E-15
chr20	10969029	10969030	rs1327235	Blood pressure	JAG1	.26	4E-8
chr20	11157010	11157011	rs6040399	Response to citalopram treatment	Intergenic	NR	1E-6
chr20	11157010	11157011	rs6040399	Response to citalopram treatment	Intergenic	NR	7E-7
chr20	11174902	11174903	rs2207418	Cardiac hypertrophy	C20orf94,BTBD3,SNAP25,MKK5,JAG1	NR	9E-6
chr20	12874584	12874585	rs2073233	Brain structure	Intergenic	NR	1E-6
chr20	12969399	12969400	rs680379	Sphingolipid levels	SPTLC3	.00	2E-16
chr20	12969399	12969400	rs680379	Sphingolipid levels	SPTLC3	.10	8E-15
chr20	13123732	13123733	rs17190927	Personality dimensions	SPTLC3	NR	8E-7
chr20	13296911	13296912	rs1223271	Parkinson's disease	C20orf82	1.18	5E-6
chr20	14327898	14327899	rs6079395	Non-alcoholic fatty liver disease histology (other)	MACROD2	.92	7E-6
chr20	14388214	14388215	rs6110278	Mean platelet volume	NR	.01	4E-7
chr20	14747470	14747471	rs4141463	Autism	MACROD2	1.37	4E-8
chr20	15335753	15335754	rs6110577	Obesity (extreme)	C20orf133	1.40	5E-6
chr20	15599530	15599531	rs200752	Hypertension	MACROD2	NR	7E-9
chr20	15606420	15606421	rs200759	Hypertension	MACROD2	NR	7E-9
chr20	16311309	16311310	rs2208059	Ileal carcinoids	KIF16B	2.42	4E-7
chr20	16451641	16451642	rs6043979	Intelligence	KIF16B	NR	1E-8
chr20	16455773	16455774	rs932541	Intelligence	KIF16B	NR	1E-8
chr20	16459308	16459309	rs6044001	Intelligence	KIF16B	NR	1E-8
chr20	16460714	16460715	rs6044003	Intelligence	KIF16B	NR	1E-8
chr20	16536413	16536414	rs6044112	Response to taxane treatment (docetaxel)	C20orf23	NR	7E-7
chr20	17122592	17122593	rs852069	Menarche (age at onset)	PCSK2	2.10	3E-8
chr20	17357572	17357573	rs4814615	Dialysis-related mortality	PCSK2	1.59	5E-6
chr20	17368541	17368542	rs6044777	Biochemical measures	PCSK2	.23	8E-6
chr20	18079130	18079131	rs17725255	Anorexia nervosa	CSRP2BP	NR	2E-6
chr20	19363978	19363979	rs2424234	Pulmonary function decline	SLC24A3	.21	3E-6
chr20	19571580	19571581	rs3790268	Matrix metalloproteinase levels	SLC24A3	NR	3E-7
chr20	19852502	19852503	rs6046396	Bipolar disorder and schizophrenia	RIN2	1.28	4E-7
chr20	21853099	21853100	rs2180439	Male-pattern baldness	Intergenic	2.08	4E-17
chr20	21853099	21853100	rs2180439	Male-pattern baldness	PAX1, BQ013595, BE789145	1.82	3E-15
chr20	22037574	22037575	rs6047844	Male-pattern baldness	PAX1, FOXA2	1.60	2E-39
chr20	22050502	22050503	rs1160312	Male-pattern baldness	PAX1	1.60	1E-14
chr20	22559600	22559601	rs6048205	Fasting glucose-related traits (interaction with BMI)	FOXA2	NR	2E-12
chr20	23578188	23578189	rs1158167	Cystatin C	CST9L, CST9, CST3	NR	9E-9
chr20	23612736	23612737	rs911119	Chronic kidney disease	CST3,CST4,CST9	NR	2E-138
chr20	23847008	23847009	rs6138150	Response to TNF antagonist treatment	CST5	NR	3E-6
chr20	24058406	24058407	rs6049375	Erectile dysfunction and prostate cancer treatment	GGTLC1	4.84	8E-6
chr20	24717084	24717085	rs2424635	Bipolar disorder and schizophrenia	NR	1.23	7E-6
chr20	25019098	25019099	rs6050267	Cognitive performance	ACSS1	NR	9E-6
chr20	25206653	25206654	rs1044573	Allergic rhinitis	ENTPD6	1.15	1E-6
chr20	25298086	25298087	rs7267979	Liver enzyme levels (alkaline phosphatase)	ABHD12,GINS1, PYGB	1.50	7E-10
chr20	31277093	31277094	rs210135	Hematological parameters	BAK1	5.44	4E-10
chr20	31531543	31531544	rs13045180	Type 1 diabetes nephropathy	Intergenic	1.28	9E-6
chr20	31950844	31950845	rs291671	Hair color	ASIP	.22	2E-15
chr20	32333180	32333181	rs7274811	Height	ZNF341	.04	6E-22
chr20	32588094	32588095	rs2284378	Breast cancer	RALY, EIF2S2, ASIP	1.16	1E-8
chr20	32729443	32729444	rs4911414	Skin sensitivity to sun	ASIP	1.76	2E-24
chr20	32729443	32729444	rs4911414	Red vs. non-red hair color	ASIP	1.76	3E-9
chr20	32729443	32729444	rs4911414	Freckles	ASIP	1.95	8E-29
chr20	32729443	32729444	rs4911414	Burning and freckling	ASIP	2.56	6E-37
chr20	32738611	32738612	rs1015362	Skin sensitivity to sun	ASIP	1.76	2E-24
chr20	32738611	32738612	rs1015362	Red vs. non-red hair color	ASIP	1.76	3E-9
chr20	32738611	32738612	rs1015362	Freckles	ASIP	1.95	8E-29
chr20	32738611	32738612	rs1015362	Burning and freckling	ASIP	2.56	6E-37
chr20	33171771	33171772	rs910873	Melanoma	CDC91L1	1.75	1E-15
chr20	33545615	33545616	rs17310467	Hemostatic factors and hematological phenotypes	GSS, EDEM2, PROCR	19.27	4E-34
chr20	33565754	33565755	rs11906160	Anticoagulant levels	MYH7B	NR	1E-6
chr20	33722862	33722863	rs2295888	Prothrombin time	EDEM2, TRPC4AP, PROCR, MYH7B,	.02	5E-13
chr20	33730386	33730387	rs6120849	Protein C levels	EDEM2	.14	7E-37
chr20	33745675	33745676	rs6088735	Hemostatic factors and hematological phenotypes	GSS, EDEM2, PROCR	19.27	4E-34
chr20	33753261	33753262	rs6060278	Hemostatic factors and hematological phenotypes	GSS, EDEM2, PROCR	19.27	4E-34
chr20	33764553	33764554	rs867186	Hemostatic factors and hematological phenotypes	GSS, EDEM2, PROCR	19.27	4E-34
chr20	33764553	33764554	rs867186	Hemostatic factors and hematological phenotypes	PROCR	.37	2E-6
chr20	33764553	33764554	rs867186	Anticoagulant levels	PROCR	.85	4E-9
chr20	33764553	33764554	rs867186	D-dimer levels	PROCR	.05	4E-6
chr20	33764553	33764554	rs867186	Protein C levels	PROCR	.47	2E-200
chr20	33764553	33764554	rs867186	Coagulation factor levels	PROCR	NR	6E-37
chr20	33849178	33849179	rs1555322	Attention deficit hyperactivity disorder	MMP24	NR	4E-6
chr20	33867696	33867697	rs619865	Freckling	ASIP	.77	5E-14
chr20	33907160	33907161	rs6060369	Height	GDF5,UQCC	.44	1E-16
chr20	33907160	33907161	rs6060369	Height	BFZB	.44	2E-16
chr20	33909783	33909784	rs6088792	Height	UQCC, GDF5, CEP250, EIF6, MMP24	4.70	8E-7
chr20	33914207	33914208	rs6060373	Height	GDF5	.08	2E-17
chr20	33975180	33975181	rs6088813	Height	UQCC	.09	1E-13
chr20	34025755	34025756	rs143384	Height	GDF5	.06	1E-58
chr20	34097352	34097353	rs2236164	Height	GDF5, UQCC	.06	2E-6
chr20	34152781	34152782	rs2277862	Cholesterol, total	ERGIC3	1.19	4E-10
chr20	35766336	35766337	rs8115854	Hippocampal atrophy	C20orf132	NR	2E-6
chr20	35809782	35809783	rs6031882	Hippocampal atrophy	RPN2	NR	6E-6
chr20	36469693	36469694	rs4811196	Bone mineral density	CTNNBL1	NR	1E-6
chr20	36957836	36957837	rs6024905	Bipolar disorder and schizophrenia	NR	1.24	1E-6
chr20	37690463	37690464	rs926392	Dialysis-related mortality	LOC339568, DHX35	2.37	5E-7
chr20	37845476	37845477	rs6028335	Alcohol and nictotine co-dependence	LOC339568	NR	5E-6
chr20	38129001	38129002	rs6028466	Telomere length	DHX35	.19	3E-7
chr20	38300806	38300807	rs6016142	Estradiol levels	Intergenic	.18	6E-8
chr20	38685540	38685541	rs2870137	Cytomegalovirus antibody response	Intergenic	.26	3E-6
chr20	38820804	38820805	rs6028945	Response to TNF antagonist treatment	MAFB	NR	2E-7
chr20	39028435	39028436	rs8124695	Dupuytren's disease	AL049691.1, MAFB	1.48	8E-10
chr20	39091486	39091487	rs2902940	LDL cholesterol	MAFB	.98	1E-8
chr20	39091486	39091487	rs2902940	Cholesterol, total	MAFB	1.38	6E-11
chr20	39228783	39228784	rs6102059	LDL cholesterol	MAFB	.06	4E-9
chr20	39269073	39269074	rs13041247	Orofacial clefts	NR	1.19	6E-9
chr20	39672617	39672618	rs6029526	LDL cholesterol	TOP1	1.41	3E-19
chr20	39672617	39672618	rs6029526	Cholesterol, total	TOP1	1.52	3E-17
chr20	40064558	40064559	rs13037749	Hippocampal atrophy	CHD6	NR	8E-6
chr20	42487203	42487204	rs6103489	Response to amphetamines	Intergenic	NR	4E-6
chr20	42573821	42573822	rs6031252	Conduct disorder (symptom count)	TOX2	.11	6E-6
chr20	42854133	42854134	rs6017291	Cognitive performance	RP5-995J12.2	NR	6E-6
chr20	42946965	42946966	rs6017317	Type 2 diabetes	FITM2,R3HDML,HNF4A	1.09	1E-11
chr20	42989266	42989267	rs4812829	Type 2 diabetes	HNF4A	1.09	3E-10
chr20	43042363	43042364	rs1800961	C-reactive protein	HNF4A	.27	8E-6
chr20	43042363	43042364	rs1800961	C-reactive protein	HNF4A	.09	2E-9
chr20	43042363	43042364	rs1800961	HDL cholesterol	HNF4A	1.88	1E-15
chr20	43042363	43042364	rs1800961	Cholesterol, total	HNF4A	4.73	6E-13
chr20	43042363	43042364	rs1800961	HDL cholesterol	HNF4A	.19	8E-10
chr20	43065027	43065028	rs6017342	Ulcerative colitis	SERINC3	1.20	1E-20
chr20	43065027	43065028	rs6017342	Ulcerative colitis	HNF4A	1.17	9E-17
chr20	43721492	43721493	rs6124684	Bipolar disorder	SERINC3	1.73	9E-6
chr20	43980725	43980726	rs1008953	Psoriasis	SDC4	1.14	1E-7
chr20	44124522	44124523	rs11696501	Brain structure	WFDC2, SPINT3	NR	9E-7
chr20	44534650	44534651	rs6065904	Lipid metabolism phenotypes	PLTP	.22	2E-31
chr20	44545047	44545048	rs4810479	Metabolite levels	PLTP	NR	2E-42
chr20	44554014	44554015	rs6065906	Triglycerides	PLTP	3.32	5E-18
chr20	44554014	44554015	rs6065906	HDL cholesterol	PLTP	.93	2E-22
chr20	44576501	44576502	rs7679	Triglycerides	PLTP	.07	7E-11
chr20	44576501	44576502	rs7679	HDL cholesterol	PLTP	.07	4E-9
chr20	44702119	44702120	rs2425752	Multiple sclerosis	NCOA5, CD40	1.11	5E-10
chr20	44740195	44740196	rs6074022	Multiple sclerosis	CD40	1.15	5E-6
chr20	44740195	44740196	rs6074022	Multiple sclerosis	CD40	1.20	1E-7
chr20	44742063	44742064	rs1569723	Kawasaki disease	CD40	1.42	6E-9
chr20	44747946	44747947	rs4810485	Rheumatoid arthritis	CD40	1.18	3E-9
chr20	44747946	44747947	rs4810485	Rheumatoid arthritis	CD40	1.15	8E-9
chr20	44761484	44761485	rs12480534	Response to amphetamines	Intergenic	NR	9E-6
chr20	44763283	44763284	rs4813003	Kawasaki disease	CD40	1.41	5E-8
chr20	45460322	45460323	rs6066084	Quantitative traits	Intergenic	.85	2E-6
chr20	45497722	45497723	rs6124878	Visceral adipose tissue/subcutaneous adipose tissue ratio	EYA2	NR	4E-6
chr20	46208604	46208605	rs6125048	Response to treatment for acute lymphoblastic leukemia	NCOA3	2.73	2E-6
chr20	46400712	46400713	rs4810685	Attention deficit hyperactivity disorder (time to onset)	SULF2	NR	7E-6
chr20	46425575	46425576	rs13038095	Atrial fibrillation	NR	1.47	2E-7
chr20	46779234	46779235	rs11086243	Nephrotic syndrome (acquired)	SULF2, PREX1	1.37	3E-6
chr20	47343058	47343059	rs6063312	Tonometry	PREX1	NR	2E-6
chr20	47903018	47903019	rs237743	Height	ZNFX1	.04	1E-20
chr20	48522329	48522330	rs495337	Psoriasis	ZNF313	1.20	2E-6
chr20	48522329	48522330	rs495337	Psoriasis	RNF114,SPATA2,SLC9A8,SNAI1	1.21	2E-7
chr20	48522329	48522330	rs495337	Psoriasis	SPATA2	1.25	1E-8
chr20	48554976	48554977	rs2235617	Psoriasis	ZNF313	1.20	2E-6
chr20	49375241	49375242	rs6122972	Bipolar disorder	PARD6B	2.02	3E-6
chr20	50559651	50559652	rs6068020	Male infertility	SALL4	NR	5E-7
chr20	50637659	50637660	rs6013355	Subcutaneous adipose tissue	ZFP64	NR	5E-6
chr20	50702632	50702633	rs6013382	Amyotrophic lateral sclerosis	ZFP64	1.43	5E-6
chr20	51318350	51318351	rs6013509	Hemoglobin	TSHZ2	.06	1E-10
chr20	52349891	52349892	rs6091737	Calcium levels	Intergenic	.02	6E-6
chr20	52447302	52447303	rs6022786	Polycystic ovary syndrome	SUMO1P1	1.13	2E-9
chr20	52610495	52610496	rs2276498	Bipolar disorder and schizophrenia	NR	1.31	7E-6
chr20	52791517	52791518	rs2248359	Multiple sclerosis	CYP24A1	1.12	3E-11
chr20	52807220	52807221	rs16999165	Atopic dermatitis	CYP24A1, PFDN4	1.19	2E-8
chr20	53267110	53267111	rs2023454	Functional MRI	DOK5	.22	5E-7
chr20	53801128	53801129	rs6092078	Response to antipsychotic treatment	Intergenic	NR	3E-6
chr20	55638536	55638537	rs331615	White blood cell types	BMP7	.06	9E-7
chr20	55638749	55638750	rs6127921	Response to citalopram treatment	BMP7	1.64	3E-6
chr20	55638749	55638750	rs6127921	Response to citalopram treatment	BMP7	1.75	1E-6
chr20	56044183	56044184	rs6070116	Response to statin therapy	HMG1L1,CTCFL,RBM38	NR	4E-6
chr20	56190633	56190634	rs2073145	Hippocampal atrophy	ZBP1	NR	2E-6
chr20	56428704	56428705	rs12481680	Response to fenofibrate (adiponectin levels)	PMEPA1, PCK1, ZBP1	.22	2E-7
chr20	56663273	56663274	rs6070346	Pulmonary function decline	Intergenic	.17	4E-6
chr20	56796783	56796784	rs4811971	Height	ANKRD60	.70	6E-6
chr20	57164854	57164855	rs127430	Cardiovascular disease risk factors	APCDD1L,STX16	.19	1E-6
chr20	57469072	57469073	rs6026584	Renal function-related traits (BUN)	GNAS	.01	9E-9
chr20	57475190	57475191	rs13831	Event-related brain oscillations	GNAS1	.21	6E-6
chr20	57587770	57587771	rs4812048	Mean platelet volume	CTSZ,TUBB1	.01	1E-9
chr20	57614001	57614002	rs151361	Mean platelet volume	SLMO2, TUBB1	4.49	9E-9
chr20	57751116	57751117	rs6015450	Systolic blood pressure	GNAS, EDN3	.90	4E-23
chr20	57751116	57751117	rs6015450	Hypertension	GNAS, EDN3	.11	4E-14
chr20	57751116	57751117	rs6015450	Diastolic blood pressure	GNAS, EDN3	.56	6E-23
chr20	57751116	57751117	rs6015450	Blood pressure	GNAS, EDN3	.35	2E-6
chr20	57751116	57751117	rs6015450	Blood pressure	GNAS, EDN3	.52	2E-12
chr20	57758719	57758720	rs16982520	Hypertension	ZNF831, EDN3	.13	2E-7
chr20	57790435	57790436	rs12625057	Response to antipsychotic therapy (extrapyramidal side effects)	ZNF831	NR	7E-6
chr20	58177614	58177615	rs6026990	Response to tocilizumab in rheumatoid arthritis	Intergenic	.63	6E-7
chr20	58895845	58895846	rs11698685	Type 1 diabetes nephropathy	RP5-1043L13.1	1.27	1E-6
chr20	58896714	58896715	rs6027506	Type 1 diabetes nephropathy	RP5, 1043L13.1	1.22	5E-6
chr20	58898208	58898209	rs6027511	Lentiform nucleus volume	Intergenic	122.24	9E-6
chr20	59268709	59268710	rs6027755	Non-alcoholic fatty liver disease histology (other)	Intergenic	1.09	6E-6
chr20	59853937	59853938	rs1970546	Volumetric brain MRI	CDH4	NR	4E-8
chr20	59928236	59928237	rs4468878	Longevity	AL365229.1	NR	1E-6
chr20	59947043	59947044	rs4925189	T-tau	CDH4	NR	6E-7
chr20	60212493	60212494	rs2024714	Longevity	CDH4	NR	1E-6
chr20	60243410	60243411	rs944260	Sudden cardiac arrest	CDH4	1.10	2E-6
chr20	60921043	60921044	rs4925386	Colorectal cancer	LAMA5	1.08	2E-10
chr20	61669035	61669036	rs6089829	Prostate cancer (gene x gene interaction)	LOC63930	1.35	3E-6
chr20	61895919	61895920	rs1406961	Cardiovascular disease risk factors	Intergenic	12.33	5E-7
chr20	62309838	62309839	rs6010620	Glioma	RTEL1,TNFRSF6B	1.43	1E-10
chr20	62309838	62309839	rs6010620	Glioma	RTEL1	1.24	2E-9
chr20	62309838	62309839	rs6010620	Glioma	RTEL1	1.28	3E-12
chr20	62309838	62309839	rs6010620	Glioma (high-grade)	RTEL1	1.52	3E-9
chr20	62318219	62318220	rs4809324	Glioma (high-grade)	RTEL1	1.60	2E-9
chr20	62327581	62327582	rs2297441	Ulcerative colitis	SLC2A4RG, STMN3, ZBTB46, ZGPAT, RTEL1, TNFRSF6B	1.09	2E-10
chr20	62343955	62343956	rs2315008	Inflammatory bowel disease	TNFRSF6B	1.36	9E-15
chr20	62349585	62349586	rs4809330	Crohn's disease	RTEL1,TNFRS-F6B,SLC2A4RG	1.12	3E-15
chr20	62409712	62409713	rs6062314	Multiple sclerosis	ZBTB46	1.16	1E-7
chr21	11002010	11002011	rs240444	Bipolar disorder and schizophrenia	NR	1.31	2E-6
chr21	15845051	15845052	rs1006899	Bone mineral density (spine)	NR	.09	6E-6
chr21	16340288	16340289	rs2229741	Cognitive performance	NRIP1	NR	6E-7
chr21	16805219	16805220	rs1736135	Ulcerative colitis	NR	1.20	2E-7
chr21	16805219	16805220	rs1736135	Crohn's disease	Intergenic	1.18	7E-9
chr21	16812551	16812552	rs1736020	Crohn's disease	intergenic	1.16	9E-12
chr21	16817050	16817051	rs1297265	Ulcerative colitis	Intergenic	1.11	7E-13
chr21	16914904	16914905	rs2823357	Parkinson's disease	USP25	1.15	6E-7
chr21	17069165	17069166	rs2823455	Panic disorder	USP25	NR	9E-6
chr21	17667719	17667720	rs2823743	Chronic obstructive pulmonary disease-related biomarkers	C21orf34	NR	1E-6
chr21	17828290	17828291	rs2823819	Attention deficit hyperactivity disorder	C21orf34	1.65	7E-7
chr21	18046231	18046232	rs2823962	Amyotrophic lateral sclerosis	NR	NR	9E-6
chr21	20536648	20536649	rs2825388	Attention deficit hyperactivity disorder symptoms (interaction)	Intergenic	1.06	8E-6
chr21	21777729	21777730	rs1888414	Hippocampal atrophy	FDPSP	NR	2E-7
chr21	21885301	21885302	rs2826340	Attention deficit hyperactivity disorder and conduct disorder	Intergenic	NR	2E-6
chr21	22689343	22689344	rs11088859	Obesity	NCAM2	NR	4E-8
chr21	22910115	22910116	rs2826891	Longevity	NCAM2	NR	1E-6
chr21	23631675	23631676	rs2827312	Alcoholism (heaviness of drinking)	Intergenic	.09	8E-6
chr21	24198814	24198815	rs7279441	Self-rated health	Intergenic	.03	8E-6
chr21	24789555	24789557	rs3819055	Visceral fat	NCAM2	NR	5E-6
chr21	25080395	25080396	rs2829459	Dental caries	Intergenic	NR	3E-6
chr21	25143118	25143119	rs2828520	Major depressive disorder	Intergenic	1.35	4E-7
chr21	26279350	26279351	rs2829459	Dental caries	Intergenic	NR	3E-6
chr21	26645082	26645083	rs9977253	Non-alcoholic fatty liver disease histology (other)	Intergenic	.76	5E-6
chr21	27002376	27002377	rs17001239	Cognitive performance	JAM2	NR	2E-6
chr21	27716653	27716654	rs9975851	Airflow obstruction	CYYR1	1.17	4E-6
chr21	28665346	28665347	rs2830840	Response to citalopram treatment	EIF4A1P	1.47	5E-6
chr21	28696475	28696476	rs239713	AB1-42	Intergenic	NR	5E-7
chr21	28734996	28734997	rs9977499	Dialysis-related mortality	NCRNA00113, ADAMTS5	1.57	4E-6
chr21	28744355	28744356	rs1452093	Dialysis-related mortality	NCRNA00113, ADAMTS5	1.59	2E-6
chr21	29475195	29475196	rs9305354	Urinary albumin excretion	Intergenic	NR	8E-6
chr21	30141020	30141021	rs2832077	Cognitive test performance	Intergenic	NR	2E-6
chr21	30713597	30713598	rs17744121	Visceral fat	BACH1	NR	6E-6
chr21	30717736	30717737	rs372883	Pancreatic cancer	BACH1	1.27	2E-13
chr21	31050816	31050817	rs363512	Hyperactive-impulsive symptoms	GRIK1	NR	4E-6
chr21	31100796	31100797	rs933117	Body mass index	GRIK1	.85	6E-6
chr21	31146168	31146169	rs455804	Hepatocellular carcinoma	GRIK1	1.19	5E-10
chr21	31177510	31177511	rs458685	Breast cancer	GRIK1	NR	6E-6
chr21	31386242	31386243	rs9305406	Response to statin therapy	GRIK1, CLDN17, CLDN8	NR	8E-6
chr21	32216252	32216253	rs7283316	Information processing speed	KRTARP7-1	.37	9E-6
chr21	32440539	32440540	rs1475591	Coronary heart disease	Intergenic	1.18	6E-6
chr21	32817506	32817507	rs580140	Renal sinus fat	TIAM1	.18	3E-6
chr21	32918293	32918294	rs13048019	Amyotrophic lateral sclerosis	SOD1	2.02	3E-8
chr21	33285299	33285300	rs2833556	Reasoning	HUNK	NR	5E-7
chr21	33381039	33381040	rs2833607	Vitiligo	HUNK	NR	2E-6
chr21	33385185	33385186	rs2833610	Type 2 diabetes	HUNK	1.17	4E-6
chr21	33552511	33552512	rs2833693	Temperament	C21orf45	.17	4E-6
chr21	34542786	34542787	rs6517147	Inflammatory biomarkers	Intergenic	NR	7E-7
chr21	34796885	34796886	rs2834215	Crohn's disease	IFNGR2	1.22	3E-7
chr21	35599127	35599128	rs9982601	Coronary heart disease	MRPS6	1.18	4E-10
chr21	35599127	35599128	rs9982601	Myocardial infarction (early onset)	SLC5A3, MRPS6, KCNE2	1.20	6E-11
chr21	35652238	35652239	rs9978142	Pulmonary function	KCNE2	.04	3E-8
chr21	35690785	35690786	rs2834442	Height	KCNE2	.03	5E-12
chr21	35880071	35880072	rs727957	Electrocardiographic traits	KCNE1	11.70	2E-12
chr21	36238506	36238507	rs2834655	Immune response to smallpox vaccine (IL-6)	RUNX1	NR	5E-7
chr21	36357860	36357861	rs2014300	Esophageal cancer	RUNX1	1.43	8E-22
chr21	36416331	36416332	rs9983044	Phospholipid levels (plasma)	RUNX1	.07	2E-7
chr21	36533661	36533662	rs2834812	HIV-1 control	NR	NR	9E-6
chr21	36688527	36688528	rs2834902	Corneal curvature	Intergenic	.04	8E-6
chr21	36849418	36849419	rs16993221	C-reactive protein and white blood cell count	LOC100506403	.46	2E-8
chr21	37809376	37809377	rs9984974	Myopia (pathological)	Intergenic	NR	2E-6
chr21	37833306	37833307	rs219780	Kidney stones	CLDN14	1.25	4E-12
chr21	37935668	37935669	rs9984896	QT interval	NR	2.85	5E-6
chr21	38491094	38491095	rs1003719	Eye color traits	TTC3,DSCR9	.10	2E-10
chr21	38740823	38740824	rs12483205	HIV-1 replication	DYRK1A	NR	5E-6
chr21	38932777	38932778	rs2835810	Metabolic syndrome	DYRK1A	NR	6E-6
chr21	39027271	39027272	rs2835872	Electroencephalographic traits in alcoholism	KCNJ6	.15	5E-10
chr21	39852550	39852551	rs7275212	White blood cell types	ERG	.20	2E-18
chr21	40056422	40056423	rs743446	Neonatal lupus	NCRNA00114, ERG	2.40	5E-6
chr21	40173527	40173528	rs1209950	Non-small cell lung cancer	ETS2	4.96	3E-7
chr21	40291739	40291740	rs2836754	Crohn's disease	Intergenic	1.15	5E-7
chr21	40314703	40314704	rs2836770	Immune response to smallpox vaccine (IL-6)	FLJ45139	NR	3E-6
chr21	40380248	40380249	rs2836823	Nicotine dependence	NR	1.46	2E-6
chr21	40465177	40465178	rs2242944	Ankylosing spondylitis	PSMG1	1.39	8E-20
chr21	40465533	40465534	rs2836878	C-reactive protein	PSMG1	.03	2E-7
chr21	40465533	40465534	rs2836878	Ulcerative colitis	Intergenic	1.25	2E-22
chr21	40465533	40465534	rs2836878	Inflammatory bowel disease	PSMG1	1.41	4E-12
chr21	40469519	40469520	rs378108	Ankylosing spondylitis	Intergenic	NR	2E-11
chr21	40569778	40569779	rs2150410	Temperament (bipolar disorder)	BRWD1	1.69	4E-6
chr21	41123300	41123301	rs1735151	Coronary heart disease	IGSF5	1.16	9E-6
chr21	41415043	41415044	rs9981861	Non-small cell lung cancer	DSCAM	1.33	4E-6
chr21	42174959	42174960	rs2837828	Neutrophil count	DSCAM	NR	1E-6
chr21	42471627	42471628	rs16998084	Economic and political preferences (immigration/crime)	Intergenic	.40	5E-6
chr21	42511917	42511918	rs2837960	Rheumatoid arthritis	NR	1.05	2E-6
chr21	42746080	42746081	rs45430	Melanoma	MX2	1.14	3E-9
chr21	43227914	43227915	rs7279297	Tanning	PRDM15	.12	3E-6
chr21	43275494	43275495	rs915832	Response to taxane treatment (placlitaxel)	PRDM15	NR	7E-6
chr21	43286351	43286352	rs2839398	Parkinson's disease	PRDM15	1.23	5E-6
chr21	43707100	43707101	rs425215	Common traits (Other)	NR	NR	8E-7
chr21	43778894	43778895	rs1547374	Pancreatic cancer	TFF1	1.27	4E-13
chr21	43836185	43836186	rs11203203	Celiac disease and Rheumatoid arthritis	UBASH3A	NR	1E-8
chr21	43836185	43836186	rs11203203	Rheumatoid arthritis	UBASH3A	1.11	4E-6
chr21	43836185	43836186	rs11203203	Vitiligo	UBASH3A	1.27	1E-9
chr21	43836185	43836186	rs11203203	Type 1 diabetes	UBASH3A	NR	2E-9
chr21	43836389	43836390	rs9976767	Type 1 diabetes	UBASH3A	1.16	2E-8
chr21	43841327	43841328	rs3788013	Type 1 diabetes autoantibodies	UBASH3A	1.10	1E-7
chr21	44156768	44156769	rs9979235	Pulmonary function decline	Intergenic	.62	6E-6
chr21	44436176	44436177	rs2839619	Biochemical measures	PKNOX1	.13	8E-6
chr21	44436176	44436177	rs2839619	Biochemical measures	PKNOX1	.13	8E-6
chr21	44445291	44445292	rs234720	Cognitive performance	PKNOX1	NR	2E-7
chr21	44448717	44448718	rs2839627	Information processing speed	PKNOX1	.27	6E-6
chr21	44478496	44478497	rs6586282	Homocysteine levels	CBS	.03	3E-10
chr21	44768561	44768562	rs643608	Non-alcoholic fatty liver disease histology (other)	Intergenic	.74	1E-6
chr21	44779679	44779680	rs496300	Metabolic syndrome	FLJ41733	.03	4E-7
chr21	45404337	45404338	rs7435	Phospholipid levels (plasma)	AGPAT3	.02	2E-7
chr21	45615022	45615023	rs2838519	Ulcerative colitis	ICOSLG	1.14	6E-11
chr21	45615022	45615023	rs2838519	Crohn's disease	ICOSLG	1.18	2E-14
chr21	45615560	45615561	rs762421	Crohn's disease	ICOSLG	1.13	1E-9
chr21	45647420	45647421	rs4819388	Celiac disease	ICOSLG	1.14	2E-9
chr21	45709152	45709153	rs2075876	Rheumatoid arthritis	AIRE, PFKL	1.18	4E-9
chr21	46629589	46629590	rs2838815	Pulmonary function	ADARB1	NR	3E-6
chr21	46846943	46846944	rs2838923	Hippocampal atrophy	COL18A1	NR	8E-7
chr21	47124177	47124178	rs4819143	Insulin resistance/response	PCBP3	17.00	1E-6
chr21	47165428	47165429	rs8127571	Immune reponse to smallpox (secreted IFN-alpha)	LOC100129027	NR	2E-7
chr21	47445790	47445791	rs4293630	Alcoholism (alcohol dependence factor score)	Intergenic	.11	7E-6
chr21	48019867	48019868	rs881827	Lymphocyte counts	S100B	NR	9E-6
chr22	17057137	17057138	rs5746647	HIV-1 viral setpoint	KB-67B5.12	NR	2E-6
chr22	18439957	18439958	rs1076540	Liver enzyme levels (gamma-glutamyl transferase)	MICAL3	4.80	1E-16
chr22	18972449	18972450	rs2023634	Metabolic traits	PRODH	.11	2E-22
chr22	19154521	19154522	rs807669	Metabolite levels	SLC25A1	.14	3E-16
chr22	19156116	19156117	rs712964	Metabolite levels	GSC2, SLC25A1, CLTCL1	NR	3E-11
chr22	19889824	19889825	rs3788317	Glaucoma (primary open-angle)	TXNRD2	1.22	2E-7
chr22	19984276	19984277	rs1034566	Platelet counts	ARVCF	2.13	3E-8
chr22	21917189	21917190	rs131654	Systemic lupus erythematosus	HIC2, UBE2L3	1.28	1E-16
chr22	21928640	21928641	rs181359	Crohn's disease	YDJC	1.10	5E-16
chr22	21932067	21932068	rs181362	HDL cholesterol	UBE2L3	.46	1E-8
chr22	21939674	21939675	rs5754217	Systemic lupus erythematosus	UBE2L3	1.38	2E-6
chr22	21982891	21982892	rs2298428	Celiac disease and Rheumatoid arthritis	UBE2L3	NR	3E-10
chr22	21982891	21982892	rs2298428	Celiac disease	UBE2L3, YDJC	1.13	2E-7
chr22	22131124	22131125	rs2283792	Multiple sclerosis	MAPK1	1.10	5E-9
chr22	22307518	22307519	rs412050	Attention deficit hyperactivity disorder	PPM1F	NR	6E-6
chr22	22845239	22845240	rs5751168	Prostate cancer (gene x gene interaction)	ZNF280B	1.44	4E-6
chr22	23593050	23593051	rs5751614	Height	BCR, GNAZ, RTDR1, IGLL1	4.30	6E-6
chr22	23644793	23644794	rs9608102	Immune response to smallpox vaccine (IL-6)	BCR	NR	8E-6
chr22	23765264	23765265	rs4822410	Pulmonary function decline	Intergenic	.54	3E-6
chr22	23922982	23922983	rs140174	Migraine	IGLL1	1.08	8E-6
chr22	24295285	24295286	rs2739330	Liver enzyme levels (gamma-glutamyl transferase)	DDT, DDTL, GSTT1, GSTT2B, MIF	3.70	2E-9
chr22	24990212	24990213	rs4820599	Gamma glutamyl transpeptidase	GGT1, C22orf36	.01	7E-53
chr22	24990212	24990213	rs4820599	Liver enzyme levels	GGT1, C22orf36	.01	4E-11
chr22	24992265	24992266	rs5751901	Protein quantitative trait loci	GGT1	NR	2E-7
chr22	24999103	24999104	rs2073398	Liver enzyme levels (gamma-glutamyl transferase)	GGT1, GGTLC2	12.30	1E-109
chr22	25875264	25875265	rs1930961	Bipolar disorder (mood-incongruent)	CRYBB2P1	1.39	9E-6
chr22	26394723	26394724	rs8139900	Uric acid levels	MYO18B	.17	4E-6
chr22	26403598	26403599	rs1001021	Schizophrenia, bipolar disorder and depression (combined)	MYO18B	NR	2E-6
chr22	26653361	26653362	rs1207393	Airflow obstruction	SEZ6L	1.19	5E-6
chr22	26689634	26689635	rs688034	Coronary heart disease	Intergenic	1.11	4E-6
chr22	26697194	26697195	rs591044	Insulin resistance/response	SEZ6L	9.00	6E-6
chr22	27011419	27011420	rs4822752	Bipolar disorder and schizophrenia	NR	1.22	9E-6
chr22	27042105	27042106	rs744016	RR interval (heart rate)	Intergenic	.17	5E-6
chr22	27852182	27852183	rs6005451	Prostate cancer (gene x gene interaction)	MN1	1.42	4E-6
chr22	28090206	28090207	rs5762311	Sudden cardiac arrest	Intergenic	2.03	7E-6
chr22	28378471	28378472	rs5762430	Obesity	PITPNB	NR	7E-7
chr22	29100710	29100711	rs1547014	Vertical cup-disc ratio	CHEK2	.01	1E-8
chr22	29115065	29115066	rs4822983	Esophageal cancer (squamous cell)	CHEK2	1.27	2E-22
chr22	29130011	29130012	rs738722	Esophageal cancer and gastric cancer	CHEK2,HSCB	1.30	1E-8
chr22	29161006	29161007	rs4820792	Breast size	CHEK2, MTFP1, LOC646513, SEC14L2, SDC4P	.11	4E-7
chr22	29192669	29192670	rs2239815	Esophageal cancer (squamous cell)	XBP1	1.18	4E-15
chr22	29451670	29451671	rs4823006	Waist-hip ratio	ZNRF3, KREMEN1	.03	3E-11
chr22	29793640	29793641	rs2267138	Myopia (pathological)	Intergenic	NR	3E-6
chr22	29847721	29847722	rs13053817	Carotid atherosclerosis in HIV infection	RFPL1, AP1B1, THOC5, NF2	NR	2E-6
chr22	30337585	30337586	rs36600	Lung cancer	MTMR3	1.29	6E-13
chr22	30423459	30423460	rs12537	IgA nephropathy	MTMR3	1.28	1E-11
chr22	30494370	30494371	rs2412971	Nephropathy	HORMAD2, MTMR3, LIF, OSM	1.25	2E-9
chr22	30529630	30529631	rs2412973	Inflammatory bowel disease (early onset)	HORMAD2, MTMR3, LIF	1.15	2E-9
chr22	30581721	30581722	rs5753037	Type 1 diabetes	Intergenic	1.10	3E-16
chr22	30592068	30592069	rs2412980	Dialysis-related mortality	LOC729980	1.65	4E-6
chr22	30592486	30592487	rs713875	Crohn's disease	MTMR3	1.08	7E-12
chr22	31013295	31013296	rs2283873	Wilms tumor	NR	2.05	5E-12
chr22	31645758	31645759	rs2106294	Type 2 diabetes nephropathy	LIMK2	1.75	4E-6
chr22	32024979	32024980	rs11703808	Intelligence	PISD	NR	7E-8
chr22	32025912	32025913	rs761746	Intelligence	PISD	NR	7E-8
chr22	32027448	32027449	rs12627933	Intelligence	PISD	NR	7E-8
chr22	32049916	32049917	rs9621305	Intelligence	PISD	NR	7E-8
chr22	32229648	32229649	rs5994434	Intelligence	DEPDC5	6.29	5E-7
chr22	32265902	32265903	rs1012068	Chronic Hepatitis C infection	DEPDC5	1.75	1E-13
chr22	32745915	32745916	rs5998432	T-tau	Intergenic	NR	9E-7
chr22	32867527	32867528	rs9609565	Hematological parameters	FBX07	.37	4E-10
chr22	33056340	33056341	rs4821083	Height	SYN3	.03	3E-10
chr22	33059664	33059665	rs5749482	Height	SYN3	.04	5E-7
chr22	33084510	33084511	rs9621532	Age-related macular degeneration	TIMP3	1.59	2E-15
chr22	33084510	33084511	rs9621532	Age-related macular degeneration	TIMP3	1.61	4E-9
chr22	33084510	33084511	rs9621532	Age-related macular degeneration	TIMP3, SYN3	1.41	1E-11
chr22	33561745	33561746	rs743793	Visceral adipose tissue/subcutaneous adipose tissue ratio	LARGE	NR	6E-7
chr22	33566586	33566587	rs4821132	Visceral adipose tissue adjusted for BMI	LARGE	NR	6E-6
chr22	33746525	33746526	rs2267193	Visceral fat	LARGE	NR	8E-6
chr22	34859792	34859793	rs130575	Attention deficit hyperactivity disorder	Intergenic	NR	5E-6
chr22	34889096	34889097	rs738968	Immune reponse to smallpox (secreted TNF-alpha)	LOC441996	NR	8E-8
chr22	36616444	36616445	rs4821469	End-stage renal disease (non-diabetic)	MYH9	2.86	2E-19
chr22	36661329	36661330	rs2239785	Glomerulosclerosis	APOL1, MYH9	NR	5E-13
chr22	36679057	36679058	rs735854	Optic disc size (rim)	MYH9	.16	9E-6
chr22	37209295	37209296	rs4820255	Sexual dysfunction (female)	PVALB	.37	2E-6
chr22	37258502	37258503	rs4821544	Atopic dermatitis	NCF4	1.09	6E-6
chr22	37310045	37310046	rs2075726	Ankylosing spondylitis	NR	1.14	9E-6
chr22	37462935	37462936	rs855791	Hepcidin levels	TMPRSS6	.24	9E-11
chr22	37462935	37462936	rs855791	Hepcidin levels	TMPRSS6	.19	5E-7
chr22	37462935	37462936	rs855791	Hepcidin levels	TMPRSS6	.22	4E-9
chr22	37462935	37462936	rs855791	Iron status biomarkers	TMPRSS6	.02	2E-15
chr22	37462935	37462936	rs855791	Red blood cell traits	TMPRSS6	.62	5E-9
chr22	37462935	37462936	rs855791	Red blood cell traits	TMPRSS6	.29	1E-12
chr22	37462935	37462936	rs855791	Glycated hemoglobin levels	TMPRSS6	.03	3E-14
chr22	37462935	37462936	rs855791	Hemoglobin	TMPRSS6	.09	3E-25
chr22	37462935	37462936	rs855791	Iron status biomarkers	TMPRSS6	.10	5E-7
chr22	37462935	37462936	rs855791	Iron status biomarkers	TMPRSS6	.13	1E-10
chr22	37462935	37462936	rs855791	Hemoglobin	TMPRSS6	.13	2E-13
chr22	37467391	37467392	rs5756506	Hematological parameters	TMPRSS6	.14	1E-9
chr22	37469590	37469591	rs4820268	Iron levels	TMPRSS6	4.24	4E-11
chr22	37469590	37469591	rs4820268	Red blood cell traits	TMPRSS6	.09	1E-12
chr22	37469590	37469591	rs4820268	Iron levels	TMPRSS6	4.39	5E-9
chr22	37469590	37469591	rs4820268	Hematology traits	TMPRSS6	.13	4E-12
chr22	37469590	37469591	rs4820268	Hematology traits	TMPRSS6	.15	3E-10
chr22	37469590	37469591	rs4820268	Iron status biomarkers	TMPRSS6	NR	6E-6
chr22	37470223	37470224	rs2413450	Mean corpuscular volume	TMPRSS6	.01	3E-41
chr22	37470223	37470224	rs2413450	Mean corpuscular hemoglobin	TMPRSS6	.01	9E-34
chr22	37470223	37470224	rs2413450	Hematocrit	TMPRSS6	.17	2E-13
chr22	37534033	37534034	rs2284033	Asthma	IL2RB	1.12	1E-8
chr22	37551606	37551607	rs743777	Type 1 diabetes autoantibodies	IL2RB	1.10	2E-6
chr22	37551606	37551607	rs743777	Rheumatoid arthritis	IL2RB	1.19	2E-6
chr22	37551606	37551607	rs743777	Rheumatoid arthritis	NR	1.09	1E-6
chr22	37581421	37581422	rs229526	Hypothyroidism	C1QTNF6	1.22	9E-6
chr22	37581484	37581485	rs229527	Vitiligo	C1QTNF6	1.38	2E-16
chr22	37591317	37591318	rs229541	Type 1 diabetes	C1QTNF6	NR	2E-7
chr22	37591317	37591318	rs229541	Type 1 diabetes	C1QTNF6	1.11	2E-8
chr22	37613308	37613309	rs13053175	Longevity	RAC2	NR	1E-6
chr22	37919266	37919267	rs9607469	Optic disc parameters	CARD10	.05	3E-12
chr22	37982011	37982012	rs12157904	Response to antidepressant treatment	LGALS2	NR	2E-6
chr22	38544297	38544298	rs2284063	Cutaneous nevi	PLA2G6	.08	3E-8
chr22	38544297	38544298	rs2284063	Melanoma	Intergenic	1.20	2E-9
chr22	38545618	38545619	rs6001027	Melanoma	PLA2G6	1.18	2E-6
chr22	38546032	38546033	rs5756931	Triglycerides	PLA2G6	1.54	4E-8
chr22	38569005	38569006	rs738322	Cutaneous nevi	PLA2G6	.06	1E-6
chr22	39332622	39332623	rs1014971	Bladder cancer	CBX6,APOBEC3A	1.18	8E-12
chr22	39659772	39659773	rs2413583	Crohn's disease	MAP3K7IP1	1.23	1E-26
chr22	39670850	39670851	rs968451	Primary biliary cirrhosis	MAP3K7IP1	1.27	1E-9
chr22	39687483	39687484	rs54211	Sudden cardiac arrest	Intergenic	1.57	8E-7
chr22	39955872	39955873	rs9611198	Schizophrenia	CACNA1I	1.22	8E-6
chr22	40436972	40436973	rs11704416	Prostate cancer	TNRC6B	1.06	4E-7
chr22	40436972	40436973	rs11704416	Prostate cancer	TNRC6B	1.05	4E-6
chr22	40452118	40452119	rs9623117	Prostate cancer	TNRC6B	1.18	5E-7
chr22	40652872	40652873	rs12484776	Uterine fibroids	TNRC6B	1.23	3E-12
chr22	40654275	40654276	rs12628051	Prostate cancer (gene x gene interaction)	TNRC6B	1.30	3E-6
chr22	40675090	40675091	rs4821941	Prostate cancer (gene x gene interaction)	TNRC6B	1.30	4E-6
chr22	40697580	40697581	rs139909	Height	TNRC6B, ADSL	.25	2E-7
chr22	40820150	40820151	rs5757949	Height	SGSM3, MKL1	NR	4E-6
chr22	40996366	40996367	rs17002034	Bipolar disorder and schizophrenia	NR	1.40	4E-6
chr22	41042090	41042091	rs12159200	Treatment response for severe sepsis	MKL1	NR	6E-7
chr22	41431341	41431342	rs4820425	Crohn's disease	RBX1, EP300	1.27	3E-8
chr22	41757646	41757647	rs4822024	Vitiligo	TOB2	1.28	7E-10
chr22	42218855	42218856	rs7364180	Alzheimer's disease biomarkers	CCDC134	NR	1E-6
chr22	42670964	42670965	rs134882	Bipolar disorder and schizophrenia	NR	1.22	7E-6
chr22	43500211	43500212	rs5759167	Prostate cancer	NR	1.16	6E-29
chr22	43518274	43518275	rs742134	Prostate cancer	BIK	1.16	6E-6
chr22	43635572	43635573	rs5751452	Response to fenofibrate (adiponectin levels)	SCUBE1	.31	2E-6
chr22	44324726	44324727	rs738409	Nonalcoholic fatty liver disease	PNPLA3	1.66	1E-10
chr22	44324726	44324727	rs738409	Liver enzyme levels (alanine transaminase)	PNPLA3, SAMM50	6.00	1E-45
chr22	44324726	44324727	rs738409	Nonalcoholic fatty liver disease	PNPLA3	.26	4E-34
chr22	44325995	44325996	rs12483959	Metabolite levels	PNPLA3	.00	2E-39
chr22	44325995	44325996	rs12483959	Metabolite levels	PNPLA3	.00	2E-18
chr22	44332569	44332570	rs2281135	Liver enzyme levels	PNPLA3, SAMM50	.06	8E-16
chr22	44391685	44391686	rs2143571	Nonalcoholic fatty liver disease	SAMM50	1.47	6E-7
chr22	44394401	44394402	rs2073080	Nonalcoholic fatty liver disease	PARVB	1.47	8E-7
chr22	44968529	44968530	rs138597	Economic and political preferences (time)	LOC388910	.12	7E-6
chr22	45011760	45011761	rs4823246	Economic and political preferences (feminism/equality)	Intergenic	.10	3E-6
chr22	45150658	45150659	rs5765956	Orofacial clefts	NR	NR	2E-6
chr22	45183013	45183014	rs16992796	Electroencephalographic traits in alcoholism	PRR5, ARHGAP8	.24	3E-6
chr22	45961903	45961904	rs1985671	Temperament (bipolar disorder)	FBLN1	1.06	2E-8
chr22	46421841	46421842	rs6519955	Dupuytren's disease	RP11-398F12.1, WNT7B	1.54	3E-33
chr22	47532395	47532396	rs5766691	Longevity	TBC1D22A	NR	1E-6
chr22	48284513	48284514	rs9627183	Attention deficit hyperactivity disorder	Intergenic	NR	3E-6
chr22	48453590	48453591	rs117294	Economic and political preferences (fairness)	Intergenic	.11	7E-6
chr22	48929568	48929569	rs5768709	Pancreatic cancer	FAM19A5	1.25	1E-10
chr22	49812501	49812502	rs17000918	Immune reponse to smallpox (secreted IL-1beta)	FLJ44385	NR	4E-9
chr22	50086372	50086373	rs6009824	Natriuretic peptide levels	BRD1	.13	7E-6
chr22	50350970	50350971	rs28372448	Cannabis dependence	PIM3	1.68	8E-6
chr22	50435479	50435480	rs5771069	Ulcerative colitis	PIM3, IL17REL	1.11	2E-7
chr22	50435479	50435480	rs5771069	Ulcerative colitis	IL17REL	1.17	4E-8
chr22	50971265	50971266	rs140522	Multiple sclerosis	ODF3B, SCO2	1.10	2E-8
chr22	50971751	50971752	rs131794	Mean corpuscular volume	ECGF1	.00	1E-15
chr22	51017352	51017353	rs5770917	Narcolepsy	CPT1B	1.63	6E-8
chr22	51104679	51104680	rs9616906	Longevity	AC000050.2	NR	1E-6
chr3	108992	108993	rs9841287	Fasting insulin-related traits (interaction with BMI)	CHL1	NR	7E-9
chr3	149985	149986	rs12485321	Prostate cancer (gene x gene interaction)	CHL1	1.23	3E-6
chr3	172476	172477	rs6795349	Response to antidepressant treatment	CHL1	NR	2E-6
chr3	191046	191047	rs10510181	Scoliosis	CHL1,LOC642891	1.37	8E-7
chr3	312348	312349	rs6764363	Sudden cardiac arrest	CHL1	1.19	6E-6
chr3	883850	883851	rs4684585	Response to statin therapy	LOC402123, CNTN6, CHL1	NR	9E-7
chr3	898660	898661	rs35964523	Response to statin therapy	CNTN6,LOC402123,CHL1	NR	8E-6
chr3	1345424	1345425	rs9861887	Visceral adipose tissue/subcutaneous adipose tissue ratio	CNTN6	NR	9E-6
chr3	1512586	1512587	rs6763848	Prostate cancer (gene x gene interaction)	CNTN6	1.30	4E-6
chr3	1623392	1623393	rs402675	Estradiol levels	Intergenic	.10	6E-6
chr3	1741764	1741765	rs73001827	Response to amphetamines	Intergenic	NR	1E-6
chr3	1839692	1839693	rs10510217	Total ventricular volume	CNTN4	.00	3E-6
chr3	1897972	1897973	rs2727943	Bipolar disorder	Intergenic	NR	3E-8
chr3	2624937	2624938	rs2619566	Amyotrophic lateral sclerosis	CNTN4	3.03	7E-6
chr3	2654690	2654691	rs4370013	Blood pressure	CNTN4	NR	4E-6
chr3	2846315	2846316	rs975334	Gallbladder cancer	NR	8.30	9E-7
chr3	2881574	2881575	rs6781149	Intelligence	CNTN4	NR	1E-7
chr3	2886526	2886527	rs17584516	Intelligence	CNTN4	NR	1E-7
chr3	2893273	2893274	rs4629318	Intelligence	CNTN4	NR	1E-7
chr3	2895683	2895684	rs11713158	Intelligence	CNTN4	NR	1E-7
chr3	2895683	2895684	rs11713158	Intelligence	CNTN4	5.04	9E-7
chr3	3130644	3130645	rs3804795	Immune response to smallpox vaccine (IL-6)	IL5RA	NR	1E-6
chr3	3147980	3147981	rs17879755	QT interval	NR	5.64	2E-6
chr3	3375783	3375784	rs9835812	Immune response to smallpox vaccine (IL-6)	CRBN	NR	8E-7
chr3	3614886	3614887	rs9815663	Asthma (childhood onset)	IL5RA	.17	2E-8
chr3	3650238	3650239	rs9837561	Response to amphetamines	Intergenic	NR	3E-6
chr3	3658839	3658840	rs1601875	Bipolar disorder	NR	1.14	7E-6
chr3	3679851	3679852	rs17034687	Disc degeneration (lumbar)	Intergenic	.23	2E-9
chr3	4437357	4437358	rs794185	Multiple sclerosis--Brain Glutamate Levels	SUMF1	NR	6E-7
chr3	4633491	4633492	rs2322734	Airflow obstruction	ITPR1	1.45	8E-6
chr3	5013875	5013876	rs6442925	Corneal structure	BHLHB2	1.56	2E-6
chr3	5188245	5188246	rs11918654	Disc degeneration (lumbar)	ARL8B	.11	7E-6
chr3	5705051	5705052	rs11710433	Bipolar disorder (mood-incongruent)	Intergenic	1.23	1E-6
chr3	6255996	6255997	rs6774280	Response to tocilizumab in rheumatoid arthritis	Intergenic	5.50	9E-7
chr3	6377694	6377695	rs271066	Alzheimer's disease (age of onset)	NR	NR	3E-6
chr3	6481624	6481625	rs17216035	Visceral adipose tissue adjusted for BMI	GRM7	NR	3E-6
chr3	6903296	6903297	rs3749380	Panic disorder	GRM7	NR	2E-6
chr3	7403645	7403646	rs13080594	Personality dimensions	GRM7	NR	8E-7
chr3	7529554	7529555	rs9870680	Major depressive disorder (broad)	GRM7	1.19	1E-6
chr3	7538201	7538202	rs1450100	Orofacial clefts	GRM7	1.54	8E-6
chr3	7982826	7982827	rs4591494	Factor VII	Intergenic	NR	9E-6
chr3	8250789	8250790	rs9866825	QT interval	NR	1.18	8E-6
chr3	8808514	8808515	rs237899	Depression and alcohol dependence	OXTR	1.69	2E-6
chr3	10535770	10535771	rs6807064	Metabolite levels	ATP2B2	NR	1E-7
chr3	10774758	10774759	rs1682825	Economic and political preferences (feminism/equality)	Intergenic	.12	4E-6
chr3	10877610	10877611	rs1809529	Response to tocilizumab in rheumatoid arthritis	SLC6A11	.28	3E-7
chr3	11040438	11040439	rs9990174	Conduct disorder (interaction)	SLC6A1	2.52	6E-6
chr3	11075013	11075014	rs2675163	Response to Vitamin E supplementation	SLC6A1	.68	6E-6
chr3	11675788	11675789	rs6782029	Anorexia nervosa	VGLL4	NR	9E-6
chr3	11956597	11956598	rs6777876	Alcohol dependence	C3orf31	NR	4E-7
chr3	12116619	12116620	rs308971	Fasting insulin-related traits (interaction with BMI)	SYN2	NR	2E-7
chr3	12267647	12267648	rs7616006	Platelet counts	SYN2	2.00	5E-8
chr3	12277844	12277845	rs17036101	Type 2 diabetes	SYN2, PPARG	1.15	2E-7
chr3	12289799	12289800	rs13081389	Type 2 diabetes	PPARG	1.24	2E-7
chr3	12330410	12330411	rs17036170	Drug-induced liver injury	PPARG	11.30	2E-8
chr3	12385827	12385828	rs11128603	Plasminogen activator inhibitor type 1 levels (PAI-1)	PPARG	.07	9E-8
chr3	12393124	12393125	rs1801282	Fasting insulin-related traits (interaction with BMI)	PPARG	NR	2E-7
chr3	12393124	12393125	rs1801282	Type 2 diabetes	PPARG	1.14	2E-6
chr3	12393124	12393125	rs1801282	Type 2 diabetes	PPARG	1.14	2E-6
chr3	12393124	12393125	rs1801282	Type 2 diabetes	PPARG	1.14	2E-6
chr3	12551806	12551807	rs6766510	Prostate cancer (gene x gene interaction)	TSEN2	1.58	2E-6
chr3	12626515	12626516	rs3729931	Cardiac hypertrophy	RAF1	NR	7E-7
chr3	12628919	12628920	rs2290159	Cholesterol, total	RAF1	1.42	4E-9
chr3	13555835	13555836	rs2597513	Height	HDAC11	.04	7E-10
chr3	13736999	13737000	rs4450798	Bipolar disorder (mood-incongruent)	FBLN2	1.26	2E-6
chr3	13743131	13743132	rs9846232	Personality dimensions	BC039529	NR	1E-8
chr3	13857968	13857969	rs1124480	Chronic obstructive pulmonary disease-related biomarkers	WNT7A	NR	9E-6
chr3	13961156	13961157	rs9875589	Ovarian reserve	TPRXL	NR	4E-6
chr3	14480777	14480778	rs6790433	Response to taxane treatment (docetaxel)	SLC6A6	NR	1E-6
chr3	14530720	14530721	rs9036	Cognitive performance	GRIP2	NR	3E-6
chr3	15295363	15295364	rs1318937	Alcohol and nictotine co-dependence	SH3BP5, NR2C2, ZFYVE20	NR	4E-7
chr3	15295363	15295364	rs1318937	Alcohol dependence	SH3BP5	NR	3E-6
chr3	15440555	15440556	rs6442522	Uric acid levels	NR	.05	5E-6
chr3	15648003	15648004	rs7651039	Coronary heart disease	Intergenic	1.06	2E-6
chr3	16395667	16395668	rs690037	Optic disc size (cup)	RFTN1	.21	2E-7
chr3	16408488	16408489	rs12635698	Obesity (extreme)	RAFTLIN	1.41	5E-6
chr3	16955258	16955259	rs1372072	Primary biliary cirrhosis	PLCL2	1.20	2E-8
chr3	16970937	16970938	rs9821630	Multiple sclerosis	PLCL2	1.08	4E-6
chr3	18311411	18311412	rs7641175	Platelet counts	SATB1	2.76	3E-11
chr3	18706857	18706858	rs13073817	Crohn's disease	intergenic	1.08	7E-9
chr3	18784422	18784423	rs6809854	Psoriasis	Intergenic	1.14	1E-7
chr3	19375790	19375791	rs2053506	Hip geometry	KCNH8	NR	4E-6
chr3	20108545	20108546	rs1124376	Bipolar disorder and schizophrenia	NR	1.28	5E-6
chr3	20220711	20220712	rs6767049	Temperament (bipolar disorder)	SGOL1	.77	2E-6
chr3	20615272	20615273	rs1395103	Bipolar disorder and schizophrenia	NR	1.24	9E-6
chr3	21248641	21248642	rs11720452	Bipolar disorder	NR	1.15	5E-6
chr3	21706368	21706369	rs3821396	Bipolar disorder	NR	1.23	5E-6
chr3	21719245	21719246	rs1490157	Partial epilepsies	ZNF385D	1.20	5E-6
chr3	21955197	21955198	rs11719664	Attention deficit hyperactivity disorder	Intergenic	NR	2E-6
chr3	22122395	22122396	rs2593321	HIV-1 control	AC023798.16	NR	8E-6
chr3	23093573	23093574	rs9310709	Chronic kidney disease and serum creatinine levels	NR	1.15	2E-6
chr3	25112170	25112171	rs993804	Bipolar disorder and schizophrenia	NR	1.28	1E-6
chr3	25520581	25520582	rs1529672	Pulmonary function	RARB	.05	4E-14
chr3	25538316	25538317	rs1997352	Airflow obstruction	RARB	1.19	9E-7
chr3	25560230	25560231	rs1435703	Obesity (extreme)	RARB	1.66	4E-6
chr3	27416012	27416013	rs4973768	Breast cancer	SLC4A7	1.14	2E-8
chr3	27416012	27416013	rs4973768	Breast cancer	SLC4A7	1.16	6E-7
chr3	27537908	27537909	rs13082711	Systolic blood pressure	SLC4A7	.32	2E-6
chr3	27537908	27537909	rs13082711	Diastolic blood pressure	SLC4A7	.24	4E-9
chr3	27537908	27537909	rs13082711	Blood pressure	SLC4A7	.34	5E-9
chr3	27788779	27788780	rs11129295	Multiple sclerosis	EOMES	1.11	1E-9
chr3	28071443	28071444	rs669607	Multiple sclerosis	Intergenic	1.13	2E-15
chr3	28079084	28079085	rs170934	Multiple sclerosis	EOMES	1.17	2E-8
chr3	28705763	28705764	rs7617877	Parkinson's disease	NR	1.23	3E-6
chr3	28928859	28928860	rs2221154	Alzheimer's disease	Intergenic	1.75	3E-6
chr3	29209150	29209151	rs6549915	Breast size	MESTP4, RBMS3	.08	9E-6
chr3	29575462	29575463	rs1530057	Lung cancer	NR	1.26	3E-6
chr3	29853402	29853403	rs10510628	Bone mineral density	RBMS3	NR	3E-6
chr3	30346967	30346968	rs10510634	Fasting plasma glucose	Intergenic	NR	5E-6
chr3	30462402	30462403	rs7640543	Migraine	TGFBR2	1.19	1E-9
chr3	30710242	30710243	rs3773643	Tonometry	TGFBR2	NR	2E-7
chr3	31445579	31445580	rs17027625	HIV-1 control	Intergenic	NR	4E-6
chr3	31795569	31795570	rs1902341	Peripheral artery disease	OSBPL10	1.31	5E-7
chr3	32240118	32240119	rs9825310	Alcohol dependence	GPD1L	1.25	8E-6
chr3	32329496	32329497	rs4380451	Bipolar disorder	NR	1.18	4E-6
chr3	32347823	32347824	rs4627791	Bipolar disorder	NR	NR	2E-6
chr3	32378270	32378271	rs6776297	HIV-1 viral setpoint	CMTM8	NR	5E-6
chr3	32488533	32488534	rs12638540	Mortality among heart failure patients	CMTM7	1.53	3E-7
chr3	32842100	32842101	rs9845475	Attention deficit hyperactivity disorder (time to onset)	Intergenic	NR	4E-6
chr3	32929114	32929115	rs9310995	Pulmonary function	TRIM71	.02	4E-6
chr3	33015468	33015469	rs13314993	Celiac disease	CCR4	1.13	3E-9
chr3	33020034	33020035	rs4678680	Hepatocellular carcinoma	GLB1	2.27	2E-7
chr3	33065338	33065339	rs7613051	Atopic dermatitis	GLB1	1.29	6E-21
chr3	34212165	34212166	rs6781182	Visceral adipose tissue adjusted for BMI	PDCD6IP	NR	3E-6
chr3	34962668	34962669	rs10514688	Tonometry	Intergenic	NR	6E-6
chr3	35142510	35142511	rs11129640	Entorhinal cortical thickness	ARPP-21	.12	6E-8
chr3	35982129	35982130	rs6799705	Cognitive performance	ARPP-21	NR	2E-7
chr3	36680098	36680099	rs950146	Erectile dysfunction	STAC	NR	4E-6
chr3	36856029	36856030	rs9834970	Bipolar disorder (mood-incongruent)	TRANK1, LBA	1.22	1E-7
chr3	36856029	36856030	rs9834970	Bipolar disorder	TRANK1	NR	1E-12
chr3	36862979	36862980	rs4624519	Schizophrenia	NR	1.09	2E-7
chr3	36864488	36864489	rs6550435	Bipolar disorder	LBA1	1.09	9E-6
chr3	37234588	37234589	rs7631605	P-tau181p	Intergenic	NR	1E-6
chr3	37515826	37515827	rs197770	Phospholipid levels (plasma)	ITGA9	.80	2E-8
chr3	37518544	37518545	rs189897	Nasopharyngeal carcinoma	ITGA9	3.18	7E-8
chr3	37574023	37574024	rs267567	PR interval	ITGA9	2.73	4E-11
chr3	37996476	37996477	rs9311171	Prostate cancer	CTDSPL	NR	2E-6
chr3	38442489	38442490	rs2070488	Electrocardiographic conduction measures	SCN5A	5.00	4E-6
chr3	38589162	38589163	rs11129795	Electrocardiographic traits	SCN5A	8.24	5E-10
chr3	38589162	38589163	rs11129795	QT interval	SCN5A	1.27	5E-14
chr3	38593392	38593393	rs12053903	Electrocardiographic traits	SCN5A	6.59	1E-7
chr3	38593392	38593393	rs12053903	QT interval	SCN5A	1.23	1E-14
chr3	38594972	38594973	rs7638909	Electrocardiographic conduction measures	SCN5A	4.80	2E-6
chr3	38624252	38624253	rs3922844	PR interval	SCN5A	4.54	5E-43
chr3	38624252	38624253	rs3922844	PR interval	SCN5A	5.11	3E-23
chr3	38633922	38633923	rs11708996	Ventricular conduction	SCN5A	.47	7E-6
chr3	38633922	38633923	rs11708996	PR interval	SCN5A	3.04	6E-26
chr3	38657898	38657899	rs11710077	Ventricular conduction	SCN5A	.44	1E-6
chr3	38681393	38681394	rs6763048	PR interval	SCN5A	2.62	4E-12
chr3	38719934	38719935	rs9851724	Ventricular conduction	SCN10A,SCN5A	.60	6E-16
chr3	38766674	38766675	rs6795970	Electrocardiographic traits	SCN10A	5.17	4E-9
chr3	38766674	38766675	rs6795970	Electrocardiographic traits	SCN10A	14.81	1E-58
chr3	38766674	38766675	rs6795970	Electrocardiographic traits	SCN10A	3.33	3E-15
chr3	38767314	38767315	rs6801957	PR interval	SCN10A	3.36	9E-9
chr3	38767314	38767315	rs6801957	Ventricular conduction	SCN10A	.54	3E-14
chr3	38774831	38774832	rs6800541	Atrioventricular conduction	SCN10A	2.60	5E-7
chr3	38774831	38774832	rs6800541	PR interval	SCN10A	3.77	2E-74
chr3	39523002	39523003	rs1768208	Progressive supranuclear palsy	MOBP	1.37	5E-17
chr3	39553787	39553788	rs816488	Cognitive performance	MOBP	NR	4E-6
chr3	39555579	39555580	rs864643	Attention deficit hyperactivity disorder	MOBP	NR	1E-8
chr3	39847071	39847072	rs17079534	Acute lymphoblastic leukemia (childhood)	MYRIP	4.07	2E-7
chr3	40008633	40008634	rs9985399	Information processing speed	MYRIP	.26	9E-6
chr3	40096617	40096618	rs6599077	Sleep duration	MYRIP	NR	1E-7
chr3	41123734	41123735	rs10490823	Bone mineral density (hip)	NR	.06	9E-6
chr3	41137671	41137672	rs87938	Bone mineral density (hip)	CTNNB1	.07	8E-10
chr3	41877413	41877414	rs3774372	Blood pressure	ULK4	.30	8E-7
chr3	41912650	41912651	rs9815354	Diastolic blood pressure	ULK4	.49	3E-9
chr3	41925397	41925398	rs1052501	Multiple myeloma	ULK4	1.32	2E-8
chr3	42093421	42093422	rs1498095	Visceral adipose tissue/subcutaneous adipose tissue ratio	TRAK1	NR	8E-6
chr3	42303073	42303074	rs4377469	Body mass index	CCK	.04	2E-7
chr3	42448470	42448471	rs2286720	Reasoning	LYZL4	NR	1E-6
chr3	43230722	43230723	rs17075286	Bipolar disorder and schizophrenia	C3orf39	NR	8E-7
chr3	45731450	45731451	rs2742417	Response to antidepressant treatment	SACM1L	NR	5E-7
chr3	45814093	45814094	rs17279437	Urinary metabolites	SLC6A20	NR	3E-19
chr3	45817417	45817418	rs758386	Immune reponse to smallpox (secreted TNF-alpha)	SLC6A20	NR	2E-7
chr3	46235200	46235201	rs13098911	Celiac disease	CCR1, CCR2, CCRL2, CCR3, CCR5, CCR9	1.30	3E-17
chr3	46282390	46282391	rs12636651	Monocyte chemoattractant protein-1	CCR3	NR	7E-9
chr3	46339811	46339812	rs9990343	Brain structure	Intergenic	NR	4E-7
chr3	46352383	46352384	rs6441961	Celiac disease	CCR1, CCR3	1.21	3E-7
chr3	46428189	46428190	rs6441975	AIDS progression	CCRL2	1.48	5E-6
chr3	46451679	46451680	rs1015164	AIDS progression	LTF	1.46	9E-6
chr3	47927483	47927484	rs319690	Blood pressure	MAP4	.30	3E-8
chr3	48487047	48487048	rs730566	Prion diseases	NR	1.27	7E-6
chr3	48487337	48487338	rs9876781	Longevity	RP11-24C3.2	NR	1E-6
chr3	49210731	49210732	rs7617480	Menarche (age at onset)	KLHDC8B	2.40	3E-8
chr3	49701982	49701983	rs9858542	Ulcerative colitis	MST1	NR	7E-9
chr3	49701982	49701983	rs9858542	Crohn's disease	BSN, MST1	1.09	4E-8
chr3	49701982	49701983	rs9858542	Crohn's disease	MST1	1.17	5E-8
chr3	49719728	49719729	rs9822268	Ulcerative colitis	MST1, UBA7, APEH, AMIGO3, GMPPB, BSN	1.21	2E-17
chr3	49721531	49721532	rs3197999	Primary sclerosing cholangitis	MST1	1.39	1E-16
chr3	49721531	49721532	rs3197999	Crohn's disease	MST1,GPX1,BSN	1.22	6E-17
chr3	49721531	49721532	rs3197999	Ulcerative colitis	MST1	1.20	4E-9
chr3	49721531	49721532	rs3197999	Crohn's disease	MST1	1.20	1E-12
chr3	50093208	50093209	rs6762477	Menarche (age at onset)	RBM6	2.50	2E-8
chr3	50352199	50352200	rs11130248	Keloid	NR	1.34	5E-7
chr3	51071712	51071713	rs13088462	Height	DOCK3	.05	4E-10
chr3	52279593	52279594	rs7618915	Bipolar disorder	Intergenic	NR	3E-10
chr3	52506425	52506426	rs6784615	Waist-hip ratio	NISCH, STAB1	.04	4E-10
chr3	52584786	52584787	rs2251219	Major mood disorders	PBRM1	1.14	2E-9
chr3	52622085	52622086	rs2590838	Adiponectin levels	GNL3	.03	2E-13
chr3	52718279	52718280	rs10865974	Bipolar disorder (mood-incongruent)	PBRM1, GNL3	1.19	2E-6
chr3	52720079	52720080	rs1108842	Adiponectin levels	GNL3	.03	1E-13
chr3	52721304	52721305	rs11177	Osteoarthritis	GNL3, GLT8D1	1.09	5E-9
chr3	52821010	52821011	rs1042779	Bipolar disorder	ITIH1, NEK4	1.19	2E-7
chr3	52835353	52835354	rs736408	Bipolar disorder	WDR82, TWF2, TNNC1, TMEM110, TLR9, STAB1,SPCS1, SNORD69, SNORD19, SNORD19B, SFMBT1, SEMA3G, RFT1, PRKCD, PPM1M, PHF7, PBRM1, NT5DC2, NISCH, NEK4, MUSTN1, LOC440957, ITIH1, ITIH3, ITIH4, GNL3, GLYCTK, GLT8D1, DNAH1, BAP1, ALAS1	1.10	2E-6
chr3	52844533	52844534	rs17331151	Immune reponse to smallpox (secreted IL-2)	ITIH3, ITIH4	NR	2E-9
chr3	52855228	52855229	rs2239547	Schizophrenia	ITIH3, ITIH4	1.10	6E-8
chr3	52913278	52913279	rs3796352	Immune reponse to smallpox (secreted IL-2)	TMEM110	NR	5E-7
chr3	53118738	53118739	rs2336725	Height	RTF1	.03	1E-12
chr3	53147575	53147576	rs13088281	Immune reponse to smallpox (secreted IL-2)	RFT1	NR	3E-11
chr3	53282302	53282303	rs4687718	Ventricular conduction	TKT, PRKCD, CACNA1D	.63	6E-9
chr3	53680123	53680124	rs1401492	Insulin resistance/response	CACNA1D	16.00	5E-6
chr3	53680123	53680124	rs1401492	Insulin resistance/response	CACNA1D	15.00	3E-6
chr3	54632546	54632547	rs13064588	Bipolar disorder and schizophrenia	NR	1.24	4E-6
chr3	55035873	55035874	rs4955826	Immune response to smallpox vaccine (IL-6)	CACNA2D3	NR	5E-6
chr3	55188272	55188273	rs11706236	Insomnia (caffeine-induced)	RP11-889D3.1	1.59	4E-6
chr3	55313399	55313400	rs358806	Type 2 diabetes	NR	1.16	3E-6
chr3	55571759	55571760	rs1795648	Bipolar disorder and schizophrenia	ERC2	NR	6E-6
chr3	56530708	56530709	rs2054989	Hip geometry	ERC2	NR	6E-7
chr3	56667681	56667682	rs9835332	Height	C3orf63	.03	5E-13
chr3	56735179	56735180	rs6773931	Height	Intergenic	.05	8E-8
chr3	56849748	56849749	rs1354034	Platelet counts	ARHGEF3	6.85	3E-54
chr3	56849748	56849749	rs1354034	Mean platelet volume	ARHGEF3	.02	3E-69
chr3	56865775	56865776	rs12485738	Mean platelet volume	ARHGEF3	.02	6E-31
chr3	56865775	56865776	rs12485738	Mean platelet volume	ARHGEF3	.02	4E-27
chr3	56966245	56966246	rs2062583	Rheumatoid arthritis	ARHGEF3	1.59	2E-6
chr3	56966245	56966246	rs2062583	Rheumatoid arthritis	ARHGEF3	1.59	2E-6
chr3	57394765	57394766	rs1916284	Prostate cancer (gene x gene interaction)	DNAH12	1.27	1E-6
chr3	58370176	58370177	rs6445975	Systemic lupus erythematosus	PXK	1.25	7E-9
chr3	58556840	58556841	rs13315591	Rheumatoid arthritis	PXK	1.29	5E-8
chr3	59354157	59354158	rs6771019	Capecitabine sensitivity	Intergenic	NR	2E-6
chr3	59902800	59902801	rs1825630	Aortic root size	FHIT	.09	8E-6
chr3	59921019	59921020	rs4502542	Response to citalopram treatment	FHIT	NR	2E-6
chr3	59928850	59928851	rs931317	Myopia (pathological)	FHIT	NR	3E-6
chr3	59981524	59981525	rs212016	Orofacial clefts	FHIT	1.54	7E-6
chr3	60123521	60123522	rs10510829	Adverse response to lamotrigine and phenytoin	FHIT	NR	7E-7
chr3	60289841	60289842	rs10510837	Asperger disorder	FHIT	NR	4E-6
chr3	60508339	60508340	rs80171647	Response to amphetamines	FHIT	NR	2E-6
chr3	60763255	60763256	rs11919041	Breast size	NPCDR1,PTPRG	.08	2E-6
chr3	60771107	60771108	rs6791644	Attention deficit hyperactivity disorder	FHIT	NR	8E-6
chr3	61413813	61413814	rs10514718	Major depressive disorder	FHIT, PTPRG	2.12	4E-6
chr3	61794053	61794054	rs652889	QT interval	PTPRG	.15	8E-7
chr3	62036723	62036724	rs10490775	Fuchs's corneal dystrophy	PTPRG	2.30	1E-6
chr3	62064768	62064769	rs11130874	Schizophrenia	NR	1.10	2E-6
chr3	62478193	62478194	rs13325751	Economic and political preferences (environmentalism)	CADPS	.13	6E-6
chr3	62733365	62733366	rs580384	Breast size	CADPS	.12	4E-6
chr3	64048296	64048297	rs831571	Type 2 diabetes	PSMD6	1.09	8E-11
chr3	64078008	64078009	rs153734	Folate pathway vitamin levels	PRICKLE2	.29	7E-6
chr3	64705364	64705365	rs6795735	Waist-hip ratio	ADAMTS9	.04	2E-16
chr3	64711903	64711904	rs4607103	Type 2 diabetes	ADAMTS9	1.09	1E-8
chr3	64727085	64727086	rs7433808	Visceral adipose tissue/subcutaneous adipose tissue ratio	ADAMTS9	NR	2E-7
chr3	64727085	64727086	rs7433808	Visceral adipose tissue/subcutaneous adipose tissue ratio	ADAMTS9	NR	2E-7
chr3	64729891	64729892	rs7638389	Visceral adipose tissue adjusted for BMI	ADAMTS9	NR	8E-6
chr3	64927024	64927025	rs704454	Alzheimer's disease (age of onset)	ADAMTS9	NR	3E-6
chr3	66431601	66431602	rs2242285	Ventricular conduction	LRIG1,SLC25A26	.37	1E-8
chr3	66768363	66768364	rs17045031	Carotid intima media thickness	LRIG1	.30	4E-7
chr3	66798949	66798950	rs13069000	Renal function-related traits (BUN)	LRIG1, KBTBD8	.01	1E-19
chr3	66809941	66809942	rs13069049	Metabolite levels	Intergenic	.02	3E-18
chr3	67373976	67373977	rs977102	Response to amphetamines	Intergenic	NR	2E-6
chr3	67416321	67416322	rs17806888	Height	SUCLG2	.04	2E-9
chr3	67531387	67531388	rs6792584	Corneal astigmatism	SUCLG2	1.24	5E-6
chr3	69173374	69173375	rs7638995	Alzheimer's disease (late onset)	Intergenic	NR	2E-6
chr3	69252898	69252899	rs6806528	Celiac disease	FRMD4B	1.19	2E-7
chr3	69442636	69442637	rs922948	Hip geometry	Intergenic	NR	2E-6
chr3	69623187	69623188	rs7647307	Brain imaging	LOC642487	NR	NS
chr3	70463329	70463330	rs1024889	Body mass index	NR	.12	6E-6
chr3	70626359	70626360	rs7628219	Insomnia (caffeine-induced)	RP11-430J3.1	1.61	2E-6
chr3	71020489	71020490	rs17651978	Attention deficit hyperactivity disorder	FOXP1	NR	6E-6
chr3	71115750	71115751	rs7616330	QT interval	NR	1.72	6E-6
chr3	71300566	71300567	rs17008402	Subcutaneous adipose tissue	FOXP1	NR	2E-6
chr3	72023699	72023700	rs2135319	Bilirubin levels	RP11-648C16.1	.19	4E-6
chr3	72437412	72437413	rs9863706	Height	RYBP	.03	4E-13
chr3	73540617	73540618	rs4557101	QT interval	NR	1.72	4E-6
chr3	73619560	73619561	rs11128347	Dialysis-related mortality	PDZRN3	1.85	6E-7
chr3	74627702	74627703	rs13073838	Economic and political preferences	Intergenic	.12	3E-6
chr3	76484182	76484183	rs3849491	Sex hormone-binding globulin levels	Intergenic	.07	6E-6
chr3	78044688	78044689	rs9836484	Brain imaging in schizophrenia (interaction)	ROBO2, ROBO1	NR	4E-6
chr3	78353590	78353591	rs9831754	Calcium levels	Intergenic	.02	8E-6
chr3	78498996	78498997	rs9834373	Protein quantitative trait loci	ROBO1	NR	4E-6
chr3	80865763	80865764	rs9850225	Erectile dysfunction	SLC25A36	NR	5E-8
chr3	84481067	84481068	rs10511089	Brain structure	Intergenic	NR	7E-7
chr3	85502844	85502845	rs13323436	Visceral fat	CADM2	NR	3E-6
chr3	85874475	85874476	rs12494658	Temperament	CADM2	.08	5E-6
chr3	85884149	85884150	rs13078807	Body mass index	CADM2	.10	4E-11
chr3	86158884	86158885	rs2324999	Subcutaneous adipose tissue	CADM2	NR	4E-6
chr3	86158884	86158885	rs2324999	Subcutaneous adipose tissue	CADM2	NR	2E-6
chr3	86255671	86255672	rs7428796	Myopia (pathological)	Intergenic	NR	2E-18
chr3	86894477	86894478	rs9757252	Prostate cancer (gene x gene interaction)	VGLL3	1.25	5E-6
chr3	86916881	86916882	rs7642134	Menarche (age at onset)	VGLL3	2.40	4E-10
chr3	87110673	87110674	rs2660753	Prostate cancer	Intergenic	1.18	3E-8
chr3	87134799	87134800	rs17023900	Prostate cancer	NR	1.41	6E-8
chr3	87152168	87152169	rs9284813	Prostate cancer	Intergenic	NR	5E-9
chr3	87173323	87173324	rs17181170	Prostate cancer	NR	NR	3E-8
chr3	87241496	87241497	rs7629490	Prostate cancer	Intergenic	1.06	1E-7
chr3	87783975	87783976	rs9860340	Electroencephalographic traits in alcoholism	Intergenic	.12	4E-6
chr3	88524174	88524175	rs2880961	Response to acetaminophen (hepatotoxicity)	C3orf38	NR	2E-7
chr3	89534376	89534377	rs7632427	Orofacial clefts	NR	NR	4E-8
chr3	89534376	89534377	rs7632427	Orofacial clefts	EPHA3	1.37	4E-8
chr3	95688842	95688843	rs9814870	Male infertility	ARL6	NR	7E-7
chr3	98034525	98034526	rs1497546	Drug-induced liver injury (flucloxacillin)	OR5H2	6.57	2E-7
chr3	99167106	99167107	rs2670321	RR interval (heart rate)	Intergenic	.16	2E-6
chr3	99266336	99266337	rs13070584	Chronic kidney disease and serum creatinine levels	NR	1.42	2E-6
chr3	99396271	99396272	rs13095226	Age-related macular degeneration	COL8A1	1.24	3E-6
chr3	99592595	99592596	rs813218	Orofacial clefts	NR	NR	1E-6
chr3	99956555	99956556	rs12486865	Visceral adipose tissue/subcutaneous adipose tissue ratio	TBC1D23, C3orf26	NR	7E-6
chr3	101411977	101411978	rs112553552	Response to amphetamines	Intergenic	NR	3E-6
chr3	101748637	101748638	rs771767	Multiple sclerosis	NFKBIZ	1.10	9E-9
chr3	101774042	101774043	rs991258	Hip geometry	Intergenic	NR	5E-7
chr3	102203044	102203045	rs2063640	Type 2 diabetes	ZPLD1	1.23	3E-6
chr3	103245091	103245092	rs1397924	Economic and political preferences (environmentalism)	Intergenic	.09	1E-6
chr3	103292225	103292226	rs4856162	Economic and political preferences (environmentalism)	Intergenic	.09	1E-6
chr3	103307641	103307642	rs7612581	Economic and political preferences (environmentalism)	Intergenic	.09	2E-6
chr3	103331482	103331483	rs9820695	Economic and political preferences (environmentalism)	Intergenic	.09	9E-7
chr3	103345438	103345439	rs9821642	Economic and political preferences (environmentalism)	Intergenic	.09	7E-7
chr3	103359217	103359218	rs10937540	Economic and political preferences (environmentalism)	Intergenic	.09	4E-7
chr3	103363060	103363061	rs10937544	Economic and political preferences (environmentalism)	Intergenic	.09	6E-6
chr3	103380851	103380852	rs6775909	Economic and political preferences (environmentalism)	Intergenic	.09	6E-7
chr3	103397768	103397769	rs12485744	Economic and political preferences (environmentalism)	Intergenic	.09	2E-6
chr3	103400081	103400082	rs7628767	Economic and political preferences (environmentalism)	Intergenic	.09	1E-6
chr3	103403513	103403514	rs10511217	Economic and political preferences (environmentalism)	Intergenic	.09	2E-6
chr3	103438873	103438874	rs4493441	Economic and political preferences (environmentalism)	Intergenic	.09	1E-6
chr3	105010889	105010890	rs9810233	Erectile dysfunction	ALCAM	NR	7E-7
chr3	105586713	105586714	rs9657904	Multiple sclerosis	CBLB	1.40	2E-10
chr3	105869801	105869802	rs2199936	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	ABCG2	2.80	2E-10
chr3	105869801	105869802	rs2199936	Cardiovascular disease risk factors	ABCG2	.19	2E-17
chr3	105869801	105869802	rs2199936	Urate levels	ABCG2	1.86	3E-23
chr3	105869801	105869802	rs2199936	Urate levels	ABCG2	18.08	1E-75
chr3	106288949	106288950	rs12491921	Cannabis dependence	Intergenic	1.39	1E-6
chr3	107465816	107465817	rs6437740	Smoking behavior	BBX	.10	2E-7
chr3	108243550	108243551	rs2603127	Hemostatic factors and hematological phenotypes	MYH15	2.79	5E-6
chr3	109204412	109204413	rs769554	Cardiac hypertrophy	DPPA4	NR	3E-6
chr3	109927375	109927376	rs13323983	Neutrophil count	AC078918.1, RP11-696F10.1	NR	5E-6
chr3	111201784	111201785	rs76884941	Chronic obstructive pulmonary disease	Intergenic	2.11	1E-7
chr3	111233238	111233239	rs56238310	Chronic obstructive pulmonary disease	CD96	2.11	1E-7
chr3	111423128	111423129	rs4450776	Cognitive performance	PHLDB2,PLCXD2	NR	5E-6
chr3	112376307	112376308	rs12634229	Atopic dermatitis	CCDC80, LOC100630917	1.29	2E-19
chr3	112497879	112497880	rs1002979	Prostate cancer (gene x gene interaction)	CD200R1L	1.59	3E-6
chr3	112681584	112681585	rs1488193	Economic and political preferences	CD200R1	.23	6E-6
chr3	112822321	112822322	rs9811423	Alzheimer's disease	RP11-572M11.4	1.28	4E-6
chr3	113680950	113680951	rs1386478	Crohn's disease and psoriasis	ZDHHC23	1.12	7E-6
chr3	114362763	114362764	rs9841504	Gastric cancer	ZBTB20	1.32	2E-9
chr3	117307566	117307567	rs1875517	Waist circumference	Intergenic	NR	2E-6
chr3	117574821	117574822	rs6438424	Menarche (age at onset)	Intergenic	2.70	1E-13
chr3	118745935	118745936	rs2160050	Response to amphetamines	IGSF11	NR	9E-6
chr3	119118795	119118796	rs11712165	Celiac disease	CD80, KTELC1	1.13	8E-9
chr3	119219933	119219934	rs2293370	Primary biliary cirrhosis	CD80	1.48	3E-9
chr3	119219933	119219934	rs2293370	Multiple sclerosis	C3orf1, TMEM39A	1.13	3E-9
chr3	119219933	119219934	rs2293370	Primary biliary cirrhosis	CD80	1.35	3E-11
chr3	119227246	119227247	rs4688011	Arthritis (juvenile idiopathic)	C3orf1	1.23	1E-7
chr3	119288413	119288414	rs59374417	Vitiligo	CD80	1.34	4E-10
chr3	120017479	120017480	rs796825	HIV-1 susceptibility	LRRC58	.00	8E-6
chr3	120043835	120043836	rs10511400	Economic and political preferences (feminism/equality)	LRRC58	.16	8E-6
chr3	121344139	121344140	rs3772130	Cognitive performance	FBXO40	NR	6E-6
chr3	121660663	121660664	rs4285028	Multiple sclerosis	SLC15A2, CD86	1.10	2E-8
chr3	121769521	121769522	rs2681424	Multiple sclerosis	ILDR1, CD86	1.16	2E-7
chr3	121793186	121793187	rs4308217	Multiple sclerosis	CD86	1.10	6E-8
chr3	121796767	121796768	rs9282641	Multiple sclerosis	CD86	1.21	1E-11
chr3	121993246	121993247	rs17251221	Calcium levels	CASR,CSTA,WDR5B,KPNA1,C3orf28,CCDC58	.06	2E-22
chr3	122003756	122003757	rs1801725	Calcium levels	CASR	.00	6E-37
chr3	122048643	122048644	rs17265703	Phosphorus levels	CASR,CCDC58	.04	4E-9
chr3	122329159	122329160	rs2173763	Major depressive disorder	PARP9,DTX3L,PARP15	NR	6E-6
chr3	122368346	122368347	rs2650951	QT interval	Intergenic	.29	1E-6
chr3	122380922	122380923	rs790116	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)	EIF4BP8	NR	2E-7
chr3	122388992	122388993	rs790123	Response to angiotensin II receptor blocker therapy	EIF4BP8	1.07	6E-6
chr3	122730909	122730910	rs9868873	Esophageal cancer	SEMA5B	1.19	1E-7
chr3	122839875	122839876	rs3792366	Platelet counts	PDIA5	2.15	4E-9
chr3	123065777	123065778	rs11708067	Type 2 diabetes	ADCY5	1.25	6E-8
chr3	123065777	123065778	rs11708067	Fasting glucose-related traits (interaction with BMI)	ADCY5	NR	3E-10
chr3	123065777	123065778	rs11708067	Fasting glucose-related traits	ADCY5	NR	7E-22
chr3	123065777	123065778	rs11708067	Fasting glucose-related traits	ADCY5	NR	3E-12
chr3	123094450	123094451	rs2877716	Two-hour glucose challenge	ADCY5	.09	7E-16
chr3	123096819	123096820	rs9883204	Birth weight	ADCY5	.06	7E-15
chr3	124340221	124340222	rs10512627	Mean platelet volume	KALRN	.01	5E-10
chr3	126961147	126961148	rs13075436	Response to angiotensin II receptor blocker therapy	AC112482.3	1.30	6E-6
chr3	126993098	126993099	rs9871760	MRI atrophy measures	PLXNA1	.01	4E-6
chr3	127895225	127895226	rs2687729	Menarche (age at onset)	EEFSEC	2.30	1E-7
chr3	128038372	128038373	rs10934853	Prostate cancer	Intergenic	1.12	3E-10
chr3	128260549	128260550	rs4857855	Eosinophil counts	GATA2	9.40	9E-17
chr3	128316434	128316435	rs4328821	White blood cell types	GATA2	.16	5E-40
chr3	128316434	128316435	rs4328821	White blood cell types	GATA2	.10	3E-17
chr3	128652552	128652553	rs9810890	Dental caries	ACAD9	NR	6E-6
chr3	129050755	129050756	rs6439167	Height	C3orf47	.03	9E-15
chr3	129971100	129971101	rs9813712	Response to amphetamines	Intergenic	NR	2E-6
chr3	131713565	131713566	rs1320900	Amyotrophic lateral sclerosis	CPNE4	1.19	7E-6
chr3	131813899	131813900	rs6775745	Neutrophil count	CPNE4	NR	2E-7
chr3	132610751	132610752	rs6439371	Menarche (age at onset)	TMEM108, NPHP3	2.30	1E-8
chr3	132693587	132693588	rs2369955	Alcoholism (heaviness of drinking)	Intergenic	.14	2E-6
chr3	132727902	132727903	rs7617456	IgE grass sensitization	TMEM108	1.18	3E-6
chr3	133399701	133399702	rs2718812	Iron status biomarkers	TOPBP1	NR	1E-6
chr3	133410660	133410661	rs1867504	Iron status biomarkers	TF	NR	2E-6
chr3	133475721	133475722	rs1799852	Iron status biomarkers	TF	.43	5E-6
chr3	133475811	133475812	rs1799899	Alcohol consumption	TF	.40	1E-9
chr3	133484028	133484029	rs3811647	Hepcidin levels	TF	.34	2E-16
chr3	133484028	133484029	rs3811647	Alcohol consumption	TF	.36	1E-35
chr3	133484028	133484029	rs3811647	Iron levels	TF	15.34	3E-47
chr3	133484028	133484029	rs3811647	Iron status biomarkers	TF	.46	3E-15
chr3	133494353	133494354	rs1049296	Alcohol consumption	TF	.29	5E-43
chr3	133508463	133508464	rs1830084	Iron status biomarkers	TF	.43	1E-9
chr3	133537066	133537067	rs1534166	Alcohol consumption	SRPRB	.29	2E-17
chr3	133589323	133589324	rs9835973	Immune reponse to smallpox (secreted IL-1beta)	RAB6B	NR	7E-8
chr3	134233091	134233092	rs10935120	Height	ANAPC13,CEP63	.06	7E-8
chr3	135225248	135225249	rs11712655	Visceral adipose tissue/subcutaneous adipose tissue ratio	EPHB1	NR	1E-6
chr3	135235357	135235358	rs1502172	Visceral adipose tissue adjusted for BMI	EPHB1	NR	3E-6
chr3	135587810	135587811	rs1401543	Anticoagulant levels	PPP2R3A	NR	8E-6
chr3	135926621	135926622	rs645040	Triglycerides	MSL2L1	2.22	3E-8
chr3	135950920	135950921	rs511154	Fibrinogen	PCCB	.05	6E-10
chr3	135974215	135974216	rs9844666	Height	PCCB	.02	4E-9
chr3	137108481	137108482	rs1382269	Metabolite levels	Intergenic	NR	5E-7
chr3	137447484	137447485	rs10935268	Acenocoumarol maintenance dosage	CNTN4	NR	8E-7
chr3	138025395	138025396	rs9846480	MRI atrophy measures	TXNDC6	.01	8E-6
chr3	138119951	138119952	rs2306374	Coronary heart disease	MRAS	1.12	3E-8
chr3	138122121	138122122	rs9818870	Coronary heart disease	MRAS	1.15	7E-13
chr3	138713703	138713704	rs1511412	Keloid	LOC389151, FOXL2	1.87	2E-13
chr3	138903984	138903985	rs7638110	Obesity and blood pressure	MRPS22	NR	5E-8
chr3	138903984	138903985	rs7638110	Obesity and blood pressure	MRPS22	NR	2E-6
chr3	139043235	139043236	rs4894410	Kawasaki disease	COPB2	2.09	8E-6
chr3	139606793	139606794	rs2554152	Visceral adipose tissue adjusted for BMI	CLSTN2	NR	7E-6
chr3	140175359	140175360	rs11708189	Sudden cardiac arrest	CLSTN2	1.12	2E-6
chr3	140247176	140247177	rs4683505	Myopia (pathological)	CLSTN2	NR	4E-7
chr3	140540717	140540718	rs908821	Multiple sclerosis	SLC25A36	1.37	3E-6
chr3	140799212	140799213	rs16851055	Stroke (ischemic)	SPSB4	1.12	6E-7
chr3	140979410	140979411	rs16851254	Cognitive performance	ACPL2	NR	8E-6
chr3	141078187	141078188	rs9857275	Prion diseases	ZBTB38, RASA2	1.28	2E-6
chr3	141094208	141094209	rs6440003	Height	ZBTB38	.07	2E-10
chr3	141094208	141094209	rs6440003	Height	ZBTB38	.07	2E-24
chr3	141102832	141102833	rs6763931	Prostate cancer	ZBTB38	1.04	2E-8
chr3	141102832	141102833	rs6763931	Height	ZBTB38	.07	3E-12
chr3	141102832	141102833	rs6763931	Height	ZBTB38	7.40	1E-27
chr3	141105569	141105570	rs724016	Height	ZBTB38	.07	3E-86
chr3	141105569	141105570	rs724016	Height	ZBTB38	.37	8E-22
chr3	141105569	141105570	rs724016	Height	ZBTB38	.61	1E-6
chr3	141137034	141137035	rs9825379	Height	ZBTB38	.07	6E-9
chr3	141143429	141143430	rs10513137	Height	ZBTB38, ACPL2	.49	8E-8
chr3	141143429	141143430	rs10513137	Height	ZBTB38	.46	6E-12
chr3	141463297	141463298	rs16851720	Hepatitis C induced liver fibrosis	RNF7	NR	9E-9
chr3	141807136	141807137	rs347685	Chronic kidney disease	TFDP2	1.09	3E-11
chr3	142430999	142431000	rs3773506	Type 2 diabetes	PLS1	1.81	9E-6
chr3	142649109	142649110	rs9832727	Phospholipid levels (plasma)	PAQR9	.00	6E-29
chr3	142894410	142894411	rs894177	Non-alcoholic fatty liver disease histology (other)	Intergenic	.28	3E-6
chr3	142982898	142982899	rs9810857	Attention deficit hyperactivity disorder	SLC9A9	1.41	6E-6
chr3	143056466	143056467	rs7632299	Non-alcoholic fatty liver disease histology (lobular)	Intergenic	.45	4E-6
chr3	143250069	143250070	rs1371924	Tonometry	SLC9A9	NR	4E-6
chr3	143424821	143424822	rs2800	Non-alcoholic fatty liver disease histology (other)	SLC9A9	.61	3E-6
chr3	143504532	143504533	rs2166775	Response to angiotensin II receptor blocker therapy	SLC9A9	.99	3E-6
chr3	143772246	143772247	rs13068298	Economic and political preferences (feminism/equality)	Intergenic	.10	8E-6
chr3	143778707	143778708	rs16854884	Economic and political preferences (feminism/equality)	Intergenic	.10	7E-6
chr3	143902026	143902027	rs4839680	Myopia (pathological)	Intergenic	NR	1E-15
chr3	144340204	144340205	rs800082	Smoking behavior	Intergenic	.12	3E-6
chr3	145173787	145173788	rs345013	Prostate cancer	Intergenic	NR	5E-6
chr3	146402170	146402171	rs1912785	Barrett's esophagus	NR	.15	8E-6
chr3	146632163	146632164	rs12629805	Subcutaneous adipose tissue	PLSCR5	NR	3E-6
chr3	147756685	147756686	rs1841770	Multiple sclerosis	ZIC1	1.34	8E-6
chr3	148977313	148977314	rs7617219	Subcutaneous adipose tissue	CP	NR	1E-6
chr3	150042617	150042618	rs4301033	Adiponectin levels	TSC22D2	.04	6E-7
chr3	150467807	150467808	rs6788895	Breast cancer	SIAH2	1.22	9E-8
chr3	151579872	151579873	rs6798928	Immunoglobulin A	AADAC, SUCNR1	1.35	3E-6
chr3	151830308	151830309	rs11712066	Infantile hypertrophic pyloric stenosis	MBNL1	1.61	2E-17
chr3	152535364	152535365	rs10513432	Immune reponse to smallpox (secreted IL-2)	P2RY1	NR	4E-7
chr3	152672778	152672779	rs6785504	Response to antineoplastic agents	Intergenic	2.11	7E-6
chr3	152721974	152721975	rs9883654	Response to antineoplastic agents	Intergenic	2.20	2E-6
chr3	153184655	153184656	rs6778194	Immune reponse to smallpox (secreted IFN-alpha)	LOC152118	NR	2E-9
chr3	153472162	153472163	rs573872	Infantile hypertrophic pyloric stenosis	Intergenic	1.41	4E-12
chr3	156102733	156102734	rs3772255	Aging traits	KCNAB1	NR	8E-6
chr3	156397748	156397749	rs2665390	Ovarian cancer	TIPARP	1.19	3E-7
chr3	156626090	156626091	rs12638253	Multiple sclerosis (severity)	FLJ16641	NR	2E-6
chr3	156798774	156798775	rs900400	Birth weight	CCNL1, LEKR1	.09	2E-35
chr3	156836905	156836906	rs7624327	Eating disorders	CCNL1, LEKR1	1.13	3E-6
chr3	156854741	156854742	rs13064954	Diabetic retinopathy	LEKR1, CCNL1	1.02	7E-7
chr3	156950578	156950579	rs9866141	Diabetic retinopathy	KRT18P34, VEPH1	1.02	9E-7
chr3	159259290	159259291	rs2222328	Quantitative traits	SCHIP1	.22	8E-7
chr3	159665049	159665050	rs17810546	Celiac disease	IL12A	1.36	4E-28
chr3	159665049	159665050	rs17810546	Celiac disease	IL12A, SCHIP1	1.35	1E-9
chr3	159698944	159698945	rs4680534	Multiple sclerosis	IL12A	1.12	6E-6
chr3	159709650	159709651	rs2243123	Multiple sclerosis	IL12A	1.08	7E-6
chr3	159728877	159728878	rs6441286	Primary biliary cirrhosis	IL12A	1.44	8E-12
chr3	159728877	159728878	rs6441286	Primary biliary cirrhosis	IL12A	1.54	2E-14
chr3	159745862	159745863	rs485499	Primary biliary cirrhosis	IL12A	1.38	2E-16
chr3	160340895	160340896	rs4679904	Primary biliary cirrhosis	ARF7	1.38	1E-6
chr3	160776963	160776964	rs9290065	Kawasaki disease	PPM1L	2.12	9E-6
chr3	161392575	161392576	rs6808138	Hyperactive-impulsive symptoms	Intergenic	NR	8E-6
chr3	161392575	161392576	rs6808138	Hyperactive-impulsive symptoms	Intergenic	NR	5E-6
chr3	162131407	162131408	rs12636148	Visceral adipose tissue/subcutaneous adipose tissue ratio	LOC131149	NR	5E-6
chr3	162161615	162161616	rs11924705	Coronary heart disease	Intergenic	NR	4E-14
chr3	162167395	162167396	rs6789378	Coronary heart disease	Intergenic	NR	4E-14
chr3	162681994	162681995	rs1425609	Aging (time to death)	OTOL1	.08	1E-6
chr3	162834300	162834301	rs9824150	Capecitabine sensitivity	Intergenic	NR	7E-6
chr3	163761963	163761964	rs7427021	Bipolar disorder	NR	1.16	5E-6
chr3	165125158	165125159	rs9878522	Response to amphetamines	Intergenic	NR	6E-6
chr3	165280208	165280209	rs1523288	Heart failure	BCHE	1.15	6E-6
chr3	165491279	165491280	rs1803274	Cardiovascular disease risk factors	BCHE	.37	6E-92
chr3	165491279	165491280	rs1803274	Butyrylcholinesterase levels	BCHE	.71	6E-262
chr3	167348837	167348838	rs7627289	Visceral fat	WDR49	NR	2E-6
chr3	167837747	167837748	rs4345115	Height	GOLIM4, SERPINI1	4.40	7E-6
chr3	168686675	168686676	rs16852912	Aging (time to event)	MECOM	1.18	3E-6
chr3	169080184	169080185	rs9883650	Immune reponse to smallpox (secreted IL-1beta)	MDS1	NR	4E-7
chr3	169082632	169082633	rs6774494	Nasopharyngeal carcinoma	MDS1,EVI1	1.19	1E-8
chr3	169100885	169100886	rs419076	Systolic blood pressure	MECOM	.41	2E-13
chr3	169100885	169100886	rs419076	Diastolic blood pressure	MECOM	.24	2E-12
chr3	169100885	169100886	rs419076	Blood pressure	MECOM	.34	8E-13
chr3	169100898	169100899	rs448378	Magnesium levels	MDS1	.00	1E-8
chr3	169100898	169100899	rs448378	Systolic blood pressure	MDS1	.51	1E-7
chr3	169150631	169150632	rs16853722	Renal function-related traits (BUN)	MECOM	.01	3E-14
chr3	169165887	169165888	rs1918974	Diastolic blood pressure	MDS1	.27	8E-8
chr3	169300218	169300219	rs1344555	Pulmonary function	MECOM	.03	3E-8
chr3	169481270	169481271	rs12696304	Telomere length	TERC	.03	2E-14
chr3	169481270	169481271	rs12696304	Telomere length	TERC	.11	4E-14
chr3	169492100	169492101	rs10936599	Multiple sclerosis	MYNN	1.10	7E-7
chr3	169492100	169492101	rs10936599	Colorectal cancer	MYNN	1.04	3E-8
chr3	169492100	169492101	rs10936599	Celiac disease	Intergenic	1.12	5E-7
chr3	169497584	169497585	rs1317082	Telomere length	TERC	.07	1E-8
chr3	170130101	170130102	rs10936632	Prostate cancer	CLDN11, SKIL	1.11	7E-22
chr3	170163473	170163474	rs6444931	Bipolar disorder and schizophrenia	TMEM212	1.34	6E-7
chr3	170494408	170494409	rs4955755	Menopause (age at onset)	NR	.34	7E-7
chr3	170717520	170717521	rs11920090	Fasting glucose-related traits (interaction with BMI)	SLC2A2	NR	8E-11
chr3	170717520	170717521	rs11920090	Fasting glucose-related traits	SLC2A2	NR	8E-13
chr3	170717520	170717521	rs11920090	Fasting glucose-related traits	SLC2A2	NR	5E-6
chr3	170725541	170725542	rs10513686	Liver enzyme levels (gamma-glutamyl transferase)	SLC2A2	4.90	6E-11
chr3	170834558	170834559	rs11920719	Coronary heart disease	TNIK	.10	4E-6
chr3	170971290	170971291	rs2088885	Brain imaging in schizophrenia (interaction)	TNIK	NR	6E-6
chr3	171558343	171558344	rs6794092	Body mass index	PP13439, TMEM212	.17	2E-6
chr3	171653902	171653903	rs3913363	Response to angiotensin II receptor blocker therapy	TMEM212	1.30	4E-7
chr3	171969076	171969077	rs7652177	Height	GHSR	NR	7E-11
chr3	172165726	172165727	rs572169	Height	GHSR	.03	3E-18
chr3	172843276	172843277	rs11720607	Prostate cancer (gene x gene interaction)	SPATA16	1.37	5E-6
chr3	174029044	174029045	rs13074924	Major depressive disorder	NLGN1	1.18	9E-6
chr3	174893774	174893775	rs17531088	Kawasaki disease	NAALADL2	1.43	1E-6
chr3	174961386	174961387	rs1463525	Systemic lupus erythematosus	NAALADL2	1.37	8E-6
chr3	175647164	175647165	rs6772209	Esophageal cancer	TBL1XR1	1.49	3E-7
chr3	176030095	176030096	rs6799767	Eosinophilic esophagitis (pediatric)	NR	1.49	4E-7
chr3	176422651	176422652	rs1490075	Response to amphetamines	Intergenic	NR	2E-6
chr3	177095071	177095072	rs12629106	Systemic lupus erythematosus	Intergenic	1.56	4E-6
chr3	177291696	177291697	rs644695	Major depressive disorder (broad)	NR	1.35	5E-6
chr3	177596988	177596989	rs7612209	Cognitive performance	AC007953.21	NR	4E-6
chr3	177766463	177766464	rs7634528	Myopia (pathological)	Intergenic	NR	1E-6
chr3	177793106	177793107	rs1982821	Uric acid levels	AC007953.1	.17	4E-6
chr3	178341581	178341582	rs2054399	Bipolar disorder and schizophrenia	KCNMB2	1.22	1E-6
chr3	178429938	178429939	rs9290663	Acute lymphoblastic leukemia (childhood)	KCNMB2	1.58	6E-6
chr3	179661317	179661318	rs7630877	Type 2 diabetes	PEX5L	1.32	7E-6
chr3	180550701	180550702	rs6782299	Schizophrenia	FXR1	1.10	1E-7
chr3	180551213	180551214	rs1879248	Schizophrenia	NR	1.07	7E-6
chr3	182760072	182760073	rs10513789	Parkinson's disease	MCCC1, LAMP3	1.25	3E-10
chr3	182821274	182821275	rs11711441	Parkinson's disease	MCCC1, LAMP3	1.19	8E-12
chr3	182869817	182869818	rs683395	Bipolar disorder	NR	1.47	5E-6
chr3	182870435	182870436	rs514636	Bipolar disorder	NR	NR	7E-7
chr3	183876511	183876512	rs1969253	Major depressive disorder	HTR3D,HTR3C,HTR3E,EIF2B5,DVL3,AP2M1,ABCF3,VWA5B2,MIR1224,ALG3,ECE2,CAMK2N2	NR	5E-6
chr3	184010047	184010048	rs3914188	Menarche (age at onset)	ECE2	2.20	3E-7
chr3	184090265	184090266	rs6141	Platelet counts	THPO	2.47	6E-8
chr3	184216129	184216130	rs3930234	Alcoholism (alcohol use disorder factor score)	Intergenic	.10	8E-6
chr3	184514612	184514613	rs4686760	vWF and FVIII levels	VPS8	.15	1E-6
chr3	184876782	184876783	rs7647854	Major depressive disorder	C3orf70,EHHADH	1.19	5E-6
chr3	184945848	184945849	rs7374394	Cognitive performance	EHHADH	NR	2E-6
chr3	185141856	185141857	rs7629245	Airflow obstruction	MAP3K13	1.22	9E-6
chr3	185511686	185511687	rs4402960	Type 2 diabetes	IG2BP2	1.15	3E-9
chr3	185511686	185511687	rs4402960	Type 2 diabetes	IGF2BP2	1.14	1E-6
chr3	185511686	185511687	rs4402960	Type 2 diabetes	IGF2BP2	1.17	8E-8
chr3	185511686	185511687	rs4402960	Type 2 diabetes	IGF2BP2	1.14	9E-16
chr3	185511686	185511687	rs4402960	Type 2 diabetes	IGF2BP2	1.14	9E-16
chr3	185511686	185511687	rs4402960	Type 2 diabetes	IGF2BP2	1.17	2E-9
chr3	185529079	185529080	rs1470579	Fasting glucose-related traits (interaction with BMI)	IGF2BP2	NR	6E-7
chr3	185529079	185529080	rs1470579	Diabetes (gestational)	IGF2BP2	1.33	2E-7
chr3	185529079	185529080	rs1470579	Type 2 diabetes	IGF2BP2	1.14	2E-9
chr3	185530289	185530290	rs6769511	Type 2 diabetes	IGF2BP2	1.23	1E-9
chr3	185531660	185531661	rs1374910	Type 2 diabetes	IGF2BP2	1.24	1E-7
chr3	185548682	185548683	rs720390	Height	IGF2BP2	.03	2E-14
chr3	185621828	185621829	rs6444087	Smoking behavior	Intergenic	1.28	9E-6
chr3	185629567	185629568	rs2002675	Menarche (age at onset)	TRA2B, ETV5	2.20	1E-9
chr3	185686740	185686741	rs10049246	Attention deficit hyperactivity disorder symptoms (interaction)	Intergenic	.60	8E-6
chr3	185834289	185834290	rs7647305	Weight	SFRS10, ETV5, DGKG	4.00	4E-9
chr3	185834289	185834290	rs7647305	Body mass index	SFRS10, ETV5, DGKG	4.42	7E-11
chr3	185834498	185834499	rs9816226	Body mass index	ETV5	.14	2E-18
chr3	186390626	186390627	rs9898	Activated partial thromboplastin time	AHSG, FETUB, HRG	1.00	1E-111
chr3	186390626	186390627	rs9898	Activated partial thromboplastin time	HRG	.26	1E-11
chr3	186433098	186433099	rs11924390	Adiponectin levels	KNG1	.06	2E-9
chr3	186459926	186459927	rs710446	Activated partial thromboplastin time	KNG1, RFC4, ADIPOQ	1.18	2E-203
chr3	186459926	186459927	rs710446	Activated partial thromboplastin time	KNG1	.36	1E-21
chr3	186466251	186466252	rs1656966	Myopia (pathological)	Intergenic	NR	4E-21
chr3	186480205	186480206	rs822354	Adiponectin levels	ADIPOQ	NR	4E-8
chr3	186530483	186530484	rs266717	Adiponectin levels	ADIPOQ	1.07	9E-19
chr3	186548564	186548565	rs6810075	Adiponectin levels	ADIPOQ	.06	2E-42
chr3	186551710	186551711	rs1648707	Adiponectin levels	ADIPOQ	.94	3E-12
chr3	186554291	186554292	rs864265	Adiponectin levels	ADIPOQ	.13	1E-19
chr3	186560781	186560782	rs182052	Adiponectin levels	ADIPOQ	.06	5E-44
chr3	186570452	186570453	rs17366568	Adiponectin levels	ADIPOQ	.13	1E-41
chr3	186573704	186573705	rs6773957	Adiponectin levels	ADIPOQ	NR	5E-8
chr3	186650789	186650790	rs10937275	Drug-induced liver injury (flucloxacillin)	ST6GAL1	4.10	1E-8
chr3	186666460	186666461	rs16861329	Type 2 diabetes	ST6GAL1	1.09	3E-8
chr3	186793241	186793242	rs2239612	Esophageal cancer (squamous cell)	ST6GAL1	1.21	6E-14
chr3	187413990	187413991	rs6764050	Response to citalopram treatment	RPT2	NR	9E-7
chr3	187687889	187687890	rs16862782	Myopia (pathological)	Intergenic	NR	5E-7
chr3	187713717	187713718	rs10937329	Renal function-related traits (BUN)	BCL6, LPP	.01	9E-30
chr3	187717539	187717540	rs4686914	Metabolite levels	Intergenic	.02	3E-21
chr3	187763397	187763398	rs6789987	Visceral adipose tissue/subcutaneous adipose tissue ratio	LPP	NR	3E-6
chr3	187763397	187763398	rs6789987	Visceral adipose tissue adjusted for BMI	LPP	NR	9E-6
chr3	188087627	188087628	rs9851967	Vitiligo	LPP	1.14	9E-8
chr3	188112553	188112554	rs1464510	Vitiligo	LPP	1.31	1E-11
chr3	188112553	188112554	rs1464510	Celiac disease	LPP	1.29	3E-40
chr3	188112553	188112554	rs1464510	Celiac disease	LPP	1.23	5E-9
chr3	188420896	188420897	rs1152846	Weight	NR	1.70	6E-6
chr3	188420896	188420897	rs1152846	Body mass index	NR	.09	3E-6
chr3	188442479	188442480	rs9290877	IgE levels	LPP	.04	2E-6
chr3	188584678	188584679	rs13067593	Immune reponse to smallpox (secreted IFN-alpha)	LPP	NR	8E-8
chr3	189343423	189343424	rs7610017	Brain imaging	TP63	NR	NS
chr3	189356260	189356261	rs4488809	Lung cancer	TP63	1.19	4E-9
chr3	189356260	189356261	rs4488809	Lung cancer	TP63	1.26	7E-26
chr3	189383182	189383183	rs10937405	Lung adenocarcinoma	TP63	1.25	7E-17
chr3	189383182	189383183	rs10937405	Lung adenocarcinoma	TP63	1.31	7E-12
chr3	189401775	189401776	rs17505102	Acute lymphoblastic leukemia (childhood)	TP63	NR	9E-9
chr3	189401775	189401776	rs17505102	Acute lymphoblastic leukemia (childhood)	TP63	1.47	2E-8
chr3	189645932	189645933	rs710521	Bladder cancer	TP63	1.18	2E-10
chr3	189645932	189645933	rs710521	Urinary bladder cancer	TP63	1.19	6E-8
chr3	189645932	189645933	rs710521	Urinary bladder cancer	TP63	1.19	1E-7
chr3	189997395	189997396	rs16865258	Working memory	CLDN1	NR	2E-6
chr3	190252634	190252635	rs9290936	Waist circumference	IL1RAP	1.79	4E-6
chr3	190350460	190350461	rs7626795	Lung cancer	IL1RAP	1.16	8E-6
chr3	191000807	191000808	rs10937470	Total ventricular volume	UTS2D	.00	9E-6
chr3	191196591	191196592	rs16822582	Bipolar disorder and schizophrenia	NR	1.50	8E-6
chr3	191521851	191521852	rs1516489	Immune response to smallpox vaccine (IL-6)	LOC100129725	NR	8E-8
chr3	191667776	191667777	rs7635839	Response to antipsychotic treatment	Intergenic	9.00	3E-6
chr3	191897217	191897218	rs975121	Ileal carcinoids	FGF12	2.17	7E-6
chr3	192093974	192093975	rs4453795	Metabolite levels	FGF12	NR	4E-7
chr3	194327097	194327098	rs789852	QT interval	LOC100132805	.25	7E-7
chr3	194758009	194758010	rs3892715	Attention deficit hyperactivity disorder (time to onset)	Intergenic	NR	6E-6
chr3	194858373	194858374	rs2131877	Non-small cell lung cancer	C3orf21	1.30	2E-8
chr3	195751629	195751630	rs4927850	Pancreatic cancer	TFRC	1.24	2E-7
chr3	195800546	195800547	rs9859260	Mean corpuscular volume	TFRC	.00	8E-14
chr3	195809138	195809139	rs11915082	Mean corpuscular hemoglobin	TFRC	.00	8E-13
chr3	195928853	195928854	rs11924930	HIV-1 susceptibility	ZDHHC19	NR	7E-6
chr3	196553866	196553867	rs2084385	Total ventricular volume	PAK2	.01	5E-6
chr4	282498	282499	rs11723261	Immune response to smallpox vaccine (IL-6)	LOC654254	NR	4E-6
chr4	735149	735150	rs4234853	Hemostatic factors and hematological phenotypes	PCGF3	4.88	6E-6
chr4	852312	852313	rs1564282	Parkinson's disease (familial)	GAK, DGKQ	1.70	7E-7
chr4	858331	858332	rs11248051	Parkinson's disease	GAK	1.46	3E-9
chr4	939086	939087	rs6599388	Parkinson's disease	GAK	1.16	4E-12
chr4	939112	939113	rs6599389	Parkinson's disease	GAK	1.31	4E-8
chr4	964358	964359	rs11248060	Parkinson's disease	DGKQ	1.26	3E-9
chr4	964358	964359	rs11248060	Parkinson's disease	GAK, DGKQ	1.21	3E-12
chr4	964358	964359	rs11248060	Parkinson's disease	DGKQ	NR	2E-6
chr4	1078186	1078187	rs1670533	Recombination rate (females)	RNF212,SPON2	88.20	2E-12
chr4	1095280	1095281	rs3796619	Recombination rate (males)	RNF212,SPON2	70.70	3E-24
chr4	1254534	1254535	rs7656416	Type 2 diabetes	MGC21675	1.15	1E-8
chr4	1309900	1309901	rs6815464	Type 2 diabetes	MAEA	1.13	2E-20
chr4	1365126	1365127	rs13118159	Longevity	RP11-1244E8.1	NR	1E-6
chr4	1701316	1701317	rs2247341	Height	SLBP/FGFR3	.03	2E-11
chr4	1734238	1734239	rs798766	Bladder cancer	TMEM129,TACC3,FGFR3	1.20	4E-13
chr4	1734238	1734239	rs798766	Urinary bladder cancer	TACC3,TMEM129,SLBP,FGFR3	1.24	1E-11
chr4	2103095	2103096	rs1923775	Alzheimer's disease	POLN	1.60	6E-6
chr4	4704013	4704014	rs4476553	Response to amphetamines	Intergenic	NR	3E-6
chr4	4719493	4719494	rs1000579	Alcohol dependence	NR	1.30	4E-7
chr4	5221537	5221538	rs2008242	Electrocardiographic conduction measures	MSX1	NR	3E-6
chr4	5367984	5367985	rs7697839	Coronary heart disease	STK32B	NR	2E-11
chr4	5368223	5368224	rs7673097	Coronary heart disease	STK32B	NR	2E-11
chr4	5758868	5758869	rs735172	Prostate cancer (gene x gene interaction)	EVC	1.31	2E-6
chr4	6058496	6058497	rs16838131	Response to angiotensin II receptor blocker therapy	JAKMIP1	2.26	2E-6
chr4	6270055	6270056	rs4689388	Type 2 diabetes and other traits	WFS1, PPP2R2C	1.16	1E-8
chr4	6303021	6303022	rs1801214	Type 2 diabetes	WFS1	1.13	3E-8
chr4	6891518	6891519	rs11734132	Mean platelet volume	KIAA0232	.01	1E-11
chr4	7219932	7219933	rs4234798	Insulin-like growth factors	SORCS2	NR	5E-10
chr4	8503358	8503359	rs1949733	Response to antineoplastic agents	C4orf23, ACOX3	2.36	8E-7
chr4	9790711	9790712	rs1850744	Economic and political preferences	Intergenic	.31	4E-6
chr4	9922166	9922167	rs16890979	Urate levels	SLC2A9	.34	7E-168
chr4	9922166	9922167	rs16890979	Uric acid levels	GLUT9	.44	1E-11
chr4	9923003	9923004	rs734553	Uric acid levels	SLC2A9	.22	1E-41
chr4	9923003	9923004	rs734553	Uric acid levels	SLC2A9	.40	1E-192
chr4	9926966	9926967	rs13129697	Uric acid levels	SLC2A9, WDR1	28.99	2E-19
chr4	9926966	9926967	rs13129697	Urate levels	SLC2A9	1.52	4E-13
chr4	9926966	9926967	rs13129697	Urate levels	SLC2A9	22.21	2E-242
chr4	9926966	9926967	rs13129697	Biochemical measures	SLC2A9	.29	1E-9
chr4	9934743	9934744	rs737267	Urate levels	SLC2A9	.88	3E-9
chr4	9935909	9935910	rs6855911	Urate levels	GLUT9	.32	2E-16
chr4	9956078	9956079	rs4481233	Metabolic traits	SLC2A9	.07	6E-34
chr4	9966379	9966380	rs7442295	Urate levels	SLC2A9	.35	3E-70
chr4	9966379	9966380	rs7442295	Urate levels	SLC2A9,WDR1	.02	2E-15
chr4	9995181	9995182	rs3775948	Renal function-related traits (urea)	SLC2A9	.18	2E-65
chr4	9995181	9995182	rs3775948	Uric acid levels	SLC2A9	.18	1E-9
chr4	10050140	10050141	rs733175	Alzheimer's disease	SLC2A9	1.37	5E-6
chr4	10056375	10056376	rs7671266	Cardiovascular disease risk factors	WDR1	.31	9E-71
chr4	10062325	10062326	rs6834555	Alzheimer's disease	SLC2A9	1.40	3E-7
chr4	10104669	10104670	rs717615	Uric acid levels	WDR1	.13	5E-6
chr4	10324159	10324160	rs9291683	Bone mineral density	Intergenic	NR	2E-6
chr4	10331293	10331294	rs4698036	Cardiovascular disease risk factors	Intergenic	.26	2E-52
chr4	10726852	10726853	rs16872571	Myopia (pathological)	Intergenic	NR	2E-10
chr4	10726852	10726853	rs16872571	Vitiligo	CLNK	1.21	2E-8
chr4	11503603	11503604	rs1390096	Nonalcoholic fatty liver disease	HS3ST1	1.44	3E-6
chr4	13102350	13102351	rs13122273	Inflammatory biomarkers	Intergenic	NR	9E-7
chr4	13116761	13116762	rs491376	Response to antidepressant treatment	Intergenic	NR	2E-6
chr4	13122534	13122535	rs573332	Response to antidepressant treatment	Intergenic	NR	1E-6
chr4	13794415	13794416	rs10489087	Hemostatic factors and hematological phenotypes	Intergenic	NR	5E-6
chr4	13914372	13914373	rs10805321	Response to antipsychotic therapy (extrapyramidal side effects)	NR	.39	9E-6
chr4	15397363	15397364	rs16891867	Conduct disorder (symptom count)	C1QTNF7	.15	3E-9
chr4	15397905	15397906	rs1861046	Conduct disorder (case status)	C1QTNF7	1.65	6E-8
chr4	15482359	15482360	rs1861050	Conduct disorder (case status)	KIAA1345	1.63	8E-6
chr4	15737100	15737101	rs11724635	Parkinson's disease	BST1	1.15	1E-16
chr4	15737347	15737348	rs4698412	Parkinson's disease	BST1	1.14	3E-7
chr4	15737347	15737348	rs4698412	Parkinson's disease	BST1	1.14	2E-6
chr4	15737936	15737937	rs4538475	Parkinson's disease	BST1	1.24	3E-9
chr4	16002287	16002288	rs17478107	Self-rated health	PROM1	.02	9E-6
chr4	16018323	16018324	rs2531154	Dental caries	PROM1	NR	9E-7
chr4	17135342	17135343	rs4698169	Temperament (bipolar disorder)	Intergenic	2.11	2E-6
chr4	17797965	17797966	rs7678436	Height	NCAPG, LCORL	.09	8E-15
chr4	17919810	17919811	rs925098	Height	LCORL	.06	3E-14
chr4	17944839	17944840	rs16896068	Height	LCORL	.07	2E-13
chr4	17946431	17946432	rs2724475	Height	LCORL	NR	2E-9
chr4	17993409	17993410	rs724577	Height	LCORL	.07	1E-15
chr4	18017729	18017730	rs6830062	Height	LC0RL	.09	8E-6
chr4	18017729	18017730	rs6830062	Height	LCORL	.10	5E-9
chr4	18017729	18017730	rs6830062	Height	LCORL, NCAPG	6.30	1E-10
chr4	18033487	18033488	rs6449353	Height	LCORL	.08	7E-46
chr4	20495134	20495135	rs666088	Echocardiographic traits	SLIT2	NR	5E-6
chr4	20620682	20620683	rs1379659	Echocardiographic traits	SLIT2	NR	1E-7
chr4	21476989	21476990	rs358592	Suicidal ideation	KCNIP4	2.56	3E-6
chr4	24578096	24578097	rs6841898	Myopia (pathological)	DHX15	NR	3E-26
chr4	25403265	25403266	rs16877106	Weight	ANAPC4	5.42	1E-6
chr4	25417243	25417244	rs3816587	Rheumatoid arthritis	NR	1.09	9E-6
chr4	25810095	25810096	rs959903	Non-alcoholic fatty liver disease histology (other)	23231	3.81	7E-6
chr4	26085510	26085511	rs10517086	Type 1 diabetes	Intergenic	1.09	5E-10
chr4	26108196	26108197	rs874040	Rheumatoid arthritis	RBPJ	1.14	1E-16
chr4	26944313	26944314	rs6844153	Phospholipid levels (plasma)	STIM2	.02	6E-7
chr4	27194070	27194071	rs13149020	QT interval	NR	10.69	8E-6
chr4	27744717	27744718	rs4692256	Brain imaging	LOC391642	NR	E
chr4	29903051	29903052	rs7442317	Attention deficit hyperactivity disorder motor coordination	Intergenic	NR	4E-6
chr4	30468165	30468166	rs6856768	Alzheimer's disease	Intergenic	1.18	5E-6
chr4	31397617	31397618	rs6448771	Lipid traits	PCDH7	.03	5E-9
chr4	33203139	33203140	rs10517270	Alzheimer's disease (age of onset)	NR	NR	4E-6
chr4	33624701	33624702	rs10517287	Response to antidepressant treatment	Intergenic	NR	2E-7
chr4	34893854	34893855	rs17390445	Response to antipsychotic treatment	Intergenic	17.00	1E-7
chr4	35372097	35372098	rs437943	Response to TNF antagonist treatment	CENTD1	NR	4E-6
chr4	35410630	35410631	rs1533317	QT interval	Intergenic	.14	2E-6
chr4	36079593	36079594	rs12651329	Amyotrophic lateral sclerosis (age of onset)	ARAP2	NR	5E-7
chr4	37064330	37064331	rs13117816	Multiple sclerosis--Brain Glutamate Levels	FLJ11017	NR	7E-6
chr4	37938517	37938518	rs10010758	Periodontal microbiota	TBC1D1, PTTG2	1.91	4E-6
chr4	40303632	40303633	rs6832151	Graves' disease	RHOH, CHRNA9	1.24	1E-13
chr4	41284710	41284711	rs4861096	Cognitive performance	UCHL1	NR	9E-6
chr4	42453252	42453253	rs10517025	Immune reponse to smallpox (secreted IFN-alpha)	ATP8A1	NR	2E-7
chr4	43537599	43537600	rs13130255	Anticoagulant levels	KCTD8	NR	3E-6
chr4	44212164	44212165	rs17641529	Response to amphetamines	KCTD8	NR	9E-6
chr4	45182526	45182527	rs10938397	Body mass index	GNPDA2	.18	4E-31
chr4	45182526	45182527	rs10938397	Body mass index	GNPDA2	.19	3E-16
chr4	45364913	45364914	rs10517133	Adiponectin levels	AC108043.3-1	NR	5E-6
chr4	45867460	45867461	rs7674482	HIV-1 viral setpoint	AC095058.3	NR	5E-6
chr4	47551862	47551863	rs13106975	Sphingolipid levels	ATP10D	.00	2E-19
chr4	47563447	47563448	rs10938494	Sphingolipid levels	ATP10D	.06	8E-19
chr4	49062891	49062892	rs11725957	Response to hepatitis C treatment	CWH43	.73	8E-6
chr4	53412128	53412129	rs346923	Biochemical measures	USP46	.28	2E-6
chr4	53756999	53757000	rs2898681	Optic disc size (cup)	SCFD2	.17	2E-6
chr4	54799244	54799245	rs871606	Blood pressure	CHIC2	.43	1E-8
chr4	55087580	55087581	rs17084051	Corneal astigmatism	Intergenic	1.21	2E-6
chr4	55092625	55092626	rs2114039	Corneal curvature	PDGFRA	.13	1E-9
chr4	55124459	55124460	rs7677751	Corneal astigmatism	PDGFRA	1.26	8E-9
chr4	55234824	55234825	rs17690232	Height	PDGFRA	.86	4E-7
chr4	55241580	55241581	rs9312648	Response to amphetamines	Intergenic	NR	6E-6
chr4	55407761	55407762	rs172629	Mean corpuscular volume	KIT	.00	1E-15
chr4	55482817	55482818	rs2537859	Bipolar disorder	KIT	1.16	4E-6
chr4	56298193	56298194	rs6832769	Personality dimensions	CLOCK	.14	2E-6
chr4	56467213	56467214	rs13434995	Adiponectin levels	NR	.02	9E-6
chr4	56668430	56668431	rs753129	Alzheimer's disease	AC110611.1	1.52	3E-7
chr4	57334111	57334112	rs12505749	Airflow obstruction	SRP72	1.27	5E-6
chr4	57786449	57786450	rs1713985	Age-related macular degeneration	REST, C4orf14, POLR2B, IGFBP7	1.30	2E-8
chr4	57821308	57821309	rs708547	Bleomycin sensitivity	C4orf14, REST	.18	9E-7
chr4	57823475	57823476	rs17081935	Height	POLR2B	.03	4E-11
chr4	59008411	59008412	rs10517437	Cognitive performance	Intergenic	NR	4E-6
chr4	59305131	59305132	rs1869463	Corneal curvature	Intergenic	.03	9E-6
chr4	59503725	59503726	rs282708	Acute lymphoblastic leukemia (childhood)	Intergenic	1.23	8E-6
chr4	60748828	60748829	rs10517480	Metabolite levels	Intergenic	NR	2E-7
chr4	61966272	61966273	rs4599440	Biochemical measures	LPHN3	.20	2E-6
chr4	62437317	62437318	rs6856328	Working memory	LPHN3	NR	8E-7
chr4	62453208	62453209	rs2172802	Partial epilepsies	LPHN3	NR	3E-6
chr4	65170414	65170415	rs7656244	Kawasaki disease	SRD5A2L2	1.39	3E-7
chr4	66470812	66470813	rs4404602	HIV-1 viral setpoint	EPHA5	NR	1E-6
chr4	67733856	67733857	rs1155865	Cognitive test performance	Intergenic	NR	2E-6
chr4	68064439	68064440	rs10518025	Multiple sclerosis (severity)	CENPC1	NR	4E-6
chr4	68447248	68447249	rs2242330	Parkinson's disease	BRDG1	2.00	2E-6
chr4	69591781	69591782	rs293428	Sex hormone-binding globulin levels	UGT2B15	.02	6E-6
chr4	69591781	69591782	rs293428	Sex hormone-binding globulin levels	UGT2B15	.03	3E-8
chr4	71329489	71329490	rs1109501	Alcoholism (heaviness of drinking)	Intergenic	.10	5E-6
chr4	72126888	72126889	rs2579330	QT interval	NR	1.36	1E-6
chr4	72608382	72608383	rs2282679	Vitamin D levels	GC	NR	2E-14
chr4	72608382	72608383	rs2282679	Vitamin D insufficiency	GC	NR	2E-109
chr4	72608382	72608383	rs2282679	Vitamin D levels	GC	.38	2E-49
chr4	72707820	72707821	rs1851024	Metabolite levels	GC	NR	1E-14
chr4	73322564	73322565	rs115136538	Lipid metabolism phenotypes	ALB	.51	5E-18
chr4	73515312	73515313	rs7697556	Height	ADAMTS3	.03	2E-14
chr4	73645350	73645351	rs12507628	Metabolite levels	ADAMTS3	NR	3E-9
chr4	73783403	73783404	rs6816344	Dialysis-related mortality	COX18, ADAMTS3	1.70	1E-6
chr4	74872444	74872445	rs16850360	Metabolite levels	CXCL5, PF4, PPBP	NR	3E-10
chr4	74956371	74956372	rs546829	White blood cell types	CXCL2	.06	3E-7
chr4	74977836	74977837	rs1371799	White blood cell count	CXCL2	NR	2E-17
chr4	75160823	75160824	rs16850864	Immune reponse to smallpox (secreted IL-1beta)	MTHFD2L	NR	7E-9
chr4	75170139	75170140	rs16850885	Immune reponse to smallpox (secreted IL-1beta)	EPGN, MTHFD2L	NR	7E-9
chr4	75223710	75223711	rs2168889	Metabolite levels	EREG	NR	6E-14
chr4	75224589	75224590	rs1350666	Attention deficit hyperactivity disorder	EREG	NR	8E-6
chr4	75502486	75502487	rs62314947	Breast size	AREG, EREG, EPGN, AREGB	.10	5E-8
chr4	76030920	76030921	rs1426063	QT interval	NR	1.18	8E-6
chr4	76332974	76332975	rs2903698	Prion diseases	NR	1.25	6E-6
chr4	76416386	76416387	rs13137105	Response to tocilizumab in rheumatoid arthritis	RCHY1	6.39	9E-7
chr4	76481729	76481730	rs17000647	Parkinson's disease (motor and cognition)	C4orf26	5.58	5E-6
chr4	76889387	76889388	rs2273	Longevity	SDAD1	NR	1E-6
chr4	77198985	77198986	rs6812193	Parkinson's disease	SCARB2	1.19	8E-10
chr4	77198985	77198986	rs6812193	Parkinson's disease	STBD1	1.12	4E-7
chr4	77360430	77360431	rs9992101	Creatinine levels	SHROOM3	NR	6E-9
chr4	77368846	77368847	rs17319721	Chronic kidney disease	SHROOM3, CCDC158	NR	1E-19
chr4	77368846	77368847	rs17319721	Renal function and chronic kidney disease	SHROOM3	.01	1E-12
chr4	77412139	77412140	rs13146355	Renal function-related traits (sCR)	SHROOM3	.00	9E-12
chr4	77412139	77412140	rs13146355	Renal function-related traits (eGRFcrea)	SHROOM3	.01	7E-11
chr4	77412139	77412140	rs13146355	Magnesium levels	SHROOM3	.01	6E-13
chr4	77418680	77418681	rs13106227	Eosinophilic esophagitis (pediatric)	NR	1.52	4E-6
chr4	77420783	77420784	rs1986734	Eosinophilic esophagitis (pediatric)	NR	1.54	1E-6
chr4	77771344	77771345	rs17002253	Adverse response to lamotrigine and phenytoin	RP11-123J14.1	NR	7E-6
chr4	78136932	78136933	rs11937061	Response to tocilizumab in rheumatoid arthritis	Intergenic	6.70	2E-7
chr4	79280692	79280693	rs1268789	Hair morphology	FRAS1	NR	7E-8
chr4	79513214	79513215	rs2867461	Rheumatoid arthritis	ANXA3	1.13	1E-12
chr4	79589044	79589045	rs10007186	Non-albumin protein levels	ANXA3	.09	1E-9
chr4	80564507	80564508	rs10518224	Quantitative traits	Intergenic	.19	7E-6
chr4	80946474	80946475	rs4389526	Ankylosing spondylitis	ANTXR2	NR	9E-8
chr4	80949828	80949829	rs4333130	Ankylosing spondylitis	ANTXR2	1.22	9E-8
chr4	81164722	81164723	rs1458038	Systolic blood pressure	FGF5	.71	2E-23
chr4	81164722	81164723	rs1458038	Diastolic blood pressure	FGF5	.46	9E-25
chr4	81164722	81164723	rs1458038	Blood pressure	FGF5	.40	3E-14
chr4	81184340	81184341	rs16998073	Diastolic blood pressure	FGF5, PRDM8, c4orf22	.50	1E-21
chr4	82009706	82009707	rs3796804	HIV-1 susceptibility	PRKG2	.00	9E-6
chr4	82149830	82149831	rs710841	Height	PRKG2	.07	2E-8
chr4	82149830	82149831	rs710841	Height	BMP3, PRKG2, RASGEF1B	5.00	2E-6
chr4	82150005	82150006	rs788867	Height	PRKG2/BMP3	.04	9E-28
chr4	82165789	82165790	rs994014	Height	Intergenic	.05	8E-10
chr4	83499312	83499313	rs7658637	Cognitive performance	AC067942.6-1	NR	6E-7
chr4	84373621	84373622	rs4693089	Menopause (age at onset)	HELQ	.23	2E-19
chr4	84374479	84374480	rs1494961	Upper aerodigestive tract cancers	HEL308, ADH, FAM175A	1.12	1E-8
chr4	86641148	86641149	rs7692808	PR interval	ARHGAP24	2.01	6E-20
chr4	86651463	86651464	rs7660702	Electrocardiographic traits	ARHGAP24	8.46	3E-17
chr4	86683559	86683560	rs11732231	PR interval	ARHGAP24	2.28	3E-9
chr4	87754418	87754419	rs10050311	Insulin-related traits	SLC10A6	.25	8E-6
chr4	87832600	87832601	rs3113494	Amyotrophic lateral sclerosis	LOC100506746	1.43	9E-7
chr4	87958394	87958395	rs340630	Systemic lupus erythematosus	AFF1	1.21	8E-9
chr4	88030260	88030261	rs442177	Triglycerides	AFF1	.02	3E-10
chr4	88030260	88030261	rs442177	Triglycerides	AFF1,KLHL8	2.25	9E-12
chr4	88186508	88186509	rs7694379	Platelet counts	HSD17B13	2.13	9E-9
chr4	88213807	88213808	rs6834314	Liver enzyme levels (alanine transaminase)	HSD17B13, MAPK10	2.60	3E-9
chr4	88732691	88732692	rs1054627	Bone mineral density	IBSP	.05	8E-7
chr4	88755827	88755828	rs7698623	Cardiovascular disease risk factors	MEPE	6.37	3E-7
chr4	88775242	88775243	rs1471403	Bone mineral density (spine)	MEPE	.07	2E-8
chr4	88775242	88775243	rs1471403	Bone mineral density (hip)	MEPE	.06	8E-7
chr4	88805207	88805208	rs12644436	HIV-1 viral setpoint	HSP90AB3P	NR	6E-6
chr4	88919105	88919106	rs2725236	Caffeine consumption	Intergenic	.07	5E-6
chr4	88959921	88959922	rs2725220	Renal function-related traits (urea)	ABCG2	.14	4E-30
chr4	89039081	89039082	rs1481012	Response to statin therapy (LDL-C)	ABCG2	5.10	2E-15
chr4	89052322	89052323	rs2231142	Uric acid levels	ABCG2	27.40	5E-6
chr4	89052322	89052323	rs2231142	Uric acid levels	ABCG2	.22	2E-18
chr4	89052322	89052323	rs2231142	Uric acid levels	ABCG2	.14	1E-10
chr4	89052322	89052323	rs2231142	Urate levels	ABCG2	.24	3E-60
chr4	89064580	89064581	rs3114018	Dental caries	ABCG2,PKD2, SPP1, MEPE, IBSP, DMP1, DSPP	NR	7E-8
chr4	89203669	89203670	rs893971	Conduct disorder (interaction)	PPM1K	1.15	7E-6
chr4	89220943	89220944	rs9995093	Bipolar disorder	PIGY	2.07	7E-6
chr4	89226421	89226422	rs1440581	Metabolite levels	PPM1K, HERC6	NR	1E-10
chr4	89226421	89226422	rs1440581	Metabolite levels	PPM1K	.13	2E-16
chr4	89421085	89421086	rs10516809	Pulmonary function decline	HERC5	.31	9E-6
chr4	89869331	89869332	rs2869967	Pulmonary function	FAM13A	.30	1E-7
chr4	89875908	89875909	rs1964516	Chronic obstructive pulmonary disease	FAM13A	1.37	2E-9
chr4	89883978	89883979	rs7671167	Chronic obstructive pulmonary disease	FAM13A	1.32	1E-11
chr4	89978799	89978800	rs16996151	Response to antipsychotic therapy (extrapyramidal side effects)	KIAA0914	NR	6E-6
chr4	90637600	90637601	rs356219	Parkinson's disease	SNCA	1.29	6E-65
chr4	90637600	90637601	rs356219	Parkinson's disease	SNCA	1.29	2E-47
chr4	90639514	90639515	rs11931074	Parkinson's disease	SNCA	1.37	7E-17
chr4	90641339	90641340	rs356220	Parkinson's disease	SNCA	1.38	8E-35
chr4	90641339	90641340	rs356220	Parkinson's disease	SNCA	1.29	2E-19
chr4	90641339	90641340	rs356220	Parkinson's disease	SNCA	1.37	3E-8
chr4	90641339	90641340	rs356220	Parkinson's disease	SNCA	1.27	9E-16
chr4	90641339	90641340	rs356220	Parkinson's disease	SNCA	1.38	3E-11
chr4	90678540	90678541	rs2736990	Parkinson's disease	SNCA	1.29	7E-8
chr4	90678540	90678541	rs2736990	Parkinson's disease	SNCA	1.23	2E-16
chr4	90780901	90780902	rs6532194	Parkinson's disease	SNCA	1.29	5E-11
chr4	90797300	90797301	rs6532197	Parkinson's disease	MMRN1	1.32	1E-7
chr4	92003896	92003897	rs6532271	Response to amphetamines	FAM190A	NR	3E-6
chr4	95146134	95146135	rs11097407	Bipolar disorder and schizophrenia	NR	1.25	4E-6
chr4	95153348	95153349	rs3106136	Capecitabine sensitivity	SMARCAD1	NR	7E-6
chr4	95514608	95514609	rs12500426	Prostate cancer	PDLIM5	1.08	1E-11
chr4	95562876	95562877	rs17021918	Prostate cancer	PDLIM5	1.11	4E-15
chr4	95614277	95614278	rs17022027	Visceral fat	PDLIM5	NR	9E-6
chr4	95643956	95643957	rs10027628	QT interval	NR	1.81	6E-6
chr4	95834033	95834034	rs1859156	Attention deficit hyperactivity disorder	BMPR1B	1.54	2E-6
chr4	95856680	95856681	rs10021303	Hypertension	NR	NR	7E-6
chr4	96159816	96159817	rs12643654	P-tau181p	UNC5C	NR	5E-7
chr4	99337880	99337881	rs10516430	Biochemical measures	RAP1GDS1	.16	6E-6
chr4	99796783	99796784	rs7665590	Primary biliary cirrhosis	NFKB1	1.35	1E-7
chr4	100056997	100056998	rs3805322	Esophageal cancer  (alcohol interaction)	ADH4	1.23	6E-7
chr4	100228465	100228466	rs1042026	Esophageal cancer  (alcohol interaction)	ADH1B	1.27	3E-7
chr4	100239318	100239319	rs1229984	Upper aerodigestive tract cancers	ADH1B	1.56	1E-20
chr4	100239318	100239319	rs1229984	Esophageal cancer	ADH6, ADH1B	1.79	8E-24
chr4	100250418	100250419	rs1789891	Alcohol dependence	ADH1B, ADH1C	1.46	1E-8
chr4	100250418	100250419	rs1789891	Conduct disorder (interaction)	ADH1C	1.47	3E-6
chr4	100274285	100274286	rs1789924	Upper aerodigestive tract cancers	ADH1C	1.12	3E-7
chr4	100322444	100322445	rs991316	Hypertension	ADH7	1.62	5E-6
chr4	100341860	100341861	rs971074	Upper aerodigestive tract cancers	ADH7	1.33	9E-17
chr4	100713764	100713765	rs11735070	Response to antipsychotic treatment	Intergenic	NR	1E-6
chr4	101806531	101806532	rs13107740	Response to angiotensin II receptor blocker therapy	EMCN	1.51	5E-6
chr4	101931825	101931826	rs1405687	Response to antipsychotic treatment	Intergenic	NR	5E-8
chr4	102037718	102037719	rs2659546	Corneal structure	PPP3CA	1.63	4E-6
chr4	102402214	102402215	rs6846071	C-reactive protein and white blood cell count	Intergenic	.22	1E-11
chr4	102560289	102560290	rs17031508	Blood pressure	BANK1, PPP3CA	NR	8E-8
chr4	102751075	102751076	rs10516487	Systemic lupus erythematosus	BANK1	1.38	4E-10
chr4	103188708	103188709	rs13107325	Systolic blood pressure	SLC39A8	.98	3E-14
chr4	103188708	103188709	rs13107325	Hypertension	SLC39A8	.11	5E-7
chr4	103188708	103188709	rs13107325	Diastolic blood pressure	SLC39A8	.68	2E-17
chr4	103188708	103188709	rs13107325	Blood pressure	SLC39A8	.63	1E-10
chr4	103188708	103188709	rs13107325	Body mass index	SLC39A8	.19	2E-13
chr4	103188708	103188709	rs13107325	HDL cholesterol	SLC39A8	.84	7E-11
chr4	103457417	103457418	rs230529	Schizophrenia (treatment refractory)	NFKB1	1.45	2E-7
chr4	103551602	103551603	rs7665090	Primary biliary cirrhosis	NFKB1	1.26	4E-12
chr4	103578636	103578637	rs228614	Multiple sclerosis	MANBA, NFKB1	1.09	1E-7
chr4	104137789	104137790	rs4699052	Testicular germ cell tumor	Intergenic	1.21	2E-7
chr4	105844272	105844273	rs10005603	Tuberculosis	NR	1.20	7E-6
chr4	106048359	106048360	rs1541374	Pulmonary function	TET2	.03	6E-7
chr4	106061533	106061534	rs7679673	Prostate cancer	TET2	1.10	3E-14
chr4	106106352	106106353	rs10010325	Height	TET2	.02	4E-11
chr4	106268593	106268594	rs2647264	Immune response to anthrax vaccine	TET2, PPA2	.17	9E-6
chr4	106451310	106451311	rs12499086	Economic and political preferences (time)	Intergenic	.13	2E-6
chr4	106457329	106457330	rs7669317	Response to antipsychotic therapy (extrapyramidal side effects)	Intergenic	NR	8E-8
chr4	106463712	106463713	rs11730243	Economic and political preferences (time)	Intergenic	.13	2E-6
chr4	106619139	106619140	rs11727189	Pulmonary function	INTS12, NPNT, FLJ20184, GSTCD	64.70	5E-17
chr4	106688903	106688904	rs10516526	Pulmonary function	GSTCD	.14	2E-23
chr4	107000461	107000462	rs11097912	Airflow obstruction	MGC16169	1.18	6E-6
chr4	108115221	108115222	rs10516541	Mean forced vital capacity from 2 exams	Intergenic	NR	4E-6
chr4	109046959	109046960	rs956237	Systemic lupus erythematosus	LEF1	1.18	2E-6
chr4	109217928	109217929	rs13144621	Airflow obstruction	LEF1	1.16	1E-6
chr4	109723125	109723126	rs4956211	Systemic lupus erythematosus	COL25A1	1.33	1E-6
chr4	110638809	110638810	rs2285714	Age-related macular degeneration	CFI	1.31	3E-7
chr4	110659066	110659067	rs10033900	Age-related macular degeneration (GA)	CFI	1.32	4E-6
chr4	110659066	110659067	rs10033900	Age-related macular degeneration (CNV)	CF1	1.31	6E-9
chr4	110659066	110659067	rs10033900	Age-related macular degeneration	CFI	1.18	4E-10
chr4	110659066	110659067	rs10033900	Age-related macular degeneration	CFI	NR	9E-9
chr4	110800096	110800097	rs6847149	Exercise treadmill test traits	NOLA1	NR	3E-6
chr4	110825633	110825634	rs17316633	Hair morphology	EGF	NR	9E-6
chr4	111026926	111026927	rs10011926	Attention deficit hyperactivity disorder	ELOVL6	1.49	8E-6
chr4	111334729	111334730	rs2087160	Metabolic traits	ENPEP	.12	7E-13
chr4	111381637	111381638	rs6825911	Blood pressure	ENPEP	.39	9E-9
chr4	111381637	111381638	rs6825911	Blood pressure	ENPEP	.60	7E-8
chr4	111705767	111705768	rs6817105	Atrial fibrillation	PITX2	1.64	2E-74
chr4	111708286	111708287	rs17042171	Atrial fibrillation	PITX2	1.65	4E-63
chr4	111710168	111710169	rs2200733	Atrial fibrillation	Intergenic	1.42	1E-14
chr4	111710168	111710169	rs2200733	Stroke (ischemic)	NR	1.26	2E-10
chr4	111710168	111710169	rs2200733	Atrial fibrillation/atrial flutter	PITX2,ENPEP	1.72	3E-41
chr4	111718066	111718067	rs6843082	Stroke (ischemic)	PITX2	1.36	3E-16
chr4	111718066	111718067	rs6843082	Stroke (ischemic)	PITX2	1.11	2E-7
chr4	111718066	111718067	rs6843082	Atrial fibrillation	PITX2	2.03	3E-28
chr4	111720760	111720761	rs10033464	Atrial fibrillation/atrial flutter	PITX2,ENPEP	1.39	7E-11
chr4	112611749	112611750	rs10034228	Myopia (pathological)	MYP11	1.23	8E-13
chr4	112702634	112702635	rs1585471	Myopia (pathological)	MYP11	1.15	2E-6
chr4	112923236	112923237	rs17589290	Coronary heart disease	Intergenic	1.43	6E-6
chr4	113311789	113311790	rs4833407	Obesity	ALPK1	1.11	1E-6
chr4	113328077	113328078	rs6838440	Epirubicin-induced leukopenia	ALPK1	2.10	3E-6
chr4	114000955	114000956	rs7694725	Prostate cancer (gene x gene interaction)	ANK2	1.36	2E-6
chr4	116196305	116196306	rs13144478	Resistin levels	NDST4	.13	6E-18
chr4	117254288	117254289	rs2389202	Sudden cardiac arrest	Intergenic	1.43	4E-7
chr4	118079906	118079907	rs10516635	Visceral adipose tissue adjusted for BMI	TRAM1L1	NR	8E-6
chr4	118093136	118093137	rs10433903	Obesity (extreme)	TRAM1L1	1.33	3E-6
chr4	118332254	118332255	rs4318720	QT interval	Intergenic	.28	8E-7
chr4	118651822	118651823	rs4422476	Neutrophil count	AC109592.1, AC092661.1	NR	8E-6
chr4	120962384	120962385	rs1845344	F-cell distribution	MAD2L1	.97	7E-6
chr4	121041285	121041286	rs1493682	HIV-1 viral setpoint	MAD2L1	NR	6E-6
chr4	121513214	121513215	rs10017284	F-cell distribution	PRDM5	.85	6E-6
chr4	121801789	121801790	rs180730	Fasting plasma glucose	PRDM5	NR	6E-6
chr4	121801789	121801790	rs180730	Fasting plasma glucose	PRDM5	NR	5E-6
chr4	122607177	122607178	rs55645543	Chronic obstructive pulmonary disease	ANXA5	4.39	5E-7
chr4	122665513	122665514	rs7659604	Type 2 diabetes	NR	1.35	9E-6
chr4	123115501	123115502	rs13151961	Celiac disease	IL2, IL21	1.35	2E-27
chr4	123132491	123132492	rs4505848	Type 1 diabetes	IL2	NR	5E-13
chr4	123198434	123198435	rs6534347	Type 1 diabetes	NR	1.30	2E-6
chr4	123218312	123218313	rs13119723	Rheumatoid arthritis	IL2,IL21	1.12	7E-7
chr4	123329361	123329362	rs17388568	Type 1 diabetes autoantibodies	ADAD1	1.10	6E-6
chr4	123329361	123329362	rs17388568	Ulcerative colitis	IL21, IL2, ADAD1	1.12	9E-7
chr4	123329361	123329362	rs17388568	Type 1 diabetes	NR	1.26	3E-6
chr4	123373132	123373133	rs2069772	IgE grass sensitization	IL2	1.19	1E-6
chr4	123377979	123377980	rs2069762	Type 1 diabetes autoantibodies	IL2	1.12	5E-7
chr4	123478715	123478716	rs6852535	Progressive supranuclear palsy	IL2, IL21	1.23	1E-7
chr4	123509420	123509421	rs6822844	Celiac disease	KIAA1109, ADAD1, IL2, IL21	1.44	3E-13
chr4	123509420	123509421	rs6822844	Celiac disease	KIAA1109,TENR,IL2,IL21	1.59	1E-14
chr4	123523874	123523875	rs7682241	Alopecia areata	IL2,IL21	1.34	4E-8
chr4	125993501	125993502	rs1986655	Bilirubin levels	Intergenic	.02	2E-6
chr4	126359455	126359456	rs1395241	Bipolar disorder and major depressive disorder (combined)	FAT4	NR	8E-6
chr4	126426694	126426695	rs12639834	Cognitive performance	FAT4	NR	6E-6
chr4	126431918	126431919	rs950063	Smoking behavior	Intergenic	.08	9E-6
chr4	126933291	126933292	rs1320267	Subclinical atherosclerosis traits (other)	Intergenic	NR	7E-6
chr4	130731283	130731284	rs4864201	Obesity	BC041448	1.12	2E-7
chr4	131127632	131127633	rs1908039	Intelligence	CYCSP14	NR	9E-8
chr4	131131415	131131416	rs11099040	Intelligence	CYCSP14	NR	9E-8
chr4	131132899	131132900	rs13113376	Intelligence	CYCSP14	NR	9E-8
chr4	131133490	131133491	rs1908038	Intelligence	CYCSP14	NR	9E-8
chr4	131137760	131137761	rs1024020	RR interval (heart rate)	Intergenic	.18	4E-7
chr4	131790500	131790501	rs1478091	Multiple sclerosis (severity)	LOC132321	NR	2E-6
chr4	133326394	133326395	rs7690467	Eating disorders	Intergenic	1.12	7E-6
chr4	135522739	135522740	rs10026364	Coronary heart disease	Intergenic	1.28	4E-6
chr4	137660382	137660383	rs6813479	Longevity	RP11-138I17.1	NR	1E-6
chr4	138227608	138227609	rs987360	Temperament	PCDH18	.27	2E-6
chr4	138692249	138692250	rs2313132	Systemic lupus erythematosus	Intergenic	NR	8E-6
chr4	140423133	140423134	rs17050782	Smoking behavior	SET7	.03	8E-6
chr4	142005572	142005573	rs10007052	Chronic obstructive pulmonary disease-related biomarkers	RNF150	NR	1E-7
chr4	142117423	142117424	rs1550057	Conduct disorder (case status)	Intergenic	1.39	4E-6
chr4	142142728	142142729	rs17007017	Conduct disorder (case status)	ZNF330	1.34	7E-6
chr4	142709722	142709723	rs17007695	Response to treatment for acute lymphoblastic leukemia	IL15	2.67	9E-7
chr4	144003158	144003159	rs7686660	Asthma	LOC729675	1.16	2E-12
chr4	144357736	144357737	rs3805236	Asthma	GAB1	1.12	7E-8
chr4	145436323	145436324	rs12504628	Pulmonary function	HHIP	.27	6E-13
chr4	145460229	145460230	rs13147758	Pulmonary function	HHIP	.10	8E-11
chr4	145480779	145480780	rs1828591	Chronic obstructive pulmonary disease	HHIP	1.38	1E-7
chr4	145485737	145485738	rs1980057	Pulmonary function	HHIP	.52	3E-20
chr4	145486388	145486389	rs13118928	Chronic obstructive pulmonary disease	HHIP	1.25	5E-7
chr4	145506455	145506456	rs13141641	Chronic obstructive pulmonary disease	HHIP	1.32	3E-7
chr4	145522757	145522758	rs2353398	Height	HHIP	NR	2E-9
chr4	145568351	145568352	rs7689420	Height	HHIP	.07	6E-51
chr4	145574843	145574844	rs1812175	Height	HHIP	.12	1E-9
chr4	145574843	145574844	rs1812175	Height	HHIP	.06	4E-6
chr4	145574843	145574844	rs1812175	Height	HHIP	8.30	1E-11
chr4	145643078	145643079	rs6854783	Height	HHIP	.06	2E-9
chr4	145650020	145650021	rs1492820	Height	HHIP	.29	1E-11
chr4	146794620	146794621	rs4547811	Liver enzyme levels (gamma-glutamyl transferase)	ZNF827	6.40	3E-27
chr4	146821409	146821410	rs4835265	Gamma glutamyl transpeptidase	ZNF827	.00	1E-14
chr4	146853164	146853165	rs2048161	Immune reponse to smallpox (secreted IFN-alpha)	ZNF827	NR	6E-12
chr4	146904303	146904304	rs11100904	Dental caries	ZNF827	NR	2E-6
chr4	148047549	148047550	rs1395821	Coronary heart disease	Intergenic	NR	7E-7
chr4	148282341	148282342	rs1429138	Dental caries	EDNRA	NR	2E-7
chr4	148393663	148393664	rs1878406	Carotid intima media thickness	EDNRA	.01	7E-7
chr4	148393663	148393664	rs1878406	Carotid intima media thickness	EDNRA	.20	7E-12
chr4	148400818	148400819	rs6842241	Intracranial aneurysm	EDNRA	1.25	1E-8
chr4	148884188	148884189	rs7658486	Immune reponse to smallpox (secreted IL-12p40)	ARHGAP10	NR	1E-8
chr4	148974601	148974602	rs6845865	QT interval	ARHGAP10	.19	7E-7
chr4	149311727	149311728	rs11725509	Subcutaneous adipose tissue	NR3C2	NR	1E-6
chr4	149321345	149321346	rs1490453	Biochemical measures	NR3C2	.25	3E-6
chr4	149570679	149570680	rs2358462	Non-alcoholic fatty liver disease histology (other)	Intergenic	.60	4E-6
chr4	149635024	149635025	rs10519980	Hypothyroidism	ATP5LP4, LOC285423	1.16	7E-6
chr4	149652609	149652610	rs10028213	Thyroid function	NR3C2	.08	3E-10
chr4	150725211	150725212	rs10030601	Epilepsy (generalized)	Intergenic	1.58	1E-6
chr4	150901756	150901757	rs11930273	Visceral adipose tissue adjusted for BMI	DCLK2	NR	1E-6
chr4	152907699	152907700	rs360929	Volumetric brain MRI	Intergenic	NR	9E-6
chr4	153893353	153893354	rs11099864	Amyotrophic lateral sclerosis	KIAA1727	1.00	9E-6
chr4	154153999	154154000	rs12644284	Multiple sclerosis	TRIM2	2.04	4E-6
chr4	154703595	154703596	rs17030434	Electrocardiographic conduction measures	NR	NR	5E-6
chr4	155301058	155301059	rs12651106	Fibrinogen	DCHS2	.14	2E-12
chr4	155316121	155316122	rs902464	Immune reponse to smallpox (secreted IL-1beta)	DCHS2	NR	3E-7
chr4	155347392	155347393	rs1466662	Alzheimer's disease (age of onset)	DCHS2	NR	5E-7
chr4	155451758	155451759	rs12511469	Fibrinogen	PLRG1	.18	2E-36
chr4	155481288	155481289	rs4508864	Chronic obstructive pulmonary disease-related biomarkers	FGB	NR	6E-6
chr4	155482742	155482743	rs1800789	Fibrinogen	FGB	.09	2E-30
chr4	155483913	155483914	rs1800788	Fibrinogen	FGB	.19	1E-39
chr4	155488820	155488821	rs6056	Fibrinogen	FGB, FGA, FGG	12.94	8E-39
chr4	155507589	155507590	rs6050	Fibrinogen	FGA	.26	9E-90
chr4	155514878	155514879	rs13109457	D-dimer levels	FGA, FGG	6.30	3E-18
chr4	155520929	155520930	rs7659024	Venous thromboembolism	FGG, FGA	1.53	2E-13
chr4	155542247	155542248	rs7681423	Fibrinogen	FGG	.29	1E-109
chr4	155654420	155654421	rs727153	Alzheimer's disease	Intergenic	1.63	3E-6
chr4	156511458	156511459	rs1842896	Coronary heart disease	GUCY1A3	1.14	1E-11
chr4	156645512	156645513	rs13139571	Systolic blood pressure	GUCY1A3, GUCY1B3	.32	1E-6
chr4	156645512	156645513	rs13139571	Diastolic blood pressure	GUCY1A3, GUCY1B3	.26	2E-10
chr4	156645512	156645513	rs13139571	Blood pressure	GUCY1A3, GUCY1B3	.29	3E-7
chr4	156998540	156998541	rs4234898	Speech perception in dyslexia	CTSO, TDO2, PDGFC	NR	5E-8
chr4	157720123	157720124	rs4691380	Fasting insulin-related traits (interaction with BMI)	PDGFC	NR	5E-9
chr4	159630816	159630817	rs8396	Metabolic traits	ETFDH	.10	6E-15
chr4	159630816	159630817	rs8396	Metabolite levels	ETFDH	5.60	4E-24
chr4	161506896	161506897	rs17291045	HIV-1 control	Intergenic	NR	5E-8
chr4	162173479	162173480	rs7676384	Response to amphetamines	Intergenic	NR	8E-6
chr4	162250931	162250932	rs4470583	Diabetic retinopathy	Intergenic	NR	4E-7
chr4	162602208	162602209	rs17638464	Height	FSTL5	1.38	2E-6
chr4	163738120	163738121	rs6840361	Hair morphology	NAF1	NR	4E-6
chr4	164532800	164532801	rs3792615	Type 2 diabetes	MARCH1	1.93	9E-6
chr4	166255703	166255704	rs17046216	Insulin-related traits	SC4MOL	.19	3E-8
chr4	166255703	166255704	rs17046216	Insulin-related traits	SC4MOL	.18	2E-8
chr4	167455492	167455493	rs11941399	Capecitabine sensitivity	Intergenic	NR	1E-6
chr4	168264248	168264249	rs13111850	Immune reponse to smallpox (secreted IL-10)	SPOCK3	NR	3E-11
chr4	169409957	169409958	rs2710833	Non-alcoholic fatty liver disease histology (AST)	DDX60L,PALLD	.41	6E-7
chr4	169530257	169530258	rs17054392	Response to iloperidone treatment (QT prolongation)	PALLD	NR	3E-6
chr4	170880882	170880883	rs11723530	Myopia (pathological)	Intergenic	NR	4E-6
chr4	174515681	174515682	rs12646107	Response to amphetamines	Intergenic	NR	4E-6
chr4	174574405	174574406	rs11723864	Type 1 diabetes nephropathy	Intergenic	1.51	7E-7
chr4	175300778	175300779	rs6852435	Response to acetaminophen (hepatotoxicity)	KIAA1712	NR	6E-6
chr4	176662086	176662087	rs17599018	Temperament (bipolar disorder)	GPM6A	.98	2E-6
chr4	176859025	176859026	rs7687921	Mortality among heart failure patients	GPM6A	1.77	4E-6
chr4	177542972	177542973	rs13111989	HIV-1 viral setpoint	VEGFC	NR	2E-7
chr4	178318190	178318191	rs1395479	Heart rate variability traits	NEIL3	NR	7E-6
chr4	180048361	180048362	rs17067123	Response to hepatitis C treatment	Intergenic	NR	8E-6
chr4	180383311	180383312	rs2716816	Breast size	RPL19P8	.10	7E-6
chr4	180655624	180655625	rs17746001	Bipolar disorder and schizophrenia	Intergenic	1.75	3E-7
chr4	180655624	180655625	rs17746001	Bipolar disorder and schizophrenia	Intergenic	1.75	3E-7
chr4	180655624	180655625	rs17746001	Bipolar disorder	Intergenic	2.03	3E-7
chr4	180664652	180664653	rs2383393	Body mass index	NR	.10	2E-6
chr4	180687999	180688000	rs6844851	Bipolar disorder	NR	NR	9E-7
chr4	182399694	182399695	rs7672826	Multiple sclerosis	MGC45800	1.37	8E-6
chr4	183137397	183137398	rs2726807	Schizophrenia	Intergenic	1.29	6E-6
chr4	183687788	183687789	rs10017238	Response to amphetamines	ODZ3	NR	7E-6
chr4	184215674	184215675	rs955748	Height	WWC2	.02	4E-8
chr4	185639168	185639169	rs2130392	Kawasaki disease	MLF1IP	1.42	3E-8
chr4	186612674	186612675	rs4376189	Visceral adipose tissue/subcutaneous adipose tissue ratio	SORBS2	NR	2E-6
chr4	187149539	187149540	rs1912826	Metabolite levels	CYP4V2, KLKB1	NR	4E-12
chr4	187152326	187152327	rs4241816	Metabolite levels	KLKB1	.12	6E-13
chr4	187157457	187157458	rs4253252	Metabolic traits	KLKB1	.24	7E-18
chr4	187185384	187185385	rs3756008	Venous thromboembolism	F11	1.40	6E-11
chr4	187195550	187195551	rs1593	Activated partial thromboplastin time	F11	.54	2E-18
chr4	187207380	187207381	rs2289252	Activated partial thromboplastin time	F11	.48	6E-43
chr4	187257575	187257576	rs13148903	Response to statin therapy	LOC544042, F11, KLKB1	NR	3E-6
chr4	187338334	187338335	rs11935103	Response to citalopram treatment	Intergenic	NR	2E-6
chr4	187338334	187338335	rs11935103	Response to citalopram treatment	Intergenic	NR	1E-6
chr4	187678865	187678866	rs925642	Obesity	FAT1, MTNR1A	NR	7E-6
chr4	188191305	188191306	rs4478239	Major depressive disorder	Intergenic	NR	5E-6
chr4	188345367	188345368	rs1431005	Response to statin therapy	LOC644282,LOC644325,MRPS36P2	NR	2E-7
chr4	189120910	189120911	rs6857559	Myopia (pathological)	Intergenic	NR	3E-21
chr4	189587078	189587079	rs7659062	Cognitive performance	AC093909.2	NR	9E-6
chr4	189587078	189587079	rs7659062	Cognitive performance	AC093909.2	NR	8E-6
chr4	189590858	189590859	rs7662358	Cognitive performance	AC093909.2	NR	9E-6
chr4	189590858	189590859	rs7662358	Cognitive performance	AC093909.2	NR	8E-6
chr4	190123317	190123318	rs7665939	Amyotrophic lateral sclerosis	Intergenic	1.23	9E-6
chr4	190641169	190641170	rs11132733	Testosterone levels	Intergenic	.23	3E-6
chr4_ctg9_hap1	304359	304360	rs293428	Sex hormone-binding globulin levels	UGT2B15	.02	6E-6
chr4_ctg9_hap1	304359	304360	rs293428	Sex hormone-binding globulin levels	UGT2B15	.03	3E-8
chr5	428235	428236	rs12188164	Cystic fibrosis severity	AHRR	NR	4E-6
chr5	583441	583442	rs4957048	Ulcerative colitis	CEP72,TPPP	1.30	1E-9
chr5	594082	594083	rs11739663	Ulcerative colitis	EXOC3	1.15	3E-8
chr5	1279789	1279790	rs10069690	Breast cancer	TERT	1.18	1E-10
chr5	1280027	1280028	rs2242652	Prostate cancer	TERT	1.15	3E-24
chr5	1286515	1286516	rs2736100	Lung cancer	TERT, hTERT	1.38	4E-27
chr5	1286515	1286516	rs2736100	Glioma	TERT	1.30	4E-9
chr5	1286515	1286516	rs2736100	Glioma	TERT	NR	7E-9
chr5	1286515	1286516	rs2736100	Lung cancer	TERT	1.27	1E-27
chr5	1286515	1286516	rs2736100	Glioma	TERT	1.25	1E-14
chr5	1286515	1286516	rs2736100	Lung adenocarcinoma	TERT	1.27	3E-11
chr5	1286515	1286516	rs2736100	Lung adenocarcinoma	CLPTM1L,TERT	1.46	2E-22
chr5	1286515	1286516	rs2736100	Testicular germ cell cancer	TERT	1.33	8E-15
chr5	1286515	1286516	rs2736100	Lung adenocarcinoma	TERT	1.12	2E-10
chr5	1286515	1286516	rs2736100	Glioma	TERT	1.27	2E-17
chr5	1286515	1286516	rs2736100	Idiopathic pulmonary fibrosis	TERT	2.11	3E-8
chr5	1287193	1287194	rs2853677	Lung adenocarcinoma	TERT	1.41	3E-40
chr5	1288546	1288547	rs2853676	Glioma	TERT	1.26	4E-14
chr5	1308551	1308552	rs4635969	Testicular germ cell cancer	TERT, CLPTM1L	1.54	1E-23
chr5	1315659	1315660	rs4975616	Lung cancer	CLPTM1L	1.15	3E-9
chr5	1320721	1320722	rs402710	Lung cancer	TERT, CLPTM1L	1.18	4E-6
chr5	1322086	1322087	rs401681	Melanoma	TERT, CLPTM1L	1.20	3E-8
chr5	1322086	1322087	rs401681	Prostate-specific antigen levels	TERT	7.00	1E-10
chr5	1322086	1322087	rs401681	Bladder cancer	TERT,CLPTM1L	1.11	5E-7
chr5	1322086	1322087	rs401681	Pancreatic cancer	CLPTM1L	1.19	7E-7
chr5	1322086	1322087	rs401681	Lung cancer	CLPTM1L	1.15	8E-9
chr5	1342713	1342714	rs31489	Lung adenocarcinoma	CLPTM1L	1.12	2E-10
chr5	1877279	1877280	rs4975709	Cardiovascular disease risk factors	IRX4	5.06	8E-7
chr5	1895828	1895829	rs12653946	Prostate cancer	NR	1.39	3E-7
chr5	1895828	1895829	rs12653946	Prostate cancer	Intergenic	1.26	4E-18
chr5	2109900	2109901	rs6879627	Pancreatic cancer	LOC731559	1.25	8E-6
chr5	2335580	2335581	rs17586674	Cognitive performance	AC138982.2	NR	5E-6
chr5	3092191	3092192	rs6873793	QT interval	NR	1.47	1E-6
chr5	3558537	3558538	rs10512697	Immune response to smallpox vaccine (IL-6)	IRX1	NR	9E-7
chr5	3939475	3939476	rs492478	Cognitive performance	AC025187.6	NR	4E-6
chr5	4029788	4029789	rs11748327	Myocardial infarction	Intergenic	1.25	5E-13
chr5	4720584	4720585	rs7727102	Bipolar disorder and schizophrenia	NR	1.31	1E-6
chr5	5792506	5792507	rs32566	Morbidity-free survival	Intergenic	NR	2E-9
chr5	5897693	5897694	rs7728043	QT interval	Intergenic	.14	1E-6
chr5	6599221	6599222	rs6876835	Visceral fat	NSUN2,SRD5A1	NR	3E-6
chr5	6635590	6635591	rs472402	Response to amphetamines	SRD5A1	NR	3E-7
chr5	6821913	6821914	rs1566039	Sphingolipid levels	PAPD7	.80	1E-8
chr5	6834166	6834167	rs11134178	Attention deficit hyperactivity disorder	Intergenic	NR	3E-6
chr5	7228046	7228047	rs7729273	Cognitive performance	AC091951.3	NR	1E-6
chr5	7368844	7368845	rs13172324	Myopia (pathological)	Intergenic	NR	3E-10
chr5	7649859	7649860	rs4702484	Capecitabine sensitivity	ADCY2, MTRR	NR	6E-7
chr5	7649859	7649860	rs4702484	Capecitabine sensitivity	ADCY2, MTRR	NR	5E-8
chr5	7816644	7816645	rs326155	Visceral fat	ADCY2	NR	4E-6
chr5	8652869	8652870	rs200113	Uric acid levels	SEMA5A	28.59	7E-8
chr5	9332280	9332281	rs7702187	Parkinson's disease	SEMA5A	1.74	8E-6
chr5	9623621	9623622	rs10513025	Autism	SEMA5A, TAS2R1	1.81	3E-7
chr5	10169822	10169823	rs13361160	Pain	CCT5, FAM173B	1.17	5E-7
chr5	10372617	10372618	rs2607292	Body mass index	MARCH6	.77	4E-6
chr5	10464106	10464107	rs2967951	Body mass index	ROPN1L	.81	1E-6
chr5	10467701	10467702	rs1092913	Breast cancer	ROPN1L	1.45	2E-6
chr5	10752314	10752315	rs267939	Ulcerative colitis	DAP	1.10	6E-12
chr5	10811473	10811474	rs17176973	Bipolar disorder and schizophrenia	NR	1.78	5E-6
chr5	11111770	11111771	rs6884431	Pulmonary function decline	Intergenic	.18	6E-6
chr5	11169944	11169945	rs6885224	Myopia (pathological)	CTNND2	1.24	8E-6
chr5	11298222	11298223	rs2530215	Bipolar disorder and schizophrenia	NR	1.22	7E-6
chr5	13242973	13242974	rs10066447	Visceral fat	DNAH5	NR	7E-6
chr5	13505431	13505432	rs4463179	Prostate cancer (gene x gene interaction)	DNAH5	1.56	2E-6
chr5	13740975	13740976	rs6554809	IgE grass sensitization	DNAH5	1.29	3E-6
chr5	13764418	13764419	rs2896103	Subclinical atherosclerosis traits (other)	DNAH5	NR	5E-6
chr5	13769973	13769974	rs7715811	Subclinical atherosclerosis traits (other)	DNAH5	NR	6E-6
chr5	13779742	13779743	rs1502050	Subclinical atherosclerosis traits (other)	DNAH5	NR	9E-6
chr5	15285413	15285414	rs745978	Visceral fat	FBXL7	NR	7E-6
chr5	15582004	15582005	rs1978633	Economic and political preferences (feminism/equality)	FBXL7	.09	5E-6
chr5	17148910	17148911	rs682748	Hippocampal atrophy	NR	NR	8E-6
chr5	17215443	17215444	rs2962370	Bipolar disorder (mood-incongruent)	BASP1	1.19	5E-6
chr5	19440167	19440168	rs349475	Depression (quantitative trait)	CDH18	.18	2E-6
chr5	21749347	21749348	rs12109285	Response to tocilizumab in rheumatoid arthritis	Intergenic	130.20	1E-7
chr5	21779153	21779154	rs4701252	Waist circumference	CDH12	NR	2E-6
chr5	23244024	23244025	rs17376026	Economic and political preferences (immigration/crime)	Intergenic	.12	6E-6
chr5	25087724	25087725	rs2047267	Uric acid levels	AC106810.1	.17	4E-6
chr5	25760678	25760679	rs7727656	Hippocampal atrophy	Intergenic	NR	8E-6
chr5	25902341	25902342	rs10038113	Autism	Intergenic	1.33	3E-6
chr5	25967702	25967703	rs4307059	Autism	CDH10,CDH9	1.19	2E-10
chr5	26139137	26139138	rs4701523	Visceral fat	CDH9	NR	3E-6
chr5	26389261	26389262	rs969088	Response to platinum-based chemotherapy in non-small-cell lung cancer	CDH9	1.40	3E-6
chr5	26389261	26389262	rs969088	Response to platinum-based chemotherapy in non-small-cell lung cancer	CDH9	1.43	2E-6
chr5	26723782	26723783	rs4479806	Anorexia nervosa	CDH9	NR	8E-6
chr5	28340172	28340173	rs11949289	Response to antidepressant treatment	Intergenic	NR	2E-7
chr5	28747322	28747323	rs2548003	Hip geometry	Intergenic	NR	2E-7
chr5	30661572	30661573	rs9292394	Emphysema-related traits	CDH6	1.83	2E-6
chr5	30899516	30899517	rs6871087	Response to angiotensin II receptor blocker therapy	CTD-2127O16.1	1.40	1E-6
chr5	31020520	31020521	rs6888304	Liver enzyme levels (gamma-glutamyl transferase)	CDH6	2.70	1E-9
chr5	32748636	32748637	rs10061804	Ovarian reserve	NPR3	NR	1E-6
chr5	32768633	32768634	rs3792752	Height	NPR3	NR	7E-10
chr5	32804527	32804528	rs1173766	Blood pressure	NPR3	.63	2E-8
chr5	32804527	32804528	rs1173766	Blood pressure	NPR3	.36	1E-7
chr5	32815027	32815028	rs1173771	Systolic blood pressure	NPR3, C5orf23	.50	2E-16
chr5	32815027	32815028	rs1173771	Hypertension	NPR3, C5orf23	.06	3E-10
chr5	32815027	32815028	rs1173771	Diastolic blood pressure	NPR3, C5orf23	.26	9E-12
chr5	32815027	32815028	rs1173771	Blood pressure	NPR3, C5orf23	.28	5E-9
chr5	32815027	32815028	rs1173771	Blood pressure	NPR3, C5orf23	.28	4E-9
chr5	32830520	32830521	rs1173727	Height	NPR3	.03	2E-21
chr5	32888817	32888818	rs10472828	Height	C5orf23, NPR3	.22	3E-7
chr5	32888817	32888818	rs10472828	Height	NPR3	.06	3E-7
chr5	33636593	33636594	rs6868223	Mortality among heart failure patients	ADAMTS12	1.58	2E-6
chr5	33879791	33879792	rs1364044	Stroke (pediatric)	ADAMTS12	1.91	3E-6
chr5	33951692	33951693	rs16891982	Hair color	SLC45A2	1.10	4E-20
chr5	33951692	33951693	rs16891982	Hair color	NR	NR	4E-20
chr5	33951692	33951693	rs16891982	Eye color	SLC45A2	.84	1E-12
chr5	33951692	33951693	rs16891982	Skin pigmentation	SLC45A2	4.86	3E-11
chr5	33955325	33955326	rs35390	Melanoma	SLC45A2	2.78	2E-7
chr5	33955672	33955673	rs35391	Tanning	MATP	.44	3E-10
chr5	33958958	33958959	rs28777	Black vs. red hair color	MATP	.46	9E-14
chr5	33958958	33958959	rs28777	Black vs. blond hair color	MATP	.46	1E-17
chr5	34628626	34628627	rs409045	Left ventricular mass	RAI14	.00	8E-7
chr5	34951149	34951150	rs37439	Response to angiotensin II receptor blocker therapy	DNAJC21	1.00	9E-6
chr5	35037114	35037115	rs37369	Metabolite levels	AGXT2	1.25	1E-6
chr5	35037114	35037115	rs37369	Urinary metabolites	AGXT2	NR	2E-182
chr5	35803576	35803577	rs931555	Multiple sclerosis	IL7R	1.25	4E-7
chr5	35852310	35852311	rs6890853	Primary biliary cirrhosis	IL7R	1.47	4E-8
chr5	35874574	35874575	rs6897932	Multiple sclerosis	IL7R	1.11	2E-8
chr5	35874574	35874575	rs6897932	Multiple sclerosis	IL7R	1.12	2E-6
chr5	35874574	35874575	rs6897932	Multiple sclerosis	IL7RA	1.18	3E-7
chr5	35874574	35874575	rs6897932	Type 1 diabetes	IL7R	1.12	8E-6
chr5	35876273	35876274	rs3194051	Ulcerative colitis	IL7R	1.07	4E-8
chr5	35910528	35910529	rs1445898	Type 1 diabetes	CAPSL	1.12	8E-6
chr5	35943041	35943042	rs860413	Primary biliary cirrhosis	IL7R	1.30	1E-11
chr5	36137619	36137620	rs267759	Response to treatment for acute lymphoblastic leukemia	LMBRD2	3.23	7E-6
chr5	36309096	36309097	rs16902947	Serum tamsulosin hydrochloride concentration	RANBP3L	19.48	1E-7
chr5	36423930	36423931	rs7735940	Hypertension	RANBP3L	NR	5E-13
chr5	36425592	36425593	rs12522034	Hypertension	RANBP3L	NR	5E-13
chr5	36473236	36473237	rs2937550	Height	Intergenic	.05	8E-6
chr5	38051592	38051593	rs270545	Major depressive disorder	GDNF	1.37	1E-6
chr5	38452893	38452894	rs7715172	Response to citalopram treatment	EGFLAM	NR	3E-6
chr5	39394988	39394989	rs2255280	Pancreatic cancer	DAB2	1.23	4E-10
chr5	39397131	39397132	rs11959928	Chronic kidney disease	DAB2,C9	.01	1E-7
chr5	39979171	39979172	rs10053502	Myopia (pathological)	Intergenic	NR	1E-16
chr5	40134776	40134777	rs2548145	Alcoholism (alcohol use disorder factor score)	Intergenic	.08	2E-6
chr5	40392727	40392728	rs4613763	Multiple sclerosis	PTGER4	1.20	3E-16
chr5	40392727	40392728	rs4613763	Crohn's disease	PTGER4	1.32	7E-27
chr5	40401508	40401509	rs17234657	Crohn's disease	Intergenic	1.54	2E-12
chr5	40410583	40410584	rs11742570	Crohn's disease	PTGER4	1.32	1E-6
chr5	40410583	40410584	rs11742570	Crohn's disease	PTGER4	1.33	7E-36
chr5	40410934	40410935	rs6451493	Ulcerative colitis	PTGER4	1.08	3E-9
chr5	40415066	40415067	rs1992660	Crohn's disease	PTGER4	1.42	4E-7
chr5	40424425	40424426	rs6896969	Multiple sclerosis	PTGER4	1.10	2E-7
chr5	40431182	40431183	rs1373692	Crohn's disease	Intergenic	1.46	2E-12
chr5	40437947	40437948	rs9292777	Multiple sclerosis	PTGER4	1.19	1E-9
chr5	40437947	40437948	rs9292777	Crohn's disease	PTGER4	1.37	2E-11
chr5	40437947	40437948	rs9292777	Crohn's disease	Intergenic	1.34	3E-18
chr5	40490789	40490790	rs10440635	Ankylosing spondylitis	PTGER4	NR	3E-7
chr5	40626752	40626753	rs11955175	Bipolar disorder and schizophrenia	NR	1.47	6E-6
chr5	40791883	40791884	rs13361707	Gastric cancer	PRKAA1, PTGER4	1.41	8E-29
chr5	41234045	41234046	rs7443270	Response to fenofibrate (adiponectin levels)	C6	.04	5E-6
chr5	42288592	42288593	rs11748684	Response to taxane treatment (docetaxel)	GHR	NR	3E-6
chr5	42375242	42375243	rs979233	Systemic lupus erythematosus	GHR	NR	4E-6
chr5	42473554	42473555	rs13188386	Iron status biomarkers	GHR	NR	8E-6
chr5	44186667	44186668	rs4296809	Brain structure	Intergenic	NR	9E-7
chr5	44365544	44365545	rs2121875	Prostate cancer	FGF10	1.05	4E-8
chr5	44662514	44662515	rs4415084	Breast cancer	Intergenic	1.17	8E-11
chr5	44875004	44875005	rs7716600	Breast cancer	MRPS30	1.24	7E-7
chr5	45197778	45197779	rs10941694	Chronic kidney disease and serum creatinine levels	NR	1.35	9E-6
chr5	45285717	45285718	rs981782	Breast cancer	Intergenic	1.04	9E-6
chr5	50026464	50026465	rs282544	Myopia (pathological)	PARP8	.10	4E-6
chr5	51217850	51217851	rs10042348	Bipolar disorder and schizophrenia	NR	1.29	5E-6
chr5	52020395	52020396	rs830884	Response to platinum-based agents	ITGA1, PELO	3.13	2E-6
chr5	52193124	52193125	rs4074793	Liver enzyme levels (gamma-glutamyl transferase)	ITGA1	5.50	3E-10
chr5	52195032	52195033	rs1551943	Pulmonary function	ITGA1	.03	2E-6
chr5	53298024	53298025	rs6450176	Adiponectin levels	ARL15	.03	6E-8
chr5	53298024	53298025	rs6450176	HDL cholesterol	ARL15	.49	5E-8
chr5	53300661	53300662	rs4311394	Adiponectin levels	ARL15	.96	3E-8
chr5	53902338	53902339	rs2548621	Immune response to smallpox vaccine (IL-6)	SNX18	NR	9E-7
chr5	55001898	55001899	rs11958779	Height	SLC38A9	.03	2E-12
chr5	55438579	55438580	rs6859219	Rheumatoid arthritis	ANKRD55,IL6ST	1.28	1E-11
chr5	55560026	55560027	rs1020388	Celiac disease and Rheumatoid arthritis	ANKRD55	NR	3E-7
chr5	55854152	55854153	rs6867983	Triglycerides	C5orf35	.02	3E-6
chr5	55861785	55861786	rs9686661	Triglycerides	ANKRD55,MAP3K1	2.57	1E-10
chr5	56023082	56023083	rs16886165	Breast cancer	MAP3K1	1.23	5E-7
chr5	56031883	56031884	rs889312	Breast cancer	MAP3K1	1.22	5E-9
chr5	56031883	56031884	rs889312	Breast cancer	MAP3K1	1.13	7E-20
chr5	57130817	57130818	rs10940579	Prostate cancer (gene x gene interaction)	ACTBL2	1.32	4E-6
chr5	57320953	57320954	rs1844437	Hoarding	Intergenic	.62	2E-6
chr5	58407770	58407771	rs10052657	Esophageal cancer	PDE4D	1.49	2E-19
chr5	58560716	58560717	rs17444059	Immune response to smallpox vaccine (IL-6)	PDE4D	NR	2E-8
chr5	58676048	58676049	rs1823068	Sleepiness	PDE4D	NR	3E-8
chr5	58842773	58842774	rs702543	Neuroticism	PDE4D	1.27	2E-6
chr5	59369793	59369794	rs1588265	Asthma	PDE4D	1.18	3E-8
chr5	60731457	60731458	rs7709645	Schizophrenia	Intergenic	1.11	4E-8
chr5	60950210	60950211	rs11738335	Alzheimer's disease	FLJ37543	1.20	5E-6
chr5	62817899	62817900	rs255414	Body mass index	HTR1A	NR	1E-6
chr5	64417677	64417678	rs7729539	QT interval	NR	2.59	1E-6
chr5	64534640	64534641	rs13183791	Bipolar disorder and schizophrenia	NR	1.57	6E-6
chr5	65739438	65739439	rs10514995	RR interval (heart rate)	Intergenic	.15	1E-6
chr5	66152257	66152258	rs39861	Epilepsy (generalized)	MAST4	1.26	3E-7
chr5	66452174	66452175	rs1697137	Carotid atherosclerosis in HIV infection	MAST4	NR	2E-6
chr5	66833256	66833257	rs7717572	Prostate cancer (gene x gene interaction)	CD180	1.94	3E-6
chr5	71410355	71410356	rs2199161	Attention deficit hyperactivity disorder	MAP1B	NR	2E-6
chr5	71716927	71716928	rs10515148	Hip geometry	ZNF366	NR	6E-7
chr5	72432035	72432036	rs17663555	Renal function-related traits (BUN)	TMEM171, TMEM174	.00	2E-6
chr5	72551133	72551134	rs7702331	Crohn's disease	intergenic	1.12	6E-12
chr5	73215236	73215237	rs16871023	D-dimer levels	RGNEF	.08	1E-6
chr5	74480287	74480288	rs4704187	Response to amphetamines	ANKRD31	NR	6E-6
chr5	74625486	74625487	rs7703051	LDL cholesterol	HMGCR	18.00	1E-8
chr5	74648602	74648603	rs12654264	Metabolite levels	HMGCR	2.71	1E-20
chr5	74648602	74648603	rs12654264	LDL cholesterol	HMGCR	.10	1E-20
chr5	74651083	74651084	rs3846662	LDL cholesterol	HMGCR	.08	2E-11
chr5	74651083	74651084	rs3846662	Cholesterol, total	HMGCR	.09	3E-19
chr5	74655725	74655726	rs3846663	Quantitative traits	COL4A3BP, HMGCR	.19	6E-6
chr5	74655725	74655726	rs3846663	Quantitative traits	COL4A3BP, HMGCR	.21	1E-6
chr5	74655725	74655726	rs3846663	LDL cholesterol	HMGCR	.07	8E-12
chr5	74656538	74656539	rs12916	LDL cholesterol	HMGCR	.02	1E-11
chr5	74656538	74656539	rs12916	LDL cholesterol	HMGCR	2.45	5E-45
chr5	74656538	74656539	rs12916	Cholesterol, total	HMGCR	2.84	9E-47
chr5	75015241	75015242	rs2112347	Body mass index	FLJ35779, HMGCR	.10	2E-13
chr5	75920971	75920972	rs457717	Hearing impairment	IQGAP2	NR	4E-7
chr5	76023493	76023494	rs2227831	Mean platelet volume	F2R	.02	1E-15
chr5	76046938	76046939	rs17568628	Platelet counts	F2R	6.07	1E-9
chr5	76424948	76424949	rs4457053	Type 2 diabetes	ZBED3	1.08	3E-12
chr5	76518441	76518442	rs4704397	Hypothyroidism	PDE8B	1.17	2E-6
chr5	76535810	76535811	rs2046045	Thyroid function	PDE8B	.12	3E-27
chr5	76781470	76781471	rs163030	Caudate nucleus volume	WDR41,PDE8B	117.50	2E-7
chr5	77291939	77291940	rs12655917	Insulin resistance/response	AP3B1	40.00	6E-7
chr5	77630853	77630854	rs6881634	Hippocampal atrophy	SCAMP1, LHFPL2	NR	2E-6
chr5	77987523	77987524	rs784420	Economic and political preferences	Intergenic	.12	8E-6
chr5	78259887	78259888	rs337847	Hippocampal atrophy	ARSB	NR	7E-6
chr5	78272941	78272942	rs2052550	Iron status biomarkers	ARSB	NR	8E-6
chr5	78756777	78756778	rs10078095	Height	HOMER1	.90	3E-6
chr5	78829248	78829249	rs7713917	Major depressive disorder	HOMER1	1.33	1E-6
chr5	78845710	78845711	rs13358260	Adiponectin levels	PAPD4	NR	5E-6
chr5	79099463	79099464	rs7735699	Bipolar disorder and schizophrenia	NR	1.23	6E-6
chr5	80411220	80411221	rs4703822	Orofacial clefts	RASGRF2	1.59	4E-6
chr5	80654965	80654966	rs4703516	Orofacial clefts	NR	NR	3E-6
chr5	80719124	80719125	rs7732320	Glioblastoma	SSBP2	1.64	1E-6
chr5	81087533	81087534	rs410644	Anorexia nervosa	SSBP2	NR	7E-6
chr5	81939317	81939318	rs1032757	Eosinophilic esophagitis (pediatric)	NR	1.96	2E-6
chr5	82433780	82433781	rs6452524	Hypertension	XRCC4	NR	2E-7
chr5	82436360	82436361	rs6887846	Hypertension	XRCC4	NR	2E-7
chr5	82889909	82889910	rs310501	Major depressive disorder	VCAN	1.16	7E-6
chr5	82960733	82960734	rs3846635	Visceral fat	HAPLN1	NR	2E-6
chr5	82985738	82985739	rs4466137	Prostate cancer	HAPLN1	NR	3E-6
chr5	83173592	83173593	rs4552569	Ankylosing spondylitis	HAPLN1, EDIL3	1.21	9E-10
chr5	83499642	83499643	rs347344	Chemerin levels	EDIL3	NR	1E-6
chr5	84606527	84606528	rs4920799	Echocardiographic traits	Intergenic	NR	7E-6
chr5	86432616	86432617	rs2032794	Personality dimensions	RASA1	.48	2E-6
chr5	87847585	87847586	rs17421627	Retinal vascular caliber	MEF2C	3.00	7E-16
chr5	88088438	88088439	rs770189	Tonometry	MEF2C	NR	3E-6
chr5	88099950	88099951	rs4521516	Mean platelet volume	MEF2C	.01	2E-9
chr5	88152116	88152117	rs700585	Platelet counts	MEF2C	2.70	1E-9
chr5	88354674	88354675	rs10037512	Height	MEF2C	.03	2E-18
chr5	88376060	88376061	rs1366594	Bone mineral density	MEF2C	.14	8E-10
chr5	88376060	88376061	rs1366594	Bone mineral density	MEF2C	.35	1E-7
chr5	88376060	88376061	rs1366594	Bone mineral density (hip)	MEF2C	.09	1E-13
chr5	89109749	89109750	rs10514317	Sex hormone-binding globulin levels	Intergenic	.13	7E-7
chr5	89546108	89546109	rs12518099	Type 2 diabetes and other traits	LOC72901, CETN3	1.16	7E-7
chr5	89780970	89780971	rs2562519	Nevirapine-induced rash	POLR3G	NR	5E-6
chr5	90299222	90299223	rs1967256	Response to antipsychotic treatment	GPR98	NR	3E-8
chr5	90424278	90424279	rs10514345	Hip geometry	GPR98	NR	2E-7
chr5	90762747	90762748	rs933688	Smoking behavior	LOC133789	1.48	6E-6
chr5	90981386	90981387	rs13153333	Subcutaneous adipose tissue	ARRDC3	NR	8E-6
chr5	91518720	91518721	rs10055544	Immune reponse to smallpox (secreted IL-10)	LOC100131236	NR	1E-7
chr5	91893791	91893792	rs1027643	Wilms tumor	NR	1.43	5E-10
chr5	92567538	92567539	rs4869419	Natriuretic peptide levels	CCT7P2	.20	4E-6
chr5	93557701	93557702	rs17376456	Diabetic retinopathy	Intergenic	NR	3E-15
chr5	93810207	93810208	rs6869388	Gallbladder cancer	NR	72.70	7E-6
chr5	94154587	94154588	rs17418283	Bipolar disorder	MCTP1	1.21	1E-7
chr5	95036699	95036700	rs153916	Pulmonary function	SPATA9	.03	2E-8
chr5	95234790	95234791	rs3777200	Serum total protein level	ELL2	.02	1E-8
chr5	95521776	95521777	rs58263042	Breast size	NOL4	.17	9E-6
chr5	95542725	95542726	rs13179048	Fasting glucose-related traits (interaction with BMI)	PCSK1	NR	2E-10
chr5	95728897	95728898	rs6235	Proinsulin levels	PCSK1	NR	1E-26
chr5	95850249	95850250	rs261967	Body mass index	PCSK1	3.77	5E-9
chr5	96101943	96101944	rs27524	Hodgkin's lymphoma	ERAP1	1.22	7E-6
chr5	96101943	96101944	rs27524	Psoriasis	ERAP1	1.13	3E-11
chr5	96111370	96111371	rs13160562	Alcohol dependence	CAST, ERAP1	1.27	7E-6
chr5	96124329	96124330	rs30187	Ankylosing spondylitis	ERAP1	NR	2E-27
chr5	96129511	96129512	rs27434	Ankylosing spondylitis	ERAP1	1.19	5E-12
chr5	96244548	96244549	rs2549794	Crohn's disease	ERAP2,LRAP	1.05	1E-10
chr5	97888735	97888736	rs4703129	Asperger disorder	RGMB	NR	1E-6
chr5	98579963	98579964	rs17736767	Renal sinus fat	CHD1	.21	7E-6
chr5	98781102	98781103	rs1829883	Hemostatic factors and hematological phenotypes	Intergenic	NR	6E-6
chr5	99342046	99342047	rs10067427	Non-alcoholic fatty liver disease histology (lobular)	Intergenic	.75	5E-6
chr5	99991647	99991648	rs4702982	Panic disorder	Intergenic	NR	6E-6
chr5	100948544	100948545	rs13188771	Conduct disorder (interaction)	Intergenic	4.24	2E-6
chr5	101859316	101859317	rs1502844	Schizophrenia	SLCO6A1	1.09	1E-6
chr5	101946797	101946798	rs7705924	Crohn's disease	SLCO6A1	1.48	2E-8
chr5	102596719	102596720	rs26232	Rheumatoid arthritis	C5orf30	1.14	4E-8
chr5	102759657	102759658	rs17155315	QT interval	NR	4.73	7E-6
chr5	104867935	104867936	rs7447447	Caffeine consumption	NR	.15	7E-6
chr5	104954327	104954328	rs10479334	Personality dimensions	Intergenic	NR	2E-9
chr5	106724587	106724588	rs252817	Bipolar disorder and schizophrenia	NR	1.24	2E-6
chr5	106982559	106982560	rs10074258	Hippocampal atrophy	EFNA5	NR	2E-7
chr5	107400504	107400505	rs288139	Eye color	FBXL17	.21	1E-6
chr5	107401450	107401451	rs11242661	Response to amphetamines	FBXL17	NR	1E-6
chr5	107915735	107915736	rs10447248	Adiponectin levels	FER	NR	5E-8
chr5	108113343	108113344	rs13177718	Height	FER	.04	3E-8
chr5	109496959	109496960	rs4460176	Hemostatic factors and hematological phenotypes	Intergenic	NR	3E-6
chr5	110008213	110008214	rs17132261	Cardiac structure and function	SLC25A46	.06	9E-7
chr5	110146445	110146446	rs17513503	IgE grass sensitization	TMEM232, SLCA25A46	1.39	1E-8
chr5	110146445	110146446	rs17513503	Allergic rhinitis	TMEM232, SLCA25A46	1.28	7E-7
chr5	110401871	110401872	rs1837253	Asthma	TSLP	NR	1E-14
chr5	110401871	110401872	rs1837253	Asthma	TSLP	1.17	1E-16
chr5	110405674	110405675	rs3806932	Eosinophilic esophagitis (pediatric)	WDR36	1.85	3E-9
chr5	110408001	110408002	rs1898671	Allergic rhinitis	TSLP	1.15	5E-6
chr5	110435489	110435490	rs2416257	Eosinophil counts	WDR36, TSLP	6.10	1E-6
chr5	110772403	110772404	rs10491334	Longevity	CAMKIV	1.82	2E-6
chr5	110772403	110772404	rs10491334	Blood pressure	CAMK4	NR	4E-6
chr5	111107114	111107115	rs173896	Bipolar disorder and schizophrenia	NR	1.43	7E-6
chr5	111693370	111693371	rs379440	vWF and FVIII levels	EPB41L4A	.34	1E-6
chr5	112242967	112242968	rs469727	Attention deficit hyperactivity disorder	REEP5	NR	8E-6
chr5	112580289	112580290	rs17323670	Bipolar disorder and schizophrenia	NR	1.75	7E-6
chr5	112723566	112723567	rs1318772	F-cell distribution	TSSK1	.91	1E-6
chr5	112996653	112996654	rs17135859	F-cell distribution	YTHDC2	.97	8E-6
chr5	113030163	113030164	rs4621553	Sudden cardiac arrest	Intergenic	1.40	4E-8
chr5	115512351	115512352	rs1396485	Inflammatory biomarkers	COMMD10	NR	7E-7
chr5	115568756	115568757	rs253959	Bipolar disorder and schizophrenia	COMMD10	1.21	8E-6
chr5	115727837	115727838	rs7702057	Amyotrophic lateral sclerosis	SEMA6A	2.05	8E-6
chr5	115975655	115975656	rs6898653	Allergic rhinitis	SEMA6A	1.23	1E-6
chr5	117337752	117337753	rs13166814	Subcutaneous adipose tissue	DTWD2	NR	5E-7
chr5	118356414	118356415	rs111649495	Response to amphetamines	Intergenic	NR	2E-6
chr5	119937690	119937691	rs1584468	Immune reponse to smallpox (secreted IL-12p40)	PRR16	NR	9E-8
chr5	122531346	122531347	rs17470137	Aortic root size	CCDC100, PPIC	.03	1E-11
chr5	122657198	122657199	rs1582931	Height	CEP120	.02	2E-10
chr5	122685127	122685128	rs2115172	Weight	NR	2.71	2E-6
chr5	122774784	122774785	rs7705033	Visceral adipose tissue/subcutaneous adipose tissue ratio	CCDC100	NR	2E-6
chr5	123119564	123119565	rs11241713	Amyotrophic lateral sclerosis	CSNK1G3	.79	3E-6
chr5	123157421	123157422	rs257016	Alzheimer's disease	AC008541.1	1.43	4E-6
chr5	123571159	123571160	rs17501712	Subcutaneous adipose tissue	ZNF608	NR	7E-7
chr5	124332102	124332103	rs4836133	Body mass index	ZNF608	.07	2E-9
chr5	124365966	124365967	rs6862844	Erectile dysfunction and prostate cancer treatment	ZNF608	6.72	4E-6
chr5	124743266	124743267	rs2637496	HIV-1 control	Intergenic	NR	9E-6
chr5	125319455	125319456	rs1073203	Diabetic retinopathy	LOC100130551, GRAMD3	1.54	9E-6
chr5	125338474	125338475	rs13169113	Cognitive performance	GRAMD3	NR	9E-6
chr5	125918147	125918148	rs13182402	Osteoporosis	ALDH7A1	2.25	2E-9
chr5	126032963	126032964	rs1546498	QT interval	NR	7.69	2E-6
chr5	126181861	126181862	rs959573	Parkinson's disease (motor and cognition)	LMNB1	1.92	5E-6
chr5	127151975	127151976	rs1421746	Amyotrophic lateral sclerosis (age of onset)	Intergenic	NR	8E-6
chr5	127169211	127169212	rs245201	Brain imaging in schizophrenia (interaction)	CTXN3, SLC12A2	NR	9E-8
chr5	127522542	127522543	rs10089	Ileal carcinoids	SLC12A2	2.56	2E-6
chr5	127640860	127640861	rs27855	Height	FBN2	.05	4E-6
chr5	127653021	127653022	rs10057405	Temperament	FBN2	.11	9E-6
chr5	127699374	127699375	rs374748	Obesity (extreme)	FBN2	1.47	4E-6
chr5	129000385	129000386	rs13436218	Sexual dysfunction (SSRI/SNRI-related)	ADAMTS19	5.92	1E-6
chr5	129792133	129792134	rs6894216	Response to amphetamines	Intergenic	NR	4E-6
chr5	129943318	129943319	rs7731657	Fasting plasma glucose	Intergenic	NR	7E-6
chr5	131402737	131402738	rs3091338	Crohn's disease	IL3, ACSL6, P4HA2, PDLIM4, SLC22A4	1.23	4E-8
chr5	131430117	131430118	rs657075	Rheumatoid arthritis	CSF2	1.12	3E-10
chr5	131665377	131665378	rs272889	Metabolic traits	SLC22A4	.08	7E-16
chr5	131699866	131699867	rs274546	Height	SLC22A5	.03	7E-16
chr5	131723287	131723288	rs2073643	Asthma	SLC22A5	1.11	2E-7
chr5	131742227	131742228	rs6596075	Crohn's disease	Intergenic	1.55	3E-6
chr5	131744573	131744574	rs1016988	Fibrinogen	SLC22A5, SLC22A4, IRF1	6.84	1E-12
chr5	131770804	131770805	rs2188962	Crohn's disease	IBD5	1.36	1E-7
chr5	131770804	131770805	rs2188962	Crohn's disease	Intergenic	1.25	2E-18
chr5	131784392	131784393	rs12521868	Crohn's disease	SLC22A4,SLC22A5,IRF1,IL3	1.23	1E-20
chr5	131796921	131796922	rs11745587	Asthma	C5orf56	1.26	2E-6
chr5	131801725	131801726	rs2522056	Fibrinogen	IRF1	.06	1E-15
chr5	131819920	131819921	rs2070729	Platelet counts	IRF1	2.39	1E-10
chr5	131839617	131839618	rs4705952	C-reactive protein	IRF1	.04	1E-8
chr5	131862976	131862977	rs4143832	Eosinophil counts	IL5	7.10	1E-10
chr5	131901224	131901225	rs2244012	Asthma	RAD50	1.64	3E-7
chr5	131973176	131973177	rs2040704	IgE levels	RAD50	13.90	4E-8
chr5	131995842	131995843	rs1295686	Atopic dermatitis	KIF3A, IL13	1.22	2E-6
chr5	131995842	131995843	rs1295686	Asthma	IL13	1.15	1E-7
chr5	131995963	131995964	rs20541	Hodgkin's lymphoma	IL13	1.47	1E-8
chr5	131995963	131995964	rs20541	IgE levels	IL13	.08	3E-18
chr5	131995963	131995964	rs20541	Psoriasis	IL13	1.27	5E-15
chr5	132049026	132049027	rs2897442	Atopic dermatitis	KIF3A	1.11	4E-8
chr5	132628883	132628884	rs17166496	Type 1 diabetes	NR	1.30	5E-6
chr5	133021850	133021851	rs6596140	Hypertension	FSTL4	NR	9E-8
chr5	133203595	133203596	rs1644305	Attention deficit hyperactivity disorder and conduct disorder	C5orf15	NR	8E-6
chr5	133446574	133446575	rs756699	Multiple sclerosis	TCF7	1.12	6E-7
chr5	133849176	133849177	rs13187289	Menarche (age at onset)	PHF15	3.00	2E-10
chr5	134356704	134356705	rs526896	Height	PITX1	.03	2E-13
chr5	134372684	134372685	rs31198	Height	PITX1, PCBD2, CATSPER3, TXNDC15,DDX46, CAMLG	4.80	8E-6
chr5	134443605	134443606	rs254560	Ulcerative colitis	Intergenic	1.07	1E-9
chr5	134467699	134467700	rs477687	AIDS progression	H2AFY	1.55	6E-6
chr5	134563156	134563157	rs634308	Immune response to anthrax vaccine	PITX1,H2AFY	.10	4E-6
chr5	137419988	137419989	rs2040862	Atrial fibrillation	WNT8A	1.12	3E-7
chr5	137599333	137599334	rs11242417	Immune reponse to smallpox (secreted IL-12p40)	GFRA3	NR	6E-8
chr5	137707314	137707315	rs757647	Menarche (age at onset)	KDM3B	2.40	5E-8
chr5	138850904	138850905	rs13181561	Chronic obstructive pulmonary disease-related biomarkers	AC138517.1	NR	6E-6
chr5	138850904	138850905	rs13181561	Immune reponse to smallpox (secreted IFN-alpha)	ECSM2, TMEM173	NR	3E-14
chr5	138949361	138949362	rs261532	Immune reponse to smallpox (secreted IFN-alpha)	UBE2D2	NR	3E-7
chr5	140372221	140372222	rs31872	Visceral adipose tissue adjusted for BMI	PCDHAC1	NR	3E-6
chr5	140700488	140700489	rs10875595	Pulmonary function decline	Intergenic	.25	1E-6
chr5	141445979	141445980	rs6867913	Asthma	NDFIP1	1.33	4E-6
chr5	141479064	141479065	rs11167764	Crohn's disease	NDFIP1	1.06	2E-9
chr5	141522999	141523000	rs1062158	Multiple sclerosis	NDFIP1	1.08	2E-6
chr5	141681787	141681788	rs4624820	Testicular germ cell cancer	SPRY4	1.47	1E-14
chr5	141681787	141681788	rs4624820	Testicular germ cell tumor	SPRY4	1.37	3E-13
chr5	141863603	141863604	rs17577085	Coronary heart disease	Intergenic	2.63	4E-6
chr5	142017859	142017860	rs152528	Cardiac hypertrophy	FGF1	NR	8E-7
chr5	142441793	142441794	rs3776331	Uric acid levels	NR	.30	8E-6
chr5	143003604	143003605	rs17100498	Response to antipsychotic treatment	Intergenic	NR	5E-7
chr5	145038830	145038831	rs10515552	Vitamin B12 levels	Intergenic	43.93	4E-8
chr5	146320822	146320823	rs1864982	Alcohol dependence	PPP2R2B	1.36	3E-6
chr5	146415215	146415216	rs9325032	Cognitive test performance	Intergenic	NR	3E-6
chr5	147805119	147805120	rs10043775	Periodontal microbiota	FBXO38, HTR4	2.06	2E-6
chr5	147842352	147842353	rs11168048	Pulmonary function	HTR4	.40	1E-11
chr5	147845814	147845815	rs3995090	Pulmonary function	HTR4	.07	4E-9
chr5	147856332	147856333	rs7733088	Airflow obstruction	HTR4	1.23	4E-9
chr5	148904091	148904092	rs10058728	Esophageal cancer	CSNK1A1	2.04	5E-9
chr5	149142066	149142067	rs9285640	Response to fenofibrate	PPARC1B	29.95	3E-7
chr5	149210847	149210848	rs32579	Tanning	PPARGC1B	.11	4E-6
chr5	149406732	149406733	rs2304069	HIV-1 control	NR	NR	7E-6
chr5	149825869	149825870	rs13177918	Visceral adipose tissue/subcutaneous adipose tissue ratio	RPS14	NR	8E-6
chr5	150223386	150223387	rs13361189	Crohn's disease	IRGM	1.38	2E-10
chr5	150240075	150240076	rs1000113	Crohn's disease	IRGM	1.54	3E-7
chr5	150258866	150258867	rs11747270	Crohn's disease	IRGM	1.33	3E-16
chr5	150270419	150270420	rs7714584	Crohn's disease	IRGM	1.37	8E-19
chr5	150440096	150440097	rs2233287	Systemic sclerosis	TNIP1	1.31	5E-9
chr5	150450235	150450236	rs4958881	Myasthenia gravis	TNIP1	1.73	3E-10
chr5	150458145	150458146	rs10036748	Systemic lupus erythematosus	TNIP1	1.23	2E-9
chr5	150473673	150473674	rs999556	Myopia (pathological)	Intergenic	NR	1E-15
chr5	150478317	150478318	rs17728338	Psoriasis	TNIP1	1.59	1E-20
chr5	151344557	151344558	rs170020	Interstitial lung disease	Intergenic	2.96	4E-6
chr5	151734108	151734109	rs1010254	Optic disc size (cup)	NMUR2	.18	8E-6
chr5	152288452	152288453	rs4262150	Bipolar disorder and schizophrenia	NMUR2	1.22	7E-6
chr5	152504928	152504929	rs1438949	Response to amphetamines	Intergenic	NR	6E-6
chr5	152639676	152639677	rs3112530	Aging (time to event)	GRIA1	1.18	7E-6
chr5	152979553	152979554	rs12658202	Anthropometric traits	AMPA1, GRIA1	.11	9E-6
chr5	153057547	153057548	rs12189362	Sudden cardiac arrest	GRIA1	1.50	3E-10
chr5	153509595	153509596	rs2033195	Body mass index	MFAP3, GALNT10	.09	6E-6
chr5	153869039	153869040	rs13165478	Ventricular conduction	HAND1,SAP30L	.55	7E-14
chr5	155202527	155202528	rs11134474	Smoking behavior	Intergenic	NR	8E-6
chr5	155500991	155500992	rs4704970	Multiple sclerosis (age of onset)	SGCD	NR	7E-6
chr5	156139568	156139569	rs157350	Anthropometric traits	SGCD	.31	6E-6
chr5	156139568	156139569	rs157350	Anthropometric traits	SGCD	.31	4E-6
chr5	156390296	156390297	rs6882076	Triglycerides	TIMD4,HAVCR1	2.63	4E-12
chr5	156390296	156390297	rs6882076	LDL cholesterol	TIMD4,HAVCR1	1.67	2E-22
chr5	156390296	156390297	rs6882076	Cholesterol, total	TIMD4,HAVCR1	1.98	7E-28
chr5	156398168	156398169	rs1501908	LDL cholesterol	TIMD4, HAVCR1	.07	1E-11
chr5	156608999	156609000	rs411174	Personality dimensions	ITK	NR	1E-6
chr5	156932375	156932376	rs2277027	Pulmonary function	ADAM19	.38	1E-10
chr5	156942284	156942285	rs11740562	Bipolar disorder and schizophrenia	NR	1.56	1E-6
chr5	157804456	157804457	rs9313772	Blood pressure	EBF1	.34	1E-11
chr5	157845401	157845402	rs11953630	Systolic blood pressure	EBF1	.41	3E-11
chr5	157845401	157845402	rs11953630	Hypertension	EBF1	.05	2E-7
chr5	157845401	157845402	rs11953630	Diastolic blood pressure	EBF1	.28	4E-13
chr5	158603570	158603571	rs1473247	Mean platelet volume	NR	.01	3E-7
chr5	158604962	158604963	rs10076782	Mean platelet volume	RNF145	.01	4E-8
chr5	158717788	158717789	rs2082412	Psoriasis	IL12B	1.44	2E-28
chr5	158750768	158750769	rs3213094	Psoriasis	IL12B	1.39	5E-11
chr5	158750768	158750769	rs3213094	Psoriasis	IL12B	1.28	3E-26
chr5	158759899	158759900	rs2546890	Multiple sclerosis	IL12B	1.16	8E-8
chr5	158759899	158759900	rs2546890	Multiple sclerosis	IL12B	1.11	1E-11
chr5	158759899	158759900	rs2546890	Psoriasis	IL12B	1.54	1E-20
chr5	158787384	158787385	rs6556412	Crohn's disease	IL12B	1.18	5E-14
chr5	158814532	158814533	rs10045431	Crohn's disease	IL12B	1.45	7E-8
chr5	158814532	158814533	rs10045431	Crohn's disease	IL12B	1.11	4E-13
chr5	158818744	158818745	rs6556416	Ankylosing spondylitis	IL12B	NR	2E-8
chr5	158822644	158822645	rs6887695	Crohn's disease	IL12B	1.26	9E-6
chr5	158826791	158826792	rs6871626	Ulcerative colitis	IL12B	1.17	1E-21
chr5	158829526	158829527	rs12188300	Psoriatic arthritis	IL12B	1.70	7E-17
chr5	158904312	158904313	rs12657996	Response to taxane treatment (placlitaxel)	IL12B	NR	9E-6
chr5	158918893	158918894	rs10866713	Multiple sclerosis	IL12B	1.17	7E-7
chr5	159849585	159849586	rs1895320	Insulin-related traits	PTTG1	.22	6E-6
chr5	159879977	159879978	rs2431697	Systemic lupus erythematosus	PTTG1	1.32	2E-6
chr5	162083517	162083518	rs7711337	Autism	Intergenic	1.22	8E-7
chr5	162998514	162998515	rs294588	Aging	MAT2B, LOC391844	NR	1E-6
chr5	163889279	163889280	rs6556756	Breast cancer	Intergenic	NR	5E-7
chr5	164764086	164764087	rs1145652	Phospholipid levels (plasma)	MAT2B	.04	8E-8
chr5	165063883	165063884	rs958994	Carotid atherosclerosis in HIV infection	Intergenic	NR	8E-6
chr5	165377698	165377699	rs9313296	Weight	Intergenic	10.00	7E-7
chr5	165377698	165377699	rs9313296	Waist circumference	Intergenic	9.40	6E-6
chr5	165957085	165957086	rs2122554	Conduct disorder (symptom count)	Intergenic	.10	3E-6
chr5	166318189	166318190	rs3853240	Adverse response to lamotrigine and phenytoin	CTB-7E3.1	NR	1E-6
chr5	166389492	166389493	rs17404956	Diabetic retinopathy	LOC441114, ODZ2	1.16	1E-6
chr5	167210471	167210472	rs2973662	Immune response to smallpox vaccine (IL-6)	ODZ2	NR	5E-7
chr5	167500459	167500460	rs13358864	Uric acid levels	ODZ2	24.09	5E-6
chr5	167643544	167643545	rs6885116	Periodontal microbiota	ODZ2, WWC1	2.57	1E-6
chr5	168256239	168256240	rs4282339	Height	SLIT3	.04	7E-16
chr5	168899986	168899987	rs13156607	Waist circumference	CCDC99	3.91	5E-6
chr5	169074055	169074056	rs169082	Protein quantitative trait loci	DOCK2	NR	1E-6
chr5	169950393	169950394	rs11957313	Normalized brain volume	KCNIP1	NR	9E-6
chr5	170720732	170720733	rs2278255	Visceral fat	RANBP17	NR	5E-6
chr5	171015622	171015623	rs6892884	Height	FBXW11	NR	4E-8
chr5	171076226	171076227	rs254893	Quantitative traits	Intergenic	.58	6E-6
chr5	171203437	171203438	rs12153391	Height	FBXW11	.03	4E-12
chr5	172480335	172480336	rs251253	PR interval	NKX2-5, C5orf41	1.49	9E-13
chr5	172595307	172595308	rs29784	Infantile hypertrophic pyloric stenosis	BNIP1, NKX2-5	1.42	1E-15
chr5	172934897	172934898	rs7722022	Adiponectin levels	Intergenic	NR	9E-6
chr5	172984113	172984114	rs889014	Height	BOD1	.03	9E-16
chr5	173279841	173279842	rs359457	Crohn's disease	CPEB4	1.08	3E-12
chr5	173359330	173359331	rs17763373	Prion diseases	NR	1.51	7E-6
chr5	173362457	173362458	rs6861681	Waist-hip ratio	CPEB4	.02	2E-9
chr5	173648437	173648438	rs10475598	Information processing speed	CTC-430J12.2	.15	8E-7
chr5	173695777	173695778	rs11952171	Subcutaneous adipose tissue	HMP19	NR	7E-6
chr5	174761094	174761095	rs12652255	Treatment response for severe sepsis	DRD1	NR	8E-6
chr5	175956270	175956271	rs890835	Menopause (age at onset)	RNF44	.18	6E-6
chr5	176378573	176378574	rs365132	Menopause (age at onset)	UIMC1	.29	9E-32
chr5	176378573	176378574	rs365132	Menarche and menopause (age at onset)	UIMC1	.39	8E-14
chr5	176517325	176517326	rs422421	Height	FGFR4/NSD1	.03	1E-12
chr5	176784511	176784512	rs4075958	Multiple sclerosis	RGS14	1.09	5E-7
chr5	176794190	176794191	rs12654812	Renal function-related traits (sCR)	RGS14	.00	5E-7
chr5	176794190	176794191	rs12654812	Renal function-related traits (eGRFcrea)	RGS14	.00	2E-7
chr5	176798305	176798306	rs11746443	Nephrolithiasis	RGS14, SLC34A1,PFN3, F12	1.19	9E-12
chr5	176817635	176817636	rs6420094	Chronic kidney disease	SLC34A1,GRK6,RGS14,LMAN2,PRR7,F12,PFN3	.01	1E-14
chr5	176841338	176841339	rs2545801	Activated partial thromboplastin time	UIMC1, FGFR4, NSD1, PRELID1, MXD3, LMAN2, RGS14, SLC34A1, PRR7, DBN1, F12, GRK6	1.68	6E-88
chr5	176841338	176841339	rs2545801	Metabolite levels	F12	.12	9E-11
chr5	176842473	176842474	rs2731672	Metabolite levels	PFN3, F12, GRK6	NR	3E-14
chr5	176842473	176842474	rs2731672	Platelet function and related traits	F12	NR	1E-6
chr5	176842473	176842474	rs2731672	Activated partial thromboplastin time	F12	.45	2E-30
chr5	178570913	178570914	rs10039254	Attention deficit hyperactivity disorder (time to onset)	ADAMTS2	NR	8E-6
chr5	178663407	178663408	rs469568	Stroke (pediatric)	ADAMTS2	1.77	8E-6
chr5	178699310	178699311	rs901254	Visceral adipose tissue adjusted for BMI	ADAMTS2	NR	9E-6
chr5	179032487	179032488	rs6894268	Eating disorders	RUFY1	1.44	3E-6
chr5	179471200	179471201	rs13161895	Coronary heart disease	RNF130	.15	6E-7
chr5	179731013	179731014	rs6879260	Height	GFPT2	.02	2E-9
chr5	179794207	179794208	rs10464059	Parkinson's disease	NR	1.33	3E-6
chr5	180170818	180170819	rs12517906	Weight	MGAT1	2.96	7E-8
chr5	180170818	180170819	rs12517906	Body mass index	NR	.16	6E-6
chr5	180226672	180226673	rs655601	Quantitative traits	MGAT1	.23	5E-6
chr5	180595137	180595138	rs1279750	Platelet counts	AC008620.2	NR	2E-6
chr6	383545	383546	rs1033180	Celiac disease	IRF4	1.21	6E-8
chr6	396320	396321	rs12203592	Progressive supranuclear palsy	IRF4	1.48	6E-15
chr6	396320	396321	rs12203592	Hair color	NR	NR	4E-7
chr6	396320	396321	rs12203592	Hair color	IRF4	.59	2E-28
chr6	396320	396321	rs12203592	Freckling	IRF4	1.61	2E-91
chr6	396320	396321	rs12203592	Eye color	IRF4	.42	2E-15
chr6	396320	396321	rs12203592	Black vs. red hair color	IRF4	.31	9E-28
chr6	396320	396321	rs12203592	Black vs. blond hair color	IRF4	.35	7E-127
chr6	411063	411064	rs872071	Chronic lymphocytic leukemia	NR	1.47	8E-14
chr6	411063	411064	rs872071	Chronic lymphocytic leukemia	IRF4	1.54	2E-20
chr6	417726	417727	rs9378805	Chronic lymphocytic leukemia	NR	1.38	2E-6
chr6	466032	466033	rs1540771	Freckles	SEC5L1,IRF4	1.40	4E-18
chr6	475488	475489	rs12210050	Schizophrenia	EXOC2,9648	1.20	3E-6
chr6	475488	475489	rs12210050	Schizophrenia	EXOC2, 9648	1.18	4E-6
chr6	475488	475489	rs12210050	Basal cell carcinoma	EXOC2	1.24	1E-9
chr6	475488	475489	rs12210050	Tanning	EXOC2	.22	5E-14
chr6	542158	542159	rs6918152	Black vs. red hair color	EXOC2	.11	5E-7
chr6	542158	542159	rs6918152	Black vs. blond hair color	EXOC2	.11	6E-8
chr6	566740	566741	rs2476842	Dental caries	EXOC2	NR	3E-6
chr6	858969	858970	rs1572438	Aging	HUS1B, FOXQ1	NR	9E-6
chr6	1340188	1340189	rs9502893	Pancreatic cancer	FOXQ1	1.29	3E-7
chr6	1535997	1535998	rs11242704	Response to hepatitis C treatment	RP11-157J24.1	.26	5E-6
chr6	1573612	1573613	rs2338	Response to platinum-based agents	FOXC1, GMDS	2.27	5E-6
chr6	2235632	2235633	rs9378688	Caudate nucleus volume	GMDS	154.20	6E-6
chr6	3359336	3359337	rs4959235	Antipsychotic-induced QTc interval prolongation	SLC22A23	NR	2E-7
chr6	3433317	3433318	rs17309827	Crohn's disease	intergenic	1.10	7E-9
chr6	4512978	4512979	rs6942328	Uric acid levels	AL162718.1	.55	1E-6
chr6	4874758	4874759	rs73717741	Chronic obstructive pulmonary disease	CDYL	11.90	3E-7
chr6	5260935	5260936	rs2224391	Height	LYRM4	.05	3E-6
chr6	6283665	6283666	rs749005	MRI atrophy measures	F13A1	.00	3E-7
chr6	6612466	6612467	rs2326810	Major depressive disorder (broad)	LY86	1.41	7E-6
chr6	6743148	6743149	rs1294421	Waist-hip ratio	LY86	.03	2E-17
chr6	7102083	7102084	rs675209	Urate levels	RREB1	4.39	1E-9
chr6	7106315	7106316	rs2842895	Visceral adipose tissue adjusted for BMI	RREB1	NR	4E-6
chr6	7106315	7106316	rs2842895	Visceral adipose tissue adjusted for BMI	RREB1	NR	4E-6
chr6	7118989	7118990	rs11755724	Multiple sclerosis	RREB1	1.08	3E-6
chr6	7118989	7118990	rs11755724	Age-related macular degeneration	RREB1	1.15	1E-6
chr6	7240576	7240577	rs2714337	Fasting glucose-related traits (interaction with BMI)	RREB1	NR	3E-7
chr6	7720058	7720059	rs12198986	Height	BMP6	6.80	2E-11
chr6	7725759	7725760	rs3812163	Height	BMP6	.04	1E-23
chr6	7736742	7736743	rs2068361	Orofacial clefts	BMP6	1.64	5E-6
chr6	7743662	7743663	rs9505270	Myopia (pathological)	BMP6	NR	4E-7
chr6	9030335	9030336	rs438259	Attention deficit hyperactivity disorder	LOC389365	1.49	4E-6
chr6	9451196	9451197	rs10484246	Morbidity-free survival	Intergenic	NR	8E-8
chr6	9853918	9853919	rs4716055	Adiponectin levels	NR	.03	4E-6
chr6	10163967	10163968	rs13195786	Calcium levels	Intergenic	.03	7E-6
chr6	10897487	10897488	rs2153157	Menopause (age at onset)	SYCP2L	.17	8E-12
chr6	10897487	10897488	rs2153157	Menarche and menopause (age at onset)	GCM2, SYCP2L	.29	5E-8
chr6	10960157	10960158	rs6918936	Phospholipid levels (plasma)	SYCP2L	.03	3E-8
chr6	10969140	10969141	rs4713103	Phospholipid levels (plasma)	SYCP2L	.11	8E-14
chr6	10969140	10969141	rs4713103	Phospholipid levels (plasma)	SYCP2L	.04	3E-36
chr6	10982358	10982359	rs17606561	Phospholipid levels (plasma)	ELOVL2	.00	1E-11
chr6	10982972	10982973	rs3734398	Phospholipid levels (plasma)	ELOVL2	.04	1E-43
chr6	10995014	10995015	rs2236212	Phospholipid levels (plasma)	ELOVL2	.11	1E-15
chr6	11008621	11008622	rs3798713	Phospholipid levels (plasma)	ELOVL2	.04	2E-12
chr6	11040422	11040423	rs3798722	Metabolite levels	ELOVL2	NR	4E-9
chr6	11042908	11042909	rs9393903	Metabolic traits	ELOVL2	.06	2E-14
chr6	11074346	11074347	rs4711171	Phospholipid levels (plasma)	HERV, FRD	.01	5E-13
chr6	11076025	11076026	rs1321535	Phospholipid levels (plasma)	HERV, FRD	.04	5E-11
chr6	11076025	11076026	rs1321535	Phospholipid levels (plasma)	HERV, FRD	.04	1E-38
chr6	11310418	11310419	rs4437462	HIV-1 susceptibility	NEDD9	.00	2E-6
chr6	11943525	11943526	rs1205863	Disc degeneration (lumbar)	Intergenic	.21	6E-6
chr6	12048826	12048827	rs1570989	Alcohol and nictotine co-dependence	HIVEP1	NR	2E-6
chr6	12197212	12197213	rs1040994	Response to antipsychotic treatment	Intergenic	9.00	2E-6
chr6	12889003	12889004	rs1332844	Coronary heart disease	PHACTR1	1.11	6E-8
chr6	12903956	12903957	rs9349379	Coronary heart disease	PHACTR1	1.15	2E-9
chr6	12903956	12903957	rs9349379	Coronary heart disease	PHACTR1	1.34	8E-10
chr6	12903956	12903957	rs9349379	Coronary heart disease	PHACTR1	1.19	6E-12
chr6	12903956	12903957	rs9349379	Coronary heart disease	PHACTR1	1.23	4E-7
chr6	12903956	12903957	rs9349379	Migraine	PHACTR1	1.16	3E-8
chr6	12903956	12903957	rs9349379	Coronary artery calcification	PHACTR1	.20	4E-22
chr6	12903956	12903957	rs9349379	Coronary heart disease	PHACTR1	NR	9E-26
chr6	12903956	12903957	rs9349379	Coronary heart disease	PHACTR1	NR	9E-26
chr6	12927543	12927544	rs12526453	Coronary heart disease	PHACTR1	1.10	1E-9
chr6	12927543	12927544	rs12526453	Myocardial infarction (early onset)	PHACTR1	1.12	1E-9
chr6	13216057	13216058	rs4715166	Hip geometry	PHACTR1	NR	3E-6
chr6	13270944	13270945	rs1223397	Blood pressure	PHACTR1	NR	1E-7
chr6	13332466	13332467	rs499818	Major CVD	Intergenic	NR	7E-6
chr6	14096657	14096658	rs12529514	Rheumatoid arthritis	CD83	1.14	2E-8
chr6	14173427	14173428	rs853356	Height	Intergenic	.04	3E-6
chr6	14587002	14587003	rs12213875	Ovarian reserve	JARID2	NR	3E-7
chr6	14596364	14596365	rs6914079	Cognitive test performance	Intergenic	NR	2E-6
chr6	14598819	14598820	rs7770731	Working memory	Intergenic	NR	1E-6
chr6	15089150	15089151	rs6941421	Multiple sclerosis (severity)	JARID2	NR	6E-6
chr6	16127406	16127407	rs3757354	LDL cholesterol	IDOL	1.43	1E-11
chr6	16127406	16127407	rs3757354	Cholesterol, total	IDOL	1.46	3E-9
chr6	16161424	16161425	rs6924995	Response to statin therapy (LDL-C)	GMPR, IDOL, MYLIP	4.10	5E-7
chr6	16197193	16197194	rs2142672	LDL cholesterol	MYLIP,GMPR	.01	2E-8
chr6	16343055	16343056	rs9383153	Gambling	ATXN1, GMPR	.33	5E-6
chr6	16742032	16742033	rs697739	Amyotrophic lateral sclerosis	ATXN1	2.04	4E-6
chr6	17241153	17241154	rs1322846	Immune response to smallpox vaccine (IL-6)	RBM24	NR	6E-7
chr6	17699321	17699322	rs12199222	Height	NUP153, CAP2, KIF13A	4.40	7E-7
chr6	17813824	17813825	rs10456809	Prostate cancer (gene x gene interaction)	KIF13A	1.25	5E-6
chr6	18791722	18791723	rs41441749	Hyperactive-impulsive symptoms	Intergenic	NR	1E-6
chr6	19785587	19785588	rs7739264	Endometriosis	NR	1.17	4E-10
chr6	19841492	19841493	rs1047014	Height	ID4	.03	2E-13
chr6	19969637	19969638	rs16883019	Response to statin therapy	LOC729105, ID4, MBOAT1	NR	7E-7
chr6	20156173	20156174	rs1202199	Hyperactive-impulsive symptoms	Intergenic	NR	9E-6
chr6	20652716	20652717	rs9295474	Type 2 diabetes	CDKAL1	1.16	9E-6
chr6	20657563	20657564	rs4712523	Type 2 diabetes and other traits	CDKAL1	1.20	2E-12
chr6	20657563	20657564	rs4712523	Type 2 diabetes	CDKAL1	1.27	7E-20
chr6	20657864	20657865	rs4712524	Type 2 diabetes	CDKAL1	1.22	3E-10
chr6	20661033	20661034	rs10946398	Type 2 diabetes	CDKAL	1.18	7E-7
chr6	20661033	20661034	rs10946398	Type 2 diabetes	CDKAL1	1.16	1E-8
chr6	20661249	20661250	rs7754840	Type 2 diabetes	CDKAL1	1.35	7E-10
chr6	20661249	20661250	rs7754840	Diabetes (gestational)	CDKAL1	1.52	7E-16
chr6	20661249	20661250	rs7754840	Type 2 diabetes	CDKAL1	1.12	4E-11
chr6	20661249	20661250	rs7754840	Type 2 diabetes	CDKAL1	1.12	4E-11
chr6	20679708	20679709	rs7756992	Type 2 diabetes	CDKAL1	1.20	8E-9
chr6	20685485	20685486	rs9356744	Body mass index	CDKAL1	3.39	2E-11
chr6	20686572	20686573	rs7766070	Type 2 diabetes	CDKAL1	1.26	7E-10
chr6	20686572	20686573	rs7766070	Type 2 diabetes	CDKAL1	1.21	6E-11
chr6	20688120	20688121	rs10440833	Type 2 diabetes	CDKAL1	1.25	2E-22
chr6	20694883	20694884	rs2206734	Body mass index	CDKAL1	.04	1E-11
chr6	20694883	20694884	rs2206734	Ileal carcinoids	CDKAL1	3.45	8E-6
chr6	20703951	20703952	rs6931514	Type 2 diabetes	CDKAL1	1.25	1E-11
chr6	20717254	20717255	rs9465871	Type 2 diabetes	CDKAL1	1.18	3E-7
chr6	20725422	20725423	rs7747752	Glycated hemoglobin levels	CDKAL1	.05	1E-11
chr6	20728730	20728731	rs6908425	Crohn's disease	CDKAL1	1.17	1E-8
chr6	20728730	20728731	rs6908425	Crohn's disease	CDKAL1	1.21	9E-10
chr6	21384612	21384613	rs9466056	Bone mineral density	SOX4	.05	4E-6
chr6	22017737	22017738	rs1928168	Pulmonary function	AK026189	.03	2E-7
chr6	22125963	22125964	rs4712653	Neuroblastoma	FLJ22536, FLJ44180	1.40	8E-17
chr6	22131928	22131929	rs9295536	Neuroblastoma	LINC00340, FLJ44180	1.36	8E-16
chr6	22140003	22140004	rs6939340	Neuroblastoma	FLJ22536, FLJ44180	1.37	9E-15
chr6	22246603	22246604	rs4236016	Cardiac hypertrophy	SOX4	NR	4E-6
chr6	22304203	22304204	rs1341239	Paget's disease	PRL	1.20	4E-6
chr6	22743402	22743403	rs10498712	Quantitative traits	Intergenic	.23	9E-6
chr6	23077310	23077311	rs9393366	Tourette syndrome	Intergenic	1.27	8E-6
chr6	23437675	23437676	rs7771911	Immune reponse to smallpox (secreted IL-12p40)	LOC100131805	NR	2E-12
chr6	24107092	24107093	rs6922632	Information processing speed	NRSN1	.19	4E-6
chr6	24234932	24234933	rs793834	Information processing speed	DCDC2	.15	3E-6
chr6	24306386	24306387	rs16889038	Airflow obstruction	DCDC2	1.39	8E-7
chr6	24441745	24441746	rs9467160	Liver enzyme levels	GPLD1	.03	1E-11
chr6	24491474	24491475	rs1883415	Liver enzyme levels (alkaline phosphatase)	ALDH5A1, GPLD1	3.10	6E-26
chr6	24544966	24544967	rs16889440	Radiation response	KIAA0319	NR	2E-6
chr6	24749412	24749413	rs17419851	Neutrophil count	AL133264.1, RP3-369A17.4	NR	9E-6
chr6	24863074	24863075	rs4256430	Electroencephalographic traits in alcoholism	FAM65B	.10	8E-6
chr6	25488582	25488583	rs2274089	Iron status biomarkers	LRRC16A	NR	5E-6
chr6	25488582	25488583	rs2274089	Iron status biomarkers	LRRC16	NR	8E-7
chr6	25488582	25488583	rs2274089	Iron status biomarkers	LRRC16	NR	3E-7
chr6	25533533	25533534	rs12526480	Mean platelet volume	LRRC16A	4.39	9E-9
chr6	25548287	25548288	rs441460	Platelet counts	LRRC16	3.08	9E-18
chr6	25607570	25607571	rs742132	Uric acid levels	LRRC16A, SCGN	.05	9E-9
chr6	25641199	25641200	rs932316	Iron status biomarkers	SCGN	NR	9E-6
chr6	25772046	25772047	rs4712972	Carotid intima media thickness	SLC17A4	.01	8E-8
chr6	25776948	25776949	rs11754288	Cardiovascular disease risk factors	SLC17A4	.08	4E-9
chr6	25813149	25813150	rs1165196	Urate levels	SLC17A1	6.21	5E-25
chr6	25820438	25820439	rs17270561	Iron status biomarkers	SLC17A1	NR	5E-7
chr6	25821769	25821770	rs17342717	Iron levels	SLC17A1	36.50	5E-9
chr6	25821769	25821770	rs17342717	Iron status biomarkers	HFE	.09	9E-10
chr6	25821769	25821770	rs17342717	Red blood cell traits	SLC17A1	.38	5E-8
chr6	25823443	25823444	rs1183201	Uric acid levels	SLC17A1	.06	3E-14
chr6	25842950	25842951	rs1408272	Iron status biomarkers	HFE	.04	9E-9
chr6	25842950	25842951	rs1408272	Mean corpuscular hemoglobin	SLC17A3	.02	4E-39
chr6	25842950	25842951	rs1408272	Hematology traits	HFE	.32	1E-11
chr6	25870541	25870542	rs1165205	Urate levels	SLC17A3	.09	4E-29
chr6	25997457	25997458	rs12216125	Iron status biomarkers	TRIM38	NR	4E-6
chr6	26031612	26031613	rs10484434	HIV-1 viral setpoint	HIST1H4A	NR	1E-6
chr6	26091178	26091179	rs1799945	Systolic blood pressure	HFE	.63	8E-12
chr6	26091178	26091179	rs1799945	Hypertension	HFE	.10	2E-10
chr6	26091178	26091179	rs1799945	Diastolic blood pressure	HFE	.46	2E-15
chr6	26091178	26091179	rs1799945	Iron levels	HFE	4.95	3E-9
chr6	26093140	26093141	rs1800562	Cardiovascular disease risk factors	HFE	.18	5E-12
chr6	26093140	26093141	rs1800562	Hepcidin levels	HFE	.51	5E-11
chr6	26093140	26093141	rs1800562	Hepcidin levels	HFE	.44	4E-9
chr6	26093140	26093141	rs1800562	Hepcidin levels	HFE	.39	3E-7
chr6	26093140	26093141	rs1800562	Hepcidin levels	HFE	.61	3E-15
chr6	26093140	26093141	rs1800562	Alcohol consumption	HFE	.63	2E-32
chr6	26093140	26093141	rs1800562	Red blood cell traits	HFE	1.09	6E-7
chr6	26093140	26093141	rs1800562	Red blood cell traits	HFE	.49	3E-9
chr6	26093140	26093141	rs1800562	Red blood cell traits	HFE	.49	3E-9
chr6	26093140	26093141	rs1800562	Glycated hemoglobin levels	HFE	.06	3E-20
chr6	26093140	26093141	rs1800562	LDL cholesterol	HFE,HIST1H4C	2.22	6E-10
chr6	26093140	26093141	rs1800562	Cholesterol, total	HFE,HIST1H4C	2.16	2E-8
chr6	26093140	26093141	rs1800562	Mean corpuscular volume	HFE	.01	1E-46
chr6	26093140	26093141	rs1800562	Hemoglobin	HFE	.16	6E-19
chr6	26093140	26093141	rs1800562	Hematocrit	HFE	.31	2E-9
chr6	26093140	26093141	rs1800562	Iron status biomarkers	HFE	.20	5E-7
chr6	26093140	26093141	rs1800562	Iron status biomarkers	HFE	.22	2E-8
chr6	26093140	26093141	rs1800562	Hematological parameters	HFE	1.41	1E-23
chr6	26093140	26093141	rs1800562	Iron status biomarkers	HFE	NR	4E-15
chr6	26093140	26093141	rs1800562	Iron status biomarkers	HFE	.66	4E-11
chr6	26093140	26093141	rs1800562	Iron status biomarkers	HFE	.68	1E-10
chr6	26107462	26107463	rs198846	Blood pressure	HFE	.48	2E-12
chr6	26107462	26107463	rs198846	Hemoglobin	HFE	NR	1E-8
chr6	26116981	26116982	rs12206204	Bilirubin levels	HIST1H2BC	.18	8E-7
chr6	26200676	26200677	rs806794	Height	Histone cluster	.05	1E-39
chr6	26233386	26233387	rs10946808	Height	HIST1H1D	.07	6E-12
chr6	26233386	26233387	rs10946808	Height	Histone class 1, Butyrophilin genes	5.60	6E-10
chr6	26233386	26233387	rs10946808	Height	HIST1H1D	.36	4E-17
chr6	26500562	26500563	rs13194984	Iron status biomarkers	BTN1A1	NR	6E-8
chr6	27037079	27037080	rs13194491	Iron status biomarkers	HIST1H2BJ	NR	1E-8
chr6	27143882	27143883	rs13194053	Schizophrenia	MHC	1.22	1E-8
chr6	27143882	27143883	rs13194053	Schizophrenia	SLC17A1, SLC17A3, BTN3A2, BTN2A2, BTN3A1, HIST1H2AG, HIST1H2BJ, PRSS16, POM121L2, ZNF184	1.28	1E-8
chr6	27248930	27248931	rs6932590	Schizophrenia	MHC, PRSS16	1.16	1E-12
chr6	27710164	27710165	rs17693963	Schizophrenia	MHC	1.24	3E-11
chr6	28227603	28227604	rs1635	Schizophrenia	NKAPL	1.28	7E-12
chr6	28322295	28322296	rs6903823	Pulmonary function	ZKSCAN3, ZNF323	.04	2E-10
chr6	28776116	28776117	rs4324798	Lung adenocarcinoma	TRNAA-UGC	1.16	2E-8
chr6	28916251	28916252	rs4947339	Platelet aggregation	TRIM27	NR	2E-6
chr6	29084231	29084232	rs3129109	Height	OR2J3	.03	2E-17
chr6	29355201	29355202	rs3094548	Pulmonary function	OR12D2	.03	1E-7
chr6	29356330	29356331	rs9257809	Barrett's esophagus	MHC, OR2D12, OR2D13	1.21	4E-9
chr6	29434413	29434414	rs4713226	Immune reponse to smallpox (secreted IFN-alpha)	OR2H1	NR	2E-8
chr6	29611430	29611431	rs29232	Nasopharyngeal carcinoma	GABBR1	1.67	9E-17
chr6	29670260	29670261	rs3129055	Nasopharyngeal carcinoma	HLA-F	1.51	7E-11
chr6	29702509	29702510	rs2523395	Prostate cancer (gene x gene interaction)	LOC285830	1.24	2E-6
chr6	29705658	29705659	rs2523393	Multiple sclerosis	HLA-B	1.28	1E-17
chr6	29723160	29723161	rs9258260	Crohn's disease	HLA-F, MOG, HLA-G, GABBR1, HLA-H, UBD, HLA-A	1.45	2E-10
chr6	29789170	29789171	rs1610677	Rheumatoid arthritis	HLA-G	1.32	4E-15
chr6	29828659	29828660	rs2523822	Drug-induced liver injury (amoxicillin-clavulanate)	HLA-A	2.30	2E-10
chr6	29849618	29849619	rs2523809	IgE levels	HLA-G	.06	4E-8
chr6	29899676	29899677	rs2524005	Bipolar disorder and schizophrenia	MHC, other genes	1.32	5E-7
chr6	29906690	29906691	rs2860580	Nasopharyngeal carcinoma	HLA-A	1.72	5E-67
chr6	29913297	29913298	rs1061235	Adverse response to carbamapezine	HLA-A*3101	9.12	1E-7
chr6	29918098	29918099	rs2517713	Nasopharyngeal carcinoma	HLA-A	1.88	4E-20
chr6	29920331	29920332	rs9260489	Multiple sclerosis	HLA-B	1.21	1E-11
chr6	29923837	29923838	rs2571391	IgE levels	HLA-A	.06	1E-15
chr6	29935249	29935250	rs3893464	Graves' disease	MHC	1.53	2E-20
chr6	29941942	29941943	rs2523946	IgA nephropathy	HLA-A	1.21	2E-11
chr6	29943066	29943067	rs6904029	Vitiligo	HLA-A,HCG9	1.49	1E-21
chr6	29970588	29970589	rs7758512	HIV-1 control	ZNRD1, RNF39, HLA-A	NR	2E-8
chr6	29973924	29973925	rs4313034	Graves' disease	MHC	1.67	2E-15
chr6	30017070	30017071	rs6917603	Lipid metabolism phenotypes	PPP1R11	.24	3E-29
chr6	30025502	30025503	rs259919	HIV-1 control	C6orf12, ZNRD1	NR	3E-7
chr6	30032521	30032522	rs8321	AIDS progression	ZNRD1, RNF39	NR	5E-7
chr6	30080368	30080369	rs34704616	Cognitive performance	XXbac-BPG250I8.13	NR	6E-6
chr6	30093363	30093364	rs10947055	Cardiac hypertrophy	TRIM38	NR	2E-7
chr6	30119889	30119890	rs9468692	HIV-1 control	TRIM10	NR	1E-6
chr6	30165272	30165273	rs2523722	Schizophrenia	MHC, TRIM26	1.25	1E-16
chr6	30174130	30174131	rs2021722	Schizophrenia	TRIM26	1.15	2E-12
chr6	30537605	30537606	rs3132613	Graves' disease	MHC	1.43	1E-13
chr6	30736150	30736151	rs12526186	Response to antipsychotic treatment	Intergenic	9.00	3E-6
chr6	30782001	30782002	rs886424	Bipolar disorder and schizophrenia	MHC, other genes	1.37	9E-7
chr6	30795170	30795171	rs7772131	Response to angiotensin II receptor blocker therapy	C6orf214	6.73	3E-6
chr6	30848252	30848253	rs7756521	HIV-1 control	DDR1, VARS2, DPCR1	NR	1E-6
chr6	30876151	30876152	rs1052693	Complement C3 and C4 levels	HLA-A	.10	3E-48
chr6	31002615	31002616	rs4248154	Graves' disease	MHC	1.38	1E-13
chr6	31006854	31006855	rs2844665	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	C6orf205	1.54	3E-7
chr6	31018406	31018407	rs2517532	Hypothyroidism	LOC729792, HCG22, C6orf15, HLA-C, HLA-B, DHFRP2, HCP5	1.16	1E-8
chr6	31024807	31024808	rs9262632	HIV-1 control	Intergenic	3.10	1E-8
chr6	31058177	31058178	rs4947296	Behcet's disease	HCG22	2.57	1E-11
chr6	31058177	31058178	rs4947296	Graves' disease	MUC21, C6orf15	1.77	4E-51
chr6	31058339	31058340	rs3130544	Myasthenia gravis	NR	5.64	2E-90
chr6	31074029	31074030	rs6457327	Follicular lymphoma	C6orf15	1.47	7E-6
chr6	31074029	31074030	rs6457327	Follicular lymphoma	STG, PSORS1	1.69	5E-11
chr6	31093586	31093587	rs3815087	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	PSORS1C1	1.53	3E-7
chr6	31093586	31093587	rs3815087	HIV-1 control	CDSN	NR	8E-8
chr6	31097300	31097301	rs3130559	Chronic obstructive pulmonary disease-related biomarkers	PSORS1C1	NR	8E-9
chr6	31099576	31099577	rs4959053	Behcet's disease	PSORS1C1	4.38	2E-20
chr6	31106267	31106268	rs3130573	Systemic sclerosis	PSORS1C1	1.25	6E-10
chr6	31107186	31107187	rs1265093	Chronic obstructive pulmonary disease-related biomarkers	PSORS1C1, CCHCR1	NR	6E-9
chr6	31111355	31111356	rs9263739	Ulcerative colitis	HLA	2.73	4E-67
chr6	31118018	31118019	rs1265112	Nevirapine-induced rash	CCHCR1	4.36	1E-8
chr6	31118510	31118511	rs130067	Prostate cancer	CCHCR1	1.05	3E-8
chr6	31136452	31136453	rs3130501	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	POU5F1	1.74	2E-8
chr6	31139451	31139452	rs879882	Height	MICA	NR	2E-7
chr6	31143581	31143582	rs3131018	HIV-1 control	PSORS1C3	2.10	4E-16
chr6	31155784	31155785	rs1265181	Psoriasis	MHC	22.62	NS
chr6	31168028	31168029	rs6903896	Common traits (Other)	NR	NR	6E-7
chr6	31184195	31184196	rs3869109	Coronary heart disease	HCG27, HLA-C	1.14	1E-9
chr6	31221667	31221668	rs3095254	White blood cell types	MHC	.07	6E-11
chr6	31240430	31240431	rs2074488	Chronic obstructive pulmonary disease-related biomarkers	HLA-C	NR	2E-10
chr6	31241108	31241109	rs13191343	Psoriatic arthritis	HLA-C	2.37	2E-72
chr6	31252395	31252396	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.31	6E-21
chr6	31252395	31252396	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.37	2E-28
chr6	31252924	31252925	rs12191877	Psoriasis	HLA-C	2.79	4E-32
chr6	31252924	31252925	rs12191877	Psoriasis	HLA-C	2.64	1E-100
chr6	31258836	31258837	rs9468925	Vitiligo	HLA	1.35	2E-33
chr6	31263750	31263751	rs2894207	Nasopharyngeal carcinoma	HLA-B,HLA-C	1.64	3E-33
chr6	31265489	31265490	rs2247056	Triglycerides	HLA	2.99	2E-15
chr6	31271715	31271716	rs9461688	Protein quantitative trait loci	HLA-C	NR	4E-6
chr6	31272320	31272321	rs9368677	Atopic dermatitis	HLA-C	1.36	1E-17
chr6	31274379	31274380	rs9264942	HIV-1 control	HLA-C	2.90	3E-35
chr6	31274379	31274380	rs9264942	HIV-1 control	HLA-C	5.30	6E-32
chr6	31274379	31274380	rs9264942	HIV-1 control	HLA-C	NR	6E-12
chr6	31274554	31274555	rs10484554	Psoriasis	HLA-C	4.66	4E-214
chr6	31274554	31274555	rs10484554	AIDS progression	HLA-C	NR	6E-8
chr6	31274554	31274555	rs10484554	Psoriasis	HLA-C	2.80	2E-39
chr6	31312325	31312326	rs3134792	Psoriasis	HLA-C	NR	1E-9
chr6	31322366	31322367	rs3819299	Platelet counts	HLA-B	5.05	9E-10
chr6	31322558	31322559	rs2523608	HIV-1 control	HLA-B	2.60	9E-20
chr6	31322558	31322559	rs2523608	HIV-1 control	HLA-B	NR	3E-6
chr6	31327063	31327064	rs2523590	HIV-1 control	HLA-B	2.40	2E-13
chr6	31327700	31327701	rs9378249	Bipolar disorder	NR	NR	1E-8
chr6	31336099	31336100	rs7743761	Ankylosing spondylitis	MHC	NR	5E-304
chr6	31336417	31336418	rs9266406	Behcet's disease	MICA, MICB, DHFRP2	2.29	2E-10
chr6	31346821	31346822	rs9266629	Chronic obstructive pulmonary disease-related biomarkers	FGFR3P	NR	4E-10
chr6	31350703	31350704	rs1521	Graves' disease	HLA-B	1.92	2E-65
chr6	31354559	31354560	rs13437082	Height	HLA-B	.07	5E-8
chr6	31365786	31365787	rs4349859	Ankylosing spondylitis	HLA-B	NR	1E-200
chr6	31366594	31366595	rs2596542	Hepatocellular carcinoma	MICA	1.39	4E-13
chr6	31377586	31377587	rs12175489	Visceral adipose tissue adjusted for BMI	HLA-B, HCP5	NR	2E-6
chr6	31379930	31379931	rs1063635	Rheumatoid arthritis	MICA	1.35	1E-17
chr6	31380528	31380529	rs2256183	Height	MICA	.04	8E-29
chr6	31391400	31391401	rs4418214	HIV-1 control	MICA	4.40	1E-34
chr6	31407827	31407828	rs9469003	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	HCP5	1.73	2E-9
chr6	31408264	31408265	rs2524276	Capecitabine sensitivity	Intergenic	NR	6E-6
chr6	31431690	31431691	rs2255221	HIV-1 control	Intergenic	2.70	4E-14
chr6	31431779	31431780	rs2395029	HIV-1 control	HLA-B	5.30	1E-25
chr6	31431779	31431780	rs2395029	HIV-1 control	HCP5, HLA-B	5.80	5E-35
chr6	31431779	31431780	rs2395029	HIV-1 control	HCP5, HLA-B	NR	1E-11
chr6	31431779	31431780	rs2395029	Drug-induced liver injury (flucloxacillin)	HCP5, HLA-B	45.00	9E-33
chr6	31431779	31431780	rs2395029	AIDS progression	HCP5, MICB, MCCD1, BAT1, LTB, TNF	3.47	3E-19
chr6	31431779	31431780	rs2395029	Psoriasis	HLA-C	4.10	2E-26
chr6	31440668	31440669	rs3828890	Renal function-related traits (sCR)	MHC	.01	3E-9
chr6	31440668	31440669	rs3828890	Renal function-related traits (eGRFcrea)	MHC	.01	1E-9
chr6	31446795	31446796	rs2248462	Hodgkin's lymphoma	MICB	1.64	7E-16
chr6	31448975	31448976	rs3099844	Metabolic syndrome	HCG26, MICB	.15	2E-8
chr6	31448975	31448976	rs3099844	Neonatal lupus	TNF,NFKBIL1,LTA,LTB,AIF1	3.34	5E-10
chr6	31472719	31472720	rs2855812	Pulmonary function	MICB	.03	2E-7
chr6	31475485	31475486	rs3132468	Dengue shock syndrome	MICB	1.34	4E-11
chr6	31481298	31481299	rs2516399	White blood cell types	MHC	.11	2E-12
chr6	31499602	31499603	rs3853601	Atopic dermatitis	BAT1	1.13	2E-6
chr6	31505479	31505480	rs2734583	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	BAT1, HCP5, MICC, PPIAP9, PSORS1C1, POLR2LP, CCHCR1, TCF19, POU5F1, HLA-C, HCP5, PSORS1C3, HLA-B*5801	66.80	2E-8
chr6	31542307	31542308	rs1799964	Crohn's disease	LTA,HLA-DQA2,TNF,LST1,LTB	1.19	4E-11
chr6	31557790	31557791	rs11575839	Complement C3 and C4 levels	HLA-C	.23	1E-54
chr6	31568468	31568469	rs2857595	Pulmonary function	NCR3	.04	2E-10
chr6	31572955	31572956	rs2844479	Weight	AIF1, NCR3	3.58	2E-8
chr6	31575275	31575276	rs9348876	Crohn's disease	AIF1	1.41	3E-6
chr6	31602966	31602967	rs1046089	Menopause (age at onset)	PRRC2A	.21	2E-16
chr6	31616365	31616366	rs805303	Systolic blood pressure	BAT2, BAT5	.38	2E-11
chr6	31616365	31616366	rs805303	Hypertension	BAT2, BAT5	.05	1E-10
chr6	31616365	31616366	rs805303	Diastolic blood pressure	BAT2, BAT5	.23	3E-11
chr6	31620519	31620520	rs3117582	Lung adenocarcinoma	BAT3, APOM	1.22	5E-12
chr6	31620519	31620520	rs3117582	Lung cancer	BAT3	1.24	4E-10
chr6	31620519	31620520	rs3117582	Lung cancer	BAT3,MSH5	1.24	5E-10
chr6	31622605	31622606	rs805297	Rheumatoid arthritis	APOM	1.56	3E-10
chr6	31721032	31721033	rs3131379	Systemic lupus erythematosus	HLA region	2.36	2E-52
chr6	31778528	31778529	rs2075799	Complement C3 and C4 levels	C4	.17	6E-97
chr6	31802540	31802541	rs9368699	HIV-1 control	SNORD52	NR	5E-8
chr6	31837065	31837066	rs11966200	Vitiligo	HLA-C,HLA-B	1.90	1E-48
chr6	31838712	31838713	rs494620	Menopause (age at onset)	NR	.30	5E-7
chr6	31843923	31843924	rs2736428	Telomere length	SLC44A4	.05	3E-6
chr6	31867252	31867253	rs9267663	Economic and political preferences (environmentalism)	EHMT2	.29	6E-6
chr6	31870855	31870856	rs9267665	Hepatitis B vaccine response	HLA	2.05	1E-17
chr6	31883678	31883679	rs9267673	Hepatocellular carcinoma	C2	1.97	2E-6
chr6	31903803	31903804	rs9332739	Age-related macular degeneration (GA)	C2	2.63	1E-6
chr6	31903803	31903804	rs9332739	Age-related macular degeneration (CNV)	C2	2.08	2E-8
chr6	31903803	31903804	rs9332739	Age-related macular degeneration	C2	2.17	2E-23
chr6	31906009	31906010	rs9380272	Age-related macular degeneration	C2,CFB	4.31	2E-8
chr6	31914179	31914180	rs641153	Age-related macular degeneration (GA)	CFB	2.13	2E-9
chr6	31914179	31914180	rs641153	Age-related macular degeneration (CNV)	CFB	2.22	1E-17
chr6	31914179	31914180	rs641153	Age-related macular degeneration	CFB	1.85	6E-31
chr6	31914179	31914180	rs641153	Age-related macular degeneration	CFB,C2	NR	2E-20
chr6	31916950	31916951	rs541862	Age-related macular degeneration	CFB	1.89	9E-17
chr6	31930461	31930462	rs429608	Age-related macular degeneration	SKIV2L,BF	1.85	5E-15
chr6	31930461	31930462	rs429608	Age-related macular degeneration	C2,CFB	2.16	3E-21
chr6	32019745	32019746	rs2857009	Complement C3 and C4 levels	C4	.08	1E-22
chr6	32026807	32026808	rs12198173	HIV-1 control	TNXB	NR	3E-6
chr6	32050066	32050067	rs185819	Height	HLA class III	5.20	3E-8
chr6	32050757	32050758	rs1150754	Systemic lupus erythematosus	TNXB	2.21	6E-29
chr6	32071016	32071017	rs3117181	Phospholipid levels (plasma)	TNXB	.02	5E-7
chr6	32074803	32074804	rs12153855	Age-related macular degeneration	TNXB	1.44	1E-9
chr6	32076498	32076499	rs2269426	Eosinophil counts	MHC	4.60	3E-6
chr6	32109978	32109979	rs204999	Serum total protein level	Intergenic	.03	4E-11
chr6	32109978	32109979	rs204999	Serum total protein level	Intergenic	.03	3E-9
chr6	32109978	32109979	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6	32109978	32109979	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6	32136546	32136547	rs1061808	Phospholipid levels (plasma)	AGPAT1	.90	8E-10
chr6	32151442	32151443	rs2070600	Pulmonary function	AGER, PPT2	1.00	3E-14
chr6	32151442	32151443	rs2070600	Pulmonary function	AGER	.09	3E-15
chr6	32155580	32155581	rs204993	Asthma	PBX2	1.17	2E-15
chr6	32158318	32158319	rs176095	Atopic dermatitis	GPSM3	1.40	8E-20
chr6	32165443	32165444	rs2071278	Complement C3 and C4 levels	HLA-DRA	.13	4E-72
chr6	32171682	32171683	rs2071277	Age-related macular degeneration	NOTCH4	1.30	2E-11
chr6	32172992	32172993	rs3131296	Schizophrenia	MHC, NOTCH4	1.19	2E-10
chr6	32184344	32184345	rs404860	Asthma	NOTCH4	1.21	4E-23
chr6	32190405	32190406	rs443198	Systemic sclerosis	NOTCH4	1.82	9E-21
chr6	32218842	32218843	rs3115573	Nephropathy	Intergenic	1.62	1E-9
chr6	32218988	32218989	rs9296015	Systemic sclerosis	NOTCH4	1.85	1E-8
chr6	32218988	32218989	rs9296015	Rheumatoid arthritis	HLA locus	NR	2E-38
chr6	32223257	32223258	rs3130320	Systemic lupus erythematosus	NOTCH4, C6orf10	1.39	3E-6
chr6	32244626	32244627	rs3130340	Bone mineral density (spine)	MHC, C6orf10	.10	1E-7
chr6	32282853	32282854	rs6910071	Rheumatoid arthritis	HLA-DRB1	2.88	1E-299
chr6	32305978	32305979	rs3129900	Lumiracoxib-related liver injury	HLA-DRB1	7.50	7E-25
chr6	32308907	32308908	rs9469099	Atopic dermatitis	C6orf10	1.61	5E-19
chr6	32321553	32321554	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6	32321553	32321554	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6	32321553	32321554	rs2395148	Arthritis (juvenile idiopathic)	HLA-DRB1	5.37	2E-10
chr6	32325370	32325371	rs13196329	Visceral fat	C6orf10	NR	3E-6
chr6	32336186	32336187	rs3129934	Multiple sclerosis	C6orf10	2.34	7E-16
chr6	32336186	32336187	rs3129934	Multiple sclerosis	HLA-DRB1	3.30	9E-11
chr6	32337629	32337630	rs2273017	Graves' disease	MHC	1.53	2E-22
chr6	32338694	32338695	rs3129943	Asthma	C6orf10	1.17	3E-15
chr6	32339075	32339076	rs2050190	Activated partial thromboplastin time	C6orf10	.25	7E-7
chr6	32341352	32341353	rs9268402	Coronary heart disease	C6orf10, BTNL2	1.16	3E-15
chr6	32345282	32345283	rs7758128	Vitiligo	C6orf10, BTNL2	NR	8E-11
chr6	32358269	32358270	rs3117099	Bipolar disorder and schizophrenia	MHC, other genes	1.25	3E-6
chr6	32358512	32358513	rs3117098	Asthma	BTNL2	1.16	5E-12
chr6	32363214	32363215	rs1980493	Anti-cyclic Citrullinated Peptide Antibody	HLA-DRA, BTNL2	NR	5E-7
chr6	32363815	32363816	rs2076530	Sarcoidosis	BTNL2	NR	3E-11
chr6	32363843	32363844	rs9268480	Ulcerative colitis	BTNL2	1.82	3E-6
chr6	32363954	32363955	rs2076529	Waist-hip ratio	BTNL2	.02	4E-7
chr6	32368086	32368087	rs3817963	Lung adenocarcinoma	BTNL2	1.18	3E-10
chr6	32373311	32373312	rs10947262	Knee osteoarthritis	BTNL2, HLA-DQA2, HLA-DQB1	1.31	5E-9
chr6	32373697	32373698	rs3806156	Vitiligo	BTNL2,HLA-DRA,HLA-DQA1	1.42	7E-19
chr6	32376470	32376471	rs3763313	HIV-1 control	BTNL2, NOTCH4	NR	2E-6
chr6	32376787	32376788	rs3763317	Complement C3 and C4 levels	HLA-DRB	.12	9E-66
chr6	32379488	32379489	rs9268516	Asthma	BTNL2, HLA-DRA	1.15	1E-8
chr6	32383107	32383108	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6	32383107	32383108	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6	32384720	32384721	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6	32384720	32384721	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6	32387808	32387809	rs2395163	Parkinson's disease	LOC642072	1.24	3E-11
chr6	32389647	32389648	rs3135363	Hepatitis B vaccine response	HLA-DR	1.53	7E-22
chr6	32389647	32389648	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6	32389647	32389648	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6	32401216	32401217	rs3135338	Multiple sclerosis	HLA	3.43	2E-25
chr6	32408526	32408527	rs9268645	Type 1 diabetes	MHC	NR	1E-100
chr6	32409529	32409530	rs3129882	Systemic sclerosis	HLA-DRA	2.17	2E-27
chr6	32409529	32409530	rs3129882	Parkinson's disease	HLA-DRA	1.26	2E-10
chr6	32411645	32411646	rs7192	Non-obstructive azoospermia	HLA-DRA	1.29	3E-6
chr6	32412434	32412435	rs3177928	LDL cholesterol	HLA	1.83	2E-15
chr6	32412434	32412435	rs3177928	Cholesterol, total	HLA	2.31	4E-19
chr6	32413050	32413051	rs3135388	Multiple sclerosis	HLA-DRB1	2.75	4E-225
chr6	32413050	32413051	rs3135388	Multiple sclerosis	HLA-DRA	1.99	9E-81
chr6	32413458	32413459	rs2227139	Hematological parameters	Intergenic	.02	1E-7
chr6	32413544	32413545	rs3129889	Multiple sclerosis	HLA-DRB1	2.97	1E-206
chr6	32414272	32414273	rs3129890	Asthma	HLA-DRA	1.15	5E-13
chr6	32428284	32428285	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6	32428284	32428285	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6	32428284	32428285	rs6903608	Hodgkin's lymphoma	HLA-DRA	1.70	3E-50
chr6	32429642	32429643	rs9268853	Rheumatoid arthritis	HLA-DRA	2.40	5E-109
chr6	32429642	32429643	rs9268853	Ulcerative colitis	HLA-DRB5, HLA-DQA1, HLA-DRB1, HLA-DRA, BTNL2	1.40	1E-55
chr6	32431146	32431147	rs9268877	Ulcerative colitis	MHC	NR	4E-23
chr6	32431146	32431147	rs9268877	Ulcerative colitis	HLA-DRA, BTNL2	1.45	6E-18
chr6	32432076	32432077	rs9268905	Cystic fibrosis severity	HLA-DRA	NR	1E-7
chr6	32432834	32432835	rs9268923	Ulcerative colitis	HLA-DRA	1.45	4E-15
chr6	32433166	32433167	rs2395185	Lung cancer	HLA class II	1.17	1E-8
chr6	32433166	32433167	rs2395185	Hodgkin's lymphoma	HLA-DRA	1.82	4E-31
chr6	32433166	32433167	rs2395185	Ulcerative colitis	Intergenic	1.92	5E-22
chr6	32433166	32433167	rs2395185	Ulcerative colitis	BTNL2, HLA-DRA, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1	1.52	1E-16
chr6	32560858	32560859	rs28366298	Lung cancer	HLA class II	1.17	1E-8
chr6	32569690	32569691	rs477515	Inflammatory bowel disease	HLA-DQA1	1.38	1E-8
chr6	32572250	32572251	rs2858870	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6	32572250	32572251	rs2858870	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6	32574170	32574171	rs615672	Rheumatoid arthritis	HLA-DRB1	NR	8E-27
chr6	32576477	32576478	rs9271100	Systemic lupus erythematosus	HLA-DRB1	1.90	1E-12
chr6	32577379	32577380	rs660895	IgA nephropathy	HLA-DRB1	1.34	4E-20
chr6	32577379	32577380	rs660895	Rheumatoid arthritis	HLA-DRB1	3.62	1E-108
chr6	32578081	32578082	rs674313	Chronic lymphocytic leukemia	HLA-DRB5	1.69	7E-9
chr6	32586853	32586854	rs9271366	Inflammatory bowel disease	MHC	1.79	8E-11
chr6	32586853	32586854	rs9271366	Inflammatory bowel disease	MHC	2.41	3E-31
chr6	32586853	32586854	rs9271366	Inflammatory bowel disease	MHC	4.44	2E-70
chr6	32586853	32586854	rs9271366	Immunoglobulin A	HLA-DRB1	7.69	3E-33
chr6	32586853	32586854	rs9271366	Multiple sclerosis	DQA1	2.62	4E-17
chr6	32586853	32586854	rs9271366	Multiple sclerosis	HLA-DRB1	2.78	7E-184
chr6	32590924	32590925	rs3129763	Systemic sclerosis	HLA-DQA1, HLA-DRB1	1.65	1E-11
chr6	32592736	32592737	rs28421666	Nasopharyngeal carcinoma	HLA-DQ,HLA-DR	1.49	2E-18
chr6	32599998	32599999	rs9272105	Hepatocellular carcinoma	HLA-DQA1, HLA-DRB1	1.28	5E-22
chr6	32599998	32599999	rs9272105	Response to interferon beta therapy	HLA-DQA1, HLA-DRB1	.26	4E-10
chr6	32602268	32602269	rs9272219	Rheumatoid arthritis	HLA-DQA1	1.92	1E-45
chr6	32602268	32602269	rs9272219	Schizophrenia	HLA-DQA1	1.14	7E-8
chr6	32603006	32603007	rs2040406	Multiple sclerosis	HLA-DRB,HLA-DQB1	2.05	1E-20
chr6	32604371	32604372	rs9272346	Type 1 diabetes	HLA	NR	6E-129
chr6	32604371	32604372	rs9272346	Type 1 diabetes	MHC	5.49	5E-134
chr6	32605883	32605884	rs2187668	Systemic lupus erythematosus	HLA-DR3	2.23	6E-28
chr6	32605883	32605884	rs2187668	Nephropathy (idiopathic membranous)	HLA-DQA1	4.32	8E-93
chr6	32605883	32605884	rs2187668	Immunoglobulin A	HLA-DRB1	2.53	2E-33
chr6	32605883	32605884	rs2187668	Celiac disease	HLA-DQA1, HLA-DQB1	6.23	1E-50
chr6	32605883	32605884	rs2187668	Systemic lupus erythematosus	HLA-DQA1	NR	3E-21
chr6	32605883	32605884	rs2187668	Celiac disease	HLA-DQA1	7.04	1E-19
chr6	32606755	32606756	rs9272535	Chronic lymphocytic leukemia	HLA-DQA1	1.61	9E-8
chr6	32625868	32625869	rs9273349	Asthma	HLA-DQ	1.18	7E-14
chr6	32632831	32632832	rs9274407	Drug-induced liver injury (amoxicillin-clavulanate)	HLA-DRB1-DQB1	3.10	5E-14
chr6	32655217	32655218	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6	32655217	32655218	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6	32657577	32657578	rs7774434	Primary biliary cirrhosis	MHC	1.60	4E-34
chr6	32657577	32657578	rs7774434	Primary biliary cirrhosis	HLA-DQB1	1.75	3E-26
chr6	32658078	32658079	rs7775228	IgE grass sensitization	HLA region	1.33	2E-9
chr6	32658078	32658079	rs7775228	Asthma	HLA-DQB1	1.17	5E-15
chr6	32658309	32658310	rs9469220	Crohn's disease	NR	1.14	2E-6
chr6	32663630	32663631	rs3129720	Hypothyroidism	HLA-DRB9, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DQA2	1.16	5E-7
chr6	32663850	32663851	rs6457617	Graves' disease	HLA, DRB1, DQA1, DQB1	1.40	7E-33
chr6	32663850	32663851	rs6457617	Systemic sclerosis	HLA, DQB1	1.61	2E-37
chr6	32663850	32663851	rs6457617	Systemic sclerosis	HLA-DQB1	1.37	4E-17
chr6	32663850	32663851	rs6457617	Rheumatoid arthritis	HLA-DQA1, HLA-DQA2	NR	1E-9
chr6	32663850	32663851	rs6457617	Rheumatoid arthritis	MHC	2.36	5E-75
chr6	32663998	32663999	rs6457620	Height	HLA locus	.03	2E-16
chr6	32663998	32663999	rs6457620	Rheumatoid arthritis	HLA-DRB1	2.55	4E-186
chr6	32664457	32664458	rs2647012	Follicular lymphoma	HLA-DQB1	1.56	2E-21
chr6	32664457	32664458	rs2647012	Systemic lupus erythematosus	HLA-DQA1, HLA-DQA2	1.38	8E-6
chr6	32664959	32664960	rs9357152	HPV seropositivity	HLA-DQB1	NR	1E-14
chr6	32664959	32664960	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6	32664959	32664960	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6	32665419	32665420	rs10484561	Follicular lymphoma	HLA-DQB1	1.95	1E-29
chr6	32667909	32667910	rs2647044	Pulmonary function	HLA-DQB1	.04	6E-6
chr6	32667909	32667910	rs2647044	Type 1 diabetes	HLA-DRB1	8.30	1E-16
chr6	32669155	32669156	rs9275390	Systemic sclerosis	HLA-DQB1	1.61	1E-7
chr6	32669155	32669156	rs9275390	Systemic sclerosis	HLA-DQB1	2.38	3E-54
chr6	32669372	32669373	rs11752643	Coronary heart disease	HLA, DRB-DQB	1.26	5E-7
chr6	32670254	32670255	rs2856718	Hepatitis B	HLA-DQB1	1.56	4E-37
chr6	32671102	32671103	rs13192471	Rheumatoid arthritis	HLA-DRB1	1.97	2E-58
chr6	32671247	32671248	rs1794275	IgA nephropathy	HLA-DQA/B	1.30	3E-13
chr6	32678998	32678999	rs9275572	Hepatocellular carcinoma	HLA-DQ, HLA-DR	1.30	6E-9
chr6	32678998	32678999	rs9275572	Alopecia areata	HLA-DQA2	2.21	1E-35
chr6	32680927	32680928	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6	32680927	32680928	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6	32681276	32681277	rs2858331	IgE levels	HLA-DQA2	.04	1E-8
chr6	32681630	32681631	rs9275596	Nephropathy	HLA-DRB1, HLA-DQA1, HLA-DQB1	1.59	2E-26
chr6	32681675	32681676	rs3104402	Immune response to anthrax vaccine	HLA-DRB1,HLA-DQA1	.17	6E-6
chr6	32685549	32685550	rs3916765	Type 2 diabetes	HLA-DQA2	1.21	1E-6
chr6	32687972	32687973	rs9275698	Asthma	HLA-DQA2	1.18	5E-12
chr6	32700082	32700083	rs2858884	Narcolepsy	HLA-DQA2	1.79	3E-8
chr6	32725192	32725193	rs2301271	Systemic lupus erythematosus	HLA-DQA2	1.47	2E-12
chr6	32730011	32730012	rs7453920	Hepatitis B	HAL-DQB2	1.81	6E-28
chr6	32730085	32730086	rs2051549	Systemic lupus erythematosus	HLA-DQA2	NR	3E-22
chr6	32736694	32736695	rs9276606	Complement C3 and C4 levels	HLA-DQB	.09	3E-22
chr6	32763513	32763514	rs2857151	Kawasaki disease	HLA-DQB2, HLA-DOB	1.47	5E-11
chr6	32804069	32804070	rs241428	Complement C3 and C4 levels	HLA-DQB	.23	9E-83
chr6	32809847	32809848	rs9357155	Nephropathy	TAP2, TAP1, PSMB8, PSMB9	1.41	2E-12
chr6	32852646	32852647	rs2187689	Disc degeneration (lumbar)	PSMB9	.23	3E-8
chr6	32854696	32854697	rs10046257	Disc degeneration (lumbar)	Intergenic	.19	3E-7
chr6	32855716	32855717	rs6457690	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6	32856380	32856381	rs1029296	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6	32856481	32856482	rs1029295	Disc degeneration (lumbar)	Intergenic	.19	5E-7
chr6	32856933	32856934	rs6936004	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6	32857418	32857419	rs10214886	Disc degeneration (lumbar)	Intergenic	.19	2E-7
chr6	32859711	32859712	rs7744666	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6	32859747	32859748	rs11969002	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6	32860751	32860752	rs9469300	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6	32862606	32862607	rs3749982	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6	32961360	32961361	rs9500927	Asthma	HLA-DOA	1.13	4E-9
chr6	32975013	32975014	rs399604	Platelet counts	HLA-DOA	2.35	1E-10
chr6	33033021	33033022	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.82	4E-45
chr6	33033021	33033022	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.67	1E-9
chr6	33033021	33033022	rs3077	Hepatitis B	HLA-DPA1	1.87	2E-61
chr6	33042879	33042880	rs987870	Asthma	HLA, DPB1	1.40	2E-10
chr6	33042879	33042880	rs987870	Systemic sclerosis	HLA-DPA1, HLA-DPB1	2.09	2E-20
chr6	33054860	33054861	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.64	2E-21
chr6	33054860	33054861	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.52	2E-17
chr6	33054860	33054861	rs9277535	Hepatitis B vaccine response	HLA-DPB1	1.39	3E-12
chr6	33054860	33054861	rs9277535	Hepatitis B	HLA-DPB1	1.77	3E-54
chr6	33054860	33054861	rs9277535	Hepatitis B	HLA-DPB1	1.75	6E-39
chr6	33060117	33060118	rs2281388	Graves' disease	HLA, DPB1	1.64	2E-65
chr6	33069892	33069893	rs3117242	Antineutrophil cytoplasmic antibody-associated vasculitis	HLA-DP, COL11A2	3.67	1E-71
chr6	33086248	33086249	rs3117035	RR interval (heart rate)	Intergenic	.14	1E-6
chr6	33086447	33086448	rs1883414	Nephropathy	HLA-DPA1, HLA-DPB1, HLA-DPB2	1.28	5E-9
chr6	33143947	33143948	rs2254287	LDL cholesterol	B3GALT4	1.91	5E-8
chr6	33465481	33465482	rs9394152	Chronic obstructive pulmonary disease	ZBTB9	22.22	7E-8
chr6	33478495	33478496	rs9296092	Chronic obstructive pulmonary disease	Intergenic	NR	6E-7
chr6	33540208	33540209	rs210134	Mean platelet volume	BAK1	6.16	2E-15
chr6	33540208	33540209	rs210134	Platelet counts	BAK1	4.96	7E-36
chr6	33540691	33540692	rs210135	Hematological parameters	BAK1	5.44	4E-10
chr6	33542537	33542538	rs210138	Testicular germ cell tumor	BAK1	1.50	1E-13
chr6	33546836	33546837	rs210142	Chronic lymphocytic leukemia	BAK1	1.40	9E-16
chr6	33618161	33618162	rs9394159	Graves' disease	MHC	1.36	4E-12
chr6	33624732	33624733	rs999943	Obesity (extreme)	ITPR3	1.37	1E-6
chr6	33659045	33659046	rs4711336	Height	HMGA1	NR	3E-8
chr6	33706478	33706479	rs9469578	Phosphorus levels	ITPR3,LEMD2,MLN	.06	1E-11
chr6	33762241	33762242	rs2274459	Obesity (extreme)	MLN	1.38	6E-6
chr6	33817928	33817929	rs4713693	Graves' disease	MHC	1.40	7E-13
chr6	33825357	33825358	rs2104362	Alzheimer's disease (age of onset)	MIR1275, LEMD2, MLN	NR	7E-6
chr6	33851172	33851173	rs16869652	Schizophrenia	Intergenic	1.45	5E-6
chr6	34165720	34165721	rs7742369	Height	HMGA1	.11	1E-13
chr6	34195010	34195011	rs1776897	Height	HMGA1	.11	7E-6
chr6	34195010	34195011	rs1776897	Height	HMGA1,C6orf106	.12	8E-11
chr6	34195010	34195011	rs1776897	Height	HMGA1, LBH	8.80	1E-8
chr6	34199091	34199092	rs2780226	Height	HMGA1	.08	8E-28
chr6	34214321	34214322	rs1150781	Height	HMGA1	.05	2E-8
chr6	34238513	34238514	rs6918981	Height	HMGA1, C6orf1, NUDT3	.55	2E-8
chr6	34238513	34238514	rs6918981	Height	HMGA1	.40	3E-8
chr6	34302868	34302869	rs206936	Body mass index	NUDT3, HMGA1	.06	3E-8
chr6	34546559	34546560	rs2814982	Cholesterol, total	C6orf106	1.86	5E-11
chr6	34552796	34552797	rs2814944	HDL cholesterol	C6orf106	.49	4E-9
chr6	34618892	34618893	rs2814993	Height	C6orf106	.09	4E-12
chr6	34683634	34683635	rs6938239	Height	HMGA1	NR	6E-12
chr6	34845448	34845449	rs4646949	Fasting insulin-related traits (interaction with BMI)	UHRF1BP1	NR	4E-8
chr6	34923863	34923864	rs847845	Non-small cell lung cancer	ANKS1A	NR	6E-6
chr6	34975414	34975415	rs2140418	Alcoholism (alcohol use disorder factor score)	ANKS1	.10	4E-6
chr6	34975414	34975415	rs2140418	Alcoholism (alcohol dependence factor score)	ANKS1	.10	4E-6
chr6	35034799	35034800	rs17609940	Coronary heart disease	ANKS1A	1.07	1E-8
chr6	35322762	35322763	rs7744392	Cataracts in type 2 diabetes	PPARD	NR	3E-6
chr6	35341849	35341850	rs9470004	Height	PPARD	.08	1E-11
chr6	35363756	35363757	rs9658108	Response to antipsychotic treatment	PPARD	NR	5E-7
chr6	35402784	35402785	rs4713858	Height	ANKS1A, TCP11, ZNF76, DEF6,SCUBE3	6.80	4E-8
chr6	35402804	35402805	rs6457821	Height	PPARD/FANCE	.10	2E-12
chr6	35502201	35502202	rs9380516	Hepatitis C induced liver fibrosis	TULP1	NR	5E-7
chr6	36622899	36622900	rs1321311	Colorectal cancer	CDKN1A	1.10	1E-10
chr6	36622899	36622900	rs1321311	Electrocardiographic traits	CDKN1A	6.52	3E-10
chr6	36623378	36623379	rs9470361	Ventricular conduction	CDKN1A	.87	3E-27
chr6	36922683	36922684	rs1405069	Chemerin levels	PI16	NR	6E-6
chr6	37174744	37174745	rs1680005	Bipolar disorder (mood-incongruent)	TMEM217	1.18	7E-6
chr6	37451695	37451696	rs904251	Cognitive performance	C6orf129	NR	7E-6
chr6	37487043	37487044	rs1757171	Cognitive performance	AL353597.20	NR	7E-6
chr6	38036419	38036420	rs17589516	Insulin resistance/response	ZFAND3	45.00	4E-6
chr6	38106843	38106844	rs9470794	Type 2 diabetes	ZFAND3	1.12	2E-10
chr6	38365840	38365841	rs9296249	Restless legs syndrome	BTBD9	1.67	4E-18
chr6	38365872	38365873	rs9357271	Restless legs syndrome	BTBD9	1.47	8E-22
chr6	38440969	38440970	rs3923809	Restless legs syndrome	BTBD9	1.90	1E-17
chr6	39284049	39284050	rs1535500	Type 2 diabetes	KCNK16	1.08	2E-8
chr6	39528981	39528982	rs9380880	Immune response to smallpox vaccine (IL-6)	KIF6, LOC100131899	NR	1E-7
chr6	39539206	39539207	rs4714261	Attention deficit hyperactivity disorder symptoms (interaction)	KIF6	.95	2E-6
chr6	39784364	39784365	rs2395730	Pulmonary function	DAAM2	.07	8E-8
chr6	40536127	40536128	rs2494938	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	LRFN2	1.18	5E-9
chr6	40536127	40536128	rs2494938	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	LRFN2	1.15	2E-6
chr6	40536127	40536128	rs2494938	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	LRFN2	1.15	1E-12
chr6	40802260	40802261	rs10484761	Esophageal cancer	UNC5CL	1.33	7E-12
chr6	41127971	41127972	rs7748513	C-reactive protein	TREM2	NR	1E-10
chr6	41303804	41303805	rs9471576	Total ventricular volume	NCR2	.01	2E-6
chr6	41536426	41536427	rs1983891	Prostate cancer	FOXP4	1.15	8E-8
chr6	41623032	41623033	rs2143678	Cardiovascular disease risk factors	MDF1	3.05	4E-7
chr6	41650735	41650736	rs2842643	Attention deficit hyperactivity disorder	TFEB	NR	3E-6
chr6	41925158	41925159	rs9349205	Mean corpuscular volume	CCND3, BYSL	.01	1E-31
chr6	41925158	41925159	rs9349205	Mean corpuscular hemoglobin	CCND3, BYSL	.01	8E-20
chr6	41925289	41925290	rs11970772	Hematological parameters	BYSL, CCND3	.58	7E-19
chr6	41925303	41925304	rs11968166	Neutrophil count	CCND3	NR	8E-6
chr6	42731114	42731115	rs6458307	Bipolar disorder	NR	1.19	4E-6
chr6	43757895	43757896	rs998584	Adiponectin levels	VEGFA	.03	3E-8
chr6	43758872	43758873	rs6905288	Coronary heart disease	VEGFA	1.23	7E-8
chr6	43758872	43758873	rs6905288	Waist-hip ratio	VEGFA	.05	2E-26
chr6	43795967	43795968	rs943072	Ulcerative colitis	Intergenic	1.15	2E-10
chr6	43806608	43806609	rs881858	Chronic kidney disease	VEGFA	1.08	9E-14
chr6	43811761	43811762	rs9472138	Type 2 diabetes	VEGFA	1.06	4E-6
chr6	43828581	43828582	rs4711751	Age-related macular degeneration	VEGFA	1.15	9E-9
chr6	43897726	43897727	rs9472155	Vascular endothelial growth factor levels	MGC45491, VEGF	NR	2E-26
chr6	43925525	43925526	rs4513773	Vascular endothelial growth factor levels	MGC45491, MRPL14	NR	1E-584
chr6	44232919	44232920	rs2233434	Rheumatoid arthritis	NFKBIE	1.20	1E-15
chr6	44232919	44232920	rs2233434	Rheumatoid arthritis	NFKBIE	1.19	6E-19
chr6	44594158	44594159	rs556621	Stroke (ischemic)	CDC5L, SUPT3H	1.21	5E-8
chr6	44777690	44777691	rs10948172	Osteoarthritis	SUPT3H, CDC5L	1.08	6E-7
chr6	44837355	44837356	rs3799977	Attention deficit hyperactivity disorder	SUPT3H	NR	5E-6
chr6	44946505	44946506	rs9472414	Height	SUPT3H/RUNX2	.03	2E-9
chr6	44967489	44967490	rs10948197	Height	SUPT3H	.51	8E-6
chr6	45095162	45095163	rs9395066	Height	SUPT3H, RUNX2	3.50	8E-6
chr6	45696787	45696788	rs1932040	Periodontal microbiota	CLIC5, RUNX2	2.47	1E-6
chr6	46675024	46675025	rs7756935	Lipoprotein-associated phospholipase A2 activity and mass	PLA2G7	.03	1E-10
chr6	46682078	46682079	rs1362931	Lipoprotein-associated phospholipase A2 activity and mass	PLA2G7	.02	3E-19
chr6	46684221	46684222	rs1805017	Lipoprotein-associated phospholipase A2 activity and mass	PLA2G7	.04	2E-23
chr6	46684221	46684222	rs1805017	Lipoprotein-associated phospholipase A2 activity and mass	PLA2G7	11.10	6E-14
chr6	47230614	47230615	rs2103868	Panic disorder	TNFRSF21	NR	5E-6
chr6	47453377	47453378	rs9349407	Alzheimer's disease (late onset)	CD2AP	1.11	9E-9
chr6	49488907	49488908	rs9473582	Brain structure	GLYATL3	NR	8E-7
chr6	50786007	50786008	rs2206271	Renal function-related traits (BUN)	TFAP2B	.01	2E-7
chr6	50798525	50798526	rs2206277	Metabolic syndrome (bivariate traits)	TFAP2B	.17	1E-7
chr6	50803049	50803050	rs987237	Body mass index	TFAP2B	.13	3E-20
chr6	50803049	50803050	rs987237	Adiposity	TFAP2B	.04	2E-11
chr6	50836278	50836279	rs734597	Obesity (extreme)	TFAP2B	NR	3E-8
chr6	50987767	50987768	rs190759	Sudden cardiac arrest	Intergenic	1.11	5E-6
chr6	51058720	51058721	rs283566	Electrocardiographic conduction measures	NR	NR	9E-6
chr6	51159994	51159995	rs1555967	Waist circumference	PKHD1	NR	3E-6
chr6	51666630	51666631	rs10498792	Prostate cancer	PKHD1	NR	3E-6
chr6	52101738	52101739	rs763780	Response to gemcitabine in pancreatic cancer	IL17F	3.30	3E-8
chr6	53123117	53123118	rs735860	Glaucoma	ELOVL5	1.69	4E-6
chr6	53307693	53307694	rs9395865	Electroencephalographic traits in alcoholism	Intergenic	.11	6E-6
chr6	53924696	53924697	rs9296736	Liver enzyme levels (gamma-glutamyl transferase)	MLIP	3.00	3E-9
chr6	54265395	54265396	rs16885294	Radiation response	TINAG	NR	4E-7
chr6	55148102	55148103	rs9367630	HIV-1 control	HCRTR2	NR	1E-7
chr6	58308954	58308955	rs9500256	Eosinophilic esophagitis (pediatric)	NR	2.04	5E-6
chr6	62697745	62697746	rs6455128	Protein quantitative trait loci	KHDRBS2	NR	3E-7
chr6	63160146	63160147	rs682238	Calcium levels	Intergenic	.03	3E-6
chr6	65635922	65635923	rs11754641	Disc degeneration (lumbar)	Intergenic	.29	8E-6
chr6	66565352	66565353	rs9354308	Metabolite levels	Intergenic	NR	3E-7
chr6	66598193	66598194	rs10455590	HIV-1 viral setpoint	AL391500.13	NR	2E-6
chr6	67649215	67649216	rs11970254	Brain structure	Intergenic	NR	6E-7
chr6	68181696	68181697	rs4710654	Response to amphetamines	Intergenic	NR	8E-7
chr6	68327029	68327030	rs875033	Response to amphetamines	Intergenic	NR	8E-6
chr6	68984929	68984930	rs10455657	Cannbis use (initiation)	RP11, 406O16.1	.03	6E-6
chr6	69142007	69142008	rs9363918	Pancreatic cancer	BAI3	1.27	1E-6
chr6	69294484	69294485	rs9351730	Prostate cancer (gene x gene interaction)	BAI3	1.25	5E-6
chr6	69337786	69337787	rs2585617	Phospholipid levels (plasma)	BAI3	.03	6E-7
chr6	70074231	70074232	rs3757057	Response to statin therapy	BAI3, LMBRD1, COL19A1	NR	4E-6
chr6	71289188	71289189	rs1048886	Type 2 diabetes	C6orf57	1.54	3E-8
chr6	71776970	71776971	rs11968814	F-cell distribution	B3GAT2	1.17	9E-7
chr6	72139571	72139572	rs1727638	AB1-42	Intergenic	NR	1E-6
chr6	72482457	72482458	rs10455248	Cognitive performance	RIMS1	NR	4E-6
chr6	76265641	76265642	rs9360921	Height	SENP6	.04	3E-13
chr6	76556618	76556619	rs3798440	Hypertension	MYO6	NR	3E-10
chr6	76560497	76560498	rs9350602	Hypertension	MYO6	NR	3E-10
chr6	77290798	77290799	rs12198063	Capecitabine sensitivity	LOC643281	NR	8E-6
chr6	77789807	77789808	rs7738636	Acute lymphoblastic leukemia (childhood)	Intergenic	1.27	6E-6
chr6	80257280	80257281	rs3747767	Hoarding	LCA5	1.81	7E-7
chr6	80466123	80466124	rs6925255	Aging	SH3BGRL2, ELOVL4	NR	1E-6
chr6	80564835	80564836	rs346291	Partial epilepsies	AL132875.2, SH3BGRL2, ELOVL4	1.20	3E-7
chr6	81800361	81800362	rs310405	Height	FAM46A	.03	2E-13
chr6	82193108	82193109	rs17530068	Breast cancer	FAM46A, C6orf37	1.16	3E-7
chr6	82515314	82515315	rs16893526	Coronary heart disease	Intergenic	1.13	5E-6
chr6	84226594	84226595	rs1171113	Bipolar disorder (mood-incongruent)	PRSS35, SNAP91	1.23	1E-7
chr6	86117128	86117129	rs494562	Metabolic traits	NT5E	.30	7E-13
chr6	86691939	86691940	rs1577917	Response to antipsychotic treatment	Intergenic	NR	3E-6
chr6	87155253	87155254	rs13202860	Sexual dysfunction (female)	Intergenic	.42	1E-7
chr6	87466491	87466492	rs493187	Bipolar disorder and schizophrenia	NR	1.23	3E-6
chr6	87867062	87867063	rs1925690	MRI atrophy measures	ZNF292	.00	3E-8
chr6	88652579	88652580	rs2509458	Blood pressure	Intergenic	NR	7E-6
chr6	88717765	88717766	rs366676	Echocardiographic traits	SPACA1	NR	2E-6
chr6	88975976	88975977	rs16880441	Conduct disorder (interaction)	Intergenic	1.63	9E-6
chr6	89112816	89112817	rs10485165	Select biomarker traits	Intergenic	NR	1E-6
chr6	89183579	89183580	rs11757661	Subcutaneous adipose tissue	RNGTT	NR	8E-6
chr6	89293744	89293745	rs12527253	Response to statin therapy	RNGTT, ACTBP8, LOC644119	NR	1E-6
chr6	89732100	89732101	rs12201676	Bipolar disorder and schizophrenia	GABRR1	1.31	4E-8
chr6	90310965	90310966	rs6454764	vWF and FVIII levels	ANKRD6	.31	5E-6
chr6	90640490	90640491	rs2289577	Cognitive performance	BACH2	NR	9E-6
chr6	90698273	90698274	rs12204127	Visceral adipose tissue/subcutaneous adipose tissue ratio	BACH2	NR	6E-7
chr6	90921739	90921740	rs370409	Graves' disease	BACH2, MAP3K7	1.15	2E-6
chr6	90926611	90926612	rs10806425	Celiac disease	BACH2, MAP3K7	1.13	4E-10
chr6	90957462	90957463	rs3757247	Vitiligo	BACH2	1.20	3E-8
chr6	90957462	90957463	rs3757247	Type 1 diabetes	BACH2	1.13	1E-6
chr6	90958230	90958231	rs11755527	Type 1 diabetes autoantibodies	BACH2	1.10	3E-8
chr6	90958230	90958231	rs11755527	Type 1 diabetes	BACH2	NR	5E-8
chr6	90958230	90958231	rs11755527	Type 1 diabetes	BACH2	1.13	5E-12
chr6	90973158	90973159	rs1847472	Crohn's disease	BACH2	1.07	5E-9
chr6	90996768	90996769	rs12212193	Multiple sclerosis	BACH2	1.09	4E-8
chr6	91207350	91207351	rs806276	Attention deficit hyperactivity disorder (time to onset)	Intergenic	NR	3E-7
chr6	91417751	91417752	rs713155	Brain structure	Intergenic	NR	5E-7
chr6	93369654	93369655	rs6918777	Amyotrophic lateral sclerosis	Intergenic	1.15	7E-6
chr6	93615449	93615450	rs2506933	Cognitive performance	RP11-538A16.1	NR	6E-6
chr6	93713804	93713805	rs652520	Chronic obstructive pulmonary disease-related biomarkers	RP1-23E21.2	NR	2E-6
chr6	93847883	93847884	rs594442	Dialysis-related mortality	EPHA7	1.99	1E-6
chr6	93852251	93852252	rs1408282	C-reactive protein	NR	.41	1E-6
chr6	93911118	93911119	rs12527818	Response to hepatitis C treatment	EPHA7	.27	7E-6
chr6	96884885	96884886	rs11757063	Migraine	FHL5	1.20	6E-8
chr6	97080197	97080198	rs12200560	Coronary heart disease	FHL5	1.11	6E-7
chr6	98739773	98739774	rs6909430	Quantitative traits	Intergenic	.49	8E-6
chr6	98919263	98919264	rs9491640	Brain imaging in schizophrenia (interaction)	POU3F2	NR	9E-6
chr6	98937145	98937146	rs2213553	Response to amphetamines	Intergenic	NR	5E-6
chr6	98990488	98990489	rs6904416	C-reactive protein and white blood cell count	Intergenic	.18	9E-10
chr6	99011500	99011501	rs2086512	Cytomegalovirus antibody response	Intergenic	.32	9E-6
chr6	99672013	99672014	rs2132683	Brain structure	Intergenic	NR	1E-6
chr6	100208437	100208438	rs4840086	Menarche (age at onset)	PRDM13, MCHR2	2.10	2E-8
chr6	100756686	100756687	rs2841307	Bipolar disorder and schizophrenia	NR	1.36	1E-6
chr6	100957343	100957344	rs240768	Economic and political preferences (immigration/crime)	ASCC3	.27	2E-6
chr6	101395406	101395407	rs11969893	Economic and political preferences (immigration/crime)	Intergenic	.32	4E-6
chr6	101674289	101674290	rs2797369	Renal function-related traits (eGRFcrea)	GRIK2	.00	1E-7
chr6	102355866	102355867	rs12207601	Biochemical measures	GRIK2	.26	2E-6
chr6	104432164	104432165	rs4520040	Cardiac hypertrophy	GRIK2	NR	3E-6
chr6	104445366	104445367	rs9499708	Obsessive-compulsive disorder	GRIK2, HACE1	1.20	3E-6
chr6	104593866	104593867	rs9377619	Bipolar disorder and schizophrenia	NR	1.34	2E-6
chr6	105180784	105180785	rs4336470	Neuroblastoma	HACE1	1.26	3E-11
chr6	105232232	105232233	rs9322817	Thyroid stimulating hormone	HACE1	NR	7E-6
chr6	105378953	105378954	rs7759938	Menarche (age at onset)	LIN28B	6.40	5E-60
chr6	105378953	105378954	rs7759938	Height	LIN28B	.05	8E-31
chr6	105378953	105378954	rs7759938	Menarche (age at onset)	LIN28B	.09	7E-9
chr6	105400836	105400837	rs314280	Menarche (age at onset)	LIN28B, HACE1, E3 ubiquitin protein ligase 1, BVES, POPDC3	1.20	2E-14
chr6	105406273	105406274	rs17065417	Neuroblastoma	LIN28B	1.38	1E-8
chr6	105407661	105407662	rs314277	Digit length ratio	LIN28B	.63	2E-6
chr6	105407661	105407662	rs314277	Menarche and menopause (age at onset)	LIN28B	.16	3E-13
chr6	105407661	105407662	rs314277	Height	LIN28B	.41	1E-8
chr6	105407998	105407999	rs314276	Menarche (age at onset)	LIN28B	.14	4E-16
chr6	105417977	105417978	rs314268	Height	LIN28B, HACE1, BVES, POPDC3	4.60	8E-7
chr6	105612219	105612220	rs11962089	Multiple sclerosis	POPDC3	.69	8E-6
chr6	106094056	106094057	rs9386463	Primary tooth development (time to first tooth eruption)	Intergenic	.38	6E-7
chr6	106435024	106435025	rs6568421	Crohn's disease	PRDM1	1.13	4E-8
chr6	106435268	106435269	rs7746082	Crohn's disease	Unknown	1.17	2E-10
chr6	106522026	106522027	rs6911490	Ulcerative colitis	PDRM1	1.08	1E-8
chr6	106568033	106568034	rs548234	Systemic lupus erythematosus	PRDM1, ATG5	1.25	5E-12
chr6	106829536	106829537	rs6568433	Longevity	AL109920.3	NR	1E-6
chr6	106899225	106899226	rs1417352	Select biomarker traits	Intergenic	NR	2E-6
chr6	106987369	106987370	rs783396	Stroke	AIM1	2.17	9E-6
chr6	108017670	108017671	rs12525668	Myopia (pathological)	Intergenic	NR	8E-11
chr6	108323758	108323759	rs17069122	Bipolar disorder and schizophrenia	NR	2.33	1E-6
chr6	108916572	108916573	rs9480865	Normalized brain volume	FOXO3	NR	7E-6
chr6	108988183	108988184	rs2153960	Insulin-like growth factors	FOXO3	NR	5E-7
chr6	109268049	109268050	rs2798641	Pulmonary function	ARMC2	.04	8E-9
chr6	109268049	109268050	rs2798641	Pulmonary function	ARMC2	.03	5E-6
chr6	109598963	109598964	rs13210693	Ankylosing spondylitis	Intergenic	1.15	9E-7
chr6	109616419	109616420	rs9374080	Mean corpuscular volume	CD164	.00	4E-10
chr6	109742014	109742015	rs9487094	Height	PPIL6, CD164, SMPD2,MNICAL1,ZBTB24	4.70	4E-6
chr6	109783940	109783941	rs1046943	Height	ZBTB24	.02	3E-8
chr6	110007646	110007647	rs9400317	Response to hepatitis C treatment	AKD2	NR	7E-6
chr6	110090048	110090049	rs4947019	Hematological parameters	Intergenic	.01	8E-6
chr6	111655529	111655530	rs465969	Psoriasis	TRAF3IP2	1.37	2E-16
chr6	111673713	111673714	rs240993	Psoriasis	TRAF3IP2	1.25	5E-20
chr6	111696090	111696091	rs458017	Psoriasis	TRAF3IP2	1.37	2E-16
chr6	111747082	111747083	rs7760535	Metabolic traits	SLC16A10	.04	1E-12
chr6	111794408	111794409	rs6900341	Metabolite levels	SLC16A10	.13	4E-15
chr6	111913261	111913262	rs33980500	Psoriasis	TRAF3IP2	NR	1E-16
chr6	111913261	111913262	rs33980500	Psoriatic arthritis	TRAF3IP2	1.95	1E-20
chr6	114017132	114017133	rs9488238	Disc degeneration (lumbar)	Intergenic	.28	5E-6
chr6	114591985	114591986	rs9488363	Optic disc size (rim)	hCG_1820801	.15	2E-6
chr6	116312892	116312893	rs9488822	LDL cholesterol	FRK	.89	3E-9
chr6	116312892	116312893	rs9488822	Cholesterol, total	FRK	1.18	2E-10
chr6	116387133	116387134	rs1999930	Age-related macular degeneration	FRK, COL10A1	1.15	1E-8
chr6	116543846	116543847	rs1204798	Dental caries	NT5DC1	NR	2E-6
chr6	117086377	117086378	rs654128	Telomere length	KPNA5	.12	3E-6
chr6	117114024	117114025	rs6901250	C-reactive protein	GPRC6A	.04	5E-8
chr6	117210051	117210052	rs339331	Prostate cancer	GPRC6A,RFX6	1.22	2E-12
chr6	117522155	117522156	rs961764	Height	VGLL2	.02	1E-11
chr6	117605990	117605991	rs13201929	Myopia (pathological)	Intergenic	NR	3E-6
chr6	117786179	117786180	rs9387478	Lung cancer	ROS1, DCBLD1	1.18	4E-10
chr6	117844071	117844072	rs210648	Economic and political preferences	DCBLD1	.12	2E-6
chr6	118130306	118130307	rs2199936	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	ABCG2	2.80	2E-10
chr6	118130306	118130307	rs2199936	Cardiovascular disease risk factors	ABCG2	.19	2E-17
chr6	118130306	118130307	rs2199936	Urate levels	ABCG2	1.86	3E-23
chr6	118130306	118130307	rs2199936	Urate levels	ABCG2	18.08	1E-75
chr6	118574060	118574061	rs281868	Resting heart rate	SLC35F1	6.30	4E-10
chr6	118578042	118578043	rs89107	Cardiac structure and function	SLC35F1, C6orf204, PLN	.03	1E-9
chr6	118653203	118653204	rs12210810	QT interval	PLN	3.13	2E-17
chr6	118667521	118667522	rs11153730	Ventricular conduction	C6orf204,SLC35F1,PLN,BRD7P3	.59	1E-18
chr6	118667521	118667522	rs11153730	QT interval	SLC35F1, C6orf204, PLN	.09	2E-29
chr6	118680373	118680374	rs11970286	Electrocardiographic traits	C6orf204	6.19	8E-7
chr6	118680373	118680374	rs11970286	QT interval	PLN	1.64	2E-24
chr6	118788651	118788652	rs11752626	QT interval	PLN	1.56	2E-6
chr6	118807846	118807847	rs25422	Renal cell carcinoma	NR	NR	5E-6
chr6	118993631	118993632	rs11756438	QT interval	c6orf204,SLC35F1, PLN, ASF1A	1.40	5E-22
chr6	119866140	119866141	rs1392089	Immune reponse to smallpox (secreted IL-2)	LOC728727	NR	4E-7
chr6	121098456	121098457	rs2817937	Primary tooth development (number of teeth)	Intergenic	.25	3E-6
chr6	121100136	121100137	rs2789066	HIV-1 control	RP11-100A16.1	NR	9E-6
chr6	121339178	121339179	rs1343075	Cognitive performance	C6orf170	NR	2E-6
chr6	121748541	121748542	rs11154022	Resting heart rate	GJA1	5.80	7E-8
chr6	121902868	121902869	rs4541776	Protein quantitative trait loci	GJA1	NR	2E-6
chr6	122146033	122146034	rs9398652	Resting heart rate	GJA1	12.60	4E-15
chr6	122158269	122158270	rs12110693	Biomedical quantitative traits	LOC644502	.66	2E-9
chr6	123282940	123282941	rs13192613	Prostate cancer (gene x gene interaction)	CLVS2	1.37	3E-6
chr6	124691236	124691237	rs9491140	Neuroticism	NKAIN2	.91	3E-7
chr6	125156448	125156449	rs11154271	Subcutaneous adipose tissue	TCBA1	NR	1E-6
chr6	126698718	126698719	rs9388489	Type 1 diabetes	C6orf173	1.17	4E-13
chr6	126767599	126767600	rs1361108	Height	Intergenic	.04	9E-6
chr6	126767599	126767600	rs1361108	Menarche (age at onset)	C6orf173, TRMT11	2.10	2E-8
chr6	126835654	126835655	rs1490388	Height	C6orf173	4.80	6E-7
chr6	126851159	126851160	rs1490384	Height	C6orf173	.03	4E-21
chr6	126964509	126964510	rs4273712	Intracranial volume	RSPO3, RNF146, CENPW	12.50	2E-13
chr6	126966307	126966308	rs4549631	Height	LOC387103	.06	5E-13
chr6	127167071	127167072	rs13204965	Bone mineral density	RSPO3	.07	3E-8
chr6	127391843	127391844	rs972275	Iron status biomarkers	RSPO3	NR	2E-6
chr6	127436063	127436064	rs1936800	Renal function-related traits (BUN)	RSPO3	.01	1E-11
chr6	127452638	127452639	rs9491696	Waist-hip ratio	RSPO3	.05	2E-32
chr6	127452638	127452639	rs9491696	Waist-hip ratio	RSPO3	.03	1E-11
chr6	127493610	127493611	rs6569474	Metabolite levels	RSPO3	.01	1E-8
chr6	127600629	127600630	rs2180341	Breast cancer	ECHDC1,RNF146	1.41	3E-8
chr6	128021802	128021803	rs17299841	Immune response to smallpox vaccine (IL-6)	C6orf190	NR	2E-7
chr6	128278797	128278798	rs802734	Multiple sclerosis	PTPRK, THEMIS	1.10	6E-9
chr6	128278797	128278798	rs802734	Celiac disease	PTPRK, THEMIS	1.17	3E-14
chr6	128492181	128492182	rs10499138	Hearing impairment	NR	NR	2E-6
chr6	129861391	129861392	rs2275215	Body mass index	LAMA2	.09	4E-7
chr6	130031492	130031493	rs17057678	Antineutrophil cytoplasmic antibody-associated vasculitis	ARHGAP18	1.25	6E-7
chr6	130216509	130216510	rs9375674	Renal sinus fat	C6orf191	.16	6E-6
chr6	130349118	130349119	rs6569648	Height	L3MBTL3	.04	1E-21
chr6	130358427	130358428	rs6899976	Height	L3MBTL3, SAMD3	3.80	6E-6
chr6	131256363	131256364	rs7769153	Response to statin therapy (LDL-C)	EPB41L2	10.30	2E-7
chr6	131282209	131282210	rs6941712	Lentiform nucleus volume	EPB41L2	149.67	5E-6
chr6	131809919	131809920	rs2807278	Obesity	ARG1	NR	3E-7
chr6	132058946	132058947	rs12199015	Response to fenofibrate (adiponectin levels)	ENPP3	.09	5E-6
chr6	133146795	133146796	rs7769051	Type 2 diabetes nephropathy	RPS12	1.28	2E-6
chr6	133663588	133663589	rs11753937	Response to angiotensin II receptor blocker therapy	EYA4	1.12	6E-6
chr6	133860344	133860345	rs9402515	Protein quantitative trait loci	EYA4	NR	1E-6
chr6	133867801	133867802	rs9375969	Visceral fat	EYA4	NR	9E-6
chr6	134158799	134158800	rs1208285	Infantile hypertrophic pyloric stenosis	NR	1.25	6E-7
chr6	134196673	134196674	rs12524865	Coronary heart disease	TCF21	1.11	2E-7
chr6	134214524	134214525	rs12190287	Coronary heart disease	TCF21	1.08	1E-12
chr6	134576510	134576511	rs9493873	Immune reponse to smallpox (secreted IFN-alpha)	SGK1	NR	4E-7
chr6	134773553	134773554	rs9321453	Urate levels	Intergenic	.14	1E-9
chr6	134898455	134898456	rs228437	Melanoma	ASIP	1.21	1E-7
chr6	135138989	135138990	rs2049953	Non-alcoholic fatty liver disease histology (AST)	Intergenic	.26	4E-6
chr6	135418634	135418635	rs7775698	Red blood cell traits	HBS1L,MYB	.09	1E-14
chr6	135418634	135418635	rs7775698	Red blood cell traits	HBS1L, MYB	.38	1E-15
chr6	135418634	135418635	rs7775698	Hematology traits	HBS1L,MYB	.19	8E-18
chr6	135418634	135418635	rs7775698	Hematology traits	HBS1L,MYB	.19	5E-13
chr6	135418915	135418916	rs7776054	Mean corpuscular hemoglobin	HBS1L, MYB	.01	7E-69
chr6	135419017	135419018	rs9399137	HbA2 levels	HBS1L,MYB	NR	5E-9
chr6	135419017	135419018	rs9399137	Platelet counts	HBS1L,MYB	5.90	5E-47
chr6	135419017	135419018	rs9399137	Hematology traits	HBS1L,MYB	.16	1E-9
chr6	135419017	135419018	rs9399137	F-cell distribution	Intergenic	15.80	3E-36
chr6	135423208	135423209	rs9373124	White blood cell types	HBS1L, MYB	.08	1E-10
chr6	135423208	135423209	rs9373124	Other erythrocyte phenotypes	HBS1L, MYB	.00	7E-14
chr6	135426572	135426573	rs4895441	Mean corpuscular volume	HBS1L, MYB	.01	7E-86
chr6	135427143	135427144	rs9376092	Beta thalassemia/hemoglobin E disease	HBS1L, MYB	2.91	2E-11
chr6	135427816	135427817	rs9402686	Hematological parameters	HBS1L, MYB	.82	7E-42
chr6	135432551	135432552	rs9494145	Mean platelet volume	HBS1L, MYB	8.19	3E-9
chr6	135432551	135432552	rs9494145	Red blood cell traits	HBS1L, MYB	.98	3E-15
chr6	135435500	135435501	rs9483788	Other erythrocyte phenotypes	HBS1L, MYB	.00	1E-47
chr6	135435500	135435501	rs9483788	Hematocrit	HBS1L, MYB	.22	3E-15
chr6	135452151	135452152	rs6569992	Red blood cell traits	HBS1L,MYB	.07	6E-9
chr6	135452151	135452152	rs6569992	Red blood cell traits	HBS1L,MYB	.75	3E-8
chr6	135452151	135452152	rs6569992	Red blood cell traits	HBS1L,MYB	.30	1E-8
chr6	135494874	135494875	rs9321490	Multiple sclerosis	MYB	1.10	2E-6
chr6	135739354	135739355	rs11154801	Multiple sclerosis	AHI1	1.13	1E-13
chr6	136001002	136001003	rs9389316	Immune reponse to smallpox (secreted IL-2)	GAPDHL19	NR	7E-13
chr6	136133658	136133659	rs947583	Phosphorus levels	PDE7B	.04	3E-12
chr6	137452907	137452908	rs17066096	Multiple sclerosis	IL22RA2	1.14	6E-13
chr6	137967213	137967214	rs13192841	Multiple sclerosis	OLIG3	1.10	1E-8
chr6	137973067	137973068	rs2327832	Celiac disease	TNFAIP3	1.23	4E-19
chr6	138002636	138002637	rs10499194	Rheumatoid arthritis	TNFAIP3, OLIG3	1.33	1E-9
chr6	138006503	138006504	rs6920220	Ulcerative colitis	Intergenic	1.14	8E-17
chr6	138006503	138006504	rs6920220	Rheumatoid arthritis	TNFAIP3	1.22	9E-13
chr6	138006503	138006504	rs6920220	Rheumatoid arthritis	OLIG3, TNFIP3	1.24	2E-9
chr6	138006503	138006504	rs6920220	Rheumatoid arthritis	TNFAIP3, OLIG3	1.22	1E-7
chr6	138195722	138195723	rs5029939	Systemic lupus erythematosus	TNFAIP3	2.28	3E-12
chr6	138196065	138196066	rs2230926	Rheumatoid arthritis	OLIG3,TNFAIP3	1.31	2E-6
chr6	138196065	138196066	rs2230926	Systemic lupus erythematosus	TNFAIP3	1.72	1E-17
chr6	138199416	138199417	rs610604	Psoriasis	TNFAIP3	1.22	7E-7
chr6	138199416	138199417	rs610604	Psoriasis	TNFAIP3	1.19	9E-12
chr6	139829665	139829666	rs605066	HDL cholesterol	CITED2	.39	3E-8
chr6	139835688	139835689	rs668459	Adiponectin levels	NR	.02	3E-6
chr6	139838418	139838419	rs628751	Mean corpuscular hemoglobin	CITED2	.00	1E-17
chr6	139839422	139839423	rs643381	Mean corpuscular volume	CITED2	.00	5E-25
chr6	139840692	139840693	rs592423	Adiponectin levels	Intergenic	.02	4E-7
chr6	140273646	140273647	rs642858	Type 2 diabetes	Intergenic	1.35	2E-6
chr6	141169824	141169825	rs11155133	Acute lymphoblastic leukemia (childhood)	Intergenic	3.62	3E-7
chr6	142527141	142527142	rs225694	Height	GPR126	NR	1E-7
chr6	142548098	142548099	rs225717	Retinal vascular caliber	VTA1,NMBR	1.90	1E-16
chr6	142679571	142679572	rs6570507	Height	GPR126	.08	2E-7
chr6	142679571	142679572	rs6570507	Height	GPR126	.08	4E-11
chr6	142703876	142703877	rs4896582	Height	GPR126	.38	2E-18
chr6	142750515	142750516	rs3817928	Pulmonary function	GPR126	.42	1E-9
chr6	142753337	142753338	rs1329705	Airflow obstruction	GPR126	1.27	3E-6
chr6	142767632	142767633	rs3748069	Height	GPR126	6.50	5E-14
chr6	142797288	142797289	rs7763064	Height	GPR126	.05	1E-33
chr6	142822216	142822217	rs9496398	Neutrophil count	AL161904.1, RP11-440G9.1	NR	4E-6
chr6	143943313	143943314	rs9390123	Lung Cancer (DNA repair capacity)	PHACTR2	NR	7E-6
chr6	144079853	144079854	rs6931865	Erectile dysfunction	PHACTR2	NR	4E-6
chr6	146918949	146918950	rs2275606	Leprosy	RAB32	1.30	4E-14
chr6	147680358	147680359	rs9390459	Coagulation factor levels	STXBP5	4.80	1E-22
chr6	147701132	147701133	rs9373523	Tuberculosis	NR	1.30	1E-6
chr6	147971573	147971574	rs1302019	Myopia (pathological)	Intergenic	NR	2E-23
chr6	148423370	148423371	rs9390537	Alzheimer's disease	SASH1	NR	8E-6
chr6	148547801	148547802	rs9497975	HIV-1 control	Intergenic	NR	7E-8
chr6	148704953	148704954	rs6930576	Type 2 diabetes nephropathy	SASH1	1.31	7E-7
chr6	148788005	148788006	rs6930337	Protein quantitative trait loci	SASH1	NR	1E-6
chr6	149329266	149329267	rs2500535	Response to antidepressants	UST	29.70	9E-6
chr6	149329266	149329267	rs2500535	Response to antidepressants	UST	27.00	4E-8
chr6	149435110	149435111	rs7772697	Diabetic retinopathy	LOC729200, MAP3K7IP2	1.35	3E-6
chr6	149525605	149525606	rs636864	Hemostatic factors and hematological phenotypes	Intergenic	NR	6E-6
chr6	149593919	149593920	rs727979	Hemostatic factors and hematological phenotypes	MAP3K7IP2	NR	8E-6
chr6	149608873	149608874	rs9485372	Breast cancer	TAB2	1.11	4E-12
chr6	149762536	149762537	rs2179367	Dupuytren's disease	ZC3H12D, TAB2	1.23	3E-7
chr6	150298841	150298842	rs1853665	Radiation response	ULBP1	NR	7E-6
chr6	150358011	150358012	rs9479482	Alopecia areata	ULBP3,ULBP6	1.65	4E-19
chr6	150570866	150570867	rs3734729	Pulmonary function	PPP1R14C	.06	4E-6
chr6	150651899	150651900	rs1591830	Metabolite levels	C6orf71	NR	1E-7
chr6	150913960	150913961	rs9372078	Panic disorder	PLEKHG1	NR	5E-7
chr6	151163114	151163115	rs17427389	Alcohol and nictotine co-dependence	PLEKHG1	NR	1E-6
chr6	151207077	151207078	rs11754661	Alzheimer's disease (late onset)	MTHFD1L	2.10	2E-10
chr6	151252984	151252985	rs6922269	Coronary heart disease	MTHFD1L	1.23	3E-8
chr6	151901408	151901409	rs4870044	Bone mineral density (spine)	ESR1	.11	2E-11
chr6	151901408	151901409	rs4870044	Bone mineral density (hip)	ESR1, C6orf97	.08	2E-7
chr6	151907747	151907748	rs4869742	Chronic myeloid leukemia	MTHFD1L, AKAP12, ZBTB2, RMND1, C6orf211, C6orf97, ESR1	1.67	2E-6
chr6	151914112	151914113	rs3757318	Breast cancer	ESR1,C6orf97	1.30	3E-6
chr6	151933174	151933175	rs1038304	Bone mineral density (hip)	ESR1	.08	4E-10
chr6	151933174	151933175	rs1038304	Bone mineral density (spine)	ESR1, C6orf97	.10	4E-11
chr6	151933174	151933175	rs1038304	Bone mineral density (hip)	ESR1	.08	5E-9
chr6	151936676	151936677	rs6929137	Bone mineral density (spine)	C6orf97, ESR1	.10	2E-10
chr6	151939349	151939350	rs3734805	Breast cancer	ESR1	1.19	1E-7
chr6	151948365	151948366	rs2046210	Breast cancer	ESR1, C6orf97	1.29	2E-15
chr6	151957713	151957714	rs12173570	Breast size	ESR1, C6orf97	.17	6E-11
chr6	151987356	151987357	rs9383938	Breast cancer	NR	1.28	2E-10
chr6	152009637	152009638	rs2941740	Bone mineral density (hip)	ESR1	.07	2E-10
chr6	152068363	152068364	rs1999805	Bone mineral density (spine)	ESR1, C6orf97	.09	2E-8
chr6	152090706	152090707	rs2504063	Bone mineral density (spine)	ESR1	.08	6E-11
chr6	152110942	152110943	rs543650	Height	ESR1	.03	1E-17
chr6	152157880	152157881	rs6902771	Alcohol dependence	ESR1	1.24	8E-6
chr6	152285686	152285687	rs2982694	Sudden cardiac arrest	ESR1	1.43	7E-10
chr6	152295612	152295613	rs9383951	Breast cancer	ESR1	1.14	2E-6
chr6	152738753	152738754	rs17082664	Bipolar disorder and major depressive disorder (combined)	SYNE1	NR	1E-6
chr6	152738753	152738754	rs17082664	Bipolar disorder	NR	1.22	4E-6
chr6	152790572	152790573	rs9371601	Bipolar disorder	SYNE1	1.10	7E-7
chr6	152791473	152791474	rs7747960	Bipolar disorder	SYNE1	1.23	9E-6
chr6	152947952	152947953	rs1322512	Tonometry	SYNE1	NR	8E-6
chr6	154414562	154414563	rs675026	Coronary heart disease	OPRM1	1.20	5E-6
chr6	154726987	154726988	rs2275336	Parkinson's disease	CNKSR3	1.36	9E-7
chr6	154986663	154986664	rs9397738	Renal function-related traits (eGRFcrea)	CNKSR3, RBM16	.00	5E-6
chr6	155929800	155929801	rs35229355	Response to treatment for acute lymphoblastic leukemia	intergenic	7.24	5E-6
chr6	156197501	156197502	rs4269383	Pancreatic cancer	ARID1B	1.20	7E-7
chr6	157441049	157441050	rs9478751	Uric acid levels	ARID1B	.15	3E-6
chr6	158041282	158041283	rs2163287	Response to antidepressant treatment	ZDHHC14	NR	3E-6
chr6	158389740	158389741	rs9458975	Cannbis use (initiation)	SYNJ2	.03	7E-6
chr6	158929441	158929442	rs9456307	Height	TULP4	.05	2E-9
chr6	159465976	159465977	rs1738074	Multiple sclerosis	TAGAP	1.15	4E-7
chr6	159465976	159465977	rs1738074	Multiple sclerosis	TAGAP	1.13	7E-15
chr6	159465976	159465977	rs1738074	Celiac disease	TAGAP	1.16	3E-15
chr6	159465976	159465977	rs1738074	Celiac disease	TAGAP	1.21	7E-8
chr6	159490435	159490436	rs212388	Crohn's disease and celiac disease	TAGAP	NR	2E-10
chr6	159490435	159490436	rs212388	Crohn's disease	TAGAP	1.10	2E-11
chr6	159646332	159646333	rs365302	Coronary heart disease	FNDC1	1.11	8E-7
chr6	160071158	160071159	rs2842992	Age-related macular degeneration (GA)	SOD2	1.43	3E-7
chr6	160137686	160137687	rs4516970	Iron status biomarkers	WTAP	NR	1E-6
chr6	160402704	160402705	rs6917747	Brain lesion load	IGF2R	NR	7E-6
chr6	160564475	160564476	rs662138	Metabolic traits	SLC22A1	.16	7E-25
chr6	160578859	160578860	rs1564348	LDL cholesterol	LPA	1.95	2E-17
chr6	160578859	160578860	rs1564348	Cholesterol, total	LPA	2.18	1E-16
chr6	160581373	160581374	rs651164	Prostate cancer	SLC22A1	1.15	2E-10
chr6	160581373	160581374	rs651164	Prostate cancer	NR	NR	2E-9
chr6	160668388	160668389	rs2279463	Chronic kidney disease	SLC22A2	.01	6E-12
chr6	160681392	160681393	rs3127573	Creatinine levels	SLC22A2	1.10	7E-10
chr6	160741621	160741622	rs3120139	Lp (a) levels	SLC22A3	.32	4E-9
chr6	160789295	160789296	rs402219	Monocyte early outgrowth colony forming units	SLC22A, LPAL2, LPA	.19	6E-7
chr6	160824027	160824028	rs2504916	Response to hepatitis C treatment	SLC22A3	.31	2E-6
chr6	160833663	160833664	rs9364554	Prostate cancer	SLC22A3	1.17	6E-10
chr6	160840251	160840252	rs7758229	Colorectal cancer	SLC22A3	1.28	8E-9
chr6	160863531	160863532	rs2048327	Coronary heart disease	SLC22A3,LPAL2,LPA	1.82	4E-15
chr6	160863531	160863532	rs2048327	Coronary heart disease	SLC22A3,LPAL2,LPA	1.20	1E-9
chr6	160907133	160907134	rs3127599	Coronary heart disease	SLC22A3,LPAL2,LPA	1.82	4E-15
chr6	160907133	160907134	rs3127599	Coronary heart disease	SLC22A3,LPAL2,LPA	1.20	1E-9
chr6	160910516	160910517	rs12214416	Lp (a) levels	LPAL2	.50	5E-8
chr6	160960358	160960359	rs6919346	Lp (a) levels	LPA	.66	4E-11
chr6	160961136	160961137	rs3798220	Coronary heart disease	LPA	1.51	3E-11
chr6	160962502	160962503	rs7767084	Coronary heart disease	SLC22A3,LPAL2,LPA	1.82	4E-15
chr6	160962502	160962503	rs7767084	Coronary heart disease	SLC22A3,LPAL2,LPA	1.20	1E-9
chr6	160969737	160969738	rs10755578	Coronary heart disease	SLC22A3,LPAL2,LPA	1.82	4E-15
chr6	160969737	160969738	rs10755578	Coronary heart disease	SLC22A3,LPAL2,LPA	1.20	1E-9
chr6	161010117	161010118	rs10455872	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	LPA	4.80	2E-16
chr6	161010117	161010118	rs10455872	Response to statin therapy	LPA	.28	1E-9
chr6	161010117	161010118	rs10455872	Response to statin therapy (LDL-C)	LPA	6.80	5E-15
chr6	161010117	161010118	rs10455872	Lp (a) levels	LPA	1.28	5E-39
chr6	161018173	161018174	rs7770628	Protein quantitative trait loci	LPA	NR	4E-10
chr6	161089816	161089817	rs1084651	HDL cholesterol	LPA	.56	3E-8
chr6	161137989	161137990	rs783147	Lp (a) levels	PLG	.30	3E-17
chr6	161333936	161333937	rs1247318	Aging	PLG, MAP3K4	NR	3E-6
chr6	161933934	161933935	rs16892673	Aging	PARK2	NR	5E-6
chr6	162001435	162001436	rs992037	Metabolite levels	PARK2	NR	1E-7
chr6	162161618	162161619	rs926849	Disc degeneration (lumbar)	PARK2	.13	3E-8
chr6	162236074	162236075	rs3016539	Pancreatic cancer	PARK2	1.50	7E-6
chr6	164186676	164186677	rs10945919	Response to TNF antagonist treatment	QKI	NR	3E-7
chr6	164900597	164900598	rs4709845	Major depressive disorder	LOC728275	1.21	9E-6
chr6	165466350	165466351	rs227458	Visceral adipose tissue adjusted for BMI	C6orf118	NR	3E-6
chr6	165935420	165935421	rs519595	Response to fenofibrate	PDE10	.58	5E-6
chr6	165935420	165935421	rs519595	Response to fenofibrate	PDE10	.60	2E-6
chr6	166015430	166015431	rs7762160	Conduct disorder (symptom count)	PDE10A	.07	1E-6
chr6	166128637	166128638	rs9364813	Economic and political preferences (immigration/crime)	Intergenic	.27	8E-6
chr6	166155456	166155457	rs1039002	Bipolar disorder	RP11-252P19.1	NR	2E-8
chr6	166534741	166534742	rs6456042	Asthma	T	NR	6E-6
chr6	166571442	166571443	rs1056053	Visceral adipose tissue/subcutaneous adipose tissue ratio	T	NR	4E-6
chr6	166706168	166706169	rs6915183	Longevity	PRR18	NR	1E-6
chr6	167360388	167360389	rs2236313	Vitiligo	RNASET2, FGFR1OP, CCR6	1.20	1E-16
chr6	167383074	167383075	rs9355610	Graves' disease	RNASET2, FGFR1OP	1.19	7E-10
chr6	167406632	167406633	rs415890	Crohn's disease	CCR6	1.17	3E-12
chr6	167437987	167437988	rs2301436	Crohn's disease	CCR6,FGFR10P,RNASE2	1.37	6E-8
chr6	167437987	167437988	rs2301436	Crohn's disease	CCR6	1.21	1E-12
chr6	167532792	167532793	rs3093024	Rheumatoid arthritis	CCR6	1.19	8E-19
chr6	167534289	167534290	rs3093023	Rheumatoid arthritis	CCR6	1.13	2E-11
chr6	168511015	168511016	rs1473500	Immune reponse to smallpox (secreted IL-2)	FRMD1	NR	3E-7
chr6	168941623	168941624	rs13208776	Vitiligo	SMOC2	NR	9E-8
chr6	169958981	169958982	rs3734905	HIV-1 control	NR	NR	2E-6
chr6	170379024	170379025	rs924043	Type 1 diabetes	WDR27, C6orf120, PHF10, TCTE3, C6orf208, LOC154449, DLL1, FAM120B, PSMB1, TBP, PCD2	1.35	8E-9
chr6_apd_hap1	79517	79518	rs4324798	Lung adenocarcinoma	TRNAA-UGC	1.16	2E-8
chr6_apd_hap1	387667	387668	rs3129109	Height	OR2J3	.03	2E-17
chr6_apd_hap1	737891	737892	rs4713226	Immune reponse to smallpox (secreted IFN-alpha)	OR2H1	NR	2E-8
chr6_apd_hap1	914963	914964	rs29232	Nasopharyngeal carcinoma	GABBR1	1.67	9E-17
chr6_apd_hap1	1091481	1091482	rs2523809	IgE levels	HLA-G	.06	4E-8
chr6_apd_hap1	1146572	1146573	rs2860580	Nasopharyngeal carcinoma	HLA-A	1.72	5E-67
chr6_apd_hap1	1153184	1153185	rs1061235	Adverse response to carbamapezine	HLA-A*3101	9.12	1E-7
chr6_apd_hap1	1157989	1157990	rs2517713	Nasopharyngeal carcinoma	HLA-A	1.88	4E-20
chr6_apd_hap1	1160222	1160223	rs9260489	Multiple sclerosis	HLA-B	1.21	1E-11
chr6_apd_hap1	1163712	1163713	rs2571391	IgE levels	HLA-A	.06	1E-15
chr6_apd_hap1	1210439	1210440	rs7758512	HIV-1 control	ZNRD1, RNF39, HLA-A	NR	2E-8
chr6_apd_hap1	1213772	1213773	rs4313034	Graves' disease	MHC	1.67	2E-15
chr6_apd_hap1	1257285	1257286	rs6917603	Lipid metabolism phenotypes	PPP1R11	.24	3E-29
chr6_apd_hap1	1265739	1265740	rs259919	HIV-1 control	C6orf12, ZNRD1	NR	3E-7
chr6_apd_hap1	1272752	1272753	rs8321	AIDS progression	ZNRD1, RNF39	NR	5E-7
chr6_apd_hap1	1320597	1320598	rs34704616	Cognitive performance	XXbac-BPG250I8.13	NR	6E-6
chr6_apd_hap1	1333595	1333596	rs10947055	Cardiac hypertrophy	TRIM38	NR	2E-7
chr6_apd_hap1	1360124	1360125	rs9468692	HIV-1 control	TRIM10	NR	1E-6
chr6_apd_hap1	1405472	1405473	rs2523722	Schizophrenia	MHC, TRIM26	1.25	1E-16
chr6_apd_hap1	1414330	1414331	rs2021722	Schizophrenia	TRIM26	1.15	2E-12
chr6_apd_hap1	2314595	2314596	rs4248154	Graves' disease	MHC	1.38	1E-13
chr6_apd_hap1	2318834	2318835	rs2844665	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	C6orf205	1.54	3E-7
chr6_apd_hap1	2333114	2333115	rs2517532	Hypothyroidism	LOC729792, HCG22, C6orf15, HLA-C, HLA-B, DHFRP2, HCP5	1.16	1E-8
chr6_apd_hap1	2339517	2339518	rs9262632	HIV-1 control	Intergenic	3.10	1E-8
chr6_apd_hap1	2761505	2761506	rs2248462	Hodgkin's lymphoma	MICB	1.64	7E-16
chr6_apd_hap1	2763685	2763686	rs3099844	Metabolic syndrome	HCG26, MICB	.15	2E-8
chr6_apd_hap1	2763685	2763686	rs3099844	Neonatal lupus	TNF,NFKBIL1,LTA,LTB,AIF1	3.34	5E-10
chr6_apd_hap1	2787408	2787409	rs2855812	Pulmonary function	MICB	.03	2E-7
chr6_apd_hap1	2790174	2790175	rs3132468	Dengue shock syndrome	MICB	1.34	4E-11
chr6_apd_hap1	2795987	2795988	rs2516399	White blood cell types	MHC	.11	2E-12
chr6_apd_hap1	2814290	2814291	rs3853601	Atopic dermatitis	BAT1	1.13	2E-6
chr6_apd_hap1	2820167	2820168	rs2734583	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	BAT1, HCP5, MICC, PPIAP9, PSORS1C1, POLR2LP, CCHCR1, TCF19, POU5F1, HLA-C, HCP5, PSORS1C3, HLA-B*5801	66.80	2E-8
chr6_apd_hap1	2872508	2872509	rs11575839	Complement C3 and C4 levels	HLA-C	.23	1E-54
chr6_apd_hap1	2883186	2883187	rs2857595	Pulmonary function	NCR3	.04	2E-10
chr6_apd_hap1	2887673	2887674	rs2844479	Weight	AIF1, NCR3	3.58	2E-8
chr6_apd_hap1	2890015	2890016	rs9348876	Crohn's disease	AIF1	1.41	3E-6
chr6_apd_hap1	3093289	3093290	rs2075799	Complement C3 and C4 levels	C4	.17	6E-97
chr6_apd_hap1	3117294	3117295	rs9368699	HIV-1 control	SNORD52	NR	5E-8
chr6_apd_hap1	3151820	3151821	rs11966200	Vitiligo	HLA-C,HLA-B	1.90	1E-48
chr6_apd_hap1	3153465	3153466	rs494620	Menopause (age at onset)	NR	.30	5E-7
chr6_apd_hap1	3158677	3158678	rs2736428	Telomere length	SLC44A4	.05	3E-6
chr6_apd_hap1	3364805	3364806	rs185819	Height	HLA class III	5.20	3E-8
chr6_apd_hap1	3365496	3365497	rs1150754	Systemic lupus erythematosus	TNXB	2.21	6E-29
chr6_apd_hap1	3424715	3424716	rs204999	Serum total protein level	Intergenic	.03	4E-11
chr6_apd_hap1	3424715	3424716	rs204999	Serum total protein level	Intergenic	.03	3E-9
chr6_apd_hap1	3424715	3424716	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_apd_hap1	3424715	3424716	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_apd_hap1	3451287	3451288	rs1061808	Phospholipid levels (plasma)	AGPAT1	.90	8E-10
chr6_apd_hap1	3466183	3466184	rs2070600	Pulmonary function	AGER, PPT2	1.00	3E-14
chr6_apd_hap1	3466183	3466184	rs2070600	Pulmonary function	AGER	.09	3E-15
chr6_apd_hap1	3470318	3470319	rs204993	Asthma	PBX2	1.17	2E-15
chr6_apd_hap1	3473056	3473057	rs176095	Atopic dermatitis	GPSM3	1.40	8E-20
chr6_apd_hap1	3480181	3480182	rs2071278	Complement C3 and C4 levels	HLA-DRA	.13	4E-72
chr6_apd_hap1	3486431	3486432	rs2071277	Age-related macular degeneration	NOTCH4	1.30	2E-11
chr6_apd_hap1	3487741	3487742	rs3131296	Schizophrenia	MHC, NOTCH4	1.19	2E-10
chr6_apd_hap1	3597576	3597577	rs6910071	Rheumatoid arthritis	HLA-DRB1	2.88	1E-299
chr6_apd_hap1	3620711	3620712	rs3129900	Lumiracoxib-related liver injury	HLA-DRB1	7.50	7E-25
chr6_apd_hap1	3623637	3623638	rs9469099	Atopic dermatitis	C6orf10	1.61	5E-19
chr6_apd_hap1	3635926	3635927	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_apd_hap1	3635926	3635927	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_apd_hap1	3635926	3635927	rs2395148	Arthritis (juvenile idiopathic)	HLA-DRB1	5.37	2E-10
chr6_apd_hap1	3650578	3650579	rs3129934	Multiple sclerosis	C6orf10	2.34	7E-16
chr6_apd_hap1	3650578	3650579	rs3129934	Multiple sclerosis	HLA-DRB1	3.30	9E-11
chr6_apd_hap1	3652023	3652024	rs2273017	Graves' disease	MHC	1.53	2E-22
chr6_apd_hap1	3653080	3653081	rs3129943	Asthma	C6orf10	1.17	3E-15
chr6_apd_hap1	3653460	3653461	rs2050190	Activated partial thromboplastin time	C6orf10	.25	7E-7
chr6_apd_hap1	3655737	3655738	rs9268402	Coronary heart disease	C6orf10, BTNL2	1.16	3E-15
chr6_apd_hap1	3659665	3659666	rs7758128	Vitiligo	C6orf10, BTNL2	NR	8E-11
chr6_apd_hap1	3672639	3672640	rs3117099	Bipolar disorder and schizophrenia	MHC, other genes	1.25	3E-6
chr6_apd_hap1	3672882	3672883	rs3117098	Asthma	BTNL2	1.16	5E-12
chr6_apd_hap1	3677584	3677585	rs1980493	Anti-cyclic Citrullinated Peptide Antibody	HLA-DRA, BTNL2	NR	5E-7
chr6_apd_hap1	3678185	3678186	rs2076530	Sarcoidosis	BTNL2	NR	3E-11
chr6_apd_hap1	3678213	3678214	rs9268480	Ulcerative colitis	BTNL2	1.82	3E-6
chr6_apd_hap1	3678324	3678325	rs2076529	Waist-hip ratio	BTNL2	.02	4E-7
chr6_apd_hap1	3682456	3682457	rs3817963	Lung adenocarcinoma	BTNL2	1.18	3E-10
chr6_apd_hap1	3687679	3687680	rs10947262	Knee osteoarthritis	BTNL2, HLA-DQA2, HLA-DQB1	1.31	5E-9
chr6_apd_hap1	3688065	3688066	rs3806156	Vitiligo	BTNL2,HLA-DRA,HLA-DQA1	1.42	7E-19
chr6_apd_hap1	3690838	3690839	rs3763313	HIV-1 control	BTNL2, NOTCH4	NR	2E-6
chr6_apd_hap1	3691155	3691156	rs3763317	Complement C3 and C4 levels	HLA-DRB	.12	9E-66
chr6_apd_hap1	3693857	3693858	rs9268516	Asthma	BTNL2, HLA-DRA	1.15	1E-8
chr6_apd_hap1	3742665	3742666	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_apd_hap1	3742665	3742666	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_apd_hap1	3742665	3742666	rs6903608	Hodgkin's lymphoma	HLA-DRA	1.70	3E-50
chr6_apd_hap1	3744023	3744024	rs9268853	Rheumatoid arthritis	HLA-DRA	2.40	5E-109
chr6_apd_hap1	3744023	3744024	rs9268853	Ulcerative colitis	HLA-DRB5, HLA-DQA1, HLA-DRB1, HLA-DRA, BTNL2	1.40	1E-55
chr6_apd_hap1	3745527	3745528	rs9268877	Ulcerative colitis	MHC	NR	4E-23
chr6_apd_hap1	3745527	3745528	rs9268877	Ulcerative colitis	HLA-DRA, BTNL2	1.45	6E-18
chr6_apd_hap1	3746460	3746461	rs9268905	Cystic fibrosis severity	HLA-DRA	NR	1E-7
chr6_apd_hap1	3747218	3747219	rs9268923	Ulcerative colitis	HLA-DRA	1.45	4E-15
chr6_apd_hap1	3747550	3747551	rs2395185	Lung cancer	HLA class II	1.17	1E-8
chr6_apd_hap1	3747550	3747551	rs2395185	Hodgkin's lymphoma	HLA-DRA	1.82	4E-31
chr6_apd_hap1	3747550	3747551	rs2395185	Ulcerative colitis	Intergenic	1.92	5E-22
chr6_apd_hap1	3747550	3747551	rs2395185	Ulcerative colitis	BTNL2, HLA-DRA, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1	1.52	1E-16
chr6_apd_hap1	3973536	3973537	rs3916765	Type 2 diabetes	HLA-DQA2	1.21	1E-6
chr6_apd_hap1	3975932	3975933	rs9275698	Asthma	HLA-DQA2	1.18	5E-12
chr6_apd_hap1	3988042	3988043	rs2858884	Narcolepsy	HLA-DQA2	1.79	3E-8
chr6_apd_hap1	4013471	4013472	rs2301271	Systemic lupus erythematosus	HLA-DQA2	1.47	2E-12
chr6_apd_hap1	4018290	4018291	rs7453920	Hepatitis B	HAL-DQB2	1.81	6E-28
chr6_apd_hap1	4018364	4018365	rs2051549	Systemic lupus erythematosus	HLA-DQA2	NR	3E-22
chr6_apd_hap1	4024976	4024977	rs9276606	Complement C3 and C4 levels	HLA-DQB	.09	3E-22
chr6_apd_hap1	4051418	4051419	rs2857151	Kawasaki disease	HLA-DQB2, HLA-DOB	1.47	5E-11
chr6_apd_hap1	4091074	4091075	rs241428	Complement C3 and C4 levels	HLA-DQB	.23	9E-83
chr6_apd_hap1	4096851	4096852	rs9357155	Nephropathy	TAP2, TAP1, PSMB8, PSMB9	1.41	2E-12
chr6_apd_hap1	4139609	4139610	rs2187689	Disc degeneration (lumbar)	PSMB9	.23	3E-8
chr6_apd_hap1	4141654	4141655	rs10046257	Disc degeneration (lumbar)	Intergenic	.19	3E-7
chr6_apd_hap1	4142674	4142675	rs6457690	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_apd_hap1	4143343	4143344	rs1029296	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_apd_hap1	4143444	4143445	rs1029295	Disc degeneration (lumbar)	Intergenic	.19	5E-7
chr6_apd_hap1	4143896	4143897	rs6936004	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_apd_hap1	4144379	4144380	rs10214886	Disc degeneration (lumbar)	Intergenic	.19	2E-7
chr6_apd_hap1	4146672	4146673	rs7744666	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_apd_hap1	4146708	4146709	rs11969002	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_apd_hap1	4147712	4147713	rs9469300	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_apd_hap1	4149567	4149568	rs3749982	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_apd_hap1	4319840	4319841	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.82	4E-45
chr6_apd_hap1	4319840	4319841	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.67	1E-9
chr6_apd_hap1	4319840	4319841	rs3077	Hepatitis B	HLA-DPA1	1.87	2E-61
chr6_apd_hap1	4329680	4329681	rs987870	Asthma	HLA, DPB1	1.40	2E-10
chr6_apd_hap1	4329680	4329681	rs987870	Systemic sclerosis	HLA-DPA1, HLA-DPB1	2.09	2E-20
chr6_apd_hap1	4341651	4341652	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.64	2E-21
chr6_apd_hap1	4341651	4341652	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.52	2E-17
chr6_apd_hap1	4341651	4341652	rs9277535	Hepatitis B vaccine response	HLA-DPB1	1.39	3E-12
chr6_apd_hap1	4341651	4341652	rs9277535	Hepatitis B	HLA-DPB1	1.77	3E-54
chr6_apd_hap1	4341651	4341652	rs9277535	Hepatitis B	HLA-DPB1	1.75	6E-39
chr6_apd_hap1	4346908	4346909	rs2281388	Graves' disease	HLA, DPB1	1.64	2E-65
chr6_apd_hap1	4356683	4356684	rs3117242	Antineutrophil cytoplasmic antibody-associated vasculitis	HLA-DP, COL11A2	3.67	1E-71
chr6_apd_hap1	4373011	4373012	rs3117035	RR interval (heart rate)	Intergenic	.14	1E-6
chr6_apd_hap1	4373210	4373211	rs1883414	Nephropathy	HLA-DPA1, HLA-DPB1, HLA-DPB2	1.28	5E-9
chr6_cox_hap2	298991	298992	rs4324798	Lung adenocarcinoma	TRNAA-UGC	1.16	2E-8
chr6_cox_hap2	434987	434988	rs4947339	Platelet aggregation	TRIM27	NR	2E-6
chr6_cox_hap2	603109	603110	rs3129109	Height	OR2J3	.03	2E-17
chr6_cox_hap2	874134	874135	rs3094548	Pulmonary function	OR12D2	.03	1E-7
chr6_cox_hap2	875263	875264	rs9257809	Barrett's esophagus	MHC, OR2D12, OR2D13	1.21	4E-9
chr6_cox_hap2	953194	953195	rs4713226	Immune reponse to smallpox (secreted IFN-alpha)	OR2H1	NR	2E-8
chr6_cox_hap2	1130238	1130239	rs29232	Nasopharyngeal carcinoma	GABBR1	1.67	9E-17
chr6_cox_hap2	1189126	1189127	rs3129055	Nasopharyngeal carcinoma	HLA-F	1.51	7E-11
chr6_cox_hap2	1218677	1218678	rs2523395	Prostate cancer (gene x gene interaction)	LOC285830	1.24	2E-6
chr6_cox_hap2	1221837	1221838	rs2523393	Multiple sclerosis	HLA-B	1.28	1E-17
chr6_cox_hap2	1239325	1239326	rs9258260	Crohn's disease	HLA-F, MOG, HLA-G, GABBR1, HLA-H, UBD, HLA-A	1.45	2E-10
chr6_cox_hap2	1305060	1305061	rs1610677	Rheumatoid arthritis	HLA-G	1.32	4E-15
chr6_cox_hap2	1348041	1348042	rs2523822	Drug-induced liver injury (amoxicillin-clavulanate)	HLA-A	2.30	2E-10
chr6_cox_hap2	1363345	1363346	rs2523809	IgE levels	HLA-G	.06	4E-8
chr6_cox_hap2	1418437	1418438	rs2860580	Nasopharyngeal carcinoma	HLA-A	1.72	5E-67
chr6_cox_hap2	1425049	1425050	rs1061235	Adverse response to carbamapezine	HLA-A*3101	9.12	1E-7
chr6_cox_hap2	1429854	1429855	rs2517713	Nasopharyngeal carcinoma	HLA-A	1.88	4E-20
chr6_cox_hap2	1432087	1432088	rs9260489	Multiple sclerosis	HLA-B	1.21	1E-11
chr6_cox_hap2	1435577	1435578	rs2571391	IgE levels	HLA-A	.06	1E-15
chr6_cox_hap2	1446963	1446964	rs3893464	Graves' disease	MHC	1.53	2E-20
chr6_cox_hap2	1453645	1453646	rs2523946	IgA nephropathy	HLA-A	1.21	2E-11
chr6_cox_hap2	1454769	1454770	rs6904029	Vitiligo	HLA-A,HCG9	1.49	1E-21
chr6_cox_hap2	1482305	1482306	rs7758512	HIV-1 control	ZNRD1, RNF39, HLA-A	NR	2E-8
chr6_cox_hap2	1485638	1485639	rs4313034	Graves' disease	MHC	1.67	2E-15
chr6_cox_hap2	1529150	1529151	rs6917603	Lipid metabolism phenotypes	PPP1R11	.24	3E-29
chr6_cox_hap2	1537608	1537609	rs259919	HIV-1 control	C6orf12, ZNRD1	NR	3E-7
chr6_cox_hap2	1544621	1544622	rs8321	AIDS progression	ZNRD1, RNF39	NR	5E-7
chr6_cox_hap2	1592500	1592501	rs34704616	Cognitive performance	XXbac-BPG250I8.13	NR	6E-6
chr6_cox_hap2	1605498	1605499	rs10947055	Cardiac hypertrophy	TRIM38	NR	2E-7
chr6_cox_hap2	1632026	1632027	rs9468692	HIV-1 control	TRIM10	NR	1E-6
chr6_cox_hap2	1677373	1677374	rs2523722	Schizophrenia	MHC, TRIM26	1.25	1E-16
chr6_cox_hap2	1686226	1686227	rs2021722	Schizophrenia	TRIM26	1.15	2E-12
chr6_cox_hap2	2049656	2049657	rs3132613	Graves' disease	MHC	1.43	1E-13
chr6_cox_hap2	2248189	2248190	rs12526186	Response to antipsychotic treatment	Intergenic	9.00	3E-6
chr6_cox_hap2	2294055	2294056	rs886424	Bipolar disorder and schizophrenia	MHC, other genes	1.37	9E-7
chr6_cox_hap2	2307232	2307233	rs7772131	Response to angiotensin II receptor blocker therapy	C6orf214	6.73	3E-6
chr6_cox_hap2	2360350	2360351	rs7756521	HIV-1 control	DDR1, VARS2, DPCR1	NR	1E-6
chr6_cox_hap2	2388226	2388227	rs1052693	Complement C3 and C4 levels	HLA-A	.10	3E-48
chr6_cox_hap2	2514638	2514639	rs4248154	Graves' disease	MHC	1.38	1E-13
chr6_cox_hap2	2518876	2518877	rs2844665	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	C6orf205	1.54	3E-7
chr6_cox_hap2	2533148	2533149	rs2517532	Hypothyroidism	LOC729792, HCG22, C6orf15, HLA-C, HLA-B, DHFRP2, HCP5	1.16	1E-8
chr6_cox_hap2	2539514	2539515	rs9262632	HIV-1 control	Intergenic	3.10	1E-8
chr6_cox_hap2	2572866	2572867	rs4947296	Behcet's disease	HCG22	2.57	1E-11
chr6_cox_hap2	2572866	2572867	rs4947296	Graves' disease	MUC21, C6orf15	1.77	4E-51
chr6_cox_hap2	2573028	2573029	rs3130544	Myasthenia gravis	NR	5.64	2E-90
chr6_cox_hap2	2588742	2588743	rs6457327	Follicular lymphoma	C6orf15	1.47	7E-6
chr6_cox_hap2	2588742	2588743	rs6457327	Follicular lymphoma	STG, PSORS1	1.69	5E-11
chr6_cox_hap2	2608293	2608294	rs3815087	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	PSORS1C1	1.53	3E-7
chr6_cox_hap2	2608293	2608294	rs3815087	HIV-1 control	CDSN	NR	8E-8
chr6_cox_hap2	2612019	2612020	rs3130559	Chronic obstructive pulmonary disease-related biomarkers	PSORS1C1	NR	8E-9
chr6_cox_hap2	2614296	2614297	rs4959053	Behcet's disease	PSORS1C1	4.38	2E-20
chr6_cox_hap2	2620989	2620990	rs3130573	Systemic sclerosis	PSORS1C1	1.25	6E-10
chr6_cox_hap2	2621908	2621909	rs1265093	Chronic obstructive pulmonary disease-related biomarkers	PSORS1C1, CCHCR1	NR	6E-9
chr6_cox_hap2	2626115	2626116	rs9263739	Ulcerative colitis	HLA	2.73	4E-67
chr6_cox_hap2	2632764	2632765	rs1265112	Nevirapine-induced rash	CCHCR1	4.36	1E-8
chr6_cox_hap2	2633256	2633257	rs130067	Prostate cancer	CCHCR1	1.05	3E-8
chr6_cox_hap2	2651219	2651220	rs3130501	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	POU5F1	1.74	2E-8
chr6_cox_hap2	2654221	2654222	rs879882	Height	MICA	NR	2E-7
chr6_cox_hap2	2658351	2658352	rs3131018	HIV-1 control	PSORS1C3	2.10	4E-16
chr6_cox_hap2	2670565	2670566	rs1265181	Psoriasis	MHC	22.62	NS
chr6_cox_hap2	2682801	2682802	rs6903896	Common traits (Other)	NR	NR	6E-7
chr6_cox_hap2	2698962	2698963	rs3869109	Coronary heart disease	HCG27, HLA-C	1.14	1E-9
chr6_cox_hap2	2734916	2734917	rs3095254	White blood cell types	MHC	.07	6E-11
chr6_cox_hap2	2753685	2753686	rs2074488	Chronic obstructive pulmonary disease-related biomarkers	HLA-C	NR	2E-10
chr6_cox_hap2	2754363	2754364	rs13191343	Psoriatic arthritis	HLA-C	2.37	2E-72
chr6_cox_hap2	2765635	2765636	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.31	6E-21
chr6_cox_hap2	2765635	2765636	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.37	2E-28
chr6_cox_hap2	2766164	2766165	rs12191877	Psoriasis	HLA-C	2.79	4E-32
chr6_cox_hap2	2766164	2766165	rs12191877	Psoriasis	HLA-C	2.64	1E-100
chr6_cox_hap2	2772076	2772077	rs9468925	Vitiligo	HLA	1.35	2E-33
chr6_cox_hap2	2776986	2776987	rs2894207	Nasopharyngeal carcinoma	HLA-B,HLA-C	1.64	3E-33
chr6_cox_hap2	2778725	2778726	rs2247056	Triglycerides	HLA	2.99	2E-15
chr6_cox_hap2	2784951	2784952	rs9461688	Protein quantitative trait loci	HLA-C	NR	4E-6
chr6_cox_hap2	2785556	2785557	rs9368677	Atopic dermatitis	HLA-C	1.36	1E-17
chr6_cox_hap2	2787615	2787616	rs9264942	HIV-1 control	HLA-C	2.90	3E-35
chr6_cox_hap2	2787615	2787616	rs9264942	HIV-1 control	HLA-C	5.30	6E-32
chr6_cox_hap2	2787615	2787616	rs9264942	HIV-1 control	HLA-C	NR	6E-12
chr6_cox_hap2	2787790	2787791	rs10484554	Psoriasis	HLA-C	4.66	4E-214
chr6_cox_hap2	2787790	2787791	rs10484554	AIDS progression	HLA-C	NR	6E-8
chr6_cox_hap2	2787790	2787791	rs10484554	Psoriasis	HLA-C	2.80	2E-39
chr6_cox_hap2	2824997	2824998	rs3134792	Psoriasis	HLA-C	NR	1E-9
chr6_cox_hap2	2835055	2835056	rs3819299	Platelet counts	HLA-B	5.05	9E-10
chr6_cox_hap2	2835247	2835248	rs2523608	HIV-1 control	HLA-B	2.60	9E-20
chr6_cox_hap2	2835247	2835248	rs2523608	HIV-1 control	HLA-B	NR	3E-6
chr6_cox_hap2	2839749	2839750	rs2523590	HIV-1 control	HLA-B	2.40	2E-13
chr6_cox_hap2	2840386	2840387	rs9378249	Bipolar disorder	NR	NR	1E-8
chr6_cox_hap2	2848782	2848783	rs7743761	Ankylosing spondylitis	MHC	NR	5E-304
chr6_cox_hap2	2849100	2849101	rs9266406	Behcet's disease	MICA, MICB, DHFRP2	2.29	2E-10
chr6_cox_hap2	2859483	2859484	rs9266629	Chronic obstructive pulmonary disease-related biomarkers	FGFR3P	NR	4E-10
chr6_cox_hap2	2863381	2863382	rs1521	Graves' disease	HLA-B	1.92	2E-65
chr6_cox_hap2	2867237	2867238	rs13437082	Height	HLA-B	.07	5E-8
chr6_cox_hap2	2878483	2878484	rs4349859	Ankylosing spondylitis	HLA-B	NR	1E-200
chr6_cox_hap2	2879291	2879292	rs2596542	Hepatocellular carcinoma	MICA	1.39	4E-13
chr6_cox_hap2	2890286	2890287	rs12175489	Visceral adipose tissue adjusted for BMI	HLA-B, HCP5	NR	2E-6
chr6_cox_hap2	2892630	2892631	rs1063635	Rheumatoid arthritis	MICA	1.35	1E-17
chr6_cox_hap2	2893228	2893229	rs2256183	Height	MICA	.04	8E-29
chr6_cox_hap2	2904100	2904101	rs4418214	HIV-1 control	MICA	4.40	1E-34
chr6_cox_hap2	2920461	2920462	rs9469003	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	HCP5	1.73	2E-9
chr6_cox_hap2	2920898	2920899	rs2524276	Capecitabine sensitivity	Intergenic	NR	6E-6
chr6_cox_hap2	2941344	2941345	rs2255221	HIV-1 control	Intergenic	2.70	4E-14
chr6_cox_hap2	2941433	2941434	rs2395029	HIV-1 control	HLA-B	5.30	1E-25
chr6_cox_hap2	2941433	2941434	rs2395029	HIV-1 control	HCP5, HLA-B	5.80	5E-35
chr6_cox_hap2	2941433	2941434	rs2395029	HIV-1 control	HCP5, HLA-B	NR	1E-11
chr6_cox_hap2	2941433	2941434	rs2395029	Drug-induced liver injury (flucloxacillin)	HCP5, HLA-B	45.00	9E-33
chr6_cox_hap2	2941433	2941434	rs2395029	AIDS progression	HCP5, MICB, MCCD1, BAT1, LTB, TNF	3.47	3E-19
chr6_cox_hap2	2941433	2941434	rs2395029	Psoriasis	HLA-C	4.10	2E-26
chr6_cox_hap2	2950322	2950323	rs3828890	Renal function-related traits (sCR)	MHC	.01	3E-9
chr6_cox_hap2	2950322	2950323	rs3828890	Renal function-related traits (eGRFcrea)	MHC	.01	1E-9
chr6_cox_hap2	2956453	2956454	rs2248462	Hodgkin's lymphoma	MICB	1.64	7E-16
chr6_cox_hap2	2958633	2958634	rs3099844	Metabolic syndrome	HCG26, MICB	.15	2E-8
chr6_cox_hap2	2958633	2958634	rs3099844	Neonatal lupus	TNF,NFKBIL1,LTA,LTB,AIF1	3.34	5E-10
chr6_cox_hap2	2982390	2982391	rs2855812	Pulmonary function	MICB	.03	2E-7
chr6_cox_hap2	2985156	2985157	rs3132468	Dengue shock syndrome	MICB	1.34	4E-11
chr6_cox_hap2	2990969	2990970	rs2516399	White blood cell types	MHC	.11	2E-12
chr6_cox_hap2	3009264	3009265	rs3853601	Atopic dermatitis	BAT1	1.13	2E-6
chr6_cox_hap2	3015141	3015142	rs2734583	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	BAT1, HCP5, MICC, PPIAP9, PSORS1C1, POLR2LP, CCHCR1, TCF19, POU5F1, HLA-C, HCP5, PSORS1C3, HLA-B*5801	66.80	2E-8
chr6_cox_hap2	3051923	3051924	rs1799964	Crohn's disease	LTA,HLA-DQA2,TNF,LST1,LTB	1.19	4E-11
chr6_cox_hap2	3067402	3067403	rs11575839	Complement C3 and C4 levels	HLA-C	.23	1E-54
chr6_cox_hap2	3078075	3078076	rs2857595	Pulmonary function	NCR3	.04	2E-10
chr6_cox_hap2	3082563	3082564	rs2844479	Weight	AIF1, NCR3	3.58	2E-8
chr6_cox_hap2	3084897	3084898	rs9348876	Crohn's disease	AIF1	1.41	3E-6
chr6_cox_hap2	3112582	3112583	rs1046089	Menopause (age at onset)	PRRC2A	.21	2E-16
chr6_cox_hap2	3125984	3125985	rs805303	Systolic blood pressure	BAT2, BAT5	.38	2E-11
chr6_cox_hap2	3125984	3125985	rs805303	Hypertension	BAT2, BAT5	.05	1E-10
chr6_cox_hap2	3125984	3125985	rs805303	Diastolic blood pressure	BAT2, BAT5	.23	3E-11
chr6_cox_hap2	3130137	3130138	rs3117582	Lung adenocarcinoma	BAT3, APOM	1.22	5E-12
chr6_cox_hap2	3130137	3130138	rs3117582	Lung cancer	BAT3	1.24	4E-10
chr6_cox_hap2	3130137	3130138	rs3117582	Lung cancer	BAT3,MSH5	1.24	5E-10
chr6_cox_hap2	3132223	3132224	rs805297	Rheumatoid arthritis	APOM	1.56	3E-10
chr6_cox_hap2	3230626	3230627	rs3131379	Systemic lupus erythematosus	HLA region	2.36	2E-52
chr6_cox_hap2	3288109	3288110	rs2075799	Complement C3 and C4 levels	C4	.17	6E-97
chr6_cox_hap2	3312116	3312117	rs9368699	HIV-1 control	SNORD52	NR	5E-8
chr6_cox_hap2	3346819	3346820	rs11966200	Vitiligo	HLA-C,HLA-B	1.90	1E-48
chr6_cox_hap2	3348466	3348467	rs494620	Menopause (age at onset)	NR	.30	5E-7
chr6_cox_hap2	3353677	3353678	rs2736428	Telomere length	SLC44A4	.05	3E-6
chr6_cox_hap2	3377006	3377007	rs9267663	Economic and political preferences (environmentalism)	EHMT2	.29	6E-6
chr6_cox_hap2	3380609	3380610	rs9267665	Hepatitis B vaccine response	HLA	2.05	1E-17
chr6_cox_hap2	3393435	3393436	rs9267673	Hepatocellular carcinoma	C2	1.97	2E-6
chr6_cox_hap2	3413559	3413560	rs9332739	Age-related macular degeneration (GA)	C2	2.63	1E-6
chr6_cox_hap2	3413559	3413560	rs9332739	Age-related macular degeneration (CNV)	C2	2.08	2E-8
chr6_cox_hap2	3413559	3413560	rs9332739	Age-related macular degeneration	C2	2.17	2E-23
chr6_cox_hap2	3415765	3415766	rs9380272	Age-related macular degeneration	C2,CFB	4.31	2E-8
chr6_cox_hap2	3423935	3423936	rs641153	Age-related macular degeneration (GA)	CFB	2.13	2E-9
chr6_cox_hap2	3423935	3423936	rs641153	Age-related macular degeneration (CNV)	CFB	2.22	1E-17
chr6_cox_hap2	3423935	3423936	rs641153	Age-related macular degeneration	CFB	1.85	6E-31
chr6_cox_hap2	3423935	3423936	rs641153	Age-related macular degeneration	CFB,C2	NR	2E-20
chr6_cox_hap2	3426706	3426707	rs541862	Age-related macular degeneration	CFB	1.89	9E-17
chr6_cox_hap2	3440217	3440218	rs429608	Age-related macular degeneration	SKIV2L,BF	1.85	5E-15
chr6_cox_hap2	3440217	3440218	rs429608	Age-related macular degeneration	C2,CFB	2.16	3E-21
chr6_cox_hap2	3490396	3490397	rs2857009	Complement C3 and C4 levels	C4	.08	1E-22
chr6_cox_hap2	3497458	3497459	rs12198173	HIV-1 control	TNXB	NR	3E-6
chr6_cox_hap2	3520732	3520733	rs185819	Height	HLA class III	5.20	3E-8
chr6_cox_hap2	3521423	3521424	rs1150754	Systemic lupus erythematosus	TNXB	2.21	6E-29
chr6_cox_hap2	3541677	3541678	rs3117181	Phospholipid levels (plasma)	TNXB	.02	5E-7
chr6_cox_hap2	3545465	3545466	rs12153855	Age-related macular degeneration	TNXB	1.44	1E-9
chr6_cox_hap2	3547160	3547161	rs2269426	Eosinophil counts	MHC	4.60	3E-6
chr6_cox_hap2	3580642	3580643	rs204999	Serum total protein level	Intergenic	.03	4E-11
chr6_cox_hap2	3580642	3580643	rs204999	Serum total protein level	Intergenic	.03	3E-9
chr6_cox_hap2	3580642	3580643	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_cox_hap2	3580642	3580643	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_cox_hap2	3607227	3607228	rs1061808	Phospholipid levels (plasma)	AGPAT1	.90	8E-10
chr6_cox_hap2	3622123	3622124	rs2070600	Pulmonary function	AGER, PPT2	1.00	3E-14
chr6_cox_hap2	3622123	3622124	rs2070600	Pulmonary function	AGER	.09	3E-15
chr6_cox_hap2	3626258	3626259	rs204993	Asthma	PBX2	1.17	2E-15
chr6_cox_hap2	3628996	3628997	rs176095	Atopic dermatitis	GPSM3	1.40	8E-20
chr6_cox_hap2	3636121	3636122	rs2071278	Complement C3 and C4 levels	HLA-DRA	.13	4E-72
chr6_cox_hap2	3642371	3642372	rs2071277	Age-related macular degeneration	NOTCH4	1.30	2E-11
chr6_cox_hap2	3643681	3643682	rs3131296	Schizophrenia	MHC, NOTCH4	1.19	2E-10
chr6_cox_hap2	3655019	3655020	rs404860	Asthma	NOTCH4	1.21	4E-23
chr6_cox_hap2	3661075	3661076	rs443198	Systemic sclerosis	NOTCH4	1.82	9E-21
chr6_cox_hap2	3689552	3689553	rs3115573	Nephropathy	Intergenic	1.62	1E-9
chr6_cox_hap2	3689698	3689699	rs9296015	Systemic sclerosis	NOTCH4	1.85	1E-8
chr6_cox_hap2	3689698	3689699	rs9296015	Rheumatoid arthritis	HLA locus	NR	2E-38
chr6_cox_hap2	3693997	3693998	rs3130320	Systemic lupus erythematosus	NOTCH4, C6orf10	1.39	3E-6
chr6_cox_hap2	3715370	3715371	rs3130340	Bone mineral density (spine)	MHC, C6orf10	.10	1E-7
chr6_cox_hap2	3753655	3753656	rs6910071	Rheumatoid arthritis	HLA-DRB1	2.88	1E-299
chr6_cox_hap2	3776779	3776780	rs3129900	Lumiracoxib-related liver injury	HLA-DRB1	7.50	7E-25
chr6_cox_hap2	3779709	3779710	rs9469099	Atopic dermatitis	C6orf10	1.61	5E-19
chr6_cox_hap2	3792000	3792001	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_cox_hap2	3792000	3792001	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_cox_hap2	3792000	3792001	rs2395148	Arthritis (juvenile idiopathic)	HLA-DRB1	5.37	2E-10
chr6_cox_hap2	3795817	3795818	rs13196329	Visceral fat	C6orf10	NR	3E-6
chr6_cox_hap2	3806666	3806667	rs3129934	Multiple sclerosis	C6orf10	2.34	7E-16
chr6_cox_hap2	3806666	3806667	rs3129934	Multiple sclerosis	HLA-DRB1	3.30	9E-11
chr6_cox_hap2	3808110	3808111	rs2273017	Graves' disease	MHC	1.53	2E-22
chr6_cox_hap2	3809155	3809156	rs3129943	Asthma	C6orf10	1.17	3E-15
chr6_cox_hap2	3809535	3809536	rs2050190	Activated partial thromboplastin time	C6orf10	.25	7E-7
chr6_cox_hap2	3811812	3811813	rs9268402	Coronary heart disease	C6orf10, BTNL2	1.16	3E-15
chr6_cox_hap2	3815726	3815727	rs7758128	Vitiligo	C6orf10, BTNL2	NR	8E-11
chr6_cox_hap2	3828698	3828699	rs3117099	Bipolar disorder and schizophrenia	MHC, other genes	1.25	3E-6
chr6_cox_hap2	3828941	3828942	rs3117098	Asthma	BTNL2	1.16	5E-12
chr6_cox_hap2	3833635	3833636	rs1980493	Anti-cyclic Citrullinated Peptide Antibody	HLA-DRA, BTNL2	NR	5E-7
chr6_cox_hap2	3834236	3834237	rs2076530	Sarcoidosis	BTNL2	NR	3E-11
chr6_cox_hap2	3834264	3834265	rs9268480	Ulcerative colitis	BTNL2	1.82	3E-6
chr6_cox_hap2	3834375	3834376	rs2076529	Waist-hip ratio	BTNL2	.02	4E-7
chr6_cox_hap2	3838507	3838508	rs3817963	Lung adenocarcinoma	BTNL2	1.18	3E-10
chr6_cox_hap2	3843717	3843718	rs10947262	Knee osteoarthritis	BTNL2, HLA-DQA2, HLA-DQB1	1.31	5E-9
chr6_cox_hap2	3844104	3844105	rs3806156	Vitiligo	BTNL2,HLA-DRA,HLA-DQA1	1.42	7E-19
chr6_cox_hap2	3846877	3846878	rs3763313	HIV-1 control	BTNL2, NOTCH4	NR	2E-6
chr6_cox_hap2	3847194	3847195	rs3763317	Complement C3 and C4 levels	HLA-DRB	.12	9E-66
chr6_cox_hap2	3849892	3849893	rs9268516	Asthma	BTNL2, HLA-DRA	1.15	1E-8
chr6_cox_hap2	3853518	3853519	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_cox_hap2	3853518	3853519	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_cox_hap2	3855131	3855132	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_cox_hap2	3855131	3855132	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_cox_hap2	3858220	3858221	rs2395163	Parkinson's disease	LOC642072	1.24	3E-11
chr6_cox_hap2	3860059	3860060	rs3135363	Hepatitis B vaccine response	HLA-DR	1.53	7E-22
chr6_cox_hap2	3860059	3860060	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_cox_hap2	3860059	3860060	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_cox_hap2	3871653	3871654	rs3135338	Multiple sclerosis	HLA	3.43	2E-25
chr6_cox_hap2	3878979	3878980	rs9268645	Type 1 diabetes	MHC	NR	1E-100
chr6_cox_hap2	3879981	3879982	rs3129882	Systemic sclerosis	HLA-DRA	2.17	2E-27
chr6_cox_hap2	3879981	3879982	rs3129882	Parkinson's disease	HLA-DRA	1.26	2E-10
chr6_cox_hap2	3882097	3882098	rs7192	Non-obstructive azoospermia	HLA-DRA	1.29	3E-6
chr6_cox_hap2	3882852	3882853	rs3177928	LDL cholesterol	HLA	1.83	2E-15
chr6_cox_hap2	3882852	3882853	rs3177928	Cholesterol, total	HLA	2.31	4E-19
chr6_cox_hap2	3883468	3883469	rs3135388	Multiple sclerosis	HLA-DRB1	2.75	4E-225
chr6_cox_hap2	3883468	3883469	rs3135388	Multiple sclerosis	HLA-DRA	1.99	9E-81
chr6_cox_hap2	3883876	3883877	rs2227139	Hematological parameters	Intergenic	.02	1E-7
chr6_cox_hap2	3883962	3883963	rs3129889	Multiple sclerosis	HLA-DRB1	2.97	1E-206
chr6_cox_hap2	3884695	3884696	rs3129890	Asthma	HLA-DRA	1.15	5E-13
chr6_cox_hap2	3898693	3898694	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_cox_hap2	3898693	3898694	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_cox_hap2	3898693	3898694	rs6903608	Hodgkin's lymphoma	HLA-DRA	1.70	3E-50
chr6_cox_hap2	3900052	3900053	rs9268853	Rheumatoid arthritis	HLA-DRA	2.40	5E-109
chr6_cox_hap2	3900052	3900053	rs9268853	Ulcerative colitis	HLA-DRB5, HLA-DQA1, HLA-DRB1, HLA-DRA, BTNL2	1.40	1E-55
chr6_cox_hap2	3901550	3901551	rs9268877	Ulcerative colitis	MHC	NR	4E-23
chr6_cox_hap2	3901550	3901551	rs9268877	Ulcerative colitis	HLA-DRA, BTNL2	1.45	6E-18
chr6_cox_hap2	3902483	3902484	rs9268905	Cystic fibrosis severity	HLA-DRA	NR	1E-7
chr6_cox_hap2	3903256	3903257	rs9268923	Ulcerative colitis	HLA-DRA	1.45	4E-15
chr6_cox_hap2	3903588	3903589	rs2395185	Lung cancer	HLA class II	1.17	1E-8
chr6_cox_hap2	3903588	3903589	rs2395185	Hodgkin's lymphoma	HLA-DRA	1.82	4E-31
chr6_cox_hap2	3903588	3903589	rs2395185	Ulcerative colitis	Intergenic	1.92	5E-22
chr6_cox_hap2	3903588	3903589	rs2395185	Ulcerative colitis	BTNL2, HLA-DRA, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1	1.52	1E-16
chr6_cox_hap2	4014452	4014453	rs28366298	Lung cancer	HLA class II	1.17	1E-8
chr6_cox_hap2	4020675	4020676	rs477515	Inflammatory bowel disease	HLA-DQA1	1.38	1E-8
chr6_cox_hap2	4022933	4022934	rs2858870	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_cox_hap2	4022933	4022934	rs2858870	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_cox_hap2	4024853	4024854	rs615672	Rheumatoid arthritis	HLA-DRB1	NR	8E-27
chr6_cox_hap2	4027185	4027186	rs9271100	Systemic lupus erythematosus	HLA-DRB1	1.90	1E-12
chr6_cox_hap2	4028085	4028086	rs660895	IgA nephropathy	HLA-DRB1	1.34	4E-20
chr6_cox_hap2	4028085	4028086	rs660895	Rheumatoid arthritis	HLA-DRB1	3.62	1E-108
chr6_cox_hap2	4028786	4028787	rs674313	Chronic lymphocytic leukemia	HLA-DRB5	1.69	7E-9
chr6_cox_hap2	4037577	4037578	rs9271366	Inflammatory bowel disease	MHC	1.79	8E-11
chr6_cox_hap2	4037577	4037578	rs9271366	Inflammatory bowel disease	MHC	2.41	3E-31
chr6_cox_hap2	4037577	4037578	rs9271366	Inflammatory bowel disease	MHC	4.44	2E-70
chr6_cox_hap2	4037577	4037578	rs9271366	Immunoglobulin A	HLA-DRB1	7.69	3E-33
chr6_cox_hap2	4037577	4037578	rs9271366	Multiple sclerosis	DQA1	2.62	4E-17
chr6_cox_hap2	4037577	4037578	rs9271366	Multiple sclerosis	HLA-DRB1	2.78	7E-184
chr6_cox_hap2	4041660	4041661	rs3129763	Systemic sclerosis	HLA-DQA1, HLA-DRB1	1.65	1E-11
chr6_cox_hap2	4050374	4050375	rs9272105	Hepatocellular carcinoma	HLA-DQA1, HLA-DRB1	1.28	5E-22
chr6_cox_hap2	4050374	4050375	rs9272105	Response to interferon beta therapy	HLA-DQA1, HLA-DRB1	.26	4E-10
chr6_cox_hap2	4052650	4052651	rs9272219	Rheumatoid arthritis	HLA-DQA1	1.92	1E-45
chr6_cox_hap2	4052650	4052651	rs9272219	Schizophrenia	HLA-DQA1	1.14	7E-8
chr6_cox_hap2	4053380	4053381	rs2040406	Multiple sclerosis	HLA-DRB,HLA-DQB1	2.05	1E-20
chr6_cox_hap2	4054758	4054759	rs9272346	Type 1 diabetes	HLA	NR	6E-129
chr6_cox_hap2	4054758	4054759	rs9272346	Type 1 diabetes	MHC	5.49	5E-134
chr6_cox_hap2	4056276	4056277	rs2187668	Systemic lupus erythematosus	HLA-DR3	2.23	6E-28
chr6_cox_hap2	4056276	4056277	rs2187668	Nephropathy (idiopathic membranous)	HLA-DQA1	4.32	8E-93
chr6_cox_hap2	4056276	4056277	rs2187668	Immunoglobulin A	HLA-DRB1	2.53	2E-33
chr6_cox_hap2	4056276	4056277	rs2187668	Celiac disease	HLA-DQA1, HLA-DQB1	6.23	1E-50
chr6_cox_hap2	4056276	4056277	rs2187668	Systemic lupus erythematosus	HLA-DQA1	NR	3E-21
chr6_cox_hap2	4056276	4056277	rs2187668	Celiac disease	HLA-DQA1	7.04	1E-19
chr6_cox_hap2	4057221	4057222	rs9272535	Chronic lymphocytic leukemia	HLA-DQA1	1.61	9E-8
chr6_cox_hap2	4071148	4071149	rs9273349	Asthma	HLA-DQ	1.18	7E-14
chr6_cox_hap2	4078472	4078473	rs9274407	Drug-induced liver injury (amoxicillin-clavulanate)	HLA-DRB1-DQB1	3.10	5E-14
chr6_cox_hap2	4100870	4100871	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_cox_hap2	4100870	4100871	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_cox_hap2	4103230	4103231	rs7774434	Primary biliary cirrhosis	MHC	1.60	4E-34
chr6_cox_hap2	4103230	4103231	rs7774434	Primary biliary cirrhosis	HLA-DQB1	1.75	3E-26
chr6_cox_hap2	4103731	4103732	rs7775228	IgE grass sensitization	HLA region	1.33	2E-9
chr6_cox_hap2	4103731	4103732	rs7775228	Asthma	HLA-DQB1	1.17	5E-15
chr6_cox_hap2	4103962	4103963	rs9469220	Crohn's disease	NR	1.14	2E-6
chr6_cox_hap2	4109285	4109286	rs3129720	Hypothyroidism	HLA-DRB9, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DQA2	1.16	5E-7
chr6_cox_hap2	4109505	4109506	rs6457617	Graves' disease	HLA, DRB1, DQA1, DQB1	1.40	7E-33
chr6_cox_hap2	4109505	4109506	rs6457617	Systemic sclerosis	HLA, DQB1	1.61	2E-37
chr6_cox_hap2	4109505	4109506	rs6457617	Systemic sclerosis	HLA-DQB1	1.37	4E-17
chr6_cox_hap2	4109505	4109506	rs6457617	Rheumatoid arthritis	HLA-DQA1, HLA-DQA2	NR	1E-9
chr6_cox_hap2	4109505	4109506	rs6457617	Rheumatoid arthritis	MHC	2.36	5E-75
chr6_cox_hap2	4109653	4109654	rs6457620	Height	HLA locus	.03	2E-16
chr6_cox_hap2	4109653	4109654	rs6457620	Rheumatoid arthritis	HLA-DRB1	2.55	4E-186
chr6_cox_hap2	4110112	4110113	rs2647012	Follicular lymphoma	HLA-DQB1	1.56	2E-21
chr6_cox_hap2	4110112	4110113	rs2647012	Systemic lupus erythematosus	HLA-DQA1, HLA-DQA2	1.38	8E-6
chr6_cox_hap2	4110614	4110615	rs9357152	HPV seropositivity	HLA-DQB1	NR	1E-14
chr6_cox_hap2	4110614	4110615	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_cox_hap2	4110614	4110615	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_cox_hap2	4111074	4111075	rs10484561	Follicular lymphoma	HLA-DQB1	1.95	1E-29
chr6_cox_hap2	4113556	4113557	rs2647044	Pulmonary function	HLA-DQB1	.04	6E-6
chr6_cox_hap2	4113556	4113557	rs2647044	Type 1 diabetes	HLA-DRB1	8.30	1E-16
chr6_cox_hap2	4114802	4114803	rs9275390	Systemic sclerosis	HLA-DQB1	1.61	1E-7
chr6_cox_hap2	4114802	4114803	rs9275390	Systemic sclerosis	HLA-DQB1	2.38	3E-54
chr6_cox_hap2	4115019	4115020	rs11752643	Coronary heart disease	HLA, DRB-DQB	1.26	5E-7
chr6_cox_hap2	4115895	4115896	rs2856718	Hepatitis B	HLA-DQB1	1.56	4E-37
chr6_cox_hap2	4116743	4116744	rs13192471	Rheumatoid arthritis	HLA-DRB1	1.97	2E-58
chr6_cox_hap2	4116888	4116889	rs1794275	IgA nephropathy	HLA-DQA/B	1.30	3E-13
chr6_cox_hap2	4124613	4124614	rs9275572	Hepatocellular carcinoma	HLA-DQ, HLA-DR	1.30	6E-9
chr6_cox_hap2	4124613	4124614	rs9275572	Alopecia areata	HLA-DQA2	2.21	1E-35
chr6_cox_hap2	4126542	4126543	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6_cox_hap2	4126542	4126543	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6_cox_hap2	4126891	4126892	rs2858331	IgE levels	HLA-DQA2	.04	1E-8
chr6_cox_hap2	4127245	4127246	rs9275596	Nephropathy	HLA-DRB1, HLA-DQA1, HLA-DQB1	1.59	2E-26
chr6_cox_hap2	4127290	4127291	rs3104402	Immune response to anthrax vaccine	HLA-DRB1,HLA-DQA1	.17	6E-6
chr6_cox_hap2	4131158	4131159	rs3916765	Type 2 diabetes	HLA-DQA2	1.21	1E-6
chr6_cox_hap2	4133556	4133557	rs9275698	Asthma	HLA-DQA2	1.18	5E-12
chr6_cox_hap2	4145666	4145667	rs2858884	Narcolepsy	HLA-DQA2	1.79	3E-8
chr6_cox_hap2	4171095	4171096	rs2301271	Systemic lupus erythematosus	HLA-DQA2	1.47	2E-12
chr6_cox_hap2	4175914	4175915	rs7453920	Hepatitis B	HAL-DQB2	1.81	6E-28
chr6_cox_hap2	4175988	4175989	rs2051549	Systemic lupus erythematosus	HLA-DQA2	NR	3E-22
chr6_cox_hap2	4182600	4182601	rs9276606	Complement C3 and C4 levels	HLA-DQB	.09	3E-22
chr6_cox_hap2	4209120	4209121	rs2857151	Kawasaki disease	HLA-DQB2, HLA-DOB	1.47	5E-11
chr6_cox_hap2	4248597	4248598	rs241428	Complement C3 and C4 levels	HLA-DQB	.23	9E-83
chr6_cox_hap2	4254375	4254376	rs9357155	Nephropathy	TAP2, TAP1, PSMB8, PSMB9	1.41	2E-12
chr6_cox_hap2	4297174	4297175	rs2187689	Disc degeneration (lumbar)	PSMB9	.23	3E-8
chr6_cox_hap2	4299220	4299221	rs10046257	Disc degeneration (lumbar)	Intergenic	.19	3E-7
chr6_cox_hap2	4300240	4300241	rs6457690	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_cox_hap2	4300904	4300905	rs1029296	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_cox_hap2	4301005	4301006	rs1029295	Disc degeneration (lumbar)	Intergenic	.19	5E-7
chr6_cox_hap2	4301457	4301458	rs6936004	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_cox_hap2	4301942	4301943	rs10214886	Disc degeneration (lumbar)	Intergenic	.19	2E-7
chr6_cox_hap2	4304235	4304236	rs7744666	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_cox_hap2	4304271	4304272	rs11969002	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_cox_hap2	4305275	4305276	rs9469300	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_cox_hap2	4307130	4307131	rs3749982	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_cox_hap2	4405886	4405887	rs9500927	Asthma	HLA-DOA	1.13	4E-9
chr6_cox_hap2	4419510	4419511	rs399604	Platelet counts	HLA-DOA	2.35	1E-10
chr6_cox_hap2	4477201	4477202	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.82	4E-45
chr6_cox_hap2	4477201	4477202	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.67	1E-9
chr6_cox_hap2	4477201	4477202	rs3077	Hepatitis B	HLA-DPA1	1.87	2E-61
chr6_cox_hap2	4487059	4487060	rs987870	Asthma	HLA, DPB1	1.40	2E-10
chr6_cox_hap2	4487059	4487060	rs987870	Systemic sclerosis	HLA-DPA1, HLA-DPB1	2.09	2E-20
chr6_cox_hap2	4498975	4498976	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.64	2E-21
chr6_cox_hap2	4498975	4498976	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.52	2E-17
chr6_cox_hap2	4498975	4498976	rs9277535	Hepatitis B vaccine response	HLA-DPB1	1.39	3E-12
chr6_cox_hap2	4498975	4498976	rs9277535	Hepatitis B	HLA-DPB1	1.77	3E-54
chr6_cox_hap2	4498975	4498976	rs9277535	Hepatitis B	HLA-DPB1	1.75	6E-39
chr6_cox_hap2	4504219	4504220	rs2281388	Graves' disease	HLA, DPB1	1.64	2E-65
chr6_cox_hap2	4514039	4514040	rs3117242	Antineutrophil cytoplasmic antibody-associated vasculitis	HLA-DP, COL11A2	3.67	1E-71
chr6_cox_hap2	4530357	4530358	rs3117035	RR interval (heart rate)	Intergenic	.14	1E-6
chr6_cox_hap2	4530556	4530557	rs1883414	Nephropathy	HLA-DPA1, HLA-DPB1, HLA-DPB2	1.28	5E-9
chr6_cox_hap2	4587783	4587784	rs2254287	LDL cholesterol	B3GALT4	1.91	5E-8
chr6_dbb_hap3	79526	79527	rs4324798	Lung adenocarcinoma	TRNAA-UGC	1.16	2E-8
chr6_dbb_hap3	387640	387641	rs3129109	Height	OR2J3	.03	2E-17
chr6_dbb_hap3	658655	658656	rs3094548	Pulmonary function	OR12D2	.03	1E-7
chr6_dbb_hap3	659784	659785	rs9257809	Barrett's esophagus	MHC, OR2D12, OR2D13	1.21	4E-9
chr6_dbb_hap3	737744	737745	rs4713226	Immune reponse to smallpox (secreted IFN-alpha)	OR2H1	NR	2E-8
chr6_dbb_hap3	914776	914777	rs29232	Nasopharyngeal carcinoma	GABBR1	1.67	9E-17
chr6_dbb_hap3	973605	973606	rs3129055	Nasopharyngeal carcinoma	HLA-F	1.51	7E-11
chr6_dbb_hap3	1003398	1003399	rs2523395	Prostate cancer (gene x gene interaction)	LOC285830	1.24	2E-6
chr6_dbb_hap3	1006539	1006540	rs2523393	Multiple sclerosis	HLA-B	1.28	1E-17
chr6_dbb_hap3	1024026	1024027	rs9258260	Crohn's disease	HLA-F, MOG, HLA-G, GABBR1, HLA-H, UBD, HLA-A	1.45	2E-10
chr6_dbb_hap3	1089791	1089792	rs1610677	Rheumatoid arthritis	HLA-G	1.32	4E-15
chr6_dbb_hap3	1129258	1129259	rs2523822	Drug-induced liver injury (amoxicillin-clavulanate)	HLA-A	2.30	2E-10
chr6_dbb_hap3	1144620	1144621	rs2523809	IgE levels	HLA-G	.06	4E-8
chr6_dbb_hap3	1200047	1200048	rs2860580	Nasopharyngeal carcinoma	HLA-A	1.72	5E-67
chr6_dbb_hap3	1206673	1206674	rs1061235	Adverse response to carbamapezine	HLA-A*3101	9.12	1E-7
chr6_dbb_hap3	1211484	1211485	rs2517713	Nasopharyngeal carcinoma	HLA-A	1.88	4E-20
chr6_dbb_hap3	1213718	1213719	rs9260489	Multiple sclerosis	HLA-B	1.21	1E-11
chr6_dbb_hap3	1217206	1217207	rs2571391	IgE levels	HLA-A	.06	1E-15
chr6_dbb_hap3	1228594	1228595	rs3893464	Graves' disease	MHC	1.53	2E-20
chr6_dbb_hap3	1235276	1235277	rs2523946	IgA nephropathy	HLA-A	1.21	2E-11
chr6_dbb_hap3	1236400	1236401	rs6904029	Vitiligo	HLA-A,HCG9	1.49	1E-21
chr6_dbb_hap3	1263934	1263935	rs7758512	HIV-1 control	ZNRD1, RNF39, HLA-A	NR	2E-8
chr6_dbb_hap3	1267267	1267268	rs4313034	Graves' disease	MHC	1.67	2E-15
chr6_dbb_hap3	1310780	1310781	rs6917603	Lipid metabolism phenotypes	PPP1R11	.24	3E-29
chr6_dbb_hap3	1319232	1319233	rs259919	HIV-1 control	C6orf12, ZNRD1	NR	3E-7
chr6_dbb_hap3	1326245	1326246	rs8321	AIDS progression	ZNRD1, RNF39	NR	5E-7
chr6_dbb_hap3	1374086	1374087	rs34704616	Cognitive performance	XXbac-BPG250I8.13	NR	6E-6
chr6_dbb_hap3	1387084	1387085	rs10947055	Cardiac hypertrophy	TRIM38	NR	2E-7
chr6_dbb_hap3	1413614	1413615	rs9468692	HIV-1 control	TRIM10	NR	1E-6
chr6_dbb_hap3	1458962	1458963	rs2523722	Schizophrenia	MHC, TRIM26	1.25	1E-16
chr6_dbb_hap3	1467820	1467821	rs2021722	Schizophrenia	TRIM26	1.15	2E-12
chr6_dbb_hap3	1831240	1831241	rs3132613	Graves' disease	MHC	1.43	1E-13
chr6_dbb_hap3	2029928	2029929	rs12526186	Response to antipsychotic treatment	Intergenic	9.00	3E-6
chr6_dbb_hap3	2076115	2076116	rs886424	Bipolar disorder and schizophrenia	MHC, other genes	1.37	9E-7
chr6_dbb_hap3	2089241	2089242	rs7772131	Response to angiotensin II receptor blocker therapy	C6orf214	6.73	3E-6
chr6_dbb_hap3	2142355	2142356	rs7756521	HIV-1 control	DDR1, VARS2, DPCR1	NR	1E-6
chr6_dbb_hap3	2170263	2170264	rs1052693	Complement C3 and C4 levels	HLA-A	.10	3E-48
chr6_dbb_hap3	2297069	2297070	rs4248154	Graves' disease	MHC	1.38	1E-13
chr6_dbb_hap3	2301308	2301309	rs2844665	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	C6orf205	1.54	3E-7
chr6_dbb_hap3	2315588	2315589	rs2517532	Hypothyroidism	LOC729792, HCG22, C6orf15, HLA-C, HLA-B, DHFRP2, HCP5	1.16	1E-8
chr6_dbb_hap3	2321987	2321988	rs9262632	HIV-1 control	Intergenic	3.10	1E-8
chr6_dbb_hap3	2355358	2355359	rs4947296	Behcet's disease	HCG22	2.57	1E-11
chr6_dbb_hap3	2355358	2355359	rs4947296	Graves' disease	MUC21, C6orf15	1.77	4E-51
chr6_dbb_hap3	2355520	2355521	rs3130544	Myasthenia gravis	NR	5.64	2E-90
chr6_dbb_hap3	2371200	2371201	rs6457327	Follicular lymphoma	C6orf15	1.47	7E-6
chr6_dbb_hap3	2371200	2371201	rs6457327	Follicular lymphoma	STG, PSORS1	1.69	5E-11
chr6_dbb_hap3	2390756	2390757	rs3815087	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	PSORS1C1	1.53	3E-7
chr6_dbb_hap3	2390756	2390757	rs3815087	HIV-1 control	CDSN	NR	8E-8
chr6_dbb_hap3	2394466	2394467	rs3130559	Chronic obstructive pulmonary disease-related biomarkers	PSORS1C1	NR	8E-9
chr6_dbb_hap3	2396738	2396739	rs4959053	Behcet's disease	PSORS1C1	4.38	2E-20
chr6_dbb_hap3	2403405	2403406	rs3130573	Systemic sclerosis	PSORS1C1	1.25	6E-10
chr6_dbb_hap3	2404324	2404325	rs1265093	Chronic obstructive pulmonary disease-related biomarkers	PSORS1C1, CCHCR1	NR	6E-9
chr6_dbb_hap3	2408485	2408486	rs9263739	Ulcerative colitis	HLA	2.73	4E-67
chr6_dbb_hap3	2415134	2415135	rs1265112	Nevirapine-induced rash	CCHCR1	4.36	1E-8
chr6_dbb_hap3	2415626	2415627	rs130067	Prostate cancer	CCHCR1	1.05	3E-8
chr6_dbb_hap3	2433590	2433591	rs3130501	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	POU5F1	1.74	2E-8
chr6_dbb_hap3	2436592	2436593	rs879882	Height	MICA	NR	2E-7
chr6_dbb_hap3	2440722	2440723	rs3131018	HIV-1 control	PSORS1C3	2.10	4E-16
chr6_dbb_hap3	2452932	2452933	rs1265181	Psoriasis	MHC	22.62	NS
chr6_dbb_hap3	2465168	2465169	rs6903896	Common traits (Other)	NR	NR	6E-7
chr6_dbb_hap3	2481329	2481330	rs3869109	Coronary heart disease	HCG27, HLA-C	1.14	1E-9
chr6_dbb_hap3	2517269	2517270	rs3095254	White blood cell types	MHC	.07	6E-11
chr6_dbb_hap3	2536023	2536024	rs2074488	Chronic obstructive pulmonary disease-related biomarkers	HLA-C	NR	2E-10
chr6_dbb_hap3	2536700	2536701	rs13191343	Psoriatic arthritis	HLA-C	2.37	2E-72
chr6_dbb_hap3	2547943	2547944	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.31	6E-21
chr6_dbb_hap3	2547943	2547944	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.37	2E-28
chr6_dbb_hap3	2548472	2548473	rs12191877	Psoriasis	HLA-C	2.79	4E-32
chr6_dbb_hap3	2548472	2548473	rs12191877	Psoriasis	HLA-C	2.64	1E-100
chr6_dbb_hap3	2554384	2554385	rs9468925	Vitiligo	HLA	1.35	2E-33
chr6_dbb_hap3	2559312	2559313	rs2894207	Nasopharyngeal carcinoma	HLA-B,HLA-C	1.64	3E-33
chr6_dbb_hap3	2561039	2561040	rs2247056	Triglycerides	HLA	2.99	2E-15
chr6_dbb_hap3	2567263	2567264	rs9461688	Protein quantitative trait loci	HLA-C	NR	4E-6
chr6_dbb_hap3	2567868	2567869	rs9368677	Atopic dermatitis	HLA-C	1.36	1E-17
chr6_dbb_hap3	2569927	2569928	rs9264942	HIV-1 control	HLA-C	2.90	3E-35
chr6_dbb_hap3	2569927	2569928	rs9264942	HIV-1 control	HLA-C	5.30	6E-32
chr6_dbb_hap3	2569927	2569928	rs9264942	HIV-1 control	HLA-C	NR	6E-12
chr6_dbb_hap3	2570102	2570103	rs10484554	Psoriasis	HLA-C	4.66	4E-214
chr6_dbb_hap3	2570102	2570103	rs10484554	AIDS progression	HLA-C	NR	6E-8
chr6_dbb_hap3	2570102	2570103	rs10484554	Psoriasis	HLA-C	2.80	2E-39
chr6_dbb_hap3	2726002	2726003	rs3828890	Renal function-related traits (sCR)	MHC	.01	3E-9
chr6_dbb_hap3	2726002	2726003	rs3828890	Renal function-related traits (eGRFcrea)	MHC	.01	1E-9
chr6_dbb_hap3	2732129	2732130	rs2248462	Hodgkin's lymphoma	MICB	1.64	7E-16
chr6_dbb_hap3	2734309	2734310	rs3099844	Metabolic syndrome	HCG26, MICB	.15	2E-8
chr6_dbb_hap3	2734309	2734310	rs3099844	Neonatal lupus	TNF,NFKBIL1,LTA,LTB,AIF1	3.34	5E-10
chr6_dbb_hap3	2758315	2758316	rs2855812	Pulmonary function	MICB	.03	2E-7
chr6_dbb_hap3	2761081	2761082	rs3132468	Dengue shock syndrome	MICB	1.34	4E-11
chr6_dbb_hap3	2766892	2766893	rs2516399	White blood cell types	MHC	.11	2E-12
chr6_dbb_hap3	2785182	2785183	rs3853601	Atopic dermatitis	BAT1	1.13	2E-6
chr6_dbb_hap3	2791059	2791060	rs2734583	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	BAT1, HCP5, MICC, PPIAP9, PSORS1C1, POLR2LP, CCHCR1, TCF19, POU5F1, HLA-C, HCP5, PSORS1C3, HLA-B*5801	66.80	2E-8
chr6_dbb_hap3	2827848	2827849	rs1799964	Crohn's disease	LTA,HLA-DQA2,TNF,LST1,LTB	1.19	4E-11
chr6_dbb_hap3	2843335	2843336	rs11575839	Complement C3 and C4 levels	HLA-C	.23	1E-54
chr6_dbb_hap3	2854024	2854025	rs2857595	Pulmonary function	NCR3	.04	2E-10
chr6_dbb_hap3	2858508	2858509	rs2844479	Weight	AIF1, NCR3	3.58	2E-8
chr6_dbb_hap3	2860842	2860843	rs9348876	Crohn's disease	AIF1	1.41	3E-6
chr6_dbb_hap3	2888538	2888539	rs1046089	Menopause (age at onset)	PRRC2A	.21	2E-16
chr6_dbb_hap3	2901940	2901941	rs805303	Systolic blood pressure	BAT2, BAT5	.38	2E-11
chr6_dbb_hap3	2901940	2901941	rs805303	Hypertension	BAT2, BAT5	.05	1E-10
chr6_dbb_hap3	2901940	2901941	rs805303	Diastolic blood pressure	BAT2, BAT5	.23	3E-11
chr6_dbb_hap3	2906098	2906099	rs3117582	Lung adenocarcinoma	BAT3, APOM	1.22	5E-12
chr6_dbb_hap3	2906098	2906099	rs3117582	Lung cancer	BAT3	1.24	4E-10
chr6_dbb_hap3	2906098	2906099	rs3117582	Lung cancer	BAT3,MSH5	1.24	5E-10
chr6_dbb_hap3	2908184	2908185	rs805297	Rheumatoid arthritis	APOM	1.56	3E-10
chr6_dbb_hap3	3006610	3006611	rs3131379	Systemic lupus erythematosus	HLA region	2.36	2E-52
chr6_dbb_hap3	3064115	3064116	rs2075799	Complement C3 and C4 levels	C4	.17	6E-97
chr6_dbb_hap3	3088127	3088128	rs9368699	HIV-1 control	SNORD52	NR	5E-8
chr6_dbb_hap3	3122647	3122648	rs11966200	Vitiligo	HLA-C,HLA-B	1.90	1E-48
chr6_dbb_hap3	3124294	3124295	rs494620	Menopause (age at onset)	NR	.30	5E-7
chr6_dbb_hap3	3129505	3129506	rs2736428	Telomere length	SLC44A4	.05	3E-6
chr6_dbb_hap3	3152834	3152835	rs9267663	Economic and political preferences (environmentalism)	EHMT2	.29	6E-6
chr6_dbb_hap3	3156437	3156438	rs9267665	Hepatitis B vaccine response	HLA	2.05	1E-17
chr6_dbb_hap3	3169264	3169265	rs9267673	Hepatocellular carcinoma	C2	1.97	2E-6
chr6_dbb_hap3	3189390	3189391	rs9332739	Age-related macular degeneration (GA)	C2	2.63	1E-6
chr6_dbb_hap3	3189390	3189391	rs9332739	Age-related macular degeneration (CNV)	C2	2.08	2E-8
chr6_dbb_hap3	3189390	3189391	rs9332739	Age-related macular degeneration	C2	2.17	2E-23
chr6_dbb_hap3	3191597	3191598	rs9380272	Age-related macular degeneration	C2,CFB	4.31	2E-8
chr6_dbb_hap3	3199767	3199768	rs641153	Age-related macular degeneration (GA)	CFB	2.13	2E-9
chr6_dbb_hap3	3199767	3199768	rs641153	Age-related macular degeneration (CNV)	CFB	2.22	1E-17
chr6_dbb_hap3	3199767	3199768	rs641153	Age-related macular degeneration	CFB	1.85	6E-31
chr6_dbb_hap3	3199767	3199768	rs641153	Age-related macular degeneration	CFB,C2	NR	2E-20
chr6_dbb_hap3	3202538	3202539	rs541862	Age-related macular degeneration	CFB	1.89	9E-17
chr6_dbb_hap3	3216044	3216045	rs429608	Age-related macular degeneration	SKIV2L,BF	1.85	5E-15
chr6_dbb_hap3	3216044	3216045	rs429608	Age-related macular degeneration	C2,CFB	2.16	3E-21
chr6_dbb_hap3	3298962	3298963	rs2857009	Complement C3 and C4 levels	C4	.08	1E-22
chr6_dbb_hap3	3306023	3306024	rs12198173	HIV-1 control	TNXB	NR	3E-6
chr6_dbb_hap3	3329280	3329281	rs185819	Height	HLA class III	5.20	3E-8
chr6_dbb_hap3	3329971	3329972	rs1150754	Systemic lupus erythematosus	TNXB	2.21	6E-29
chr6_dbb_hap3	3350191	3350192	rs3117181	Phospholipid levels (plasma)	TNXB	.02	5E-7
chr6_dbb_hap3	3353977	3353978	rs12153855	Age-related macular degeneration	TNXB	1.44	1E-9
chr6_dbb_hap3	3355672	3355673	rs2269426	Eosinophil counts	MHC	4.60	3E-6
chr6_dbb_hap3	3389147	3389148	rs204999	Serum total protein level	Intergenic	.03	4E-11
chr6_dbb_hap3	3389147	3389148	rs204999	Serum total protein level	Intergenic	.03	3E-9
chr6_dbb_hap3	3389147	3389148	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_dbb_hap3	3389147	3389148	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_dbb_hap3	3498039	3498040	rs3115573	Nephropathy	Intergenic	1.62	1E-9
chr6_dbb_hap3	3498185	3498186	rs9296015	Systemic sclerosis	NOTCH4	1.85	1E-8
chr6_dbb_hap3	3498185	3498186	rs9296015	Rheumatoid arthritis	HLA locus	NR	2E-38
chr6_dbb_hap3	3502485	3502486	rs3130320	Systemic lupus erythematosus	NOTCH4, C6orf10	1.39	3E-6
chr6_dbb_hap3	3523854	3523855	rs3130340	Bone mineral density (spine)	MHC, C6orf10	.10	1E-7
chr6_dbb_hap3	3562123	3562124	rs6910071	Rheumatoid arthritis	HLA-DRB1	2.88	1E-299
chr6_dbb_hap3	3585250	3585251	rs3129900	Lumiracoxib-related liver injury	HLA-DRB1	7.50	7E-25
chr6_dbb_hap3	3588180	3588181	rs9469099	Atopic dermatitis	C6orf10	1.61	5E-19
chr6_dbb_hap3	3600470	3600471	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_dbb_hap3	3600470	3600471	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_dbb_hap3	3600470	3600471	rs2395148	Arthritis (juvenile idiopathic)	HLA-DRB1	5.37	2E-10
chr6_dbb_hap3	3604288	3604289	rs13196329	Visceral fat	C6orf10	NR	3E-6
chr6_dbb_hap3	3615125	3615126	rs3129934	Multiple sclerosis	C6orf10	2.34	7E-16
chr6_dbb_hap3	3615125	3615126	rs3129934	Multiple sclerosis	HLA-DRB1	3.30	9E-11
chr6_dbb_hap3	3616570	3616571	rs2273017	Graves' disease	MHC	1.53	2E-22
chr6_dbb_hap3	3617617	3617618	rs3129943	Asthma	C6orf10	1.17	3E-15
chr6_dbb_hap3	3617997	3617998	rs2050190	Activated partial thromboplastin time	C6orf10	.25	7E-7
chr6_dbb_hap3	3620274	3620275	rs9268402	Coronary heart disease	C6orf10, BTNL2	1.16	3E-15
chr6_dbb_hap3	3624198	3624199	rs7758128	Vitiligo	C6orf10, BTNL2	NR	8E-11
chr6_dbb_hap3	3637168	3637169	rs3117099	Bipolar disorder and schizophrenia	MHC, other genes	1.25	3E-6
chr6_dbb_hap3	3637411	3637412	rs3117098	Asthma	BTNL2	1.16	5E-12
chr6_dbb_hap3	3642113	3642114	rs1980493	Anti-cyclic Citrullinated Peptide Antibody	HLA-DRA, BTNL2	NR	5E-7
chr6_dbb_hap3	3642714	3642715	rs2076530	Sarcoidosis	BTNL2	NR	3E-11
chr6_dbb_hap3	3642742	3642743	rs9268480	Ulcerative colitis	BTNL2	1.82	3E-6
chr6_dbb_hap3	3642853	3642854	rs2076529	Waist-hip ratio	BTNL2	.02	4E-7
chr6_dbb_hap3	3646985	3646986	rs3817963	Lung adenocarcinoma	BTNL2	1.18	3E-10
chr6_dbb_hap3	3652196	3652197	rs10947262	Knee osteoarthritis	BTNL2, HLA-DQA2, HLA-DQB1	1.31	5E-9
chr6_dbb_hap3	3652583	3652584	rs3806156	Vitiligo	BTNL2,HLA-DRA,HLA-DQA1	1.42	7E-19
chr6_dbb_hap3	3655356	3655357	rs3763313	HIV-1 control	BTNL2, NOTCH4	NR	2E-6
chr6_dbb_hap3	3655673	3655674	rs3763317	Complement C3 and C4 levels	HLA-DRB	.12	9E-66
chr6_dbb_hap3	3657585	3657586	rs9268516	Asthma	BTNL2, HLA-DRA	1.15	1E-8
chr6_dbb_hap3	3661216	3661217	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_dbb_hap3	3661216	3661217	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_dbb_hap3	3662829	3662830	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_dbb_hap3	3662829	3662830	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_dbb_hap3	3665917	3665918	rs2395163	Parkinson's disease	LOC642072	1.24	3E-11
chr6_dbb_hap3	3667756	3667757	rs3135363	Hepatitis B vaccine response	HLA-DR	1.53	7E-22
chr6_dbb_hap3	3667756	3667757	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_dbb_hap3	3667756	3667757	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_dbb_hap3	3679342	3679343	rs3135338	Multiple sclerosis	HLA	3.43	2E-25
chr6_dbb_hap3	3686637	3686638	rs9268645	Type 1 diabetes	MHC	NR	1E-100
chr6_dbb_hap3	3687640	3687641	rs3129882	Systemic sclerosis	HLA-DRA	2.17	2E-27
chr6_dbb_hap3	3687640	3687641	rs3129882	Parkinson's disease	HLA-DRA	1.26	2E-10
chr6_dbb_hap3	3689756	3689757	rs7192	Non-obstructive azoospermia	HLA-DRA	1.29	3E-6
chr6_dbb_hap3	3690553	3690554	rs3177928	LDL cholesterol	HLA	1.83	2E-15
chr6_dbb_hap3	3690553	3690554	rs3177928	Cholesterol, total	HLA	2.31	4E-19
chr6_dbb_hap3	3691169	3691170	rs3135388	Multiple sclerosis	HLA-DRB1	2.75	4E-225
chr6_dbb_hap3	3691169	3691170	rs3135388	Multiple sclerosis	HLA-DRA	1.99	9E-81
chr6_dbb_hap3	3691577	3691578	rs2227139	Hematological parameters	Intergenic	.02	1E-7
chr6_dbb_hap3	3691663	3691664	rs3129889	Multiple sclerosis	HLA-DRB1	2.97	1E-206
chr6_dbb_hap3	3692391	3692392	rs3129890	Asthma	HLA-DRA	1.15	5E-13
chr6_dbb_hap3	3706381	3706382	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_dbb_hap3	3706381	3706382	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_dbb_hap3	3706381	3706382	rs6903608	Hodgkin's lymphoma	HLA-DRA	1.70	3E-50
chr6_dbb_hap3	3707739	3707740	rs9268853	Rheumatoid arthritis	HLA-DRA	2.40	5E-109
chr6_dbb_hap3	3707739	3707740	rs9268853	Ulcerative colitis	HLA-DRB5, HLA-DQA1, HLA-DRB1, HLA-DRA, BTNL2	1.40	1E-55
chr6_dbb_hap3	3709240	3709241	rs9268877	Ulcerative colitis	MHC	NR	4E-23
chr6_dbb_hap3	3709240	3709241	rs9268877	Ulcerative colitis	HLA-DRA, BTNL2	1.45	6E-18
chr6_dbb_hap3	3710173	3710174	rs9268905	Cystic fibrosis severity	HLA-DRA	NR	1E-7
chr6_dbb_hap3	3710931	3710932	rs9268923	Ulcerative colitis	HLA-DRA	1.45	4E-15
chr6_dbb_hap3	3711264	3711265	rs2395185	Lung cancer	HLA class II	1.17	1E-8
chr6_dbb_hap3	3711264	3711265	rs2395185	Hodgkin's lymphoma	HLA-DRA	1.82	4E-31
chr6_dbb_hap3	3711264	3711265	rs2395185	Ulcerative colitis	Intergenic	1.92	5E-22
chr6_dbb_hap3	3711264	3711265	rs2395185	Ulcerative colitis	BTNL2, HLA-DRA, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1	1.52	1E-16
chr6_dbb_hap3	3839985	3839986	rs28366298	Lung cancer	HLA class II	1.17	1E-8
chr6_dbb_hap3	3846166	3846167	rs477515	Inflammatory bowel disease	HLA-DQA1	1.38	1E-8
chr6_dbb_hap3	3848423	3848424	rs2858870	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_dbb_hap3	3848423	3848424	rs2858870	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_dbb_hap3	3850340	3850341	rs615672	Rheumatoid arthritis	HLA-DRB1	NR	8E-27
chr6_dbb_hap3	3852657	3852658	rs9271100	Systemic lupus erythematosus	HLA-DRB1	1.90	1E-12
chr6_dbb_hap3	3853557	3853558	rs660895	IgA nephropathy	HLA-DRB1	1.34	4E-20
chr6_dbb_hap3	3853557	3853558	rs660895	Rheumatoid arthritis	HLA-DRB1	3.62	1E-108
chr6_dbb_hap3	3854258	3854259	rs674313	Chronic lymphocytic leukemia	HLA-DRB5	1.69	7E-9
chr6_dbb_hap3	3862676	3862677	rs9271366	Inflammatory bowel disease	MHC	1.79	8E-11
chr6_dbb_hap3	3862676	3862677	rs9271366	Inflammatory bowel disease	MHC	2.41	3E-31
chr6_dbb_hap3	3862676	3862677	rs9271366	Inflammatory bowel disease	MHC	4.44	2E-70
chr6_dbb_hap3	3862676	3862677	rs9271366	Immunoglobulin A	HLA-DRB1	7.69	3E-33
chr6_dbb_hap3	3862676	3862677	rs9271366	Multiple sclerosis	DQA1	2.62	4E-17
chr6_dbb_hap3	3862676	3862677	rs9271366	Multiple sclerosis	HLA-DRB1	2.78	7E-184
chr6_dbb_hap3	3872791	3872792	rs3129763	Systemic sclerosis	HLA-DQA1, HLA-DRB1	1.65	1E-11
chr6_dbb_hap3	3874460	3874461	rs28421666	Nasopharyngeal carcinoma	HLA-DQ,HLA-DR	1.49	2E-18
chr6_dbb_hap3	3881720	3881721	rs9272105	Hepatocellular carcinoma	HLA-DQA1, HLA-DRB1	1.28	5E-22
chr6_dbb_hap3	3881720	3881721	rs9272105	Response to interferon beta therapy	HLA-DQA1, HLA-DRB1	.26	4E-10
chr6_dbb_hap3	3883991	3883992	rs9272219	Rheumatoid arthritis	HLA-DQA1	1.92	1E-45
chr6_dbb_hap3	3883991	3883992	rs9272219	Schizophrenia	HLA-DQA1	1.14	7E-8
chr6_dbb_hap3	3884729	3884730	rs2040406	Multiple sclerosis	HLA-DRB,HLA-DQB1	2.05	1E-20
chr6_dbb_hap3	3886094	3886095	rs9272346	Type 1 diabetes	HLA	NR	6E-129
chr6_dbb_hap3	3886094	3886095	rs9272346	Type 1 diabetes	MHC	5.49	5E-134
chr6_dbb_hap3	3887610	3887611	rs2187668	Systemic lupus erythematosus	HLA-DR3	2.23	6E-28
chr6_dbb_hap3	3887610	3887611	rs2187668	Nephropathy (idiopathic membranous)	HLA-DQA1	4.32	8E-93
chr6_dbb_hap3	3887610	3887611	rs2187668	Immunoglobulin A	HLA-DRB1	2.53	2E-33
chr6_dbb_hap3	3887610	3887611	rs2187668	Celiac disease	HLA-DQA1, HLA-DQB1	6.23	1E-50
chr6_dbb_hap3	3887610	3887611	rs2187668	Systemic lupus erythematosus	HLA-DQA1	NR	3E-21
chr6_dbb_hap3	3887610	3887611	rs2187668	Celiac disease	HLA-DQA1	7.04	1E-19
chr6_dbb_hap3	3888457	3888458	rs9272535	Chronic lymphocytic leukemia	HLA-DQA1	1.61	9E-8
chr6_dbb_hap3	3904489	3904490	rs9273349	Asthma	HLA-DQ	1.18	7E-14
chr6_dbb_hap3	3930257	3930258	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_dbb_hap3	3930257	3930258	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_dbb_hap3	3939336	3939337	rs7774434	Primary biliary cirrhosis	MHC	1.60	4E-34
chr6_dbb_hap3	3939336	3939337	rs7774434	Primary biliary cirrhosis	HLA-DQB1	1.75	3E-26
chr6_dbb_hap3	3939838	3939839	rs7775228	IgE grass sensitization	HLA region	1.33	2E-9
chr6_dbb_hap3	3939838	3939839	rs7775228	Asthma	HLA-DQB1	1.17	5E-15
chr6_dbb_hap3	3940069	3940070	rs9469220	Crohn's disease	NR	1.14	2E-6
chr6_dbb_hap3	3946073	3946074	rs3129720	Hypothyroidism	HLA-DRB9, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DQA2	1.16	5E-7
chr6_dbb_hap3	3946294	3946295	rs6457617	Graves' disease	HLA, DRB1, DQA1, DQB1	1.40	7E-33
chr6_dbb_hap3	3946294	3946295	rs6457617	Systemic sclerosis	HLA, DQB1	1.61	2E-37
chr6_dbb_hap3	3946294	3946295	rs6457617	Systemic sclerosis	HLA-DQB1	1.37	4E-17
chr6_dbb_hap3	3946294	3946295	rs6457617	Rheumatoid arthritis	HLA-DQA1, HLA-DQA2	NR	1E-9
chr6_dbb_hap3	3946294	3946295	rs6457617	Rheumatoid arthritis	MHC	2.36	5E-75
chr6_dbb_hap3	3946442	3946443	rs6457620	Height	HLA locus	.03	2E-16
chr6_dbb_hap3	3946442	3946443	rs6457620	Rheumatoid arthritis	HLA-DRB1	2.55	4E-186
chr6_dbb_hap3	3946901	3946902	rs2647012	Follicular lymphoma	HLA-DQB1	1.56	2E-21
chr6_dbb_hap3	3946901	3946902	rs2647012	Systemic lupus erythematosus	HLA-DQA1, HLA-DQA2	1.38	8E-6
chr6_dbb_hap3	3947403	3947404	rs9357152	HPV seropositivity	HLA-DQB1	NR	1E-14
chr6_dbb_hap3	3947403	3947404	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_dbb_hap3	3947403	3947404	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_dbb_hap3	3947863	3947864	rs10484561	Follicular lymphoma	HLA-DQB1	1.95	1E-29
chr6_dbb_hap3	3950332	3950333	rs2647044	Pulmonary function	HLA-DQB1	.04	6E-6
chr6_dbb_hap3	3950332	3950333	rs2647044	Type 1 diabetes	HLA-DRB1	8.30	1E-16
chr6_dbb_hap3	3951579	3951580	rs9275390	Systemic sclerosis	HLA-DQB1	1.61	1E-7
chr6_dbb_hap3	3951579	3951580	rs9275390	Systemic sclerosis	HLA-DQB1	2.38	3E-54
chr6_dbb_hap3	3951795	3951796	rs11752643	Coronary heart disease	HLA, DRB-DQB	1.26	5E-7
chr6_dbb_hap3	3952669	3952670	rs2856718	Hepatitis B	HLA-DQB1	1.56	4E-37
chr6_dbb_hap3	3953517	3953518	rs13192471	Rheumatoid arthritis	HLA-DRB1	1.97	2E-58
chr6_dbb_hap3	3953662	3953663	rs1794275	IgA nephropathy	HLA-DQA/B	1.30	3E-13
chr6_dbb_hap3	3960903	3960904	rs9275572	Hepatocellular carcinoma	HLA-DQ, HLA-DR	1.30	6E-9
chr6_dbb_hap3	3960903	3960904	rs9275572	Alopecia areata	HLA-DQA2	2.21	1E-35
chr6_dbb_hap3	3962837	3962838	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6_dbb_hap3	3962837	3962838	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6_dbb_hap3	3963186	3963187	rs2858331	IgE levels	HLA-DQA2	.04	1E-8
chr6_dbb_hap3	3963540	3963541	rs9275596	Nephropathy	HLA-DRB1, HLA-DQA1, HLA-DQB1	1.59	2E-26
chr6_dbb_hap3	3963585	3963586	rs3104402	Immune response to anthrax vaccine	HLA-DRB1,HLA-DQA1	.17	6E-6
chr6_dbb_hap3	3967463	3967464	rs3916765	Type 2 diabetes	HLA-DQA2	1.21	1E-6
chr6_dbb_hap3	3970179	3970180	rs9275698	Asthma	HLA-DQA2	1.18	5E-12
chr6_dbb_hap3	3982660	3982661	rs2858884	Narcolepsy	HLA-DQA2	1.79	3E-8
chr6_dbb_hap3	4007758	4007759	rs2301271	Systemic lupus erythematosus	HLA-DQA2	1.47	2E-12
chr6_dbb_hap3	4012578	4012579	rs7453920	Hepatitis B	HAL-DQB2	1.81	6E-28
chr6_dbb_hap3	4012652	4012653	rs2051549	Systemic lupus erythematosus	HLA-DQA2	NR	3E-22
chr6_dbb_hap3	4019250	4019251	rs9276606	Complement C3 and C4 levels	HLA-DQB	.09	3E-22
chr6_dbb_hap3	4045780	4045781	rs2857151	Kawasaki disease	HLA-DQB2, HLA-DOB	1.47	5E-11
chr6_dbb_hap3	4085448	4085449	rs241428	Complement C3 and C4 levels	HLA-DQB	.23	9E-83
chr6_dbb_hap3	4091225	4091226	rs9357155	Nephropathy	TAP2, TAP1, PSMB8, PSMB9	1.41	2E-12
chr6_dbb_hap3	4133978	4133979	rs2187689	Disc degeneration (lumbar)	PSMB9	.23	3E-8
chr6_dbb_hap3	4136022	4136023	rs10046257	Disc degeneration (lumbar)	Intergenic	.19	3E-7
chr6_dbb_hap3	4137042	4137043	rs6457690	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_dbb_hap3	4137706	4137707	rs1029296	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_dbb_hap3	4137807	4137808	rs1029295	Disc degeneration (lumbar)	Intergenic	.19	5E-7
chr6_dbb_hap3	4138259	4138260	rs6936004	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_dbb_hap3	4138744	4138745	rs10214886	Disc degeneration (lumbar)	Intergenic	.19	2E-7
chr6_dbb_hap3	4141037	4141038	rs7744666	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_dbb_hap3	4141073	4141074	rs11969002	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_dbb_hap3	4142077	4142078	rs9469300	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_dbb_hap3	4143932	4143933	rs3749982	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_dbb_hap3	4242703	4242704	rs9500927	Asthma	HLA-DOA	1.13	4E-9
chr6_dbb_hap3	4256361	4256362	rs399604	Platelet counts	HLA-DOA	2.35	1E-10
chr6_dbb_hap3	4314360	4314361	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.82	4E-45
chr6_dbb_hap3	4314360	4314361	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.67	1E-9
chr6_dbb_hap3	4314360	4314361	rs3077	Hepatitis B	HLA-DPA1	1.87	2E-61
chr6_dbb_hap3	4324218	4324219	rs987870	Asthma	HLA, DPB1	1.40	2E-10
chr6_dbb_hap3	4324218	4324219	rs987870	Systemic sclerosis	HLA-DPA1, HLA-DPB1	2.09	2E-20
chr6_dbb_hap3	4336191	4336192	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.64	2E-21
chr6_dbb_hap3	4336191	4336192	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.52	2E-17
chr6_dbb_hap3	4336191	4336192	rs9277535	Hepatitis B vaccine response	HLA-DPB1	1.39	3E-12
chr6_dbb_hap3	4336191	4336192	rs9277535	Hepatitis B	HLA-DPB1	1.77	3E-54
chr6_dbb_hap3	4336191	4336192	rs9277535	Hepatitis B	HLA-DPB1	1.75	6E-39
chr6_dbb_hap3	4341448	4341449	rs2281388	Graves' disease	HLA, DPB1	1.64	2E-65
chr6_dbb_hap3	4351223	4351224	rs3117242	Antineutrophil cytoplasmic antibody-associated vasculitis	HLA-DP, COL11A2	3.67	1E-71
chr6_dbb_hap3	4425254	4425255	rs2254287	LDL cholesterol	B3GALT4	1.91	5E-8
chr6_mann_hap4	79517	79518	rs4324798	Lung adenocarcinoma	TRNAA-UGC	1.16	2E-8
chr6_mann_hap4	219656	219657	rs4947339	Platelet aggregation	TRIM27	NR	2E-6
chr6_mann_hap4	387633	387634	rs3129109	Height	OR2J3	.03	2E-17
chr6_mann_hap4	658332	658333	rs3094548	Pulmonary function	OR12D2	.03	1E-7
chr6_mann_hap4	659461	659462	rs9257809	Barrett's esophagus	MHC, OR2D12, OR2D13	1.21	4E-9
chr6_mann_hap4	737381	737382	rs4713226	Immune reponse to smallpox (secreted IFN-alpha)	OR2H1	NR	2E-8
chr6_mann_hap4	914386	914387	rs29232	Nasopharyngeal carcinoma	GABBR1	1.67	9E-17
chr6_mann_hap4	973209	973210	rs3129055	Nasopharyngeal carcinoma	HLA-F	1.51	7E-11
chr6_mann_hap4	1003026	1003027	rs2523395	Prostate cancer (gene x gene interaction)	LOC285830	1.24	2E-6
chr6_mann_hap4	1006165	1006166	rs2523393	Multiple sclerosis	HLA-B	1.28	1E-17
chr6_mann_hap4	1023655	1023656	rs9258260	Crohn's disease	HLA-F, MOG, HLA-G, GABBR1, HLA-H, UBD, HLA-A	1.45	2E-10
chr6_mann_hap4	1089500	1089501	rs1610677	Rheumatoid arthritis	HLA-G	1.32	4E-15
chr6_mann_hap4	1128619	1128620	rs2523822	Drug-induced liver injury (amoxicillin-clavulanate)	HLA-A	2.30	2E-10
chr6_mann_hap4	1143897	1143898	rs2523809	IgE levels	HLA-G	.06	4E-8
chr6_mann_hap4	1199066	1199067	rs2860580	Nasopharyngeal carcinoma	HLA-A	1.72	5E-67
chr6_mann_hap4	1205698	1205699	rs1061235	Adverse response to carbamapezine	HLA-A*3101	9.12	1E-7
chr6_mann_hap4	1210471	1210472	rs2517713	Nasopharyngeal carcinoma	HLA-A	1.88	4E-20
chr6_mann_hap4	1218935	1218936	rs9260489	Multiple sclerosis	HLA-B	1.21	1E-11
chr6_mann_hap4	1222461	1222462	rs2571391	IgE levels	HLA-A	.06	1E-15
chr6_mann_hap4	1233831	1233832	rs3893464	Graves' disease	MHC	1.53	2E-20
chr6_mann_hap4	1240515	1240516	rs2523946	IgA nephropathy	HLA-A	1.21	2E-11
chr6_mann_hap4	1241647	1241648	rs6904029	Vitiligo	HLA-A,HCG9	1.49	1E-21
chr6_mann_hap4	1269161	1269162	rs7758512	HIV-1 control	ZNRD1, RNF39, HLA-A	NR	2E-8
chr6_mann_hap4	1272498	1272499	rs4313034	Graves' disease	MHC	1.67	2E-15
chr6_mann_hap4	1315679	1315680	rs6917603	Lipid metabolism phenotypes	PPP1R11	.24	3E-29
chr6_mann_hap4	1324102	1324103	rs259919	HIV-1 control	C6orf12, ZNRD1	NR	3E-7
chr6_mann_hap4	1331113	1331114	rs8321	AIDS progression	ZNRD1, RNF39	NR	5E-7
chr6_mann_hap4	1378921	1378922	rs34704616	Cognitive performance	XXbac-BPG250I8.13	NR	6E-6
chr6_mann_hap4	1441923	1441924	rs10947055	Cardiac hypertrophy	TRIM38	NR	2E-7
chr6_mann_hap4	1468454	1468455	rs9468692	HIV-1 control	TRIM10	NR	1E-6
chr6_mann_hap4	1513771	1513772	rs2523722	Schizophrenia	MHC, TRIM26	1.25	1E-16
chr6_mann_hap4	1522627	1522628	rs2021722	Schizophrenia	TRIM26	1.15	2E-12
chr6_mann_hap4	1885677	1885678	rs3132613	Graves' disease	MHC	1.43	1E-13
chr6_mann_hap4	2084235	2084236	rs12526186	Response to antipsychotic treatment	Intergenic	9.00	3E-6
chr6_mann_hap4	2130086	2130087	rs886424	Bipolar disorder and schizophrenia	MHC, other genes	1.37	9E-7
chr6_mann_hap4	2143260	2143261	rs7772131	Response to angiotensin II receptor blocker therapy	C6orf214	6.73	3E-6
chr6_mann_hap4	2196337	2196338	rs7756521	HIV-1 control	DDR1, VARS2, DPCR1	NR	1E-6
chr6_mann_hap4	2224230	2224231	rs1052693	Complement C3 and C4 levels	HLA-A	.10	3E-48
chr6_mann_hap4	2350973	2350974	rs4248154	Graves' disease	MHC	1.38	1E-13
chr6_mann_hap4	2355212	2355213	rs2844665	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	C6orf205	1.54	3E-7
chr6_mann_hap4	2366765	2366766	rs2517532	Hypothyroidism	LOC729792, HCG22, C6orf15, HLA-C, HLA-B, DHFRP2, HCP5	1.16	1E-8
chr6_mann_hap4	2373158	2373159	rs9262632	HIV-1 control	Intergenic	3.10	1E-8
chr6_mann_hap4	2406520	2406521	rs4947296	Behcet's disease	HCG22	2.57	1E-11
chr6_mann_hap4	2406520	2406521	rs4947296	Graves' disease	MUC21, C6orf15	1.77	4E-51
chr6_mann_hap4	2406682	2406683	rs3130544	Myasthenia gravis	NR	5.64	2E-90
chr6_mann_hap4	2422375	2422376	rs6457327	Follicular lymphoma	C6orf15	1.47	7E-6
chr6_mann_hap4	2422375	2422376	rs6457327	Follicular lymphoma	STG, PSORS1	1.69	5E-11
chr6_mann_hap4	2441941	2441942	rs3815087	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	PSORS1C1	1.53	3E-7
chr6_mann_hap4	2441941	2441942	rs3815087	HIV-1 control	CDSN	NR	8E-8
chr6_mann_hap4	2445667	2445668	rs3130559	Chronic obstructive pulmonary disease-related biomarkers	PSORS1C1	NR	8E-9
chr6_mann_hap4	2447943	2447944	rs4959053	Behcet's disease	PSORS1C1	4.38	2E-20
chr6_mann_hap4	2454635	2454636	rs3130573	Systemic sclerosis	PSORS1C1	1.25	6E-10
chr6_mann_hap4	2455554	2455555	rs1265093	Chronic obstructive pulmonary disease-related biomarkers	PSORS1C1, CCHCR1	NR	6E-9
chr6_mann_hap4	2459713	2459714	rs9263739	Ulcerative colitis	HLA	2.73	4E-67
chr6_mann_hap4	2466368	2466369	rs1265112	Nevirapine-induced rash	CCHCR1	4.36	1E-8
chr6_mann_hap4	2466860	2466861	rs130067	Prostate cancer	CCHCR1	1.05	3E-8
chr6_mann_hap4	2484811	2484812	rs3130501	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	POU5F1	1.74	2E-8
chr6_mann_hap4	2487813	2487814	rs879882	Height	MICA	NR	2E-7
chr6_mann_hap4	2491943	2491944	rs3131018	HIV-1 control	PSORS1C3	2.10	4E-16
chr6_mann_hap4	2504160	2504161	rs1265181	Psoriasis	MHC	22.62	NS
chr6_mann_hap4	2516420	2516421	rs6903896	Common traits (Other)	NR	NR	6E-7
chr6_mann_hap4	2568561	2568562	rs3095254	White blood cell types	MHC	.07	6E-11
chr6_mann_hap4	2587310	2587311	rs2074488	Chronic obstructive pulmonary disease-related biomarkers	HLA-C	NR	2E-10
chr6_mann_hap4	2587988	2587989	rs13191343	Psoriatic arthritis	HLA-C	2.37	2E-72
chr6_mann_hap4	2599237	2599238	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.31	6E-21
chr6_mann_hap4	2599237	2599238	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.37	2E-28
chr6_mann_hap4	2599766	2599767	rs12191877	Psoriasis	HLA-C	2.79	4E-32
chr6_mann_hap4	2599766	2599767	rs12191877	Psoriasis	HLA-C	2.64	1E-100
chr6_mann_hap4	2605673	2605674	rs9468925	Vitiligo	HLA	1.35	2E-33
chr6_mann_hap4	2610575	2610576	rs2894207	Nasopharyngeal carcinoma	HLA-B,HLA-C	1.64	3E-33
chr6_mann_hap4	2612320	2612321	rs2247056	Triglycerides	HLA	2.99	2E-15
chr6_mann_hap4	2618537	2618538	rs9461688	Protein quantitative trait loci	HLA-C	NR	4E-6
chr6_mann_hap4	2619142	2619143	rs9368677	Atopic dermatitis	HLA-C	1.36	1E-17
chr6_mann_hap4	2621201	2621202	rs9264942	HIV-1 control	HLA-C	2.90	3E-35
chr6_mann_hap4	2621201	2621202	rs9264942	HIV-1 control	HLA-C	5.30	6E-32
chr6_mann_hap4	2621201	2621202	rs9264942	HIV-1 control	HLA-C	NR	6E-12
chr6_mann_hap4	2621395	2621396	rs10484554	Psoriasis	HLA-C	4.66	4E-214
chr6_mann_hap4	2621395	2621396	rs10484554	AIDS progression	HLA-C	NR	6E-8
chr6_mann_hap4	2621395	2621396	rs10484554	Psoriasis	HLA-C	2.80	2E-39
chr6_mann_hap4	2668821	2668822	rs3819299	Platelet counts	HLA-B	5.05	9E-10
chr6_mann_hap4	2669013	2669014	rs2523608	HIV-1 control	HLA-B	2.60	9E-20
chr6_mann_hap4	2669013	2669014	rs2523608	HIV-1 control	HLA-B	NR	3E-6
chr6_mann_hap4	2673518	2673519	rs2523590	HIV-1 control	HLA-B	2.40	2E-13
chr6_mann_hap4	2674155	2674156	rs9378249	Bipolar disorder	NR	NR	1E-8
chr6_mann_hap4	2682549	2682550	rs7743761	Ankylosing spondylitis	MHC	NR	5E-304
chr6_mann_hap4	2682867	2682868	rs9266406	Behcet's disease	MICA, MICB, DHFRP2	2.29	2E-10
chr6_mann_hap4	2693270	2693271	rs9266629	Chronic obstructive pulmonary disease-related biomarkers	FGFR3P	NR	4E-10
chr6_mann_hap4	2697153	2697154	rs1521	Graves' disease	HLA-B	1.92	2E-65
chr6_mann_hap4	2701009	2701010	rs13437082	Height	HLA-B	.07	5E-8
chr6_mann_hap4	2712230	2712231	rs4349859	Ankylosing spondylitis	HLA-B	NR	1E-200
chr6_mann_hap4	2713038	2713039	rs2596542	Hepatocellular carcinoma	MICA	1.39	4E-13
chr6_mann_hap4	2724019	2724020	rs12175489	Visceral adipose tissue adjusted for BMI	HLA-B, HCP5	NR	2E-6
chr6_mann_hap4	2726358	2726359	rs1063635	Rheumatoid arthritis	MICA	1.35	1E-17
chr6_mann_hap4	2726958	2726959	rs2256183	Height	MICA	.04	8E-29
chr6_mann_hap4	2737829	2737830	rs4418214	HIV-1 control	MICA	4.40	1E-34
chr6_mann_hap4	2753709	2753710	rs9469003	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	HCP5	1.73	2E-9
chr6_mann_hap4	2754146	2754147	rs2524276	Capecitabine sensitivity	Intergenic	NR	6E-6
chr6_mann_hap4	2815640	2815641	rs2855812	Pulmonary function	MICB	.03	2E-7
chr6_mann_hap4	2818406	2818407	rs3132468	Dengue shock syndrome	MICB	1.34	4E-11
chr6_mann_hap4	2824219	2824220	rs2516399	White blood cell types	MHC	.11	2E-12
chr6_mann_hap4	2842517	2842518	rs3853601	Atopic dermatitis	BAT1	1.13	2E-6
chr6_mann_hap4	2848393	2848394	rs2734583	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	BAT1, HCP5, MICC, PPIAP9, PSORS1C1, POLR2LP, CCHCR1, TCF19, POU5F1, HLA-C, HCP5, PSORS1C3, HLA-B*5801	66.80	2E-8
chr6_mann_hap4	2885191	2885192	rs1799964	Crohn's disease	LTA,HLA-DQA2,TNF,LST1,LTB	1.19	4E-11
chr6_mann_hap4	2900674	2900675	rs11575839	Complement C3 and C4 levels	HLA-C	.23	1E-54
chr6_mann_hap4	2911346	2911347	rs2857595	Pulmonary function	NCR3	.04	2E-10
chr6_mann_hap4	2915831	2915832	rs2844479	Weight	AIF1, NCR3	3.58	2E-8
chr6_mann_hap4	2918162	2918163	rs9348876	Crohn's disease	AIF1	1.41	3E-6
chr6_mann_hap4	2945850	2945851	rs1046089	Menopause (age at onset)	PRRC2A	.21	2E-16
chr6_mann_hap4	2959254	2959255	rs805303	Systolic blood pressure	BAT2, BAT5	.38	2E-11
chr6_mann_hap4	2959254	2959255	rs805303	Hypertension	BAT2, BAT5	.05	1E-10
chr6_mann_hap4	2959254	2959255	rs805303	Diastolic blood pressure	BAT2, BAT5	.23	3E-11
chr6_mann_hap4	2963408	2963409	rs3117582	Lung adenocarcinoma	BAT3, APOM	1.22	5E-12
chr6_mann_hap4	2963408	2963409	rs3117582	Lung cancer	BAT3	1.24	4E-10
chr6_mann_hap4	2963408	2963409	rs3117582	Lung cancer	BAT3,MSH5	1.24	5E-10
chr6_mann_hap4	2965494	2965495	rs805297	Rheumatoid arthritis	APOM	1.56	3E-10
chr6_mann_hap4	3246609	3246610	rs9332739	Age-related macular degeneration (GA)	C2	2.63	1E-6
chr6_mann_hap4	3246609	3246610	rs9332739	Age-related macular degeneration (CNV)	C2	2.08	2E-8
chr6_mann_hap4	3246609	3246610	rs9332739	Age-related macular degeneration	C2	2.17	2E-23
chr6_mann_hap4	3248813	3248814	rs9380272	Age-related macular degeneration	C2,CFB	4.31	2E-8
chr6_mann_hap4	3256999	3257000	rs641153	Age-related macular degeneration (GA)	CFB	2.13	2E-9
chr6_mann_hap4	3256999	3257000	rs641153	Age-related macular degeneration (CNV)	CFB	2.22	1E-17
chr6_mann_hap4	3256999	3257000	rs641153	Age-related macular degeneration	CFB	1.85	6E-31
chr6_mann_hap4	3256999	3257000	rs641153	Age-related macular degeneration	CFB,C2	NR	2E-20
chr6_mann_hap4	3259770	3259771	rs541862	Age-related macular degeneration	CFB	1.89	9E-17
chr6_mann_hap4	3392914	3392915	rs185819	Height	HLA class III	5.20	3E-8
chr6_mann_hap4	3393605	3393606	rs1150754	Systemic lupus erythematosus	TNXB	2.21	6E-29
chr6_mann_hap4	3452822	3452823	rs204999	Serum total protein level	Intergenic	.03	4E-11
chr6_mann_hap4	3452822	3452823	rs204999	Serum total protein level	Intergenic	.03	3E-9
chr6_mann_hap4	3452822	3452823	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_mann_hap4	3452822	3452823	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_mann_hap4	3479370	3479371	rs1061808	Phospholipid levels (plasma)	AGPAT1	.90	8E-10
chr6_mann_hap4	3494266	3494267	rs2070600	Pulmonary function	AGER, PPT2	1.00	3E-14
chr6_mann_hap4	3494266	3494267	rs2070600	Pulmonary function	AGER	.09	3E-15
chr6_mann_hap4	3498401	3498402	rs204993	Asthma	PBX2	1.17	2E-15
chr6_mann_hap4	3501139	3501140	rs176095	Atopic dermatitis	GPSM3	1.40	8E-20
chr6_mann_hap4	3508264	3508265	rs2071278	Complement C3 and C4 levels	HLA-DRA	.13	4E-72
chr6_mann_hap4	3514508	3514509	rs2071277	Age-related macular degeneration	NOTCH4	1.30	2E-11
chr6_mann_hap4	3515818	3515819	rs3131296	Schizophrenia	MHC, NOTCH4	1.19	2E-10
chr6_mann_hap4	3527196	3527197	rs404860	Asthma	NOTCH4	1.21	4E-23
chr6_mann_hap4	3533253	3533254	rs443198	Systemic sclerosis	NOTCH4	1.82	9E-21
chr6_mann_hap4	3561663	3561664	rs3115573	Nephropathy	Intergenic	1.62	1E-9
chr6_mann_hap4	3561809	3561810	rs9296015	Systemic sclerosis	NOTCH4	1.85	1E-8
chr6_mann_hap4	3561809	3561810	rs9296015	Rheumatoid arthritis	HLA locus	NR	2E-38
chr6_mann_hap4	3566111	3566112	rs3130320	Systemic lupus erythematosus	NOTCH4, C6orf10	1.39	3E-6
chr6_mann_hap4	3587459	3587460	rs3130340	Bone mineral density (spine)	MHC, C6orf10	.10	1E-7
chr6_mann_hap4	3625693	3625694	rs6910071	Rheumatoid arthritis	HLA-DRB1	2.88	1E-299
chr6_mann_hap4	3648821	3648822	rs3129900	Lumiracoxib-related liver injury	HLA-DRB1	7.50	7E-25
chr6_mann_hap4	3651751	3651752	rs9469099	Atopic dermatitis	C6orf10	1.61	5E-19
chr6_mann_hap4	3664400	3664401	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_mann_hap4	3664400	3664401	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_mann_hap4	3664400	3664401	rs2395148	Arthritis (juvenile idiopathic)	HLA-DRB1	5.37	2E-10
chr6_mann_hap4	3668217	3668218	rs13196329	Visceral fat	C6orf10	NR	3E-6
chr6_mann_hap4	3679029	3679030	rs3129934	Multiple sclerosis	C6orf10	2.34	7E-16
chr6_mann_hap4	3679029	3679030	rs3129934	Multiple sclerosis	HLA-DRB1	3.30	9E-11
chr6_mann_hap4	3680473	3680474	rs2273017	Graves' disease	MHC	1.53	2E-22
chr6_mann_hap4	3681533	3681534	rs3129943	Asthma	C6orf10	1.17	3E-15
chr6_mann_hap4	3681914	3681915	rs2050190	Activated partial thromboplastin time	C6orf10	.25	7E-7
chr6_mann_hap4	3684191	3684192	rs9268402	Coronary heart disease	C6orf10, BTNL2	1.16	3E-15
chr6_mann_hap4	3688111	3688112	rs7758128	Vitiligo	C6orf10, BTNL2	NR	8E-11
chr6_mann_hap4	3701104	3701105	rs3117099	Bipolar disorder and schizophrenia	MHC, other genes	1.25	3E-6
chr6_mann_hap4	3701348	3701349	rs3117098	Asthma	BTNL2	1.16	5E-12
chr6_mann_hap4	3706050	3706051	rs1980493	Anti-cyclic Citrullinated Peptide Antibody	HLA-DRA, BTNL2	NR	5E-7
chr6_mann_hap4	3706651	3706652	rs2076530	Sarcoidosis	BTNL2	NR	3E-11
chr6_mann_hap4	3706679	3706680	rs9268480	Ulcerative colitis	BTNL2	1.82	3E-6
chr6_mann_hap4	3706790	3706791	rs2076529	Waist-hip ratio	BTNL2	.02	4E-7
chr6_mann_hap4	3710921	3710922	rs3817963	Lung adenocarcinoma	BTNL2	1.18	3E-10
chr6_mann_hap4	3716170	3716171	rs10947262	Knee osteoarthritis	BTNL2, HLA-DQA2, HLA-DQB1	1.31	5E-9
chr6_mann_hap4	3716558	3716559	rs3806156	Vitiligo	BTNL2,HLA-DRA,HLA-DQA1	1.42	7E-19
chr6_mann_hap4	3719328	3719329	rs3763313	HIV-1 control	BTNL2, NOTCH4	NR	2E-6
chr6_mann_hap4	3719645	3719646	rs3763317	Complement C3 and C4 levels	HLA-DRB	.12	9E-66
chr6_mann_hap4	3721559	3721560	rs9268516	Asthma	BTNL2, HLA-DRA	1.15	1E-8
chr6_mann_hap4	3725185	3725186	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_mann_hap4	3725185	3725186	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_mann_hap4	3726798	3726799	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_mann_hap4	3726798	3726799	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_mann_hap4	3729886	3729887	rs2395163	Parkinson's disease	LOC642072	1.24	3E-11
chr6_mann_hap4	3731725	3731726	rs3135363	Hepatitis B vaccine response	HLA-DR	1.53	7E-22
chr6_mann_hap4	3731725	3731726	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_mann_hap4	3731725	3731726	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_mann_hap4	3743281	3743282	rs3135338	Multiple sclerosis	HLA	3.43	2E-25
chr6_mann_hap4	3750585	3750586	rs9268645	Type 1 diabetes	MHC	NR	1E-100
chr6_mann_hap4	3751588	3751589	rs3129882	Systemic sclerosis	HLA-DRA	2.17	2E-27
chr6_mann_hap4	3751588	3751589	rs3129882	Parkinson's disease	HLA-DRA	1.26	2E-10
chr6_mann_hap4	3753704	3753705	rs7192	Non-obstructive azoospermia	HLA-DRA	1.29	3E-6
chr6_mann_hap4	3754501	3754502	rs3177928	LDL cholesterol	HLA	1.83	2E-15
chr6_mann_hap4	3754501	3754502	rs3177928	Cholesterol, total	HLA	2.31	4E-19
chr6_mann_hap4	3755117	3755118	rs3135388	Multiple sclerosis	HLA-DRB1	2.75	4E-225
chr6_mann_hap4	3755117	3755118	rs3135388	Multiple sclerosis	HLA-DRA	1.99	9E-81
chr6_mann_hap4	3755525	3755526	rs2227139	Hematological parameters	Intergenic	.02	1E-7
chr6_mann_hap4	3755611	3755612	rs3129889	Multiple sclerosis	HLA-DRB1	2.97	1E-206
chr6_mann_hap4	3756339	3756340	rs3129890	Asthma	HLA-DRA	1.15	5E-13
chr6_mann_hap4	3770379	3770380	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_mann_hap4	3770379	3770380	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_mann_hap4	3770379	3770380	rs6903608	Hodgkin's lymphoma	HLA-DRA	1.70	3E-50
chr6_mann_hap4	3771737	3771738	rs9268853	Rheumatoid arthritis	HLA-DRA	2.40	5E-109
chr6_mann_hap4	3771737	3771738	rs9268853	Ulcerative colitis	HLA-DRB5, HLA-DQA1, HLA-DRB1, HLA-DRA, BTNL2	1.40	1E-55
chr6_mann_hap4	3773238	3773239	rs9268877	Ulcerative colitis	MHC	NR	4E-23
chr6_mann_hap4	3773238	3773239	rs9268877	Ulcerative colitis	HLA-DRA, BTNL2	1.45	6E-18
chr6_mann_hap4	3774171	3774172	rs9268905	Cystic fibrosis severity	HLA-DRA	NR	1E-7
chr6_mann_hap4	3774929	3774930	rs9268923	Ulcerative colitis	HLA-DRA	1.45	4E-15
chr6_mann_hap4	3775262	3775263	rs2395185	Lung cancer	HLA class II	1.17	1E-8
chr6_mann_hap4	3775262	3775263	rs2395185	Hodgkin's lymphoma	HLA-DRA	1.82	4E-31
chr6_mann_hap4	3775262	3775263	rs2395185	Ulcerative colitis	Intergenic	1.92	5E-22
chr6_mann_hap4	3775262	3775263	rs2395185	Ulcerative colitis	BTNL2, HLA-DRA, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1	1.52	1E-16
chr6_mann_hap4	4014418	4014419	rs28366298	Lung cancer	HLA class II	1.17	1E-8
chr6_mann_hap4	4020599	4020600	rs477515	Inflammatory bowel disease	HLA-DQA1	1.38	1E-8
chr6_mann_hap4	4022856	4022857	rs2858870	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_mann_hap4	4022856	4022857	rs2858870	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_mann_hap4	4024773	4024774	rs615672	Rheumatoid arthritis	HLA-DRB1	NR	8E-27
chr6_mann_hap4	4027090	4027091	rs9271100	Systemic lupus erythematosus	HLA-DRB1	1.90	1E-12
chr6_mann_hap4	4027990	4027991	rs660895	IgA nephropathy	HLA-DRB1	1.34	4E-20
chr6_mann_hap4	4027990	4027991	rs660895	Rheumatoid arthritis	HLA-DRB1	3.62	1E-108
chr6_mann_hap4	4028691	4028692	rs674313	Chronic lymphocytic leukemia	HLA-DRB5	1.69	7E-9
chr6_mann_hap4	4037109	4037110	rs9271366	Inflammatory bowel disease	MHC	1.79	8E-11
chr6_mann_hap4	4037109	4037110	rs9271366	Inflammatory bowel disease	MHC	2.41	3E-31
chr6_mann_hap4	4037109	4037110	rs9271366	Inflammatory bowel disease	MHC	4.44	2E-70
chr6_mann_hap4	4037109	4037110	rs9271366	Immunoglobulin A	HLA-DRB1	7.69	3E-33
chr6_mann_hap4	4037109	4037110	rs9271366	Multiple sclerosis	DQA1	2.62	4E-17
chr6_mann_hap4	4037109	4037110	rs9271366	Multiple sclerosis	HLA-DRB1	2.78	7E-184
chr6_mann_hap4	4047224	4047225	rs3129763	Systemic sclerosis	HLA-DQA1, HLA-DRB1	1.65	1E-11
chr6_mann_hap4	4048893	4048894	rs28421666	Nasopharyngeal carcinoma	HLA-DQ,HLA-DR	1.49	2E-18
chr6_mann_hap4	4056153	4056154	rs9272105	Hepatocellular carcinoma	HLA-DQA1, HLA-DRB1	1.28	5E-22
chr6_mann_hap4	4056153	4056154	rs9272105	Response to interferon beta therapy	HLA-DQA1, HLA-DRB1	.26	4E-10
chr6_mann_hap4	4058424	4058425	rs9272219	Rheumatoid arthritis	HLA-DQA1	1.92	1E-45
chr6_mann_hap4	4058424	4058425	rs9272219	Schizophrenia	HLA-DQA1	1.14	7E-8
chr6_mann_hap4	4059162	4059163	rs2040406	Multiple sclerosis	HLA-DRB,HLA-DQB1	2.05	1E-20
chr6_mann_hap4	4060527	4060528	rs9272346	Type 1 diabetes	HLA	NR	6E-129
chr6_mann_hap4	4060527	4060528	rs9272346	Type 1 diabetes	MHC	5.49	5E-134
chr6_mann_hap4	4062043	4062044	rs2187668	Systemic lupus erythematosus	HLA-DR3	2.23	6E-28
chr6_mann_hap4	4062043	4062044	rs2187668	Nephropathy (idiopathic membranous)	HLA-DQA1	4.32	8E-93
chr6_mann_hap4	4062043	4062044	rs2187668	Immunoglobulin A	HLA-DRB1	2.53	2E-33
chr6_mann_hap4	4062043	4062044	rs2187668	Celiac disease	HLA-DQA1, HLA-DQB1	6.23	1E-50
chr6_mann_hap4	4062043	4062044	rs2187668	Systemic lupus erythematosus	HLA-DQA1	NR	3E-21
chr6_mann_hap4	4062043	4062044	rs2187668	Celiac disease	HLA-DQA1	7.04	1E-19
chr6_mann_hap4	4062890	4062891	rs9272535	Chronic lymphocytic leukemia	HLA-DQA1	1.61	9E-8
chr6_mann_hap4	4078943	4078944	rs9273349	Asthma	HLA-DQ	1.18	7E-14
chr6_mann_hap4	4088492	4088493	rs9274407	Drug-induced liver injury (amoxicillin-clavulanate)	HLA-DRB1-DQB1	3.10	5E-14
chr6_mann_hap4	4112593	4112594	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_mann_hap4	4112593	4112594	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_mann_hap4	4114966	4114967	rs7774434	Primary biliary cirrhosis	MHC	1.60	4E-34
chr6_mann_hap4	4114966	4114967	rs7774434	Primary biliary cirrhosis	HLA-DQB1	1.75	3E-26
chr6_mann_hap4	4115784	4115785	rs7775228	IgE grass sensitization	HLA region	1.33	2E-9
chr6_mann_hap4	4115784	4115785	rs7775228	Asthma	HLA-DQB1	1.17	5E-15
chr6_mann_hap4	4116015	4116016	rs9469220	Crohn's disease	NR	1.14	2E-6
chr6_mann_hap4	4121319	4121320	rs3129720	Hypothyroidism	HLA-DRB9, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DQA2	1.16	5E-7
chr6_mann_hap4	4121540	4121541	rs6457617	Graves' disease	HLA, DRB1, DQA1, DQB1	1.40	7E-33
chr6_mann_hap4	4121540	4121541	rs6457617	Systemic sclerosis	HLA, DQB1	1.61	2E-37
chr6_mann_hap4	4121540	4121541	rs6457617	Systemic sclerosis	HLA-DQB1	1.37	4E-17
chr6_mann_hap4	4121540	4121541	rs6457617	Rheumatoid arthritis	HLA-DQA1, HLA-DQA2	NR	1E-9
chr6_mann_hap4	4121540	4121541	rs6457617	Rheumatoid arthritis	MHC	2.36	5E-75
chr6_mann_hap4	4121688	4121689	rs6457620	Height	HLA locus	.03	2E-16
chr6_mann_hap4	4121688	4121689	rs6457620	Rheumatoid arthritis	HLA-DRB1	2.55	4E-186
chr6_mann_hap4	4122147	4122148	rs2647012	Follicular lymphoma	HLA-DQB1	1.56	2E-21
chr6_mann_hap4	4122147	4122148	rs2647012	Systemic lupus erythematosus	HLA-DQA1, HLA-DQA2	1.38	8E-6
chr6_mann_hap4	4122649	4122650	rs9357152	HPV seropositivity	HLA-DQB1	NR	1E-14
chr6_mann_hap4	4122649	4122650	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_mann_hap4	4122649	4122650	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_mann_hap4	4123109	4123110	rs10484561	Follicular lymphoma	HLA-DQB1	1.95	1E-29
chr6_mann_hap4	4125578	4125579	rs2647044	Pulmonary function	HLA-DQB1	.04	6E-6
chr6_mann_hap4	4125578	4125579	rs2647044	Type 1 diabetes	HLA-DRB1	8.30	1E-16
chr6_mann_hap4	4126826	4126827	rs9275390	Systemic sclerosis	HLA-DQB1	1.61	1E-7
chr6_mann_hap4	4126826	4126827	rs9275390	Systemic sclerosis	HLA-DQB1	2.38	3E-54
chr6_mann_hap4	4127043	4127044	rs11752643	Coronary heart disease	HLA, DRB-DQB	1.26	5E-7
chr6_mann_hap4	4127917	4127918	rs2856718	Hepatitis B	HLA-DQB1	1.56	4E-37
chr6_mann_hap4	4128765	4128766	rs13192471	Rheumatoid arthritis	HLA-DRB1	1.97	2E-58
chr6_mann_hap4	4128910	4128911	rs1794275	IgA nephropathy	HLA-DQA/B	1.30	3E-13
chr6_mann_hap4	4136139	4136140	rs9275572	Hepatocellular carcinoma	HLA-DQ, HLA-DR	1.30	6E-9
chr6_mann_hap4	4136139	4136140	rs9275572	Alopecia areata	HLA-DQA2	2.21	1E-35
chr6_mann_hap4	4138073	4138074	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6_mann_hap4	4138073	4138074	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6_mann_hap4	4138422	4138423	rs2858331	IgE levels	HLA-DQA2	.04	1E-8
chr6_mann_hap4	4138776	4138777	rs9275596	Nephropathy	HLA-DRB1, HLA-DQA1, HLA-DQB1	1.59	2E-26
chr6_mann_hap4	4138821	4138822	rs3104402	Immune response to anthrax vaccine	HLA-DRB1,HLA-DQA1	.17	6E-6
chr6_mann_hap4	4142695	4142696	rs3916765	Type 2 diabetes	HLA-DQA2	1.21	1E-6
chr6_mann_hap4	4145100	4145101	rs9275698	Asthma	HLA-DQA2	1.18	5E-12
chr6_mann_hap4	4157230	4157231	rs2858884	Narcolepsy	HLA-DQA2	1.79	3E-8
chr6_mann_hap4	4182389	4182390	rs2301271	Systemic lupus erythematosus	HLA-DQA2	1.47	2E-12
chr6_mann_hap4	4187209	4187210	rs7453920	Hepatitis B	HAL-DQB2	1.81	6E-28
chr6_mann_hap4	4187283	4187284	rs2051549	Systemic lupus erythematosus	HLA-DQA2	NR	3E-22
chr6_mann_hap4	4193887	4193888	rs9276606	Complement C3 and C4 levels	HLA-DQB	.09	3E-22
chr6_mann_hap4	4220706	4220707	rs2857151	Kawasaki disease	HLA-DQB2, HLA-DOB	1.47	5E-11
chr6_mann_hap4	4261264	4261265	rs241428	Complement C3 and C4 levels	HLA-DQB	.23	9E-83
chr6_mann_hap4	4267043	4267044	rs9357155	Nephropathy	TAP2, TAP1, PSMB8, PSMB9	1.41	2E-12
chr6_mann_hap4	4309842	4309843	rs2187689	Disc degeneration (lumbar)	PSMB9	.23	3E-8
chr6_mann_hap4	4311888	4311889	rs10046257	Disc degeneration (lumbar)	Intergenic	.19	3E-7
chr6_mann_hap4	4312908	4312909	rs6457690	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_mann_hap4	4313572	4313573	rs1029296	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_mann_hap4	4313673	4313674	rs1029295	Disc degeneration (lumbar)	Intergenic	.19	5E-7
chr6_mann_hap4	4314125	4314126	rs6936004	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_mann_hap4	4314610	4314611	rs10214886	Disc degeneration (lumbar)	Intergenic	.19	2E-7
chr6_mann_hap4	4316903	4316904	rs7744666	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_mann_hap4	4316939	4316940	rs11969002	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_mann_hap4	4317943	4317944	rs9469300	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_mann_hap4	4319798	4319799	rs3749982	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_mann_hap4	4418580	4418581	rs9500927	Asthma	HLA-DOA	1.13	4E-9
chr6_mann_hap4	4432204	4432205	rs399604	Platelet counts	HLA-DOA	2.35	1E-10
chr6_mann_hap4	4490561	4490562	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.82	4E-45
chr6_mann_hap4	4490561	4490562	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.67	1E-9
chr6_mann_hap4	4490561	4490562	rs3077	Hepatitis B	HLA-DPA1	1.87	2E-61
chr6_mann_hap4	4500419	4500420	rs987870	Asthma	HLA, DPB1	1.40	2E-10
chr6_mann_hap4	4500419	4500420	rs987870	Systemic sclerosis	HLA-DPA1, HLA-DPB1	2.09	2E-20
chr6_mann_hap4	4512406	4512407	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.64	2E-21
chr6_mann_hap4	4512406	4512407	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.52	2E-17
chr6_mann_hap4	4512406	4512407	rs9277535	Hepatitis B vaccine response	HLA-DPB1	1.39	3E-12
chr6_mann_hap4	4512406	4512407	rs9277535	Hepatitis B	HLA-DPB1	1.77	3E-54
chr6_mann_hap4	4512406	4512407	rs9277535	Hepatitis B	HLA-DPB1	1.75	6E-39
chr6_mann_hap4	4517663	4517664	rs2281388	Graves' disease	HLA, DPB1	1.64	2E-65
chr6_mann_hap4	4527438	4527439	rs3117242	Antineutrophil cytoplasmic antibody-associated vasculitis	HLA-DP, COL11A2	3.67	1E-71
chr6_mann_hap4	4543833	4543834	rs3117035	RR interval (heart rate)	Intergenic	.14	1E-6
chr6_mann_hap4	4544032	4544033	rs1883414	Nephropathy	HLA-DPA1, HLA-DPB1, HLA-DPB2	1.28	5E-9
chr6_mann_hap4	4601263	4601264	rs2254287	LDL cholesterol	B3GALT4	1.91	5E-8
chr6_mcf_hap5	79517	79518	rs4324798	Lung adenocarcinoma	TRNAA-UGC	1.16	2E-8
chr6_mcf_hap5	219807	219808	rs4947339	Platelet aggregation	TRIM27	NR	2E-6
chr6_mcf_hap5	658521	658522	rs3094548	Pulmonary function	OR12D2	.03	1E-7
chr6_mcf_hap5	659650	659651	rs9257809	Barrett's esophagus	MHC, OR2D12, OR2D13	1.21	4E-9
chr6_mcf_hap5	737595	737596	rs4713226	Immune reponse to smallpox (secreted IFN-alpha)	OR2H1	NR	2E-8
chr6_mcf_hap5	914630	914631	rs29232	Nasopharyngeal carcinoma	GABBR1	1.67	9E-17
chr6_mcf_hap5	973425	973426	rs3129055	Nasopharyngeal carcinoma	HLA-F	1.51	7E-11
chr6_mcf_hap5	1023689	1023690	rs9258260	Crohn's disease	HLA-F, MOG, HLA-G, GABBR1, HLA-H, UBD, HLA-A	1.45	2E-10
chr6_mcf_hap5	1089449	1089450	rs1610677	Rheumatoid arthritis	HLA-G	1.32	4E-15
chr6_mcf_hap5	1128898	1128899	rs2523822	Drug-induced liver injury (amoxicillin-clavulanate)	HLA-A	2.30	2E-10
chr6_mcf_hap5	1144256	1144257	rs2523809	IgE levels	HLA-G	.06	4E-8
chr6_mcf_hap5	1295200	1295201	rs1061235	Adverse response to carbamapezine	HLA-A*3101	9.12	1E-7
chr6_mcf_hap5	1300011	1300012	rs2517713	Nasopharyngeal carcinoma	HLA-A	1.88	4E-20
chr6_mcf_hap5	1302245	1302246	rs9260489	Multiple sclerosis	HLA-B	1.21	1E-11
chr6_mcf_hap5	1305733	1305734	rs2571391	IgE levels	HLA-A	.06	1E-15
chr6_mcf_hap5	1317113	1317114	rs3893464	Graves' disease	MHC	1.53	2E-20
chr6_mcf_hap5	1323797	1323798	rs2523946	IgA nephropathy	HLA-A	1.21	2E-11
chr6_mcf_hap5	1324927	1324928	rs6904029	Vitiligo	HLA-A,HCG9	1.49	1E-21
chr6_mcf_hap5	1352452	1352453	rs7758512	HIV-1 control	ZNRD1, RNF39, HLA-A	NR	2E-8
chr6_mcf_hap5	1355788	1355789	rs4313034	Graves' disease	MHC	1.67	2E-15
chr6_mcf_hap5	1398963	1398964	rs6917603	Lipid metabolism phenotypes	PPP1R11	.24	3E-29
chr6_mcf_hap5	1407403	1407404	rs259919	HIV-1 control	C6orf12, ZNRD1	NR	3E-7
chr6_mcf_hap5	1414419	1414420	rs8321	AIDS progression	ZNRD1, RNF39	NR	5E-7
chr6_mcf_hap5	1462249	1462250	rs34704616	Cognitive performance	XXbac-BPG250I8.13	NR	6E-6
chr6_mcf_hap5	1475248	1475249	rs10947055	Cardiac hypertrophy	TRIM38	NR	2E-7
chr6_mcf_hap5	1501772	1501773	rs9468692	HIV-1 control	TRIM10	NR	1E-6
chr6_mcf_hap5	1547107	1547108	rs2523722	Schizophrenia	MHC, TRIM26	1.25	1E-16
chr6_mcf_hap5	1555966	1555967	rs2021722	Schizophrenia	TRIM26	1.15	2E-12
chr6_mcf_hap5	1919459	1919460	rs3132613	Graves' disease	MHC	1.43	1E-13
chr6_mcf_hap5	2230209	2230210	rs7756521	HIV-1 control	DDR1, VARS2, DPCR1	NR	1E-6
chr6_mcf_hap5	2258106	2258107	rs1052693	Complement C3 and C4 levels	HLA-A	.10	3E-48
chr6_mcf_hap5	2384562	2384563	rs4248154	Graves' disease	MHC	1.38	1E-13
chr6_mcf_hap5	2388801	2388802	rs2844665	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	C6orf205	1.54	3E-7
chr6_mcf_hap5	2400354	2400355	rs2517532	Hypothyroidism	LOC729792, HCG22, C6orf15, HLA-C, HLA-B, DHFRP2, HCP5	1.16	1E-8
chr6_mcf_hap5	2406731	2406732	rs9262632	HIV-1 control	Intergenic	3.10	1E-8
chr6_mcf_hap5	2440099	2440100	rs4947296	Behcet's disease	HCG22	2.57	1E-11
chr6_mcf_hap5	2440099	2440100	rs4947296	Graves' disease	MUC21, C6orf15	1.77	4E-51
chr6_mcf_hap5	2440261	2440262	rs3130544	Myasthenia gravis	NR	5.64	2E-90
chr6_mcf_hap5	2455954	2455955	rs6457327	Follicular lymphoma	C6orf15	1.47	7E-6
chr6_mcf_hap5	2455954	2455955	rs6457327	Follicular lymphoma	STG, PSORS1	1.69	5E-11
chr6_mcf_hap5	2475509	2475510	rs3815087	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	PSORS1C1	1.53	3E-7
chr6_mcf_hap5	2475509	2475510	rs3815087	HIV-1 control	CDSN	NR	8E-8
chr6_mcf_hap5	2479244	2479245	rs3130559	Chronic obstructive pulmonary disease-related biomarkers	PSORS1C1	NR	8E-9
chr6_mcf_hap5	2481520	2481521	rs4959053	Behcet's disease	PSORS1C1	4.38	2E-20
chr6_mcf_hap5	2488212	2488213	rs3130573	Systemic sclerosis	PSORS1C1	1.25	6E-10
chr6_mcf_hap5	2489131	2489132	rs1265093	Chronic obstructive pulmonary disease-related biomarkers	PSORS1C1, CCHCR1	NR	6E-9
chr6_mcf_hap5	2493291	2493292	rs9263739	Ulcerative colitis	HLA	2.73	4E-67
chr6_mcf_hap5	2499947	2499948	rs1265112	Nevirapine-induced rash	CCHCR1	4.36	1E-8
chr6_mcf_hap5	2500439	2500440	rs130067	Prostate cancer	CCHCR1	1.05	3E-8
chr6_mcf_hap5	2518390	2518391	rs3130501	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	POU5F1	1.74	2E-8
chr6_mcf_hap5	2521392	2521393	rs879882	Height	MICA	NR	2E-7
chr6_mcf_hap5	2525522	2525523	rs3131018	HIV-1 control	PSORS1C3	2.10	4E-16
chr6_mcf_hap5	2537739	2537740	rs1265181	Psoriasis	MHC	22.62	NS
chr6_mcf_hap5	2549999	2550000	rs6903896	Common traits (Other)	NR	NR	6E-7
chr6_mcf_hap5	2566224	2566225	rs3869109	Coronary heart disease	HCG27, HLA-C	1.14	1E-9
chr6_mcf_hap5	2602203	2602204	rs3095254	White blood cell types	MHC	.07	6E-11
chr6_mcf_hap5	2620952	2620953	rs2074488	Chronic obstructive pulmonary disease-related biomarkers	HLA-C	NR	2E-10
chr6_mcf_hap5	2621630	2621631	rs13191343	Psoriatic arthritis	HLA-C	2.37	2E-72
chr6_mcf_hap5	2632888	2632889	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.31	6E-21
chr6_mcf_hap5	2632888	2632889	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.37	2E-28
chr6_mcf_hap5	2633417	2633418	rs12191877	Psoriasis	HLA-C	2.79	4E-32
chr6_mcf_hap5	2633417	2633418	rs12191877	Psoriasis	HLA-C	2.64	1E-100
chr6_mcf_hap5	2639328	2639329	rs9468925	Vitiligo	HLA	1.35	2E-33
chr6_mcf_hap5	2644246	2644247	rs2894207	Nasopharyngeal carcinoma	HLA-B,HLA-C	1.64	3E-33
chr6_mcf_hap5	2645994	2645995	rs2247056	Triglycerides	HLA	2.99	2E-15
chr6_mcf_hap5	2652210	2652211	rs9461688	Protein quantitative trait loci	HLA-C	NR	4E-6
chr6_mcf_hap5	2652815	2652816	rs9368677	Atopic dermatitis	HLA-C	1.36	1E-17
chr6_mcf_hap5	2654874	2654875	rs9264942	HIV-1 control	HLA-C	2.90	3E-35
chr6_mcf_hap5	2654874	2654875	rs9264942	HIV-1 control	HLA-C	5.30	6E-32
chr6_mcf_hap5	2654874	2654875	rs9264942	HIV-1 control	HLA-C	NR	6E-12
chr6_mcf_hap5	2655068	2655069	rs10484554	Psoriasis	HLA-C	4.66	4E-214
chr6_mcf_hap5	2655068	2655069	rs10484554	AIDS progression	HLA-C	NR	6E-8
chr6_mcf_hap5	2655068	2655069	rs10484554	Psoriasis	HLA-C	2.80	2E-39
chr6_mcf_hap5	2692065	2692066	rs3134792	Psoriasis	HLA-C	NR	1E-9
chr6_mcf_hap5	2702146	2702147	rs3819299	Platelet counts	HLA-B	5.05	9E-10
chr6_mcf_hap5	2702338	2702339	rs2523608	HIV-1 control	HLA-B	2.60	9E-20
chr6_mcf_hap5	2702338	2702339	rs2523608	HIV-1 control	HLA-B	NR	3E-6
chr6_mcf_hap5	2706855	2706856	rs2523590	HIV-1 control	HLA-B	2.40	2E-13
chr6_mcf_hap5	2707492	2707493	rs9378249	Bipolar disorder	NR	NR	1E-8
chr6_mcf_hap5	2820448	2820449	rs3828890	Renal function-related traits (sCR)	MHC	.01	3E-9
chr6_mcf_hap5	2820448	2820449	rs3828890	Renal function-related traits (eGRFcrea)	MHC	.01	1E-9
chr6_mcf_hap5	2826579	2826580	rs2248462	Hodgkin's lymphoma	MICB	1.64	7E-16
chr6_mcf_hap5	2828759	2828760	rs3099844	Metabolic syndrome	HCG26, MICB	.15	2E-8
chr6_mcf_hap5	2828759	2828760	rs3099844	Neonatal lupus	TNF,NFKBIL1,LTA,LTB,AIF1	3.34	5E-10
chr6_mcf_hap5	2852476	2852477	rs2855812	Pulmonary function	MICB	.03	2E-7
chr6_mcf_hap5	2855242	2855243	rs3132468	Dengue shock syndrome	MICB	1.34	4E-11
chr6_mcf_hap5	2861055	2861056	rs2516399	White blood cell types	MHC	.11	2E-12
chr6_mcf_hap5	2879352	2879353	rs3853601	Atopic dermatitis	BAT1	1.13	2E-6
chr6_mcf_hap5	2885229	2885230	rs2734583	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	BAT1, HCP5, MICC, PPIAP9, PSORS1C1, POLR2LP, CCHCR1, TCF19, POU5F1, HLA-C, HCP5, PSORS1C3, HLA-B*5801	66.80	2E-8
chr6_mcf_hap5	2922013	2922014	rs1799964	Crohn's disease	LTA,HLA-DQA2,TNF,LST1,LTB	1.19	4E-11
chr6_mcf_hap5	2937491	2937492	rs11575839	Complement C3 and C4 levels	HLA-C	.23	1E-54
chr6_mcf_hap5	2982654	2982655	rs1046089	Menopause (age at onset)	PRRC2A	.21	2E-16
chr6_mcf_hap5	2996039	2996040	rs805303	Systolic blood pressure	BAT2, BAT5	.38	2E-11
chr6_mcf_hap5	2996039	2996040	rs805303	Hypertension	BAT2, BAT5	.05	1E-10
chr6_mcf_hap5	2996039	2996040	rs805303	Diastolic blood pressure	BAT2, BAT5	.23	3E-11
chr6_mcf_hap5	3000199	3000200	rs3117582	Lung adenocarcinoma	BAT3, APOM	1.22	5E-12
chr6_mcf_hap5	3000199	3000200	rs3117582	Lung cancer	BAT3	1.24	4E-10
chr6_mcf_hap5	3000199	3000200	rs3117582	Lung cancer	BAT3,MSH5	1.24	5E-10
chr6_mcf_hap5	3002285	3002286	rs805297	Rheumatoid arthritis	APOM	1.56	3E-10
chr6_mcf_hap5	3100721	3100722	rs3131379	Systemic lupus erythematosus	HLA region	2.36	2E-52
chr6_mcf_hap5	3216939	3216940	rs11966200	Vitiligo	HLA-C,HLA-B	1.90	1E-48
chr6_mcf_hap5	3218584	3218585	rs494620	Menopause (age at onset)	NR	.30	5E-7
chr6_mcf_hap5	3223796	3223797	rs2736428	Telomere length	SLC44A4	.05	3E-6
chr6_mcf_hap5	3247135	3247136	rs9267663	Economic and political preferences (environmentalism)	EHMT2	.29	6E-6
chr6_mcf_hap5	3250738	3250739	rs9267665	Hepatitis B vaccine response	HLA	2.05	1E-17
chr6_mcf_hap5	3263572	3263573	rs9267673	Hepatocellular carcinoma	C2	1.97	2E-6
chr6_mcf_hap5	3283647	3283648	rs9332739	Age-related macular degeneration (GA)	C2	2.63	1E-6
chr6_mcf_hap5	3283647	3283648	rs9332739	Age-related macular degeneration (CNV)	C2	2.08	2E-8
chr6_mcf_hap5	3283647	3283648	rs9332739	Age-related macular degeneration	C2	2.17	2E-23
chr6_mcf_hap5	3285852	3285853	rs9380272	Age-related macular degeneration	C2,CFB	4.31	2E-8
chr6_mcf_hap5	3294023	3294024	rs641153	Age-related macular degeneration (GA)	CFB	2.13	2E-9
chr6_mcf_hap5	3294023	3294024	rs641153	Age-related macular degeneration (CNV)	CFB	2.22	1E-17
chr6_mcf_hap5	3294023	3294024	rs641153	Age-related macular degeneration	CFB	1.85	6E-31
chr6_mcf_hap5	3294023	3294024	rs641153	Age-related macular degeneration	CFB,C2	NR	2E-20
chr6_mcf_hap5	3296794	3296795	rs541862	Age-related macular degeneration	CFB	1.89	9E-17
chr6_mcf_hap5	3310305	3310306	rs429608	Age-related macular degeneration	SKIV2L,BF	1.85	5E-15
chr6_mcf_hap5	3310305	3310306	rs429608	Age-related macular degeneration	C2,CFB	2.16	3E-21
chr6_mcf_hap5	3399586	3399587	rs2857009	Complement C3 and C4 levels	C4	.08	1E-22
chr6_mcf_hap5	3406648	3406649	rs12198173	HIV-1 control	TNXB	NR	3E-6
chr6_mcf_hap5	3429905	3429906	rs185819	Height	HLA class III	5.20	3E-8
chr6_mcf_hap5	3430596	3430597	rs1150754	Systemic lupus erythematosus	TNXB	2.21	6E-29
chr6_mcf_hap5	3450843	3450844	rs3117181	Phospholipid levels (plasma)	TNXB	.02	5E-7
chr6_mcf_hap5	3454631	3454632	rs12153855	Age-related macular degeneration	TNXB	1.44	1E-9
chr6_mcf_hap5	3456326	3456327	rs2269426	Eosinophil counts	MHC	4.60	3E-6
chr6_mcf_hap5	3489802	3489803	rs204999	Serum total protein level	Intergenic	.03	4E-11
chr6_mcf_hap5	3489802	3489803	rs204999	Serum total protein level	Intergenic	.03	3E-9
chr6_mcf_hap5	3489802	3489803	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_mcf_hap5	3489802	3489803	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_mcf_hap5	3516375	3516376	rs1061808	Phospholipid levels (plasma)	AGPAT1	.90	8E-10
chr6_mcf_hap5	3531269	3531270	rs2070600	Pulmonary function	AGER, PPT2	1.00	3E-14
chr6_mcf_hap5	3531269	3531270	rs2070600	Pulmonary function	AGER	.09	3E-15
chr6_mcf_hap5	3535404	3535405	rs204993	Asthma	PBX2	1.17	2E-15
chr6_mcf_hap5	3538142	3538143	rs176095	Atopic dermatitis	GPSM3	1.40	8E-20
chr6_mcf_hap5	3545267	3545268	rs2071278	Complement C3 and C4 levels	HLA-DRA	.13	4E-72
chr6_mcf_hap5	3551516	3551517	rs2071277	Age-related macular degeneration	NOTCH4	1.30	2E-11
chr6_mcf_hap5	3552826	3552827	rs3131296	Schizophrenia	MHC, NOTCH4	1.19	2E-10
chr6_mcf_hap5	3564194	3564195	rs404860	Asthma	NOTCH4	1.21	4E-23
chr6_mcf_hap5	3570252	3570253	rs443198	Systemic sclerosis	NOTCH4	1.82	9E-21
chr6_mcf_hap5	3598689	3598690	rs3115573	Nephropathy	Intergenic	1.62	1E-9
chr6_mcf_hap5	3598835	3598836	rs9296015	Systemic sclerosis	NOTCH4	1.85	1E-8
chr6_mcf_hap5	3598835	3598836	rs9296015	Rheumatoid arthritis	HLA locus	NR	2E-38
chr6_mcf_hap5	3662754	3662755	rs6910071	Rheumatoid arthritis	HLA-DRB1	2.88	1E-299
chr6_mcf_hap5	3685891	3685892	rs3129900	Lumiracoxib-related liver injury	HLA-DRB1	7.50	7E-25
chr6_mcf_hap5	3688822	3688823	rs9469099	Atopic dermatitis	C6orf10	1.61	5E-19
chr6_mcf_hap5	3701111	3701112	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_mcf_hap5	3701111	3701112	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_mcf_hap5	3701111	3701112	rs2395148	Arthritis (juvenile idiopathic)	HLA-DRB1	5.37	2E-10
chr6_mcf_hap5	3704928	3704929	rs13196329	Visceral fat	C6orf10	NR	3E-6
chr6_mcf_hap5	3715760	3715761	rs3129934	Multiple sclerosis	C6orf10	2.34	7E-16
chr6_mcf_hap5	3715760	3715761	rs3129934	Multiple sclerosis	HLA-DRB1	3.30	9E-11
chr6_mcf_hap5	3717205	3717206	rs2273017	Graves' disease	MHC	1.53	2E-22
chr6_mcf_hap5	3718280	3718281	rs3129943	Asthma	C6orf10	1.17	3E-15
chr6_mcf_hap5	3718660	3718661	rs2050190	Activated partial thromboplastin time	C6orf10	.25	7E-7
chr6_mcf_hap5	3720937	3720938	rs9268402	Coronary heart disease	C6orf10, BTNL2	1.16	3E-15
chr6_mcf_hap5	3724862	3724863	rs7758128	Vitiligo	C6orf10, BTNL2	NR	8E-11
chr6_mcf_hap5	3737826	3737827	rs3117099	Bipolar disorder and schizophrenia	MHC, other genes	1.25	3E-6
chr6_mcf_hap5	3738070	3738071	rs3117098	Asthma	BTNL2	1.16	5E-12
chr6_mcf_hap5	3742772	3742773	rs1980493	Anti-cyclic Citrullinated Peptide Antibody	HLA-DRA, BTNL2	NR	5E-7
chr6_mcf_hap5	3743373	3743374	rs2076530	Sarcoidosis	BTNL2	NR	3E-11
chr6_mcf_hap5	3743401	3743402	rs9268480	Ulcerative colitis	BTNL2	1.82	3E-6
chr6_mcf_hap5	3743512	3743513	rs2076529	Waist-hip ratio	BTNL2	.02	4E-7
chr6_mcf_hap5	3747644	3747645	rs3817963	Lung adenocarcinoma	BTNL2	1.18	3E-10
chr6_mcf_hap5	3752873	3752874	rs10947262	Knee osteoarthritis	BTNL2, HLA-DQA2, HLA-DQB1	1.31	5E-9
chr6_mcf_hap5	3753261	3753262	rs3806156	Vitiligo	BTNL2,HLA-DRA,HLA-DQA1	1.42	7E-19
chr6_mcf_hap5	3756031	3756032	rs3763313	HIV-1 control	BTNL2, NOTCH4	NR	2E-6
chr6_mcf_hap5	3756348	3756349	rs3763317	Complement C3 and C4 levels	HLA-DRB	.12	9E-66
chr6_mcf_hap5	3758262	3758263	rs9268516	Asthma	BTNL2, HLA-DRA	1.15	1E-8
chr6_mcf_hap5	3761885	3761886	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_mcf_hap5	3761885	3761886	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_mcf_hap5	3763498	3763499	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_mcf_hap5	3763498	3763499	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_mcf_hap5	3766582	3766583	rs2395163	Parkinson's disease	LOC642072	1.24	3E-11
chr6_mcf_hap5	3768421	3768422	rs3135363	Hepatitis B vaccine response	HLA-DR	1.53	7E-22
chr6_mcf_hap5	3768421	3768422	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_mcf_hap5	3768421	3768422	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_mcf_hap5	3779987	3779988	rs3135338	Multiple sclerosis	HLA	3.43	2E-25
chr6_mcf_hap5	3787298	3787299	rs9268645	Type 1 diabetes	MHC	NR	1E-100
chr6_mcf_hap5	3788301	3788302	rs3129882	Systemic sclerosis	HLA-DRA	2.17	2E-27
chr6_mcf_hap5	3788301	3788302	rs3129882	Parkinson's disease	HLA-DRA	1.26	2E-10
chr6_mcf_hap5	3790417	3790418	rs7192	Non-obstructive azoospermia	HLA-DRA	1.29	3E-6
chr6_mcf_hap5	3791214	3791215	rs3177928	LDL cholesterol	HLA	1.83	2E-15
chr6_mcf_hap5	3791214	3791215	rs3177928	Cholesterol, total	HLA	2.31	4E-19
chr6_mcf_hap5	3791830	3791831	rs3135388	Multiple sclerosis	HLA-DRB1	2.75	4E-225
chr6_mcf_hap5	3791830	3791831	rs3135388	Multiple sclerosis	HLA-DRA	1.99	9E-81
chr6_mcf_hap5	3792238	3792239	rs2227139	Hematological parameters	Intergenic	.02	1E-7
chr6_mcf_hap5	3792324	3792325	rs3129889	Multiple sclerosis	HLA-DRB1	2.97	1E-206
chr6_mcf_hap5	3793050	3793051	rs3129890	Asthma	HLA-DRA	1.15	5E-13
chr6_mcf_hap5	3806976	3806977	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_mcf_hap5	3806976	3806977	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_mcf_hap5	3806976	3806977	rs6903608	Hodgkin's lymphoma	HLA-DRA	1.70	3E-50
chr6_mcf_hap5	3808334	3808335	rs9268853	Rheumatoid arthritis	HLA-DRA	2.40	5E-109
chr6_mcf_hap5	3808334	3808335	rs9268853	Ulcerative colitis	HLA-DRB5, HLA-DQA1, HLA-DRB1, HLA-DRA, BTNL2	1.40	1E-55
chr6_mcf_hap5	3809835	3809836	rs9268877	Ulcerative colitis	MHC	NR	4E-23
chr6_mcf_hap5	3809835	3809836	rs9268877	Ulcerative colitis	HLA-DRA, BTNL2	1.45	6E-18
chr6_mcf_hap5	3810768	3810769	rs9268905	Cystic fibrosis severity	HLA-DRA	NR	1E-7
chr6_mcf_hap5	3811526	3811527	rs9268923	Ulcerative colitis	HLA-DRA	1.45	4E-15
chr6_mcf_hap5	3811859	3811860	rs2395185	Lung cancer	HLA class II	1.17	1E-8
chr6_mcf_hap5	3811859	3811860	rs2395185	Hodgkin's lymphoma	HLA-DRA	1.82	4E-31
chr6_mcf_hap5	3811859	3811860	rs2395185	Ulcerative colitis	Intergenic	1.92	5E-22
chr6_mcf_hap5	3811859	3811860	rs2395185	Ulcerative colitis	BTNL2, HLA-DRA, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1	1.52	1E-16
chr6_mcf_hap5	3929938	3929939	rs3129763	Systemic sclerosis	HLA-DQA1, HLA-DRB1	1.65	1E-11
chr6_mcf_hap5	3931609	3931610	rs28421666	Nasopharyngeal carcinoma	HLA-DQ,HLA-DR	1.49	2E-18
chr6_mcf_hap5	3938862	3938863	rs9272105	Hepatocellular carcinoma	HLA-DQA1, HLA-DRB1	1.28	5E-22
chr6_mcf_hap5	3938862	3938863	rs9272105	Response to interferon beta therapy	HLA-DQA1, HLA-DRB1	.26	4E-10
chr6_mcf_hap5	3941131	3941132	rs9272219	Rheumatoid arthritis	HLA-DQA1	1.92	1E-45
chr6_mcf_hap5	3941131	3941132	rs9272219	Schizophrenia	HLA-DQA1	1.14	7E-8
chr6_mcf_hap5	3941869	3941870	rs2040406	Multiple sclerosis	HLA-DRB,HLA-DQB1	2.05	1E-20
chr6_mcf_hap5	3943237	3943238	rs9272346	Type 1 diabetes	HLA	NR	6E-129
chr6_mcf_hap5	3943237	3943238	rs9272346	Type 1 diabetes	MHC	5.49	5E-134
chr6_mcf_hap5	3944753	3944754	rs2187668	Systemic lupus erythematosus	HLA-DR3	2.23	6E-28
chr6_mcf_hap5	3944753	3944754	rs2187668	Nephropathy (idiopathic membranous)	HLA-DQA1	4.32	8E-93
chr6_mcf_hap5	3944753	3944754	rs2187668	Immunoglobulin A	HLA-DRB1	2.53	2E-33
chr6_mcf_hap5	3944753	3944754	rs2187668	Celiac disease	HLA-DQA1, HLA-DQB1	6.23	1E-50
chr6_mcf_hap5	3944753	3944754	rs2187668	Systemic lupus erythematosus	HLA-DQA1	NR	3E-21
chr6_mcf_hap5	3944753	3944754	rs2187668	Celiac disease	HLA-DQA1	7.04	1E-19
chr6_mcf_hap5	3945602	3945603	rs9272535	Chronic lymphocytic leukemia	HLA-DQA1	1.61	9E-8
chr6_mcf_hap5	3960029	3960030	rs9273349	Asthma	HLA-DQ	1.18	7E-14
chr6_mcf_hap5	3967117	3967118	rs9274407	Drug-induced liver injury (amoxicillin-clavulanate)	HLA-DRB1-DQB1	3.10	5E-14
chr6_mcf_hap5	3984900	3984901	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_mcf_hap5	3984900	3984901	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_mcf_hap5	3993971	3993972	rs7774434	Primary biliary cirrhosis	MHC	1.60	4E-34
chr6_mcf_hap5	3993971	3993972	rs7774434	Primary biliary cirrhosis	HLA-DQB1	1.75	3E-26
chr6_mcf_hap5	3994473	3994474	rs7775228	IgE grass sensitization	HLA region	1.33	2E-9
chr6_mcf_hap5	3994473	3994474	rs7775228	Asthma	HLA-DQB1	1.17	5E-15
chr6_mcf_hap5	3994704	3994705	rs9469220	Crohn's disease	NR	1.14	2E-6
chr6_mcf_hap5	4000708	4000709	rs3129720	Hypothyroidism	HLA-DRB9, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DQA2	1.16	5E-7
chr6_mcf_hap5	4000929	4000930	rs6457617	Graves' disease	HLA, DRB1, DQA1, DQB1	1.40	7E-33
chr6_mcf_hap5	4000929	4000930	rs6457617	Systemic sclerosis	HLA, DQB1	1.61	2E-37
chr6_mcf_hap5	4000929	4000930	rs6457617	Systemic sclerosis	HLA-DQB1	1.37	4E-17
chr6_mcf_hap5	4000929	4000930	rs6457617	Rheumatoid arthritis	HLA-DQA1, HLA-DQA2	NR	1E-9
chr6_mcf_hap5	4000929	4000930	rs6457617	Rheumatoid arthritis	MHC	2.36	5E-75
chr6_mcf_hap5	4001077	4001078	rs6457620	Height	HLA locus	.03	2E-16
chr6_mcf_hap5	4001077	4001078	rs6457620	Rheumatoid arthritis	HLA-DRB1	2.55	4E-186
chr6_mcf_hap5	4001536	4001537	rs2647012	Follicular lymphoma	HLA-DQB1	1.56	2E-21
chr6_mcf_hap5	4001536	4001537	rs2647012	Systemic lupus erythematosus	HLA-DQA1, HLA-DQA2	1.38	8E-6
chr6_mcf_hap5	4002038	4002039	rs9357152	HPV seropositivity	HLA-DQB1	NR	1E-14
chr6_mcf_hap5	4002038	4002039	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_mcf_hap5	4002038	4002039	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_mcf_hap5	4002498	4002499	rs10484561	Follicular lymphoma	HLA-DQB1	1.95	1E-29
chr6_mcf_hap5	4004967	4004968	rs2647044	Pulmonary function	HLA-DQB1	.04	6E-6
chr6_mcf_hap5	4004967	4004968	rs2647044	Type 1 diabetes	HLA-DRB1	8.30	1E-16
chr6_mcf_hap5	4006214	4006215	rs9275390	Systemic sclerosis	HLA-DQB1	1.61	1E-7
chr6_mcf_hap5	4006214	4006215	rs9275390	Systemic sclerosis	HLA-DQB1	2.38	3E-54
chr6_mcf_hap5	4006430	4006431	rs11752643	Coronary heart disease	HLA, DRB-DQB	1.26	5E-7
chr6_mcf_hap5	4007304	4007305	rs2856718	Hepatitis B	HLA-DQB1	1.56	4E-37
chr6_mcf_hap5	4008152	4008153	rs13192471	Rheumatoid arthritis	HLA-DRB1	1.97	2E-58
chr6_mcf_hap5	4008297	4008298	rs1794275	IgA nephropathy	HLA-DQA/B	1.30	3E-13
chr6_mcf_hap5	4015538	4015539	rs9275572	Hepatocellular carcinoma	HLA-DQ, HLA-DR	1.30	6E-9
chr6_mcf_hap5	4015538	4015539	rs9275572	Alopecia areata	HLA-DQA2	2.21	1E-35
chr6_mcf_hap5	4017469	4017470	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6_mcf_hap5	4017469	4017470	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6_mcf_hap5	4017818	4017819	rs2858331	IgE levels	HLA-DQA2	.04	1E-8
chr6_mcf_hap5	4018172	4018173	rs9275596	Nephropathy	HLA-DRB1, HLA-DQA1, HLA-DQB1	1.59	2E-26
chr6_mcf_hap5	4018217	4018218	rs3104402	Immune response to anthrax vaccine	HLA-DRB1,HLA-DQA1	.17	6E-6
chr6_mcf_hap5	4022091	4022092	rs3916765	Type 2 diabetes	HLA-DQA2	1.21	1E-6
chr6_mcf_hap5	4024808	4024809	rs9275698	Asthma	HLA-DQA2	1.18	5E-12
chr6_mcf_hap5	4037279	4037280	rs2858884	Narcolepsy	HLA-DQA2	1.79	3E-8
chr6_mcf_hap5	4062377	4062378	rs2301271	Systemic lupus erythematosus	HLA-DQA2	1.47	2E-12
chr6_mcf_hap5	4067197	4067198	rs7453920	Hepatitis B	HAL-DQB2	1.81	6E-28
chr6_mcf_hap5	4067271	4067272	rs2051549	Systemic lupus erythematosus	HLA-DQA2	NR	3E-22
chr6_mcf_hap5	4073871	4073872	rs9276606	Complement C3 and C4 levels	HLA-DQB	.09	3E-22
chr6_mcf_hap5	4100409	4100410	rs2857151	Kawasaki disease	HLA-DQB2, HLA-DOB	1.47	5E-11
chr6_mcf_hap5	4140947	4140948	rs241428	Complement C3 and C4 levels	HLA-DQB	.23	9E-83
chr6_mcf_hap5	4146724	4146725	rs9357155	Nephropathy	TAP2, TAP1, PSMB8, PSMB9	1.41	2E-12
chr6_mcf_hap5	4189481	4189482	rs2187689	Disc degeneration (lumbar)	PSMB9	.23	3E-8
chr6_mcf_hap5	4191527	4191528	rs10046257	Disc degeneration (lumbar)	Intergenic	.19	3E-7
chr6_mcf_hap5	4192547	4192548	rs6457690	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_mcf_hap5	4193216	4193217	rs1029296	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_mcf_hap5	4193317	4193318	rs1029295	Disc degeneration (lumbar)	Intergenic	.19	5E-7
chr6_mcf_hap5	4193769	4193770	rs6936004	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_mcf_hap5	4194252	4194253	rs10214886	Disc degeneration (lumbar)	Intergenic	.19	2E-7
chr6_mcf_hap5	4196545	4196546	rs7744666	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_mcf_hap5	4196581	4196582	rs11969002	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_mcf_hap5	4197585	4197586	rs9469300	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_mcf_hap5	4199440	4199441	rs3749982	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_mcf_hap5	4311876	4311877	rs399604	Platelet counts	HLA-DOA	2.35	1E-10
chr6_mcf_hap5	4369894	4369895	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.82	4E-45
chr6_mcf_hap5	4369894	4369895	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.67	1E-9
chr6_mcf_hap5	4369894	4369895	rs3077	Hepatitis B	HLA-DPA1	1.87	2E-61
chr6_mcf_hap5	4379734	4379735	rs987870	Asthma	HLA, DPB1	1.40	2E-10
chr6_mcf_hap5	4379734	4379735	rs987870	Systemic sclerosis	HLA-DPA1, HLA-DPB1	2.09	2E-20
chr6_mcf_hap5	4391705	4391706	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.64	2E-21
chr6_mcf_hap5	4391705	4391706	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.52	2E-17
chr6_mcf_hap5	4391705	4391706	rs9277535	Hepatitis B vaccine response	HLA-DPB1	1.39	3E-12
chr6_mcf_hap5	4391705	4391706	rs9277535	Hepatitis B	HLA-DPB1	1.77	3E-54
chr6_mcf_hap5	4391705	4391706	rs9277535	Hepatitis B	HLA-DPB1	1.75	6E-39
chr6_mcf_hap5	4396962	4396963	rs2281388	Graves' disease	HLA, DPB1	1.64	2E-65
chr6_mcf_hap5	4406737	4406738	rs3117242	Antineutrophil cytoplasmic antibody-associated vasculitis	HLA-DP, COL11A2	3.67	1E-71
chr6_mcf_hap5	4617712	4617713	rs2254287	LDL cholesterol	B3GALT4	1.91	5E-8
chr6_qbl_hap6	79517	79518	rs4324798	Lung adenocarcinoma	TRNAA-UGC	1.16	2E-8
chr6_qbl_hap6	219651	219652	rs4947339	Platelet aggregation	TRIM27	NR	2E-6
chr6_qbl_hap6	387634	387635	rs3129109	Height	OR2J3	.03	2E-17
chr6_qbl_hap6	737698	737699	rs4713226	Immune reponse to smallpox (secreted IFN-alpha)	OR2H1	NR	2E-8
chr6_qbl_hap6	914742	914743	rs29232	Nasopharyngeal carcinoma	GABBR1	1.67	9E-17
chr6_qbl_hap6	973571	973572	rs3129055	Nasopharyngeal carcinoma	HLA-F	1.51	7E-11
chr6_qbl_hap6	1003379	1003380	rs2523395	Prostate cancer (gene x gene interaction)	LOC285830	1.24	2E-6
chr6_qbl_hap6	1006520	1006521	rs2523393	Multiple sclerosis	HLA-B	1.28	1E-17
chr6_qbl_hap6	1024011	1024012	rs9258260	Crohn's disease	HLA-F, MOG, HLA-G, GABBR1, HLA-H, UBD, HLA-A	1.45	2E-10
chr6_qbl_hap6	1089754	1089755	rs1610677	Rheumatoid arthritis	HLA-G	1.32	4E-15
chr6_qbl_hap6	1129014	1129015	rs2523822	Drug-induced liver injury (amoxicillin-clavulanate)	HLA-A	2.30	2E-10
chr6_qbl_hap6	1144296	1144297	rs2523809	IgE levels	HLA-G	.06	4E-8
chr6_qbl_hap6	1199455	1199456	rs2860580	Nasopharyngeal carcinoma	HLA-A	1.72	5E-67
chr6_qbl_hap6	1206090	1206091	rs1061235	Adverse response to carbamapezine	HLA-A*3101	9.12	1E-7
chr6_qbl_hap6	1210909	1210910	rs2517713	Nasopharyngeal carcinoma	HLA-A	1.88	4E-20
chr6_qbl_hap6	1213188	1213189	rs9260489	Multiple sclerosis	HLA-B	1.21	1E-11
chr6_qbl_hap6	1216661	1216662	rs2571391	IgE levels	HLA-A	.06	1E-15
chr6_qbl_hap6	1228049	1228050	rs3893464	Graves' disease	MHC	1.53	2E-20
chr6_qbl_hap6	1234734	1234735	rs2523946	IgA nephropathy	HLA-A	1.21	2E-11
chr6_qbl_hap6	1235858	1235859	rs6904029	Vitiligo	HLA-A,HCG9	1.49	1E-21
chr6_qbl_hap6	1263503	1263504	rs7758512	HIV-1 control	ZNRD1, RNF39, HLA-A	NR	2E-8
chr6_qbl_hap6	1266840	1266841	rs4313034	Graves' disease	MHC	1.67	2E-15
chr6_qbl_hap6	1310027	1310028	rs6917603	Lipid metabolism phenotypes	PPP1R11	.24	3E-29
chr6_qbl_hap6	1318499	1318500	rs259919	HIV-1 control	C6orf12, ZNRD1	NR	3E-7
chr6_qbl_hap6	1325501	1325502	rs8321	AIDS progression	ZNRD1, RNF39	NR	5E-7
chr6_qbl_hap6	1373328	1373329	rs34704616	Cognitive performance	XXbac-BPG250I8.13	NR	6E-6
chr6_qbl_hap6	1386321	1386322	rs10947055	Cardiac hypertrophy	TRIM38	NR	2E-7
chr6_qbl_hap6	1412837	1412838	rs9468692	HIV-1 control	TRIM10	NR	1E-6
chr6_qbl_hap6	1458199	1458200	rs2523722	Schizophrenia	MHC, TRIM26	1.25	1E-16
chr6_qbl_hap6	1467057	1467058	rs2021722	Schizophrenia	TRIM26	1.15	2E-12
chr6_qbl_hap6	1830511	1830512	rs3132613	Graves' disease	MHC	1.43	1E-13
chr6_qbl_hap6	2029058	2029059	rs12526186	Response to antipsychotic treatment	Intergenic	9.00	3E-6
chr6_qbl_hap6	2074925	2074926	rs886424	Bipolar disorder and schizophrenia	MHC, other genes	1.37	9E-7
chr6_qbl_hap6	2088097	2088098	rs7772131	Response to angiotensin II receptor blocker therapy	C6orf214	6.73	3E-6
chr6_qbl_hap6	2141239	2141240	rs7756521	HIV-1 control	DDR1, VARS2, DPCR1	NR	1E-6
chr6_qbl_hap6	2169136	2169137	rs1052693	Complement C3 and C4 levels	HLA-A	.10	3E-48
chr6_qbl_hap6	2296071	2296072	rs4248154	Graves' disease	MHC	1.38	1E-13
chr6_qbl_hap6	2300308	2300309	rs2844665	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	C6orf205	1.54	3E-7
chr6_qbl_hap6	2314578	2314579	rs2517532	Hypothyroidism	LOC729792, HCG22, C6orf15, HLA-C, HLA-B, DHFRP2, HCP5	1.16	1E-8
chr6_qbl_hap6	2320591	2320592	rs9262632	HIV-1 control	Intergenic	3.10	1E-8
chr6_qbl_hap6	2353987	2353988	rs4947296	Behcet's disease	HCG22	2.57	1E-11
chr6_qbl_hap6	2353987	2353988	rs4947296	Graves' disease	MUC21, C6orf15	1.77	4E-51
chr6_qbl_hap6	2354149	2354150	rs3130544	Myasthenia gravis	NR	5.64	2E-90
chr6_qbl_hap6	2369856	2369857	rs6457327	Follicular lymphoma	C6orf15	1.47	7E-6
chr6_qbl_hap6	2369856	2369857	rs6457327	Follicular lymphoma	STG, PSORS1	1.69	5E-11
chr6_qbl_hap6	2389409	2389410	rs3815087	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	PSORS1C1	1.53	3E-7
chr6_qbl_hap6	2389409	2389410	rs3815087	HIV-1 control	CDSN	NR	8E-8
chr6_qbl_hap6	2393143	2393144	rs3130559	Chronic obstructive pulmonary disease-related biomarkers	PSORS1C1	NR	8E-9
chr6_qbl_hap6	2395420	2395421	rs4959053	Behcet's disease	PSORS1C1	4.38	2E-20
chr6_qbl_hap6	2402113	2402114	rs3130573	Systemic sclerosis	PSORS1C1	1.25	6E-10
chr6_qbl_hap6	2403031	2403032	rs1265093	Chronic obstructive pulmonary disease-related biomarkers	PSORS1C1, CCHCR1	NR	6E-9
chr6_qbl_hap6	2407189	2407190	rs9263739	Ulcerative colitis	HLA	2.73	4E-67
chr6_qbl_hap6	2413851	2413852	rs1265112	Nevirapine-induced rash	CCHCR1	4.36	1E-8
chr6_qbl_hap6	2414343	2414344	rs130067	Prostate cancer	CCHCR1	1.05	3E-8
chr6_qbl_hap6	2432321	2432322	rs3130501	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	POU5F1	1.74	2E-8
chr6_qbl_hap6	2435320	2435321	rs879882	Height	MICA	NR	2E-7
chr6_qbl_hap6	2439450	2439451	rs3131018	HIV-1 control	PSORS1C3	2.10	4E-16
chr6_qbl_hap6	2451642	2451643	rs1265181	Psoriasis	MHC	22.62	NS
chr6_qbl_hap6	2463877	2463878	rs6903896	Common traits (Other)	NR	NR	6E-7
chr6_qbl_hap6	2480051	2480052	rs3869109	Coronary heart disease	HCG27, HLA-C	1.14	1E-9
chr6_qbl_hap6	2514925	2514926	rs3095254	White blood cell types	MHC	.07	6E-11
chr6_qbl_hap6	2533666	2533667	rs2074488	Chronic obstructive pulmonary disease-related biomarkers	HLA-C	NR	2E-10
chr6_qbl_hap6	2534343	2534344	rs13191343	Psoriatic arthritis	HLA-C	2.37	2E-72
chr6_qbl_hap6	2545593	2545594	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.31	6E-21
chr6_qbl_hap6	2545593	2545594	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.37	2E-28
chr6_qbl_hap6	2546122	2546123	rs12191877	Psoriasis	HLA-C	2.79	4E-32
chr6_qbl_hap6	2546122	2546123	rs12191877	Psoriasis	HLA-C	2.64	1E-100
chr6_qbl_hap6	2552317	2552318	rs9468925	Vitiligo	HLA	1.35	2E-33
chr6_qbl_hap6	2557222	2557223	rs2894207	Nasopharyngeal carcinoma	HLA-B,HLA-C	1.64	3E-33
chr6_qbl_hap6	2558955	2558956	rs2247056	Triglycerides	HLA	2.99	2E-15
chr6_qbl_hap6	2565244	2565245	rs9461688	Protein quantitative trait loci	HLA-C	NR	4E-6
chr6_qbl_hap6	2565851	2565852	rs9368677	Atopic dermatitis	HLA-C	1.36	1E-17
chr6_qbl_hap6	2567903	2567904	rs9264942	HIV-1 control	HLA-C	2.90	3E-35
chr6_qbl_hap6	2567903	2567904	rs9264942	HIV-1 control	HLA-C	5.30	6E-32
chr6_qbl_hap6	2567903	2567904	rs9264942	HIV-1 control	HLA-C	NR	6E-12
chr6_qbl_hap6	2568078	2568079	rs10484554	Psoriasis	HLA-C	4.66	4E-214
chr6_qbl_hap6	2568078	2568079	rs10484554	AIDS progression	HLA-C	NR	6E-8
chr6_qbl_hap6	2568078	2568079	rs10484554	Psoriasis	HLA-C	2.80	2E-39
chr6_qbl_hap6	2605801	2605802	rs3134792	Psoriasis	HLA-C	NR	1E-9
chr6_qbl_hap6	2615872	2615873	rs3819299	Platelet counts	HLA-B	5.05	9E-10
chr6_qbl_hap6	2616064	2616065	rs2523608	HIV-1 control	HLA-B	2.60	9E-20
chr6_qbl_hap6	2616064	2616065	rs2523608	HIV-1 control	HLA-B	NR	3E-6
chr6_qbl_hap6	2620579	2620580	rs2523590	HIV-1 control	HLA-B	2.40	2E-13
chr6_qbl_hap6	2621215	2621216	rs9378249	Bipolar disorder	NR	NR	1E-8
chr6_qbl_hap6	2629609	2629610	rs7743761	Ankylosing spondylitis	MHC	NR	5E-304
chr6_qbl_hap6	2629927	2629928	rs9266406	Behcet's disease	MICA, MICB, DHFRP2	2.29	2E-10
chr6_qbl_hap6	2640333	2640334	rs9266629	Chronic obstructive pulmonary disease-related biomarkers	FGFR3P	NR	4E-10
chr6_qbl_hap6	2644202	2644203	rs1521	Graves' disease	HLA-B	1.92	2E-65
chr6_qbl_hap6	2648060	2648061	rs13437082	Height	HLA-B	.07	5E-8
chr6_qbl_hap6	2659237	2659238	rs4349859	Ankylosing spondylitis	HLA-B	NR	1E-200
chr6_qbl_hap6	2660045	2660046	rs2596542	Hepatocellular carcinoma	MICA	1.39	4E-13
chr6_qbl_hap6	2671051	2671052	rs12175489	Visceral adipose tissue adjusted for BMI	HLA-B, HCP5	NR	2E-6
chr6_qbl_hap6	2673477	2673478	rs1063635	Rheumatoid arthritis	MICA	1.35	1E-17
chr6_qbl_hap6	2674072	2674073	rs2256183	Height	MICA	.04	8E-29
chr6_qbl_hap6	2734374	2734375	rs3828890	Renal function-related traits (sCR)	MHC	.01	3E-9
chr6_qbl_hap6	2734374	2734375	rs3828890	Renal function-related traits (eGRFcrea)	MHC	.01	1E-9
chr6_qbl_hap6	2740501	2740502	rs2248462	Hodgkin's lymphoma	MICB	1.64	7E-16
chr6_qbl_hap6	2742681	2742682	rs3099844	Metabolic syndrome	HCG26, MICB	.15	2E-8
chr6_qbl_hap6	2742681	2742682	rs3099844	Neonatal lupus	TNF,NFKBIL1,LTA,LTB,AIF1	3.34	5E-10
chr6_qbl_hap6	2766424	2766425	rs2855812	Pulmonary function	MICB	.03	2E-7
chr6_qbl_hap6	2769190	2769191	rs3132468	Dengue shock syndrome	MICB	1.34	4E-11
chr6_qbl_hap6	2774996	2774997	rs2516399	White blood cell types	MHC	.11	2E-12
chr6_qbl_hap6	2793282	2793283	rs3853601	Atopic dermatitis	BAT1	1.13	2E-6
chr6_qbl_hap6	2799157	2799158	rs2734583	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	BAT1, HCP5, MICC, PPIAP9, PSORS1C1, POLR2LP, CCHCR1, TCF19, POU5F1, HLA-C, HCP5, PSORS1C3, HLA-B*5801	66.80	2E-8
chr6_qbl_hap6	2835945	2835946	rs1799964	Crohn's disease	LTA,HLA-DQA2,TNF,LST1,LTB	1.19	4E-11
chr6_qbl_hap6	2851432	2851433	rs11575839	Complement C3 and C4 levels	HLA-C	.23	1E-54
chr6_qbl_hap6	2862103	2862104	rs2857595	Pulmonary function	NCR3	.04	2E-10
chr6_qbl_hap6	2866585	2866586	rs2844479	Weight	AIF1, NCR3	3.58	2E-8
chr6_qbl_hap6	2868919	2868920	rs9348876	Crohn's disease	AIF1	1.41	3E-6
chr6_qbl_hap6	2896603	2896604	rs1046089	Menopause (age at onset)	PRRC2A	.21	2E-16
chr6_qbl_hap6	2910005	2910006	rs805303	Systolic blood pressure	BAT2, BAT5	.38	2E-11
chr6_qbl_hap6	2910005	2910006	rs805303	Hypertension	BAT2, BAT5	.05	1E-10
chr6_qbl_hap6	2910005	2910006	rs805303	Diastolic blood pressure	BAT2, BAT5	.23	3E-11
chr6_qbl_hap6	2914156	2914157	rs3117582	Lung adenocarcinoma	BAT3, APOM	1.22	5E-12
chr6_qbl_hap6	2914156	2914157	rs3117582	Lung cancer	BAT3	1.24	4E-10
chr6_qbl_hap6	2914156	2914157	rs3117582	Lung cancer	BAT3,MSH5	1.24	5E-10
chr6_qbl_hap6	2916242	2916243	rs805297	Rheumatoid arthritis	APOM	1.56	3E-10
chr6_qbl_hap6	3014676	3014677	rs3131379	Systemic lupus erythematosus	HLA region	2.36	2E-52
chr6_qbl_hap6	3072176	3072177	rs2075799	Complement C3 and C4 levels	C4	.17	6E-97
chr6_qbl_hap6	3096199	3096200	rs9368699	HIV-1 control	SNORD52	NR	5E-8
chr6_qbl_hap6	3130854	3130855	rs11966200	Vitiligo	HLA-C,HLA-B	1.90	1E-48
chr6_qbl_hap6	3132501	3132502	rs494620	Menopause (age at onset)	NR	.30	5E-7
chr6_qbl_hap6	3137715	3137716	rs2736428	Telomere length	SLC44A4	.05	3E-6
chr6_qbl_hap6	3161044	3161045	rs9267663	Economic and political preferences (environmentalism)	EHMT2	.29	6E-6
chr6_qbl_hap6	3164649	3164650	rs9267665	Hepatitis B vaccine response	HLA	2.05	1E-17
chr6_qbl_hap6	3177470	3177471	rs9267673	Hepatocellular carcinoma	C2	1.97	2E-6
chr6_qbl_hap6	3197596	3197597	rs9332739	Age-related macular degeneration (GA)	C2	2.63	1E-6
chr6_qbl_hap6	3197596	3197597	rs9332739	Age-related macular degeneration (CNV)	C2	2.08	2E-8
chr6_qbl_hap6	3197596	3197597	rs9332739	Age-related macular degeneration	C2	2.17	2E-23
chr6_qbl_hap6	3199802	3199803	rs9380272	Age-related macular degeneration	C2,CFB	4.31	2E-8
chr6_qbl_hap6	3207973	3207974	rs641153	Age-related macular degeneration (GA)	CFB	2.13	2E-9
chr6_qbl_hap6	3207973	3207974	rs641153	Age-related macular degeneration (CNV)	CFB	2.22	1E-17
chr6_qbl_hap6	3207973	3207974	rs641153	Age-related macular degeneration	CFB	1.85	6E-31
chr6_qbl_hap6	3207973	3207974	rs641153	Age-related macular degeneration	CFB,C2	NR	2E-20
chr6_qbl_hap6	3210744	3210745	rs541862	Age-related macular degeneration	CFB	1.89	9E-17
chr6_qbl_hap6	3224250	3224251	rs429608	Age-related macular degeneration	SKIV2L,BF	1.85	5E-15
chr6_qbl_hap6	3224250	3224251	rs429608	Age-related macular degeneration	C2,CFB	2.16	3E-21
chr6_qbl_hap6	3280799	3280800	rs2857009	Complement C3 and C4 levels	C4	.08	1E-22
chr6_qbl_hap6	3287861	3287862	rs12198173	HIV-1 control	TNXB	NR	3E-6
chr6_qbl_hap6	3311089	3311090	rs185819	Height	HLA class III	5.20	3E-8
chr6_qbl_hap6	3311780	3311781	rs1150754	Systemic lupus erythematosus	TNXB	2.21	6E-29
chr6_qbl_hap6	3370994	3370995	rs204999	Serum total protein level	Intergenic	.03	4E-11
chr6_qbl_hap6	3370994	3370995	rs204999	Serum total protein level	Intergenic	.03	3E-9
chr6_qbl_hap6	3370994	3370995	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_qbl_hap6	3370994	3370995	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_qbl_hap6	3397566	3397567	rs1061808	Phospholipid levels (plasma)	AGPAT1	.90	8E-10
chr6_qbl_hap6	3412462	3412463	rs2070600	Pulmonary function	AGER, PPT2	1.00	3E-14
chr6_qbl_hap6	3412462	3412463	rs2070600	Pulmonary function	AGER	.09	3E-15
chr6_qbl_hap6	3416597	3416598	rs204993	Asthma	PBX2	1.17	2E-15
chr6_qbl_hap6	3419336	3419337	rs176095	Atopic dermatitis	GPSM3	1.40	8E-20
chr6_qbl_hap6	3426460	3426461	rs2071278	Complement C3 and C4 levels	HLA-DRA	.13	4E-72
chr6_qbl_hap6	3432709	3432710	rs2071277	Age-related macular degeneration	NOTCH4	1.30	2E-11
chr6_qbl_hap6	3434019	3434020	rs3131296	Schizophrenia	MHC, NOTCH4	1.19	2E-10
chr6_qbl_hap6	3445365	3445366	rs404860	Asthma	NOTCH4	1.21	4E-23
chr6_qbl_hap6	3451426	3451427	rs443198	Systemic sclerosis	NOTCH4	1.82	9E-21
chr6_qbl_hap6	3479858	3479859	rs3115573	Nephropathy	Intergenic	1.62	1E-9
chr6_qbl_hap6	3480004	3480005	rs9296015	Systemic sclerosis	NOTCH4	1.85	1E-8
chr6_qbl_hap6	3480004	3480005	rs9296015	Rheumatoid arthritis	HLA locus	NR	2E-38
chr6_qbl_hap6	3484444	3484445	rs3130320	Systemic lupus erythematosus	NOTCH4, C6orf10	1.39	3E-6
chr6_qbl_hap6	3505824	3505825	rs3130340	Bone mineral density (spine)	MHC, C6orf10	.10	1E-7
chr6_qbl_hap6	3544050	3544051	rs6910071	Rheumatoid arthritis	HLA-DRB1	2.88	1E-299
chr6_qbl_hap6	3567182	3567183	rs3129900	Lumiracoxib-related liver injury	HLA-DRB1	7.50	7E-25
chr6_qbl_hap6	3570113	3570114	rs9469099	Atopic dermatitis	C6orf10	1.61	5E-19
chr6_qbl_hap6	3582415	3582416	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_qbl_hap6	3582415	3582416	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_qbl_hap6	3582415	3582416	rs2395148	Arthritis (juvenile idiopathic)	HLA-DRB1	5.37	2E-10
chr6_qbl_hap6	3586229	3586230	rs13196329	Visceral fat	C6orf10	NR	3E-6
chr6_qbl_hap6	3597061	3597062	rs3129934	Multiple sclerosis	C6orf10	2.34	7E-16
chr6_qbl_hap6	3597061	3597062	rs3129934	Multiple sclerosis	HLA-DRB1	3.30	9E-11
chr6_qbl_hap6	3598506	3598507	rs2273017	Graves' disease	MHC	1.53	2E-22
chr6_qbl_hap6	3599563	3599564	rs3129943	Asthma	C6orf10	1.17	3E-15
chr6_qbl_hap6	3599943	3599944	rs2050190	Activated partial thromboplastin time	C6orf10	.25	7E-7
chr6_qbl_hap6	3602220	3602221	rs9268402	Coronary heart disease	C6orf10, BTNL2	1.16	3E-15
chr6_qbl_hap6	3606148	3606149	rs7758128	Vitiligo	C6orf10, BTNL2	NR	8E-11
chr6_qbl_hap6	3619128	3619129	rs3117099	Bipolar disorder and schizophrenia	MHC, other genes	1.25	3E-6
chr6_qbl_hap6	3619371	3619372	rs3117098	Asthma	BTNL2	1.16	5E-12
chr6_qbl_hap6	3624072	3624073	rs1980493	Anti-cyclic Citrullinated Peptide Antibody	HLA-DRA, BTNL2	NR	5E-7
chr6_qbl_hap6	3624673	3624674	rs2076530	Sarcoidosis	BTNL2	NR	3E-11
chr6_qbl_hap6	3624701	3624702	rs9268480	Ulcerative colitis	BTNL2	1.82	3E-6
chr6_qbl_hap6	3624812	3624813	rs2076529	Waist-hip ratio	BTNL2	.02	4E-7
chr6_qbl_hap6	3628944	3628945	rs3817963	Lung adenocarcinoma	BTNL2	1.18	3E-10
chr6_qbl_hap6	3634165	3634166	rs10947262	Knee osteoarthritis	BTNL2, HLA-DQA2, HLA-DQB1	1.31	5E-9
chr6_qbl_hap6	3634562	3634563	rs3806156	Vitiligo	BTNL2,HLA-DRA,HLA-DQA1	1.42	7E-19
chr6_qbl_hap6	3637335	3637336	rs3763313	HIV-1 control	BTNL2, NOTCH4	NR	2E-6
chr6_qbl_hap6	3637652	3637653	rs3763317	Complement C3 and C4 levels	HLA-DRB	.12	9E-66
chr6_qbl_hap6	3640355	3640356	rs9268516	Asthma	BTNL2, HLA-DRA	1.15	1E-8
chr6_qbl_hap6	3643979	3643980	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_qbl_hap6	3643979	3643980	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_qbl_hap6	3645592	3645593	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_qbl_hap6	3645592	3645593	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_qbl_hap6	3648680	3648681	rs2395163	Parkinson's disease	LOC642072	1.24	3E-11
chr6_qbl_hap6	3650519	3650520	rs3135363	Hepatitis B vaccine response	HLA-DR	1.53	7E-22
chr6_qbl_hap6	3650519	3650520	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_qbl_hap6	3650519	3650520	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_qbl_hap6	3662089	3662090	rs3135338	Multiple sclerosis	HLA	3.43	2E-25
chr6_qbl_hap6	3669392	3669393	rs9268645	Type 1 diabetes	MHC	NR	1E-100
chr6_qbl_hap6	3670395	3670396	rs3129882	Systemic sclerosis	HLA-DRA	2.17	2E-27
chr6_qbl_hap6	3670395	3670396	rs3129882	Parkinson's disease	HLA-DRA	1.26	2E-10
chr6_qbl_hap6	3672511	3672512	rs7192	Non-obstructive azoospermia	HLA-DRA	1.29	3E-6
chr6_qbl_hap6	3673308	3673309	rs3177928	LDL cholesterol	HLA	1.83	2E-15
chr6_qbl_hap6	3673308	3673309	rs3177928	Cholesterol, total	HLA	2.31	4E-19
chr6_qbl_hap6	3673924	3673925	rs3135388	Multiple sclerosis	HLA-DRB1	2.75	4E-225
chr6_qbl_hap6	3673924	3673925	rs3135388	Multiple sclerosis	HLA-DRA	1.99	9E-81
chr6_qbl_hap6	3674332	3674333	rs2227139	Hematological parameters	Intergenic	.02	1E-7
chr6_qbl_hap6	3674418	3674419	rs3129889	Multiple sclerosis	HLA-DRB1	2.97	1E-206
chr6_qbl_hap6	3675145	3675146	rs3129890	Asthma	HLA-DRA	1.15	5E-13
chr6_qbl_hap6	3689191	3689192	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_qbl_hap6	3689191	3689192	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_qbl_hap6	3689191	3689192	rs6903608	Hodgkin's lymphoma	HLA-DRA	1.70	3E-50
chr6_qbl_hap6	3690549	3690550	rs9268853	Rheumatoid arthritis	HLA-DRA	2.40	5E-109
chr6_qbl_hap6	3690549	3690550	rs9268853	Ulcerative colitis	HLA-DRB5, HLA-DQA1, HLA-DRB1, HLA-DRA, BTNL2	1.40	1E-55
chr6_qbl_hap6	3692054	3692055	rs9268877	Ulcerative colitis	MHC	NR	4E-23
chr6_qbl_hap6	3692054	3692055	rs9268877	Ulcerative colitis	HLA-DRA, BTNL2	1.45	6E-18
chr6_qbl_hap6	3692987	3692988	rs9268905	Cystic fibrosis severity	HLA-DRA	NR	1E-7
chr6_qbl_hap6	3693745	3693746	rs9268923	Ulcerative colitis	HLA-DRA	1.45	4E-15
chr6_qbl_hap6	3694077	3694078	rs2395185	Lung cancer	HLA class II	1.17	1E-8
chr6_qbl_hap6	3694077	3694078	rs2395185	Hodgkin's lymphoma	HLA-DRA	1.82	4E-31
chr6_qbl_hap6	3694077	3694078	rs2395185	Ulcerative colitis	Intergenic	1.92	5E-22
chr6_qbl_hap6	3694077	3694078	rs2395185	Ulcerative colitis	BTNL2, HLA-DRA, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1	1.52	1E-16
chr6_qbl_hap6	3800911	3800912	rs28366298	Lung cancer	HLA class II	1.17	1E-8
chr6_qbl_hap6	3807134	3807135	rs477515	Inflammatory bowel disease	HLA-DQA1	1.38	1E-8
chr6_qbl_hap6	3809392	3809393	rs2858870	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_qbl_hap6	3809392	3809393	rs2858870	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_qbl_hap6	3811312	3811313	rs615672	Rheumatoid arthritis	HLA-DRB1	NR	8E-27
chr6_qbl_hap6	3813644	3813645	rs9271100	Systemic lupus erythematosus	HLA-DRB1	1.90	1E-12
chr6_qbl_hap6	3814544	3814545	rs660895	IgA nephropathy	HLA-DRB1	1.34	4E-20
chr6_qbl_hap6	3814544	3814545	rs660895	Rheumatoid arthritis	HLA-DRB1	3.62	1E-108
chr6_qbl_hap6	3815245	3815246	rs674313	Chronic lymphocytic leukemia	HLA-DRB5	1.69	7E-9
chr6_qbl_hap6	3824037	3824038	rs9271366	Inflammatory bowel disease	MHC	1.79	8E-11
chr6_qbl_hap6	3824037	3824038	rs9271366	Inflammatory bowel disease	MHC	2.41	3E-31
chr6_qbl_hap6	3824037	3824038	rs9271366	Inflammatory bowel disease	MHC	4.44	2E-70
chr6_qbl_hap6	3824037	3824038	rs9271366	Immunoglobulin A	HLA-DRB1	7.69	3E-33
chr6_qbl_hap6	3824037	3824038	rs9271366	Multiple sclerosis	DQA1	2.62	4E-17
chr6_qbl_hap6	3824037	3824038	rs9271366	Multiple sclerosis	HLA-DRB1	2.78	7E-184
chr6_qbl_hap6	3828120	3828121	rs3129763	Systemic sclerosis	HLA-DQA1, HLA-DRB1	1.65	1E-11
chr6_qbl_hap6	3836833	3836834	rs9272105	Hepatocellular carcinoma	HLA-DQA1, HLA-DRB1	1.28	5E-22
chr6_qbl_hap6	3836833	3836834	rs9272105	Response to interferon beta therapy	HLA-DQA1, HLA-DRB1	.26	4E-10
chr6_qbl_hap6	3839109	3839110	rs9272219	Rheumatoid arthritis	HLA-DQA1	1.92	1E-45
chr6_qbl_hap6	3839109	3839110	rs9272219	Schizophrenia	HLA-DQA1	1.14	7E-8
chr6_qbl_hap6	3839839	3839840	rs2040406	Multiple sclerosis	HLA-DRB,HLA-DQB1	2.05	1E-20
chr6_qbl_hap6	3841217	3841218	rs9272346	Type 1 diabetes	HLA	NR	6E-129
chr6_qbl_hap6	3841217	3841218	rs9272346	Type 1 diabetes	MHC	5.49	5E-134
chr6_qbl_hap6	3842735	3842736	rs2187668	Systemic lupus erythematosus	HLA-DR3	2.23	6E-28
chr6_qbl_hap6	3842735	3842736	rs2187668	Nephropathy (idiopathic membranous)	HLA-DQA1	4.32	8E-93
chr6_qbl_hap6	3842735	3842736	rs2187668	Immunoglobulin A	HLA-DRB1	2.53	2E-33
chr6_qbl_hap6	3842735	3842736	rs2187668	Celiac disease	HLA-DQA1, HLA-DQB1	6.23	1E-50
chr6_qbl_hap6	3842735	3842736	rs2187668	Systemic lupus erythematosus	HLA-DQA1	NR	3E-21
chr6_qbl_hap6	3842735	3842736	rs2187668	Celiac disease	HLA-DQA1	7.04	1E-19
chr6_qbl_hap6	3843680	3843681	rs9272535	Chronic lymphocytic leukemia	HLA-DQA1	1.61	9E-8
chr6_qbl_hap6	3857602	3857603	rs9273349	Asthma	HLA-DQ	1.18	7E-14
chr6_qbl_hap6	3864926	3864927	rs9274407	Drug-induced liver injury (amoxicillin-clavulanate)	HLA-DRB1-DQB1	3.10	5E-14
chr6_qbl_hap6	3887324	3887325	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_qbl_hap6	3887324	3887325	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_qbl_hap6	3889684	3889685	rs7774434	Primary biliary cirrhosis	MHC	1.60	4E-34
chr6_qbl_hap6	3889684	3889685	rs7774434	Primary biliary cirrhosis	HLA-DQB1	1.75	3E-26
chr6_qbl_hap6	3890185	3890186	rs7775228	IgE grass sensitization	HLA region	1.33	2E-9
chr6_qbl_hap6	3890185	3890186	rs7775228	Asthma	HLA-DQB1	1.17	5E-15
chr6_qbl_hap6	3890416	3890417	rs9469220	Crohn's disease	NR	1.14	2E-6
chr6_qbl_hap6	3895739	3895740	rs3129720	Hypothyroidism	HLA-DRB9, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DQA2	1.16	5E-7
chr6_qbl_hap6	3895959	3895960	rs6457617	Graves' disease	HLA, DRB1, DQA1, DQB1	1.40	7E-33
chr6_qbl_hap6	3895959	3895960	rs6457617	Systemic sclerosis	HLA, DQB1	1.61	2E-37
chr6_qbl_hap6	3895959	3895960	rs6457617	Systemic sclerosis	HLA-DQB1	1.37	4E-17
chr6_qbl_hap6	3895959	3895960	rs6457617	Rheumatoid arthritis	HLA-DQA1, HLA-DQA2	NR	1E-9
chr6_qbl_hap6	3895959	3895960	rs6457617	Rheumatoid arthritis	MHC	2.36	5E-75
chr6_qbl_hap6	3896107	3896108	rs6457620	Height	HLA locus	.03	2E-16
chr6_qbl_hap6	3896107	3896108	rs6457620	Rheumatoid arthritis	HLA-DRB1	2.55	4E-186
chr6_qbl_hap6	3896566	3896567	rs2647012	Follicular lymphoma	HLA-DQB1	1.56	2E-21
chr6_qbl_hap6	3896566	3896567	rs2647012	Systemic lupus erythematosus	HLA-DQA1, HLA-DQA2	1.38	8E-6
chr6_qbl_hap6	3897068	3897069	rs9357152	HPV seropositivity	HLA-DQB1	NR	1E-14
chr6_qbl_hap6	3897068	3897069	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_qbl_hap6	3897068	3897069	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_qbl_hap6	3897528	3897529	rs10484561	Follicular lymphoma	HLA-DQB1	1.95	1E-29
chr6_qbl_hap6	3900010	3900011	rs2647044	Pulmonary function	HLA-DQB1	.04	6E-6
chr6_qbl_hap6	3900010	3900011	rs2647044	Type 1 diabetes	HLA-DRB1	8.30	1E-16
chr6_qbl_hap6	3901256	3901257	rs9275390	Systemic sclerosis	HLA-DQB1	1.61	1E-7
chr6_qbl_hap6	3901256	3901257	rs9275390	Systemic sclerosis	HLA-DQB1	2.38	3E-54
chr6_qbl_hap6	3901473	3901474	rs11752643	Coronary heart disease	HLA, DRB-DQB	1.26	5E-7
chr6_qbl_hap6	3902349	3902350	rs2856718	Hepatitis B	HLA-DQB1	1.56	4E-37
chr6_qbl_hap6	3903197	3903198	rs13192471	Rheumatoid arthritis	HLA-DRB1	1.97	2E-58
chr6_qbl_hap6	3903342	3903343	rs1794275	IgA nephropathy	HLA-DQA/B	1.30	3E-13
chr6_qbl_hap6	3911067	3911068	rs9275572	Hepatocellular carcinoma	HLA-DQ, HLA-DR	1.30	6E-9
chr6_qbl_hap6	3911067	3911068	rs9275572	Alopecia areata	HLA-DQA2	2.21	1E-35
chr6_qbl_hap6	3912996	3912997	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6_qbl_hap6	3912996	3912997	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6_qbl_hap6	3913345	3913346	rs2858331	IgE levels	HLA-DQA2	.04	1E-8
chr6_qbl_hap6	3913699	3913700	rs9275596	Nephropathy	HLA-DRB1, HLA-DQA1, HLA-DQB1	1.59	2E-26
chr6_qbl_hap6	3913744	3913745	rs3104402	Immune response to anthrax vaccine	HLA-DRB1,HLA-DQA1	.17	6E-6
chr6_qbl_hap6	3917620	3917621	rs3916765	Type 2 diabetes	HLA-DQA2	1.21	1E-6
chr6_qbl_hap6	3920025	3920026	rs9275698	Asthma	HLA-DQA2	1.18	5E-12
chr6_qbl_hap6	3932155	3932156	rs2858884	Narcolepsy	HLA-DQA2	1.79	3E-8
chr6_qbl_hap6	3957314	3957315	rs2301271	Systemic lupus erythematosus	HLA-DQA2	1.47	2E-12
chr6_qbl_hap6	3962134	3962135	rs7453920	Hepatitis B	HAL-DQB2	1.81	6E-28
chr6_qbl_hap6	3962208	3962209	rs2051549	Systemic lupus erythematosus	HLA-DQA2	NR	3E-22
chr6_qbl_hap6	3968812	3968813	rs9276606	Complement C3 and C4 levels	HLA-DQB	.09	3E-22
chr6_qbl_hap6	4036175	4036176	rs241428	Complement C3 and C4 levels	HLA-DQB	.23	9E-83
chr6_qbl_hap6	4041954	4041955	rs9357155	Nephropathy	TAP2, TAP1, PSMB8, PSMB9	1.41	2E-12
chr6_qbl_hap6	4084752	4084753	rs2187689	Disc degeneration (lumbar)	PSMB9	.23	3E-8
chr6_qbl_hap6	4086798	4086799	rs10046257	Disc degeneration (lumbar)	Intergenic	.19	3E-7
chr6_qbl_hap6	4087818	4087819	rs6457690	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_qbl_hap6	4088482	4088483	rs1029296	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_qbl_hap6	4088583	4088584	rs1029295	Disc degeneration (lumbar)	Intergenic	.19	5E-7
chr6_qbl_hap6	4089035	4089036	rs6936004	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_qbl_hap6	4089520	4089521	rs10214886	Disc degeneration (lumbar)	Intergenic	.19	2E-7
chr6_qbl_hap6	4091813	4091814	rs7744666	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_qbl_hap6	4091849	4091850	rs11969002	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_qbl_hap6	4092853	4092854	rs9469300	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_qbl_hap6	4094708	4094709	rs3749982	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_qbl_hap6	4193500	4193501	rs9500927	Asthma	HLA-DOA	1.13	4E-9
chr6_qbl_hap6	4207106	4207107	rs399604	Platelet counts	HLA-DOA	2.35	1E-10
chr6_qbl_hap6	4265472	4265473	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.82	4E-45
chr6_qbl_hap6	4265472	4265473	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.67	1E-9
chr6_qbl_hap6	4265472	4265473	rs3077	Hepatitis B	HLA-DPA1	1.87	2E-61
chr6_qbl_hap6	4275330	4275331	rs987870	Asthma	HLA, DPB1	1.40	2E-10
chr6_qbl_hap6	4275330	4275331	rs987870	Systemic sclerosis	HLA-DPA1, HLA-DPB1	2.09	2E-20
chr6_qbl_hap6	4287313	4287314	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.64	2E-21
chr6_qbl_hap6	4287313	4287314	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.52	2E-17
chr6_qbl_hap6	4287313	4287314	rs9277535	Hepatitis B vaccine response	HLA-DPB1	1.39	3E-12
chr6_qbl_hap6	4287313	4287314	rs9277535	Hepatitis B	HLA-DPB1	1.77	3E-54
chr6_qbl_hap6	4287313	4287314	rs9277535	Hepatitis B	HLA-DPB1	1.75	6E-39
chr6_qbl_hap6	4292570	4292571	rs2281388	Graves' disease	HLA, DPB1	1.64	2E-65
chr6_qbl_hap6	4302345	4302346	rs3117242	Antineutrophil cytoplasmic antibody-associated vasculitis	HLA-DP, COL11A2	3.67	1E-71
chr6_qbl_hap6	4318740	4318741	rs3117035	RR interval (heart rate)	Intergenic	.14	1E-6
chr6_qbl_hap6	4318939	4318940	rs1883414	Nephropathy	HLA-DPA1, HLA-DPB1, HLA-DPB2	1.28	5E-9
chr6_qbl_hap6	4376170	4376171	rs2254287	LDL cholesterol	B3GALT4	1.91	5E-8
chr6_ssto_hap7	116879	116880	rs4324798	Lung adenocarcinoma	TRNAA-UGC	1.16	2E-8
chr6_ssto_hap7	257161	257162	rs4947339	Platelet aggregation	TRIM27	NR	2E-6
chr6_ssto_hap7	425115	425116	rs3129109	Height	OR2J3	.03	2E-17
chr6_ssto_hap7	695864	695865	rs3094548	Pulmonary function	OR12D2	.03	1E-7
chr6_ssto_hap7	696993	696994	rs9257809	Barrett's esophagus	MHC, OR2D12, OR2D13	1.21	4E-9
chr6_ssto_hap7	774947	774948	rs4713226	Immune reponse to smallpox (secreted IFN-alpha)	OR2H1	NR	2E-8
chr6_ssto_hap7	951988	951989	rs29232	Nasopharyngeal carcinoma	GABBR1	1.67	9E-17
chr6_ssto_hap7	1010816	1010817	rs3129055	Nasopharyngeal carcinoma	HLA-F	1.51	7E-11
chr6_ssto_hap7	1040272	1040273	rs2523395	Prostate cancer (gene x gene interaction)	LOC285830	1.24	2E-6
chr6_ssto_hap7	1043421	1043422	rs2523393	Multiple sclerosis	HLA-B	1.28	1E-17
chr6_ssto_hap7	1060895	1060896	rs9258260	Crohn's disease	HLA-F, MOG, HLA-G, GABBR1, HLA-H, UBD, HLA-A	1.45	2E-10
chr6_ssto_hap7	1126722	1126723	rs1610677	Rheumatoid arthritis	HLA-G	1.32	4E-15
chr6_ssto_hap7	1165688	1165689	rs2523822	Drug-induced liver injury (amoxicillin-clavulanate)	HLA-A	2.30	2E-10
chr6_ssto_hap7	1180957	1180958	rs2523809	IgE levels	HLA-G	.06	4E-8
chr6_ssto_hap7	1236024	1236025	rs2860580	Nasopharyngeal carcinoma	HLA-A	1.72	5E-67
chr6_ssto_hap7	1242648	1242649	rs1061235	Adverse response to carbamapezine	HLA-A*3101	9.12	1E-7
chr6_ssto_hap7	1247419	1247420	rs2517713	Nasopharyngeal carcinoma	HLA-A	1.88	4E-20
chr6_ssto_hap7	1249660	1249661	rs9260489	Multiple sclerosis	HLA-B	1.21	1E-11
chr6_ssto_hap7	1253198	1253199	rs2571391	IgE levels	HLA-A	.06	1E-15
chr6_ssto_hap7	1264569	1264570	rs3893464	Graves' disease	MHC	1.53	2E-20
chr6_ssto_hap7	1271258	1271259	rs2523946	IgA nephropathy	HLA-A	1.21	2E-11
chr6_ssto_hap7	1272390	1272391	rs6904029	Vitiligo	HLA-A,HCG9	1.49	1E-21
chr6_ssto_hap7	1299915	1299916	rs7758512	HIV-1 control	ZNRD1, RNF39, HLA-A	NR	2E-8
chr6_ssto_hap7	1303252	1303253	rs4313034	Graves' disease	MHC	1.67	2E-15
chr6_ssto_hap7	1347504	1347505	rs6917603	Lipid metabolism phenotypes	PPP1R11	.24	3E-29
chr6_ssto_hap7	1355945	1355946	rs259919	HIV-1 control	C6orf12, ZNRD1	NR	3E-7
chr6_ssto_hap7	1362961	1362962	rs8321	AIDS progression	ZNRD1, RNF39	NR	5E-7
chr6_ssto_hap7	1410812	1410813	rs34704616	Cognitive performance	XXbac-BPG250I8.13	NR	6E-6
chr6_ssto_hap7	1423811	1423812	rs10947055	Cardiac hypertrophy	TRIM38	NR	2E-7
chr6_ssto_hap7	1450335	1450336	rs9468692	HIV-1 control	TRIM10	NR	1E-6
chr6_ssto_hap7	1495678	1495679	rs2523722	Schizophrenia	MHC, TRIM26	1.25	1E-16
chr6_ssto_hap7	1504537	1504538	rs2021722	Schizophrenia	TRIM26	1.15	2E-12
chr6_ssto_hap7	1869883	1869884	rs3132613	Graves' disease	MHC	1.43	1E-13
chr6_ssto_hap7	2114274	2114275	rs886424	Bipolar disorder and schizophrenia	MHC, other genes	1.37	9E-7
chr6_ssto_hap7	2127400	2127401	rs7772131	Response to angiotensin II receptor blocker therapy	C6orf214	6.73	3E-6
chr6_ssto_hap7	2334871	2334872	rs4248154	Graves' disease	MHC	1.38	1E-13
chr6_ssto_hap7	2339109	2339110	rs2844665	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	C6orf205	1.54	3E-7
chr6_ssto_hap7	2353384	2353385	rs2517532	Hypothyroidism	LOC729792, HCG22, C6orf15, HLA-C, HLA-B, DHFRP2, HCP5	1.16	1E-8
chr6_ssto_hap7	2359780	2359781	rs9262632	HIV-1 control	Intergenic	3.10	1E-8
chr6_ssto_hap7	2393168	2393169	rs4947296	Behcet's disease	HCG22	2.57	1E-11
chr6_ssto_hap7	2393168	2393169	rs4947296	Graves' disease	MUC21, C6orf15	1.77	4E-51
chr6_ssto_hap7	2393330	2393331	rs3130544	Myasthenia gravis	NR	5.64	2E-90
chr6_ssto_hap7	2408962	2408963	rs6457327	Follicular lymphoma	C6orf15	1.47	7E-6
chr6_ssto_hap7	2408962	2408963	rs6457327	Follicular lymphoma	STG, PSORS1	1.69	5E-11
chr6_ssto_hap7	2471405	2471406	rs3130501	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	POU5F1	1.74	2E-8
chr6_ssto_hap7	2474403	2474404	rs879882	Height	MICA	NR	2E-7
chr6_ssto_hap7	2478534	2478535	rs3131018	HIV-1 control	PSORS1C3	2.10	4E-16
chr6_ssto_hap7	2490732	2490733	rs1265181	Psoriasis	MHC	22.62	NS
chr6_ssto_hap7	2502973	2502974	rs6903896	Common traits (Other)	NR	NR	6E-7
chr6_ssto_hap7	2519124	2519125	rs3869109	Coronary heart disease	HCG27, HLA-C	1.14	1E-9
chr6_ssto_hap7	2555153	2555154	rs3095254	White blood cell types	MHC	.07	6E-11
chr6_ssto_hap7	2573894	2573895	rs2074488	Chronic obstructive pulmonary disease-related biomarkers	HLA-C	NR	2E-10
chr6_ssto_hap7	2574571	2574572	rs13191343	Psoriatic arthritis	HLA-C	2.37	2E-72
chr6_ssto_hap7	2586113	2586114	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.31	6E-21
chr6_ssto_hap7	2586113	2586114	rs2524054	CD4:CD8 lymphocyte ratio	HLA-B	.37	2E-28
chr6_ssto_hap7	2586642	2586643	rs12191877	Psoriasis	HLA-C	2.79	4E-32
chr6_ssto_hap7	2586642	2586643	rs12191877	Psoriasis	HLA-C	2.64	1E-100
chr6_ssto_hap7	2592545	2592546	rs9468925	Vitiligo	HLA	1.35	2E-33
chr6_ssto_hap7	2597450	2597451	rs2894207	Nasopharyngeal carcinoma	HLA-B,HLA-C	1.64	3E-33
chr6_ssto_hap7	2599183	2599184	rs2247056	Triglycerides	HLA	2.99	2E-15
chr6_ssto_hap7	2605472	2605473	rs9461688	Protein quantitative trait loci	HLA-C	NR	4E-6
chr6_ssto_hap7	2606079	2606080	rs9368677	Atopic dermatitis	HLA-C	1.36	1E-17
chr6_ssto_hap7	2608131	2608132	rs9264942	HIV-1 control	HLA-C	2.90	3E-35
chr6_ssto_hap7	2608131	2608132	rs9264942	HIV-1 control	HLA-C	5.30	6E-32
chr6_ssto_hap7	2608131	2608132	rs9264942	HIV-1 control	HLA-C	NR	6E-12
chr6_ssto_hap7	2608306	2608307	rs10484554	Psoriasis	HLA-C	4.66	4E-214
chr6_ssto_hap7	2608306	2608307	rs10484554	AIDS progression	HLA-C	NR	6E-8
chr6_ssto_hap7	2608306	2608307	rs10484554	Psoriasis	HLA-C	2.80	2E-39
chr6_ssto_hap7	2646044	2646045	rs3134792	Psoriasis	HLA-C	NR	1E-9
chr6_ssto_hap7	2656125	2656126	rs3819299	Platelet counts	HLA-B	5.05	9E-10
chr6_ssto_hap7	2656317	2656318	rs2523608	HIV-1 control	HLA-B	2.60	9E-20
chr6_ssto_hap7	2656317	2656318	rs2523608	HIV-1 control	HLA-B	NR	3E-6
chr6_ssto_hap7	2660822	2660823	rs2523590	HIV-1 control	HLA-B	2.40	2E-13
chr6_ssto_hap7	2661459	2661460	rs9378249	Bipolar disorder	NR	NR	1E-8
chr6_ssto_hap7	2669855	2669856	rs7743761	Ankylosing spondylitis	MHC	NR	5E-304
chr6_ssto_hap7	2670173	2670174	rs9266406	Behcet's disease	MICA, MICB, DHFRP2	2.29	2E-10
chr6_ssto_hap7	2680565	2680566	rs9266629	Chronic obstructive pulmonary disease-related biomarkers	FGFR3P	NR	4E-10
chr6_ssto_hap7	2684488	2684489	rs1521	Graves' disease	HLA-B	1.92	2E-65
chr6_ssto_hap7	2688344	2688345	rs13437082	Height	HLA-B	.07	5E-8
chr6_ssto_hap7	2699587	2699588	rs4349859	Ankylosing spondylitis	HLA-B	NR	1E-200
chr6_ssto_hap7	2700395	2700396	rs2596542	Hepatocellular carcinoma	MICA	1.39	4E-13
chr6_ssto_hap7	2711384	2711385	rs12175489	Visceral adipose tissue adjusted for BMI	HLA-B, HCP5	NR	2E-6
chr6_ssto_hap7	2713728	2713729	rs1063635	Rheumatoid arthritis	MICA	1.35	1E-17
chr6_ssto_hap7	2714326	2714327	rs2256183	Height	MICA	.04	8E-29
chr6_ssto_hap7	2725198	2725199	rs4418214	HIV-1 control	MICA	4.40	1E-34
chr6_ssto_hap7	2741567	2741568	rs9469003	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	HCP5	1.73	2E-9
chr6_ssto_hap7	2742004	2742005	rs2524276	Capecitabine sensitivity	Intergenic	NR	6E-6
chr6_ssto_hap7	2762460	2762461	rs2255221	HIV-1 control	Intergenic	2.70	4E-14
chr6_ssto_hap7	2762549	2762550	rs2395029	HIV-1 control	HLA-B	5.30	1E-25
chr6_ssto_hap7	2762549	2762550	rs2395029	HIV-1 control	HCP5, HLA-B	5.80	5E-35
chr6_ssto_hap7	2762549	2762550	rs2395029	HIV-1 control	HCP5, HLA-B	NR	1E-11
chr6_ssto_hap7	2762549	2762550	rs2395029	Drug-induced liver injury (flucloxacillin)	HCP5, HLA-B	45.00	9E-33
chr6_ssto_hap7	2762549	2762550	rs2395029	AIDS progression	HCP5, MICB, MCCD1, BAT1, LTB, TNF	3.47	3E-19
chr6_ssto_hap7	2762549	2762550	rs2395029	Psoriasis	HLA-C	4.10	2E-26
chr6_ssto_hap7	2771434	2771435	rs3828890	Renal function-related traits (sCR)	MHC	.01	3E-9
chr6_ssto_hap7	2771434	2771435	rs3828890	Renal function-related traits (eGRFcrea)	MHC	.01	1E-9
chr6_ssto_hap7	2777567	2777568	rs2248462	Hodgkin's lymphoma	MICB	1.64	7E-16
chr6_ssto_hap7	2779747	2779748	rs3099844	Metabolic syndrome	HCG26, MICB	.15	2E-8
chr6_ssto_hap7	2779747	2779748	rs3099844	Neonatal lupus	TNF,NFKBIL1,LTA,LTB,AIF1	3.34	5E-10
chr6_ssto_hap7	2803522	2803523	rs2855812	Pulmonary function	MICB	.03	2E-7
chr6_ssto_hap7	2806288	2806289	rs3132468	Dengue shock syndrome	MICB	1.34	4E-11
chr6_ssto_hap7	2812106	2812107	rs2516399	White blood cell types	MHC	.11	2E-12
chr6_ssto_hap7	2830407	2830408	rs3853601	Atopic dermatitis	BAT1	1.13	2E-6
chr6_ssto_hap7	2836284	2836285	rs2734583	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	BAT1, HCP5, MICC, PPIAP9, PSORS1C1, POLR2LP, CCHCR1, TCF19, POU5F1, HLA-C, HCP5, PSORS1C3, HLA-B*5801	66.80	2E-8
chr6_ssto_hap7	2873108	2873109	rs1799964	Crohn's disease	LTA,HLA-DQA2,TNF,LST1,LTB	1.19	4E-11
chr6_ssto_hap7	2888592	2888593	rs11575839	Complement C3 and C4 levels	HLA-C	.23	1E-54
chr6_ssto_hap7	2899265	2899266	rs2857595	Pulmonary function	NCR3	.04	2E-10
chr6_ssto_hap7	2903751	2903752	rs2844479	Weight	AIF1, NCR3	3.58	2E-8
chr6_ssto_hap7	2906085	2906086	rs9348876	Crohn's disease	AIF1	1.41	3E-6
chr6_ssto_hap7	2933768	2933769	rs1046089	Menopause (age at onset)	PRRC2A	.21	2E-16
chr6_ssto_hap7	2947170	2947171	rs805303	Systolic blood pressure	BAT2, BAT5	.38	2E-11
chr6_ssto_hap7	2947170	2947171	rs805303	Hypertension	BAT2, BAT5	.05	1E-10
chr6_ssto_hap7	2947170	2947171	rs805303	Diastolic blood pressure	BAT2, BAT5	.23	3E-11
chr6_ssto_hap7	2951317	2951318	rs3117582	Lung adenocarcinoma	BAT3, APOM	1.22	5E-12
chr6_ssto_hap7	2951317	2951318	rs3117582	Lung cancer	BAT3	1.24	4E-10
chr6_ssto_hap7	2951317	2951318	rs3117582	Lung cancer	BAT3,MSH5	1.24	5E-10
chr6_ssto_hap7	2953403	2953404	rs805297	Rheumatoid arthritis	APOM	1.56	3E-10
chr6_ssto_hap7	3169809	3169810	rs11966200	Vitiligo	HLA-C,HLA-B	1.90	1E-48
chr6_ssto_hap7	3171454	3171455	rs494620	Menopause (age at onset)	NR	.30	5E-7
chr6_ssto_hap7	3176666	3176667	rs2736428	Telomere length	SLC44A4	.05	3E-6
chr6_ssto_hap7	3216437	3216438	rs9267673	Hepatocellular carcinoma	C2	1.97	2E-6
chr6_ssto_hap7	3236513	3236514	rs9332739	Age-related macular degeneration (GA)	C2	2.63	1E-6
chr6_ssto_hap7	3236513	3236514	rs9332739	Age-related macular degeneration (CNV)	C2	2.08	2E-8
chr6_ssto_hap7	3236513	3236514	rs9332739	Age-related macular degeneration	C2	2.17	2E-23
chr6_ssto_hap7	3238718	3238719	rs9380272	Age-related macular degeneration	C2,CFB	4.31	2E-8
chr6_ssto_hap7	3246889	3246890	rs641153	Age-related macular degeneration (GA)	CFB	2.13	2E-9
chr6_ssto_hap7	3246889	3246890	rs641153	Age-related macular degeneration (CNV)	CFB	2.22	1E-17
chr6_ssto_hap7	3246889	3246890	rs641153	Age-related macular degeneration	CFB	1.85	6E-31
chr6_ssto_hap7	3246889	3246890	rs641153	Age-related macular degeneration	CFB,C2	NR	2E-20
chr6_ssto_hap7	3249660	3249661	rs541862	Age-related macular degeneration	CFB	1.89	9E-17
chr6_ssto_hap7	3263171	3263172	rs429608	Age-related macular degeneration	SKIV2L,BF	1.85	5E-15
chr6_ssto_hap7	3263171	3263172	rs429608	Age-related macular degeneration	C2,CFB	2.16	3E-21
chr6_ssto_hap7	3352453	3352454	rs2857009	Complement C3 and C4 levels	C4	.08	1E-22
chr6_ssto_hap7	3359515	3359516	rs12198173	HIV-1 control	TNXB	NR	3E-6
chr6_ssto_hap7	3457703	3457704	rs204999	Serum total protein level	Intergenic	.03	4E-11
chr6_ssto_hap7	3457703	3457704	rs204999	Serum total protein level	Intergenic	.03	3E-9
chr6_ssto_hap7	3457703	3457704	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_ssto_hap7	3457703	3457704	rs204999	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_ssto_hap7	3484274	3484275	rs1061808	Phospholipid levels (plasma)	AGPAT1	.90	8E-10
chr6_ssto_hap7	3499170	3499171	rs2070600	Pulmonary function	AGER, PPT2	1.00	3E-14
chr6_ssto_hap7	3499170	3499171	rs2070600	Pulmonary function	AGER	.09	3E-15
chr6_ssto_hap7	3503306	3503307	rs204993	Asthma	PBX2	1.17	2E-15
chr6_ssto_hap7	3506044	3506045	rs176095	Atopic dermatitis	GPSM3	1.40	8E-20
chr6_ssto_hap7	3513169	3513170	rs2071278	Complement C3 and C4 levels	HLA-DRA	.13	4E-72
chr6_ssto_hap7	3519419	3519420	rs2071277	Age-related macular degeneration	NOTCH4	1.30	2E-11
chr6_ssto_hap7	3520729	3520730	rs3131296	Schizophrenia	MHC, NOTCH4	1.19	2E-10
chr6_ssto_hap7	3532073	3532074	rs404860	Asthma	NOTCH4	1.21	4E-23
chr6_ssto_hap7	3538134	3538135	rs443198	Systemic sclerosis	NOTCH4	1.82	9E-21
chr6_ssto_hap7	3566582	3566583	rs3115573	Nephropathy	Intergenic	1.62	1E-9
chr6_ssto_hap7	3566728	3566729	rs9296015	Systemic sclerosis	NOTCH4	1.85	1E-8
chr6_ssto_hap7	3566728	3566729	rs9296015	Rheumatoid arthritis	HLA locus	NR	2E-38
chr6_ssto_hap7	3571057	3571058	rs3130320	Systemic lupus erythematosus	NOTCH4, C6orf10	1.39	3E-6
chr6_ssto_hap7	3592419	3592420	rs3130340	Bone mineral density (spine)	MHC, C6orf10	.10	1E-7
chr6_ssto_hap7	3630638	3630639	rs6910071	Rheumatoid arthritis	HLA-DRB1	2.88	1E-299
chr6_ssto_hap7	3653775	3653776	rs3129900	Lumiracoxib-related liver injury	HLA-DRB1	7.50	7E-25
chr6_ssto_hap7	3656706	3656707	rs9469099	Atopic dermatitis	C6orf10	1.61	5E-19
chr6_ssto_hap7	3668995	3668996	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_ssto_hap7	3668995	3668996	rs2395148	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_ssto_hap7	3668995	3668996	rs2395148	Arthritis (juvenile idiopathic)	HLA-DRB1	5.37	2E-10
chr6_ssto_hap7	3672812	3672813	rs13196329	Visceral fat	C6orf10	NR	3E-6
chr6_ssto_hap7	3683643	3683644	rs3129934	Multiple sclerosis	C6orf10	2.34	7E-16
chr6_ssto_hap7	3683643	3683644	rs3129934	Multiple sclerosis	HLA-DRB1	3.30	9E-11
chr6_ssto_hap7	3685088	3685089	rs2273017	Graves' disease	MHC	1.53	2E-22
chr6_ssto_hap7	3686165	3686166	rs3129943	Asthma	C6orf10	1.17	3E-15
chr6_ssto_hap7	3686545	3686546	rs2050190	Activated partial thromboplastin time	C6orf10	.25	7E-7
chr6_ssto_hap7	3688822	3688823	rs9268402	Coronary heart disease	C6orf10, BTNL2	1.16	3E-15
chr6_ssto_hap7	3692747	3692748	rs7758128	Vitiligo	C6orf10, BTNL2	NR	8E-11
chr6_ssto_hap7	3705711	3705712	rs3117099	Bipolar disorder and schizophrenia	MHC, other genes	1.25	3E-6
chr6_ssto_hap7	3705955	3705956	rs3117098	Asthma	BTNL2	1.16	5E-12
chr6_ssto_hap7	3710657	3710658	rs1980493	Anti-cyclic Citrullinated Peptide Antibody	HLA-DRA, BTNL2	NR	5E-7
chr6_ssto_hap7	3711258	3711259	rs2076530	Sarcoidosis	BTNL2	NR	3E-11
chr6_ssto_hap7	3711286	3711287	rs9268480	Ulcerative colitis	BTNL2	1.82	3E-6
chr6_ssto_hap7	3711397	3711398	rs2076529	Waist-hip ratio	BTNL2	.02	4E-7
chr6_ssto_hap7	3715529	3715530	rs3817963	Lung adenocarcinoma	BTNL2	1.18	3E-10
chr6_ssto_hap7	3720758	3720759	rs10947262	Knee osteoarthritis	BTNL2, HLA-DQA2, HLA-DQB1	1.31	5E-9
chr6_ssto_hap7	3721146	3721147	rs3806156	Vitiligo	BTNL2,HLA-DRA,HLA-DQA1	1.42	7E-19
chr6_ssto_hap7	3723916	3723917	rs3763313	HIV-1 control	BTNL2, NOTCH4	NR	2E-6
chr6_ssto_hap7	3724233	3724234	rs3763317	Complement C3 and C4 levels	HLA-DRB	.12	9E-66
chr6_ssto_hap7	3726147	3726148	rs9268516	Asthma	BTNL2, HLA-DRA	1.15	1E-8
chr6_ssto_hap7	3729770	3729771	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_ssto_hap7	3729770	3729771	rs9268528	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_ssto_hap7	3731383	3731384	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_ssto_hap7	3731383	3731384	rs9268542	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_ssto_hap7	3734467	3734468	rs2395163	Parkinson's disease	LOC642072	1.24	3E-11
chr6_ssto_hap7	3736306	3736307	rs3135363	Hepatitis B vaccine response	HLA-DR	1.53	7E-22
chr6_ssto_hap7	3736306	3736307	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_ssto_hap7	3736306	3736307	rs3135363	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_ssto_hap7	3747876	3747877	rs3135338	Multiple sclerosis	HLA	3.43	2E-25
chr6_ssto_hap7	3755188	3755189	rs9268645	Type 1 diabetes	MHC	NR	1E-100
chr6_ssto_hap7	3756191	3756192	rs3129882	Systemic sclerosis	HLA-DRA	2.17	2E-27
chr6_ssto_hap7	3756191	3756192	rs3129882	Parkinson's disease	HLA-DRA	1.26	2E-10
chr6_ssto_hap7	3758307	3758308	rs7192	Non-obstructive azoospermia	HLA-DRA	1.29	3E-6
chr6_ssto_hap7	3759104	3759105	rs3177928	LDL cholesterol	HLA	1.83	2E-15
chr6_ssto_hap7	3759104	3759105	rs3177928	Cholesterol, total	HLA	2.31	4E-19
chr6_ssto_hap7	3759720	3759721	rs3135388	Multiple sclerosis	HLA-DRB1	2.75	4E-225
chr6_ssto_hap7	3759720	3759721	rs3135388	Multiple sclerosis	HLA-DRA	1.99	9E-81
chr6_ssto_hap7	3760128	3760129	rs2227139	Hematological parameters	Intergenic	.02	1E-7
chr6_ssto_hap7	3760214	3760215	rs3129889	Multiple sclerosis	HLA-DRB1	2.97	1E-206
chr6_ssto_hap7	3760940	3760941	rs3129890	Asthma	HLA-DRA	1.15	5E-13
chr6_ssto_hap7	3775088	3775089	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_ssto_hap7	3775088	3775089	rs6903608	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_ssto_hap7	3775088	3775089	rs6903608	Hodgkin's lymphoma	HLA-DRA	1.70	3E-50
chr6_ssto_hap7	3776446	3776447	rs9268853	Rheumatoid arthritis	HLA-DRA	2.40	5E-109
chr6_ssto_hap7	3776446	3776447	rs9268853	Ulcerative colitis	HLA-DRB5, HLA-DQA1, HLA-DRB1, HLA-DRA, BTNL2	1.40	1E-55
chr6_ssto_hap7	3777947	3777948	rs9268877	Ulcerative colitis	MHC	NR	4E-23
chr6_ssto_hap7	3777947	3777948	rs9268877	Ulcerative colitis	HLA-DRA, BTNL2	1.45	6E-18
chr6_ssto_hap7	3778880	3778881	rs9268905	Cystic fibrosis severity	HLA-DRA	NR	1E-7
chr6_ssto_hap7	3779638	3779639	rs9268923	Ulcerative colitis	HLA-DRA	1.45	4E-15
chr6_ssto_hap7	3779971	3779972	rs2395185	Lung cancer	HLA class II	1.17	1E-8
chr6_ssto_hap7	3779971	3779972	rs2395185	Hodgkin's lymphoma	HLA-DRA	1.82	4E-31
chr6_ssto_hap7	3779971	3779972	rs2395185	Ulcerative colitis	Intergenic	1.92	5E-22
chr6_ssto_hap7	3779971	3779972	rs2395185	Ulcerative colitis	BTNL2, HLA-DRA, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1	1.52	1E-16
chr6_ssto_hap7	3997392	3997393	rs28366298	Lung cancer	HLA class II	1.17	1E-8
chr6_ssto_hap7	4003584	4003585	rs477515	Inflammatory bowel disease	HLA-DQA1	1.38	1E-8
chr6_ssto_hap7	4005843	4005844	rs2858870	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	2.50	8E-18
chr6_ssto_hap7	4005843	4005844	rs2858870	Nodular sclerosis Hodgkin lymphoma	HLA-DRB1, HLA-DQB1	1.70	2E-7
chr6_ssto_hap7	4007760	4007761	rs615672	Rheumatoid arthritis	HLA-DRB1	NR	8E-27
chr6_ssto_hap7	4010083	4010084	rs9271100	Systemic lupus erythematosus	HLA-DRB1	1.90	1E-12
chr6_ssto_hap7	4010983	4010984	rs660895	IgA nephropathy	HLA-DRB1	1.34	4E-20
chr6_ssto_hap7	4010983	4010984	rs660895	Rheumatoid arthritis	HLA-DRB1	3.62	1E-108
chr6_ssto_hap7	4011680	4011681	rs674313	Chronic lymphocytic leukemia	HLA-DRB5	1.69	7E-9
chr6_ssto_hap7	4020449	4020450	rs9271366	Inflammatory bowel disease	MHC	1.79	8E-11
chr6_ssto_hap7	4020449	4020450	rs9271366	Inflammatory bowel disease	MHC	2.41	3E-31
chr6_ssto_hap7	4020449	4020450	rs9271366	Inflammatory bowel disease	MHC	4.44	2E-70
chr6_ssto_hap7	4020449	4020450	rs9271366	Immunoglobulin A	HLA-DRB1	7.69	3E-33
chr6_ssto_hap7	4020449	4020450	rs9271366	Multiple sclerosis	DQA1	2.62	4E-17
chr6_ssto_hap7	4020449	4020450	rs9271366	Multiple sclerosis	HLA-DRB1	2.78	7E-184
chr6_ssto_hap7	4024521	4024522	rs3129763	Systemic sclerosis	HLA-DQA1, HLA-DRB1	1.65	1E-11
chr6_ssto_hap7	4026191	4026192	rs28421666	Nasopharyngeal carcinoma	HLA-DQ,HLA-DR	1.49	2E-18
chr6_ssto_hap7	4033444	4033445	rs9272105	Hepatocellular carcinoma	HLA-DQA1, HLA-DRB1	1.28	5E-22
chr6_ssto_hap7	4033444	4033445	rs9272105	Response to interferon beta therapy	HLA-DQA1, HLA-DRB1	.26	4E-10
chr6_ssto_hap7	4035713	4035714	rs9272219	Rheumatoid arthritis	HLA-DQA1	1.92	1E-45
chr6_ssto_hap7	4035713	4035714	rs9272219	Schizophrenia	HLA-DQA1	1.14	7E-8
chr6_ssto_hap7	4036451	4036452	rs2040406	Multiple sclerosis	HLA-DRB,HLA-DQB1	2.05	1E-20
chr6_ssto_hap7	4037819	4037820	rs9272346	Type 1 diabetes	HLA	NR	6E-129
chr6_ssto_hap7	4037819	4037820	rs9272346	Type 1 diabetes	MHC	5.49	5E-134
chr6_ssto_hap7	4039335	4039336	rs2187668	Systemic lupus erythematosus	HLA-DR3	2.23	6E-28
chr6_ssto_hap7	4039335	4039336	rs2187668	Nephropathy (idiopathic membranous)	HLA-DQA1	4.32	8E-93
chr6_ssto_hap7	4039335	4039336	rs2187668	Immunoglobulin A	HLA-DRB1	2.53	2E-33
chr6_ssto_hap7	4039335	4039336	rs2187668	Celiac disease	HLA-DQA1, HLA-DQB1	6.23	1E-50
chr6_ssto_hap7	4039335	4039336	rs2187668	Systemic lupus erythematosus	HLA-DQA1	NR	3E-21
chr6_ssto_hap7	4039335	4039336	rs2187668	Celiac disease	HLA-DQA1	7.04	1E-19
chr6_ssto_hap7	4040184	4040185	rs9272535	Chronic lymphocytic leukemia	HLA-DQA1	1.61	9E-8
chr6_ssto_hap7	4054612	4054613	rs9273349	Asthma	HLA-DQ	1.18	7E-14
chr6_ssto_hap7	4086696	4086697	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_ssto_hap7	4086696	4086697	rs2856683	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_ssto_hap7	4089063	4089064	rs7774434	Primary biliary cirrhosis	MHC	1.60	4E-34
chr6_ssto_hap7	4089063	4089064	rs7774434	Primary biliary cirrhosis	HLA-DQB1	1.75	3E-26
chr6_ssto_hap7	4089567	4089568	rs7775228	IgE grass sensitization	HLA region	1.33	2E-9
chr6_ssto_hap7	4089567	4089568	rs7775228	Asthma	HLA-DQB1	1.17	5E-15
chr6_ssto_hap7	4089798	4089799	rs9469220	Crohn's disease	NR	1.14	2E-6
chr6_ssto_hap7	4095811	4095812	rs3129720	Hypothyroidism	HLA-DRB9, HLA-DRB5, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DQA2	1.16	5E-7
chr6_ssto_hap7	4096032	4096033	rs6457617	Graves' disease	HLA, DRB1, DQA1, DQB1	1.40	7E-33
chr6_ssto_hap7	4096032	4096033	rs6457617	Systemic sclerosis	HLA, DQB1	1.61	2E-37
chr6_ssto_hap7	4096032	4096033	rs6457617	Systemic sclerosis	HLA-DQB1	1.37	4E-17
chr6_ssto_hap7	4096032	4096033	rs6457617	Rheumatoid arthritis	HLA-DQA1, HLA-DQA2	NR	1E-9
chr6_ssto_hap7	4096032	4096033	rs6457617	Rheumatoid arthritis	MHC	2.36	5E-75
chr6_ssto_hap7	4096179	4096180	rs6457620	Height	HLA locus	.03	2E-16
chr6_ssto_hap7	4096179	4096180	rs6457620	Rheumatoid arthritis	HLA-DRB1	2.55	4E-186
chr6_ssto_hap7	4096638	4096639	rs2647012	Follicular lymphoma	HLA-DQB1	1.56	2E-21
chr6_ssto_hap7	4096638	4096639	rs2647012	Systemic lupus erythematosus	HLA-DQA1, HLA-DQA2	1.38	8E-6
chr6_ssto_hap7	4097140	4097141	rs9357152	HPV seropositivity	HLA-DQB1	NR	1E-14
chr6_ssto_hap7	4097140	4097141	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	7E-10
chr6_ssto_hap7	4097140	4097141	rs9357152	Primary biliary cirrhosis	c6orf10, BTNL2, HLA-DQB1	NR	1E-10
chr6_ssto_hap7	4097600	4097601	rs10484561	Follicular lymphoma	HLA-DQB1	1.95	1E-29
chr6_ssto_hap7	4100049	4100050	rs2647044	Pulmonary function	HLA-DQB1	.04	6E-6
chr6_ssto_hap7	4100049	4100050	rs2647044	Type 1 diabetes	HLA-DRB1	8.30	1E-16
chr6_ssto_hap7	4101296	4101297	rs9275390	Systemic sclerosis	HLA-DQB1	1.61	1E-7
chr6_ssto_hap7	4101296	4101297	rs9275390	Systemic sclerosis	HLA-DQB1	2.38	3E-54
chr6_ssto_hap7	4101509	4101510	rs11752643	Coronary heart disease	HLA, DRB-DQB	1.26	5E-7
chr6_ssto_hap7	4102413	4102414	rs2856718	Hepatitis B	HLA-DQB1	1.56	4E-37
chr6_ssto_hap7	4103261	4103262	rs13192471	Rheumatoid arthritis	HLA-DRB1	1.97	2E-58
chr6_ssto_hap7	4103406	4103407	rs1794275	IgA nephropathy	HLA-DQA/B	1.30	3E-13
chr6_ssto_hap7	4110637	4110638	rs9275572	Hepatocellular carcinoma	HLA-DQ, HLA-DR	1.30	6E-9
chr6_ssto_hap7	4110637	4110638	rs9275572	Alopecia areata	HLA-DQA2	2.21	1E-35
chr6_ssto_hap7	4112572	4112573	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6_ssto_hap7	4112572	4112573	rs7765379	Rheumatoid arthritis	HLA-DRB1	2.51	5E-23
chr6_ssto_hap7	4112921	4112922	rs2858331	IgE levels	HLA-DQA2	.04	1E-8
chr6_ssto_hap7	4113275	4113276	rs9275596	Nephropathy	HLA-DRB1, HLA-DQA1, HLA-DQB1	1.59	2E-26
chr6_ssto_hap7	4113320	4113321	rs3104402	Immune response to anthrax vaccine	HLA-DRB1,HLA-DQA1	.17	6E-6
chr6_ssto_hap7	4117213	4117214	rs3916765	Type 2 diabetes	HLA-DQA2	1.21	1E-6
chr6_ssto_hap7	4119640	4119641	rs9275698	Asthma	HLA-DQA2	1.18	5E-12
chr6_ssto_hap7	4131750	4131751	rs2858884	Narcolepsy	HLA-DQA2	1.79	3E-8
chr6_ssto_hap7	4156858	4156859	rs2301271	Systemic lupus erythematosus	HLA-DQA2	1.47	2E-12
chr6_ssto_hap7	4161677	4161678	rs7453920	Hepatitis B	HAL-DQB2	1.81	6E-28
chr6_ssto_hap7	4161751	4161752	rs2051549	Systemic lupus erythematosus	HLA-DQA2	NR	3E-22
chr6_ssto_hap7	4168360	4168361	rs9276606	Complement C3 and C4 levels	HLA-DQB	.09	3E-22
chr6_ssto_hap7	4195188	4195189	rs2857151	Kawasaki disease	HLA-DQB2, HLA-DOB	1.47	5E-11
chr6_ssto_hap7	4234844	4234845	rs241428	Complement C3 and C4 levels	HLA-DQB	.23	9E-83
chr6_ssto_hap7	4240620	4240621	rs9357155	Nephropathy	TAP2, TAP1, PSMB8, PSMB9	1.41	2E-12
chr6_ssto_hap7	4283380	4283381	rs2187689	Disc degeneration (lumbar)	PSMB9	.23	3E-8
chr6_ssto_hap7	4285421	4285422	rs10046257	Disc degeneration (lumbar)	Intergenic	.19	3E-7
chr6_ssto_hap7	4286441	4286442	rs6457690	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_ssto_hap7	4287110	4287111	rs1029296	Disc degeneration (lumbar)	Intergenic	.19	9E-8
chr6_ssto_hap7	4287211	4287212	rs1029295	Disc degeneration (lumbar)	Intergenic	.19	5E-7
chr6_ssto_hap7	4287663	4287664	rs6936004	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_ssto_hap7	4288146	4288147	rs10214886	Disc degeneration (lumbar)	Intergenic	.19	2E-7
chr6_ssto_hap7	4290439	4290440	rs7744666	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_ssto_hap7	4290475	4290476	rs11969002	Disc degeneration (lumbar)	Intergenic	.20	6E-8
chr6_ssto_hap7	4291479	4291480	rs9469300	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_ssto_hap7	4293334	4293335	rs3749982	Disc degeneration (lumbar)	Intergenic	.19	1E-7
chr6_ssto_hap7	4442122	4442123	rs9500927	Asthma	HLA-DOA	1.13	4E-9
chr6_ssto_hap7	4455728	4455729	rs399604	Platelet counts	HLA-DOA	2.35	1E-10
chr6_ssto_hap7	4513525	4513526	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.82	4E-45
chr6_ssto_hap7	4513525	4513526	rs3077	Hepatitis B (viral clearance)	HLA-DPA1	1.67	1E-9
chr6_ssto_hap7	4513525	4513526	rs3077	Hepatitis B	HLA-DPA1	1.87	2E-61
chr6_ssto_hap7	4523383	4523384	rs987870	Asthma	HLA, DPB1	1.40	2E-10
chr6_ssto_hap7	4523383	4523384	rs987870	Systemic sclerosis	HLA-DPA1, HLA-DPB1	2.09	2E-20
chr6_ssto_hap7	4535364	4535365	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.64	2E-21
chr6_ssto_hap7	4535364	4535365	rs9277535	Hepatitis B (viral clearance)	HLA-DPB1	1.52	2E-17
chr6_ssto_hap7	4535364	4535365	rs9277535	Hepatitis B vaccine response	HLA-DPB1	1.39	3E-12
chr6_ssto_hap7	4535364	4535365	rs9277535	Hepatitis B	HLA-DPB1	1.77	3E-54
chr6_ssto_hap7	4535364	4535365	rs9277535	Hepatitis B	HLA-DPB1	1.75	6E-39
chr6_ssto_hap7	4540621	4540622	rs2281388	Graves' disease	HLA, DPB1	1.64	2E-65
chr6_ssto_hap7	4550396	4550397	rs3117242	Antineutrophil cytoplasmic antibody-associated vasculitis	HLA-DP, COL11A2	3.67	1E-71
chr6_ssto_hap7	4566735	4566736	rs3117035	RR interval (heart rate)	Intergenic	.14	1E-6
chr6_ssto_hap7	4566934	4566935	rs1883414	Nephropathy	HLA-DPA1, HLA-DPB1, HLA-DPB2	1.28	5E-9
chr6_ssto_hap7	4624113	4624114	rs2254287	LDL cholesterol	B3GALT4	1.91	5E-8
chr7	1039002	1039003	rs10256972	Longevity	C7orf50	NR	1E-6
chr7	1273844	1273845	rs10275044	Renal function-related traits (BUN)	UNCX	.01	4E-9
chr7	1285194	1285195	rs10277115	Renal function-related traits (sCR)	UNCX	.01	5E-11
chr7	1285194	1285195	rs10277115	Renal function-related traits (eGRFcrea)	UNCX	.01	1E-10
chr7	1886534	1886535	rs6952808	Bipolar disorder and schizophrenia	NR	1.25	2E-6
chr7	1912221	1912222	rs4721135	Longevity	MAD1L1	NR	1E-6
chr7	1950808	1950809	rs4332037	Bipolar disorder	MAD1L1	1.11	7E-6
chr7	2004420	2004421	rs12666575	Schizophrenia	MAD1L1, SNX8, NUDT1, FTSJ2	1.12	2E-9
chr7	2041431	2041432	rs1107592	Bipolar disorder and schizophrenia	NR	1.24	2E-6
chr7	2298226	2298227	rs2398668	Bipolar disorder and schizophrenia	NR	1.23	7E-6
chr7	2448492	2448493	rs6952809	Multiple sclerosis	CHST12	1.08	4E-6
chr7	2763101	2763102	rs798544	Height	GNA12	5.90	7E-15
chr7	2789879	2789880	rs798502	Ulcerative colitis	GNA12	1.13	3E-15
chr7	2795956	2795957	rs798497	Height	GNA12	.06	7E-7
chr7	2801802	2801803	rs798489	Height	GNA12	.05	2E-33
chr7	2869984	2869985	rs1182188	Height	GNA12	.07	3E-9
chr7	3128788	3128789	rs4722404	Atopic dermatitis	CARD11	1.18	8E-9
chr7	3915563	3915564	rs6462411	Quantitative traits	SDK1	.36	1E-6
chr7	4411208	4411209	rs10488360	Factor VII	Intergenic	NR	7E-6
chr7	7268430	7268431	rs10259085	Multiple sclerosis (severity)	C1GALT1	NR	4E-6
chr7	7302292	7302293	rs1299548	Visceral adipose tissue adjusted for BMI	C1GALT1	NR	4E-6
chr7	7399403	7399404	rs10486158	Bipolar disorder and schizophrenia	NR	1.27	6E-6
chr7	7571419	7571420	rs17168526	Immune reponse to smallpox (secreted IL-1beta)	COL28A1	NR	6E-8
chr7	7883322	7883323	rs7780564	Insulin-like growth factors	RPA3	NR	4E-7
chr7	8718079	8718080	rs2349775	Neuroticism	NXPH1	NR	7E-6
chr7	8838716	8838717	rs6463843	Brain imaging	NXPH1	NR	NS
chr7	8998975	8998976	rs17157663	Quantitative traits	Intergenic	.18	9E-6
chr7	9066819	9066820	rs10952132	Response to fenofibrate	NXPH1	.31	1E-6
chr7	9066819	9066820	rs10952132	Response to fenofibrate	NXPH1	.29	7E-6
chr7	9266387	9266388	rs1285407	Protein quantitative trait loci	NXPH1	NR	1E-6
chr7	9539278	9539279	rs9918508	Hippocampal atrophy	Intergenic	NR	8E-6
chr7	10149975	10149976	rs7778619	Select biomarker traits	Intergenic	NR	3E-6
chr7	10364722	10364723	rs2882834	Capecitabine sensitivity	Intergenic	NR	1E-6
chr7	12059805	12059806	rs769111	Tourette syndrome	THSD7A, TMEM106B	1.23	6E-6
chr7	12273151	12273152	rs14978	Response to amphetamines	TMEM106B	NR	7E-6
chr7	12391318	12391319	rs6967385	Response to taxane treatment (placlitaxel)	TMEM106B	NR	6E-6
chr7	12932048	12932049	rs732577	Sudden cardiac arrest	Intergenic	1.15	4E-6
chr7	12937254	12937255	rs17166499	Bipolar disorder and schizophrenia	NR	1.51	5E-6
chr7	14445916	14445917	rs6971925	Response to treatment for acute lymphoblastic leukemia	DGKB	13.91	3E-6
chr7	15063832	15063833	rs10244051	Metabolic traits	Intergenic	.05	1E-7
chr7	15064308	15064309	rs2191349	Fasting glucose-related traits (interaction with BMI)	DGKB	NR	3E-21
chr7	15064308	15064309	rs2191349	Fasting glucose-related traits	DGKB, TMEM195	NR	3E-44
chr7	15064308	15064309	rs2191349	Fasting glucose-related traits	DGKB, TMEM195	NR	3E-17
chr7	15064983	15064984	rs6947830	Metabolic syndrome	TMEM195, DGKB	.10	1E-13
chr7	15742785	15742786	rs10486776	Stroke	Intergenic	5.62	6E-6
chr7	16326645	16326646	rs35681285	Serum tamsulosin hydrochloride concentration	ISPD	16.75	4E-7
chr7	16500141	16500142	rs10270805	Response to statin therapy	SOSTDC1,LOC442511,LOC729920	NR	9E-6
chr7	17284576	17284577	rs4410790	Caffeine consumption	AHR	.15	2E-19
chr7	17287268	17287269	rs6968865	Coffee consumption	AHR	.26	2E-11
chr7	17309278	17309279	rs12670403	Metabolic traits	AHR	.29	5E-15
chr7	17561582	17561583	rs10499504	Response to antipsychotic treatment	Intergenic	NR	4E-7
chr7	18877873	18877874	rs2073963	Male-pattern baldness	HDAC9	1.29	1E-12
chr7	19031934	19031935	rs11984041	Stroke	HDAC9	1.42	2E-11
chr7	19049387	19049388	rs2107595	Stroke (ischemic)	HDAC9	1.12	4E-6
chr7	19049387	19049388	rs2107595	Stroke (ischemic)	HDAC9	1.39	2E-16
chr7	19616521	19616522	rs4470914	Height	TWISTNB	.03	9E-10
chr7	19805479	19805480	rs6977660	Thyroid stimulating hormone	Intergenic	NR	4E-6
chr7	20047574	20047575	rs38152	HIV-1 control	Intergenic	NR	7E-8
chr7	20647014	20647015	rs10950821	Response to statin therapy	LOC402642, ABCB5, SP8	NR	7E-6
chr7	20862301	20862302	rs2709736	Bipolar disorder	SP8	1.44	5E-7
chr7	20994490	20994491	rs12155172	Prostate cancer	NR	1.05	9E-6
chr7	21222789	21222790	rs6971109	Capecitabine sensitivity	Intergenic	NR	7E-6
chr7	21504426	21504427	rs17144465	Major depressive disorder	SP4	1.82	6E-6
chr7	21504426	21504427	rs17144465	Major depressive disorder (broad)	SP4	1.56	8E-7
chr7	21584087	21584088	rs2285947	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	SP4, DNAH11	1.14	3E-6
chr7	21584087	21584088	rs2285947	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	SP4, DNAH11	1.14	1E-6
chr7	21584087	21584088	rs2285947	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	SP4, DNAH11	1.17	1E-16
chr7	21584087	21584088	rs2285947	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	SP4, DNAH11	1.17	2E-8
chr7	21607351	21607352	rs12670798	LDL cholesterol	DNAH11	1.26	7E-10
chr7	21607351	21607352	rs12670798	Cholesterol, total	DNAH11	1.70	7E-10
chr7	21607351	21607352	rs12670798	LDL cholesterol	DNAH11	.09	6E-9
chr7	21607351	21607352	rs12670798	Cholesterol, total	DNAH11	.06	9E-7
chr7	21742973	21742974	rs368331	Total ventricular volume	DNAH11	.01	2E-6
chr7	21742973	21742974	rs368331	MRI atrophy measures	DNAH11	.02	4E-6
chr7	21938239	21938240	rs4487645	Multiple myeloma	DNAH11	1.38	3E-14
chr7	22024039	22024040	rs1175000	Height	CDCA7L	.05	5E-6
chr7	22109458	22109459	rs10499559	Thyroid stimulating hormone	RAPGEF5	NR	8E-6
chr7	22514052	22514053	rs17364464	Dialysis-related mortality	IL6, RAPGEF5	1.76	4E-6
chr7	22732838	22732839	rs2097677	C-reactive protein	IL6	.10	4E-11
chr7	22756462	22756463	rs10155981	Bilirubin levels	AC073072.5	.13	2E-7
chr7	22985009	22985010	rs2286492	Bipolar disorder	NR	NR	8E-6
chr7	23502973	23502974	rs12534093	Height	IGF2BP3	.03	2E-14
chr7	25608408	25608409	rs17151904	Carotid atherosclerosis in HIV infection	Intergenic	NR	1E-6
chr7	25871108	25871109	rs1055144	Waist-hip ratio	NFE2L3	.04	1E-24
chr7	25901638	25901639	rs12700667	Endometriosis	Intergenic	1.18	4E-9
chr7	25901638	25901639	rs12700667	Endometriosis	Intergenic	1.20	1E-9
chr7	26481803	26481804	rs10951138	Visceral adipose tissue/subcutaneous adipose tissue ratio	SNX10	NR	3E-6
chr7	26557617	26557618	rs886716	Smoking behavior	Intergenic	1.52	8E-6
chr7	26891664	26891665	rs7804356	Type 1 diabetes	Intergenic	1.14	5E-9
chr7	27330055	27330056	rs13225783	Heart failure	EVX1	1.38	7E-6
chr7	27335560	27335561	rs11564024	Immune reponse to smallpox (secreted IL-1beta)	LOC392008	NR	3E-8
chr7	27976562	27976563	rs10486567	Prostate cancer	JAZF1	1.12	2E-6
chr7	28180555	28180556	rs864745	Type 2 diabetes	JAZF1	1.10	5E-14
chr7	28185090	28185091	rs849141	Height	JAZF1	.08	3E-11
chr7	28189410	28189411	rs1635852	Height	JAZF1	.25	9E-10
chr7	28189945	28189946	rs1708299	Height	JAZF1	.04	6E-25
chr7	28196221	28196222	rs849134	Type 2 diabetes	JAZF1	1.13	3E-9
chr7	28229041	28229042	rs550448	Type 1 diabetes	LOC100128081	1.32	5E-7
chr7	28391141	28391142	rs11765845	Diabetic retinopathy	CREB5, tcag7.873, LOC401317	1.02	7E-6
chr7	28432475	28432476	rs7799265	Airflow obstruction	CREB5	1.54	2E6
chr7	28762962	28762963	rs2237349	Attention deficit hyperactivity disorder	CREB5	NR	5E-6
chr7	29041189	29041190	rs2252521	Cognitive performance	CPVL	NR	5E-6
chr7	29184488	29184489	rs10486607	Diabetes related insulin traits	CPVL	NR	8E-6
chr7	29921523	29921524	rs740145	Corneal curvature	WIPF3	.17	5E-6
chr7	30083020	30083021	rs10488084	Estradiol levels	FKBP14, PLEKHA8	.18	2E-6
chr7	30937177	30937178	rs1000597	Nephrolithiasis	INMT, FAM188B, AQP1	1.22	2E-14
chr7	31155346	31155347	rs1558477	Major depressive disorder	ADCYAP1R1	NR	3E-7
chr7	32347334	32347335	rs215614	Smoking behavior	Intergenic	.22	2E-7
chr7	33256038	33256039	rs10262453	Sagittal craniosynostosis	BBS9	4.17	6E-20
chr7	33673264	33673265	rs17170316	Cytomegalovirus antibody response	Intergenic	.33	8E-7
chr7	35305305	35305306	rs1362212	Ventricular conduction	TBX20	.69	1E-13
chr7	35401446	35401447	rs2392362	Information processing speed	AC007652.1	.14	2E-6
chr7	35554787	35554788	rs343064	Non-alcoholic fatty liver disease histology (other)	Intergenic	1.31	3E-8
chr7	36191698	36191699	rs4302748	Platelet counts	EEPD1	NR	5E-6
chr7	36610492	36610493	rs6948404	HIV-1 control	AOAH	NR	3E-6
chr7	36917994	36917995	rs741301	Type 2 diabetes nephropathy	ELMO1	2.67	8E-6
chr7	36952020	36952021	rs10488023	Breast size	ELMO1	.10	8E-6
chr7	36961319	36961320	rs13230047	Anticoagulant levels	ELMO1	NR	8E-6
chr7	37076853	37076854	rs10488031	QT interval	ELMO1	.26	2E-6
chr7	37266351	37266352	rs4723619	Response to treatment for acute lymphoblastic leukemia	ELMO1	3.01	3E-6
chr7	37374509	37374510	rs6974491	Primary biliary cirrhosis	Intergenic	1.25	4E-8
chr7	37374509	37374510	rs6974491	Celiac disease	ELMO1	1.14	2E-7
chr7	37436853	37436854	rs11984075	Celiac disease and Rheumatoid arthritis	ELMO1	NR	5E-8
chr7	37989094	37989095	rs16879765	Dupuytren's disease	EPDR1, SFRP4	1.98	6E-39
chr7	38004405	38004406	rs1668357	Myopia (pathological)	Intergenic	NR	4E-8
chr7	38128325	38128326	rs6959212	Height	STARD3NL	.02	2E-9
chr7	38136276	38136277	rs1524058	Bone mineral density (spine)	STARD3NL	.07	1E-9
chr7	38240907	38240908	rs4723738	Treatment response for severe sepsis	STARD3NL	NR	6E-6
chr7	38835034	38835035	rs11984145	Cognitive performance	VPS41	NR	6E-6
chr7	40954480	40954481	rs29880	Iron status biomarkers	Q4KMW4	NR	7E-6
chr7	40965126	40965127	rs7789197	Prostate cancer (gene x gene interaction)	INHBA	1.52	3E-6
chr7	41470092	41470093	rs1079866	Menarche (age at onset)	INHBA	3.90	6E-14
chr7	41478607	41478608	rs10486715	Quantitative traits	Intergenic	.44	3E-6
chr7	42264678	42264679	rs4724100	Allergic rhinitis	GLI3	1.14	2E-6
chr7	42325624	42325625	rs12532960	Inflammatory biomarkers	Intergenic	NR	3E-7
chr7	44223720	44223721	rs730497	Glycated hemoglobin levels	GCK	.03	6E-12
chr7	44229067	44229068	rs1799884	Metabolite levels	GCK	.06	2E-19
chr7	44229067	44229068	rs1799884	Glycated hemoglobin levels	GCK	.04	1E-20
chr7	44231215	44231216	rs3757840	Metabolic syndrome	GCK	.10	4E-13
chr7	44235667	44235668	rs4607517	Fasting glucose-related traits (interaction with BMI)	GCK	NR	8E-56
chr7	44235667	44235668	rs4607517	Fasting plasma glucose	GCKR	1.15	1E-7
chr7	44235667	44235668	rs4607517	Fasting glucose-related traits	GCK	NR	7E-92
chr7	44235667	44235668	rs4607517	Fasting glucose-related traits	GCK	NR	2E-16
chr7	44235667	44235668	rs4607517	Fasting plasma glucose	GCK	.06	1E-25
chr7	44259870	44259871	rs1127065	Metabolic syndrome	CAMK2B	.08	9E-11
chr7	44579179	44579180	rs2072183	LDL cholesterol	NPC1L1	1.17	4E-11
chr7	44579179	44579180	rs2072183	Cholesterol, total	NPC1L1	2.01	3E-11
chr7	46008109	46008110	rs11977526	Insulin-like growth factors	IGFBP3	NR	3E-101
chr7	46242582	46242583	rs6964415	Sudden cardiac arrest	Intergenic	1.42	5E-7
chr7	46275727	46275728	rs1486139	Select biomarker traits	Intergenic	NR	2E-6
chr7	46392566	46392567	rs17513961	Treatment response for severe sepsis	LOC222052	NR	1E-7
chr7	46620144	46620145	rs7784776	Ventricular conduction	IGFBP3	.39	1E-9
chr7	46753552	46753553	rs700752	Insulin-like growth factors	TNS3	NR	5E-9
chr7	46753552	46753553	rs700752	Insulin-like growth factors	TNS3	NR	4E-21
chr7	47779968	47779969	rs7800244	Hepatitis C induced liver fibrosis	PKD1L1	NR	3E-6
chr7	48817964	48817965	rs11767191	Response to amphetamines	Intergenic	NR	1E-6
chr7	50225390	50225391	rs7805803	Total ventricular volume	ZPBP	.00	9E-6
chr7	50269671	50269672	rs1456893	Crohn's disease	Intergenic	1.20	5E-9
chr7	50304460	50304461	rs1456896	Crohn's disease	IKZF1,ZPBP,FIGNL1	1.14	1E-8
chr7	50305862	50305863	rs4917014	Systemic lupus erythematosus	IKZF1	1.39	3E-23
chr7	50313351	50313352	rs10276619	Hippocampal atrophy	IKZF1	NR	3E-6
chr7	50428427	50428428	rs12718597	Mean corpuscular volume	IKZF1	.00	5E-13
chr7	50466303	50466304	rs11978267	Acute lymphoblastic leukemia (childhood)	IKZF1, DDC	1.69	8E-11
chr7	50470603	50470604	rs4132601	Acute lymphoblastic leukemia (childhood)	IKZF1	1.69	1E-19
chr7	50622711	50622712	rs1451375	Malaria	DDC	1.33	6E-6
chr7	50664921	50664922	rs12540874	Systemic sclerosis	GRB10	1.15	1E-6
chr7	50751089	50751090	rs10248619	Fasting glucose-related traits (interaction with BMI)	GRB10	NR	8E-8
chr7	51027193	51027194	rs4948088	Type 1 diabetes	COBL	1.30	4E-8
chr7	52472449	52472450	rs1012036	Emphysema-related traits	AC006320.2	1.47	5E-6
chr7	54181931	54181932	rs6593122	Vaccine-related adverse events	Intergenic	NR	4E-6
chr7	54978923	54978924	rs2252586	Glioma	EGFR	1.18	8E-8
chr7	55159348	55159349	rs11979158	Glioma	EGFR	1.23	7E-8
chr7	57699150	57699151	rs4870684	Bipolar disorder and schizophrenia	NR	1.27	5E-6
chr7	63733330	63733331	rs10266483	Response to statin therapy	ZNF679, LOC728927, LOC442320	NR	8E-6
chr7	65617594	65617595	rs875971	Aortic root size	CRCP	.11	4E-6
chr7	66030611	66030612	rs801193	Aortic root size	LOC401365, LOC493754	.11	4E-6
chr7	66096027	66096028	rs10263935	Aortic root size	KCTD7, RABGEF1	.11	4E-7
chr7	67059266	67059267	rs10263639	Breast cancer	Intergenic	NR	3E-6
chr7	67426322	67426323	rs6961611	Information processing speed	RP11-358M3.1	.63	7E-6
chr7	68050412	68050413	rs1403155	Immune reponse to smallpox (secreted IL-2)	AUTS2	NR	2E-8
chr7	68611959	68611960	rs6945541	Male-pattern baldness	AUTS2	1.27	2E-9
chr7	69806022	69806023	rs6943555	Alcohol consumption	AUTS2	.01	4E-8
chr7	70045940	70045941	rs10237317	Bipolar disorder	AUTS2	1.78	5E-6
chr7	71016158	71016159	rs4719147	Response to angiotensin II receptor blocker therapy	WBSCR17	1.13	2E-6
chr7	71388849	71388850	rs11766496	Airflow obstruction	CALN1	1.30	2E-6
chr7	71751315	71751316	rs12699131	Schizophrenia	NR	1.08	2E-6
chr7	72129666	72129667	rs13238203	Triglycerides	TYW1B	7.91	1E-9
chr7	72311816	72311817	rs2058059	Subcutaneous adipose tissue	POM121	NR	7E-6
chr7	72746647	72746648	rs6943090	Immune reponse to smallpox (secreted IL-12p40)	FKBP6, TRIM50	NR	3E-7
chr7	72856268	72856269	rs2240466	Caffeine consumption	NR	.11	1E-6
chr7	72856268	72856269	rs2240466	Triglycerides	MLXIPL	.14	1E-12
chr7	72856429	72856430	rs1178979	Triglycerides	BAZ1B, BCL7B, TBL2, MLXIPL	.05	2E-12
chr7	72864868	72864869	rs714052	Hypertriglyceridemia	MLXIPL	2.27	3E-6
chr7	72864868	72864869	rs714052	Triglycerides	MLXIPL	.16	3E-15
chr7	72904809	72904810	rs17145713	Protein C levels	BAZ1B	.06	3E-8
chr7	72971230	72971231	rs13233571	C-reactive protein	BCL7B	.05	4E-9
chr7	72977897	72977898	rs12539316	Gamma glutamyl transpeptidase	TBL2	.01	6E-10
chr7	72982873	72982874	rs17145738	Triglycerides	MLXIPL	7.91	9E-59
chr7	72982873	72982874	rs17145738	HDL cholesterol	MLXIPL	.57	1E-9
chr7	72982873	72982874	rs17145738	Triglycerides	BCL7B, TBL2, MLXIPL	.14	7E-22
chr7	72982873	72982874	rs17145738	Triglycerides	MLXIPL	8.21	2E-12
chr7	72987353	72987354	rs2286276	Triglycerides	TBL2, MLXIPL	.07	1E-15
chr7	73010441	73010442	rs13247874	Lipid metabolism phenotypes	MLXIPL	.16	8E-14
chr7	73017004	73017005	rs13226650	Metabolic syndrome	MLXIPL	.12	2E-11
chr7	73020336	73020337	rs3812316	Triglycerides	MLXIPL	10.50	1E-10
chr7	73026377	73026378	rs17145750	Liver enzyme levels (gamma-glutamyl transferase)	MLXIPL	4.50	3E-9
chr7	75173179	75173180	rs1167796	Systemic lupus erythematosus	NR	1.20	2E-8
chr7	75211413	75211414	rs237238	Alcoholism (12-month weekly alcohol consumption)	HIP1	.16	7E-6
chr7	75951229	75951230	rs7789940	Multiple sclerosis	LOC100289506	1.87	6E-6
chr7	75953296	75953297	rs758944	Multiple sclerosis	LOC100289506	.48	8E-6
chr7	75975585	75975586	rs7779014	Multiple sclerosis	YWHAG	.48	8E-6
chr7	75978228	75978229	rs17149161	Multiple sclerosis	YWHAG	1.87	6E-6
chr7	76639870	76639871	rs6955651	Body mass index	KIAA1505	NR	2E-6
chr7	76762950	76762951	rs12540771	Response to amphetamines	CCDC146	NR	5E-6
chr7	77416438	77416439	rs6465825	Chronic kidney disease	TMEM60,RSBN1L, PHTF2	.01	2E-9
chr7	77596811	77596812	rs848452	Dental caries	PHTF2	NR	2E-6
chr7	77964787	77964788	rs2691543	Height	RPL13AP17	3.45	5E-6
chr7	78043290	78043291	rs17150687	Response to antidepressant treatment	MAGI2	NR	3E-6
chr7	78175976	78175977	rs11525066	Hippocampal atrophy	MAGI2	NR	3E-6
chr7	78331464	78331465	rs1496766	Acute lymphoblastic leukemia (childhood)	MAGI2	2.84	5E-6
chr7	79651452	79651453	rs2199936	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	ABCG2	2.80	2E-10
chr7	79651452	79651453	rs2199936	Cardiovascular disease risk factors	ABCG2	.19	2E-17
chr7	79651452	79651453	rs2199936	Urate levels	ABCG2	1.86	3E-23
chr7	79651452	79651453	rs2199936	Urate levels	ABCG2	18.08	1E-75
chr7	80236013	80236014	rs13236689	Mean platelet volume	CD36	4.18	3E-9
chr7	80258809	80258810	rs10499859	Left ventricular mass	CD36	.09	3E-6
chr7	80286907	80286908	rs11574703	Response to fenofibrate	CD36	3.72	8E-8
chr7	80599356	80599357	rs4236644	Bilirubin levels	SEMA3C	.02	2E-6
chr7	81731445	81731446	rs258671	Response to taxane treatment (docetaxel)	CACNA2D1	NR	1E-6
chr7	81786219	81786220	rs2367911	Bipolar disorder and schizophrenia	NR	1.77	5E-6
chr7	81847650	81847651	rs10954668	Non-alcoholic fatty liver disease histology (lobular)	CACNA2D1	.32	7E-6
chr7	82337858	82337859	rs2371208	Aging traits	Intergenic	NR	3E-6
chr7	82450034	82450035	rs2715148	Major depressive disorder	PCLO	NR	1E-6
chr7	83609038	83609039	rs797820	Attention deficit hyperactivity disorder	SEMA3A	NR	8E-6
chr7	83656799	83656800	rs10235789	Iris characteristics	SEMA3A	.12	7E-11
chr7	83656799	83656800	rs10235789	Iris characteristics	SEMA3A	.09	3E-6
chr7	83911270	83911271	rs488333	Prion diseases	SEMA3A	1.27	3E-6
chr7	86696713	86696714	rs1476587	Brachial circumference	DMTF1, GRM3	.28	7E-6
chr7	86821979	86821980	rs11773103	Bipolar disorder and major depressive disorder (combined)	C7orf23,DMTF1	NR	1E-6
chr7	88481441	88481442	rs10248351	Hypothyroidism	C7orf62, ZNF804B	1.84	7E-6
chr7	88560877	88560878	rs1406503	Body mass index	ZNF804B	.07	9E-6
chr7	88596384	88596385	rs6959888	Anorexia nervosa	ZNF804B	NR	2E-6
chr7	92246743	92246744	rs42041	Rheumatoid arthritis	CDK6	1.11	4E-6
chr7	92248075	92248076	rs42235	Height	CDK6	.06	8E-47
chr7	92256904	92256905	rs2040494	Height	CDK6	.26	4E-7
chr7	92264409	92264410	rs2282978	Height	CDK6	.06	1E-8
chr7	92264409	92264410	rs2282978	Height	CDK6	.09	8E-23
chr7	92264409	92264410	rs2282978	Height	CDK6, PEX1, GATAD1, ERVWE1	5.80	1E-8
chr7	92408369	92408370	rs445	White blood cell count	CDK6	.03	4E-7
chr7	92408369	92408370	rs445	White blood cell types	CDK6	.08	7E-10
chr7	93538294	93538295	rs180273	Pulmonary function decline	Intergenic	.15	7E-6
chr7	93691743	93691744	rs9918668	Aging	BET1, COL1A2	NR	6E-7
chr7	94000472	94000473	rs10262915	Intelligence	COL1A2	NR	9E-8
chr7	94003259	94003260	rs6465411	Intelligence	COL1A2	NR	9E-8
chr7	94006993	94006994	rs13221576	Intelligence	COL1A2	NR	9E-8
chr7	94008534	94008535	rs4729127	Intelligence	COL1A2	NR	9E-8
chr7	94009633	94009634	rs7792596	Intelligence	COL1A2	4.13	6E-7
chr7	94047265	94047266	rs3736638	Immune reponse to smallpox (secreted IL-12p40)	COL1A2	NR	3E-7
chr7	94053999	94054000	rs441051	Mean forced vital capacity from 2 exams	COL1A2	NR	2E-6
chr7	94930390	94930391	rs854555	Response to TNF antagonist treatment	PON1	NR	2E-6
chr7	95600367	95600368	rs13231718	Immune reponse to smallpox (secreted IL-10)	DYNC1I1	NR	5E-9
chr7	96117917	96117918	rs4729260	Bone mineral density (spine)	FLJ42280	.08	2E-10
chr7	96133530	96133531	rs7781370	Bone mineral density (hip)	FLJ42280	.08	5E-12
chr7	96415054	96415055	rs12669076	Immunoglobulin A	SHFM1	1.35	2E-6
chr7	96581810	96581811	rs17598306	Radiation response	DLX6AS	NR	9E-6
chr7	97229777	97229778	rs10486003	Response to platinum-based agents	TAC1	3.13	5E-7
chr7	97422925	97422926	rs1229542	Myopia (pathological)	Intergenic	NR	2E-6
chr7	97620690	97620691	rs13438327	Sudden cardiac arrest	OCM2	2.05	2E-6
chr7	97816326	97816327	rs6465657	Prostate cancer	NR	NR	2E-8
chr7	97816326	97816327	rs6465657	Prostate cancer	LMTK2	1.12	1E-9
chr7	97993361	97993362	rs3779195	Sex hormone-binding globulin levels	BAIAP2L1	.03	3E-8
chr7	98021210	98021211	rs9649213	Prostate cancer (gene x gene interaction)	BAIAP2L1	1.28	1E-6
chr7	98760503	98760504	rs7809799	Ulcerative colitis	SMURF1,KPNA7	1.56	9E-11
chr7	98957879	98957880	rs740160	Dehydroepiandrosterone sulphate levels	ARPC1A	.15	2E-16
chr7	99118800	99118801	rs11761528	Dehydroepiandrosterone sulphate levels	ZKSCAN5	.16	3E-36
chr7	99207875	99207876	rs7792939	Anthropometric traits	ZNF498	.26	6E-6
chr7	99207875	99207876	rs7792939	Anthropometric traits	ZNF498	.26	5E-6
chr7	99207875	99207876	rs7792939	Anthropometric traits	ZNF498	.26	4E-6
chr7	99489570	99489571	rs17277546	Metabolic traits	CYP3A4	.48	9E-40
chr7	99489570	99489571	rs17277546	Dehydroepiandrosterone sulphate levels	TRIM4, CYP3A43	.11	2E-11
chr7	100214014	100214015	rs7786877	Mean corpuscular volume	TFR2	.00	3E-11
chr7	100235969	100235970	rs7385804	Iron levels	TFR2	3.23	7E-8
chr7	100235969	100235970	rs7385804	Hematocrit	TFR2	.15	4E-10
chr7	100235969	100235970	rs7385804	Hematological parameters	TFR2	.01	5E-10
chr7	100345105	100345106	rs2075671	Other erythrocyte phenotypes	EPO	.00	1E-9
chr7	100453207	100453208	rs314370	Resting heart rate	SLC12A9	7.60	6E-10
chr7	100458092	100458093	rs7801190	Coronary heart disease	SLC12A9	1.31	3E-8
chr7	100486753	100486754	rs12666989	Resting heart rate	UFSP1	7.00	2E-8
chr7	100490076	100490077	rs7636	Type 2 diabetes	ACHE	1.85	5E-6
chr7	100512118	100512119	rs6976053	Plasminogen activator inhibitor type 1 levels (PAI-1)	ACHE, SLC12A9, TRIP6, SRRT, UFSP1, EPHB4, MUC3	.05	6E-13
chr7	100769537	100769538	rs2227631	Plasminogen activator inhibitor type 1 levels (PAI-1)	SERPINE1	.07	3E-24
chr7	100881402	100881403	rs3757458	QT interval	NR	8.00	2E-6
chr7	101115993	101115994	rs17135437	Response to citalopram treatment	EMID2	NR	3E-6
chr7	101115993	101115994	rs17135437	Response to citalopram treatment	EMID2	NR	3E-8
chr7	101809850	101809851	rs365836	Response to antidepressants	CUX1	4.79	2E-6
chr7	102378436	102378437	rs12540771	Response to amphetamines	CCDC146	NR	5E-6
chr7	103404814	103404815	rs7341475	Schizophrenia	RELN	1.58	9E-7
chr7	103527368	103527369	rs3914132	Otosclerosis	RELN	1.54	2E-8
chr7	103625876	103625877	rs4298437	Alzheimer's disease	RELN	NR	2E-6
chr7	103628035	103628036	rs17157903	Multiple sclerosis (age of onset)	RELN	NR	3E-6
chr7	104503812	104503813	rs10953454	Obesity	LHFPL3	NR	7E-7
chr7	104758249	104758250	rs6968355	Myopia (pathological)	SRPK2	NR	2E-7
chr7	105273719	105273720	rs10242311	Dental caries	ATXN7L1	NR	6E-7
chr7	105281187	105281188	rs11983798	Alzheimer's disease (late onset)	ATXN7L1	NR	1E-6
chr7	105671266	105671267	rs10270308	Warfarin maintenance dose	NR	NR	6E-6
chr7	106359215	106359216	rs342275	Platelet counts	FLJ36031,PIK3CG	3.74	6E-25
chr7	106372218	106372219	rs342293	Mean platelet volume	PIK3CG	4.05	2E-8
chr7	106372218	106372219	rs342293	Mean platelet volume	FLJ36031,PIK3CG	.02	7E-57
chr7	106372218	106372219	rs342293	Mean platelet volume	PIK3CG	.02	2E-33
chr7	106372218	106372219	rs342293	Mean platelet volume	Intergenic	.02	1E-24
chr7	106372902	106372903	rs342296	Mean platelet volume	PIK3CG	.16	1E-11
chr7	106409451	106409452	rs17398575	Carotid intima media thickness	PIK3CG	.01	3E-6
chr7	106409451	106409452	rs17398575	Carotid intima media thickness	PIK3CG	.16	2E-12
chr7	106411857	106411858	rs17477177	Blood pressure	PIK3CG	.42	2E-13
chr7	106495808	106495809	rs17153527	Menopause (age at onset)	NR	.51	4E-7
chr7	106594884	106594885	rs7779057	Serum tamsulosin hydrochloride concentration	Intergenic	17.16	2E-7
chr7	106662082	106662083	rs7798500	Adverse response to lamotrigine and phenytoin	PRKAR2B	NR	6E-6
chr7	106763217	106763218	rs13224682	Response to antipsychotic treatment	PRKAR2B	NR	6E-8
chr7	106938419	106938420	rs3815148	Osteoarthritis	COG5	1.14	8E-8
chr7	107207694	107207695	rs4730250	Osteoarthritis	DUS4L	1.15	6E-8
chr7	107244544	107244545	rs10953541	Coronary heart disease	Intergenic	1.08	3E-8
chr7	107453102	107453103	rs2108225	Ulcerative colitis	SLC26A3	1.32	1E-7
chr7	107479518	107479519	rs4730273	Ulcerative colitis	Intergenic	1.22	5E-6
chr7	107484436	107484437	rs4730276	Ulcerative colitis	SLC26A3, DLD, LAMB1	1.22	9E-6
chr7	107492788	107492789	rs4510766	Ulcerative colitis	Intergenic	1.20	2E-16
chr7	107495433	107495434	rs886774	Ulcerative colitis	LAMB1	1.11	3E-8
chr7	107503440	107503441	rs4598195	Ulcerative colitis	DLD,LAMB1	1.09	8E-8
chr7	107503440	107503441	rs4598195	Ulcerative colitis	SLC26A3, DLD, LAMB1	1.23	1E-6
chr7	107580838	107580839	rs2158836	Ulcerative colitis	SLC26A3, DLD, LAMB1	1.21	7E-6
chr7	107782199	107782200	rs382140	Coffee consumption	LAMB4, NRCAM	.08	4E-9
chr7	108544460	108544461	rs1404697	Smoking behavior	Intergenic	NR	8E-6
chr7	108544460	108544461	rs1404697	Smoking behavior	Intergenic	NR	5E-6
chr7	108548659	108548660	rs848353	Smoking behavior	C7orf66, LOC154907, PNPLA8, THAP5, DNAJB9	NR	9E-7
chr7	108548659	108548660	rs848353	Smoking behavior	C7orf66, LOC154907, PNPLA8, THAP5, DNAJB9	NR	3E-7
chr7	108548659	108548660	rs848353	Smoking behavior	C7orf66, LOC154907, PNPLA8, THAP5, DNAJB9	NR	2E-6
chr7	109003573	109003574	rs10277209	Prostate cancer (gene x gene interaction)	C7orf66	1.36	4E-6
chr7	109152710	109152711	rs10953615	Gallbladder cancer	NR	7.51	9E-6
chr7	110047470	110047471	rs6968385	Attention deficit hyperactivity disorder (time to onset)	Intergenic	NR	2E-6
chr7	110467220	110467221	rs10279573	Cognitive performance	IMMP2L	NR	3E-6
chr7	111527559	111527560	rs10255299	C-reactive protein and white blood cell count	DOCK4	.24	7E-11
chr7	111642645	111642646	rs61159171	Breast size	ZNF277	.08	6E-6
chr7	111677905	111677906	rs10428959	Response to fenofibrate	DOCK4	6.00	1E-7
chr7	112086332	112086333	rs17159640	Mortality among heart failure patients	IFRD1	1.59	9E-6
chr7	112094742	112094743	rs6956741	Amyotrophic lateral sclerosis (age of onset)	IFRD1	NR	2E-6
chr7	112628372	112628373	rs10229603	Attention deficit hyperactivity disorder and conduct disorder	FLJ31818, GPR85	NR	5E-6
chr7	112911409	112911410	rs10953730	Metabolite levels	Intergenic	NR	2E-7
chr7	114357542	114357543	rs1869839	Crohn's disease	FOXP2	1.20	7E-6
chr7	116162728	116162729	rs4236601	Glaucoma (primary open-angle)	CAV1,CAV2	1.27	2E-11
chr7	116186240	116186241	rs3807989	Atrial fibrillation	CAV1	1.11	4E-12
chr7	116186240	116186241	rs3807989	Electrocardiographic traits	CAV1	6.40	7E-13
chr7	116186240	116186241	rs3807989	PR interval	CAV1, CAV2	2.30	4E-28
chr7	116191300	116191301	rs11773845	PR interval	CAV1	2.29	4E-12
chr7	116346602	116346603	rs10243024	Multiple sclerosis (severity)	MET	NR	6E-6
chr7	116577123	116577124	rs7782376	Cognitive performance	AC106873.3	NR	8E-6
chr7	116917117	116917118	rs4730775	Dupuytren's disease	WNT2	1.20	3E-8
chr7	117067821	117067822	rs7808424	Coronary heart disease	Intergenic	1.10	1E-6
chr7	117991894	117991895	rs41997	Response to platinum-based chemotherapy in non-small-cell lung cancer	CFTR, WNT2, ST7	1.52	4E-7
chr7	118159548	118159549	rs2106595	Smoking behavior	NR	.88	5E-6
chr7	119606631	119606632	rs17142462	Immune reponse to smallpox (secreted IL-12p40)	KCND2	NR	3E-9
chr7	120305148	120305149	rs728115	Alcohol and nictotine co-dependence	KCND2	NR	4E-6
chr7	120903814	120903815	rs4609139	Bone mineral density	C7orf58	.08	1E-10
chr7	120969768	120969769	rs2908004	Bone mineral density	WNT16	.16	1E-15
chr7	120979088	120979089	rs2707466	Cortical thickness	WNT16	.11	2E-10
chr7	121018578	121018579	rs917727	Bone mineral density	WNT16	.15	1E-27
chr7	121033120	121033121	rs7776725	Biomedical quantitative traits	FAM3C	NR	2E-6
chr7	121033120	121033121	rs7776725	Biomedical quantitative traits	FAM3C	NR	1E-11
chr7	121275228	121275229	rs10253361	Alcoholism (alcohol dependence factor score)	Intergenic	.08	6E-6
chr7	122202592	122202593	rs2429582	Brain structure	CADPS2	NR	6E-7
chr7	123411222	123411223	rs4731120	Platelet counts	WASL	4.14	3E-12
chr7	126324590	126324591	rs17691394	Carotid atherosclerosis in HIV infection	GRM8	NR	9E-7
chr7	126437896	126437897	rs11971186	Chemerin levels	GRM8	NR	9E-6
chr7	126639603	126639604	rs17864092	Depression (quantitative trait)	GRM8	.17	6E-6
chr7	127164957	127164958	rs6467136	Type 2 diabetes	GCC1,PAX4	1.11	5E-11
chr7	128568959	128568960	rs729302	Systemic lupus erythematosus	IRF5	1.29	4E-8
chr7	128573966	128573967	rs4728142	Ulcerative colitis	IRF5, TNPO3	1.07	2E-8
chr7	128573966	128573967	rs4728142	Systemic lupus erythematosus	IRF5	1.43	8E-19
chr7	128594182	128594183	rs10488631	Systemic sclerosis	IRF5	1.63	8E-7
chr7	128594182	128594183	rs10488631	Systemic sclerosis	IRF5	1.52	2E-7
chr7	128594182	128594183	rs10488631	Systemic sclerosis	IRF5	1.50	2E-10
chr7	128594182	128594183	rs10488631	Systemic sclerosis	IRF5	1.61	1E-9
chr7	128594182	128594183	rs10488631	Systemic sclerosis	TNPO3, IRF5	1.35	4E-7
chr7	128594182	128594183	rs10488631	Systemic lupus erythematosus	IRF5	1.92	7E-18
chr7	128594182	128594183	rs10488631	Primary biliary cirrhosis	IRF5,TNPO3	1.63	3E-10
chr7	128594182	128594183	rs10488631	Rheumatoid arthritis	IRF5	1.19	4E-11
chr7	128594182	128594183	rs10488631	Systemic sclerosis	TNPO, IRF5	1.50	2E-13
chr7	128594182	128594183	rs10488631	Primary biliary cirrhosis	IRF5-TNPO3	1.52	2E-7
chr7	128594182	128594183	rs10488631	Systemic lupus erythematosus	IRF5, TNPO3	NR	2E-11
chr7	128617465	128617466	rs12531711	Systemic lupus erythematosus	TNPO3	1.59	6E-13
chr7	128617465	128617466	rs12531711	Systemic lupus erythematosus	IRF5	1.58	6E-9
chr7	128617465	128617466	rs12531711	Primary biliary cirrhosis	IRF5	1.58	9E-17
chr7	128717905	128717906	rs12537284	Systemic lupus erythematosus	IRF5, TNPO3	1.54	4E-19
chr7	128993755	128993756	rs11979476	Inflammatory biomarkers	AHCYL2	NR	2E-6
chr7	129004846	129004847	rs11766298	Response to fenofibrate	AHCLY2	4.41	4E-9
chr7	129023596	129023597	rs7787531	Tuberculosis	NR	1.22	9E-6
chr7	129663495	129663496	rs11556924	Coronary heart disease	ZC3HC1	1.09	9E-18
chr7	130433383	130433384	rs4731702	HDL cholesterol	KLF14	.59	1E-15
chr7	130466853	130466854	rs972283	Type 2 diabetes	KLF14	1.07	2E-10
chr7	130653850	130653851	rs2048672	Breast cancer	NR	1.11	6E-6
chr7	130900120	130900121	rs10265216	Major depressive disorder (broad)	AK294384	1.19	3E-6
chr7	131287989	131287990	rs12534221	AB1-42	Intergenic	NR	9E-7
chr7	131370038	131370039	rs11761231	Rheumatoid arthritis	Intergenic	1.32	4E-7
chr7	131453524	131453525	rs1106683	Body mass index	Intergenic	NR	1E-7
chr7	131453664	131453665	rs1106684	Body mass index	Intergenic	NR	2E-6
chr7	131829127	131829128	rs1399090	Economic and political preferences	PLXNA4	.22	7E-6
chr7	132189688	132189689	rs10808265	Pulmonary function decline	PLXNA4B	.17	2E-6
chr7	133335175	133335176	rs10488172	Tonometry	EXOC4	NR	8E-6
chr7	134250321	134250322	rs4732038	Longevity	AKR1B15	NR	1E-6
chr7	134785740	134785741	rs17231212	Immune reponse to smallpox (secreted IL-10)	LOC100129730	NR	2E-8
chr7	135293127	135293128	rs4294134	Paget's disease	NUP205	1.45	8E-10
chr7	135488620	135488621	rs6946494	Visceral adipose tissue adjusted for BMI	UNQ194	NR	8E-6
chr7	137203818	137203819	rs6467710	AIDS progression	DGKI	4.30	6E-7
chr7	137858765	137858766	rs10255295	Bipolar disorder (mood-incongruent)	AKR1D1	1.31	5E-6
chr7	138049386	138049387	rs357394	Pulmonary function	Intergenic	NR	9E-6
chr7	138157389	138157390	rs1874326	Quantitative traits	TRIM24	.22	9E-6
chr7	138411424	138411425	rs3800569	F-cell distribution	ATP6V0A4	1.20	6E-6
chr7	139702592	139702593	rs17837497	Acute lymphoblastic leukemia (childhood)	TBXAS1	2.34	2E-6
chr7	140231129	140231130	rs10237118	Optic disc size (cup)	DENND2A	.31	4E-6
chr7	140592226	140592227	rs17623382	Response to Vitamin E supplementation	BRAF	.78	4E-6
chr7	141673344	141673345	rs713598	Bitter taste response	TAS2R38	NR	2E-104
chr7	142104570	142104571	rs361433	Capecitabine sensitivity	Intergenic	NR	9E-7
chr7	142456927	142456928	rs10273639	Pancreatitis	PRSS1, PRSS2	1.36	2E-14
chr7	143109138	143109139	rs11767557	Alzheimer's disease (late onset)	EPHA1	1.11	6E-10
chr7	144841530	144841531	rs10487524	Attention deficit hyperactivity disorder	LOC643308	1.60	9E-6
chr7	144892085	144892086	rs12531488	Brain imaging	LOC643308	NR	NS
chr7	145959242	145959243	rs802568	Bipolar disorder and schizophrenia	CNTNAP2	2.03	2E-7
chr7	146897402	146897403	rs10273775	Alzheimer's disease	CNTNAP2	1.52	9E-6
chr7	147226890	147226891	rs6464816	Visceral adipose tissue/subcutaneous adipose tissue ratio	CNTNAP2	NR	9E-6
chr7	147702691	147702692	rs2214681	Bone mineral density	CNTNAP2	NR	3E-6
chr7	148258047	148258048	rs7807268	Crohn's disease	NR	1.38	4E-6
chr7	148650633	148650634	rs822552	Height	PDIA4	.03	3E-8
chr7	149203661	149203662	rs855913	Amyotrophic lateral sclerosis	ZNF746	1.08	4E-8
chr7	149289463	149289464	rs354033	Multiple sclerosis	ZNF767, ZNF746	1.11	5E-9
chr7	150517021	150517022	rs2110001	Height	TMEM176A	.03	3E-13
chr7	150622161	150622162	rs2968864	QT interval	KCNH2	1.40	8E-16
chr7	150623136	150623137	rs2968863	QT interval	KCNH2	1.35	2E-15
chr7	150637862	150637863	rs4725982	Electrocardiographic traits	KCNH2	2.08	3E-6
chr7	150637862	150637863	rs4725982	QT interval	KCNH2	1.58	5E-16
chr7	150667209	150667210	rs3807375	Electrocardiographic traits	KCNH2	11.95	5E-11
chr7	150669975	150669976	rs3778872	QT interval	KCNH2	1.77	3E-6
chr7	151120947	151120948	rs13232179	Coronary heart disease	Intergenic	1.67	1E-6
chr7	151407800	151407801	rs7805747	Chronic kidney disease	PRKAG2	1.18	4E-12
chr7	151415040	151415041	rs10224002	Hemoglobin	PRKAG2	.07	3E-15
chr7	151415040	151415041	rs10224002	Hematocrit	PRKAG2	.20	6E-15
chr7	151546588	151546589	rs7795096	Bipolar disorder (age of onset and psychomotor symptoms)	PRKAG2	1.20	2E-6
chr7	153625842	153625843	rs6464375	Pancreatic cancer	DPP6	3.73	4E-7
chr7	154072019	154072020	rs6977820	Tardive dyskinesia	DPP6	2.32	5E-6
chr7	154210797	154210798	rs10260404	Amyotrophic lateral sclerosis	DPP6	1.37	3E-6
chr7	154210797	154210798	rs10260404	Amyotrophic lateral sclerosis	DPP6	1.30	5E-8
chr7	154210797	154210798	rs10260404	Amyotrophic lateral sclerosis	DPP6	1.37	3E-6
chr7	154970468	154970469	rs10263087	Formal thought disorder in schizophrenia	INSIG1	1.55	7E-6
chr7	155762156	155762157	rs6943029	Platelet aggregation	SHH	NR	8E-8
chr7	156048648	156048649	rs10949808	Bipolar disorder and schizophrenia	LOC393076	1.27	1E-7
chr7	156880397	156880398	rs6966038	Response to citalopram treatment	UBE3C	1.68	4E-7
chr7	156880397	156880398	rs6966038	Response to citalopram treatment	UBE3C	1.64	5E-7
chr7	157090295	157090296	rs2527866	Quantitative traits	UBE3C	.27	3E-6
chr7	157294937	157294938	rs10227331	Inattentive symptoms	Intergenic	NR	4E-6
chr7	157387440	157387441	rs10274279	Myopia (pathological)	PTPRN2	NR	4E-11
chr7	157510194	157510195	rs6459804	Bipolar disorder and schizophrenia	PTPRN2	NR	8E-6
chr7	158136985	158136986	rs4909189	Response to amphetamines	PTPRN2	NR	3E-6
chr7	158724788	158724789	rs2730245	Height	WDR60	.32	3E-7
chr8	445600	445601	rs17665859	Bilirubin levels	C8orf42	.09	5E-7
chr8	516478	516479	rs722782	Age-related macular degeneration (GA)	C80rf42	1.67	2E-6
chr8	1746949	1746950	rs11986414	Gaucher disease severity	CLN8	3.72	1E-6
chr8	2040103	2040104	rs2235121	Bipolar disorder and schizophrenia	NR	1.22	8E-6
chr8	2740501	2740502	rs641525	Emphysema-related traits	CSMD1	2.19	5E-7
chr8	3594905	3594906	rs2623702	Pulmonary function decline	CSMD1	.32	9E-6
chr8	3828137	3828138	rs1529316	Multiple sclerosis	CSMD1	1.36	2E-6
chr8	4078352	4078353	rs2407314	Insulin resistance/response	CSMD1	9.00	8E-6
chr8	4164012	4164013	rs4875320	Coronary heart disease	CSMD1	.10	6E-6
chr8	4180843	4180844	rs10503253	Schizophrenia	CSMD1	1.16	2E-8
chr8	4214178	4214179	rs10503256	Schizophrenia	CSMD1	1.10	9E-7
chr8	4282617	4282618	rs980238	Disc degeneration (lumbar)	Intergenic	.10	9E-6
chr8	4284691	4284692	rs4875102	Disc degeneration (lumbar)	Intergenic	.12	4E-7
chr8	4285389	4285390	rs1154053	Disc degeneration (lumbar)	Intergenic	.13	4E-6
chr8	4299882	4299883	rs17070309	Immune response to smallpox vaccine (IL-6)	CSMD1	NR	5E-7
chr8	4483140	4483141	rs2616984	Cognitive performance	Intergenic	NR	4E-6
chr8	4926464	4926465	rs1454292	Hair morphology	AC019176.2	NR	8E-6
chr8	5461752	5461753	rs4875598	Attention deficit hyperactivity disorder symptoms (interaction)	Intergenic	.94	9E-6
chr8	6323277	6323278	rs2916733	Epirubicin-induced leukopenia	MCPH1	2.74	2E-9
chr8	6351251	6351252	rs17077154	Cytomegalovirus antibody response	MCPH1	.30	8E-6
chr8	6822784	6822785	rs2738048	IgA nephropathy	DEFAs	1.27	3E-14
chr8	6829084	6829085	rs2738113	Endometriosis	Intergenic	1.15	3E-7
chr8	7189357	7189358	rs9692809	Optic disc size (cup)	LOC401447	.09	8E-6
chr8	7836059	7836060	rs9692809	Optic disc size (cup)	LOC401447	.09	8E-6
chr8	8717006	8717007	rs332034	Conduct disorder (interaction)	MFHAS1	1.05	6E-6
chr8	8722377	8722378	rs10108954	Prion diseases	NR	1.74	7E-6
chr8	8890097	8890098	rs1045529	Myopia (pathological)	Intergenic	NR	3E-6
chr8	8990576	8990577	rs189798	Myopia (pathological)	PPP1R3B, MYP10, MIR4660, MIR124-1, MSRA	1.92	6E-7
chr8	8999018	8999019	rs3748140	Alzheimer's disease	PPP1R3B	2.43	3E-7
chr8	9178267	9178268	rs6984305	Liver enzyme levels (alkaline phosphatase)	PPP1R3B	2.70	2E-10
chr8	9183357	9183358	rs9987289	Metabolic syndrome (bivariate traits)	LOC100129150	.24	4E-8
chr8	9183357	9183358	rs9987289	HDL Cholesterol - Triglycerides (HDLC-TG)	LOC100129150	.25	1E-8
chr8	9183357	9183358	rs9987289	C-reactive protein	PPP1R3B	.07	3E-13
chr8	9183357	9183358	rs9987289	LDL cholesterol	PPP1R3B	2.22	7E-15
chr8	9183357	9183358	rs9987289	HDL cholesterol	PPP1R3B	1.21	6E-25
chr8	9183357	9183358	rs9987289	Cholesterol, total	PPP1R3B	3.14	9E-24
chr8	9183595	9183596	rs4841132	Metabolite levels	PPP1R3B, TNKS	NR	2E-9
chr8	9183595	9183596	rs4841132	Fasting insulin-related traits (interaction with BMI)	PPP1R3B	NR	2E-10
chr8	9183595	9183596	rs4841132	Fasting glucose-related traits (interaction with BMI)	PPP1R3B	NR	8E-9
chr8	9184690	9184691	rs6601299	Coronary heart disease	PPP1R3B	.14	1E-8
chr8	9185145	9185146	rs2126259	LDL cholesterol	PPP1R3B	.02	7E-12
chr8	9814410	9814411	rs656319	Myopia (pathological)	Intergenic	NR	3E-6
chr8	9986654	9986655	rs1484642	Bipolar disorder and schizophrenia	MSRA	1.43	3E-6
chr8	10022937	10022938	rs7017212	Schizophrenia	MSRA	NR	4E-6
chr8	10071619	10071620	rs11775334	Hypertension	MSRA	.08	4E-6
chr8	10334780	10334781	rs11782819	Alzheimer's disease	MSRA	NR	3E-6
chr8	10671271	10671272	rs6601530	Carotid intima media thickness	PINX1	.01	2E-8
chr8	10683928	10683929	rs11776767	Triglycerides	PINX1,XKR6	2.01	1E-8
chr8	11045160	11045161	rs7819412	Triglycerides	XKR6, AMAC1L2	.04	3E-8
chr8	11104110	11104111	rs7824557	Retinal vascular caliber	XKR6,PINX1,SOX7,MTMR9,GATA4	1.00	4E-7
chr8	11119036	11119037	rs2251301	Response to antipsychotic therapy (extrapyramidal side effects)	Intergenic	NR	1E-6
chr8	11276541	11276542	rs2002030	Cognitive performance	C8orf12	NR	5E-6
chr8	11340180	11340181	rs7812879	Systemic lupus erythematosus	BLK	1.45	2E-24
chr8	11343679	11343680	rs2254546	Kawasaki disease	FAM167A, BLK	1.85	8E-21
chr8	11343972	11343973	rs2736340	Kawasaki disease	BLK	1.54	9E-10
chr8	11343972	11343973	rs2736340	Systemic lupus erythematosus	BLK	1.38	3E-7
chr8	11343972	11343973	rs2736340	Rheumatoid arthritis	BLK	1.19	6E-9
chr8	11349185	11349186	rs13277113	Systemic lupus erythematosus	BLK	1.39	2E-10
chr8	11349185	11349186	rs13277113	Systemic lupus erythematosus	C8orf13, BLK	1.39	1E-10
chr8	11352540	11352541	rs2618476	Systemic lupus erythematosus	BLK	1.29	2E-8
chr8	11359637	11359638	rs1600249	Rheumatoid arthritis	BLK	1.30	5E-6
chr8	11359637	11359638	rs1600249	Rheumatoid arthritis	BLK	1.30	5E-6
chr8	11409991	11409992	rs2255327	Immune response to smallpox vaccine (IL-6)	BLK	NR	3E-7
chr8	11612697	11612698	rs804280	Myopia (pathological)	GATA4	NR	4E-6
chr8	11638243	11638244	rs6601606	Neutrophil count	NEIL2	NR	1E-6
chr8	11684462	11684463	rs2645424	Non-alcoholic fatty liver disease histology (other)	FDFT1	.77	7E-7
chr8	11684462	11684463	rs2645424	Non-alcoholic fatty liver disease histology (lobular)	FDFT1	.30	3E-6
chr8	11698746	11698747	rs1296028	Parkinson's disease	Intergenic	1.15	1E-6
chr8	12711862	12711863	rs4831837	Morbidity-free survival	Intergenic	NR	5E-7
chr8	13260535	13260536	rs289585	Bipolar disorder	DLC1	1.45	5E-6
chr8	14389480	14389481	rs1903595	Platelet aggregation	SGCZ	NR	5E-6
chr8	15532584	15532585	rs4831760	Pulmonary function decline	TUSC3	.22	5E-8
chr8	15665611	15665612	rs240657	Intelligence	TUSC3	5.22	2E-6
chr8	16929634	16929635	rs10090288	Depression and alcohol dependence	EFHA2	2.55	8E-6
chr8	17143829	17143830	rs3793427	Tonometry	VPS37A	NR	2E-6
chr8	17205576	17205577	rs4921542	Creutzfeldt-Jakob disease (variant)	MTMR7	3.25	2E-8
chr8	17329826	17329827	rs2720508	Conduct disorder (case status)	Intergenic	1.61	7E-6
chr8	17800768	17800769	rs2299587	Economic and political preferences	PCM1	.13	9E-7
chr8	17977649	17977650	rs17126232	Obesity	ASAH1	NR	8E-8
chr8	17977649	17977650	rs17126232	Obesity	ASAH1	NR	4E-7
chr8	17977649	17977650	rs17126232	Obesity	ASAH1	NR	2E-7
chr8	18272437	18272438	rs4921914	Urinary metabolites	NAT2	NR	1E-28
chr8	18272880	18272881	rs1495741	Bladder cancer	NAT2	1.15	4E-11
chr8	18272880	18272881	rs1495741	Triglycerides	NAT2	2.97	4E-14
chr8	18272880	18272881	rs1495741	Cholesterol, total	NAT2	1.07	2E-9
chr8	18273299	18273300	rs1495743	Metabolic traits	NAT2	.26	2E-40
chr8	18782046	18782047	rs4921617	Neutrophil count	PSD3	NR	4E-6
chr8	19651160	19651161	rs920590	Acute lymphoblastic leukemia (childhood)	INTS10	NR	2E-6
chr8	19786890	19786891	rs7816032	Hyperactive-impulsive symptoms	LPL	NR	2E-6
chr8	19813528	19813529	rs268	Metabolic syndrome	LPL	.38	2E-12
chr8	19816237	19816238	rs295	Metabolic syndrome	LPL	.17	2E-9
chr8	19816933	19816934	rs301	Metabolic syndrome (bivariate traits)	LPL	.22	3E-11
chr8	19819327	19819328	rs325	HDL cholesterol	LPL	.05	8E-26
chr8	19819438	19819439	rs326	Triglycerides	LPL, C8orf35, SLC18A1	6.60	5E-12
chr8	19819723	19819724	rs328	Triglycerides	LPL	NR	1E-9
chr8	19819723	19819724	rs328	Triglycerides	LPL	.19	2E-28
chr8	19819723	19819724	rs328	HDL cholesterol	LPL	.17	9E-23
chr8	19819723	19819724	rs328	Triglycerides	LPL	1.00	5E-7
chr8	19824491	19824492	rs13702	HDL Cholesterol - Triglycerides (HDLC-TG)	LPL	.29	1E-16
chr8	19824666	19824667	rs15285	Triglycerides-Blood Pressure (TG-BP)	LPL	.27	1E-10
chr8	19826372	19826373	rs2197089	Metabolic syndrome (bivariate traits)	LPL	.18	2E-9
chr8	19827847	19827848	rs10105606	Triglycerides	LPL	.07	4E-26
chr8	19830920	19830921	rs10096633	Triglycerides	LPL	.17	2E-18
chr8	19830920	19830921	rs10096633	Metabolic traits	LPL	.12	5E-8
chr8	19832645	19832646	rs17482753	HDL cholesterol	LPL	2.02	3E-11
chr8	19844221	19844222	rs12678919	Metabolite levels	LPL	NR	9E-13
chr8	19844221	19844222	rs12678919	Triglycerides	LPL	13.64	2E-115
chr8	19844221	19844222	rs12678919	HDL cholesterol	LPL	2.25	1E-97
chr8	19844221	19844222	rs12678919	Triglycerides	LPL	.25	2E-41
chr8	19844221	19844222	rs12678919	HDL cholesterol	LPL	.23	2E-34
chr8	19845375	19845376	rs7841189	Metabolic syndrome	LPL	.18	1E-14
chr8	19847689	19847690	rs10503669	Triglycerides	LPL	.09	7E-39
chr8	19847689	19847690	rs10503669	HDL cholesterol	LPL	.04	8E-43
chr8	19847689	19847690	rs10503669	Triglycerides	LPL	11.57	4E-22
chr8	19847689	19847690	rs10503669	HDL cholesterol	LPL	2.09	4E-19
chr8	19849756	19849757	rs17091905	Cardiovascular disease risk factors	LPL	.15	6E-12
chr8	19849756	19849757	rs17091905	Cardiovascular disease risk factors	LPL	.17	5E-15
chr8	19865174	19865175	rs2083637	Metabolic syndrome	LPL	.04	2E-10
chr8	19865174	19865175	rs2083637	HDL cholesterol	LPL	.11	6E-18
chr8	19865174	19865175	rs2083637	Waist circumference and related phenotypes	LPL	NR	5E-6
chr8	19868385	19868386	rs1441756	Metabolic syndrome (bivariate traits)	LPL	.18	3E-8
chr8	19876745	19876746	rs7016880	Hypertriglyceridemia	LPL	3.13	2E-7
chr8	19912369	19912370	rs115849089	Lipid metabolism phenotypes	LPL	.22	4E-15
chr8	19987702	19987703	rs10503672	Amyotrophic lateral sclerosis (age of onset)	Intergenic	NR	3E-6
chr8	20066048	20066049	rs1106634	Bipolar disorder and schizophrenia	NR	1.34	4E-6
chr8	20066048	20066049	rs1106634	Major depressive disorder (broad)	ATP6V1B2, SLC18A1, LZTS1	1.30	7E-7
chr8	20336572	20336573	rs10111661	Dental caries	LZTS1	NR	2E-6
chr8	20626320	20626321	rs2122469	Serum tamsulosin hydrochloride concentration	Intergenic	18.57	7E-7
chr8	21662444	21662445	rs17581368	Entorhinal cortical thickness	DOK2	.09	7E-6
chr8	22400988	22400989	rs4872511	HIV-1 control	PPP3CC	NR	9E-6
chr8	22404839	22404840	rs2280890	HIV-1 control	SORBS3	NR	9E-6
chr8	22619550	22619551	rs11998649	Visceral fat	PEBP4	NR	7E-6
chr8	23082970	23082971	rs13278062	Age-related macular degeneration	TNFRSF10A, LOC389641	1.37	1E-12
chr8	23526462	23526463	rs1512268	Prostate cancer	NR	1.35	5E-6
chr8	23526462	23526463	rs1512268	Prostate cancer	NKX3.1	NR	4E-11
chr8	23526462	23526463	rs1512268	Prostate cancer	NKX3.1	1.18	3E-30
chr8	23534017	23534018	rs10503733	Prostate cancer	NR	1.29	8E-8
chr8	23584225	23584226	rs13273073	Treatment response for severe sepsis	NKX2-6	NR	7E-6
chr8	23751150	23751151	rs10109414	Chronic kidney disease	STC1	NR	1E-8
chr8	23818686	23818687	rs7833268	Subcutaneous adipose tissue	STC1	NR	6E-7
chr8	24116303	24116304	rs1013209	Height	ADAM28	.03	2E-9
chr8	26718879	26718880	rs4732957	Response to amphetamines	ADRA1A	NR	7E-6
chr8	27076597	27076598	rs1446682	Bipolar disorder and schizophrenia	NR	1.26	6E-6
chr8	27452846	27452847	rs17466684	Panic disorder	CLU	NR	7E-7
chr8	27456252	27456253	rs2279590	Alzheimer's disease	CLU	1.22	6E-10
chr8	27464518	27464519	rs11136000	Alzheimer's disease	CLU	1.22	6E-10
chr8	27464518	27464519	rs11136000	Alzheimer's disease	CLU	1.16	9E-10
chr8	27466314	27466315	rs1532278	Alzheimer's disease (late onset)	CLU	1.12	8E-8
chr8	27468861	27468862	rs9331888	Alzheimer's disease	CLU	1.22	6E-10
chr8	27487789	27487790	rs569214	Alzheimer's disease	CLU	1.14	4E-8
chr8	27923387	27923388	rs4732812	Suicidal ideation	Intergenic	2.56	3E-6
chr8	29360304	29360305	rs10091038	Response to statin therapy	LOC646909, DUSP4, KIF13B	NR	3E-8
chr8	30262785	30262786	rs2979481	Heart rate variability traits	RBPMS	NR	4E-6
chr8	30498858	30498859	rs2978263	Cognitive performance	GTF2E2	NR	8E-6
chr8	30936355	30936356	rs2553268	Exercise treadmill test traits	WRN	NR	6E-6
chr8	31633446	31633447	rs10503887	Hip geometry	NRG1	NR	2E-7
chr8	32411215	32411216	rs16879552	Hirschsprung's disease	NRG1	1.68	2E-8
chr8	32412358	32412359	rs2439312	Dialysis-related mortality	NRG1	2.36	7E-6
chr8	32432368	32432369	rs2439302	Thyroid cancer	NRG1	1.36	2E-9
chr8	33565377	33565378	rs4469412	Immune response to smallpox vaccine (IL-6)	VENTXP5	NR	9E-7
chr8	33665679	33665680	rs10503951	Immune response to smallpox vaccine (IL-6)	LOC388460	NR	3E-9
chr8	33673010	33673011	rs11786194	Immune response to smallpox vaccine (IL-6)	LOC388460	NR	9E-7
chr8	34126947	34126948	rs6990255	Bipolar disorder	NR	1.33	6E-6
chr8	34236991	34236992	rs2609653	Bipolar disorder	NR	NR	7E-6
chr8	34524002	34524003	rs6987004	Pulmonary function decline	Intergenic	.26	7E-6
chr8	36846108	36846109	rs7816345	Breast size	ZNF703,MRPS7P1,KCNU1	.15	2E-14
chr8	36941541	36941542	rs4739466	Bipolar disorder	NR	NR	4E-6
chr8	36951913	36951914	rs2407103	Insulin resistance/response	KCNU1	15.00	2E-6
chr8	37686748	37686749	rs6468442	Menopause (age at onset)	NR	.39	3E-7
chr8	37977731	37977732	rs2517388	Menopause (age at onset)	ASH2L	.26	9E-15
chr8	38031344	38031345	rs16887244	Schizophrenia	LSM1, WHSC1L1	1.19	1E-10
chr8	38469302	38469303	rs7832232	Pancreatic cancer	RNF5P1	1.45	5E-6
chr8	39548377	39548378	rs1349547	HIV-1 susceptibility	ADAM18	.00	2E-6
chr8	40053604	40053605	rs10958605	Parkinson's disease (motor and cognition)	C8orf4	1.81	2E-6
chr8	40252700	40252701	rs11786458	Inattentive symptoms	Intergenic	NR	9E-6
chr8	40484238	40484239	rs2722425	Fasting plasma glucose	ZMAT4	NR	9E-6
chr8	40484238	40484239	rs2722425	Fasting plasma glucose	ZMAT4	NR	2E-8
chr8	41519461	41519462	rs515071	Type 2 diabetes	ANK1	1.18	1E-8
chr8	41549193	41549194	rs6474359	Glycated hemoglobin levels	ANK1	.06	1E-8
chr8	41615137	41615138	rs7006290	Pulmonary function decline	ANK1	.18	5E-6
chr8	41630404	41630405	rs4737009	Glycated hemoglobin levels	ANK1	.03	6E-12
chr8	42546710	42546711	rs1451240	Nicotine dependence	CHRNB3	NR	7E-16
chr8	42550497	42550498	rs6474412	Smoking behavior	CHRNB3,CHRNA6	.29	1E-8
chr8	43695233	43695234	rs58810682	Response to amphetamines	Intergenic	NR	8E-6
chr8	47947700	47947701	rs2287654	Visceral adipose tissue adjusted for BMI	KIAA0146	NR	4E-6
chr8	49053164	49053165	rs11778329	Attention deficit hyperactivity disorder	Intergenic	NR	7E-6
chr8	49812200	49812201	rs12155623	Sudden cardiac arrest	EFCAB1	1.14	3E-7
chr8	51412590	51412591	rs310558	Pulmonary function	SNTG1	NR	5E-6
chr8	52216761	52216762	rs7821565	Tuberculosis	NR	1.20	8E-6
chr8	52887540	52887541	rs1015213	Glaucoma (primary open-angle)	PCMTD1-ST18	1.50	3E-9
chr8	54410207	54410208	rs10958369	Response to antineoplastic agents	Intergenic	2.33	2E-6
chr8	54555199	54555200	rs11773966	Bipolar disorder (mood-incongruent)	ATP6V1H	2.17	2E-6
chr8	55310710	55310711	rs1504749	Intracranial aneurysm	SOX17	1.17	5E-7
chr8	55327090	55327091	rs10958409	Intracranial aneurysm	SOX17	1.36	1E-10
chr8	55437523	55437524	rs9298506	Intracranial aneurysm	SOX17	1.28	1E-12
chr8	55437523	55437524	rs9298506	Intracranial aneurysm	SOX17	1.35	2E-9
chr8	55440067	55440068	rs10104997	Dengue shock syndrome	NR	1.20	9E-7
chr8	56168058	56168059	rs12542677	Immune reponse to smallpox (secreted IL-1beta)	XKR4	NR	2E-7
chr8	56599547	56599548	rs4737395	Myopia (pathological)	Intergenic	NR	5E-9
chr8	57095807	57095808	rs10958476	Height	SDR16C5	NR	1E-9
chr8	57095807	57095808	rs10958476	Height	PLAG1, MOS, CHCHD7,RDHE2, RPS20,LYN, TGS1, PENK	5.40	7E-8
chr8	57100148	57100149	rs7833986	Height	PLAG1	.12	8E-10
chr8	57100790	57100791	rs13273123	Height	PLAG1	.75	3E-6
chr8	57100790	57100791	rs13273123	Height	PLAG1	.71	1E-9
chr8	57155597	57155598	rs9650315	Height	CHCHD7,RDHE2	.43	4E-7
chr8	57179019	57179020	rs7815788	Height	PLAG1	.07	5E-6
chr8	57194162	57194163	rs7460090	Height	SDR16C5	.06	8E-27
chr8	58840923	58840924	rs1992045	Bipolar disorder and schizophrenia	FAM110B	1.56	2E-7
chr8	59388564	59388565	rs2081687	LDL cholesterol	CYP7A1	.95	4E-9
chr8	59388564	59388565	rs2081687	Cholesterol, total	CYP7A1	1.26	9E-13
chr8	59708308	59708309	rs960089	Cognitive performance	TOX	NR	6E-6
chr8	60130295	60130296	rs3110127	RR interval (heart rate)	Intergenic	.15	4E-6
chr8	60178720	60178721	rs10089517	Visceral adipose tissue/subcutaneous adipose tissue ratio	TOX	NR	2E-6
chr8	60961820	60961821	rs569688	Myopia (pathological)	Intergenic	NR	4E-7
chr8	61003896	61003897	rs6995588	Cardiac hypertrophy	CA8	NR	2E-6
chr8	61194169	61194170	rs10957125	Response to amphetamines	CA8	NR	4E-6
chr8	61346196	61346197	rs9650199	Response to amphetamines	Intergenic	NR	6E-6
chr8	61876043	61876044	rs10104895	Pulmonary function decline	CHD7	.26	2E-6
chr8	62409427	62409428	rs903027	MRI atrophy measures	RLBP1L1	.01	6E-6
chr8	63883592	63883593	rs7834588	Response to Vitamin E supplementation	NKAIN3	.03	6E-7
chr8	65640259	65640260	rs10808739	HIV-1 susceptibility	CYP7B1	.00	1E-6
chr8	66822029	66822030	rs6472235	Myopia (pathological)	Intergenic	NR	1E-7
chr8	66851730	66851731	rs4601292	HIV-1 viral setpoint	DNAJC5B	NR	6E-6
chr8	66974251	66974252	rs13279522	Response to statin therapy	DNAJC5B, TRIM55, CRH	1.59	5E-7
chr8	68799376	68799377	rs6990917	Adverse response to lamotrigine and phenytoin	RP11-396J6.2	NR	2E-6
chr8	69389216	69389217	rs1517114	Response to irinotecan in non-small-cell lung cancer	C8orf34	4.10	9E-6
chr8	69992379	69992380	rs2912522	Dupuytren's disease	C8orf34, SULF1	1.39	2E-13
chr8	70412449	70412450	rs6982250	Height	SULF1	.05	1E-6
chr8	70493973	70493974	rs13273088	Fasting insulin-related traits (interaction with BMI)	SULF1	NR	7E-7
chr8	70724753	70724754	rs16936455	HIV-1 control	NR	NR	7E-6
chr8	71167993	71167994	rs2926702	Non-small cell lung cancer	NCOA2	NR	7E-6
chr8	72263955	72263956	rs2218488	Sleepiness	EYA1	NR	3E-6
chr8	72270081	72270082	rs7006821	Chronic obstructive pulmonary disease-related biomarkers	EYA1	NR	5E-6
chr8	72561741	72561742	rs7834018	Autism	Intergenic	1.56	8E-7
chr8	73106915	73106916	rs1963982	Blood pressure	Intergenic	NR	3E-6
chr8	73236809	73236810	rs7006742	Pulmonary function decline	Intergenic	.78	1E-7
chr8	73363988	73363989	rs2116078	Multiple sclerosis (age of onset)	KCNB2	NR	3E-6
chr8	73633027	73633028	rs2247572	Cognitive performance	KCNB2	NR	1E-6
chr8	73778641	73778642	rs10504543	Echocardiographic traits	KCNB2	NR	5E-6
chr8	74007346	74007347	rs12677663	Crohn's disease	C8orf84, TERF1, RPL7, RDH10, KCNB2	1.15	2E-8
chr8	74066178	74066179	rs2383876	Corneal curvature	RPESP	.05	5E-6
chr8	74274190	74274191	rs12679254	Inattentive symptoms	Intergenic	NR	2E-6
chr8	75294974	75294975	rs4471028	Waist circumference	GDAP1	NR	2E-7
chr8	75373947	75373948	rs16938910	Response to tocilizumab in rheumatoid arthritis	Intergenic	28.66	4E-7
chr8	75513133	75513134	rs6472866	Protein quantitative trait loci	GDAP1,PI15	NR	8E-7
chr8	76147953	76147954	rs16939046	Information processing speed	AC022274.1	.22	4E-6
chr8	76573710	76573711	rs2922763	Body mass index	HNF4G	NR	6E-8
chr8	77507612	77507613	rs7846606	Orofacial clefts	NR	NR	7E-6
chr8	78093836	78093837	rs7821178	Menarche (age at onset)	PXMP3	2.40	3E-9
chr8	78160178	78160179	rs7846385	Height	PXMP3, ZFHX4	5.00	5E-8
chr8	78178484	78178485	rs6473015	Height	PEX2	.03	7E-13
chr8	78680348	78680349	rs3864663	Sudden cardiac arrest	PXMP3	1.40	2E-6
chr8	78956657	78956658	rs2219968	Prostate cancer (gene x gene interaction)	PKIA	1.30	6E-7
chr8	79401037	79401038	rs1520333	Multiple sclerosis	PKIA, IL7	1.10	2E-7
chr8	80227447	80227448	rs1460163	Creutzfeldt-Jakob disease	STMN2	NR	6E-8
chr8	81308149	81308150	rs7000782	Atopic dermatitis	ZBTB10	1.09	1E-6
chr8	81438419	81438420	rs1051920	Hypothyroidism	ZBTB10, RPSAP47	1.14	4E-6
chr8	81461973	81461974	rs440837	Sex hormone-binding globulin levels	ZBTB10	.04	7E-8
chr8	81461973	81461974	rs440837	Sex hormone-binding globulin levels	ZBTB10	.03	3E-9
chr8	81470119	81470120	rs272594	Neutrophil count	RP11-48B3.1, RPSAP47	NR	1E-6
chr8	82027671	82027672	rs10097731	Serum total protein level	PAG1	.03	6E-8
chr8	82151746	82151747	rs12216812	Myopia (pathological)	Intergenic	NR	3E-9
chr8	82445223	82445224	rs16909318	Visceral fat	LOC646486, FABP4	NR	7E-7
chr8	82928597	82928598	rs7820074	Orofacial clefts	NR	NR	9E-6
chr8	83073828	83073829	rs13264970	Prostate cancer (gene x gene interaction)	SNX16	1.30	4E-6
chr8	83669119	83669120	rs6473383	Heart failure	SNX16	1.19	3E-6
chr8	83903813	83903814	rs7015622	Response to antidepressant treatment	Intergenic	NR	1E-6
chr8	83991230	83991231	rs1375785	Information processing speed	Intergenic	.20	8E-6
chr8	84812000	84812001	rs2199936	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	ABCG2	2.80	2E-10
chr8	84812000	84812001	rs2199936	Cardiovascular disease risk factors	ABCG2	.19	2E-17
chr8	84812000	84812001	rs2199936	Urate levels	ABCG2	1.86	3E-23
chr8	84812000	84812001	rs2199936	Urate levels	ABCG2	18.08	1E-75
chr8	87025012	87025013	rs285406	Adverse response to lamotrigine and phenytoin	ATP6V0D2	NR	5E-6
chr8	88868339	88868340	rs12543318	Orofacial clefts	NR	1.27	2E-8
chr8	89585047	89585048	rs7838490	Body mass index and cholesterol (psychopharmacological treatment)	MMP16	NR	6E-8
chr8	89760310	89760311	rs7004633	Schizophrenia	MMP16	1.15	6E-8
chr8	89760310	89760311	rs7004633	Schizophrenia	MMP16	1.11	2E-7
chr8	90342185	90342186	rs4397449	Cognitive performance	RIPK2	NR	3E-6
chr8	90656987	90656988	rs160441	Tuberculosis	NR	1.20	8E-6
chr8	90778512	90778513	rs42490	Leprosy	RIPK2	1.32	1E-16
chr8	90823686	90823687	rs40457	Leprosy	RIPK2	1.30	1E-12
chr8	92559914	92559915	rs2657195	Disc degeneration (lumbar)	Intergenic	.13	8E-6
chr8	94169349	94169350	rs278567	Bipolar disorder and schizophrenia	NR	1.25	8E-6
chr8	94358097	94358098	rs7387468	Temperament	FAM92A1	.22	3E-6
chr8	94916102	94916103	rs35820208	Response to amphetamines	Intergenic	NR	3E-6
chr8	95960510	95960511	rs896854	Type 2 diabetes	TP53INP1	1.06	1E-9
chr8	96120071	96120072	rs4392868	Radiation response	PLEKHF2	NR	8E-6
chr8	96127029	96127030	rs7000734	Radiation response	PLEKHF2	NR	4E-7
chr8	98166912	98166913	rs1835740	Migraine	MTDH,PGCP	1.18	2E-11
chr8	98329764	98329765	rs6468544	Antipsychotic-induced QTc interval prolongation	Intergenic	NR	8E-7
chr8	99088580	99088581	rs13278732	Eosinophilic esophagitis (pediatric)	NR	1.31	6E-6
chr8	99129506	99129507	rs2071598	Prion diseases	NR	1.26	9E-6
chr8	100835181	100835182	rs959695	Hippocampal atrophy	Intergenic	NR	1E-6
chr8	101330208	101330209	rs1371867	Atrioventricular conduction	RNF19A, ANKRD46	2.32	9E-6
chr8	101813155	101813156	rs3847153	Premature ovarian failure	Intergenic	1.42	9E-8
chr8	101841545	101841546	rs3108919	AIDS	Intergenic	2.13	4E-6
chr8	101919320	101919321	rs931812	Attention deficit hyperactivity disorder and conduct disorder	YWHAZ	NR	5E-6
chr8	102227922	102227923	rs1264202	Reasoning	ZNF706	NR	2E-6
chr8	102944862	102944863	rs517811	Cognitive performance	NCALD	NR	5E-6
chr8	103052376	103052377	rs16868941	Coffee consumption	NCALD	.06	8E-7
chr8	103975988	103975989	rs6468852	Alzheimer's disease (late onset)	Intergenic	NR	1E-6
chr8	105359431	105359432	rs2458413	Paget's disease	TM7SF4	1.40	7E-17
chr8	105957539	105957540	rs16872085	Sudden cardiac arrest	ZFPM2	1.83	1E-6
chr8	105958019	105958020	rs284489	Glaucoma (primary open-angle)	LRP12, ZFPM2	1.61	9E-10
chr8	105992695	105992696	rs977396	Response to antipsychotic treatment	Intergenic	NR	3E-7
chr8	106581527	106581528	rs6993770	Platelet counts	ZFPM2	3.67	4E-17
chr8	106581527	106581528	rs6993770	Vascular endothelial growth factor levels	ZFPM2, LRP12	NR	5E-23
chr8	108789815	108789816	rs4534106	Brain structure	Intergenic	NR	1E-6
chr8	109228007	109228008	rs611744	Dupuytren's disease	EIF3E, RSPO2	1.33	8E-15
chr8	109629902	109629903	rs2935776	T-tau	Intergenic	NR	6E-7
chr8	110115675	110115676	rs7832552	Body mass (lean)	TRHR	.10	4E-10
chr8	110217265	110217266	rs7823896	Myopia (pathological)	Intergenic	NR	3E-6
chr8	110229393	110229394	rs2199936	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	ABCG2	2.80	2E-10
chr8	110229393	110229394	rs2199936	Cardiovascular disease risk factors	ABCG2	.19	2E-17
chr8	110229393	110229394	rs2199936	Urate levels	ABCG2	1.86	3E-23
chr8	110229393	110229394	rs2199936	Urate levels	ABCG2	18.08	1E-75
chr8	112976140	112976141	rs12549576	Bilirubin levels	AC068954.1, RP11-58O3.2	.30	1E-6
chr8	113074095	113074096	rs1996720	Temperament	CSMD3	.11	2E-6
chr8	115121026	115121027	rs9942773	Periodontal microbiota	CSMD3, TRPS1	2.07	2E-6
chr8	116110724	116110725	rs218361	Eating disorders	TRPS1	1.06	7E-6
chr8	116394074	116394075	rs17658378	Attention deficit hyperactivity disorder (time to onset)	Intergenic	NR	9E-6
chr8	116599198	116599199	rs2293889	HDL cholesterol	TRPS1	.44	6E-11
chr8	116633698	116633699	rs2721937	Major depressive disorder	TRPS1	NR	8E-6
chr8	116648564	116648565	rs2737229	Cholesterol, total	TRPS1	1.11	2E-8
chr8	116813904	116813905	rs800586	Response to tocilizumab in rheumatoid arthritis	Intergenic	9.78	2E-7
chr8	117556269	117556270	rs4876662	Aortic root size	Intergenic	.13	2E-6
chr8	117630682	117630683	rs16892766	Colorectal cancer	EIF3H	1.24	4E-7
chr8	117630682	117630683	rs16892766	Colorectal cancer	EIF3H	1.27	3E-18
chr8	117641609	117641610	rs11987235	Corneal curvature	EIF3H	.04	7E-6
chr8	118025644	118025645	rs3019885	Asthma	SLC30A8	1.34	5E-13
chr8	118184782	118184783	rs13266634	Type 2 diabetes and other traits	SLC30A8	1.16	8E-8
chr8	118184782	118184783	rs13266634	Type 2 diabetes	SLC30A8	1.22	2E-14
chr8	118184782	118184783	rs13266634	Glycated hemoglobin levels	SLC30A8	.02	5E-8
chr8	118184782	118184783	rs13266634	Type 2 diabetes	SLC30A8	1.18	7E-6
chr8	118184782	118184783	rs13266634	Type 2 diabetes	SLC30A8	1.12	5E-8
chr8	118184782	118184783	rs13266634	Type 2 diabetes	SLC30A8	1.12	5E-8
chr8	118184782	118184783	rs13266634	Type 2 diabetes	SLC30A8	1.12	5E-8
chr8	118184782	118184783	rs13266634	Type 2 diabetes	SLC30A8	1.15	3E-6
chr8	118184782	118184783	rs13266634	Type 2 diabetes	SLC30A8	1.18	6E-8
chr8	118185024	118185025	rs3802177	Type 2 diabetes	SLC30A8	1.23	4E-8
chr8	118185024	118185025	rs3802177	Type 2 diabetes	SLC30A8	1.15	1E-8
chr8	118185732	118185733	rs11558471	Fasting glucose-related traits (interaction with BMI)	SLC30A8	NR	3E-20
chr8	118185732	118185733	rs11558471	Proinsulin levels	SLC30A8	NR	3E-18
chr8	118185732	118185733	rs11558471	Fasting glucose-related traits	SLC30A8	NR	3E-11
chr8	118549375	118549376	rs17667932	Kawasaki disease	MED30	2.37	5E-7
chr8	118827838	118827839	rs11989122	Height	EXT1	.36	6E-6
chr8	119766193	119766194	rs11988997	Pancreatitis	NR	1.36	6E-6
chr8	119830679	119830680	rs903614	Chronic obstructive pulmonary disease-related biomarkers	KB-1137H10.1	NR	3E-6
chr8	119923872	119923873	rs4355801	Bone mineral density	TNFRSF11B	.09	8E-10
chr8	119977336	119977337	rs12679857	Type 1 diabetes	TNFRSF11B	1.20	4E-7
chr8	119977791	119977792	rs2062375	Osteoporosis	TNFRSF11B	.14	3E-11
chr8	120007419	120007420	rs2062377	Bone mineral density (spine)	TNFRSF11B	.09	4E-16
chr8	120012699	120012700	rs11995824	Bone mineral density (hip)	TNFRSF11B	.07	7E-9
chr8	120044828	120044829	rs6469804	Bone mineral density (spine)	OPG	.12	7E-15
chr8	120052237	120052238	rs6993813	Bone mineral density (hip)	OPG	.09	3E-11
chr8	120224805	120224806	rs1364705	Hippocampal atrophy	MAL2	NR	9E-6
chr8	120353266	120353267	rs2469997	Hypertension	NOV	NR	3E-16
chr8	120435811	120435812	rs2071518	Blood pressure	NOV	.31	4E-9
chr8	120647928	120647929	rs7007970	Height	ENPP2	.04	6E-6
chr8	121635395	121635396	rs6986718	Bipolar disorder and schizophrenia	NR	1.52	9E-6
chr8	121694649	121694650	rs11989782	Eosinophilic esophagitis (pediatric)	NR	1.53	7E-6
chr8	122622499	122622500	rs17232789	Dialysis-related mortality	HAS2	1.59	6E-6
chr8	122908502	122908503	rs7844723	Hemostatic factors and hematological phenotypes	Intergenic	NR	2E-6
chr8	122909686	122909687	rs956225	Alzheimer's disease	Intergenic	3.33	9E-6
chr8	122963214	122963215	rs907121	Weight	Intergenic	1.83	2E-6
chr8	123408090	123408091	rs11781551	Carotid intima media thickness	ZHX2	.01	2E-11
chr8	123706154	123706155	rs4871297	Type 1 diabetes nephropathy	RP11-973F15.1	1.23	2E-6
chr8	123973067	123973068	rs10108684	Immune response to smallpox vaccine (IL-6)	ZHX2	NR	1E-8
chr8	124696866	124696867	rs2294015	Event-related brain oscillations	ANXA13	.21	9E-6
chr8	124714721	124714722	rs13258681	Prostate cancer (gene x gene interaction)	ANXA13	1.32	4E-6
chr8	124765701	124765702	rs10088262	Pancreatic cancer	FAM91A1	1.40	4E-6
chr8	124831833	124831834	rs10481151	Cognitive performance	FAM91A1	NR	4E-7
chr8	126477977	126477978	rs2001945	Triglycerides	Intergenic	.04	1E-20
chr8	126481474	126481475	rs2980879	Adiponectin levels	TRIB1	.03	1E-9
chr8	126481474	126481475	rs2980879	Adiponectin levels	TRIB1	.03	7E-9
chr8	126482076	126482077	rs2954021	Liver enzyme levels (alkaline phosphatase)	TRIB1	1.40	2E-13
chr8	126482076	126482077	rs2954021	Liver enzyme levels (alanine transaminase)	TRIB1	1.60	5E-9
chr8	126482076	126482077	rs2954021	LDL cholesterol	TRIB1	.02	1E-7
chr8	126484525	126484526	rs2954026	HDL Cholesterol - Triglycerides (HDLC-TG)	TRIB1	.16	8E-9
chr8	126486408	126486409	rs17321515	Triglycerides	TRIB1	.08	4E-17
chr8	126486408	126486409	rs17321515	Triglycerides	TRIB1	6.42	7E-13
chr8	126490971	126490972	rs2954029	Triglycerides	TRIB1	.04	2E-11
chr8	126490971	126490972	rs2954029	Triglycerides	TRIB1	5.64	3E-55
chr8	126490971	126490972	rs2954029	LDL cholesterol	TRIB1	1.84	3E-29
chr8	126490971	126490972	rs2954029	HDL cholesterol	TRIB1	.61	6E-19
chr8	126490971	126490972	rs2954029	Cholesterol, total	TRIB1	2.30	5E-36
chr8	126490971	126490972	rs2954029	Triglycerides	TRIB1	.11	3E-19
chr8	126493745	126493746	rs2954033	Triglycerides-Blood Pressure (TG-BP)	TRIB1	.17	9E-9
chr8	126504725	126504726	rs6987702	LDL cholesterol	TRIB1	.07	3E-6
chr8	126504725	126504726	rs6987702	Cholesterol, total	TRIB1	.07	3E-9
chr8	126507388	126507389	rs2954038	Response to statin therapy	TRIB1, NSMCE2, KIAA0196	NR	7E-6
chr8	126537569	126537570	rs4871611	Crohn's disease	intergenic	1.17	2E-12
chr8	126540050	126540051	rs1551398	Crohn's disease	Intergenic	1.08	5E-9
chr8	127092881	127092882	rs1906493	Crohn's disease	Intergenic	1.19	3E-6
chr8	128093296	128093297	rs1016343	Prostate cancer	Intergenic	1.31	4E-10
chr8	128093296	128093297	rs1016343	Prostate cancer	Intergenic	1.37	1E-7
chr8	128095155	128095156	rs13252298	Prostate cancer	Intergenic	1.12	4E-6
chr8	128103936	128103937	rs1456315	Prostate cancer	Intergenic	NR	1E-12
chr8	128103936	128103937	rs1456315	Prostate cancer	Intergenic	NR	2E-29
chr8	128104342	128104343	rs13254738	Prostate cancer	NR	1.59	4E-10
chr8	128106879	128106880	rs6983561	Prostate cancer	NR	1.87	4E-13
chr8	128124915	128124916	rs16901979	Prostate cancer	Intergenic	1.80	3E-14
chr8	128124915	128124916	rs16901979	Prostate cancer	Intergenic	1.79	1E-12
chr8	128125194	128125195	rs10505483	Prostate cancer	NR	1.73	7E-15
chr8	128192980	128192981	rs2456449	Chronic lymphocytic leukemia	Intergenic	1.26	8E-10
chr8	128320345	128320346	rs16902094	Prostate cancer	Intergenic	1.21	6E-15
chr8	128323180	128323181	rs445114	Prostate cancer	Intergenic	1.22	5E-7
chr8	128323180	128323181	rs445114	Prostate cancer	Intergenic	1.14	5E-10
chr8	128355617	128355618	rs13281615	Breast cancer	Intergenic	1.08	5E-12
chr8	128387851	128387852	rs1562430	Breast cancer	Intergenic	1.16	3E-11
chr8	128387851	128387852	rs1562430	Breast cancer	Intergenic	1.17	6E-7
chr8	128407442	128407443	rs10505477	Colorectal cancer	ORF DQ515897	1.17	3E-11
chr8	128413304	128413305	rs6983267	Prostate cancer	Intergenic	1.20	9E-6
chr8	128413304	128413305	rs6983267	Colorectal cancer	Intergenic	1.18	2E-8
chr8	128413304	128413305	rs6983267	Colorectal cancer	Intergenic	1.24	7E-11
chr8	128413304	128413305	rs6983267	Prostate cancer	Intergenic	1.42	9E-13
chr8	128413304	128413305	rs6983267	Prostate cancer	Intergenic	1.28	7E-12
chr8	128413304	128413305	rs6983267	Colorectal cancer	Intergenic	1.27	1E-14
chr8	128413304	128413305	rs6983267	Prostate cancer	Intergenic	1.26	9E-13
chr8	128424791	128424792	rs7014346	Colorectal cancer	POU5FIP1, HsG57825, DQ515897	1.19	9E-26
chr8	128485037	128485038	rs1447295	Prostate cancer	Intergenic	1.58	2E-19
chr8	128485037	128485038	rs1447295	Prostate cancer	Intergenic	1.60	6E-18
chr8	128485037	128485038	rs1447295	Prostate cancer	Intergenic	1.43	2E-14
chr8	128504496	128504497	rs17766217	Response to antidepressant treatment	POU5F1B	NR	3E-7
chr8	128517572	128517573	rs4242382	Prostate cancer	Intergenic	1.66	3E-19
chr8	128518553	128518554	rs4242384	Prostate cancer	Intergenic	1.56	3E-16
chr8	128518553	128518554	rs4242384	Prostate cancer	NR	NR	2E-24
chr8	128518553	128518554	rs4242384	Prostate cancer	Intergenic	1.88	3E-16
chr8	128532136	128532137	rs10090154	Prostate cancer	NR	1.68	3E-6
chr8	128539359	128539360	rs7837688	Prostate cancer	Intergenic	NR	1E-25
chr8	128718067	128718068	rs9642880	Bladder cancer	MYC	1.21	2E-18
chr8	128718067	128718068	rs9642880	Urinary bladder cancer	MYC	1.21	7E-12
chr8	128718067	128718068	rs9642880	Urinary bladder cancer	MYC, BC042052	1.22	9E-12
chr8	128815028	128815029	rs4410871	Multiple sclerosis	MYC	1.11	8E-9
chr8	129072160	129072161	rs2648875	End-stage renal disease	PVT1	2.97	2E-6
chr8	129075831	129075832	rs2608053	Hodgkin's lymphoma	PVT1	1.20	1E-7
chr8	129192270	129192271	rs2019960	Multiple sclerosis	PVT1	1.12	5E-9
chr8	129192270	129192271	rs2019960	Hodgkin's lymphoma	PVT1	1.33	1E-13
chr8	129246414	129246415	rs10492294	Immunoglobulin A	PVT1	1.49	4E-6
chr8	129264588	129264589	rs9792269	Celiac disease	Intergenic	1.14	3E-9
chr8	129316013	129316014	rs975730	Celiac disease and Rheumatoid arthritis	Intergenic	NR	2E-8
chr8	129427517	129427518	rs7815944	Atopic dermatitis	MIR1208	1.16	4E-7
chr8	129543948	129543949	rs10088218	Ovarian cancer	MYC,THEM75	1.19	3E-9
chr8	129567180	129567181	rs6651252	Crohn's disease	intergenic	1.23	4E-18
chr8	129946153	129946154	rs987525	Orofacial clefts	NR	1.92	5E-35
chr8	129946153	129946154	rs987525	Orofacial clefts	NR	NR	2E-11
chr8	129946153	129946154	rs987525	Orofacial clefts	NR	NR	1E-26
chr8	129946153	129946154	rs987525	Cleft lip	Intergenic	1.78	4E-16
chr8	129946153	129946154	rs987525	Orofacial clefts	Intergenic	2.09	9E-8
chr8	129946153	129946154	rs987525	Orofacial clefts	PVT1, GSDMC	2.57	3E-24
chr8	130491751	130491752	rs891835	Glioma	CCDC26	1.24	8E-11
chr8	130572109	130572110	rs10956483	White blood cell types	MLZE	.07	2E-10
chr8	130685456	130685457	rs4295627	Glioma	CCDC26	1.40	5E-21
chr8	130685456	130685457	rs4295627	Glioma	CCDC26	1.36	2E-18
chr8	130725664	130725665	rs6470764	Height	GSDMC	.05	2E-28
chr8	130980471	130980472	rs10092658	Protein quantitative trait loci	FAM49B	NR	6E-6
chr8	131092412	131092413	rs6984045	Multiple sclerosis	ASAP1, DDEF1	1.59	2E-6
chr8	131812032	131812033	rs263238	Total ventricular volume	ADCY8	.01	2E-6
chr8	132353734	132353735	rs4596632	Eye color	ADCY8/EFR3A	.17	3E-6
chr8	133103289	133103290	rs2014357	Common traits (Other)	NR	NR	9E-7
chr8	133929916	133929917	rs853308	Vitiligo	SLA	1.20	2E-8
chr8	134071832	134071833	rs2741200	Temperament	TG, SLA	.32	5E-6
chr8	135566566	135566567	rs7827545	Hypertension	ZFAT	NR	2E-44
chr8	135567045	135567046	rs1372662	Hypertension	ZFAT	NR	2E-44
chr8	135593724	135593725	rs6577655	Visceral adipose tissue/subcutaneous adipose tissue ratio	ZFAT1	NR	5E-6
chr8	135637336	135637337	rs12680655	Height	ZFAT	.03	2E-14
chr8	135638631	135638632	rs733254	Height	ZFAT1	.04	2E-6
chr8	136713136	136713137	rs4243849	Non-alcoholic fatty liver disease histology (other)	Intergenic	.14	2E-6
chr8	136871738	136871739	rs12680546	Amyotrophic lateral sclerosis	Intergenic	1.67	3E-6
chr8	136989203	136989204	rs16905439	Insomnia (caffeine-induced)	AC105008.1	3.33	9E-6
chr8	138905295	138905296	rs9657451	Cognitive performance	FAM135B	NR	2E-6
chr8	138918944	138918945	rs2705293	Neuroticism	AK127771	NR	6E-6
chr8	139255917	139255918	rs4909764	Inflammatory biomarkers	FAM135B	NR	2E-6
chr8	139504269	139504270	rs11166827	Cognitive performance	FAM135B	NR	5E-6
chr8	140519516	140519517	rs2468677	Adiponectin levels	KCNK9	NR	8E-7
chr8	141150168	141150169	rs6992848	Response to amphetamines	TRAPPC9	NR	7E-6
chr8	142104943	142104944	rs4961252	Response to interferon beta therapy	DENND3, PTK2	.23	3E-8
chr8	142300314	142300315	rs7827290	Bipolar disorder	LOC731779, GPR20	1.10	9E-6
chr8	142359549	142359550	rs7386474	Bipolar disorder and schizophrenia	NR	1.23	3E-6
chr8	142540924	142540925	rs7837045	Breast size	FLJ43860	.09	5E-6
chr8	142632314	142632315	rs13263959	Hair color	NR	NR	8E-7
chr8	143121670	143121671	rs4917300	Amyotrophic lateral sclerosis	Intergenic	1.27	2E-6
chr8	143691837	143691838	rs7465272	Bipolar disorder and schizophrenia	NR	1.26	9E-6
chr8	143761930	143761931	rs2294008	Duodenal ulcer	PSCA	1.41	2E-33
chr8	143761930	143761931	rs2294008	Bladder cancer	PSCA	1.13	4E-11
chr8	143761930	143761931	rs2294008	Bladder cancer	PSCA	1.15	2E-10
chr8	144657599	144657600	rs2290416	Attention deficit hyperactivity disorder	NAPRT1	NR	9E-6
chr8	145005560	145005561	rs6995402	Platelet counts	PLEC1	2.30	5E-10
chr8	145043542	145043543	rs11136341	LDL cholesterol	PLEC1	1.40	4E-13
chr8	145043542	145043543	rs11136341	Cholesterol, total	PLEC1	1.34	9E-10
chr8	145139521	145139522	rs6558295	Metabolic traits	OPLAH	.12	2E-59
chr9	331489	331490	rs10813766	Mean platelet volume	DOCK8	.01	4E-12
chr9	565916	565917	rs7027930	Pulmonary function decline	Intergenic	.20	9E-6
chr9	845515	845516	rs7040024	Testicular cancer	DMRT1	1.70	1E-11
chr9	863634	863635	rs755383	Testicular cancer	DMRT1	1.50	9E-10
chr9	863634	863635	rs755383	Testicular germ cell cancer	DMRT1	1.37	1E-23
chr9	1056958	1056959	rs17641078	Hyperactive-impulsive symptoms	DMRT2	NR	5E-6
chr9	1202370	1202371	rs10809650	Dupuytren's disease	RP11-341G2.1, DMRT2	1.25	6E-9
chr9	1456796	1456797	rs1412259	Response to taxane treatment (docetaxel)	Intergenic	NR	4E-6
chr9	2548555	2548556	rs10812227	Gambling	FLJ35024, VLDLR	.22	5E-6
chr9	2551653	2551654	rs12237653	Gambling	FLJ35024, VLDLR	.23	3E-6
chr9	2691185	2691186	rs10738760	Vascular endothelial growth factor levels	KCNV2, VLDLR	NR	1E-39
chr9	2742770	2742771	rs2034764	Alzheimer's disease (age of onset)	KCNV2, VLDLR	NR	4E-6
chr9	4287465	4287466	rs7041847	Type 2 diabetes	GLIS3	1.10	2E-14
chr9	4289049	4289050	rs7034200	Fasting glucose-related traits (interaction with BMI)	GLIS3	NR	7E-7
chr9	4289049	4289050	rs7034200	Fasting glucose-related traits	GLIS3	NR	1E-13
chr9	4289049	4289050	rs7034200	Fasting glucose-related traits	GLIS3	NR	1E-12
chr9	4291746	4291747	rs7020673	Type 1 diabetes	GLIS3	1.14	5E-12
chr9	4292082	4292083	rs10758593	Type 1 diabetes	GLIS3	1.13	3E-6
chr9	4293149	4293150	rs10814916	Type 2 diabetes	GLIS3	1.11	6E-12
chr9	4426630	4426631	rs10974531	Pancreatic cancer	SLC1A1	1.24	5E-6
chr9	4744742	4744743	rs409801	Platelet counts	AK3	5.59	3E-49
chr9	4763175	4763176	rs385893	Hematological parameters	AK3	6.26	9E-17
chr9	4814947	4814948	rs13300663	Platelet counts	RCL1	5.59	1E-29
chr9	4856876	4856877	rs10758658	Mean corpuscular volume	RCL1	.00	3E-20
chr9	4856876	4856877	rs10758658	Mean corpuscular hemoglobin	RCL1	.00	2E-14
chr9	4981601	4981602	rs10758669	Ulcerative colitis	JAK2	1.17	2E-25
chr9	4981601	4981602	rs10758669	Crohn's disease	JAK2	1.18	1E-13
chr9	4981601	4981602	rs10758669	Ulcerative colitis	JAK2	1.22	1E-6
chr9	4981601	4981602	rs10758669	Crohn's disease	JAK2	1.12	3E-9
chr9	5070830	5070831	rs10974944	Myeloproliferative neoplasms	JAK2	3.10	4E-20
chr9	5213686	5213687	rs10975003	Ulcerative colitis	JAK2, INSL6, INSL4	1.34	1E-6
chr9	5893860	5893861	rs2150702	Multiple sclerosis	MLANA	1.16	3E-8
chr9	6190075	6190076	rs1342326	Asthma	IL33	1.20	9E-10
chr9	6193454	6193455	rs2381416	Asthma	IL33	NR	2E-12
chr9	6486307	6486308	rs16924631	Periodontal microbiota	UHRF2, GLDC, TPD52L3, IL33	2.29	3E-6
chr9	6784725	6784726	rs10815468	Bipolar disorder and schizophrenia	NR	1.22	7E-6
chr9	6849316	6849317	rs4742269	Radiation response	KDM4C	NR	5E-6
chr9	7043454	7043455	rs16925187	Response to fenofibrate (adiponectin levels)	KDM4C	.10	5E-6
chr9	7682600	7682601	rs842304	HIV-1 susceptibility	AL591509.5	NR	4E-6
chr9	7734249	7734250	rs10758892	Myopia (pathological)	Intergenic	NR	9E-6
chr9	7925380	7925381	rs1535480	Common traits (Other)	NR	NR	4E-7
chr9	8012417	8012418	rs12682851	Prostate cancer (gene x gene interaction)	C9orf123	1.39	2E-6
chr9	8196510	8196511	rs7044355	Platelet aggregation	PTPRD	NR	1E-7
chr9	8235632	8235633	rs10815798	Attention deficit hyperactivity disorder and conduct disorder	PTPRD	NR	6E-6
chr9	8846954	8846955	rs1975197	Restless legs syndrome	PTPRD	1.29	3E-10
chr9	8846954	8846955	rs1975197	Restless legs syndrome	PTPRD	1.31	6E-9
chr9	8879117	8879118	rs17584499	Type 2 diabetes	PTPRD	1.57	9E-10
chr9	9261736	9261737	rs4626664	Restless legs syndrome	PTPRD	1.44	6E-10
chr9	9910122	9910123	rs10759102	Airflow obstruction	PTPRD	1.23	1E-6
chr9	9924723	9924724	rs7849581	Myopia (pathological)	PTPRD	NR	9E-7
chr9	10043013	10043014	rs291272	Temperament	PTPRD	.20	5E-6
chr9	10260262	10260263	rs2475335	Partial epilepsies	PTPRD	NR	9E-6
chr9	10430601	10430602	rs649891	Type 2 diabetes	PTPRD	NR	6E-6
chr9	11257447	11257448	rs10959672	Response to amphetamines	Intergenic	NR	5E-7
chr9	12396730	12396731	rs13289810	Hair color	TYRP1	NR	1E-19
chr9	12582564	12582565	rs1325154	Attention deficit hyperactivity disorder (time to onset)	Intergenic	NR	5E-6
chr9	12672096	12672097	rs1408799	Blue vs. green eyes	TYRP1	1.40	6E-17
chr9	13007128	13007129	rs1360517	AIDS	Intergenic	3.09	3E-6
chr9	14446000	14446001	rs1556032	AIDS	NR	2.05	9E-6
chr9	14470832	14470833	rs10961534	Hypothyroidism	TRNAH, GUG, ZDHHC21	1.19	7E-6
chr9	14562313	14562314	rs10961577	Visceral adipose tissue adjusted for BMI	ZDHHC21	NR	7E-6
chr9	14898160	14898161	rs10961780	Height	FREM1	.40	2E-6
chr9	15157976	15157977	rs1780159	Calcium levels	C9orf52	.03	6E-6
chr9	15283096	15283097	rs12003180	Bipolar disorder and schizophrenia	NR	1.60	5E-6
chr9	15289577	15289578	rs471364	HDL cholesterol	TTC39B	.08	3E-10
chr9	15296033	15296034	rs643531	HDL cholesterol	TTC39B	.01	7E-9
chr9	15305377	15305378	rs581080	HDL cholesterol	TTC39B	.72	1E-13
chr9	15305377	15305378	rs581080	Cholesterol, total	TTC39B	1.57	3E-9
chr9	15309927	15309928	rs2245641	Bipolar disorder	TTC39B	1.90	2E-6
chr9	15986715	15986716	rs1927702	Body mass index	NR	.08	6E-6
chr9	16368731	16368732	rs7864648	Height	BNC2	.02	2E-8
chr9	16864520	16864521	rs2153271	Freckling	BNC2	.40	4E-10
chr9	16915020	16915021	rs3814113	Ovarian cancer	BNC2, LOC648570, CNTLN	1.22	5E-19
chr9	17458871	17458872	rs10810790	Response to amphetamines	CNTLN	NR	6E-6
chr9	17487944	17487945	rs2383024	Pulmonary function decline	Intergenic	.18	9E-6
chr9	17731920	17731921	rs1536076	Parkinson's disease	SH3GL2	1.16	5E-7
chr9	17895104	17895105	rs10810865	Cognitive performance	SH3GL2	NR	4E-6
chr9	17938350	17938351	rs1755289	Multiple sclerosis	SH3GL2	1.35	3E-6
chr9	18109234	18109235	rs2210327	Heart failure	SH3GL2	3.14	7E-7
chr9	18930221	18930222	rs1571228	Non-small cell lung cancer	FAM154A	NR	2E-7
chr9	19664080	19664081	rs4258076	Cognitive performance	SLC24A2	NR	4E-6
chr9	20098710	20098711	rs16937883	Asthma (toluene diisocyanate-induced)	Intergenic	5.29	7E-6
chr9	21747802	21747803	rs4636294	Cutaneous nevi	MTAP	.20	3E-15
chr9	21816527	21816528	rs7023329	Melanoma	CDKN2A, MTAP	1.20	7E-9
chr9	21816527	21816528	rs7023329	Melanoma	CDKN2A	1.18	4E-7
chr9	21986846	21986847	rs3731211	Platelet counts	CDKN2A	3.28	6E-14
chr9	22003366	22003367	rs1063192	Glaucoma (primary open-angle)	CDKN2B	1.33	5E-11
chr9	22003366	22003367	rs1063192	Vertical cup-disc ratio	CDKN2B	.01	4E-15
chr9	22019128	22019129	rs523096	Glaucoma	CDKN2B, CDKN2BAS, CDK2NA	2.13	5E-11
chr9	22029546	22029547	rs564398	Type 2 diabetes	CDKN2A, CDKN2B	1.13	1E-6
chr9	22031004	22031005	rs7865618	Glaucoma (primary open-angle)	CDKN2B-AS1	1.78	9E-11
chr9	22031004	22031005	rs7865618	Coronary heart disease	MTAP	1.18	2E-27
chr9	22033365	22033366	rs2157719	Glaucoma (primary open-angle)	CDKN2BAS	1.45	2E-18
chr9	22033365	22033366	rs2157719	Glaucoma (primary open-angle)	CDKN2BAS	1.72	1E-12
chr9	22033365	22033366	rs2157719	Glioma	CDKN2A, CDKN2B	1.26	5E-16
chr9	22043925	22043926	rs1412829	Nasopharyngeal carcinoma	CDNK2A,CDKN2B	1.28	5E-7
chr9	22043925	22043926	rs1412829	Glioma (high-grade)	Intergenic	1.42	2E-10
chr9	22062133	22062134	rs1011970	Breast cancer	CDKN2A,CDKN2B	1.09	3E-8
chr9	22068651	22068652	rs4977756	Glioma	CDKN2BAS	1.28	1E-8
chr9	22068651	22068652	rs4977756	Glaucoma	CDKN2B-AS1	1.39	1E-14
chr9	22068651	22068652	rs4977756	Glioma	CDKN2A, CDKN2B	1.24	7E-15
chr9	22072263	22072264	rs10757269	Ankle-brachial index	CDKN2B	.00	9E-9
chr9	22081849	22081850	rs6475606	Intracranial aneurysm	CDKN2B-AS1	1.35	4E-8
chr9	22083403	22083404	rs1333040	Intracranial aneurysm	CDKN2A,CDKN2B	1.32	2E-22
chr9	22083403	22083404	rs1333040	Intracranial aneurysm	CDKN2A, CDKN2B	1.29	1E-10
chr9	22088259	22088260	rs10757272	Intracranial aneurysm	CDKN2BAS	1.21	2E-7
chr9	22096054	22096055	rs10757274	Coronary heart disease	CDKN2A/B	1.37	8E-45
chr9	22098573	22098574	rs4977574	Coronary heart disease	CDKN2A, CDKN2B	1.29	1E-22
chr9	22098573	22098574	rs4977574	Coronary heart disease	Intergenic	1.20	2E-25
chr9	22098573	22098574	rs4977574	Myocardial infarction (early onset)	CDKN2A, CDKN2B	1.29	3E-44
chr9	22115104	22115105	rs10965235	Endometriosis	CDKN2BAS	1.44	6E-12
chr9	22115285	22115286	rs944797	Coronary heart disease	CDKN2A, CDKN2B	1.25	6E-16
chr9	22115958	22115959	rs2383207	Abdominal aortic aneurysm	CDKN2A,CKDN2B	1.27	2E-8
chr9	22124476	22124477	rs10757278	Myocardial infarction	CDKN2A,CDKN2B	1.28	1E-20
chr9	22125346	22125347	rs1333048	Coronary heart disease	CDKN2B, CDKN2A	NR	7E-14
chr9	22125502	22125503	rs1333049	Coronary artery calcification	CDKN2B	.20	3E-24
chr9	22125502	22125503	rs1333049	Coronary heart disease	CDKN2B, CDKN2A	NR	7E-14
chr9	22125502	22125503	rs1333049	Coronary heart disease	Intergenic	1.27	7E-58
chr9	22125502	22125503	rs1333049	Coronary heart disease	Intergenic	1.36	3E-19
chr9	22125502	22125503	rs1333049	Coronary heart disease	CDKN2A,CDKN2B	1.47	1E-13
chr9	22129578	22129579	rs7020996	Type 2 diabetes	CDKN2A,CDKN2B	1.26	2E-7
chr9	22132075	22132076	rs2383208	Type 2 diabetes	CDKN2B	1.22	3E-17
chr9	22132075	22132076	rs2383208	Type 2 diabetes	CDKN2A, CDKN2B	1.34	2E-29
chr9	22133283	22133284	rs10965250	Type 2 diabetes	CDKN2A,CDKN2B	1.20	1E-10
chr9	22134093	22134094	rs10811661	Fasting glucose-related traits (interaction with BMI)	CDKN2B	NR	7E-6
chr9	22134093	22134094	rs10811661	Type 2 diabetes	CDKN2B	1.26	7E-7
chr9	22134093	22134094	rs10811661	Type 2 diabetes	CDKN2A, CDKN2B	1.19	5E-6
chr9	22134093	22134094	rs10811661	Type 2 diabetes	CDKN2A,CDKN2B	1.20	8E-15
chr9	22134093	22134094	rs10811661	Type 2 diabetes	CDKN2A,CDKN2B	1.20	5E-8
chr9	22136488	22136489	rs1333051	Type 2 diabetes	CDKN2A, CDKN2B	1.22	6E-10
chr9	22137684	22137685	rs7018475	Type 2 diabetes	CDKN2B	1.35	3E-8
chr9	22169699	22169700	rs1537377	Endometriosis	CDKN2B-ASI, CDKN2B, CDKN2A, ARF	1.15	2E-9
chr9	22362103	22362104	rs961831	Personality dimensions	Intergenic	.17	7E-6
chr9	22670714	22670715	rs613391	Quantitative traits	Intergenic	.20	5E-6
chr9	22770885	22770886	rs10811771	Response to antipsychotic therapy (extrapyramidal side effects)	Intergenic	NR	8E-7
chr9	22842201	22842202	rs12554707	Response to amphetamines	Intergenic	NR	2E-6
chr9	23426270	23426271	rs12000445	Response to platinum-based chemotherapy in non-small-cell lung cancer	HuB	1.49	7E-6
chr9	24092071	24092072	rs4246856	D-dimer levels	Intergenic	.03	6E-6
chr9	24111279	24111280	rs2225614	Quantitative traits	Intergenic	.21	3E-6
chr9	25449121	25449122	rs12552736	RR interval (heart rate)	Intergenic	.25	2E-6
chr9	25452811	25452812	rs13300284	RR interval (heart rate)	Intergenic	.26	4E-6
chr9	25551356	25551357	rs17774966	Entorhinal cortical thickness	TUSC1	.15	8E-6
chr9	26208856	26208857	rs4978053	Visceral adipose tissue/subcutaneous adipose tissue ratio	TUSC1	NR	6E-6
chr9	26614846	26614847	rs10812428	Drug-induced liver injury (flucloxacillin)	C9org82	2.85	1E-6
chr9	26694887	26694888	rs13294589	Gallbladder cancer	NR	12.78	2E-6
chr9	26789939	26789940	rs1889899	Smoking behavior	Intergenic	1.26	6E-6
chr9	26935995	26935996	rs7045881	Schizophrenia	PLAA	1.16	2E-6
chr9	27490966	27490967	rs7046653	Response to TNF antagonist treatment	IFNK	NR	5E-7
chr9	27533983	27533984	rs10812610	Heart failure	MOBKL2B	1.14	5E-6
chr9	27536396	27536397	rs2814707	Amyotrophic lateral sclerosis	MOBKL2B, IFNK, C9orf72	1.22	7E-9
chr9	27543280	27543281	rs3849942	Amyotrophic lateral sclerosis	C9orf72	1.21	4E-7
chr9	27543280	27543281	rs3849942	Amyotrophic lateral sclerosis	MOBKL2B,IFNK,C9orf72	2.16	9E-11
chr9	27543280	27543281	rs3849942	Amyotrophic lateral sclerosis	Intergenic	NR	5E-11
chr9	27543280	27543281	rs3849942	Amyotrophic lateral sclerosis	Intergenic	NR	8E-10
chr9	27543280	27543281	rs3849942	Amyotrophic lateral sclerosis	MOBKL2B, IFNK, C9orf72	1.23	1E-8
chr9	27556779	27556780	rs10122902	Amyotrophic lateral sclerosis	Intergenic	NR	5E-11
chr9	27556779	27556780	rs10122902	Amyotrophic lateral sclerosis	Intergenic	NR	8E-10
chr9	27561048	27561049	rs774359	Amyotrophic lateral sclerosis	NR	1.19	3E-6
chr9	27630561	27630562	rs12555345	Total ventricular volume	LOC392298	.00	5E-6
chr9	27882652	27882653	rs7029145	Immunoglobulin A	IFNK, LINGO2	1.29	9E-6
chr9	28414338	28414339	rs10968576	Body mass index	LRRN6C	.11	3E-13
chr9	31546471	31546472	rs4576506	Alzheimer's disease	RP11-291J9.2	1.66	1E-6
chr9	32433525	32433526	rs10970976	Asthma	ACO1	1.28	4E-6
chr9	32556379	32556380	rs17290760	Immune response to smallpox vaccine (IL-6)	NDUFB6, TOPORS	NR	1E-7
chr9	32755027	32755028	rs10758161	Immune response to anthrax vaccine	TAF1L, TMEM215	.16	8E-6
chr9	32914588	32914589	rs12377462	Vitamin B12 levels	Intergenic	28.53	2E-6
chr9	33217265	33217266	rs830407	Bipolar disorder and schizophrenia	NR	1.36	8E-6
chr9	33283581	33283582	rs12336160	Erectile dysfunction and prostate cancer treatment	CHMP5	7.26	1E-6
chr9	33799369	33799370	rs216345	Bipolar disorder	NR	1.15	4E-6
chr9	34071540	34071541	rs7871764	Height	WDR40A	.06	2E-6
chr9	34710259	34710260	rs2812378	Rheumatoid arthritis	CCL21	1.12	3E-8
chr9	34743680	34743681	rs951005	Rheumatoid arthritis	CCL21	1.19	4E-10
chr9	35141704	35141705	rs10972341	Weight	NR	2.32	9E-6
chr9	35269818	35269819	rs10121009	Parkinson's disease	UNC13B	NR	3E-6
chr9	36969204	36969205	rs16933812	Obesity and blood pressure	PAX5	NR	9E-9
chr9	36969204	36969205	rs16933812	Obesity and blood pressure	PAX5	NR	5E-6
chr9	36997416	36997417	rs3758171	Intelligence	PAX5	NR	4E-8
chr9	36998992	36998993	rs1329573	Intelligence	PAX5	NR	4E-8
chr9	37000686	37000687	rs3824344	Intelligence	PAX5	NR	4E-8
chr9	37002114	37002115	rs7020413	Intelligence	PAX5	NR	4E-8
chr9	37037975	37037976	rs1329568	Response to tocilizumab in rheumatoid arthritis	Intergenic	19.64	8E-7
chr9	38041141	38041142	rs7873102	Brain structure	SHB	NR	6E-7
chr9	38456364	38456365	rs1110183	Hypertension	NR	NR	8E-6
chr9	71434706	71434707	rs4744712	Chronic kidney disease	PIP5K1B,FAM122A	.01	8E-14
chr9	71865931	71865932	rs2282335	Renal sinus fat	TJP2	.17	4E-6
chr9	71943001	71943002	rs3750552	Bipolar disorder	PGM5	1.68	5E-6
chr9	72998331	72998332	rs11142387	Body mass index	KLF9	.04	1E-9
chr9	73784263	73784264	rs4745062	Longevity	TRPM3	NR	1E-6
chr9	74887702	74887703	rs11143230	Suicidal ideation	GDA	1.88	8E-7
chr9	74887702	74887703	rs11143230	Suicidal ideation	GDA	2.22	7E-6
chr9	75764564	75764565	rs3758354	Schizophrenia, bipolar disorder and depression (combined)	ANXA1	NR	3E-6
chr9	76158681	76158682	rs11143609	HIV-1 control	Intergenic	NR	7E-6
chr9	77149836	77149837	rs7042950	Visceral adipose tissue/subcutaneous adipose tissue ratio	RORB	NR	9E-6
chr9	77499795	77499796	rs11144134	Magnesium levels	TRPM6	.01	8E-15
chr9	78276674	78276675	rs10512049	Total ventricular volume	PCSK5	.01	3E-6
chr9	78425924	78425925	rs12344488	Non-alcoholic fatty liver disease histology (AST)	Intergenic	.51	5E-6
chr9	78542285	78542286	rs11144688	Height	PCSK5	.05	1E-11
chr9	78665775	78665776	rs7047865	Amyotrophic lateral sclerosis (age of onset)	PCSK5	NR	7E-6
chr9	78841400	78841401	rs10746997	Response to fenofibrate (adiponectin levels)	PCSK5	.14	1E-6
chr9	78906149	78906150	rs2842483	Multiple sclerosis (age of onset)	RFK	NR	5E-6
chr9	79038169	79038170	rs6560517	Dialysis-related mortality	GCNT1, RPSAP9	1.56	7E-6
chr9	79408143	79408144	rs10781380	Hippocampal atrophy	PRUNE2	NR	7E-7
chr9	79610627	79610628	rs79460104	Response to amphetamines	Intergenic	NR	4E-6
chr9	80940575	80940576	rs1411916	Visceral fat	PSAT1	NR	4E-6
chr9	81310679	81310680	rs1757948	vWF and FVIII levels	KRT18P24	.15	7E-6
chr9	81889357	81889358	rs2769967	Inattentive symptoms	Intergenic	NR	3E-6
chr9	81952127	81952128	rs13292136	Type 2 diabetes	CHCHD9	1.11	3E-8
chr9	82039361	82039362	rs2378383	Asthma (childhood onset)	TLE4, CHCHD9	1.64	7E-7
chr9	82310897	82310898	rs914715	Bipolar disorder	NR	NR	1E-6
chr9	82345880	82345881	rs2151145	Menopause (age at onset)	NR	.41	1E-7
chr9	82807502	82807503	rs12554086	RR interval (heart rate)	Intergenic	.16	4E-7
chr9	84015036	84015037	rs10867752	Hippocampal atrophy	RP11-232A1.1	NR	3E-6
chr9	84213159	84213160	rs2777777	Visceral adipose tissue adjusted for BMI	TLE1	NR	9E-6
chr9	84222617	84222618	rs815847	Visceral fat	TLE1	NR	3E-6
chr9	84372740	84372741	rs11139399	Hippocampal atrophy	TLE1	NR	1E-6
chr9	85135914	85135915	rs7043482	Insulin resistance/response	Intergenic	12.00	3E-6
chr9	85311146	85311147	rs668853	Ulcerative colitis	Intergenic	1.20	2E-6
chr9	85414980	85414981	rs1998303	Select biomarker traits	Intergenic	NR	1E-6
chr9	86552204	86552205	rs7853377	Height	C9orf64	.02	5E-8
chr9	86922035	86922036	rs10123041	Response to statin therapy	SLC28A3, RMI1, LOC729388	NR	6E-6
chr9	87930044	87930045	rs2841498	Partial epilepsies	AL354897.1	NR	4E-6
chr9	89116627	89116628	rs8181166	Height	ZCCHC6	.03	3E-12
chr9	89573082	89573083	rs9792548	Insulin resistance/response	GAS1	12.00	4E-6
chr9	90031668	90031669	rs1806864	Bipolar disorder and schizophrenia	NR	1.44	1E-6
chr9	90209136	90209137	rs3095748	Immune reponse to smallpox (secreted IFN-alpha)	DAPK1	NR	5E-7
chr9	90235793	90235794	rs11141915	Response to gemcitabine in pancreatic cancer	DAPK1	4.10	1E-6
chr9	90811181	90811182	rs2814828	Height	SPIN1, CCRK	5.40	9E-7
chr9	90835725	90835726	rs2778031	Height	SPIN1	.03	9E-13
chr9	91540058	91540059	rs1875620	Response to statin therapy (LDL-C)	C9orf47, S1PR3, SHC3	2.80	7E-7
chr9	92036426	92036427	rs4132699	Orofacial clefts	NR	NR	5E-7
chr9	92249583	92249584	rs10908907	Alcoholism (heaviness of drinking)	Intergenic	.10	6E-6
chr9	92887230	92887231	rs2081670	Protein quantitative trait loci	GADD45G,DIRAS2	NR	3E-6
chr9	93181530	93181531	rs883924	Hepatitis C induced liver fibrosis	LOC340515	NR	2E-6
chr9	93409356	93409357	rs1831521	Cognitive test performance	DIRAS2	NR	8E-6
chr9	93555738	93555739	rs290258	Prostate cancer (gene x gene interaction)	SYK	1.33	1E-6
chr9	93563535	93563536	rs290986	Multiple sclerosis	SYK	1.10	9E-7
chr9	93633239	93633240	rs10993738	Type 2 diabetes	SYK	1.16	5E-6
chr9	93975470	93975471	rs773506	Type 2 diabetes nephropathy	AUH	1.32	6E-6
chr9	94822539	94822540	rs7872515	Bipolar disorder and schizophrenia	SPTLC1, ROR2	1.39	6E-7
chr9	95429119	95429120	rs9969804	Height	IPPK	.03	8E-17
chr9	95559504	95559505	rs10992471	Visceral adipose tissue/subcutaneous adipose tissue ratio	BICD2, ZNF484	NR	2E-6
chr9	96893944	96893945	rs1257763	Height	PTPDC1	.07	1E-9
chr9	97068925	97068926	rs10993160	Body mass index	ZNF169	.05	6E-7
chr9	97314740	97314741	rs16910061	Height	FBP2	.53	3E-6
chr9	97713458	97713459	rs10821415	Atrial fibrillation	C9orf3	1.11	4E-11
chr9	97741273	97741274	rs3802458	Erectile dysfunction and prostate cancer treatment	C9orf3	10.53	4E-6
chr9	97741335	97741336	rs3802457	Polycystic ovary syndrome	C9orf3	1.30	5E-14
chr9	98231007	98231008	rs16909898	Pulmonary function	PTCH1	.50	5E-7
chr9	98256234	98256235	rs473902	Height	PTCH1/FANCC	.07	2E-17
chr9	98259702	98259703	rs10512248	Height	PTCH1	.05	4E-11
chr9	98376698	98376699	rs10988802	Chemerin levels	PTCH	NR	4E-6
chr9	98429265	98429266	rs11790994	Inattentive symptoms	Intergenic	NR	2E-7
chr9	99097526	99097527	rs6479272	Non-small cell lung cancer	SLC35D2	NR	9E-6
chr9	99539137	99539138	rs10816533	Height	ZNP510	NR	2E-6
chr9	100546599	100546600	rs925489	Hypothyroidism	KRT18P13, FOXE1, C9orf156	1.28	2E-19
chr9	100549012	100549013	rs7850258	Hypothyroidism	FOXE1	1.23	4E-9
chr9	100556108	100556109	rs965513	Thyroid cancer	FOXE1	1.75	2E-27
chr9	100696202	100696203	rs755109	Quantitative traits	HEMGN, C9ORF156	.31	1E-6
chr9	100740123	100740124	rs4743150	Coronary heart disease	Intergenic	NR	5E-6
chr9	102234322	102234323	rs649057	Dental caries	TGFBR1, NR4A3	NR	5E-6
chr9	102723691	102723692	rs10760706	Alopecia areata	STX17	1.32	4E-7
chr9	104223232	104223233	rs10819937	Liver enzyme levels (alkaline phosphatase)	ALDOB, C9orf125	2.50	1E-9
chr9	104622867	104622868	rs10989661	Smoking behavior	Intergenic	1.68	6E-6
chr9	104944754	104944755	rs320209	Response to antipsychotic treatment	Intergenic	NR	4E-7
chr9	105502497	105502498	rs10990268	Tourette syndrome	Intergenic	1.29	5E-6
chr9	105735194	105735195	rs1342899	Response to antineoplastic agents	Intergenic	3.13	8E-7
chr9	106024219	106024220	rs16922670	Alzheimer's disease	RP11-341A22.2	1.63	7E-6
chr9	107588776	107588777	rs4149311	Myopia (pathological)	ABCA1	NR	9E-6
chr9	107589133	107589134	rs4149310	Metabolite levels	ABCA1	NR	2E-10
chr9	107594363	107594364	rs2515629	Coronary heart disease	ABCA1	.12	5E-7
chr9	107647219	107647220	rs4149268	HDL cholesterol	ABCA1	.82	1E-10
chr9	107647654	107647655	rs3890182	HDL cholesterol	ABCA1	.02	5E-7
chr9	107647654	107647655	rs3890182	HDL cholesterol	ABCA1	.10	3E-10
chr9	107653425	107653426	rs12686004	HDL cholesterol	ABCA1	.02	2E-18
chr9	107657069	107657070	rs3905000	MRI atrophy measures	ABCA1	.01	9E-6
chr9	107657069	107657070	rs3905000	HDL cholesterol	ABCA1	.11	9E-13
chr9	107664300	107664301	rs1883025	Metabolic syndrome	ABCA1	.10	6E-10
chr9	107664300	107664301	rs1883025	HDL cholesterol	ABCA1	.94	2E-33
chr9	107664300	107664301	rs1883025	Cholesterol, total	ABCA1	2.24	3E-27
chr9	107664300	107664301	rs1883025	HDL cholesterol	ABCA1	.08	1E-9
chr9	107665738	107665739	rs2575876	Lipid metabolism phenotypes	ABCA1	.14	2E-11
chr9	108427061	108427062	rs1463984	Cognitive performance	TAL2	NR	3E-6
chr9	108440541	108440542	rs10120372	Visceral adipose tissue/subcutaneous adipose tissue ratio	TAL2, FCMD, TMEM38B	NR	4E-6
chr9	108631949	108631950	rs9969729	Alzheimer's disease (late onset)	Intergenic	NR	2E-6
chr9	108655095	108655096	rs4742971	Protein quantitative trait loci	TMEM38B	NR	8E-7
chr9	108936673	108936674	rs7861820	Menarche and menopause (age at onset)	Intergenic	.09	3E-9
chr9	108967087	108967088	rs2090409	Menarche (age at onset)	TMEM38B	4.70	2E-33
chr9	108967087	108967088	rs2090409	Menarche (age at onset)	TMEM38B, SLC44A1, FKTN, FSD1L, TAL2, ZNF462	.10	2E-9
chr9	109599045	109599046	rs7027110	Height	ZNF462	.03	2E-13
chr9	109632352	109632353	rs4743034	Height	ZNF462	5.30	2E-8
chr9	110125810	110125811	rs817858	Body mass index	RAD23B	.04	7E-6
chr9	110156299	110156300	rs817826	Prostate cancer	RAD23B, KLF4	1.41	5E-14
chr9	110872306	110872307	rs7042864	Tonometry	Intergenic	NR	6E-6
chr9	110888477	110888478	rs865686	Breast cancer	KLF4,RAD23B,ACTL7A	1.12	2E-10
chr9	111854245	111854246	rs523340	Information processing speed	C9orf5	.21	2E-6
chr9	112526288	112526289	rs1327796	Type 2 diabetes	PALM2, AKAP2	1.13	3E-6
chr9	112945404	112945405	rs7032940	Height	PALM2-AKAP2	1.32	3E-6
chr9	113131162	113131163	rs1327533	Longevity	SVEP1	NR	1E-6
chr9	113197262	113197263	rs7042161	Bipolar disorder	NR	1.15	6E-6
chr9	113300834	113300835	rs1889321	Pulmonary function decline	MUSK	.15	7E-7
chr9	113807081	113807082	rs1468758	Height	LPAR1	.03	1E-9
chr9	114293633	114293634	rs10980926	Menarche (age at onset)	ZNF483	2.50	4E-11
chr9	114850189	114850190	rs2782931	Amyotrophic lateral sclerosis	SUSD1	1.11	6E-6
chr9	116991070	116991071	rs7868992	Tourette syndrome	COL27A1, KIF12, ORM1	1.29	3E-8
chr9	117049890	117049891	rs946053	Height	COL27A1	4.40	2E-7
chr9	117260833	117260834	rs10982256	Bipolar disorder	NR	NR	9E-6
chr9	117552884	117552885	rs3810936	Crohn's disease	TNFSF15,TNFSF8	1.21	1E-15
chr9	117553248	117553249	rs4246905	Ulcerative colitis	TNFSF8, TNFSF15	1.10	6E-12
chr9	117558702	117558703	rs6478108	Leprosy	TNFSF15	1.37	3E-21
chr9	117566439	117566440	rs4263839	Crohn's disease	TNFSF15	1.22	3E-10
chr9	117567012	117567013	rs4979462	Primary biliary cirrhosis	TNFSF15	1.56	3E-14
chr9	117568765	117568766	rs6478109	Inflammatory bowel disease	TNFSF15	1.36	3E-8
chr9	117592637	117592638	rs2006996	Inflammatory bowel disease	TNFSF15	1.67	4E-13
chr9	117592637	117592638	rs2006996	Inflammatory bowel disease	TNFSF15	1.75	4E-16
chr9	117830811	117830812	rs7847271	Prostate cancer (gene x gene interaction)	TNC	1.49	4E-6
chr9	118202715	118202716	rs9409154	Visceral adipose tissue adjusted for BMI	Intergenic	NR	2E-6
chr9	119122341	119122342	rs751543	Height	PAPPA	.03	7E-10
chr9	119134795	119134796	rs7869550	Height	PAPPA	.33	1E-6
chr9	119249338	119249339	rs7852872	Hippocampal volume	ASTN2	47.70	1E-7
chr9	119252628	119252629	rs6478241	Migraine	ASTN2	1.16	4E-8
chr9	119333682	119333683	rs10983238	Attention deficit hyperactivity disorder	ASTN2	NR	1E-7
chr9	119925094	119925095	rs6478282	Immune response to anthrax vaccine	ASTN2	.10	6E-6
chr9	119926425	119926426	rs4838255	Response to antipsychotic treatment	ASTN2	NR	3E-7
chr9	120137757	120137758	rs2226006	Economic and political preferences (fairness)	ASTN2	.11	6E-6
chr9	121031028	121031029	rs876347	Response to antipsychotic therapy (extrapyramidal side effects)	Intergenic	NR	2E-6
chr9	121346416	121346417	rs1572299	Schizophrenia	Intergenic	1.08	4E-6
chr9	121359285	121359286	rs11789399	Bipolar disorder and schizophrenia	ASTN2	1.29	6E-9
chr9	121984552	121984553	rs10984447	Multiple sclerosis	DBC1	1.17	8E-6
chr9	122059708	122059709	rs4837628	Parkinson's disease	DBC1	1.27	1E-6
chr9	122258576	122258577	rs10984561	Pulmonary function decline	Intergenic	.85	3E-6
chr9	122861296	122861297	rs16909449	Response to statin therapy	MIRN147, CDK5RAP2, MEGF9	NR	1E-6
chr9	123056636	123056637	rs4837752	Response to antipsychotic therapy (extrapyramidal side effects)	Intergenic	NR	6E-6
chr9	123640499	123640500	rs1953126	Celiac disease and Rheumatoid arthritis	TRAF1	NR	4E-11
chr9	123652897	123652898	rs881375	Rheumatoid arthritis	TRAF1, C5	NR	4E-8
chr9	123690238	123690239	rs3761847	Rheumatoid arthritis	TRAF1,C5	1.13	2E-7
chr9	123690238	123690239	rs3761847	Rheumatoid arthritis	TRAF1-C5	1.32	4E-14
chr9	123914873	123914874	rs9408926	Immune reponse to smallpox (secreted IFN-alpha)	CEP110	NR	4E-8
chr9	123951916	123951917	rs9408928	Immune reponse to smallpox (secreted IFN-alpha)	RAB14	NR	4E-9
chr9	124098534	124098535	rs767770	Bipolar disorder and schizophrenia	NR	1.72	6E-6
chr9	124422402	124422403	rs7025486	Abdominal aortic aneurysm	DAB2IP	1.21	5E-10
chr9	124565819	124565820	rs10760187	Periodontal microbiota	DAB2IP, TTLL11	2.07	5E-7
chr9	126154353	126154354	rs872863	Myopia (pathological)	DENND1A	NR	2E-11
chr9	126352217	126352218	rs7852296	Personality dimensions	DENND1A	.17	9E-6
chr9	126446777	126446778	rs10818854	Polycystic ovary syndrome	DENND1A	1.51	9E-18
chr9	126525211	126525212	rs2479106	Polycystic ovary syndrome	NR	1.35	5E-10
chr9	126525211	126525212	rs2479106	Polycystic ovary syndrome	DENND1A	1.34	8E-19
chr9	126926106	126926107	rs2807580	Cognitive performance	NEK6	NR	3E-6
chr9	128831096	128831097	rs4838320	Economic and political preferences (immigration/crime)	Intergenic	.20	9E-6
chr9	128929022	128929023	rs888219	Response to antipsychotic treatment	Intergenic	11.00	2E-7
chr9	129465324	129465325	rs867559	Body mass index	LMX1B	NR	1E-7
chr9	130107963	130107964	rs4130590	Bipolar disorder	NR	1.16	3E-6
chr9	130619636	130619637	rs7865146	Metabolic syndrome	ENG	1.19	1E-6
chr9	130976556	130976557	rs2502731	Attention deficit hyperactivity disorder	DNM1	NR	2E-6
chr9	132370359	132370360	rs10988449	Response to antidepressant treatment	C9orf50	NR	3E-6
chr9	132444098	132444099	rs7866070	Common traits (Other)	NR	NR	7E-7
chr9	133464083	133464084	rs7466269	Height	FUBP3	.03	3E-17
chr9	133464083	133464084	rs7466269	Height	FUBP3	.27	8E-7
chr9	133748082	133748083	rs2070997	Response to amphetamines	ABL1	NR	8E-6
chr9	134450072	134450073	rs11243437	Response to amphetamines	Intergenic	NR	7E-6
chr9	135096766	135096767	rs11243676	Systemic lupus erythematosus	NTNG2	NR	3E-6
chr9	135618282	135618283	rs11243897	Attention deficit hyperactivity disorder	C9orf98	NR	6E-8
chr9	135776033	135776034	rs1076160	Psoriasis	TSC1	1.09	6E-6
chr9	135845034	135845035	rs2905072	Bipolar disorder	NR	1.21	6E-6
chr9	136132908	136132908	rs8176719	Malaria	ABO	1.48	4E-21
chr9	136132908	136132908	rs8176719	Venous thromboembolism	ABO	1.47	6E-12
chr9	136137064	136137065	rs687621	Activated partial thromboplastin time	ABO, LOC653163, SURF2, SURF4, ADAMTS13, C9orf7	.82	9E-100
chr9	136137064	136137065	rs687621	D-dimer levels	ABO	.03	7E-6
chr9	136139264	136139265	rs657152	Phytosterol levels	ABO	8.00	9E-13
chr9	136139264	136139265	rs657152	Liver enzyme levels	ABO	.05	2E-30
chr9	136141869	136141870	rs2519093	Venous thromboembolism	ABO	1.69	8E-16
chr9	136142202	136142203	rs514659	Coronary heart disease	ABO	1.21	8E-9
chr9	136142216	136142217	rs644234	Protein biomarker	ABO	.07	4E-47
chr9	136142354	136142355	rs643434	Inflammatory biomarkers	ABO	NR	9E-25
chr9	136143441	136143442	rs612169	Metabolic traits	ABO	.20	9E-40
chr9	136149228	136149229	rs505922	Duodenal ulcer	ABO	1.32	1E-10
chr9	136149228	136149229	rs505922	Venous thromboembolism	ABO	1.92	1E-34
chr9	136149228	136149229	rs505922	Graves' disease	ABO	1.13	8E-6
chr9	136149228	136149229	rs505922	Pancreatic cancer	ABO	1.20	5E-8
chr9	136149228	136149229	rs505922	Venous thromboembolism	ABO	1.81	4E-15
chr9	136149228	136149229	rs505922	Protein quantitative trait loci	ABO	NR	7E-40
chr9	136149398	136149399	rs507666	Soluble ICAM-1	ABO	17.30	3E-91
chr9	136149398	136149399	rs507666	Soluble ICAM-1	ABO	17.73	5E-29
chr9	136153874	136153875	rs651007	Metabolite levels	ABO	2.28	6E-9
chr9	136153874	136153875	rs651007	E-selectin levels	ABO	9.71	2E-82
chr9	136154167	136154168	rs579459	Liver enzyme levels (alkaline phosphatase)	ABO	8.80	3E-123
chr9	136154167	136154168	rs579459	Coronary heart disease	ABO	1.10	4E-14
chr9	136154167	136154168	rs579459	Soluble levels of adhesion molecules	ABO	14.00	2E-41
chr9	136154167	136154168	rs579459	Soluble E-selectin levels	ABO	NR	1E-29
chr9	136154303	136154304	rs649129	Soluble levels of adhesion molecules	ABO	3.95	1E-15
chr9	136154866	136154867	rs495828	Venous thromboembolism	ABO	1.65	3E-16
chr9	136154866	136154867	rs495828	Angiotensin-converting enzyme activity	ABO	4.90	3E-8
chr9	136154999	136155000	rs635634	LDL cholesterol	ABO	2.05	8E-22
chr9	136154999	136155000	rs635634	Cholesterol, total	ABO	2.30	9E-21
chr9	136323753	136323754	rs4962153	Liver enzyme levels	ADAMTS13	.06	8E-21
chr9	136478354	136478355	rs3025343	Smoking behavior	DBH	1.12	4E-8
chr9	136723519	136723520	rs12344583	vWF and FVIII levels	VAV2	.20	8E-6
chr9	136835342	136835343	rs3780792	Multiple sclerosis	VAV2	1.60	1E-6
chr9	136925662	136925663	rs11789898	Platelet counts	BRD3	3.01	2E-10
chr9	137269455	137269456	rs34312136	Intelligence	RXRA	NR	8E-8
chr9	137280938	137280939	rs35079168	Intelligence	RXRA	NR	8E-8
chr9	137284922	137284923	rs4501664	Intelligence	RXRA	NR	8E-8
chr9	137285502	137285503	rs11102986	Intelligence	RXRA	NR	8E-8
chr9	137440211	137440212	rs3132306	Central corneal thickness	RXRA, COL5A1	.15	3E-10
chr9	137568050	137568051	rs7044529	Central corneal thickness	COL5A1	.13	5E-8
chr9	137704781	137704782	rs7874142	Longevity	COL5A1	NR	1E-6
chr9	138029700	138029701	rs10776934	Response to hepatitis C treatment	OLFM1	.28	1E-6
chr9	138275775	138275776	rs10858396	Attention deficit hyperactivity disorder	Intergenic	NR	6E-6
chr9	138529721	138529722	rs1537415	Periodontitis	GLT6D1	1.59	6E-9
chr9	139111869	139111870	rs7849585	Height	QSOX2	.03	5E-14
chr9	139121739	139121740	rs12338076	Height	LHX3, QSOX2	.06	2E-8
chr9	139265595	139265596	rs34971035	Monocyte chemoattractant protein-1	CARD9	NR	5E-8
chr9	139266404	139266405	rs10781499	Ulcerative colitis	CARD9, INPP5E, SDCCAG3, SEC16A, SNAPC4	1.12	3E-19
chr9	139266495	139266496	rs4077515	Crohn's disease	CARD9, SNAPC4	1.29	4E-6
chr9	139266495	139266496	rs4077515	Crohn's disease	CARD9,SNAPC4	1.18	1E-36
chr9	139266495	139266496	rs4077515	Ulcerative colitis	CARD9	1.14	5E-8
chr9	139269337	139269338	rs10781500	Ankylosing spondylitis	CARD9	NR	1E-6
chr9	139269337	139269338	rs10781500	Ulcerative colitis	CARD9	NR	7E-6
chrUn_gl000248	5640	5641	rs4821083	Height	SYN3	.03	3E-10
chrUn_gl000248	8964	8965	rs5749482	Height	SYN3	.04	5E-7
chrUn_gl000248	33819	33820	rs9621532	Age-related macular degeneration	TIMP3	1.59	2E-15
chrUn_gl000248	33819	33820	rs9621532	Age-related macular degeneration	TIMP3	1.61	4E-9
chrUn_gl000248	33819	33820	rs9621532	Age-related macular degeneration	TIMP3, SYN3	1.41	1E-11
chrX	990179	990180	rs4129148	Schizophrenia	CSF2RA,IL3RA	3.23	4E-7
chrX	2885722	2885723	rs12393627	Height	ARSE	.09	5E-12
chrX	2885722	2885723	rs12393627	Height	ARSE	.07	6E-12
chrX	3410668	3410669	rs7059886	Antineutrophil cytoplasmic antibody-associated vasculitis	MXRA5	1.16	1E-6
chrX	4596137	4596138	rs5916687	Amyotrophic lateral sclerosis	NR	1.22	3E-6
chrX	5184701	5184702	rs6638512	Antineutrophil cytoplasmic antibody-associated vasculitis	Intergenic	NR	2E-25
chrX	6220473	6220474	rs7885458	Biochemical measures	Neuroligin 4	.23	3E-6
chrX	8394252	8394253	rs7892812	Cognitive performance	VCX3B	NR	8E-6
chrX	8913825	8913826	rs5934505	Androgen levels	FAM9B	.09	2E-8
chrX	9751473	9751474	rs5934683	Colorectal cancer	SHROOM2	1.07	7E-10
chrX	10231690	10231691	rs12388359	Alcohol dependence	Intergenic	1.61	4E-6
chrX	11048691	11048692	rs5934953	Cognitive performance	HCCS	NR	1E-7
chrX	12971523	12971524	rs5979785	Celiac disease	TLR7, TLR8	1.14	6E-8
chrX	17698396	17698397	rs5955543	Wilms tumor	NR	2.64	1E-9
chrX	22134657	22134658	rs5951698	Tourette syndrome	PHEX	5.65	6E-6
chrX	22148050	22148051	rs1540283	Immune reponse to smallpox (secreted IFN-alpha)	PHEX	NR	9E-9
chrX	22160991	22160992	rs12559632	F-cell distribution	PHEX	1.16	3E-6
chrX	22892076	22892077	rs5925696	Erectile dysfunction and prostate cancer treatment	DDX53	12.52	3E-6
chrX	23383443	23383444	rs5925760	Immune reponse to smallpox (secreted IFN-alpha)	PTCHD1	NR	1E-7
chrX	25853613	25853614	rs5944185	Erectile dysfunction and prostate cancer treatment	MAGEB18	10.50	7E-6
chrX	28233052	28233053	rs5971305	Erectile dysfunction and prostate cancer treatment	WDR42B	33.69	8E-6
chrX	29640817	29640818	rs7890572	Cardiovascular disease risk factors	IL1RAPL1	.97	1E-7
chrX	32015375	32015376	rs16990008	Response to antidepressant treatment	DMD	NR	2E-6
chrX	32225254	32225255	rs1456737	Bipolar disorder and schizophrenia	NR	1.25	5E-6
chrX	37854726	37854727	rs872690	Erectile dysfunction and prostate cancer treatment	SYTL5	11.78	9E-6
chrX	43607032	43607033	rs3027409	Smoking behavior	MAOA	1.73	7E-6
chrX	44400185	44400186	rs6610953	Personality dimensions	FUNDC1	.15	6E-6
chrX	47174275	47174276	rs6611365	Optic disc size (disc)	ZNF157	.18	4E-7
chrX	50182183	50182184	rs1934179	Hypospadias	DGKK	2.60	3E-21
chrX	51210056	51210057	rs1327301	Prostate cancer	NR	NR	2E-10
chrX	51229682	51229683	rs5945572	Prostate cancer	NUDT10, NUDT11, LOC340602	1.23	4E-13
chrX	51241671	51241672	rs5945619	Prostate cancer	NUDT10, NUDT11	1.19	2E-9
chrX	53974053	53974054	rs7065696	Bipolar disorder and schizophrenia	PHF8	NR	4E-7
chrX	64367018	64367019	rs7064929	Erectile dysfunction and prostate cancer treatment	KIAA1166	13.65	7E-7
chrX	65606692	65606693	rs5965182	Erectile dysfunction and prostate cancer treatment	HEPH	11.73	6E-6
chrX	66510983	66510984	rs6625163	Male-pattern baldness	AR	3.30	5E-11
chrX	66563017	66563018	rs2497938	Male-pattern baldness	AR	2.20	2E-91
chrX	66563017	66563018	rs2497938	Male-pattern baldness	AR, EDA2R	6.50	3E-22
chrX	66942624	66942625	rs5031002	LDL cholesterol	AR	.30	2E-7
chrX	67021549	67021550	rs5919432	Prostate cancer	AR	1.06	1E-8
chrX	68805317	68805318	rs4844096	Primary tooth development (number of teeth)	EDA	.73	5E-11
chrX	68892915	68892916	rs5936487	Primary tooth development (time to first tooth eruption)	EDA	.50	6E-11
chrX	75347433	75347434	rs5937496	Amyotrophic lateral sclerosis	NR	1.38	6E-7
chrX	78649192	78649193	rs1474563	Height	ITM2A	3.50	3E-6
chrX	82535168	82535169	rs1410530	Bipolar disorder and schizophrenia	NR	1.37	4E-6
chrX	82711941	82711942	rs213443	Bipolar disorder and schizophrenia	NR	1.25	6E-6
chrX	82871194	82871195	rs5922838	Depression and alcohol dependence	Intergenic	2.17	5E-6
chrX	82954489	82954490	rs5968205	Depression and alcohol dependence	Intergenic	2.20	3E-6
chrX	86192002	86192003	rs2710057	Bone mineral density (hip)	NR	.07	1E-6
chrX	87190348	87190349	rs12012519	HIV-1 control	Intergenic	NR	7E-6
chrX	88530064	88530065	rs5941160	Antineutrophil cytoplasmic antibody-associated vasculitis	CPXCR1	NR	2E-20
chrX	89288226	89288227	rs5941436	Cognitive performance	RP13-140E4.1	NR	5E-6
chrX	89804126	89804127	rs2755459	Antineutrophil cytoplasmic antibody-associated vasculitis	TGIF2LX	1.67	9E-14
chrX	90812717	90812718	rs6618677	Antineutrophil cytoplasmic antibody-associated vasculitis	PABPC5, PCDH11X, PCDH11Y	1.43	4E-8
chrX	91402219	91402220	rs2573905	Alzheimer's disease	PCDH11X	1.29	2E-7
chrX	95079869	95079870	rs5990417	Major depressive disorder (broad)	NR	1.23	6E-6
chrX	97864353	97864354	rs4827947	Immune reponse to smallpox (secreted IL-1beta)	LOC100128151	NR	3E-7
chrX	105493918	105493919	rs379742	Pancreatitis	NR	1.20	6E-7
chrX	106244766	106244767	rs12688220	Pancreatitis	CLDN2, MORC4, RIPPLY1, TBC1D8B	1.39	2E-22
chrX	109820067	109820068	rs1573036	Sex hormone-binding globulin levels	TDGF3	.03	4E-14
chrX	109820067	109820068	rs1573036	Sex hormone-binding globulin levels	TDGF3	.04	3E-16
chrX	109939204	109939205	rs5943057	Coronary heart disease	Intergenic	NR	9E-7
chrX	111155232	111155233	rs7050529	Smoking behavior	TRPC5	.06	6E-6
chrX	111646463	111646464	rs5982533	Biochemical measures	ZCCHC16	.23	7E-6
chrX	115302191	115302192	rs1403543	Cystic fibrosis severity	AGTR2	NR	2E-6
chrX	116222262	116222263	rs6646773	Response to citalopram treatment	Intergenic	NR	1E-6
chrX	117088055	117088056	rs2430212	Iron status biomarkers	KLHL13	NR	2E-6
chrX	118567701	118567702	rs5910578	Paget's disease	SLC25A43	1.34	1E-7
chrX	119867474	119867475	rs1972809	Antineutrophil cytoplasmic antibody-associated vasculitis	Intergenic	1.28	1E-24
chrX	124073661	124073662	rs7060947	Immune reponse to smallpox (secreted IFN-alpha)	ODZ1	NR	1E-7
chrX	129199811	129199812	rs3788848	Dental caries	BCORL1	NR	3E-6
chrX	132137155	132137156	rs17324272	HIV-1 control	Intergenic	NR	2E-7
chrX	136055294	136055295	rs1190739	Coronary heart disease	Intergenic	.07	5E-6
chrX	138117408	138117409	rs10521792	Response to taxane treatment (placlitaxel)	FGF13	NR	2E-7
chrX	139166682	139166683	rs5907577	Bipolar disorder and schizophrenia	NR	1.27	5E-6
chrX	139314055	139314056	rs5955415	Bipolar disorder and schizophrenia	NR	1.46	2E-6
chrX	141360570	141360571	rs5954596	Antineutrophil cytoplasmic antibody-associated vasculitis	MAGEC2	NR	5E-9
chrX	143254696	143254697	rs9636470	Alcohol and nictotine co-dependence	RGPD2	NR	3E-8
chrX	144141318	144141319	rs6627057	Bipolar disorder and schizophrenia	CYCSP44	1.46	1E-6
chrX	145748907	145748908	rs381365	Immune reponse to smallpox (secreted IFN-alpha)	LOC100128265	NR	2E-12
chrX	146322622	146322623	rs5904726	Coronary heart disease	Intergenic	.06	9E-6
chrX	147042773	147042774	rs5904818	Antineutrophil cytoplasmic antibody-associated vasculitis	FMR1, FMR1NB	NR	2E-8
chrX	147324255	147324256	rs5936441	Response to acetaminophen (hepatotoxicity)	LOC100129661	NR	5E-6
chrX	147381020	147381021	rs2159767	Schizophrenia	Intergenic	1.33	7E-6
chrX	148567450	148567451	rs530501	Cognitive performance	IDS	NR	4E-6
chrX	149635294	149635295	rs17252936	Immune reponse to smallpox (secreted IFN-alpha)	MAMLD1	NR	6E-10
chrX	151655561	151655562	rs10856240	Cognitive performance	AC108171.5	NR	9E-6
chrX	152862637	152862638	rs12010175	Type 2 diabetes	FAM58A	1.21	2E-9
chrX	152899921	152899922	rs5945326	Type 2 diabetes	DUSP9	1.18	7E-16
chrX	152899921	152899922	rs5945326	Type 2 diabetes	DUSP9	1.27	3E-10
chrX	153006494	153006495	rs11156606	Bipolar disorder and schizophrenia	NR	1.42	3E-6
chrX	153554403	153554404	rs766420	Bilirubin levels	G6PD	.18	9E-9
chrX	153945601	153945602	rs2664170	Type 1 diabetes	Intergenic	1.16	8E-9
chrX	154233773	154233774	rs17281398	Antineutrophil cytoplasmic antibody-associated vasculitis	F8	NR	4E-7
chrY	940179	940180	rs4129148	Schizophrenia	CSF2RA,IL3RA	3.23	4E-7
chrY	6477299	6477300	rs5941160	Antineutrophil cytoplasmic antibody-associated vasculitis	CPXCR1	NR	2E-20
